U.S. patent application number 13/650762 was filed with the patent office on 2014-02-20 for kinase inhibitors and method of treating cancer with same.
This patent application is currently assigned to UNIVERISTY HEALTH NETWORKS. The applicant listed for this patent is UNIVERISTY HEALTH NETWORKS. Invention is credited to Donald E. Awrey, Louise G. Edwards, Miklos Feher, Bryan T. Forrest, Yunhui Lang, Radoslaw Laufer, Sze-Wan Li, Yong Liu, Grace Ng, Narendra Kumar B. Patel, Heinz W. Pauls, Peter B. Sampson.
Application Number | 20140051679 13/650762 |
Document ID | / |
Family ID | 48081305 |
Filed Date | 2014-02-20 |
United States Patent
Application |
20140051679 |
Kind Code |
A1 |
Pauls; Heinz W. ; et
al. |
February 20, 2014 |
KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME
Abstract
The present teachings provide a compound represented by
Structural Formula (I): ##STR00001## or a pharmaceutically
acceptable salt thereof. Also described are pharmaceutical
compositions and methods of use thereof.
Inventors: |
Pauls; Heinz W.; (Oakville,
CA) ; Laufer; Radoslaw; (Oakville, CA) ; Liu;
Yong; (North York, CA) ; Li; Sze-Wan;
(Toronto, CA) ; Forrest; Bryan T.; (Burlington,
CA) ; Lang; Yunhui; (Markham, CA) ; Patel;
Narendra Kumar B.; (Scarborough, CA) ; Edwards;
Louise G.; (Mississauga, CA) ; Ng; Grace;
(Richmond Hill, CA) ; Sampson; Peter B.;
(Oakville, CA) ; Feher; Miklos; (Toronto, CA)
; Awrey; Donald E.; (Simcoe, CA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
UNIVERISTY HEALTH NETWORKS |
Toronto |
|
CA |
|
|
Assignee: |
UNIVERISTY HEALTH NETWORKS
Toronto
CA
|
Family ID: |
48081305 |
Appl. No.: |
13/650762 |
Filed: |
October 12, 2012 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
61546533 |
Oct 12, 2011 |
|
|
|
Current U.S.
Class: |
514/210.21 ;
514/211.09; 514/221; 514/230.5; 514/234.5; 514/254.06; 514/304;
514/307; 514/316; 514/318; 514/322; 514/406; 540/552; 540/569;
544/105; 544/140; 544/371; 546/126; 546/146; 546/187; 546/194;
546/199; 548/361.1 |
Current CPC
Class: |
C07D 405/14 20130101;
C07D 451/06 20130101; C07D 401/10 20130101; C07D 403/10 20130101;
C07D 231/56 20130101; C07D 491/107 20130101; C07D 413/14 20130101;
C07D 409/12 20130101; C07D 401/12 20130101; C07D 413/10 20130101;
C07D 409/14 20130101; A61P 35/00 20180101; C07D 401/14 20130101;
C07D 413/04 20130101; C07D 493/10 20130101 |
Class at
Publication: |
514/210.21 ;
544/140; 514/234.5; 544/371; 514/254.06; 546/199; 514/322;
548/361.1; 514/406; 544/105; 514/230.5; 546/187; 514/316; 546/146;
514/307; 540/552; 514/211.09; 540/569; 514/221; 546/194; 514/318;
546/126; 514/304 |
International
Class: |
C07D 231/56 20060101
C07D231/56; C07D 401/12 20060101 C07D401/12; C07D 413/14 20060101
C07D413/14; C07D 409/12 20060101 C07D409/12; C07D 451/06 20060101
C07D451/06; C07D 413/04 20060101 C07D413/04; C07D 413/10 20060101
C07D413/10; C07D 403/10 20060101 C07D403/10; C07D 405/14 20060101
C07D405/14; C07D 401/10 20060101 C07D401/10; C07D 409/14 20060101
C07D409/14; C07D 401/14 20060101 C07D401/14 |
Claims
1. A compound represented by the following structural formula:
##STR00356## or a pharmaceutically acceptable salt thereof,
wherein: each R.sup.1 is independently selected from --H, -halogen,
--CN, --NO.sub.2, --OR.sup.c, --NR.sup.aR.sup.b,
--S(O).sub.iR.sup.c, --NR.sup.dS(O).sub.iR.sup.c,
--S(O).sub.iNR.sup.eR.sup.f, --C(.dbd.O)OR.sup.c,
--OC(.dbd.O)OR.sup.c, --C(.dbd.S)OR.sup.c, --O(C.dbd.S)R.sup.c,
--C(.dbd.O)NR.sup.eR.sup.f, --NR.sup.dC(.dbd.O)R.sup.c,
--C(.dbd.S)NR.sup.eR.sup.f, --NR.sup.dC(.dbd.S)R.sup.c,
--NR.sup.d(C.dbd.O)OR.sup.c, --O(C.dbd.O)NR.sup.eR.sup.f,
--NR.sup.d(C.dbd.S)OR.sup.c, --O(C.dbd.S)NR.sup.eR.sup.f,
--NR.sup.d(C.dbd.O)NR.sup.eR.sup.f,
--NR.sup.d(C.dbd.S)NR.sup.eR.sup.f, --C(.dbd.S)R.sup.c,
--C(.dbd.O)R.sup.c, heterocycloalkyl or alkyl, wherein the
heterocycloalkyl or the alkyl is optionally substituted with 1 to 3
substituents independently selected from -halogen, --CN,
--NO.sub.2, --OR.sup.c, --NR.sup.aR.sup.b, --S(O).sub.iR.sup.c,
--NR.sup.dS(O).sub.iR.sup.c, --S(O).sub.iNR.sup.eR.sup.f,
--C(.dbd.O)OR.sup.c, --OC(.dbd.O)OR.sup.c, --C(.dbd.S)OR.sup.c,
--O(C.dbd.S)R.sup.c, --C(.dbd.O)NR.sup.eR.sup.f,
--NR.sup.dC(.dbd.O)R.sup.c, --C(.dbd.S)NR.sup.eR.sup.f,
--NR.sup.dC(.dbd.S)R.sup.c, --NR.sup.d(C.dbd.O)OR.sup.c,
--O(C.dbd.O)NR.sup.eR.sup.f, --NR.sup.d(C.dbd.S)OR.sup.c,
--O(C.dbd.S)NR.sup.eR.sup.f, --NR.sup.d(C.dbd.O)NR.sup.eR.sup.f,
--NR.sup.d(C.dbd.S)NR.sup.eR.sup.f, --C(.dbd.S)R.sup.c and
--C(.dbd.O)R.sup.c; each R.sup.2 is independently selected from:
--(CH.sub.2).sub.0-2C(.dbd.O)NR.sup.4(CH.sub.2).sub.0-2Z--R.sup.5,
--(CH.sub.2).sub.0-2NR.sup.4C(.dbd.O)(CH.sub.2).sub.0-2Z--R.sup.5
and
--(CH.sub.2).sub.0-2NR.sup.4(C.dbd.O)NR.sup.4(CH.sub.2).sub.0-2Z--R.sup.5-
; R.sup.3 is ##STR00357## or
--O--(C.sub.1-C.sub.6)alkyl-NR.sup.aR.sup.b; or R.sup.3 taken
together with an instance of R.sup.1 and the phenyl ring to which
they are attached form a fused ring heteroaryl or heterocycloalkyl,
wherein the heteroaryl or heterocycloalkyl are optionally
substituted with 1 to 3 (C.sub.1-C.sub.3) alkyl, provided that
R.sup.3 is meta or para to the indazole ring; W is --O--,
--NR.sup.7--, --S(O).sub.i-- or --CR.sub.8R.sub.9--; X is --O--,
--CR.sup.8R.sup.9--, --NR.sup.11-- or --S(O).sub.i--; Y is
--O--(CH.sub.2).sub.r--, --NR.sup.12--(CH.sub.2).sub.r--,
--CH.sub.2-- or --S(O).sub.i--(CH.sub.2).sub.r--; R.sup.4 is --H or
an alkyl group optionally substituted with 1 to 3 substituents
independently selected from halogen, hydroxy and
(C.sub.1-C.sub.3)alkoxy; R.sup.5 is alkyl, cycloalkyl,
heterocycloalkyl, aryl or heteroaryl, each of which is optionally
substituted with 1 to 3 groups individually represented by R.sup.15
or R.sup.16; Z is a bond or --CR.sup.13R.sup.14--; R.sup.6 is
halogen, hydroxyl, (C.sub.1-C.sub.3)alkyl, (C.sub.1-C.sub.3)alkoxy,
(C.sub.1-C.sub.3)alkyl-OR.sup.c or --NR.sub.aR.sub.b; or two
instances of R.sup.6 on the same carbon are taken together form
.dbd.O; or two instances of R.sup.6 on different carbons, together
with the ring to which they are attached, form a bridged bicyclic
group; R.sup.7 is --H, (C.sub.1-C.sub.6)alkyl, cycloalkyl,
cycloalkyl(C.sub.1-C.sub.6)alkyl, heterocycloalkyl,
heterocycloalkyl(C.sub.1-C.sub.6)alkyl, --C(.dbd.O)R.sup.c or
--C(.dbd.O)OR.sup.c, wherein each of the (C.sub.1-C.sub.6)alkyl,
cycloalkyl, cycloalkyl(C.sub.1-C.sub.6)alkyl, heterocycloalkyl and
heterocycloalkyl(C.sub.1-C.sub.6)alkyl groups is optionally
substituted with 1 to 3 substituents independently selected from
halogen, hydroxy, (C.sub.1-C.sub.3)alkoxy and
--C(.dbd.O)NR.sup.eR.sup.f; R.sup.8 and R.sup.9 are each
independently selected from --H, --OR.sup.c, and
(C.sub.1-C.sub.6)alkyl, wherein the (C.sub.1-C.sub.6)alkyl group is
optionally substituted with 1 to 3 substituents independently
selected from halogen, hydroxy and (C.sub.1-C.sub.3)alkoxy;
R.sup.10 is --H or (C.sub.1-C.sub.3)alkyl, or is absent when the
nitrogen to which it is attached is attached directly to the
##STR00358## moiety; R.sup.11 is --H, (C.sub.1-C.sub.6)alkyl,
cycloalkyl, cycloalkyl(C.sub.1-C.sub.6)alkyl, heterocycloalkyl,
heterocycloalkyl(C.sub.1-C.sub.6)alkyl, --C(.dbd.O)R.sup.c or
--C(.dbd.O)OR.sup.c, wherein each of the (C.sub.1-C.sub.6)alkyl,
cycloalkyl, cycloalkyl(C.sub.1-C.sub.6)alkyl, heterocycloalkyl and
heterocycloalkyl(C.sub.1-C.sub.6)alkyl groups is optionally
substituted with 1 to 3 substituents independently selected from
halogen, hydroxy, (C.sub.1-C.sub.3)alkoxy and
--C(.dbd.O)NR.sup.eR.sup.f; R.sup.12 is --H or
(C.sub.1-C.sub.3)alkyl; R.sup.13 and R.sup.14 are each
independently selected from --H, alkyl, --OR.sup.c,
--NR.sup.aR.sup.b, --(C.sub.1-C.sub.3)alkylene-NR.sup.aR.sup.b,
--(C.sub.1-C.sub.3)alkylene-OR.sup.c,
--(C.sub.1-C.sub.3)alkylene-OH, cycloalkyl, --O-cycloalkyl and
heterocycloalkyl, wherein each of the cycloalkyl or
heterocycloalkyl groups is optionally substituted with 1 to 3
substituents independently selected from (C.sub.1-C.sub.3)alkyl and
(C.sub.1-C.sub.3)alkoxy, provided that R.sup.13 and R.sup.14 are
not both selected from --OR.sup.c and --NR.sup.aR.sup.b; each
R.sup.15 and R.sup.16 are independently selected from halogen,
--CN, --NO.sub.2, .dbd.O, --OR.sup.c, --NR.sup.aR.sup.b,
--S(O).sub.iR.sup.c, --NR.sup.dS(O).sub.iR.sup.c,
--S(O).sub.iNR.sup.eR.sup.f, C(.dbd.O)OR.sup.c,
--OC(.dbd.O)OR.sup.c, --C(.dbd.S)OR.sup.c, --O(C.dbd.S)R.sup.c,
--C(.dbd.O)NR.sup.eR.sup.f, --NR.sup.dC(.dbd.O)R.sup.c,
--C(.dbd.S)NR.sup.eR.sup.f, --NR.sup.dC(.dbd.S)R.sup.c,
--NR.sup.d(C.dbd.O)OR.sup.c, --O(C.dbd.O)NR.sup.eR.sup.f,
--NR.sup.d(C.dbd.S)OR.sup.c, --O(C.dbd.S)NR.sup.eR.sup.f,
--NR.sup.d(C.dbd.O)NR.sup.eR.sup.f,
--NR.sup.d(C.dbd.S)NR.sup.eR.sup.f, --C(.dbd.S)R.sup.c,
--C(.dbd.O)R.sup.c, (C.sub.1-C.sub.6)alkyl, aryl,
aryl(C.sub.1-C.sub.3)alkyl, heterocycloalkyl and heteroaryl;
wherein each (C.sub.1-C.sub.6)alkyl, aryl,
aryl(C.sub.1-C.sub.3)alkyl, heterocycloalkyl and heteroaryl
represented by R.sup.15 is optionally substituted with 1 to 3
substituents independently selected from -halogen, --CN,
--OR.sup.c, (C.sub.1-C.sub.6)alkyl, halo(C.sub.1-C.sub.6)alkyl,
(C.sub.1-C.sub.3)alkoxy, halo(C.sub.1-C.sub.3)alkoxy,
(C.sub.1-C.sub.3)alkoxy(C.sub.1-C.sub.6)alkyl, 3 to 8 membered
heterocycloalkyl and 3 to 8 membered heteroaryl; R.sup.a and
R.sup.b are each independently selected from --H and
(C.sub.1-C.sub.6)alkyl, optionally substituted with 1 to 3
substituents independently selected from halogen, hydroxy,
--NR.sup.gR.sup.h and (C.sub.1-C.sub.3)alkoxy; R.sup.c is --H or
(C.sub.1-C.sub.6)alkyl, optionally substituted with 1 to 3
substituents independently selected from halogen,
--NR.sup.gR.sup.h, hydroxy and (C.sub.1-C.sub.3)alkoxy; R.sup.d is
--H or (C.sub.1-C.sub.6)alkyl, optionally substituted with 1 to 3
substituents independently selected from halogen,
--NR.sup.gR.sup.h, hydroxy and (C.sub.1-C.sub.3)alkoxy; R.sup.e and
R.sup.f are each independently selected from --H and
(C.sub.1-C.sub.6)alkyl optionally substituted with 1 to 3
substituents independently selected from halogen,
--NR.sup.gR.sup.h, hydroxy and (C.sub.1-C.sub.3)alkoxy; or R.sup.e
and R.sup.f, together with the nitrogen to which they are attached,
form a 3-8 membered ring optionally substituted with 1 to 3
substituents independently selected from halogen,
--NR.sup.gR.sup.h, --CN, (C.sub.1-C.sub.6)alkyl,
halo(C.sub.1-C.sub.6)alkyl, (C.sub.1-C.sub.3)alkoxy,
halo(C.sub.1-C.sub.3)alkoxy, and
(C.sub.1-C.sub.3)alkoxy(C.sub.1-C.sub.6)alkyl; R.sup.g and R.sup.h
are each independently selected from --H, (C.sub.1-C.sub.6)alkyl,
halo(C.sub.1-C.sub.6)alkyl, hydroxy(C.sub.1-C.sub.6)alkyl and
(C.sub.1-C.sub.3)alkoxy(C.sub.1-C.sub.6)alkyl; i is 0, 1 or 2; n is
an integer from 1 to 4; m is an integer from 1 to 4; each p is 1, 2
or 3; q is 0, 1 or 2; and r is 0, 1, 2 or 3.
2. The compound of claim 1, wherein: W is --O-- or --NR.sup.7--; X
is --O--, --CR.sup.8R.sup.9-- or --NR.sup.11--; and Y is
--O--(CH.sub.2).sub.r--, --NR.sup.12--(CH.sub.2).sub.r-- or
--CH.sub.2--;
3. The compound of claim 2, wherein R.sup.5 is cycloalkyl,
heterocycloalkyl, aryl or heteroaryl, each of which is optionally
substituted with 1 to 3 groups individually represented by R.sup.15
or R.sup.16.
4. The compound of claim 3, wherein the compound is represented by
structural formula: ##STR00359## or a pharmaceutically acceptable
salt thereof, wherein: the group represented by ##STR00360## is
meta or para to the indazole ring.
5. The compound of claim 4, wherein the compound is represented by
a structural formula selected from: ##STR00361## or a
pharmaceutically acceptable salt thereof.
6-15. (canceled)
16. The compound of claim 5, wherein: Y is --O--(CH.sub.2).sub.r,
or --NR.sup.12--; R.sup.4 is --H or an alkyl group optionally
substituted with a substituent selected from halogen, hydroxy and
(C.sub.1-C.sub.3)alkoxy; R.sup.7 is --H, (C.sub.1-C.sub.6)alkyl,
cycloalkyl, heterocycloalkyl, --C(.dbd.O)R.sup.c or
--C(.dbd.O)OR.sup.c, wherein each of the (C.sub.1-C.sub.6)alkyl,
cycloalkyl, and heterocycloalkyl groups is optionally substituted
with a substituent independently selected from halogen, hydroxy,
(C.sub.1-C.sub.3)alkoxy and --C(.dbd.O)NR.sup.eR.sup.f; R.sup.13
and R.sup.14 are each independently selected from --H, alkyl,
--OR.sup.c, --(C.sub.1-C.sub.3)alkylene-OR.sup.c,
--(C.sub.1-C.sub.3)alkylene-OH, (C.sub.3-C.sub.8)cycloalklyl,
--O--(C.sub.3-C.sub.8)cycloalkyl and 3 to 8 membered
heterocycloalkyl, provided that R.sup.13 and R.sup.14 are not both
--OR.sup.c, wherein each of the cycloalkyl or heterocycloalkyl
groups is optionally substituted with a (C.sub.1-C.sub.3)alkyl; n
is an integer from 1 to 2; m is an integer from 1 to 2; and each p
is 1 or 2.
17. The compound of claim 16, wherein: each R.sup.1 is
independently selected from --H, -halogen, --CN, --NO.sub.2,
--OR.sup.c, --NR.sup.aR.sup.b, --S(O).sub.iR.sup.c,
--C(.dbd.O)OR.sup.c, --OC(.dbd.O)OR.sup.c,
--C(.dbd.O)NR.sup.eR.sup.f, --NR.sup.dC(.dbd.O)R.sup.c,
--C(.dbd.O)R.sup.c or (C.sub.1-C.sub.6)alkyl, wherein the alkyl is
optionally substituted with a substituent selected from -halogen,
--OR.sup.c, --NR.sup.aR.sup.b, and --S(O).sub.iR.sup.c; R.sup.5 is
(a) cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, morpholinyl,
thiomorpholinyl, pyrrolidinonyl, pyrrolidinyl, piperidinyl,
piperazinyl, hydantoinyl, valerolactamyl, oxiranyl, oxetanyl,
azetidinyl, dihydroimidazole, dihydrofuranyl, dihydropyranyl,
dihydropyridinyl, dihydropyrimidinyl, dihydrothienyl,
dihydrothiophenyl, dihydrothiopyranyl, tetrahydroimidazole,
tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothienyl,
tetrahydropyridinyl, tetrahydropyrimidinyl, tetrahydrothiophenyl,
tetrahydrothiopyranyl, phenyl, furanyl, imidazolyl, oxazolyl,
isoxazolyl, oxadiazolyl, pyrazolyl, pyrrolyl, pyridyl, pyrimidinyl,
pyridazinyl, thiazolyl, isothiazolyl, triazolyl, tetrazolyl or
thienyl, each of which is optionally substituted with 1 to 3 groups
represented by R.sup.15 or (b) bicyclooctanyl, decahydronaphthyl,
octahydroindenyl, dihydronaphthalenyl, tetrahydronaphthalenyl,
dihydroindolyl, dihydroisoindolyl, dihydrobenzimidazolyl,
dihydrobenzothienyl, dihydrobenzofuranyl, dihydroisobenzofuranyl,
dihydrobenzotriazolyl, dihydrobenzothiazolyl, dihydrobenzoxazolyl,
dihydrobenzisoxazolyl, dihydroquinolinyl, tetrahydroquinolinyl,
dihydroisoquinolinyl, tetrahydroisoquinolinyl, dihydroindazolyl,
dihydroacridinyl, tetrahydroacridinyl, chromanyl, isochromanyl,
chromenyl, isochromenyl, naphthyl, anthracenyl, fluorenyl, indanyl,
indenyl, carbazolyl, benzimidazolyl, benzothienyl, benzofuranyl,
isobenzofuranyl, indolyl, isoindolyl, benzotriazolyl,
benzothiazolyl, benzoxazolyl, benzisoxazolyl, quinolinyl,
isoquinolinyl, indazolyl or acridinyl, each of which is optionally
substituted with 1 to 3 groups represented by R.sup.16; R.sup.6 is
absent, halogen or (C.sub.1-C.sub.4)alkyl; or two instances of
R.sup.6 on different carbons, together with the ring to which they
are attached, form an azabicyclooctanyl, a diazabicyclooctanyl, an
oxabicyclooctanyl, a dioxabicyclooctanyl, an oxa-azabicyclooctanyl,
an azabicyclononanyl, a diazabicyclononanyl, an oxabicyclononanyl,
a dioxabicyclononanyl, or an oxa-azabicyclononanyl; R.sup.7 is --H,
(C.sub.1-C.sub.4)alkyl, halo(C.sub.1-C.sub.4)alkyl,
hydroxy(C.sub.1-C.sub.4)alkyl, methoxy(C.sub.1-C.sub.4)alkyl,
--(C.sub.1-C.sub.4)alkyl-C(.dbd.O)NMe.sub.2,
--C(.dbd.O)--(C.sub.1-C.sub.4)alkyl-NMe.sub.2, morpholinyl,
thiomorpholinyl, pyrrolidinonyl, pyrrolidinyl, piperidinyl,
piperazinyl, hydantoinyl, valerolactamyl, oxiranyl, oxetanyl,
azetidinyl, dihydroimidazole, dihydrofuranyl, dihydropyranyl,
dihydropyridinyl, dihydropyrimidinyl, dihydrothienyl,
dihydrothiophenyl, dihydrothiopyranyl, tetrahydroimidazole,
tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothienyl,
tetrahydropyridinyl, tetrahydropyrimidinyl, tetrahydrothiophenyl,
tetrahydrothiopyranyl, --C(.dbd.O)R.sup.c or --C(.dbd.O)OR.sup.c,
and wherein each R.sup.c is independently selected from --H,
(C.sub.1-C.sub.4)alkyl, amino(C.sub.1-C.sub.4)alkyl or
dimethylamino(C.sub.1-C.sub.4)alkyl; R.sup.13 is H and R.sup.14 is
--H, (C.sub.1-C.sub.6)alkyl, --OR.sup.c,
--(C.sub.1-C.sub.3)alkylene-OR.sup.c,
--(C.sub.1-C.sub.3)alkylene-OH, a cycloalkyl selected from
cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, a
--O-cycloalkyl selected from --O-cyclopropyl, --O-cyclobutyl, and
--O-cyclopentyl, --O-cyclohexyl, or a heterocycloalkyl selected
from morpholinyl, thiomorpholinyl, pyrrolidinonyl, pyrrolidinyl,
piperidinyl, piperazinyl, hydantoinyl, valerolactamyl, oxiranyl,
oxetanyl, azetidinyl, dihydroimidazole, dihydrofuranyl,
dihydropyranyl, dihydropyridinyl, dihydropyrimidinyl,
dihydrothienyl, dihydrothiophenyl, dihydrothiopyranyl,
tetrahydroimidazole, tetrahydrofuranyl, tetrahydropyranyl,
tetrahydrothienyl, tetrahydropyridinyl, tetrahydropyrimidinyl,
tetrahydrothiophenyl and tetrahydrothiopyranyl, provided that
R.sup.13 and R.sup.14 are not both --OR.sup.c, wherein each of the
--O-cycloalkyl, cycloalkyl or heterocycloalkyl groups is optionally
substituted with a (C.sub.1-C.sub.3)alkyl; and R.sup.c is --H, or
(C.sub.1-C.sub.6)alkyl; each R.sup.15 is independently selected
from halogen, --CN, --NO.sub.2, .dbd.O, --OR.sup.c,
--NR.sup.aR.sup.b, --C(.dbd.O)OR.sup.c, --OC(.dbd.O)OR.sup.c,
--C(.dbd.O)NR.sup.eR.sup.f, --NR.sup.dC(.dbd.O)R.sup.c,
--NR.sup.d(C.dbd.O)OR.sup.c, --O(C.dbd.O)NR.sup.eR.sup.f,
--NR.sup.d(C.dbd.O)NR.sup.eR.sup.f, --C(.dbd.O)R.sup.c,
(C.sub.1-C.sub.6)alkyl, morpholinyl, thiomorpholinyl,
pyrrolidinonyl, pyrrolidinyl, piperidinyl, piperazinyl,
hydantoinyl, valerolactamyl, oxiranyl, oxetanyl, azetidinyl,
dihydroimidazole, dihydrofuranyl, dihydropyranyl, dihydropyridinyl,
dihydropyrimidinyl, dihydrothienyl, dihydrothiophenyl,
dihydrothiopyranyl, tetrahydroimidazole, tetrahydrofuranyl,
tetrahydropyranyl, tetrahydrothienyl, tetrahydropyridinyl,
tetrahydropyrimidinyl, tetrahydrothiophenyl, tetrahydrothiopyranyl,
phenyl, benzyl, furanyl, imidazolyl, oxazolyl, isoxazolyl,
oxadiazolyl, pyrazolyl, pyrrolyl, pyridyl, pyrimidinyl,
pyridazinyl, thiazolyl, isothiazolyl, triazolyl, tetrazolyl, and
thienyl; wherein the (C.sub.1-C.sub.6)alkyl represented by R.sup.15
is optionally substituted with a substituent selected from
-halogen, --OR.sup.c, (C.sub.1-C.sub.6)alkyl,
(C.sub.1-C.sub.3)alkoxy, morpholinyl, thiomorpholinyl,
pyrrolidinonyl, pyrrolidinyl, piperidinyl, piperazinyl,
hydantoinyl, valerolactamyl, oxiranyl, oxetanyl, azetidinyl,
dihydroimidazole, dihydrofuranyl, dihydropyranyl, dihydropyridinyl,
dihydropyrimidinyl, dihydrothienyl, dihydrothiophenyl,
dihydrothiopyranyl, tetrahydroimidazole, tetrahydrofuranyl,
tetrahydropyranyl, tetrahydrothienyl, tetrahydropyridinyl,
tetrahydropyrimidinyl, tetrahydrothiophenyl, tetrahydrothiopyranyl,
furanyl, imidazolyl, oxazolyl, isoxazolyl, oxadiazolyl, pyrazolyl,
pyrrolyl, pyridyl, pyrimidinyl, pyridazinyl, thiazolyl,
isothiazolyl, triazolyl, tetrazolyl, and thienyl; and each R.sup.16
is independently selected from halogen, --OR.sup.c,
--NR.sup.aR.sup.b, --C(.dbd.O)OR.sup.c, --C(.dbd.O)NR.sup.eR.sup.f,
--NR.sup.dC(.dbd.O)R.sup.c, --C(.dbd.O)R.sup.c,
(C.sub.1-C.sub.6)alkyl, phenyl, phenyl(C.sub.1-C.sub.3)alkyl,
morpholinyl, thiomorpholinyl, pyrrolidinonyl, pyrrolidinyl,
piperidinyl, piperazinyl, hydantoinyl, valerolactamyl, oxiranyl,
oxetanyl, azetidinyl, dihydroimidazole, dihydrofuranyl,
dihydropyranyl, dihydropyridinyl, dihydropyrimidinyl,
dihydrothienyl, dihydrothiophenyl, dihydrothiopyranyl,
tetrahydroimidazole, tetrahydrofuranyl, tetrahydropyranyl,
tetrahydrothienyl, tetrahydropyridinyl, tetrahydropyrimidinyl,
tetrahydrothiophenyl, tetrahydrothiopyranyl, furanyl, imidazolyl,
oxazolyl, isoxazolyl, oxadiazolyl, pyrazolyl, pyrrolyl, pyridyl,
pyrimidinyl, pyridazinyl, thiazolyl, isothiazolyl, triazolyl,
tetrazolyl, and thienyl.
18. The compound of claim 17, wherein: R.sup.1 is selected from
--H, -halogen, --OCH.sub.3, --N(CH.sub.3).sub.2,
--S(O).sub.2CH.sub.3, or methyl; R.sup.5 is (a) cyclopentyl,
cyclohexyl, morpholinyl, pyrrolidinyl, piperidinyl,
dihydropyridinyl, tetrahydropyridinyl, dihydropyrimidinyl,
tetrahydropyrimidinyl, phenyl, furanyl, imidazolyl, pyrrolyl,
pyridyl, pyrimidinyl or thienyl, each of which is optionally
substituted with 1 to 3 groups represented by R.sup.15 or (b)
chromanyl, chromenyl, dihydroindolyl, dihydroisoindolyl,
dihydrobenzothienyl, dihydrobenzofuranyl, dihydroisobenzofuranyl,
dihydrobenzotriazolyl, dihydroquinolinyl, tetrahydroquinolinyl,
dihydroisoquinolinyl, tetrahydroisoquinolinyl,
dihydrobenzisoxazolyl, naphthyl, anthracenyl, fluorenyl, indanyl,
indenyl, dihydronaphthalene, tetrahydronaphthalene, carbazolyl,
benzimidazolyl, benzothienyl, benzofuranyl, isobenzofuranyl,
indolyl, quinolinyl, isoquinolinyl or isoindolyl, each of which is
optionally substituted with 1 to 3 groups represented by R.sup.16;
R.sup.6 is absent, halogen or (C.sub.1-C.sub.4)alkyl; or two
instances of R.sup.6 on different carbons, together with the ring
to which they are attached, form an azabicyclooctanyl, a
diazabicyclooctanyl, an oxa-azabicyclooctanyl, an
azabicyclononanyl, a diazabicyclononanyl, or an
oxa-azabicyclononanyl; R.sup.7 is --H, methyl, ethyl, propyl,
isopropyl, methoxyethyl, hydroxyethyl, fluoroethyl, --C(.dbd.O)H,
--C(.dbd.O)CH.sub.2N(CH.sub.3).sub.2,
--CH.sub.2--C(.dbd.O)N(CH.sub.3).sub.2, oxetanyl,
tetrahydrofuranyl, --CH.sub.2C(.dbd.O)N(CH.sub.3).sub.2,
--C(.dbd.O)O(C.sub.1-C.sub.4)alkyl; R.sup.13 is --H and R.sup.14 is
--H, (C.sub.1-C.sub.6)alkyl, --OR.sup.c,
--(C.sub.1-C.sub.3)alkylene-OR.sup.c,
--(C.sub.1-C.sub.3)alkylene-OH, cyclopropyl, cyclobutyl,
cyclopentyl, cyclohexyl, --O-cyclopropyl, --O-cyclobutyl,
--O-cyclopentyl, --O-cyclohexyl, morpholinyl, thiomorpholinyl,
pyrrolidinonyl, pyrrolidinyl, piperidinyl, piperazinyl,
hydantoinyl, valerolactamyl, oxiranyl, oxetanyl, azetidinyl,
dihydroimidazole, dihydrofuranyl, dihydropyranyl, dihydropyridinyl,
dihydropyrimidinyl, dihydrothienyl, dihydrothiophenyl,
dihydrothiopyranyl, tetrahydroimidazole, tetrahydrofuranyl,
tetrahydropyranyl, tetrahydrothienyl, tetrahydropyridinyl,
tetrahydropyrimidinyl, tetrahydrothiophenyl or
tetrahydrothiopyranyl; and R.sup.c is --H, or
(C.sub.1-C.sub.6)alkyl; each R.sup.15 is independently selected
from halogen, --OR.sup.c, --NR.sup.aR.sup.b,
(C.sub.1-C.sub.6)alkyl, morpholinyl, thiomorpholinyl,
pyrrolidinonyl, pyrrolidinyl, piperidinyl, piperazinyl,
hydantoinyl, valerolactamyl, oxiranyl, oxetanyl, azetidinyl,
dihydroimidazole, dihydrofuranyl, dihydropyranyl, dihydropyridinyl,
dihydropyrimidinyl, dihydrothienyl, dihydrothiophenyl,
dihydrothiopyranyl, tetrahydroimidazole, tetrahydrofuranyl,
tetrahydropyranyl, tetrahydrothienyl, tetrahydropyridinyl,
tetrahydropyrimidinyl, tetrahydrothiophenyl, tetrahydrothiopyranyl,
furanyl, imidazolyl, isoxazolyl, oxadiazolyl, oxazolyl, pyrazolyl,
pyrrolyl, pyridyl, pyrimidinyl, pyridazinyl, thiazolyl,
isothiazolyl, triazolyl, tetrazolyl and thienyl; wherein the
(C.sub.1-C.sub.6)alkyl represented by R.sup.15 is optionally
substituted with a substituent selected from -halogen, --OR.sup.c,
(C.sub.1-C.sub.3)alkoxy, morpholinyl, thiomorpholinyl,
pyrrolidinonyl, pyrrolidinyl, piperidinyl, piperazinyl,
hydantoinyl, valerolactamyl, oxiranyl, oxetanyl, azetidinyl,
dihydroimidazole, dihydrofuranyl, dihydropyranyl, dihydropyridinyl,
dihydropyrimidinyl, dihydrothienyl, dihydrothiophenyl,
dihydrothiopyranyl, tetrahydroimidazole, tetrahydrofuranyl,
tetrahydropyranyl, tetrahydrothienyl, tetrahydropyridinyl,
tetrahydropyrimidinyl, tetrahydrothiophenyl, tetrahydrothiopyranyl,
furanyl, imidazolyl, isoxazolyl, oxadiazolyl, oxazolyl, pyrazolyl,
pyrrolyl, pyridyl, pyrimidinyl, pyridazinyl, thiazolyl,
isothiazolyl, triazolyl, tetrazolyl and thienyl; each R.sup.16 is
independently selected from halogen, --OR.sup.c, --NR.sup.aR.sup.b,
and (C.sub.1-C.sub.6)alkyl; and m is 1.
19. (canceled)
20. The compound of claim 18, wherein two instances of R.sup.6 on
different carbons, together with the ring to which they are
attached, form an 8-azabicyclo[3.2.1]octanyl, a
9-azabicyclo[3.3.1]nonanyl, a 3-oxa-9-azabicyclo[3.3.1]nonanyl or a
3,9-diazabicyclo[3.3.1]nonanyl
21. The compound of claim 1, wherein the compound is represented by
structural formula ##STR00362## or a pharmaceutically acceptable
salt thereof; wherein: the group represented by ##STR00363## is
meta or para to the indazole ring.
22. The compound of claim 21, wherein the compound is represented
by a structural formula selected from: ##STR00364## or a
pharmaceutically acceptable salt thereof.
23. The compound of claim 22, wherein the compound is represented
by a structural formula selected from: ##STR00365## or a
pharmaceutically acceptable salt thereof.
24. The compound of claim 23, wherein the compound is represented
by a structural formula selected from: ##STR00366## or a
pharmaceutically acceptable salt thereof.
25. The compound of claim 24, wherein the compound is represented
by a structural formula selected from: ##STR00367## or a
pharmaceutically acceptable salt thereof.
26. The compound of claim 25, wherein the compound is represented
by a structural formula selected from: ##STR00368## or a
pharmaceutically acceptable salt thereof.
27-28. (canceled)
29. The compound of claim 26, wherein: X is --O--,
--CR.sup.8R.sup.9-- or --NR.sup.11--; R.sup.4 is --H or an alkyl
group optionally substituted with a substituent selected from
halogen, hydroxy and (C.sub.1-C.sub.3)alkoxy; R.sup.8 and R.sup.9
are each independently selected from --H, --OR.sup.c, and
(C.sub.1-C.sub.6)alkyl, wherein the (C.sub.1-C.sub.6)alkyl group is
optionally substituted with a substituent selected from halogen,
hydroxy and (C.sub.1-C.sub.3)alkoxy; R.sup.1 is --H,
(C.sub.1-C.sub.6)alkyl, wherein the (C.sub.1-C.sub.6)alkyl is
optionally substituted with a substituent selected from halogen,
hydroxy, (C.sub.1-C.sub.3)alkoxy and --C(.dbd.O)NR.sup.eR.sup.f;
R.sup.13 and R.sup.14 are each independently selected from --H,
alkyl, --OR.sup.c, --(C.sub.1-C.sub.3)alkylene-OR.sup.c,
--(C.sub.1-C.sub.3)alkylene-OH, (C.sub.3-C.sub.8)cycloalklyl,
--O--(C.sub.3-C.sub.8)cycloalkyl and 3 to 8 membered
heterocycloalkyl, provided that R.sup.13 and R.sup.14 are not both
--OR.sup.c, wherein each of the cycloalkyl or heterocycloalkyl
groups is optionally substituted with a (C.sub.1-C.sub.3)alkyl; n
is an integer from 1 to 2; m is an integer from 1 to 2; and each p
is 1 or 2.
30. The compound of claim 29, wherein: each R.sup.1 is
independently selected from --H, -halogen, --CN, --NO.sub.2,
--OR.sup.c, --NR.sup.aR.sup.b, --S(O).sub.iR.sup.c,
--C(.dbd.O)OR.sup.c, --OC(.dbd.O)OR.sup.c,
--C(.dbd.O)NR.sup.eR.sup.f, --NR.sup.dC(.dbd.O)R.sup.c,
--C(.dbd.O)R.sup.c or alkyl, wherein the alkyl is optionally
substituted with a substituent selected from -halogen, --OR.sup.c,
--NR.sup.aR.sup.b, and --S(O).sub.iR.sup.c; R.sup.5 is (a)
cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, morpholinyl,
thiomorpholinyl, pyrrolidinonyl, pyrrolidinyl, piperidinyl,
piperazinyl, hydantoinyl, valerolactamyl, oxiranyl, oxetanyl,
azetidinyl, dihydroimidazole, dihydrofuranyl, dihydropyranyl,
dihydropyridinyl, dihydropyrimidinyl, dihydrothienyl,
dihydrothiophenyl, dihydrothiopyranyl, tetrahydroimidazole,
tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothienyl,
tetrahydropyridinyl, tetrahydropyrimidinyl, tetrahydrothiophenyl,
tetrahydrothiopyranyl, phenyl, furanyl, imidazolyl, oxazolyl,
isoxazolyl, oxadiazolyl, pyrazolyl, pyrrolyl, pyridyl, pyrimidinyl,
pyridazinyl, thiazolyl, isothiazolyl, triazolyl, tetrazolyl or
thienyl, each of which is optionally substituted with 1 to 3 groups
represented by R.sup.15 or (b) bicyclooctanyl, decahydronaphthyl,
octahydroindenyl, dihydronaphthalenyl, tetrahydronaphthalenyl,
dihydroindolyl, dihydroisoindolyl, dihydrobenzimidazolyl,
dihydrobenzothienyl, dihydrobenzofuranyl, dihydroisobenzofuranyl,
dihydrobenzotriazolyl, dihydrobenzothiazolyl, dihydrobenzoxazolyl,
dihydrobenzisoxazolyl, dihydroquinolinyl, tetrahydroquinolinyl,
dihydroisoquinolinyl, tetrahydroisoquinolinyl, dihydroindazolyl,
dihydroacridinyl, tetrahydroacridinyl, chromanyl, isochromanyl,
chromenyl, isochromenyl, naphthyl, anthracenyl, fluorenyl, indanyl,
indenyl, carbazolyl, benzimidazolyl, benzothienyl, benzofuranyl,
isobenzofuranyl, indolyl, isoindolyl, benzotriazolyl,
benzothiazolyl, benzoxazolyl, benzisoxazolyl, quinolinyl,
isoquinolinyl, indazolyl or acridinyl, each of which is optionally
substituted with 1 to 3 groups represented by R.sup.16; R.sup.13 is
H and R.sup.14 is --H, (C.sub.1-C.sub.6)alkyl, --OR.sup.c,
--(C.sub.1-C.sub.3)alkylene-OR.sup.c,
--(C.sub.1-C.sub.3)alkylene-OH, a cycloalkyl selected from
cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, a
--O-cycloalkyl selected from --O-cyclopropyl, --O-cyclobutyl, and
--O-cyclopentyl, --O-cyclohexyl, or a heterocycloalkyl selected
from morpholinyl, thiomorpholinyl, pyrrolidinonyl, pyrrolidinyl,
piperidinyl, piperazinyl, hydantoinyl, valerolactamyl, oxiranyl,
oxetanyl, azetidinyl, dihydroimidazole, dihydrofuranyl,
dihydropyranyl, dihydropyridinyl, dihydropyrimidinyl,
dihydrothienyl, dihydrothiophenyl, dihydrothiopyranyl,
tetrahydroimidazole, tetrahydrofuranyl, tetrahydropyranyl,
tetrahydrothienyl, tetrahydropyridinyl, tetrahydropyrimidinyl,
tetrahydrothiophenyl and tetrahydrothiopyranyl, provided that
R.sup.13 and R.sup.14 are not both --OR.sup.c, wherein each of the
--O-cycloalkyl, cycloalkyl or heterocycloalkyl groups is optionally
substituted with a (C.sub.1-C.sub.3)alkyl; and R.sup.c is --H, or
(C.sub.1-C.sub.6)alkyl; each R.sup.15 is independently selected
from halogen, --CN, --NO.sub.2, .dbd.O, --OR.sup.c,
--NR.sup.aR.sup.b, --C(.dbd.O)OR.sup.c, --OC(.dbd.O)OR.sup.c,
--C(.dbd.O)NR.sup.eR.sup.f, --NR.sup.dC(.dbd.O)R.sup.c,
--NR.sup.d(C.dbd.O)OR.sup.c, --O(C.dbd.O)NR.sup.eR.sup.f,
--NR.sup.d(C.dbd.O)NR.sup.eR.sup.f, --C(.dbd.O)R.sup.c,
(C.sub.1-C.sub.6)alkyl, morpholinyl, thiomorpholinyl,
pyrrolidinonyl, pyrrolidinyl, piperidinyl, piperazinyl,
hydantoinyl, valerolactamyl, oxiranyl, oxetanyl, azetidinyl,
dihydroimidazole, dihydrofuranyl, dihydropyranyl, dihydropyridinyl,
dihydropyrimidinyl, dihydrothienyl, dihydrothiophenyl,
dihydrothiopyranyl, tetrahydroimidazole, tetrahydrofuranyl,
tetrahydropyranyl, tetrahydrothienyl, tetrahydropyridinyl,
tetrahydropyrimidinyl, tetrahydrothiophenyl, tetrahydrothiopyranyl,
phenyl, benzyl, furanyl, imidazolyl, oxazolyl, isoxazolyl,
oxadiazolyl, pyrazolyl, pyrrolyl, pyridyl, pyrimidinyl,
pyridazinyl, thiazolyl, isothiazolyl, triazolyl, tetrazolyl, and
thienyl; wherein the (C.sub.1-C.sub.6)alkyl represented by R.sup.15
is optionally substituted with a substituent selected from
-halogen, --OR.sup.c, (C.sub.1-C.sub.6)alkyl,
(C.sub.1-C.sub.3)alkoxy, morpholinyl, thiomorpholinyl,
pyrrolidinonyl, pyrrolidinyl, piperidinyl, piperazinyl,
hydantoinyl, valerolactamyl, oxiranyl, oxetanyl, azetidinyl,
dihydroimidazole, dihydrofuranyl, dihydropyranyl, dihydropyridinyl,
dihydropyrimidinyl, dihydrothienyl, dihydrothiophenyl,
dihydrothiopyranyl, tetrahydroimidazole, tetrahydrofuranyl,
tetrahydropyranyl, tetrahydrothienyl, tetrahydropyridinyl,
tetrahydropyrimidinyl, tetrahydrothiophenyl, tetrahydrothiopyranyl,
furanyl, imidazolyl, oxazolyl, isoxazolyl, oxadiazolyl, pyrazolyl,
pyrrolyl, pyridyl, pyrimidinyl, pyridazinyl, thiazolyl,
isothiazolyl, triazolyl, tetrazolyl, and thienyl; and each R.sup.16
is independently selected from halogen, --OR.sup.c,
--NR.sup.aR.sup.b, --C(.dbd.O)OR.sup.c, --C(.dbd.O)NR.sup.eR.sup.f,
--NR.sup.dC(.dbd.O)R.sup.c, --C(.dbd.O)R.sup.c,
(C.sub.1-C.sub.6)alkyl, phenyl, phenyl(C.sub.1-C.sub.3)alkyl,
morpholinyl, thiomorpholinyl, pyrrolidinonyl, pyrrolidinyl,
piperidinyl, piperazinyl, hydantoinyl, valerolactamyl, oxiranyl,
oxetanyl, azetidinyl, dihydroimidazole, dihydrofuranyl,
dihydropyranyl, dihydropyridinyl, dihydropyrimidinyl,
dihydrothienyl, dihydrothiophenyl, dihydrothiopyranyl,
tetrahydroimidazole, tetrahydrofuranyl, tetrahydropyranyl,
tetrahydrothienyl, tetrahydropyridinyl, tetrahydropyrimidinyl,
tetrahydrothiophenyl, tetrahydrothiopyranyl, furanyl, imidazolyl,
oxazolyl, isoxazolyl, oxadiazolyl, pyrazolyl, pyrrolyl, pyridyl,
pyrimidinyl, pyridazinyl, thiazolyl, isothiazolyl, triazolyl,
tetrazolyl, and thienyl.
31. The compound of claim 30, wherein: R.sup.1 is selected from
--H, -halogen, --OCH.sub.3, --N(CH.sub.3).sub.2,
--S(O).sub.2CH.sub.3, or methyl; R.sup.5 is cyclopentyl,
cyclohexyl, morpholinyl, pyrrolidinyl, piperidinyl,
dihydropyridinyl, tetrahydropyridinyl, dihydropyrimidinyl,
tetrahydropyrimidinyl, phenyl, furanyl, imidazolyl, pyrrolyl,
pyridyl, pyrimidinyl or thienyl, each of which is optionally
substituted with 1 to 3 groups represented by R.sup.15 or (b)
chromanyl, chromenyl, dihydroindolyl, dihydroisoindolyl,
dihydrobenzothienyl, dihydrobenzofuranyl, dihydroisobenzofuranyl,
dihydrobenzotriazolyl, dihydroquinolinyl, tetrahydroquinolinyl,
dihydroisoquinolinyl, tetrahydroisoquinolinyl,
dihydrobenzisoxazolyl, naphthyl, anthracenyl, fluorenyl, indanyl,
indenyl, dihydronaphthalene, tetrahydronaphthalene, carbazolyl,
benzimidazolyl, benzothienyl, benzofuranyl, isobenzofuranyl,
indolyl, quinolinyl, isoquinolinyl or isoindolyl, each of which is
optionally substituted with 1 to 3 groups represented by R.sup.16;
R.sup.13 is --H and R.sup.14 is --H, (C.sub.1-C.sub.6)alkyl,
cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, --O-cyclopropyl,
--O-cyclobutyl, --O-cyclopentyl, --O-cyclohexyl, morpholinyl,
thiomorpholinyl, pyrrolidinonyl, pyrrolidinyl, piperidinyl,
piperazinyl, hydantoinyl, valerolactamyl, oxiranyl, oxetanyl,
azetidinyl, dihydroimidazole, dihydrofuranyl, dihydropyranyl,
dihydropyridinyl, dihydropyrimidinyl, dihydrothienyl,
dihydrothiophenyl, dihydrothiopyranyl, tetrahydroimidazole,
tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothienyl,
tetrahydropyridinyl, tetrahydropyrimidinyl, tetrahydrothiophenyl or
tetrahydrothiopyranyl; R.sup.15 is independently selected from
halogen, --OR.sup.c, --NR.sup.aR.sup.b, and (C.sub.1-C.sub.6)alkyl;
each R.sup.16 is independently selected from
(C.sub.1-C.sub.6)alkyl; and m is 1.
32. (canceled)
33. The compound of claim 26, wherein X is --NR.sup.11-- and
wherein R.sup.11 is (C.sub.1-C.sub.4)alkyl.
34. The compound of claim 33, wherein R.sup.5 is cyclohexyl,
phenyl, pyridyl, or thienyl, each of which is optionally
substituted with 1 to 3 groups selected from methyl, ethyl, propyl,
halogen, hydroxymethyl, hydroxyethyl, methoxy, ethoxy, and
--(CH.sub.2).sub.0-2-morpholinyl.
35. The compound of claim 34, wherein R.sup.5 is cyclohexyl,
phenyl, pyridyl, or thienyl, each of which is optionally
substituted with 1 to 3 groups selected from methyl, ethyl, propyl
and halogen.
36. The compound of claim 35, wherein R.sup.14 is --H, methyl,
ethyl, propyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, methoxy,
ethoxy, propoxy, methoxymethyl, methoxyethyl, methoxypropyl,
cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, --O-cyclopropyl,
--O-cyclobutyl, --O-cyclopentyl, --O-cyclohexyl, morpholinyl,
oxetanyl, tetrahydrofuryl, tetrahydropyranyl, azetidinyl,
pyrrolidinyl, piperidyl, wherein the morpholinyl, tetrahydrofuryl,
tetrahydropyranyl, pyrrolidinyl or piperidyl are optionally
substituted with methyl.
37. The compound of claim 36, wherein R.sup.3 is piperidyloxy,
N-methylpiperidyloxy, morpholinyl or hydroxypiperidyl.
38. A pharmaceutical composition comprising a compound of claim 1
and a pharmaceutically acceptable carrier or diluent.
39. A method for treating cancer, the method comprising:
administering to a subject in need thereof an effective amount of a
compound of claim 1, such that the cancer is treated.
Description
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit of and priority to U.S.
Provisional Application No. 61/546,533, filed Oct. 12, 2011. The
entire contents of this application are incorporated herein by
reference.
BACKGROUND OF THE INVENTION
[0002] Protein kinases have been the subject of extensive study in
the search for new therapeutic agents in various diseases, for
example, cancer. Protein kinases are known to mediate intracellular
signal transduction by effecting a phosphoryl transfer from a
nucleoside triphosphate to a protein acceptor that is involved in a
signaling pathway. There are a number of kinases and pathways
through which extracellular and other stimuli cause a variety of
cellular responses to occur inside the cell.
[0003] Human TTK protein kinase (TTK), also known as tyrosine
threonine kinase, dual specificity protein kinase TTK, Monopolar
Spindle 1 (Mps1) and Phosphotyrosine-Picked Threonine Kinase (PYT),
is a conserved multispecific kinase that is capable of
phosphorylating serine, threonine and tyrosine residues when
expressed in E. coli (Mills et al., J. Biol. Chem. 22(5):
16000-16006 (1992)). TTK mRNA is not expressed in the majority of
physiologically normal tissues in human (Id). TTK mRNA is expressed
in some rapidly proliferating tissues, such as testis and thymus,
as well as in some tumors (for example, TTK mRNA was not expressed
in renal cell carcinoma, was expressed in 50% of breast cancer
samples, was expressed in testicular tumors and ovarian cancer
samples) (Id). TTK is expressed in some cancer cell lines and
tumors relative to normal counterparts (Id.; see also WO 02/068444
A1).
[0004] Therefore, agents which inhibit a protein kinase, in
particular TTK, have the potential to treat cancer. There is a need
for additional agents which can act as protein kinase inhibitors,
in particular TTK inhibitors.
[0005] In addition, cancer recurrence, drug resistance or
metastasis is one of the major challenges in cancer therapies.
Cancer patients who responded favorably to the initial anti-cancer
therapy often develop drug resistance and secondary tumors that
lead to the relapse of the disease. Recent research evidences
suggest that the capability of a tumor to grow and propagate is
dependent on a small subset of cells within the tumor. These cells
are termed tumor-initiating cells (TICs) or cancer stem cells. It
is thought that the TICs are responsible for drug resistance,
cancer relapse and metastasis. Compounds that can inhibit the
growth and survival of these tumor-initiating cells can be used to
treat cancer, metastasis or prevent recurrence of cancer.
Therefore, a need exists for new compounds that can inhibit the
growth and survival of tumor-initating cells.
SUMMARY OF THE INVENTION
[0006] Applicants have now discovered that certain indazole
compounds are potent kinase inhibitors, such as TTK protein kinase,
polo-like kinase 4 (PLK4) and Aurora kinases (see Example B-D).
Applicants have also now discovered that these indazole compounds
have potent anticancer activity against breast cancer cells, colon
cancer cells, and ovarian cancer cells in cell culture study (see
Example E). Based on these discoveries, indazole compounds,
pharmaceutical compositions thereof, and methods of treating cancer
with the indazole compounds are disclosed herein.
[0007] The present teachings are directed, at least in part, to an
indazole compound represented by the following structural
formula:
##STR00002##
or a pharmaceutically acceptable salt thereof, wherein:
[0008] each R.sup.1 is independently selected from H, -halogen,
--CN, --NO.sub.2, --NR.sup.aR.sup.b, --S(O).sub.iR.sup.c,
--NR.sup.dS(O).sub.iR.sup.c, --S(O).sub.iNR.sup.eR.sup.f,
--C(.dbd.O)OR.sup.c, --OC(.dbd.O)OR.sup.c, --C(.dbd.S)OR.sup.c,
--O(C.dbd.S)R.sup.c, --C(.dbd.O)NR.sup.eR.sup.f,
--NR.sup.dC(.dbd.O)R.sup.c, --C(.dbd.S)NR.sup.eR.sup.f,
--NR.sup.dC(.dbd.S)R.sup.c, --NR.sup.d(C.dbd.O)OR.sup.c,
--O(C.dbd.O)NR.sup.eR.sup.f, --NR.sup.d(C.dbd.S)OR.sup.c,
--O(C.dbd.S)NR.sup.eR.sup.f, --NR.sup.d(C.dbd.O)NR.sup.eR.sup.f,
--NR.sup.d(C.dbd.S)NR.sup.eR.sup.f, --C(.dbd.S)R.sup.c,
--C(.dbd.O)R.sup.c, heterocycloalkyl or alkyl, wherein the
heterocycloalkyl or the alkyl is optionally substituted with 1 to 3
substituents independently selected from -halogen, --CN,
--NO.sub.2, --NR.sup.aR.sup.b, --S(O).sub.iR.sup.c,
--NR.sup.dS(O).sub.iR.sup.c, --S(O).sub.iNR.sup.eR.sup.f,
--C(.dbd.O)OR.sup.c, --OC(.dbd.O)OR.sup.c, --C(.dbd.S)OR.sup.c,
--O(C.dbd.S)R.sup.c, --C(.dbd.O)NR.sup.eR.sup.f,
--NR.sup.dC(.dbd.O)R.sup.c, --C(.dbd.S)NR.sup.eR.sup.f,
--NR.sup.dC(.dbd.S)R.sup.c, --NR.sup.d(C.dbd.O)OR.sup.c,
--O(C.dbd.O)NR.sup.eR.sup.f, --NR.sup.d(C.dbd.S)OR.sup.c,
--O(C.dbd.S)NR.sup.eR.sup.f, --NR.sup.d(C.dbd.O)NR.sup.eR.sup.f,
--NR.sup.d(C.dbd.S)NR.sup.eR.sup.f, --C(.dbd.S)R.sup.c and
--C(.dbd.O)R.sup.c;
[0009] each R.sup.2 is independently selected from:
--(CH.sub.2).sub.0-2C(.dbd.O)NR.sup.4(CH.sub.2).sub.0-2Z--R.sup.5,
--(CH.sub.2).sub.0-2NR.sup.4C(.dbd.O)(CH.sub.2).sub.0-2Z--R.sup.5
and
--(CH.sub.2).sub.0-2NR.sup.4(C.dbd.O)NR.sup.4(CH.sub.2Z--R.sup.5;
##STR00003##
[0010] R.sup.3 is or --O--(C.sub.1-C.sub.6)alkyl-NR.sup.aR.sup.b;
or R.sup.3 taken together with an instance of R.sup.1 and the
phenyl ring to which they are attached form a fused ring heteroaryl
or heterocycloalkyl, wherein the heteroaryl or heterocycloalkyl are
optionally substituted with 1 to 3 (C.sub.1-C.sub.3) alkyl,
provided that R.sup.3 is meta or para to the indazole ring;
[0011] W is --O--, --NR.sup.7--, --S(O).sub.i-- or
--CR.sub.8R.sub.9--;
[0012] X is --O--, --CR.sup.8R.sup.9--, --NR.sup.11-- or
--S(O).sub.i--;
[0013] Y is --O--(CH.sub.2).sub.r--,
--NR.sup.12--(CH.sub.2).sub.r--, --CH.sub.2-- or
--S(O).sub.i--(CH.sub.2).sub.r--;
[0014] R.sup.4 is --H or an alkyl group optionally substituted with
1 to 3 substituents independently selected from halogen, hydroxy
and (C.sub.1-C.sub.3)alkoxy;
[0015] R.sup.5 is alkyl, cycloalkyl, heterocycloalkyl, aryl or
heteroaryl, each of which is optionally substituted with 1 to 3
groups individually represented by R.sup.15 or R.sup.16;
[0016] Z is a bond or --CR.sup.13R.sup.14--;
[0017] R.sup.6 is halogen, hydroxyl, (C.sub.1-C.sub.3)alkyl,
(C.sub.1-C.sub.3)alkoxy, (C.sub.1-C.sub.3)alkyl-OR.sup.c or
--NR.sub.aR.sub.b; or two instances of R.sup.6 on the same carbon
are taken together form .dbd.O; or two instances of R.sup.6 on
different carbons, together with the ring to which they are
attached, form a bridged bicyclic group;
[0018] R.sup.7 is --H, (C.sub.1-C.sub.6)alkyl, cycloalkyl,
cycloalkyl(C.sub.1-C.sub.6)alkyl, heterocycloalkyl,
heterocycloalkyl(C.sub.1-C.sub.6)alkyl, --C(.dbd.O)R.sup.c or
--C(.dbd.O)OR.sup.c, wherein each of the (C.sub.1-C.sub.6)alkyl,
cycloalkyl, cycloalkyl(C.sub.1-C.sub.6)alkyl, heterocycloalkyl and
heterocycloalkyl(C.sub.1-C.sub.6)alkyl groups is optionally
substituted with 1 to 3 substituents independently selected from
halogen, hydroxy, (C.sub.1-C.sub.3)alkoxy and
--C(.dbd.O)NR.sup.eR.sup.f;
[0019] R.sup.8 and R.sup.9 are each independently selected from
--H, --OR.sup.c, and (C.sub.1-C.sub.6)alkyl, wherein the
(C.sub.1-C.sub.6)alkyl group is optionally substituted with 1 to 3
substituents independently selected from halogen, hydroxy and
(C.sub.1-C.sub.3)alkoxy;
[0020] R.sup.10 is --H or (C.sub.1-C.sub.3)alkyl, or is absent when
the nitrogen to which it is attached is attached directly
to the
##STR00004##
moiety;
[0021] R.sup.11 is --H, (C.sub.1-C.sub.6)alkyl, cycloalkyl,
cycloalkyl(C.sub.1-C.sub.6)alkyl, heterocycloalkyl,
heterocycloalkyl(C.sub.1-C.sub.6)alkyl, --C(.dbd.O)R.sup.c or
--C(.dbd.O)OR.sup.c, wherein each of the (C.sub.1-C.sub.6)alkyl,
cycloalkyl, cycloalkyl(C.sub.1-C.sub.6)alkyl, heterocycloalkyl and
heterocycloalkyl(C.sub.1-C.sub.6)alkyl groups is optionally
substituted with 1 to 3 substituents independently selected from
halogen, hydroxy, (C.sub.1-C.sub.3)alkoxy and
--C(.dbd.O)NR.sup.eR.sup.f;
[0022] R.sup.12 is --H or (C.sub.1-C.sub.3)alkyl;
[0023] R.sup.13 and R.sup.14 are each independently selected from
--H, alkyl, --OR.sup.c, --NR.sup.aR.sup.b,
--(C.sub.1-C.sub.3)alkylene-NR.sup.aR.sup.b,
--(C.sub.1-C.sub.3)alkylene-OR.sup.c,
--(C.sub.1-C.sub.3)alkylene-OH, cycloalkyl, --O-cycloalkyl and
heterocycloalkyl, wherein each of the cycloalkyl or
heterocycloalkyl groups is optionally substituted with 1 to 3
substituents independently selected from (C.sub.1-C.sub.3)alkyl and
(C.sub.1-C.sub.3)alkoxy, provided that R.sup.13 and R.sup.14 are
not both selected from --OR.sup.c and --NR.sup.aR.sup.b;
[0024] each R.sup.15 and R.sup.16 are independently selected from
halogen, --CN, --NO.sub.2, .dbd.O, --OR.sup.c, --NR.sup.aR.sup.b,
--S(O).sub.iR.sup.c, --NR.sup.dS(O).sub.iR.sup.c,
--S(O).sub.iNR.sup.eR.sup.f, C(.dbd.O)OR.sup.c,
--OC(.dbd.O)OR.sup.c, --C(.dbd.S)OR.sup.c, --O(C.dbd.S)R.sup.c,
--C(.dbd.O)NR.sup.eR.sup.f, --NR.sup.dC(.dbd.O)R.sup.c,
--C(.dbd.S)NR.sup.eR.sup.f, --NR.sup.dC(.dbd.S)R.sup.c,
--NR.sup.d(C.dbd.O)OR.sup.c, --O(C.dbd.O)NR.sup.eR.sup.f,
--NR.sup.d(C.dbd.S)OR.sup.c, --O(C.dbd.S)NR.sup.eR.sup.f,
--NR.sup.d(C.dbd.O)NR.sup.eR.sup.f,
--NR.sup.d(C.dbd.S)NR.sup.eR.sup.f, --C(.dbd.S)R.sup.e,
--C(.dbd.O)R.sup.c, (C.sub.1-C.sub.6)alkyl, aryl,
aryl(C.sub.1-C.sub.3)alkyl, heterocycloalkyl and heteroaryl;
wherein each (C.sub.1-C.sub.6)alkyl, aryl,
aryl(C.sub.1-C.sub.3)alkyl, heterocycloalkyl and heteroaryl
represented by R.sup.15 is optionally substituted with 1 to 3
substituents independently selected from -halogen, --CN,
--OR.sup.c, (C.sub.1-C.sub.6)alkyl, halo(C.sub.1-C.sub.6)alkyl,
(C.sub.1-C.sub.3)alkoxy, halo(C.sub.1-C.sub.3)alkoxy,
(C.sub.1-C.sub.3)alkoxy(C.sub.1-C.sub.6)alkyl, 3 to 8 membered
heterocycloalkyl and 3 to 8 membered heteroaryl;
[0025] R.sup.a and R.sup.b are each independently selected from --H
and (C.sub.1-C.sub.6)alkyl, optionally substituted with 1 to 3
substituents independently selected from halogen, hydroxy,
--NR.sup.gR.sup.h and (C.sub.1-C.sub.3)alkoxy;
[0026] R.sup.c is --H or (C.sub.1-C.sub.6)alkyl, optionally
substituted with 1 to 3 substituents independently selected from
halogen, --NR.sup.gR.sup.h, hydroxy and
(C.sub.1-C.sub.3)alkoxy;
[0027] R.sup.d is --H or (C.sub.1-C.sub.6)alkyl, optionally
substituted with 1 to 3 substituents independently selected from
halogen, --NR.sup.gR.sup.h, hydroxy and
(C.sub.1-C.sub.3)alkoxy;
[0028] R.sup.e and R.sup.f are each independently selected from --H
and (C.sub.1-C.sub.6)alkyl optionally substituted with 1 to 3
substituents independently selected from halogen,
--NR.sup.gR.sup.h, hydroxy and (C.sub.1-C.sub.3)alkoxy;
[0029] or R.sup.e and R.sup.f, together with the nitrogen to which
they are attached, form a 3-8 membered ring optionally substituted
with 1 to 3 substituents independently selected from halogen,
--NR.sup.gR.sup.h, --CN, (C.sub.1-C.sub.6)alkyl,
halo(C.sub.1-C.sub.6)alkyl, (C.sub.1-C.sub.3)alkoxy,
halo(C.sub.1-C.sub.3)alkoxy, and
(C.sub.1-C.sub.3)alkoxy(C.sub.1-C.sub.6)alkyl;
[0030] R.sup.g and R.sup.h are each independently selected from
--H, (C.sub.1-C.sub.6)alkyl, halo(C.sub.1-C.sub.6)alkyl,
hydroxy(C.sub.1-C.sub.6)alkyl and
(C.sub.1-C.sub.3)alkoxy(C.sub.1-C.sub.6)alkyl;
[0031] i is 0, 1 or 2;
[0032] n is an integer from 1 to 4;
[0033] m is an integer from 1 to 4;
[0034] each p is 1, 2 or 3;
[0035] q is 0, 1 or 2; and [0036] r is 0, 1, 2 or 3.
[0037] In another embodiment, the present teachings include a
pharmaceutical composition comprising a pharmaceutically acceptable
carrier or diluent and a compound represented by Structural Formula
(I) described above or a pharmaceutically acceptable salt
thereof.
[0038] Another embodiment of the present teachings provides a
method of treating a subject having cancer comprising administering
to the subject an effective amount of a compound of Structural
Formula (I) or a pharmaceutically acceptable salt thereof.
[0039] Another embodiment of the present teachings provides a
method of inhibiting TTK activity in a subject in need of
inhibition of TTK activity, comprising administering to the subject
an effective amount of a compound represented by Structural Formula
(I) or a pharmaceutically acceptable salt thereof.
[0040] Another embodiment of the present teachings includes the use
of a compound represented by Structural Formula (I) or a
pharmaceutically acceptable salt thereof in therapy. In some
embodiments, the therapy is for treating a subject with cancer.
Alternatively, the therapy is for inhibiting TTK activity in a
subject in need of inhibition of TTK activity.
[0041] Another embodiment of the present teachings includes the use
of a compound represented by Structural Formula (I) or a
pharmaceutically acceptable salt thereof for the manufacture of a
medicament for treating a subject with cancer.
[0042] Another embodiment of the present teachings includes the use
of a compound represented by Structural Formulas (I) or a
pharamceutically acceptable salt thereof for the manufacture of a
medicament for inhibiting TTK activity in a subject in need of
inhibition of TTK activity.
DETAILED DESCRIPTION OF THE INVENTION
[0043] In one embodiment, the present teachings are directed to a
compound represented by Structural Formula (I) or a
pharmaceutically acceptable salt thereof; and values and
alternative values for the variables in Structural Formula (I) are
provided in the following paragraphs:
[0044] In a first embodiment, W is --O-- or --NR.sup.7--; X is
--O--, --CR.sup.8R.sup.9-- or --NR.sup.11--; and Y is
--O--(CH.sub.2).sub.r--, --NR.sup.12--(CH.sub.2).sub.r-- or
--CH.sub.2--; and values and alternative values for the remainder
of the variables are as described for Structural Formula (I).
[0045] In a second embodiment, R.sup.5 is cycloalkyl,
heterocycloalkyl, aryl or heteroaryl, each of which is optionally
substituted with 1 to 3 groups individually represented by R.sup.15
or R.sup.16; and values and alternative values for the remainder of
the variables are as described for Structural Formula (I) or in the
first embodiment.
[0046] In a third embodiment, the compound is represented by
structural formula:
##STR00005##
or a pharmaceutically acceptable salt thereof, wherein the group
represented by
##STR00006##
is meta or para to the indazole ring; and values and alternative
values for the remainder of the variables are as described for
Structural Formula (I) or in the first or second embodiment.
[0047] In a fourth embodiment, the compound is represented by a
structural formula selected from:
##STR00007##
or a pharmaceutically acceptable salt thereof; and values and
alternative values for the remainder of the variables are as
described for Structural Formula (I) or in the first or second
embodiment.
[0048] In a fifth embodiment, the compound is represented by a
structural formula selected from:
##STR00008##
or a pharmaceutically acceptable salt thereof; and values and
alternative values for the remainder of the variables are as
described for Structural Formula (I) or in the first or second
embodiment.
[0049] In one embodiment, for compounds described in Structural
Formula (I) or in the first, second, third, fourth or fifth
embodiment, Z is a bond. In another embodiment, for compounds
described in Structural Formula (I) or in the first, second, third,
fourth or fifth embodiment, Z is --CR.sup.13R.sup.14--.
[0050] In a sixth embodiment, the compound is represented by a
structural formula selected from:
##STR00009##
or a pharmaceutically acceptable salt thereof; wherein U is
--CH.sub.2--, --CHR.sup.15--, --NH--, --NR.sup.15-- or --O--; k is
1 or 2; and values and alternative values for the remainder of the
variables are as described for Structural Formula (I) or in the
first or second embodiment.
[0051] In a seventh embodiment, the compound is represented by a
structural formula selected from:
##STR00010##
or a pharmaceutically acceptable salt thereof; and values and
alternative values for the remainder of the variables are as
described for Structural Formula (I) or in the first or second
embodiment.
[0052] In an eighth embodiment, the compound is represented by a
structural formula selected from:
##STR00011##
or a pharmaceutically acceptable salt thereof; and values and
alternative values for the remainder of the variables are as
described for Structural Formula (I) or in the first or second
embodiment.
[0053] In a ninth embodiment, the compound is represented by a
structural formula selected from:
##STR00012##
or a pharmaceutically acceptable salt thereof; and values and
alternative values for the remainder of the variables are as
described for Structural Formula (I) or in the first or second
embodiment.
[0054] In a tenth embodiment, the compound is represented by a
structural formula selected from:
##STR00013##
or a pharmaceutically acceptable salt thereof; wherein the two
R.sup.6 groups, together with the
##STR00014##
ring to which they are attached, form a 7 to 9 membered bridged
bicyclic group containing 1 or 2 ring heteroatoms, wherein the
bridged bicyclic group is optionally substituted with --OH,
halogen, --NH.sub.2 or (C.sub.1-C.sub.3)alkyl; and values and
alternative values for the remainder of the variables are as
described for Structural Formula (I) or in the first or second
embodiment.
[0055] In an eleventh embodiment, the compound is represented by a
structural formula selected from:
##STR00015##
or a pharmaceutically acceptable salt thereof; wherein the two
R.sup.6 groups, together with the
##STR00016##
ring to which they are attached, form a 7 to 9 membered bridged
bicyclic group containing 1 or 2 ring heteroatoms, wherein the
bridged bicyclic group is optionally substituted with --OH,
halogen, --NH.sub.2 or (C.sub.1-C.sub.3)alkyl; and values and
alternative values for the remainder of the variables are as
described for Structural Formula (I) or in the first or second
embodiment.
[0056] In a twelfth embodiment, the compound is represented by a
structural formula selected from:
##STR00017##
or a pharmaceutically acceptable salt thereof; wherein the two
R.sup.6 groups, together with the
##STR00018##
ring to which they are attached, form a 7 to 9 membered bridged
bicyclic group containing 1 or 2 ring heteroatoms, wherein the
bridged bicyclic group is optionally substituted with --OH,
halogen, --NH.sub.2 or (C.sub.1-C.sub.3)alkyl; and values and
alternative values for the remainder of the variables are as
described for Structural Formula (I) or in the first or second
embodiment.
[0057] In some embodiments, for compounds described in the tenth,
eleventh or twelfth embodiment, the bridge formed by two R.sup.6
groups is exo to the --Y-indazole moiety or the --O-indazole
moiety; and values and alternative values for the remainder of the
variables are as described in Structural Formula (I) or the first
or second embodiment. In other embodiments, for compounds described
in the tenth, eleventh or twelfth embodiment, the bridge formed by
two R.sup.6 groups is endo to the --Y-indazole moiety or the
--O-indazole moiety; and values and alternative values for the
remainder of the variables are as described for Structural Formula
(I) or in the first or second embodiment.
[0058] In a thirteenth embodiment, for compounds represented by any
one of structural formulas (I), (II) or (II-A1)-(II-I4), the group
represented by Y is --O--(CH.sub.2).sub.r--, or --NR.sup.12--;
[0059] R.sup.4 is --H or an alkyl group optionally substituted with
a substituent selected from halogen, hydroxy and
(C.sub.1-C.sub.3)alkoxy;
[0060] R.sup.7 is --H, (C.sub.1-C.sub.6)alkyl, cycloalkyl,
heterocycloalkyl, --C(.dbd.O)R.sup.c or --C(.dbd.O)OR.sup.c,
wherein each of the (C.sub.1-C.sub.6)alkyl, cycloalkyl, and
heterocycloalkyl groups is optionally substituted with a
substituent independently selected from halogen, hydroxy,
(C.sub.1-C.sub.3)alkoxy and --C(.dbd.O)NR.sup.eR.sup.f;
[0061] R.sup.13 and R.sup.14 are each independently selected from
--H, alkyl, --OR.sup.c, --(C.sub.1-C.sub.3)alkylene-OR.sup.c,
--(C.sub.1-C.sub.3)alkylene-OH, (C.sub.3-C.sub.8)cycloalklyl,
--O--(C.sub.3-C.sub.8)cycloalkyl and 3 to 8 membered
heterocycloalkyl, provided that R.sup.13 and R.sup.14 are not both
--OR.sup.c, wherein each of the cycloalkyl or heterocycloalkyl
groups is optionally substituted with a (C.sub.1-C.sub.3)alkyl;
[0062] n is an integer from 1 to 2;
[0063] m is an integer from 1 to 2;
[0064] each p is 1 or 2; and values and alternative values for the
remainder of the variables are as described for Structural Formula
(I) or in the first or second embodiment.
[0065] In a fourteenth embodiment, for compounds represented by any
one of structural formulas (I), (II) or (II-A1)-(II-I4), each
R.sup.1 is independently selected from --H, -halogen, --CN,
--NO.sub.2, --OR.sup.c, --NR.sup.aR.sup.b, --S(O).sub.iR.sub.c,
--C(.dbd.O)OR.sup.c, --OC(.dbd.O)OR.sup.c,
--C(.dbd.O)NR.sup.eR.sup.f, --NR.sup.dC(.dbd.O)R.sup.c,
--C(.dbd.O)R.sup.c or (C.sub.1-C.sub.6)alkyl, wherein the alkyl is
optionally substituted with a substituent selected from -halogen,
--OR.sup.c, --NR.sup.aR.sup.b, and --S(O).sub.iR.sup.c;
[0066] R.sup.5 is (a) cyclopropyl, cyclobutyl, cyclopentyl,
cyclohexyl, morpholinyl, thiomorpholinyl, pyrrolidinonyl,
pyrrolidinyl, piperidinyl, piperazinyl, hydantoinyl,
valerolactamyl, oxiranyl, oxetanyl, azetidinyl, dihydroimidazole,
dihydrofuranyl, dihydropyranyl, dihydropyridinyl,
dihydropyrimidinyl, dihydrothienyl, dihydrothiophenyl,
dihydrothiopyranyl, tetrahydroimidazole, tetrahydrofuranyl,
tetrahydropyranyl, tetrahydrothienyl, tetrahydropyridinyl,
tetrahydropyrimidinyl, tetrahydrothiophenyl, tetrahydrothiopyranyl,
phenyl, furanyl, imidazolyl, oxazolyl, isoxazolyl, oxadiazolyl,
pyrazolyl, pyrrolyl, pyridyl, pyrimidinyl, pyridazinyl, thiazolyl,
isothiazolyl, triazolyl, tetrazolyl or thienyl, each of which is
optionally substituted with 1 to 3 groups represented by R.sup.15
or (b) bicyclooctanyl, decahydronaphthyl, octahydroindenyl,
dihydronaphthalenyl, tetrahydronaphthalenyl, dihydroindolyl,
dihydroisoindolyl, dihydrobenzimidazolyl, dihydrobenzothienyl,
dihydrobenzofuranyl, dihydroisobenzofuranyl, dihydrobenzotriazolyl,
dihydrobenzothiazolyl, dihydrobenzoxazolyl, dihydrobenzisoxazolyl,
dihydroquinolinyl, tetrahydroquinolinyl, dihydroisoquinolinyl,
tetrahydroisoquinolinyl, dihydroindazolyl, dihydroacridinyl,
tetrahydroacridinyl, chromanyl, isochromanyl, chromenyl,
isochromenyl, naphthyl, anthracenyl, fluorenyl, indanyl, indenyl,
carbazolyl, benzimidazolyl, benzothienyl, benzofuranyl,
isobenzofuranyl, indolyl, isoindolyl, benzotriazolyl,
benzothiazolyl, benzoxazolyl, benzisoxazolyl, quinolinyl,
isoquinolinyl, indazolyl or acridinyl, each of which is optionally
substituted with 1 to 3 groups represented by R.sup.16;
[0067] R.sup.6 is absent, halogen or (C.sub.1-C.sub.4)alkyl; or two
instances of R.sup.6 on different carbons, together with the ring
to which they are attached, form an azabicyclooctanyl, a
diazabicyclooctanyl, an oxabicyclooctanyl, a dioxabicyclooctanyl,
an oxa-azabicyclooctanyl, an azabicyclononanyl, a
diazabicyclononanyl, an oxabicyclononanyl, a dioxabicyclononanyl,
or an oxa-azabicyclononanyl;
[0068] R.sup.7 is --H, (C.sub.1-C.sub.4)alkyl,
halo(C.sub.1-C.sub.4)alkyl, hydroxy(C.sub.1-C.sub.4)alkyl,
methoxy(C.sub.1-C.sub.4)alkyl,
--(C.sub.1-C.sub.4)alkyl-C(.dbd.O)NMe.sub.2,
--C(.dbd.O)--(C.sub.1-C.sub.4)alkyl-NMe.sub.2, morpholinyl,
thiomorpholinyl, pyrrolidinonyl, pyrrolidinyl, piperidinyl,
piperazinyl, hydantoinyl, valerolactamyl, oxiranyl, oxetanyl,
azetidinyl, dihydroimidazole, dihydrofuranyl, dihydropyranyl,
dihydropyridinyl, dihydropyrimidinyl, dihydrothienyl,
dihydrothiophenyl, dihydrothiopyranyl, tetrahydroimidazole,
tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothienyl,
tetrahydropyridinyl, tetrahydropyrimidinyl, tetrahydrothiophenyl,
tetrahydrothiopyranyl, --C(.dbd.O)R.sup.c or --C(.dbd.O)OR.sup.c,
and wherein each R.sup.c is independently selected from --H,
(C.sub.1-C.sub.4)alkyl, amino(C.sub.1-C.sub.4)alkyl or
dimethylamino(C.sub.1-C.sub.4)alkyl;
[0069] R.sup.13 is H and R.sup.14 is --H, (C.sub.1-C.sub.6)alkyl,
--OR.sup.c, --(C.sub.1-C.sub.3)alkylene-OR.sup.c,
--(C.sub.1-C.sub.3)alkylene-OH, a cycloalkyl selected from
cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, a
--O-cycloalkyl selected from --O-cyclopropyl, --O-cyclobutyl, and
--O-cyclopentyl, --O-cyclohexyl, or a heterocycloalkyl selected
from morpholinyl, thiomorpholinyl, pyrrolidinonyl, pyrrolidinyl,
piperidinyl, piperazinyl, hydantoinyl, valerolactamyl, oxiranyl,
oxetanyl, azetidinyl, dihydroimidazole, dihydrofuranyl,
dihydropyranyl, dihydropyridinyl, dihydropyrimidinyl,
dihydrothienyl, dihydrothiophenyl, dihydrothiopyranyl,
tetrahydroimidazole, tetrahydrofuranyl, tetrahydropyranyl,
tetrahydrothienyl, tetrahydropyridinyl, tetrahydropyrimidinyl,
tetrahydrothiophenyl and tetrahydrothiopyranyl, provided that
R.sup.13 and R.sup.14 are not both --OR.sup.c, wherein each of the
--O-cycloalkyl, cycloalkyl or heterocycloalkyl groups is optionally
substituted with a (C.sub.1-C.sub.3)alkyl; and R.sup.c is --H, or
(C.sub.1-C.sub.6)alkyl;
[0070] each R.sup.15 is independently selected from halogen, --CN,
--NO.sub.2, .dbd.O, --OR.sup.c, --NR.sup.aR.sup.b,
--C(.dbd.O)OR.sup.c, --OC(.dbd.O)OR.sup.c,
--C(.dbd.O)NR.sup.eR.sup.f, --NR.sup.dC(.dbd.O)R.sup.c,
--NR.sup.d(C.dbd.O)OR.sup.c, --O(C.dbd.O)NR.sup.eR.sup.f,
--NR.sup.d(C.dbd.O)NR.sup.eR.sup.f, --C(.dbd.O)R.sup.c,
(C.sub.1-C.sub.6)alkyl, morpholinyl, thiomorpholinyl,
pyrrolidinonyl, pyrrolidinyl, piperidinyl, piperazinyl,
hydantoinyl, valerolactamyl, oxiranyl, oxetanyl, azetidinyl,
dihydroimidazole, dihydrofuranyl, dihydropyranyl, dihydropyridinyl,
dihydropyrimidinyl, dihydrothienyl, dihydrothiophenyl,
dihydrothiopyranyl, tetrahydroimidazole, tetrahydrofuranyl,
tetrahydropyranyl, tetrahydrothienyl, tetrahydropyridinyl,
tetrahydropyrimidinyl, tetrahydrothiophenyl, tetrahydrothiopyranyl,
phenyl, benzyl, furanyl, imidazolyl, oxazolyl, isoxazolyl,
oxadiazolyl, pyrazolyl, pyrrolyl, pyridyl, pyrimidinyl,
pyridazinyl, thiazolyl, isothiazolyl, triazolyl, tetrazolyl, and
thienyl; wherein the (C.sub.1-C.sub.6)alkyl represented by R.sup.15
is optionally substituted with a substituent selected from
-halogen, --OR.sup.c, (C.sub.1-C.sub.6)alkyl,
(C.sub.1-C.sub.3)alkoxy, morpholinyl, thiomorpholinyl,
pyrrolidinonyl, pyrrolidinyl, piperidinyl, piperazinyl,
hydantoinyl, valerolactamyl, oxiranyl, oxetanyl, azetidinyl,
dihydroimidazole, dihydrofuranyl, dihydropyranyl, dihydropyridinyl,
dihydropyrimidinyl, dihydrothienyl, dihydrothiophenyl,
dihydrothiopyranyl, tetrahydroimidazole, tetrahydrofuranyl,
tetrahydropyranyl, tetrahydrothienyl, tetrahydropyridinyl,
tetrahydropyrimidinyl, tetrahydrothiophenyl, tetrahydrothiopyranyl,
furanyl, imidazolyl, oxazolyl, isoxazolyl, oxadiazolyl, pyrazolyl,
pyrrolyl, pyridyl, pyrimidinyl, pyridazinyl, thiazolyl,
isothiazolyl, triazolyl, tetrazolyl, and thienyl;
[0071] each R.sup.16 is independently selected from halogen,
--OR.sup.c, --NR.sup.aR.sup.b, --C(.dbd.O)OR.sup.c,
--C(.dbd.O)NR.sup.eR.sup.f, --NR.sup.dC(.dbd.O)R.sup.c,
--C(.dbd.O)R.sup.c, (C.sub.1-C.sub.6)alkyl, phenyl,
phenyl(C.sub.1-C.sub.3)alkyl, morpholinyl, thiomorpholinyl,
pyrrolidinonyl, pyrrolidinyl, piperidinyl, piperazinyl,
hydantoinyl, valerolactamyl, oxiranyl, oxetanyl, azetidinyl,
dihydroimidazole, dihydrofuranyl, dihydropyranyl, dihydropyridinyl,
dihydropyrimidinyl, dihydrothienyl, dihydrothiophenyl,
dihydrothiopyranyl, tetrahydroimidazole, tetrahydrofuranyl,
tetrahydropyranyl, tetrahydrothienyl, tetrahydropyridinyl,
tetrahydropyrimidinyl, tetrahydrothiophenyl, tetrahydrothiopyranyl,
furanyl, imidazolyl, oxazolyl, isoxazolyl, oxadiazolyl, pyrazolyl,
pyrrolyl, pyridyl, pyrimidinyl, pyridazinyl, thiazolyl,
isothiazolyl, triazolyl, tetrazolyl, and thienyl; and values and
alternative values for the remainder of the variables are as
described for Structural Formula (I) or in the first, second or
thirteenth embodiment.
[0072] In a fifteenth embodiment, for compounds represented by any
one of structural formulas (I), (II) or (II-A1)-(II-I4), R.sup.1 is
selected from --H, -halogen, --OCH.sub.3, --N(CH.sub.3).sub.2,
--S(O).sub.2CH.sub.3, or methyl;
[0073] R.sup.5 is (a) cyclopentyl, cyclohexyl, morpholinyl,
pyrrolidinyl, piperidinyl, dihydropyridinyl, tetrahydropyridinyl,
dihydropyrimidinyl, tetrahydropyrimidinyl, phenyl, furanyl,
imidazolyl, pyrrolyl, pyridyl, pyrimidinyl or thienyl, each of
which is optionally substituted with 1 to 3 groups represented by
R.sup.15 or (b) chromanyl, chromenyl, dihydroindolyl,
dihydroisoindolyl, dihydrobenzothienyl, dihydrobenzofuranyl,
dihydroisobenzofuranyl, dihydrobenzotriazolyl, dihydroquinolinyl,
tetrahydroquinolinyl, dihydroisoquinolinyl,
tetrahydroisoquinolinyl, dihydrobenzisoxazolyl, naphthyl,
anthracenyl, fluorenyl, indanyl, indenyl, dihydronaphthalene,
tetrahydronaphthalene, carbazolyl, benzimidazolyl, benzothienyl,
benzofuranyl, isobenzofuranyl, indolyl, quinolinyl, isoquinolinyl
or isoindolyl, each of which is optionally substituted with 1 to 3
groups represented by R.sup.16;
[0074] R.sup.6 is absent, halogen or (C.sub.1-C.sub.4)alkyl; or two
instances of R.sup.6 on different carbons, together with the ring
to which they are attached, form an azabicyclooctanyl, a
diazabicyclooctanyl, an oxa-azabicyclooctanyl, an
azabicyclononanyl, a diazabicyclononanyl, or an
oxa-azabicyclononanyl;
[0075] R.sup.7 is --H, methyl, ethyl, propyl, isopropyl,
methoxyethyl, hydroxyethyl, fluoroethyl, --C(.dbd.O)H,
--C(.dbd.O)CH.sub.2N(CH.sub.3).sub.2,
--CH.sub.2--C(.dbd.O)N(CH.sub.3).sub.2, oxetanyl,
tetrahydrofuranyl, --CH.sub.2C(.dbd.O)N(CH.sub.3).sub.2,
--C(.dbd.O)O(C.sub.1-C.sub.4)alkyl;
[0076] R.sup.13 is --H and R.sup.14 is --H, (C.sub.1-C.sub.6)alkyl,
--OR.sup.c, --(C.sub.1-C.sub.3)alkylene-OR.sup.c,
--(C.sub.1-C.sub.3)alkylene-OH, cyclopropyl, cyclobutyl,
cyclopentyl, cyclohexyl, --O-cyclopropyl, --O-cyclobutyl,
--O-cyclopentyl, --O-cyclohexyl, morpholinyl, thiomorpholinyl,
pyrrolidinonyl, pyrrolidinyl, piperidinyl, piperazinyl,
hydantoinyl, valerolactamyl, oxiranyl, oxetanyl, azetidinyl,
dihydroimidazole, dihydrofuranyl, dihydropyranyl, dihydropyridinyl,
dihydropyrimidinyl, dihydrothienyl, dihydrothiophenyl,
dihydrothiopyranyl, tetrahydroimidazole, tetrahydrofuranyl,
tetrahydropyranyl, tetrahydrothienyl, tetrahydropyridinyl,
tetrahydropyrimidinyl, tetrahydrothiophenyl or
tetrahydrothiopyranyl; and R.sup.c is --H, or
(C.sub.1-C.sub.6)alkyl;
[0077] each R.sup.15 is independently selected from halogen,
--OR.sup.c, --NR.sup.aR.sup.b, (C.sub.1-C.sub.6)alkyl, morpholinyl,
thiomorpholinyl, pyrrolidinonyl, pyrrolidinyl, piperidinyl,
piperazinyl, hydantoinyl, valerolactamyl, oxiranyl, oxetanyl,
azetidinyl, dihydroimidazole, dihydrofuranyl, dihydropyranyl,
dihydropyridinyl, dihydropyrimidinyl, dihydrothienyl,
dihydrothiophenyl, dihydrothiopyranyl, tetrahydroimidazole,
tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothienyl,
tetrahydropyridinyl, tetrahydropyrimidinyl, tetrahydrothiophenyl,
tetrahydrothiopyranyl, furanyl, imidazolyl, isoxazolyl,
oxadiazolyl, oxazolyl, pyrazolyl, pyrrolyl, pyridyl, pyrimidinyl,
pyridazinyl, thiazolyl, isothiazolyl, triazolyl, tetrazolyl and
thienyl; wherein the (C.sub.1-C.sub.6)alkyl represented by R.sup.15
is optionally substituted with a substituent selected from
-halogen, --OR.sup.c, (C.sub.1-C.sub.3)alkoxy, morpholinyl,
thiomorpholinyl, pyrrolidinonyl, pyrrolidinyl, piperidinyl,
piperazinyl, hydantoinyl, valerolactamyl, oxiranyl, oxetanyl,
azetidinyl, dihydroimidazole, dihydrofuranyl, dihydropyranyl,
dihydropyridinyl, dihydropyrimidinyl, dihydrothienyl,
dihydrothiophenyl, dihydrothiopyranyl, tetrahydroimidazole,
tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothienyl,
tetrahydropyridinyl, tetrahydropyrimidinyl, tetrahydrothiophenyl,
tetrahydrothiopyranyl, furanyl, imidazolyl, isoxazolyl,
oxadiazolyl, oxazolyl, pyrazolyl, pyrrolyl, pyridyl, pyrimidinyl,
pyridazinyl, thiazolyl, isothiazolyl, triazolyl, tetrazolyl and
thienyl;
[0078] each R.sup.16 is independently selected from halogen,
--OR.sup.c, --NR.sup.aR.sup.b, and (C.sub.1-C.sub.6)alkyl;
[0079] m is 1; and values and alternative values for the remainder
of the variables are as described for Structural Formula (I) or in
the first, second, thirteenth or fourteenth embodiment.
[0080] In a sixteenth embodiment, for compounds represented by any
one of structural formulas (II-C1)-(II-I4), U is --CH.sub.2--,
--NH--, or --O--; each (R.sup.16).sub.0-1 is absent; and values and
alternative values for the remainder of the variables are as
described for Structural Formula (I) or in the first, second,
thirteenth, fourteenth or fifteenth embodiment.
[0081] In a seventeenth embodiment, for compounds represented by
any one of structural formulas (I) and (II-A1)-(II-I4), two
instances of R.sup.6 on different carbons, together with the ring
to which they are attached, form an 8-azabicyclo[3.2.1]octanyl, a
9-azabicyclo[3.3.1]nonanyl, a 3-oxa-9-azabicyclo[3.3.1]nonanyl or a
3,9-diazabicyclo[3.3.1]nonanyl; and values and alternative values
for the remainder of the variables are as described for Structural
Formula (I) or in the first, second, thirteenth, fourteenth,
fifteenth or sixteenth embodiment.
[0082] In an eighteenth embodiment, the compound is represented by
structural formula
##STR00019##
or a pharmaceutically acceptable salt thereof; wherein the group
represented by
##STR00020##
is meta or para to the indazole ring; and values and alternative
values for the remainder of the variables are as described for
Structural Formula (I) or in the first or second embodiment.
[0083] In a nineteenth embodiment, the compound is represented by a
structural formula selected from:
##STR00021##
or a pharmaceutically acceptable salt thereof; and values and
alternative values for the remainder of the variables are as
described for Structural Formula (I) or in the first or second
embodiment.
[0084] In a twentieth embodiment, the compound is represented by a
structural formula selected from:
##STR00022##
or a pharmaceutically acceptable salt thereof; and values and
alternative values for the remainder of the variables are as
described for Structural Formula (I) or in the first or second
embodiment.
[0085] In one embodiment, for compounds described in Structural
Formula (I) or in the eighteenth, nineteenth or twentieth
embodiment, Z is a bond. In another embodiment, for compounds
described in Structural Formula (I) or in the first, second, third,
fourth or fifth embodiment, Z is --CR.sup.13R.sup.14
[0086] In a twenty-first embodiment, the compound is represented by
a structural formula selected from:
##STR00023##
or a pharmaceutically acceptable salt thereof; wherein U is
--CH.sub.2--, --CHR.sup.15--, --NH--, --NR.sup.15-- or --O--; k is
1 or 2; and values and alternative values for the remainder of the
variables are as described for Structural Formula (I) or in the
first or second embodiment.
[0087] In a twenty-second embodiment, the compound is represented
by a structural formula selected from:
##STR00024##
or a pharmaceutically acceptable salt thereof; and values and
alternative values for the remainder of the variables are as
described for Structural Formula (I) or in the first or second
embodiment.
[0088] In a twenty-third embodiment, the compound is represented by
a structural formula selected from:
##STR00025##
or a pharmaceutically acceptable salt thereof; and values and
alternative values for the remainder of the variables are as
described for Structural Formula (I) or in the first or second
embodiment.
[0089] In a twenty-fourth embodiment, the compound is represented
by a structural formula selected from:
##STR00026##
or a pharmaceutically acceptable salt thereof; and values and
alternative values for the remainder of the variables are as
described for Structural Formula (I) or in the first or second
embodiment.
[0090] In a twenty-fifth embodiment, the compound is represented by
a structural formula selected from:
##STR00027##
[0091] or a pharmaceutically acceptable salt thereof, wherein
R.sup.8 is --H or (C.sub.1-C.sub.4)alkyl; R.sup.9 is --OR.sup.c or
hydroxy(C.sub.1-C.sub.4)alkyl; R.sup.c is --H or
(C.sub.1-C.sub.4)alkyl; and values and alternative values for the
remainder of the variables are as described for Structural Formula
(I) or in the first or second embodiment.
[0092] In a twenty-sixth embodiment, for compounds represented by
any one of structural formulas (I), (III) or (III-A1)-(II-G4), the
group represented by X is --O--, --CR.sup.8R.sup.9-- or
--NR.sup.11--;
[0093] R.sup.4 is --H or an alkyl group optionally substituted with
a substituent selected from halogen, hydroxy and
(C.sub.1-C.sub.3)alkoxy;
[0094] R.sup.8 and R.sup.9 are each independently selected from
--H, --OR.sup.c, and (C.sub.1-C.sub.6)alkyl, wherein the
(C.sub.1-C.sub.6)alkyl group is optionally substituted with a
substituent selected from halogen, hydroxy and
(C.sub.1-C.sub.3)alkoxy;
[0095] R.sup.11 is --H, (C.sub.1-C.sub.6)alkyl, wherein the
(C.sub.1-C.sub.6)alkyl is optionally substituted with a substituent
selected from halogen, hydroxy, (C.sub.1-C.sub.3)alkoxy and
--C(.dbd.O)NR.sup.eR.sup.f;
[0096] R.sup.13 and R.sup.14 are each independently selected from
--H, alkyl, --OR.sup.c, --(C.sub.1-C.sub.3)alkylene-OR.sup.c,
--(C.sub.1-C.sub.3)alkylene-OH, (C.sub.3-C.sub.8)cycloalklyl,
--O--(C.sub.3-C.sub.8)cycloalkyl and 3 to 8 membered
heterocycloalkyl, provided that R.sup.13 and R.sup.14 are not both
--OR.sup.c, wherein each of the cycloalkyl or heterocycloalkyl
groups is optionally substituted with a (C.sub.1-C.sub.3)alkyl;
[0097] n is an integer from 1 to 2;
[0098] m is an integer from 1 to 2;
[0099] each p is 1 or 2; and values and alternative values for the
remainder of the variables are as described for Structural Formula
(I) or in the first or second embodiment.
[0100] In a twenty-seventh embodiment, for compounds represented by
any one of structural formulas (I), (III) or (III-A1)-(II-G4), each
R.sup.1 is independently selected from --H, -halogen, --CN,
--NO.sub.2, --OR.sup.c, --NR.sup.aR.sup.b, --S(O).sub.iR.sup.c,
--C(.dbd.O)OR.sup.c, --OC(.dbd.O)OR.sup.c,
--C(.dbd.O)NR.sup.eR.sup.f, --NR.sup.dC(.dbd.O)R.sup.c,
--C(.dbd.O)R.sup.c or alkyl, wherein the alkyl is optionally
substituted with a substituent selected from -halogen, --OR.sup.c,
--NR.sup.aR.sup.b, and --S(O).sub.iR.sup.c;
[0101] R.sup.5 is (a) cyclopropyl, cyclobutyl, cyclopentyl,
cyclohexyl, morpholinyl, thiomorpholinyl, pyrrolidinonyl,
pyrrolidinyl, piperidinyl, piperazinyl, hydantoinyl,
valerolactamyl, oxiranyl, oxetanyl, azetidinyl, dihydroimidazole,
dihydrofuranyl, dihydropyranyl, dihydropyridinyl,
dihydropyrimidinyl, dihydrothienyl, dihydrothiophenyl,
dihydrothiopyranyl, tetrahydroimidazole, tetrahydrofuranyl,
tetrahydropyranyl, tetrahydrothienyl, tetrahydropyridinyl,
tetrahydropyrimidinyl, tetrahydrothiophenyl, tetrahydrothiopyranyl,
phenyl, furanyl, imidazolyl, oxazolyl, isoxazolyl, oxadiazolyl,
pyrazolyl, pyrrolyl, pyridyl, pyrimidinyl, pyridazinyl, thiazolyl,
isothiazolyl, triazolyl, tetrazolyl or thienyl, each of which is
optionally substituted with 1 to 3 groups represented by R.sup.15
or (b) (b) bicyclooctanyl, decahydronaphthyl, octahydroindenyl,
dihydronaphthalenyl, tetrahydronaphthalenyl, dihydroindolyl,
dihydroisoindolyl, dihydrobenzimidazolyl, dihydrobenzothienyl,
dihydrobenzofuranyl, dihydroisobenzofuranyl, dihydrobenzotriazolyl,
dihydrobenzothiazolyl, dihydrobenzoxazolyl, dihydrobenzisoxazolyl,
dihydroquinolinyl, tetrahydroquinolinyl, dihydroisoquinolinyl,
tetrahydroisoquinolinyl, dihydroindazolyl, dihydroacridinyl,
tetrahydroacridinyl, chromanyl, isochromanyl, chromenyl,
isochromenyl, naphthyl, anthracenyl, fluorenyl, indanyl, indenyl,
carbazolyl, benzimidazolyl, benzothienyl, benzofuranyl,
isobenzofuranyl, indolyl, isoindolyl, benzotriazolyl,
benzothiazolyl, benzoxazolyl, benzisoxazolyl, quinolinyl,
isoquinolinyl, indazolyl or acridinyl, each of which is optionally
substituted with 1 to 3 groups represented by R.sup.16;
[0102] R.sup.13 is H and R.sup.14 is --H, (C.sub.1-C.sub.6)alkyl,
--OR.sup.c, --(C.sub.1-C.sub.3)alkylene-OR.sup.c,
--(C.sub.1-C.sub.3)alkylene-OH, a cycloalkyl selected from
cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, a
--O-cycloalkyl selected from --O-cyclopropyl, --O-cyclobutyl, and
--O-cyclopentyl, --O-cyclohexyl, or a heterocycloalkyl selected
from morpholinyl, thiomorpholinyl, pyrrolidinonyl, pyrrolidinyl,
piperidinyl, piperazinyl, hydantoinyl, valerolactamyl, oxiranyl,
oxetanyl, azetidinyl, dihydroimidazole, dihydrofuranyl,
dihydropyranyl, dihydropyridinyl, dihydropyrimidinyl,
dihydrothienyl, dihydrothiophenyl, dihydrothiopyranyl,
tetrahydroimidazole, tetrahydrofuranyl, tetrahydropyranyl,
tetrahydrothienyl, tetrahydropyridinyl, tetrahydropyrimidinyl,
tetrahydrothiophenyl and tetrahydrothiopyranyl, provided that
R.sup.13 and R.sup.14 are not both --OR.sup.c, wherein each of the
--O-cycloalkyl, cycloalkyl or heterocycloalkyl groups is optionally
substituted with a (C.sub.1-C.sub.3)alkyl; and R.sup.c is --H, or
(C.sub.1-C.sub.6)alkyl
[0103] each R.sup.15 is independently selected from halogen, --CN,
--NO.sub.2, .dbd.O, --OR.sup.c, --NR.sup.aR.sup.b,
--C(.dbd.O)OR.sup.c, --OC(.dbd.O)OR.sup.c,
--C(.dbd.O)NR.sup.eR.sup.f, --NR.sup.dC(.dbd.O)R.sup.c,
--NR.sup.d(C.dbd.O)OR.sup.c, --O(C.dbd.O)NR.sup.eR.sup.f,
--NR.sup.d(C.dbd.O)NR.sup.eR.sup.f, --C(.dbd.O)R.sup.c,
(C.sub.1-C.sub.6)alkyl, morpholinyl, thiomorpholinyl,
pyrrolidinonyl, pyrrolidinyl, piperidinyl, piperazinyl,
hydantoinyl, valerolactamyl, oxiranyl, oxetanyl, azetidinyl,
dihydroimidazole, dihydrofuranyl, dihydropyranyl, dihydropyridinyl,
dihydropyrimidinyl, dihydrothienyl, dihydrothiophenyl,
dihydrothiopyranyl, tetrahydroimidazole, tetrahydrofuranyl,
tetrahydropyranyl, tetrahydrothienyl, tetrahydropyridinyl,
tetrahydropyrimidinyl, tetrahydrothiophenyl, tetrahydrothiopyranyl,
phenyl, benzyl, furanyl, imidazolyl, oxazolyl, isoxazolyl,
oxadiazolyl, pyrazolyl, pyrrolyl, pyridyl, pyrimidinyl,
pyridazinyl, thiazolyl, isothiazolyl, triazolyl, tetrazolyl, and
thienyl; wherein the (C.sub.1-C.sub.6)alkyl represented by R.sup.15
is optionally substituted with a substituent selected from
-halogen, --OR.sup.c, (C.sub.1-C.sub.6)alkyl,
(C.sub.1-C.sub.3)alkoxy, morpholinyl, thiomorpholinyl,
pyrrolidinonyl, pyrrolidinyl, piperidinyl, piperazinyl,
hydantoinyl, valerolactamyl, oxiranyl, oxetanyl, azetidinyl,
dihydroimidazole, dihydrofuranyl, dihydropyranyl, dihydropyridinyl,
dihydropyrimidinyl, dihydrothienyl, dihydrothiophenyl,
dihydrothiopyranyl, tetrahydroimidazole, tetrahydrofuranyl,
tetrahydropyranyl, tetrahydrothienyl, tetrahydropyridinyl,
tetrahydropyrimidinyl, tetrahydrothiophenyl, tetrahydrothiopyranyl,
furanyl, imidazolyl, oxazolyl, isoxazolyl, oxadiazolyl, pyrazolyl,
pyrrolyl, pyridyl, pyrimidinyl, pyridazinyl, thiazolyl,
isothiazolyl, triazolyl, tetrazolyl, and thienyl;
[0104] each R.sup.16 is independently selected from halogen,
--OR.sup.c, --NR.sup.aR.sup.b, --C(.dbd.O)OR.sup.c,
--C(.dbd.O)NR.sup.eR.sup.f, --NR.sup.dC(.dbd.O)R.sup.c,
--C(.dbd.O)R.sup.c, (C.sub.1-C.sub.6)alkyl, phenyl,
phenyl(C.sub.1-C.sub.3)alkyl, morpholinyl, thiomorpholinyl,
pyrrolidinonyl, pyrrolidinyl, piperidinyl, piperazinyl,
hydantoinyl, valerolactamyl, oxiranyl, oxetanyl, azetidinyl,
dihydroimidazole, dihydrofuranyl, dihydropyranyl, dihydropyridinyl,
dihydropyrimidinyl, dihydrothienyl, dihydrothiophenyl,
dihydrothiopyranyl, tetrahydroimidazole, tetrahydrofuranyl,
tetrahydropyranyl, tetrahydrothienyl, tetrahydropyridinyl,
tetrahydropyrimidinyl, tetrahydrothiophenyl, tetrahydrothiopyranyl,
furanyl, imidazolyl, oxazolyl, isoxazolyl, oxadiazolyl, pyrazolyl,
pyrrolyl, pyridyl, pyrimidinyl, pyridazinyl, thiazolyl,
isothiazolyl, triazolyl, tetrazolyl, and thienyl; and values and
alternative values for the remainder of the variables are as
described for Structural Formula (I) or in the first, second or
twenty-sixth embodiment.
[0105] In a twenty-eighth embodiment, for compounds represented by
any one of structural formulas (I), (III) or (III-A1)-(II-G4),
R.sup.1 is selected from --H, -halogen, --OCH.sub.3,
--N(CH.sub.3).sub.2, --S(O).sub.2CH.sub.3, or methyl;
[0106] R.sup.5 is cyclopentyl, cyclohexyl, morpholinyl,
pyrrolidinyl, piperidinyl, dihydropyridinyl, tetrahydropyridinyl,
dihydropyrimidinyl, tetrahydropyrimidinyl, phenyl, furanyl,
imidazolyl, pyrrolyl, pyridyl, pyrimidinyl or thienyl, each of
which is optionally substituted with 1 to 3 groups represented by
R.sup.15 or (b) chromanyl, chromenyl, dihydroindolyl,
dihydroisoindolyl, dihydrobenzothienyl, dihydrobenzofuranyl,
dihydroisobenzofuranyl, dihydrobenzotriazolyl, dihydroquinolinyl,
tetrahydroquinolinyl, dihydroisoquinolinyl,
tetrahydroisoquinolinyl, dihydrobenzisoxazolyl, naphthyl,
anthracenyl, fluorenyl, indanyl, indenyl, dihydronaphthalene,
tetrahydronaphthalene, carbazolyl, benzimidazolyl, benzothienyl,
benzofuranyl, isobenzofuranyl, indolyl, quinolinyl, isoquinolinyl
or isoindolyl, each of which is optionally substituted with 1 to 3
groups represented by R.sup.16;
[0107] R.sup.13 is --H and R.sup.14 is --H, (C.sub.1-C.sub.6)alkyl,
cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, --O-cyclopropyl,
--O-cyclobutyl, --O-cyclopentyl, --O-cyclohexyl, morpholinyl,
thiomorpholinyl, pyrrolidinonyl, pyrrolidinyl, piperidinyl,
piperazinyl, hydantoinyl, valerolactamyl, oxiranyl, oxetanyl,
azetidinyl, dihydroimidazole, dihydrofuranyl, dihydropyranyl,
dihydropyridinyl, dihydropyrimidinyl, dihydrothienyl,
dihydrothiophenyl, dihydrothiopyranyl, tetrahydroimidazole,
tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothienyl,
tetrahydropyridinyl, tetrahydropyrimidinyl, tetrahydrothiophenyl or
tetrahydrothiopyranyl;
[0108] R.sup.15 is independently selected from halogen, --OR.sup.c,
--NR.sup.aR.sup.b, and (C.sub.1-C.sub.6)alkyl;
[0109] each R.sup.16 is independently selected from
(C.sub.1-C.sub.6)alkyl;
[0110] m is 1; and values and alternative values for the remainder
of the variables are as described for Structural Formula (I) or in
the first, second, twenty-sixth or twenty-seventh embodiment.
[0111] In a twenty-ninth embodiment, for compounds represented by
any one of structural formulas (III-C1)-(II-G4), U is --CH.sub.2--,
--NH--, or --O--; each (R.sup.16).sub.0-1 is absent.
[0112] In a thirtieth embodiment, for compounds represented by any
one of structural formulas (I), (III) or (III-A1)-(II-E4), X is
--NR.sup.11--; R.sup.11 is (C.sub.1-C.sub.4)alkyl; and values and
alternative values for the remainder of the variables are as
described for Structural Formula (I) or in the first, second,
twenty-sixth, twenty-seventh, twenty-eighth or twenty-ninth
embodiment.
[0113] In a thirty-first embodiment, for compounds represented by
any one of structural formulas (I)-(III), (II-A1)-(II-I4) or
(III-A1)-(II-G4), R.sup.5 is cyclohexyl, phenyl, pyridyl, or
thienyl, each of which is optionally substituted with 1 to 3 groups
selected from methyl, ethyl, propyl, halogen, hydroxymethyl,
hydroxyethyl, methoxy, ethoxy, and
--(CH.sub.2).sub.0-2-morpholinyl; and values and alternative values
for the remainder of the variables are as described for Structural
Formula (I) or in the first, second, third, fourth, fifth, sixth,
seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth,
fourteenth, fifteenth, sixteenth, seventeenth, eighteenth,
nineteenth, twentieth, twenty-first, twenty-second, twenty-third,
twenty-fourth, twenty-fifth, twenty-sixth, twenty-seventh,
twenty-eighth, twenty-ninth or thirtieth embodiment.
[0114] Alternatively, in a thirty-second embodiment, for compounds
represented by any one of structural formulas (I)-(III),
(II-A1)-(II-I4) or (III-A1)-(II-G4), R.sup.5 is cyclohexyl, phenyl,
pyridyl, or thienyl, each of which is optionally substituted with 1
to 3 groups selected from methyl, ethyl, propyl and halogen; and
values and alternative values for the remainder of the variables
are as described for Structural Formula (I) or in the first,
second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth,
eleventh, twelfth, thirteenth, fourteenth, fifteenth, sixteenth,
seventeenth, eighteenth, nineteenth, twentieth, twenty-first,
twenty-second, twenty-third, twenty-fourth, twenty-fifth,
twenty-sixth, twenty-seventh, twenty-eighth, twenty-ninth or
thirtieth embodiment.
[0115] In a thirty-third embodiment, for compounds represented by
any one of structural formulas (I)-(III), (II-A1)-(II-I4) or
(III-A1)-(II-G4), R.sup.14 is --H, methyl, ethyl, propyl,
hydroxymethyl, hydroxyethyl, hydroxypropyl, methoxy, ethoxy,
propoxy, methoxymethyl, methoxyethyl, methoxypropyl, cyclopropyl,
cyclobutyl, cyclopentyl, cyclohexyl, --O-cyclopropyl,
--O-cyclobutyl, --O-cyclopentyl, --O-cyclohexyl, morpholinyl,
oxetanyl, tetrahydrofuryl, tetrahydropyranyl, azetidinyl,
pyrrolidinyl, piperidyl, wherein the morpholinyl, tetrahydrofuryl,
tetrahydropyranyl, pyrrolidinyl or piperidyl are optionally
substituted with methyl; and values and alternative values for the
remainder of the variables are as described for Structural Formula
(I) or in the first, second, third, fourth, fifth, sixth, seventh,
eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth,
fifteenth, sixteenth, seventeenth, eighteenth, nineteenth,
twentieth, twenty-first, twenty-second, twenty-third,
twenty-fourth, twenty-fifth, twenty-sixth, twenty-seventh,
twenty-eighth, twenty-ninth, thirtieth, thirty-first or
thirty-second embodiment.
[0116] In a thirty-fourth embodiment, for compounds represented by
any one of structural formulas (I)-(III), (II-A1)-(II-I4) or
(III-A1)-(II-G4), R.sup.3 is piperidyloxy, N-methylpiperidyloxy,
morpholinyl or hydroxypiperidyl; and values and alternative values
for the remainder of the variables are as described for Structural
Formula (I) or in the first, second, third, fourth, fifth, sixth,
seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth,
fourteenth, fifteenth, sixteenth, seventeenth, eighteenth,
nineteenth, twentieth, twenty-first, twenty-second, twenty-third,
twenty-fourth, twenty-fifth, twenty-sixth, twenty-seventh,
twenty-eighth, twenty-ninth, thirtieth, thirty-first, thirty-second
or thirty-third embodiment.
[0117] In certain embodiments, the present teachings provide the
compounds depicted and/or described by name in the Exemplification,
as well as neutral forms and pharmaceutically acceptable salts
thereof.
[0118] The term "alkyl" used alone or as part of a larger moiety,
such as "alkoxy", "haloalkyl", "cycloalkylalkyl",
"heterocycloalkylalkyl", "aralkyl", "heteroaralkyl" and the like,
means saturated aliphatic straight-chain or branched monovalent
hydrocarbon radical. Unless otherwise specified, an alkyl group
typically has 1-6 carbon atoms, i.e. (C.sub.1-C.sub.6)alkyl. As
used herein, a "(C.sub.1-C.sub.6)alkyl" group is means a radical
having from 1 to 6 carbon atoms in a linear or branched
arrangement.
[0119] An "alkylene group" is a saturated aliphatic branched or
straight-chain divalent hydrocarbon radical. Unless otherwise
specified, an alkylene group typically has 1-6 carbon atoms, i.e.
(C.sub.1-C.sub.6)alkylene.
[0120] An "alkenyl" means branched or straight-chain monovalent
hydrocarbon radical containing at least one double bond. Alkenyl
may be mono or polyunsaturated, and may exist in the E or Z
configuration. Unless otherwise specified, an alkenyl group
typically has 2-6 carbon atoms, i.e. (C.sub.2-C.sub.6)alkenyl. For
example, "(C.sub.2-C.sub.6)alkenyl" means a radical having from 2-6
carbon atoms in a linear or branched arrangement.
[0121] "Alkynyl" means branched or straight-chain monovalent
hydrocarbon radical containing at least one triple bond. Unless
otherwise specified, an alkynyl group typically has 2-6 carbon
atoms, i.e. (C.sub.2-C.sub.6)alkynyl. For example,
"(C.sub.2-C.sub.6)alkynyl" means a radical having from 2-6 carbon
atoms in a linear or branched arrangement.
[0122] "Alkoxy" means an alkyl radical attached through an oxygen
linking atom, represented by --O-alkyl. For example,
"(C.sub.1-C.sub.4)alkoxy" includes methoxy, ethoxy, propoxy, and
butoxy.
[0123] The terms "haloalkyl" and "haloalkoxy" means alkyl or
alkoxy, as the case may be, substituted with one or more halogen
atoms. The term "halogen" means F, Cl, Br or I. Preferably the
halogen in a haloalkyl or haloalkoxy is F.
[0124] The term "aryl group" used alone or as part of a larger
moiety as in "aralkyl", "aralkoxy", or "aryloxyalkyl", means an
aromatic hydrocarbon ring system. The term "aryl" may be used
interchangeably with the terms "aryl ring" "aromatic ring", "aryl
group" and "aromatic group". An aryl group typically has six to
fourteen ring atoms. Examples includes phenyl, naphthyl,
anthracenyl, 1,2-dihydronaphthyl, 1,2,3,4-tetrahydronaphthyl,
fluorenyl, indanyl, indenyl and the like. A "substituted aryl
group" is substituted at any one or more substitutable ring atom,
which is a ring carbon atom bonded to a hydrogen.
[0125] "Cycloalkyl" means a saturated aliphatic cyclic hydrocarbon
radical optionally containing one or more double bonds. It can be
monocyclic, bicyclic, polycyclic (e.g., tricyclic), or fused. For
example, monocyclic (C.sub.3-C.sub.8)cycloalkyl means a radical
having from 3-8 carbon atoms arranged in a monocyclic ring. A
(C.sub.3-C.sub.8)cycloalkyl includes, but is not limited to,
cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and
cyclooctyl.
[0126] "Heterocycloalkyl" means a saturated or unsaturated
non-aromatic 4-12 membered ring radical optionally containing one
or more double bonds. It can be monocyclic, bicyclic, tricyclic, or
fused. The heterocycloalkyl contains 1 to 4 heteroatoms, which may
be the same or different, selected from N, O or S. The
heterocycloalkyl ring optionally contains one or more double bonds
and/or is optionally fused with one or more aromatic rings (e.g.,
phenyl ring). The term "heterocycloalkyl" is intended to include
all the possible isomeric forms. Examples of heterocycloalkyl
include, but are not limited to, morpholinyl, thiomorpholinyl,
pyrrolidinonyl, pyrrolidinyl, piperidinyl, piperazinyl,
hydantoinyl, valerolactamyl, oxiranyl, oxetanyl, dihydroimidazole,
dihydrofuranyl, dihydropyranyl, dihydropyridinyl,
dihydropyrimidinyl, dihydrothienyl, dihydrothiophenyl,
dihydrothiopyranyl, tetrahydroimidazole, tetrahydrofuranyl,
tetrahydropyranyl, tetrahydrothienyl, tetrahydropyridinyl,
tetrahydropyrimidinyl, tetrahydrothiophenyl, and
tetrahydrothiopyranyl. Examples of polycyclic heterocycloalkyl
groups include dihydroindolyl, dihydroisoindolyl,
dihydrobenzimidazolyl, dihydrobenzothienyl, dihydrobenzofuranyl,
dihydroisobenzofuranyl, dihydrobenzotriazolyl,
dihydrobenzothiazolyl, dihydrobenzoxazolyl, dihydroquinolinyl,
tetrahydroquinolinyl, dihydroisoquinolinyl,
tetrahydroisoquinolinyl, dihydroindazolyl, dihydroacridinyl,
tetrahydroacridinyl, dihydrobenzisoxazolyl, chroman, chromene,
isochroman and isochromene.
[0127] The term "heteroaryl", "heteroaromatic", "heteroaryl ring",
"heteroaryl group", "heteroaromatic ring", and "heteroaromatic
group", are used interchangeably herein. "Heteroaryl" when used
alone or as part of a larger moiety as in "heteroaralkyl" or
"heteroarylalkoxy", refers to aromatic ring groups having five to
fourteen ring atoms selected from carbon and at least one
(typically 1 to 4, more typically 1 or 2) heteroatoms (e.g.,
oxygen, nitrogen or sulfur). "Heteroaryl" includes monocyclic rings
and polycyclic rings in which a monocyclic heteroaromatic ring is
fused to one or more other aromatic or heteroaromatic rings. As
such, "5-14 membered heteroaryl" includes monocyclic, bicyclic or
tricyclic ring systems.
[0128] Examples of monocyclic 5-6 membered heteroaryl groups
include furanyl (e.g., 2-furanyl, 3-furanyl), imidazolyl (e.g.,
N-imidazolyl, 2-imidazolyl, 4-imidazolyl, 5-imidazolyl), isoxazolyl
(e.g., 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl), oxadiazolyl
(e.g., 2-oxadiazolyl, 5-oxadiazolyl), oxazolyl (e.g., 2-oxazolyl,
4-oxazolyl, 5-oxazolyl), pyrazolyl (e.g., 3-pyrazolyl,
4-pyrazolyl), pyrrolyl (e.g., 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl),
pyridyl (e.g., 2-pyridyl, 3-pyridyl, 4-pyridyl), pyrimidinyl (e.g.,
2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl), pyridazinyl (e.g.,
3-pyridazinyl), thiazolyl (e.g., 2-thiazolyl, 4-thiazolyl,
5-thiazolyl), isothiazolyl, triazolyl (e.g., 2-triazolyl,
5-triazolyl), tetrazolyl (e.g., tetrazolyl), and thienyl (e.g.,
2-thienyl, 3-thienyl). Examples of polycyclic aromatic heteroaryl
groups include carbazolyl, benzimidazolyl, benzothienyl,
benzofuranyl, isobenzofuranyl, indolyl, benzotriazolyl,
benzothiazolyl, benzoxazolyl, quinolinyl, isoquinolinyl, indazolyl,
isoindolyl, acridinyl, or benzisoxazolyl. A "substituted heteroaryl
group" is substituted at any one or more substitutable ring atom,
which is a ring carbon or ring nitrogen atom bonded to a
hydrogen.
[0129] Unless otherwise indicated, suitable substituents for a
substituted alkyl, cycloalkyl, heterocycloalkyl, aryl group and
heteroaryl group include the groups represented by halogen,
--OR.sup.c, --NR.sup.aR.sup.b, --S(O).sub.iR.sup.c,
--NR.sup.dS(O).sub.iR.sup.c, --S(O).sub.iNR.sup.eR.sup.f,
--C(.dbd.O)OR.sup.c, --OC(.dbd.O)OR.sup.c, --C(.dbd.S)OR.sup.c,
--O(C.dbd.S)R.sup.c, --C(.dbd.O)NR.sup.eR.sup.f,
--NR.sup.dC(.dbd.O)R.sup.c, --C(.dbd.S)NR.sup.eR.sup.f,
--NR.sup.dC(.dbd.S)R.sup.c, --NR.sup.d(C.dbd.O)OR.sup.c,
--O(C.dbd.O)NR.sup.eR.sup.f, --NR.sup.d(C.dbd.S)OR.sup.c,
--O(C.dbd.S)NR.sup.eR.sup.f, --NR.sup.d(C.dbd.O)NR.sup.eR.sup.f,
--NR.sup.d(C.dbd.S)NR.sup.eR.sup.f, --C(.dbd.S)R.sup.c,
--C(.dbd.O)R.sup.c, (C.sub.1-C.sub.6)alkyl, cycloalkyl,
cycloalkyl(C.sub.1-C.sub.3)alkyl, heterocycloalkyl,
heterocycloalkyl(C.sub.1-C.sub.3)alkyl, aryl,
aryl(C.sub.1-C.sub.3)alkyl, heteroaryl and
heteroaryl(C.sub.1-C.sub.3)alkyl, wherein R.sup.a, R.sup.b,
R.sup.c, R.sup.d, R.sup.e and R.sup.f are described above for
Structural Formula (I). Each of the (C.sub.1-C.sub.6)alkyl,
cycloalkyl, cycloalkyl(C.sub.1-C.sub.3)alkyl, heterocycloalkyl,
heterocycloalkyl(C.sub.1-C.sub.3)alkyl, aryl,
aryl(C.sub.1-C.sub.3)alkyl, heteroaryl and
heteroaryl(C.sub.1-C.sub.3)alkyl substituents is optionally
substituted with halogen, --NO.sub.2, --CN,
--NR.sup.dC(.dbd.O)R.sup.c, --NR.sup.gR.sup.h,
(C.sub.1-C.sub.3)alkyl, halo(C.sub.1-C.sub.3)alkyl,
(C.sub.1-C.sub.3)alkoxy(C.sub.1-C.sub.3)alkyl,
(C.sub.1-C.sub.3)alkoxy and halo(C.sub.1-C.sub.3)alkoxy, wherein
R.sup.g and R.sup.h are as described above for Structural Formula
(I). Suitable substituents for a substituted alkyl, cycloalkyl,
heterocycloalkyl can also include .dbd.O. In certain embodiments,
suitable substituents include alkyl, haloalkyl, alkoxy, haloalkoxy,
cyano, nitro and halogen.
[0130] Regarding connectivity, an "arylalkyl" moiety, for example,
refers to an alkyl group substituted with an aryl group (e.g.,
phenylmethyl (i.e., benzyl)). Similarly, a "heteroarylalkyl" moiety
refers to an alkyl group substituted with a heteroaryl group.
[0131] As used herein, the term "bridged bicyclic group" refers to
a ring system which includes two rings that share at least three
adjacent ring atoms.
[0132] As used herein, the term "endo", when used in connection
with saturated (or partially saturated) ring substitution, refers
to two substituents being present on the same face of the ring.
Similarly, the term "exo", when used in connection with saturated
(or partially saturated) ring substitution, refers to two
substituents being present on opposing faces of the ring. For
example, endo and exo adducts of dimethylcyclohexane are as
follows:
##STR00028##
Similarly, exemplary endo and exo adducts of a bridged bicyclic
compound are as follows:
##STR00029##
[0133] The present teachings also include various isomers and
mixtures thereof. "Isomer" refers to compounds that have the same
composition and molecular weight but differ in physical and/or
chemical properties. The structural difference may be in
constitution (geometric isomers) or in the ability to rotate the
plane of polarized light (stereoisomers).
[0134] Certain of the compounds described herein may exist in
various stereoisomeric or tautomeric forms. Stereoisomers are
compounds which differ only in their spatial arrangement. The
present teachings encompass all such forms, including compounds in
the form of essentially pure enantiomers, racemic mixtures and
tautomers, which includes forms not depicted structurally. When a
disclosed compound is named or depicted by structure without
indicating stereochemistry, it is understood that the name or
structure encompasses all possible stereoisomers, tautomers,
geometric isomers or a combination thereof.
[0135] When a geometric isomer is depicted by name or structure, it
is to be understood that the geometric isomeric purity of the named
or depicted geometric isomer is at least 60%, 70%, 80%, 90%, 99% or
99.9% pure by weight. Geometric isomeric purity is determined by
dividing the weight of the named or depicted geometric isomer in
the mixture by the total weight of all of the geomeric isomers in
the mixture.
[0136] Racemic mixture means 50% of one enantiomer and 50% of is
corresponding enantiomer. The present teachings encompass all
enantiomerically-pure, enantiomerically-enriched,
diastereomerically pure, diastereomerically enriched, and racemic
mixtures, and diastereomeric mixtures of the compounds described
herein.
[0137] Enantiomeric and diastereomeric mixtures can be resolved
into their component enantiomers or stereoisomers by well known
methods, such as chiral-phase gas chromatography, chiral-phase high
performance liquid chromatography, crystallizing the compound as a
chiral salt complex, or crystallizing the compound in a chiral
solvent. Enantiomers and diastereomers can also be obtained from
diastereomerically- or enantiomerically-pure intermediates,
reagents, and catalysts by well known asymmetric synthetic
methods.
[0138] When a compound is designated by a name or structure that
indicates a single enantiomer, unless indicated otherwise, the
compound is at least 60%, 70%, 80%, 90%, 99% or 99.9% optically
pure (also referred to as "enantiomerically pure"). Optical purity
is the weight in the mixture of the named or depicted enantiomer
divided by the total weight in the mixture of both enantiomers.
[0139] When the stereochemistry of a disclosed compound is named or
depicted by structure, and the named or depicted structure
encompasses more than one stereoisomer (e.g., as in a
diastereomeric pair), it is to be understood that one of the
encompassed stereoisomers or any mixture of the encompassed
stereoisomers are included. It is to be further understood that the
stereoisomeric purity of the named or depicted stereoisomers at
least 60%, 70%, 80%, 90%, 99% or 99.9% by weight. The
stereoisomeric purity in this case is determined by dividing the
total weight in the mixture of the stereoisomers encompassed by the
name or structure by the total weight in the mixture of all of the
stereoisomers.
[0140] Included in the present teachings are pharmaceutically
acceptable salts of the compounds disclosed herein. The disclosed
compounds have basic amine groups and therefore can form
pharmaceutically acceptable salts with pharmaceutically acceptable
acid(s). Suitable pharmaceutically acceptable acid addition salts
of the compounds described herein include salts of inorganic acids
(such as hydrochloric acid, hydrobromic, phosphoric,
metaphosphoric, nitric, and sulfuric acids) and of organic acids
(such as, acetic acid, benzenesulfonic, benzoic, citric,
ethanesulfonic, fumaric, gluconic, glycolic, isethionic, lactic,
lactobionic, maleic, malic, methanesulfonic, succinic,
p-toluenesulfonic, and tartaric acids). Compounds of the present
teachings with acidic groups such as carboxylic acids can form
pharmaceutically acceptable salts with pharmaceutically acceptable
base(s). Suitable pharmaceutically acceptable basic salts include
ammonium salts, alkali metal salts (such as sodium and potassium
salts) and alkaline earth metal salts (such as magnesium and
calcium salts). Compounds with a quaternary ammonium group also
contain a counteranion such as chloride, bromide, iodide, acetate,
perchlorate and the like. Other examples of such salts include
hydrochlorides, hydrobromides, sulfates, methanesulfonates,
nitrates, maleates, acetates, citrates, fumarates, tartrates [e.g.
(+)-tartrates, (-)-tartrates or mixtures thereof including racemic
mixtures], succinates, benzoates and salts with amino acids such as
glutamic acid.
[0141] Compounds described herein can inhibit various kinases,
including the TTK, PLK (such as PLK4), Aurora A, Aurora B and CHK
(such as CHK2). Thus, generally, compounds described herein are
useful in the treatment of diseases or conditions associated with
such kinases. In some embodiments, compounds described herein can
inhibit TTK, PLK (such as PLK4), and/or Aurora B kinases.
[0142] In one embodiment, the compounds described herein are TTK,
PLK, Aurora A, Aurora B and/or CHK inhibitors, and are useful for
treating diseases, such as cancer, associated with such kinase(s).
Alternatively, the compounds described herein are TTK inhibitors
and are useful for treating diseases associated with TTK, such as
cancer. In another alternative embodiment, the compounds described
herein are Aurora A and/or B inhibitors and are useful in
inhibiting Aurora A and/or B activity for the treatment of various
conditions such as cancers. In yet another specific embodiment, the
compounds described herein are PLK inhibitors and are useful in
inhibiting PLK activity for the treatment of various conditions
such as cancers. Typically, the PLK is PLK4, PLK2 and/or PLK1. In
one example, the PLK is PLK1 and/or PLK4. In another example, the
PLK is PLK4. In another alternative embodiment, the compounds
described herein are CHK inhibitors and are useful in inhibiting
CHK activity for the treatment of various conditions such as
cancers.
[0143] Another aspect of the present teachings relates to a method
of treating a subject with cancer comprising administering to the
subject an effective amount of a compound described herein. In one
embodiment, the compounds described herein inhibit the growth of a
tumor. For example, the compounds described herein inhibit the
growth of a tumor that overexpresses at least one of TTK, PLK,
Aurora A, Aurora B, and CHK. In one embodiment, the compounds
described herein inhibit the growth of a tumor that overexpresses
TTK.
[0144] Cancers that can be treated (including reduction in the
likelihood of recurrence) by the methods of the present teachings
include lung cancer, breast cancer, colon cancer, brain cancer,
neuroblastoma, prostate cancer, melanoma, glioblastoma multiform,
ovarian cancer, lymphoma, leukemia, melanoma, sarcoma,
paraneoplasia, osteosarcoma, germinoma, glioma and mesothelioma. In
one embodiment, the cancer is selected from leukemia, acute myeloid
leukemia, chronic myelogenous leukemia, breast cancer, brain
cancer, colon cancer, colorectal cancer, head and neck cancer,
hepatocellular carcinoma, lung adenocarcinoma, metastatic melanoma,
pancreatic cancer, prostate cancer, ovanrian cancer and renal
cancer. In one embodiment, the cancer is lung cancer, colon cancer,
brain cancer, neuroblastoma, prostate cancer, melanoma,
glioblastoma mutiform or ovarian cancer. In another embodiment, the
cancer is lung cancer, breast cancer, colon cancer, brain cancer,
neuroblastoma, prostate cancer, melanoma, glioblastoma multiform or
ovarian cancer. In yet another embodiment, the cancer is breast
cancer, colon cancer and lung cancer. In yet another embodiment,
the cancer is a breast cancer. In yet another embodiment, the
cancer is a basal sub-type breast cancer or a luminal B sub-type
breast cancer. In yet another embodiment, the cancer is a basal
sub-type breast cancer that overexpresses TTK. In yet another
embodiment, the basal sub-type breast cancer is ER (estrogen
receptor), HER2 and PR (progesterone receptor) negative breast
cancer. In yet another embodiment, the cancer is a soft tissue
cancer. A "soft tissue cancer" is an art-recognized term that
encompasses tumors derived from any soft tissue of the body. Such
soft tissue connects, supports, or surrounds various structures and
organs of the body, including, but not limited to, smooth muscle,
skeletal muscle, tendons, fibrous tissues, fatty tissue, blood and
lymph vessels, perivascular tissue, nerves, mesenchymal cells and
synovial tissues. Thus, soft tissue cancers can be of fat tissue,
muscle tissue, nerve tissue, joint tissue, blood vessels, lymph
vessels, and fibrous tissues. Soft tissue cancers can be benign or
malignant. Generally, malignant soft tissue cancers are referred to
as sarcomas, or soft tissue sarcomas. There are many types of soft
tissue tumors, including lipoma, lipoblastoma, hibernoma,
liposarcoma, leiomyoma, leiomyosarcoma, rhabdomyoma,
rhabdomyosarcoma, neurofibroma, schwannoma (neurilemoma), neuroma,
malignant schwannoma, neurofibrosarcoma, neurogenic sarcoma,
nodular tenosynovitis, synovial sarcoma, hemangioma, glomus tumor,
hemangiopericytoma, hemangioendothelioma, angiosarcoma, Kaposi
sarcoma, lymphangioma, fibroma, elastofibroma, superficial
fibromatosis, fibrous histiocytoma, fibrosarcoma, fibromatosis,
dermatofibrosarcoma protuberans (DFSP), malignant fibrous
histiocytoma (MFH), myxoma, granular cell tumor, malignant
mesenchymomas, alveolar soft-part sarcoma, epithelioid sarcoma,
clear cell sarcoma, and desmoplastic small cell tumor. In a
particular embodiment, the soft tissue cancer is a sarcoma selected
from the group consisting of a fibrosarcoma, a gastrointestinal
sarcoma, a leiomyosarcoma, a dedifferentiated liposarcoma, a
pleomorphic liposarcoma, a malignant fibrous histiocytoma, a round
cell sarcoma, and a synovial sarcoma.
[0145] In some embodiments, the present teachings provide methods
of inhibiting the growth of tumor-initiating cells or reducing the
likelihood of recurrence of a cancer in a subject who is undergoing
an anti-cancer therapy. The method comprises the steps of:
[0146] a) assessing the subject to determine whether the cancer is
in remission; and
[0147] b) if the cancer is in remission; then administering to the
subject an effective amount of a TTK inhibitor (e.g., a compound
represented by Structural Formula (I)). If the cancer is not in
remission, the method optionally further comprises the step of
continuing the anti-cancer therapy until the cancer goes into
remission and then the step b) of administering an effective amount
of a TTK inhitior (e.g., a compound represented by Structural
Formula (I)).
[0148] As used herein, the term "tumor-initiating cells" or "TICs"
refer to cells present within some tumors that possess the ability
to self-renew and proliferate. These cells are sometimes called
cancer stem cells (CSCs) and may be observed to share certain
characteristics with normal stem cells, including a stem cell-like
phenotype and function. In some embodiments, TICs are characterized
by their ability to form tumors after xenotransplantation in
immunodeficient mice.
[0149] In some embodiments, the present teachings provide methods
of inhibiting the growth of tumor-initiating cells or reducing the
likelihood of recurrence of a cancer in a subject whose cancer is
in remission comprising administering to the subject an effective
amount of a TTK inhbitior (e.g, a compound represented by
Structural Formula (I)).
[0150] In some embodiments, e.g., where the subject is being
treated to reduce the likelihood of recurrence of a cancer, the
subject has already been treated with an anti-cancer therapy.
Alternatively, the subject has already been treated with an
anti-cancer therapy and the subject is in remission.
[0151] In some embodiments, the present teachings provide methods
of treating a subject with a cancer comprising administering to the
subject an effective amount of a compound represented by Structural
Formula (I) in combination with an effective anti-cancer therapy.
In one embodiment, the cancer is a metastatic cancer. A "metastatic
cancer" is a cancer that has spread from its primary site to other
parts of the body.
[0152] In another embodiment, the present teachings are directed to
a method of treating a subject with a drug-resistant cancer. A
"drug-resistant cancer" is a cancer that is not responsive to one,
two, three, four, five or more drugs that are typically used for
the treatment of the cancer. In one embodiment, the drug-resistant
cancer is mediated by the growth of tumor-initiating cells.
[0153] The term "inhibiting the growth of tumor-initiating cells"
refers to preventing or decreasing the rate of the proliferation
and/or survival of the tumor-initiating cells.
[0154] As used herein, the term "reducing the likelihood of
recurrence of a cancer" means partially or totally inhibiting,
preventing or delaying the return of a cancer at or near a primary
site and/or at a secondary site after a period of remission. It
also means that the cancer is less likely to return with treatment
described herein than in its absense.
[0155] As used herein, the term "remission" refers to a state of
cancer, wherein the clinical symptoms or indicators associated with
a cancer have disappeared or cannot be detected, typically after
the subject has been successfully treated with an anti-cancer
therapy.
[0156] As used herein, "treating a subject with a cancer" includes
achieving, partially or substantially, one or more of the
following: arresting the growth, reducing the extent of the cancer
(e.g., reducing size of a tumor), inhibiting the growth rate of the
cancer, ameliorating or improving a clinical symptom or indicator
associated with the cancer (such as tissue or serum components) or
increasing longevity of the subject; and reducing the likelihood of
recurrence of the cancer.
[0157] Suitable methods known in the art can be used for assessing
a subject to determine whether the cancer is in remission. For
example, the size of the tumor and/or tumor markers, usually
proteins associated with tumors, can be monitored to determine the
state of the cancer. Size of the tumor can be monitored with
imaging devices, such as X-ray, MRI, CAT scans, ultrasound,
mammography, PET and the like or via biopsy.
[0158] For methods described herein, e.g., coadministration
methods, the anti-cancer therapy is selected from the group
consisting of surgery, radiation therapy, immunotherapy, endocrine
therapy, gene therapy and administration of an anti-cancer agent.
Alternatively, the anti-cancer therapy is radiation therapy. In
another alternative, the anti-cancer therapy is immunotherapy. In
another alternative, the anti-cancer therapy is administration of
an anti-cancer agent. In yet another alternative, the anti-cancer
therapy is surgery.
[0159] Radiation therapy is the use of radiation to kill, destroy
or treat the cancers. Exemplary radiation therapy includes, but is
not limited to, gamma-radiation, neutron beam radiotherapy,
electron beam radiotherapy, proton therapy, brachytherapy, and
radioiosotope thereapy (i.e., systemic radioactive isotopes
therapy),
[0160] An endocrine therapy is a treatment that adds, blocks or
removes hormones. For example, chemotherapeutic agents that can
block the production or activity of estrogen have been used for
treating breast cancer. In addition, hormonal stimulation of the
immune system has been used to treat specific cancers, such as
renal cell carcinoma and melanoma. In one embodiment, the endocrine
therapy comprises administration of natural hormones, synthetic
hormones or other synthetic molecules that may block or increase
the production of the body's natural hormones. In another
embodiment, the endocrine therapy includes removal of a gland that
makes a certain hormone.
[0161] As use herein, a gene therapy is the insertion of genes into
a subject's cell and biological tissues to treat diseases, such as
cancer. Exemplary gene therapy includes, but is not limited to, a
germ line gene therapy and a somatic gene therapy.
[0162] Immunotherapy (also called biological response modifier
therapy, biologic therapy, biotherapy, immune therapy, or
biological therapy) is treatment that uses parts of the immune
system to fight disease. Immunotherapy can help the immune system
recognize cancer cells, or enhance a response against cancer cells.
Immunotherapies include active and passive immunotherapies. Active
immunotherapies stimulate the body's own immune system while
passive immunotherapies generally use immune system components
created outside of the body.
[0163] Examples of active immunotherapies include, but are not
limited to vaccines including cancer vaccines, tumor cell vaccines
(autologous or allogeneic), dendritic cell vaccines, antigen
vaccines, anti-idiotype vaccines, DNA vaccines, viral vaccines, or
Tumor-Infiltrating Lymphocyte (TIL) Vaccine with Interleukin-2
(IL-2) or Lymphokine-Activated Killer (LAK) Cell Therapy.
[0164] Examples of passive immunotherapies include but are not
limited to monoclonal antibodies and targeted therapies containing
toxins. Monoclonal antibodies include naked antibodies and
conjugated monoclonal antibodies (also called tagged, labeled, or
loaded antibodies). Naked monoclonal antibodies do not have a drug
or radioactive material attached whereas conjugated monoclonal
antibodies are joined to, for example, a chemotherapy drug
(chemolabeled), a radioactive particle (radiolabeled), or a toxin
(immunotoxin). Examples of these naked monoclonal antibody drugs
include, but are not limited to Rituximab (Rituxan), an antibody
against the CD20 antigen used to treat, for example, B cell
non-Hodgkin lymphoma; Trastuzumab (Herceptin), an antibody against
the HER2 protein used to treat, for example, advanced breast
cancer; Alemtuzumab (Campath), an antibody against the CD52 antigen
used to treat, for example, B cell chronic lymphocytic leukemia
(B-CLL); Cetuximab (Erbitux), an antibody against the EGFR protein
used, for example, in combination with irinotecan to treat, for
example, advanced colorectal cancer and head and neck cancers; and
Bevacizumab (Avastin) which is an antiangiogenesis therapy that
works against the VEGF protein and is used, for example, in
combination with chemotherapy to treat, for example, metastatic
colorectal cancer. Examples of the conjugated monoclonal antibodies
include, but are not limited to Radiolabeled antibody Ibritumomab
tiuxetan (Zevalin) which delivers radioactivity directly to
cancerous B lymphocytes and is used to treat, for example, B cell
non-Hodgkin lymphoma; radiolabeled antibody Tositumomab (Bexxar)
which is used to treat, for example, certain types of non-Hodgkin
lymphoma; and immunotoxin Gemtuzumab ozogamicin (Mylotarg) which
contains calicheamicin and is used to treat, for example, acute
myelogenous leukemia (AML). BL22 is a conjugated monoclonal
antibody for treating, for example, hairy cell leukemia,
immunotoxins for treating, for example, leukemias, lymphomas, and
brain tumors, and radiolabeled antibodies such as OncoScint for
example, for colorectal and ovarian cancers and ProstaScint for
example, for prostate cancers.
[0165] Further examples of therapeutic antibodies that can be used
include, but are not limited to, HERCEPTIN.RTM. (Trastuzumab)
(Genentech, CA) which is a humanized anti-HER2 monoclonal antibody
for the treatment of patients with metastatic breast cancer;
REOPRO.RTM. (abciximab) (Centocor) which is an anti-glycoprotein
IIb/IIIa receptor on the platelets for the prevention of clot
formation; ZENAPAX.RTM. (daclizumab) (Roche Pharmaceuticals,
Switzerland) which is an immunosuppressive, humanized anti-CD25
monoclonal antibody for the prevention of acute renal allograft
rejection; PANOREX.TM. which is a murine anti-17-IA cell surface
antigen IgG2a antibody (Glaxo Wellcome/Centocor); BEC2 which is a
murine anti-idiotype (GD3 epitope) IgG antibody (ImClone System);
IMC-C225 which is a chimeric anti-EGFR IgG antibody (ImClone
System); VITAXIN.TM. which is a humanized anti-.alpha.V.beta.3
integrin antibody (Applied Molecular Evolution/MedImmune); Campath
1H/LDP-03 which is a humanized anti CD52 IgG1 antibody (Leukosite);
Smart M195 which is a humanized anti-CD33 IgG antibody (Protein
Design Lab/Kanebo); RITUXAN.TM. which is a chimeric anti-CD20 IgG1
antibody (IDEC Pharm/Genentech, Roche/Zettyaku); LYMPHOCIDE.TM.
which is a humanized anti-CD22 IgG antibody (Immunomedics);
LYMPHOCIDE.TM. Y-90 (Immunomedics); Lymphoscan (Tc-99m-labeled;
radioimaging; Immunomedics); Nuvion (against CD3; Protein Design
Labs); CM3 is a humanized anti-ICAM3 antibody (ICOS Pharm);
IDEC-114 is a primatied anti-CD80 antibody (IDEC Pharm/Mitsubishi);
ZEVALIN.TM. is a radiolabelled murine anti-CD20 antibody
(IDEC/Schering AG); IDEC-131 is a humanized anti-CD40L antibody
(IDEC/Eisai); IDEC-151 is a primatized anti-CD4 antibody (IDEC);
IDEC-152 is a primatized anti-CD23 antibody (IDEC/Seikagaku); SMART
anti-CD3 is a humanized anti-CD3 IgG (Protein Design Lab); 5G1.1 is
a humanized anti-complement factor 5 (C5) antibody (Alexion Pharm);
D2E7 is a humanized anti-TNF-.alpha. antibody (CAT/BASF); CDP870 is
a humanized anti-TNF-.alpha. Fab fragment (Celltech); IDEC-151 is a
primatized anti-CD4 IgG1 antibody (IDEC Pharm/SmithKline Beecham);
MDX-CD4 is a human anti-CD4 IgG antibody (Medarex/Eisai/Genmab);
CD20-sreptdavidin (+biotin-yttrium 90; NeoRx); CDP571 is a
humanized anti-TNF-.alpha. IgG4 antibody (Celltech); LDP-02 is a
humanized anti-.alpha.4.delta.7 antibody (LeukoSite/Genentech);
OrthoClone OKT4A is a humanized anti-CD4 IgG antibody (Ortho
Biotech); ANTOVA.TM. is a humanized anti-CD40L IgG antibody
(Biogen); ANTEGREN.TM. is a humanized anti-VLA-4 IgG antibody
(Elan); and CAT-152 is a human anti-TGF-.beta..sub.2 antibody
(Cambridge Ab Tech).
[0166] Immunotherapies that can be used in the present teachings
include adjuvant immunotherapies. Examples include cytokines, such
as granulocyte-macrophage colony-stimulating factor (GM-CSF),
granulocyte-colony stimulating factor (G-CSF), macrophage
inflammatory protein (MIP)-1-alpha, interleukins (including IL-1,
IL-2, IL-4, IL-6, IL-7, IL-12, IL-15, IL-18, IL-21, and IL-27),
tumor necrosis factors (including TNF-alpha), and interferons
(including IFN-alpha, IFN-beta, and IFN-gamma); aluminum hydroxide
(alum); Bacille Calmette-Gudrin (BCG); Keyhole limpet hemocyanin
(KLH); Incomplete Freund's adjuvant (IFA); QS-21; DETOX;
Levamisole; and Dinitrophenyl (DNP), and combinations thereof, such
as, for example, combinations of, interleukins, for example, IL-2
with other cytokines, such as IFN-alpha.
[0167] Alternatively, the anti-cancer therapy described herein
includes administration of an anti-cancer agent. An "anti-cancer
agent" is a compound, which when administered in an effective
amount to a subject with cancer, can achieve, partially or
substantially, one or more of the following: arresting the growth,
reducing the extent of a cancer (e.g., reducing size of a tumor),
inhibiting the growth rate of a cancer, and ameliorating or
improving a clinical symptom or indicator associated with a cancer
(such as tissue or serum components) or increasing longevity of the
subject.
[0168] The anti-cancer agent suitable for use in the methods
described herein include any anti-cancer agents that have been
approved for the treatment of cancer. In one embodiment, the
anti-cancer agent includes, but is not limited to, a targeted
antibody, an angiogenisis inhibitor, an alkylating agent, an
antimetabolite, a vinca alkaloid, a taxane, a podophyllotoxin, a
topoisomerase inhibitor, a hormonal antineoplastic agent and other
antineoplastic agents.
[0169] Examples of alkylating agents useful in the methods of the
present teachings include but are not limited to, nitrogen mustards
(e.g., mechloroethamine, cyclophosphamide, chlorambucil, melphalan,
etc.), ethylenimine and methylmelamines (e.g., hexamethlymelamine,
thiotepa), alkyl sulfonates (e.g., busulfan), nitrosoureas (e.g.,
carmustine, lomusitne, semustine, streptozocin, etc.), or triazenes
(decarbazine, etc.). Examples of antimetabolites useful in the
methods of the present teachings include but are not limited to
folic acid analog (e.g., methotrexate), or pyrimidine analogs
(e.g., fluorouracil, floxouridine, Cytarabine), purine analogs
(e.g., mercaptopurine, thioguanine, pentostatin). Examples of plant
alkaloids and terpenoids or derivatives thereof include, but are
not limited to, vinca alkaloids (e.g., vincristine, vinblastine,
vinorelbine, vindesine), podophyllotoxin, and taxanes (e.g.,
paclitaxel, docetaxel). Examples of a topoisomerase inhibitor
includes, but is not limited to, irinotecan, topotecan, amsacrine,
etoposide, etoposide phosphate and teniposide. Examples of
antineoplastic agents include, but are not limited to, actinomycin,
anthracyclines (e.g., doxorubicin, daunorubicin, valrubicin,
idarubicin, epirubicin), bleomycin, plicamycin and mitomycin.
[0170] In one embodiment, the anti-cancer agents that can be used
in the present teachings include Adriamycin, Dactinomycin,
Bleomycin, Vinblastine, Cisplatin, acivicin; aclarubicin; acodazole
hydrochloride; acronine; adozelesin; aldesleukin; altretamine;
ambomycin; ametantrone acetate; aminoglutethimide; amsacrine;
anastrozole; anthramycin; asparaginase; asperlin; azacitidine;
azetepa; azotomycin; batimastat; benzodepa; bicalutamide;
bisantrene hydrochloride; bisnafide dimesylate; bizelesin;
bleomycin sulfate; brequinar sodium; bropirimine; busulfan;
cactinomycin; calusterone; caracemide; carbetimer; carboplatin;
carmustine; carubicin hydrochloride; carzelesin; cedefingol;
chlorambucil; cirolemycin; cladribine; crisnatol mesylate;
cyclophosphamide; cytarabine; dacarbazine; daunorubicin
hydrochloride; decitabine; dexormaplatin; dezaguanine; dezaguanine
mesylate; diaziquone; doxorubicin; doxorubicin hydrochloride;
droloxifene; droloxifene citrate; dromostanolone propionate;
duazomycin; edatrexate; eflornithine hydrochloride; elsamitrucin;
enloplatin; enpromate; epipropidine; epirubicin hydrochloride;
erbulozole; esorubicin hydrochloride; estramustine; estramustine
phosphate sodium; etanidazole; etoposide; etoposide phosphate;
etoprine; fadrozole hydrochloride; fazarabine; fenretinide;
floxuridine; fludarabine phosphate; fluorouracil; fluorocitabine;
fosquidone; fostriecin sodium; gemcitabine; gemcitabine
hydrochloride; hydroxyurea; idarubicin hydrochloride; ifosfamide;
ilmofosine; interleukin II (including recombinant interleukin II,
or rIL2), interferon alfa-2a; interferon alfa-2b; interferon
alfa-n1; interferon alfa-n3; interferon beta-I a; interferon
gamma-I b; iproplatin; irinotecan hydrochloride; lanreotide
acetate; letrozole; leuprolide acetate; liarozole hydrochloride;
lometrexol sodium; lomustine; losoxantrone hydrochloride;
masoprocol; maytansine; mechlorethamine hydrochloride; megestrol
acetate; melengestrol acetate; melphalan; menogaril;
mercaptopurine; methotrexate; methotrexate sodium; metoprine;
meturedepa; mitindomide; mitocarcin; mitocromin; mitogillin;
mitomalcin; mitomycin; mitosper; mitotane; mitoxantrone
hydrochloride; mycophenolic acid; nocodazole; nogalamycin;
ormaplatin; oxisuran; pegaspargase; peliomycin; pentamustine;
peplomycin sulfate; perfosfamide; pipobroman; piposulfan;
piroxantrone hydrochloride; plicamycin; plomestane; porfimer
sodium; porfiromycin; prednimustine; procarbazine hydrochloride;
puromycin; puromycin hydrochloride; pyrazofurin; riboprine;
rogletimide; safingol; safingol hydrochloride; semustine;
simtrazene; sparfosate sodium; sparsomycin; spirogermanium
hydrochloride; spiromustine; spiroplatin; streptonigrin;
streptozocin; sulofenur; talisomycin; tecogalan sodium; tegafur;
teloxantrone hydrochloride; temoporfin; teniposide; teroxirone;
testolactone; thiamiprine; thioguanine; thiotepa; tiazofurin;
tirapazamine; toremifene citrate; trestolone acetate; triciribine
phosphate; trimetrexate; trimetrexate glucuronate; triptorelin;
tubulozole hydrochloride; uracil mustard; uredepa; vapreotide;
verteporfin; vinblastine sulfate; vincristine sulfate; vindesine;
vindesine sulfate; vinepidine sulfate; vinglycinate sulfate;
vinleurosine sulfate; vinorelbine tartrate; vinrosidine sulfate;
vinzolidine sulfate; vorozole; zeniplatin; zinostatin; zorubicin
hydrochloride.
[0171] Yet other anti-cancer agents/drugs that can be used in the
present teachings include, but are not limited to: 20-epi-1,25
dihydroxyvitamin D3; 5-ethynyluracil; abiraterone; aclarubicin;
acylfulvene; adecypenol; adozelesin; aldesleukin; ALL-TK
antagonists; altretamine; ambamustine; amidox; amifostine;
aminolevulinic acid; amrubicin; amsacrine; anagrelide; anastrozole;
andrographolide; angiogenesis inhibitors; antagonist D; antagonist
G; antarelix; anti-dorsalizing morphogenetic protein-1;
antiandrogen, prostatic carcinoma; antiestrogen; antineoplaston;
antisense oligonucleotides; aphidicolin glycinate; apoptosis gene
modulators; apoptosis regulators; apurinic acid; ara-CDP-DL-PTBA;
arginine deaminase; asulacrine; atamestane; atrimustine;
axinastatin 1; axinastatin 2; axinastatin 3; azasetron; azatoxin;
azatyrosine; baccatin III derivatives; balanol; batimastat; BCR/ABL
antagonists; benzochlorins; benzoylstaurosporine; beta lactam
derivatives; beta-alethine; betaclamycin B; betulinic acid; bFGF
inhibitor; bicalutamide; bisantrene; bisaziridinylspermine;
bisnafide; bistratene A; bizelesin; breflate; bropirimine;
budotitane; buthionine sulfoximine; calcipotriol; calphostin C;
camptothecin derivatives; canarypox IL-2; capecitabine;
carboxamide-amino-triazole; carboxyamidotriazole; CaRest M3; CARN
700; cartilage derived inhibitor; carzelesin; casein kinase
inhibitors (ICOS); castanospermine; cecropin B; cetrorelix;
chlorlns; chloroquinoxaline sulfonamide; cicaprost; cis-porphyrin;
cladribine; clomifene analogues; clotrimazole; collismycin A;
collismycin B; combretastatin A4; combretastatin analogue;
conagenin; crambescidin 816; crisnatol; cryptophycin 8;
cryptophycin A derivatives; curacin A; cyclopentanthraquinones;
cycloplatam; cypemycin; cytarabine ocfosfate; cytolytic factor;
cytostatin; dacliximab; decitabine; dehydrodidemnin B; deslorelin;
dexamethasone; dexifosfamide; dexrazoxane; dexverapamil;
diaziquone; didemnin B; didox; diethylnorspermine;
dihydro-5-azacytidine; 9-dioxamycin; diphenyl spiromustine;
docosanol; dolasetron; doxifluridine; droloxifene; dronabinol;
duocarmycin SA; ebselen; ecomustine; edelfosine; edrecolomab;
eflornithine; elemene; emitefur; epirubicin; epristeride;
estramustine analogue; estrogen agonists; estrogen antagonists;
etanidazole; etoposide phosphate; exemestane; fadrozole;
fazarabine; fenretinide; filgrastim; finasteride; flavopiridol;
flezelastine; fluasterone; fludarabine; fluorodaunorunicin
hydrochloride; forfenimex; formestane; fostriecin; fotemustine;
gadolinium texaphyrin; gallium nitrate; galocitabine; ganirelix;
gelatinase inhibitors; gemcitabine; glutathione inhibitors;
hepsulfam; heregulin; hexamethylene bisacetamide; hypericin;
ibandronic acid; idarubicin; idoxifene; idramantone; ilmofosine;
ilomastat; imidazoacridones; imiquimod; immunostimulant peptides;
insulin-like growth factor-1 receptor inhibitor; interferon
agonists; interferons; interleukins; iobenguane; iododoxorubicin;
ipomeanol, 4-; iroplact; irsogladine; isobengazole;
isohomohalicondrin B; itasetron; jasplakinolide; kahalalide F;
lamellarin-N triacetate; lanreotide; leinamycin; lenograstim;
lentinan sulfate; leptolstatin; letrozole; leukemia inhibiting
factor; leukocyte alpha interferon;
leuprolide+estrogen+progesterone; leuprorelin; levamisole;
liarozole; linear polyamine analogue; lipophilic disaccharide
peptide; lipophilic platinum compounds; lissoclinamide 7;
lobaplatin; lombricine; lometrexol; lonidamine; losoxantrone;
lovastatin; loxoribine; lurtotecan; lutetium texaphyrin;
lysofylline; lytic peptides; maitansine; mannostatin A; marimastat;
masoprocol; maspin; matrilysin inhibitors; matrix metalloproteinase
inhibitors; menogaril; merbarone; meterelin; methioninase;
metoclopramide; MIF inhibitor; mifepristone; miltefosine;
mirimostim; mismatched double stranded RNA; mitoguazone;
mitolactol; mitomycin analogues; mitonafide; mitotoxin fibroblast
growth factor-saporin; mitoxantrone; mofarotene; molgramostim;
monoclonal antibody, human chorionic gonadotrophin; monophosphoryl
lipid A+myobacterium cell wall sk; mopidamol; multiple drug
resistance gene inhibitor; multiple tumor suppressor 1-based
therapy; mustard anticancer agent; mycaperoxide B; mycobacterial
cell wall extract; myriaporone; N-acetyldinaline; N-substituted
benzamides; nafarelin; nagrestip; naloxone+pentazocine; napavin;
naphterpin; nartograstim; nedaplatin; nemorubicin; neridronic acid;
neutral endopeptidase; nilutamide; nisamycin; nitric oxide
modulators; nitroxide antioxidant; nitrullyn; O6-benzylguanine;
octreotide; okicenone; oligonucleotides; onapristone; ondansetron;
ondansetron; oracin; oral cytokine inducer; ormaplatin; osaterone;
oxaliplatin; oxaunomycin; palauamine; palmitoylrhizoxin; pamidronic
acid; panaxytriol; panomifene; parabactin; pazelliptine;
pegaspargase; peldesine; pentosan polysulfate sodium; pentostatin;
pentrozole; perflubron; perfosfamide; perillyl alcohol;
phenazinomycin; phenylacetate; phosphatase inhibitors; picibanil;
pilocarpine hydrochloride; pirarubicin; piritrexim; placetin A;
placetin B; plasminogen activator inhibitor; platinum complex;
platinum compounds; platinum-triamine complex; porfimer sodium;
porfiromycin; prednisone; propyl bis-acridone; prostaglandin J2;
proteasome inhibitors; protein A-based immune modulator; protein
kinase C inhibitor; protein kinase C inhibitors, microalgal;
protein tyrosine phosphatase inhibitors; purine nucleoside
phosphorylase inhibitors; purpurins; pyrazoloacridine;
pyridoxylated hemoglobin polyoxyethylene conjugate; raf
antagonists; raltitrexed; ramosetron; ras farnesyl protein
transferase inhibitors; ras inhibitors; ras-GAP inhibitor;
retelliptine demethylated; rhenium Re 186 etidronate; rhizoxin;
ribozymes; RII retinamide; rogletimide; rohitukine; romurtide;
roquinimex; rubiginone B1; ruboxyl; safingol; saintopin; SarCNU;
sarcophytol A; sargramostim; Sdi 1 mimetics; semustine; senescence
derived inhibitor 1; sense oligonucleotides; signal transduction
inhibitors; signal transduction modulators; single chain
antigen-binding protein; sizofuran; sobuzoxane; sodium borocaptate;
sodium phenylacetate; solverol; somatomedin binding protein;
sonermin; sparfosic acid; spicamycin D; spiromustine; splenopentin;
spongistatin 1; squalamine; stem cell inhibitor; stem-cell division
inhibitors; stipiamide; stromelysin inhibitors; sulfinosine;
superactive vasoactive intestinal peptide antagonist; suradista;
suramin; swainsonine; synthetic glycosaminoglycans; tallimustine;
tamoxifen methiodide; tauromustine; tazarotene; tecogalan sodium;
tegafur; tellurapyrylium; telomerase inhibitors; temoporfin;
temozolomide; teniposide; tetrachlorodecaoxide; tetrazomine;
thaliblastine; thiocoraline; thrombopoietin; thrombopoietin
mimetic; thymalfasin; thymopoietin receptor agonist; thymotrinan;
thyroid stimulating hormone; tin ethyl etiopurpurin; tirapazamine;
titanocene bichloride; topsentin; toremifene; totipotent stem cell
factor; translation inhibitors; tretinoin; triacetyluridine;
triciribine; trimetrexate; triptorelin; tropisetron; turosteride;
tyrosine kinase inhibitors; tyrphostins; UBC inhibitors; ubenimex;
urogenital sinus-derived growth inhibitory factor; urokinase
receptor antagonists; vapreotide; variolin B; vector system,
erythrocyte gene therapy; velaresol; veramine; verdins;
verteporfin; vinorelbine; vinxaltine; vitaxin; vorozole;
zanoterone; zeniplatin; zilascorb; and zinostatin stimalamer.
Preferred additional anti-cancer drugs are 5-fluorouracil and
leucovorin.
[0172] In one embodiment, the anti-cancer agents that can be used
in methods described herein are selected from the group consisting
of paclitaxel, docetaxel, 5-fluorouracil, trastuzumab, lapatinib,
bevacizumab, letrozole, goserelin, tamoxifen, cetuximab,
panitumumab, gemcitabine, capecitabine, irinotecan, oxaliplatin,
carboplatin, cisplatin, doxorubicin, epirubicin, cyclophosphamide,
methotrexate, vinblastine, vincristine, melphalan and a combination
thereof.
[0173] In one embodiment, the anti-cancer agent and the compound
represented by Structural Formula (I) are administered
contemporaneously. When administered contemporaneously, the
anti-cancer agent and the compound can be administered in the same
formulation or in different formulations. Alternatively, the
compound and the additional anti-cancer agent are administered
separately.
[0174] In one embodiment, the subject in the methods described
herein has not been previously treated with a TTK inhibitor (e.g.,
the compound represented by Structural Formula (I)).
[0175] The term an "effective amount" means an amount when
administered to the subject which results in beneficial or desired
results, including clinical results, e.g., inhibits, suppresses or
reduces the cancer (e.g., as determined by clinical symptoms or the
amount of cancer cells) in a subject as compared to a control.
Specifically, "treating a subject with a cancer" includes
achieving, partially or substantially, one or more of the
following: arresting the growth, reducing the extent of a cancer
(e.g., reducing size of a tumor), inhibiting the growth rate of a
cancer, and ameliorating or improving a clinical symptom or
indicator associated with a cancer (such as tissue or serum
components) or increasing longevity of the subject.
[0176] Generally, an effective amount of a compound taught herein
varies depending upon various factors, such as the given drug or
compound, the pharmaceutical formulation, the route of
administration, the type of disease or disorder, the identity of
the subject or host being treated, and the like, but can
nevertheless be routinely determined by one skilled in the art. An
effective amount of a compound of the present teachings may be
readily determined by one of ordinary skill by routine methods
known in the art.
[0177] In an embodiment, an effective amount of a compound taught
herein ranges from about 0.1 to about 1000 mg/kg body weight,
alternatively about 1 to about 500 mg/kg body weight, and in
another alternative, from about 20 to about 300 mg/kg body weight.
In another embodiment, an effective amount of a compound taught
herein ranges from about 0.5 to about 5000 mg/m.sup.2,
alternatively about from 5 to about 2500 mg/m.sup.2, and in another
alternative from about 50 to about 1000 mg/m.sup.2. The skilled
artisan will appreciate that certain factors may influence the
dosage required to effectively treat a subject suffering from
cancer or reduce the likelihood of recurrence of a cancer. These
factors include, but are not limited to, the severity of the
disease or disorder, previous treatments, the general health and/or
age of the subject and other diseases present.
[0178] Moreover, for methods described herein (including treating a
subject with a cancer or reducing the likelihood of recurrence of a
cancer), a "treatment" or dosing regime of a subject with an
effective amount of the compound of the present teachings may
consist of a single administration, or alternatively comprise a
series of applications. For example, the compound of the present
teachings may be administered at least once a week. However, in
another embodiment, the compound may be administered to the subject
from about one time per week to once daily for a given treatment.
The length of the treatment period depends on a variety of factors,
such as the severity of the disease, the age of the patient, the
concentration and the activity of the compounds of the present
teachings, or a combination thereof. It will also be appreciated
that the effective dosage of the compound used for the treatment
may increase or decrease over the course of a particular treatment
regime. Changes in dosage may result and become apparent by
standard diagnostic assays known in the art. In some instances,
chronic administration may be required.
[0179] As used herein, "treatment" is an approach for obtaining
beneficial or desired results, including clinical results.
Beneficial or desired clinical results can include, but are not
limited to, alleviation or amelioration of one or more symptoms or
conditions, diminishment of extent of disease, stabilized (i.e. not
worsening) state of disease, delay or slowing of disease
progression, amelioration or palliation of the disease state, and
remission (whether partial or total), whether detectable or
undetectable. "Treatment" can also mean prolonging survival as
compared to expected survival if not receiving treatment.
[0180] A "subject" is a mammal, preferably a human, but can also be
an animal in need of veterinary treatment, e.g., companion animals
(e.g., dogs, cats, and the like), farm animals (e.g., cows, sheep,
pigs, horses, and the like) and laboratory animals (e.g., rats,
mice, guinea pigs, and the like).
[0181] The compounds taught herein can be administered to a patient
in a variety of forms depending on the selected route of
administration, as will be understood by those skilled in the art.
The compounds of the present teachings may be administered, for
example, by oral, parenteral, buccal, sublingual, nasal, rectal,
patch, pump or transdermal administration and the pharmaceutical
compositions formulated accordingly. Parenteral administration
includes intravenous, intraperitoneal, subcutaneous, intramuscular,
transepithelial, nasal, intrapulmonary, intrathecal, rectal and
topical modes of administration. Parenteral administration can be
by continuous infusion over a selected period of time.
[0182] The compounds taught herein can be suitably formulated into
pharmaceutical compositions for administration to a subject. The
pharmaceutical compositions of the present teachings optionally
include one or more pharmaceutically acceptable carriers and/or
diluents therefor, such as lactose, starch, cellulose and dextrose.
Other excipients, such as flavoring agents; sweeteners; and
preservatives, such as methyl, ethyl, propyl and butyl parabens,
can also be included. More complete listings of suitable excipients
can be found in the Handbook of Pharmaceutical Excipients (5.sup.th
Ed., Pharmaceutical Press (2005)). A person skilled in the art
would know how to prepare formulations suitable for various types
of administration routes. Conventional procedures and ingredients
for the selection and preparation of suitable formulations are
described, for example, in Remington's Pharmaceutical Sciences
(2003-20th edition) and in The United States Pharmacopeia: The
National Formulary (USP 24 NF19) published in 1999. The carriers,
diluents and/or excipients are "acceptable" in the sense of being
compatible with the other ingredients of the pharmaceutical
composition and not deleterious to the recipient thereof.
[0183] Typically, for oral therapeutic administration, a compound
of the present teachings may be incorporated with excipient and
used in the form of ingestible tablets, buccal tablets, troches,
capsules, elixirs, suspensions, syrups, wafers, and the like.
[0184] Typically for parenteral administration, solutions of a
compound of the present teachings can generally be prepared in
water suitably mixed with a surfactant such as
hydroxypropylcellulose. Dispersions can also be prepared in
glycerol, liquid polyethylene glycols, DMSO and mixtures thereof
with or without alcohol, and in oils. Under ordinary conditions of
storage and use, these preparations contain a preservative to
prevent the growth of microorganisms.
[0185] Typically, for injectable use, sterile aqueous solutions or
dispersion of, and sterile powders of, a compound described herein
for the extemporaneous preparation of sterile injectable solutions
or dispersions are appropriate.
[0186] For nasal administration, the compounds of the present
teachings can be formulated as aerosols, drops, gels and powders.
Aerosol formulations typically comprise a solution or fine
suspension of the active substance in a physiologically acceptable
aqueous or non-aqueous solvent and are usually presented in single
or multidose quantities in sterile form in a sealed container,
which can take the form of a cartridge or refill for use with an
atomizing device. Alternatively, the sealed container may be a
unitary dispensing device such as a single dose nasal inhaler or an
aerosol dispenser fitted with a metering valve which is intended
for disposal after use. Where the dosage form comprises an aerosol
dispenser, it will contain a propellant which can be a compressed
gas such as compressed air or an organic propellant such as
fluorochlorohydrocarbon. The aerosol dosage forms can also take the
form of a pump-atomizer.
[0187] For buccal or sublingual administration, the compounds of
the present teachings can be formulated with a carrier such as
sugar, acacia, tragacanth, or gelatin and glycerine, as tablets,
lozenges or pastilles.
[0188] For rectal administration, the compounds described herein
can be formulated in the form of suppositories containing a
conventional suppository base such as cocoa butter.
[0189] Compounds described herein may be prepared using the
reaction routes and syntheses described below, employing the
techniques available in the art using starting materials that are
readily available.
[0190] In one general synthetic process, compounds described herein
can be prepared according to the following reaction Scheme 1.
Halogenation of an appropriately substituted indazole wherein the
indazole is substituted as defined herein provides intermediate 1
that can be reacted with a suitable cross coupling partner, ArMet
(e.g. ArBpin), in the presence of a metal catalyst (e.g.
PdCl.sub.2(dppf) or Pd(PPh.sub.3).sub.4).
##STR00030##
[0191] Alternatively, haloindazole 2 can be converted into a
3-(trialkylstannyl)-1H-indazole that can be subjected to
Stille-type cross-coupling reaction as shown in Scheme 2 (e.g. 1.
Me.sub.6Sn.sub.2/Pd(PPh.sub.3).sub.4/PhMe 2.
ArI/Pd(PPh.sub.3).sub.4/CuI/THF ref. WO200102369).
##STR00031##
[0192] Compounds described herein can also be prepared according to
the general procedures shown in the Scheme 3. 5-Aminoindazole is
protected by a suitable aniline protecting group such as a Boc
group followed by halogenations (e.g. I.sub.2/K.sub.2CO.sub.3). A
sequence of Suzuki-Miyaura cross coupling and removal of the
protecting group yields anilines 2 that can be reacted with a
variety of electrophilic reagents (e.g. R--NCO, R'R''NH/phosgene or
triphosgene, ROH/triphosgene,
RNHSO.sub.2NHC(.dbd.O)CH.sub.2CH.sub.2Cl, RSO.sub.2Cl,
RC(.dbd.O)R'/reducing agent, RCOCl or RCO.sub.2H/coupling reagent:
TBTU, EDC, DCC, HATU, pyBOP, COMU) leading to preparation of
substituted ureas, carbamates, sulfamides, sulfonamides, anilines
and amides.
[0193] Alternatively, 5-nitro-1H-indazole can be halogenated and
reduced to provide 3-halo-5-amino indazoles 3 that can be subjected
to an amide formation followed by Pd-catalyzed cross-coupling.
##STR00032##
[0194] Alternatively, compounds described herein, containing
trisubstituted indazoles can be prepared as outlined in Scheme 4.
5-Nitro-1H-indazole is halogenated with Br.sub.2, protected with a
suitable indazole protecting group such as tetrahydropyranyl, and
subjected to Miyaura-Suzuki cross coupling conditions (e.g.
ArBpin/dioxane/H.sub.2O/PdCl.sub.2(dppf)/Na.sub.2CO.sub.3).
Hydrogenation of the intermediate 1 yields 1H-indazol-5-amine 2
that can be modified in a reaction with electrophilic reagents
(e.g. R--NCO, R'R''NH/triphosgene, ROH/triphosgene,
RNHSO.sub.2NHC(.dbd.O)CH.sub.2CH.sub.2Cl, RSO.sub.2Cl,
RC(.dbd.O)R'/reducing agent, RCOCl or RCO.sub.2H/coupling reagent:
TBTU, EDC, DCC, HATU, pyBOP, COMU) before deprotection of the THP
protecting group with HCl.
##STR00033##
[0195] Compounds described herein having an carboxamide group can
be synthesized from 3-halo-1H-indazole-5-carboxylic acid in a
two-step sequence outlined below (Scheme 5).
##STR00034##
[0196] The intermediate boronic esters described herein can be
prepared as outlined in Scheme 6. Aniline-based boronic esters can
be prepared via Cu(I) catalyzed amination of an appropriately
substituted dihalobenzene followed by borylation with a suitable
borylating agent (HBpin or (Bpin).sub.2) in the presence of a
Pd-catalyst (e.g. Cl.sub.2Pd(CH.sub.3CN).sub.2 or Cl.sub.2Pddppf).
Aryloxy-based boronic esters can be prepared via reaction of an
alcohol with an appropriately substituted halofluorobenzene in the
presence of base (e.g. NaH) followed by borylation (Pd-catalyzed or
metal-halogenexchange followed by a quench with B(OR).sub.3).
##STR00035##
[0197] Compounds described herein can be prepared in a manner
analogous to the general procedures described above or the detailed
procedures described in the examples herein.
[0198] The invention is illustrated by the following examples which
are not intended to be limiting in any way.
EXEMPLIFICATION
Example A
Synthesis
General Methods
[0199] Commercially available starting materials, reagents, and
solvents were used as received. In general, anhydrous reactions
were performed under an inert atmosphere such as nitrogen or Argon.
PoraPak.RTM. Rxn CX refers to a commercial cation-exchange resin
available from Waters.
[0200] Microwave reactions were performed with a Biotage Initiator
microwave reactor. Reaction progress was generally monitored by TLC
using Merck silica gel plates with visualization by UV at 254 nm,
by analytical HPLC or by LCMS (Bruker Exquire 4000). Flash column
chromatographic purification of intermediates or final products was
performed using 230-400 mesh silica gel 60 from EMD chemicals or
Silicycle, or purified using a Biotage Isolera with KP-SIL or
HP-SIL silica cartridges, or KP-NH basic modified silica and
corresponding samplets. RPReverse-phase RPHPLC purification was
performed on a Varian PrepStar model SD-1 HPLC system with a Varian
Monochrom 10u C-18 reverse-phase column using a of about 5-30% MeCN
or MeOH/0.05% TFA-H2O to 70-90% MeCN or MeOH/0.05% TFA-H2O over a
20-40-min period at a flow rate of 30-50 mL/min. RPpurification was
also performed using a Biotage Isolera equipped with a KP-C18-H
column using a between 10-95% MeOH/0.1% TFA in H.sub.2O. Proton
NMRs were recorded on a Bruker 400 MHz spectrometer, and mass
spectra were obtained using a Bruker Esquire 4000 spectrometer.
Optical rotations were measured at the sodium D-line (589.44 nM)
using an AA-55 polarimeter from Optical Activity Ltd with a
2.5.times.100 mm unjacketed stainless steel tube at given sample
concentrations (c, units of g/100 mL).
[0201] Compound names were generated using the software built into
ChemBioDraw Ultra version 11.0 or 12.0.
ABBREVIATIONS
[0202] aq aqueous [0203] anh anhydrous [0204] Ar Argon [0205] br.
Broad [0206] BINOL 1,1'-binaphthalene-2,2'-diol [0207] calcd
calculated [0208] COMU
(1-cyano-2-ethoxy-2-oxoethylidenaminooxy)dimethylamino-morpholino-ca-
rbenium hexafluorophosphate [0209] d doublet (only when used within
1H NMR spectra) [0210] d day [0211] DCE 1,2-dichloroethane [0212]
DCM dichloromethane [0213] DIPEA diisopropylethylamine [0214] DME
1,2-dimethoxyethane [0215] DMF N,N-dimethylformamide [0216] DMSO
dimethylsulfoxide [0217] dppf 1,1'-bis(diphenylphosphino) ferrocene
[0218] e.e. enantiomeric excess [0219] h hour [0220] HPLC high
performance liquid chromatography [0221] HATU
2-(1H-7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium
hexafluorophosphate [0222] LC-MS liquid chromatography coupled to
mass spectrometry [0223] min minute [0224] m multiplet [0225] MS
ESI mass spectra, electrospray ionization [0226] NBS
N-Bromosuccinimide [0227] NMR nuclear magnetic resonance [0228] O/N
overnight [0229] PCC pyridinium chlorochromate [0230] pin pinacol
[0231] prep preparative [0232] RBF round bottomed flask [0233] rt
room temperature [0234] Rt retention time [0235] s singlet [0236]
satd saturated [0237] SPE solid phase extraction [0238] S-Phos
2-dicyclohexylphosphino-2',6'-dimethoxybiphenyl [0239] t triplet
[0240] TBTU O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium
tetrafluoroborate [0241] temp. temperature [0242] TEA triethylamine
[0243] TFA trifluoroacetic acid [0244] TLC thin layer
chromatography [0245] THF tetrahydrofuran [0246] xs excess
Preparation of Starting Materials
Method A (Amide Coupling)
[0247] A DMF solution of 3-iodo-1H-indazol-5-amine
2,2,2-trifluoroacetate (1.0 equiv), DIPEA (3 equiv) and RCO.sub.2H
(1.05 equiv) at 0.degree. C. was treated with TBTU (1.05 equiv)
added in one portion. The reaction was stirred allowing slowly to
warm to rt. After several h or overnight stirring the crude
reaction was subsequently diluted with H.sub.2O. In the majority of
examples a filtration and washing (H.sub.2O) of the precipitate
provided the desired material with the required purity or
alternatively the material was purified directly by prepHPLC or/and
flash chromatography.
[0248] Alternatively, a DMF solution of
3-iodo-1H-indazole-5-carboxylic acid (1.0 equiv), DIPEA (3 equiv)
and RR'NH (1.05 equiv) at 0.degree. C. or rt was treated with TBTU
(1.05 equiv) added in one portion. The reaction was stirred
allowing slowly to warm to rt. After several h or overnight
stirring the crude reaction was subsequently diluted with H.sub.2O.
In the majority of examples a filtration and washing (H.sub.2O) of
the precipitate provided the desired material with the required
purity or alternatively the material was purified directly by
prepHPLC or/and flash chromatography.
Method B (Iodination)
[0249] To a cooled (0.degree. C.) DMF solution indazole (1.0 equiv)
and K.sub.2CO.sub.3 or KOH (.about.3 equiv) was added I.sub.2 (2-4
equiv) in one portion. The reaction was stirred with cooling or rt
for several h and then was treated with xs 10% aq NaHSO.sub.3 and
subsequently diluted with H.sub.2O. In the majority of examples a
filtration and washing (H.sub.2O) of the precipitate provided the
desired material with the required purity.
Method C (Suzuki-Miyaura Cross Coupling)
[0250] A mixture of 3-iodo-1H-indazole (1.0 equiv), aryl boronic
acid or boronate ester (1.2 equiv), base and palladium catalyst
(0.05 equiv e.g. and PdCl.sub.2dppf.DCM, Pd(PPh.sub.3).sub.4) in
solvents was degassed with Ar and heated sealed in a Biotage
microwave reactor. The crude material was filtered through Celite
using MeOH to rinse the pad. In the majority of examples,
purification by RPHPLC provided the target material.
Method C2 (Suzuki-Miyaura Cross Coupling with
PdCl.sub.2dppf.DCM-Na.sub.2CO.sub.3)
[0251] Aq Na.sub.2CO.sub.3 (2 M, 3-4 mmol) was added to a mixture
of 5-substituted-3-iodo-1H-indazole (1.0 mmol), aryl boronic acid
or boronate ester (1.0-1.4 mmol), and PdCl.sub.2dppf.DCM (0.1 mmol)
in PhMe:EtOH (1:1, 20 mL) was heated under Ar in a Biotage
microwave reactor, an oil bath or a reaction block at temperatures
from 100-130.degree. C. The crude material was filtered through
Celite using MeOH (alternatively, acetone/MeOH or EtOAc) to rinse
the pad or partitioned between EtOAc and H.sub.2O followed by
drying (Na.sub.2SO.sub.4 or MgSO.sub.4), and evaporated and
purified by chromatography.
Method C3 (Suzuki-Miyaura Cross Coupling with
Pd(PPh.sub.3).sub.4-LiCl--Na.sub.2CO.sub.3)
[0252] Aq Na.sub.2CO.sub.3 (2 M, 5 mmol) was added to a mixture of
5-substituted-3-iodo-1H-indazole (1.0 mmol), aryl boronic acid or
boronate ester (1.0-1.4 mmol), LiCl (3 mmol) and
Pd(PPh.sub.3).sub.4 (0.1 mmol) in dioxane (12 mL) was heated under
Ar in a Biotage microwave reactor, an oil bath or a reaction block
at temperatures from 120-130.degree. C. The crude material was
filtered through Celite using MeOH or acetone/MeOH to rinse the pad
or partitioned between EtOAc and H.sub.2O followed by drying
(Na.sub.2SO.sub.4 or MgSO.sub.4), evaporated and purified by
chromatography.
Method D (Petasis Reaction)
##STR00036##
[0254] To a mixture of arylboronic acid (1 mmol) and glyoxylic acid
monohydrate (1 mmol) in CH.sub.2C2 (5 mL) was added dialkylamine (1
mmol). The resulting mixture was stirred overnight at rt. After
evaporation of solvents, it was used crude or purified by column
chromatography.
Method E (Borylation of Aryl Halides): Using
B.sub.2pin.sub.2/Pd
[0255] A mixture of aryliodide or arylbromide (1 equiv.),
bis(pinacolato)diboron (1.2 to 1.5 equiv.), KOAc (3 equiv.) and DMF
or DMSO was purged with Ar for 10 min.
[1,1'-PdCl2dppf*CH.sub.2Cl.sub.2 (3-5 mol %) was added, the vial
sealed and heated at 85.degree. C. for 2 h. The product was
partitioned between EtOAc and satd aqNaHCO.sub.3 solution, washed
with brine, dried over Na.sub.2SO.sub.4 or MgSO.sub.4, filtered,
and concentrated to dryness. The crude product was purified by
flash chromatography to give the title compound.
Method F (Boronation of Aryl Halides): Using HBpin/Pd
[0256] To a solution of aryliodide or arylbromide (1.0 mmol) in
NEt.sub.3 (3.0 mmol) and dioxane (1.0 mL) was added under Ar and
4,4,5,5-tetramethyl-1,3,2-dioxaborolane (1.5 mmol), S-Phos (0.040
mmol) and Cl.sub.2Pd(CH.sub.3CN).sub.2 (0.010 mmol) and the
reaction heated to 110.degree. C. for 3 h. The mixture was then
transferred to a separatory funnel with EtOAc (10 mL) and washed
with NaHCO.sub.3 (satd) (2.times.10 mL), H.sub.2O (10 mL), and
brine (10 mL). The organic layer was dried over MgSO.sub.4,
filtered and the solvent removed to yield pinacol boronic esters
which were used directly for subsequent steps.
Method G (Reductive Amination)
[0257] NaBH.sub.3CN (4 mmol) was added to a solution of aryl alkyl
ketone (1 mmol) and NH.sub.4OAc (12 mmol) in MeOH (4-5 mL) under
Ar, and the reaction mixture was heated at 60.degree. C. for 14-24
h. Aq. NaOH (2 M, 15 mL) was added and the product was extracted
into Et.sub.2O (3.times.40 mL). The combined Et.sub.2O layer was
washed with H.sub.2O (10 mL) and brine (10 mL), dried
(Na.sub.2SO.sub.4), filtered, concentrated to dryness and used
crude or purified by chromatography.
Method H (Nucleophilic Substitution on
1,4-hal-C.sub.6H.sub.4--F)
[0258] NaH (60% in mineral oil, 1.2 mmol) was added portion-wise to
a solution of the alcohol (1 mmol) and 1-fluoro-4-iodobenzene (1
mmol) in DMF (1.5 mL) at 0.degree. C. After 15 min, the reaction
mixture was allowed to warm to rt, then heated at 80-85.degree. C.
for 6-14 h in an oil bath. The mixture was quenched by adding
H.sub.2O (10 mL) and the product was extracted with EtOAc (30 mL).
The organic layer was washed with brine (10 mL), dried
(Na.sub.2SO.sub.4 or MgSO.sub.4), concentrated to dryness and
purified by chromatography.
Method I (Copper Catalyzed Amination of aryl-hal)
[0259] A microwave vial was charged with 1,4-diiodobenzene or
1-bromo-4-iodobenzene (1.0 equiv), CuI (20 mol %), BINOL (20 mol
%), and K.sub.3PO.sub.4 (2 equiv.). The vial was capped and then
evacuated and backfilled with Ar. Dialklyamine (1.2 equiv) and DMF
were then added. The resulting mixture was stirred at rt for 2 to 4
d. The mixture was diluted with EtOAc, filtered through a cake of
Celite and the filtrate was concentrated to give the crude product.
Crude product was purified by flash chromatography to give the
title compound.
Method J (Urea Formation)
[0260] A solution of
3-(4-((1-methylpiperidin-4-yl)oxy)phenyl)-1H-indazol-5-amine
bis(2,2,2-trifluoroacetate) (0.073 1 mmol), DIPEA (5 mmol), and DMF
(70 mL) was cooled to 0.degree. C. and then
1,3-diethyl-2-isocyanatobenzene (2 mmol) was added dropwise. The
reaction was stirred for 2 h while warming to rt. A mixture of
mono- and di-urea products were obtained which was treated directly
with NaOMe (80 uL of a 25% wt solution in MeOH) and the mixture
stirred for 15 min and then transferred to a separatory funnel with
EtOAc (15 mL). The mixture was then washed with satd aq NaHCO.sub.3
(2.times.10 mL), H.sub.2O (1.times.10 mL), and brine (1.times.10
mL). The organic layer was dried over MgSO.sub.4, filtered, and the
solvent removed and the residue was purified by chromatography
(prep-HPLC).
Intermediates:
Synthesis of 4-(4-iodophenoxy)-1-methylpiperidine
##STR00037##
[0262] A solution of 1-methylpiperidin-4-ol (20.01 g, 174 mmol) in
DMF (30 mL) was added via pipet to a cold (ice-bath) flask
containing NaH (60% in mineral oil, 8.11 g, 203 mmol) suspended in
DMF (100 mL) under Ar, and additional DMF (3.times.10 mL) was used
to rinse the vial and pipet. After the mixture was stirred in ice
bath for 30 min, 1-fluoro-4-iodobenzene (20.0 mL, 174 mmol) was
added to the mixture and the reaction mixture was allowed to stir
at rt for 30 min, then placed in an 85.degree. C. oil bath. After a
few min, due to excessive foaming, the flask was removed from the
oil bath and allowed to stir at rt for 10 min. This was repeated 3
times until no longer foaming excessively on introduction to the
oil bath, then the reaction flask was heated at 85.degree. C. in
oil bath for 24 h. After cooling to rt, H.sub.2O (50 mL) was added
dropwise at first, then rapidly when little gas evolution occurred.
The reaction mass was then poured into H.sub.2O (450 mL) and the
resulting aq. suspension was cooled in ice bath, then the
precipitate was collected by vacuum filtration, rinsing with
H.sub.2O (2.times.50 mL). The resulting solid was dissolved in MeOH
and the solvent was removed in vacuo, then EtOH was added and the
solution was evaporated in vacuo to yield the title compound as a
tan solid (36.9 g, 67%). .sup.1H NMR (400 MHz, CDCl.sub.3) .delta.
ppm 7.55 (d, J=8.9 Hz, 2H), 6.69 (d, J=8.9 Hz, 2H), 4.24-4.32 (m,
1H), 2.68 (br. s., 2H), 2.31 (s, 3H), 2.23-2.29 (m, 2H), 1.94-2.03
(m, 2H), 1.78-1.88 (m, 2H).
Synthesis of
1-methyl-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)piperi-
dine
##STR00038##
[0264] The title compound was prepared in a manner similar to
general Method F using 4-(4-iodophenoxy)-1-methylpiperidine (9.5794
g, 30.2 mmol) with S-Phos (378.8 mg, 0.92 mmol) and
Cl.sub.2Pd(CH.sub.3CN).sub.2 (59.8 mg, 0.23 mmol) at 110.degree. C.
for 6.5 h. MeOH (2 mL) was slowly added to quench excess borane,
followed by DCM (200 mL) and NaHCO.sub.3 (50 mL). After vacuum
filtration through a pad of Celite and rinsing with DCM (150 mL)
and NaHCO.sub.3 (50 mL), the layers were separated and the aq.
layer was extracted with DCM (100 mL). The combined DCM layers were
washed with H.sub.2O (50 mL), and brine (50 mL), and dried
(Na.sub.2SO.sub.4), filtered and the solvent removed to yield the
crude product. Purification by flash chromatography (SiO2, 0-15%
MeOH/DCM) gave
1-methyl-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)piperi-
dine (white solid, 7.79 g, 90% pure, 73%). .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. ppm 7.79 (d, J=8.3 Hz, 2H), 6.90 (d, J=8.5 Hz,
2H), 4.81 (br. s., 1H), 3.42 (d, J=12.0 Hz, 1H), 3.23 (t, J=12.0
Hz, 2H), 2.79 (s, 3H), 2.72 (t, J=14.3 Hz, 2H), 2.25 (d, J=14.3 Hz,
2H), 1.34 (s, 12H). MS ESI 318.1 [M+H].sup.+, calcd for
[C.sub.18H.sub.28BNO.sub.3+H].sup.+ 318.22.
Synthesis of 4-(4-bromophenoxy)-1-(2-methoxyethyl)piperidine
##STR00039##
[0266] A mixture of 4-(4-bromophenoxy)piperidine hydrochloride (1.5
g, 5.13 mmol), 1-bromo-2-methoxyethane (0.48 mL, 5.13 mmol),
K.sub.2CO.sub.3 (2.13 g, 15.4 mmol) and DMF (15 mL) was heated to
40.degree. C. and stirred for 18 h at which time the mixture was
transferred to a separatory funnel with EtOAc (250 mL) and the
organic layer washed with satd aqNaHCO.sub.3 (1.times.100 mL) and
brine (1.times.100 mL). The organic layer was dried over
MgSO.sub.4, filtered and the solvent removed to give the alkylated
material which was used for the next step.
Synthesis of
1-(2-methoxyethyl)-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phen-
oxy)piperidine
##STR00040##
[0268] To a solution of
4-(4-bromophenoxy)-1-(2-methoxyethyl)piperidine (5.13 mmol from
step A), NEt.sub.3 (2.1 mL, 15.4 mmol), and dioxane (15 mL) under
Ar was added 4,4,5,5-tetramethyl-1,3,2-dioxaborolane (1.1 mL, 7.70
mmol), SPhos (86 mg, 0.210 mmol), and PdCl.sub.2(CH.sub.3CN).sub.2
(13 mg, 0.051 mmol) and the reaction heated to 110.degree. C. for 2
h. The mixture was then transferred to a separartory funnel with
EtOAc (100 mL) and washed successively with satd aq NaHCO.sub.3
(2.times.50 mL), H.sub.2O (2.times.50 mL), and brine (1.times.50
mL). The organic layer was dried over MgSO.sub.4, filtered, and the
solvent removed to give the product as a yellow oil. .sup.1H NMR
(400 MHz, CDCl.sub.3) .delta. ppm 7.72 (d, J=8.4 Hz, 2H), 6.88 (d,
J=8.4 Hz, 2H), 4.41-4.36 (m, 1H), 3.51 (t, J=5.6 Hz, 2H), 3.36 (s,
3H), 2.77-2.74 (m, 2H), 2.59 (t, J=5.6 Hz, 2H), 2.36-2.33 (m, 2H),
2.03-1.98 (m, 2H), 1.88-1.81 (m, 2H), 1.32 (s, 12H); MS ESI 362.1
[M+H].sup.+, calcd for [C.sub.20H.sub.32BNO.sub.4+H].sup.+
362.25.
Synthesis of tert-butyl
4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)piperidine-1-ca-
rboxylate
##STR00041##
[0270] Using Method E with 3% catalyst in DMSO, tert-butyl
4-(4-iodophenoxy)piperidine-1-carboxylate (258.6 g, 96% pure, 0.61
mmol) gave the title compound (152.7 mg, 61%) after aq. work-up and
purification by flash chromatography (SiO2, 5-25% EtOAc in hexane).
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. ppm 7.75 (d, J=8.8 Hz,
2H), 6.91 (d, J=8.5 Hz, 2H), 4.55 (tt, J=7.0, 3.4 Hz, 1H), 3.69
(ddd, J=12.9, 8.2, 4.1 Hz, 2H), 3.36 (ddd, J=13.0, 8.1, 4.3 Hz,
2H), 1.92 (br. s., 2H), 1.77 (br. s., 2H), 1.34 (s, 12H).
[0271] In a separate experiment, using Method E in DMF, tert-butyl
4-(4-iodophenoxy)piperidine-1-carboxylate gave the title compound
as a white solid (112 mg, 28% yield). .sup.1H NMR was identical to
the previous sample; MS ESI [M-C.sub.4H.sub.9+H].sup.+ 348.1, calcd
for [C.sub.18H.sub.26BNO.sub.5+H].sup.+ 348.20.
Synthesis of 4-(4-bromophenoxy)-1-isopropylpiperidine
##STR00042##
[0273] AcOH (1 drop) was added to a mixture of acetone (0.12 mL,
1.65 mmol), NaBH(OAc).sub.3 (161.5 mg, 0.76 mmol) and
4-(4-bromophenoxy)piperidine (97 mg, 0.38 mmol) in THF (1 mL) and
DCE (2 mL), and the mixture was stirred at rt under Ar for 20 h,
when second portions of AcOH (1 drop), acetone (0.12 mL, 1.65 mmol)
and NaBH(OAc).sub.3 (161.5 mg, 0.76 mmol) were added and the
mixture was heated at 40.degree. C. for 24 h. The mixture was
partitioned between EtOAc (150 mL) and half satd aqNaHCO.sub.3 (25
mL). The organic layer was washed with H.sub.2O (25 mL) and brine
(25 mL), dried, filtered and concentrated to dryness. Purification
by flash chromatography (SiO2, 2-5% 2 M NH.sub.3-MeOH/DCM) gave the
title compound (white solid, 80.4 mg, 71% yield). .sup.1H NMR (400
MHz, CDCl.sub.3) .delta. ppm 7.37 (d, J=9.0 Hz, 6H), 6.80 (d, J=9.0
Hz, 6H), 4.27 (br. s., 1H), 2.74-2.84 (m, 3H), 2.35-2.47 (m, 2H),
2.01 (br. s., 2H), 1.76-1.87 (m, 2H), 1.08 (d, J=6.5 Hz, 6H). MS
ESI 298.0 [M+H].sup.+, calcd for [C.sub.14H.sub.2BrNO+H].sup.+
298.08.
Synthesis of
1-isopropyl-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)pip-
eridine
##STR00043##
[0275] Using Method E with 3.4% catalyst in DMSO,
4-(4-bromophenoxy)-1-isopropylpiperidine (80 mg, 0.27 mmol) gave
the title compound (47.5 mg, 77% pure, 40% yield) after aq. work-up
with EtOAc and purification by flash chromatography (SiO2, 2-20%
MeOH in DCM). .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. ppm 7.74
(d, J=8.5 Hz, 2H), 6.90 (d, J=8.5 Hz, 2H), 4.40 (br. s., 1H), 2.80
(d, J=4.0 Hz, 3H), 2.45 (m, J=7.8 Hz, 2H), 2.04 (br. s., 2H), 1.85
(d, J=8.5 Hz, 2H), 1.34 (s, 12H), 1.09 (d, J=6.3 Hz, 6H). MS ESI
346.2 [M+H].sup.+, calcd for [C.sub.20H.sub.32BNO.sub.3+H].sup.+
346.26.
Synthesis of tert-butyl
4-(2-chloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)piperi-
dine-1-carboxylate
##STR00044##
[0277] DIAD (0.24 mL, 1.22 mmol) was added drop-wise to a solution
of PPh.sub.3 (308.9 mg, 1.18 mmol),
2-chloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenol
(199.8 mg, 0.785 mmol) and tert-butyl
4-hydroxypiperidine-1-carboxylate (236.7 mg, 1.18 mmol) in DCM (5
mL) under Ar and the reaction was stirred at rt for 14 d.
Purification on the Biotage without work-up or evaporation (SiO2,
0-100% EtOAc in DCM) gave the title compound (244.8 mg, 90% pure,
64%). .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. ppm 7.82 (d, J=1.5
Hz, 1H), 7.63 (dd, J=8.2, 1.6 Hz, 1H), 6.93 (d, J=8.3 Hz, 1H),
4.59-4.65 (m, 1H), 3.63 (ddd, J=13.2, 8.4, 4.3 Hz, 2H), 3.42-3.54
(m, 2H), 1.78-1.95 (m, 4H), 1.47 (s, 9H), 1.33 (s, 12H).
Synthesis of
4-(2-chloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)-1-met-
hylpiperidine
##STR00045##
[0279] DIAD (0.48 mL, 2.4 mmol) was added drop-wise to a solution
of PPh.sub.3 (610 mg, 2.3 mmol),
2-chloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenol (296
mg, 1.2 mmol) and 1-methylpiperidin-4-ol (270 mg, 2.3 mmol) in DCM
(14 mL) under Ar and the reaction was stirred at rt for 4 d.
Evaporation and purification on the Biotage (SiO2, 5-30% MeOH in
DCM) gave the title compound (403 mg, 80% pure, 79%). .sup.1H NMR
(400 MHz, CDCl.sub.3) .delta. ppm 7.83 (d, J=1.5 Hz, 1H), 7.64 (dd,
J=8.3, 1.5 Hz, 1H), 6.93 (d, J=8.3 Hz, 1H), 4.53 (br. s., 1H),
2.68-2.81 (m, 2H), 2.39 (m+s, 5H), 2.02-2.15 (m, 2H), 1.94-2.02 (m,
2H), 1.34 (s, 12H). MS ESI 352.2 [M+H].sup.+, calcd for
[C.sub.18H.sub.27BClNO.sub.3+H].sup.+ 352.19.
Synthesis of 4-(4-bromo-2-methoxyphenoxy)piperidine
##STR00046##
[0281] tert-Butyl
4-(4-bromo-2-methoxyphenoxy)piperidine-1-carboxylate (400 mg, 1.04
mmol) was dissolved in DCM (10 mL), and cooled to 0.degree. C. TFA
(3 mL) was added and the mixture was allowed to slowly warm to RT.
After 1 h, solvent was removed under reduced pressure and dissolved
in EtOAc (10 mL). The reaction was washed with NaHCO.sub.3 (15 mL)
and brine (15 mL), and dried with MgSO.sub.4. Solvent was removed
under reduced pressure to give the title compound (yellow oil, 287
mg, 96%). .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. ppm 6.98-7.04
(m, 2H), 6.80 (d, J=9.3 Hz, 1H), 4.41-4.48 (br. m, 1H), 3.84 (s,
3H), 3.28-3.39 (m, 2H), 2.97-3.07 (m, 2H), 2.06-2.17 (m, 2H), 1.97
(m, J=3.5 Hz, 2H); MS ESI 285.9, 287.9 [M+H].sup.+, calcd for
[C.sub.12H.sub.16BrNO.sub.2+H].sup.+ 286.0, 288.0.
Synthesis of 4-(4-bromo-2-methoxyphenoxy)-1-methylpiperidine
##STR00047##
[0283] In a microwave vial 4-(4-bromo-2-methoxyphenoxy)piperidine
(430 mg, 1.5 mmol) was combined with formic acid (4.5 mL) and
formalin (0.5 mL). The reaction was heated at 150.degree. C. in the
microwave reactor for 5 min. The mixture was concentrated under
reduced pressure and partitioned between 0.5 M NaOH (20 mL) and
EtOAc (10 mL). Reaction was washed with brine and dried with
MgSO.sub.4. Removal of solvent under reduced pressure gave the
title compound (clear oil, 412 mg, 92%). .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. ppm 6.98-7.03 (m, 2H), 6.80 (d, J=9.0 Hz, 1H),
4.27 (br. s, 1H), 3.84 (s, 3H), 2.77-2.89 (br. m, 2H), 2.35-2.48
(br. m, 5H), 2.00-2.10 (br. m, 2H), 1.86-1.97 (br. m, 2H); MS ESI
300.0, 302.0 [M+H].sup.+, calcd for
[C.sub.13H.sub.18BrNO.sub.2+H].sup.+ 300.1, 302.2.
Synthesis of
4-(2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)-1-me-
thylpiperidine
##STR00048##
[0285] The title compound was synthesized according to the General
Method E utilizing 4-(4-bromo-2-methoxyphenoxy)-1-methylpiperidine
(400 mg, 1.33 mmol), bis(pinacolato)diboron (509 mg, 2 mmol),
PdCl.sub.2dppf (68 mg, 0.084 mmol), KOAc (655 mg, 6.68 mmol), and
DMF (10 mL). The mixture was charged with Ar and heated at
100.degree. C. in the microwave reactor for 2 h. Purification by
RPcolumn chromatography (Biotage C.sub.18, 60 g, 90:10-10:90% 0.1%
TFA-H.sub.2O:MeOH) gave the title compound (off-white solid, 145
mg, 31%). .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. ppm 7.27-7.34
(m, 2H), 6.99 (d, J=8.3 Hz, 1H), 4.46 (br. s, 1H), 3.84 (s, 3H),
2.86-2.95 (br. m, 2H), 2.50-2.62 (br. m, 2H), 2.43 (s, 3H),
1.97-2.07 (br. m, 2H), 1.82-1.93 (br. m, 2H), 1.33 (s, 12H); MS ESI
348.2 [M+H].sup.+, calcd for [C.sub.19H.sub.30BNO.sub.4+H].sup.+
348.2.
Synthesis of
4-(4-bromo-2-methoxyphenoxy)-1-(oxetan-3-yl)piperidine
##STR00049##
[0287] The title compound was synthesized according to the General
Method G, utilizing 4-(4-bromo-2-methoxyphenoxy)piperidine (287 mg,
1 mmol), 3-oxetan 1 (86 mg, 1.2 mmol), NaBH(OAc).sub.3 (318 mg, 1.5
mmol), DCE (10 mL), and 4 drops of acetic acid. Purification by
flash chromatography (SiO.sub.2, Biotage 25 g, 0-20% MeOH in
CH.sub.2Cl.sub.2) gave the title compound (off-white solid, 230 mg,
67%). .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. ppm 6.96-7.02 (m,
2H), 6.79 (d, J=8.5 Hz, 1H), 4.58-4.69 (m, 3H), 4.20-4.30 (m, 1H),
3.84 (s, 3H), 3.45-3.54 (m, 2H), 2.54-2.64 (m, 2H), 2.07-2.20 (m,
2H), 1.93-2.03 (m, 2H), 1.80-1.93 (m, 2H); MS ESI 342.2, 344.0
[M+H].sup.+, calcd for [C.sub.15H.sub.20BrNO.sub.3+H].sup.+ 342.1,
344.1.
Synthesis of
4-(2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)-1-(o-
xetan-3-yl)piperidine
##STR00050##
[0289] The title compound was synthesized according to the General
Method E, utilizing
4-(4-bromo-2-methoxyphenoxy)-1-(oxetan-3-yl)piperidine (220 mg,
0.54 mmol), Bpin.sub.2 (195 mg, 0.77 mmol), KOAc (188 mg, 1.92
mmol), PdCl.sub.2ddpf (26 mg, 0.032 mmol) and DMF. The mixture was
heated in the microwave reactor for 2 h at 85.degree. C.
Purification by flash chromatography (SiO.sub.2, Biotage 25 g,
0-25% MeOH in CH.sub.2Cl.sub.2) gave the title compound (brown oil,
95 mg, 38%). .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. ppm
7.28-7.34 (m, 2H), 6.97 (d, J=8.0 Hz, 1H), 4.69 (t, J=6.8 Hz, 2H),
4.60 (t, J=6.3 Hz, 2H), 4.39-4.48 (m, 1H), 3.83 (s, 3H), 3.48-3.55
(m, 1H), 2.56-2.67 (m, 2H), 2.16-2.26 (m, 2H), 1.94-2.04 (m, 2H),
1.76-1.89 (m, 2H), 1.33 (s, 12H); MS ESI 390.1 [M+H].sup.+, calcd
for [C.sub.21H.sub.32BNO.sub.5+H].sup.+ 390.2.
Synthesis of
4-(4-bromo-2-methoxyphenoxy)piperidine-1-carbaldehyde
##STR00051##
[0291] The title compound was synthesized according to the General
Method A utilizing 4-(4-bromo-2-methoxyphenoxy)piperidine (400 mg,
1.39 mmol), formic acid (64 mg, 1.39 mmol), TBTU (446 mg, 1.39
mmol), DIPEA (0.73 mL, 4.18 mmol), and DMF (4 mL) to gave the title
compound (yellow solid, 372 mg, 85%). .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. ppm 8.02 (s, 1H), 7.12 (d, J=2.3 Hz, 1H), 7.02
(dd, J=8.5, 2.3 Hz, 1H), 6.94 (d, J=8.5 Hz, 1H), 4.52-4.59 (m, 1H),
3.83 (s, 3H), 3.65-3.77 (m, 2H), 3.45-3.53 (m, 1H), 3.34-3.41 (m,
1H), 1.68-1.99 (m, 4H); MS ESI 314.2, 316.0 [M+H].sup.+, calcd for
[C.sub.13H.sub.16BrNO.sub.3+H].sup.+ 314.0, 316.0.
Synthesis of
4-(2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)piper-
idine-1-carbaldehyde
##STR00052##
[0293] The title compound was synthesized according to the General
Method E, utilizing
4-(4-bromo-2-methoxyphenoxy)piperidine-1-carbaldehyde (370 mg, 1.17
mmol), bis(pinacolato)diboron (356 mg, 1.40 mmol), KOAc (344 mg,
3.51 mmol), PdCl.sub.2ddpf (48 mg, 0.06 mmol) and DMF (10 mL). The
mixture was heated in the microwave reactor for 2 h at 85.degree.
C. Purification by flash chromatography (SiO.sub.2, Biotage 25 g,
0-15% MeOH in CH.sub.2Cl.sub.2) gave the title compound (brown oil,
266 mg, 82%). .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. ppm 8.02
(s, 1H), 7.29-7.35 (m, 2H), 7.03 (d, J=8.3 Hz, 1H), 4.63-4.71 (m,
1H), 3.84 (s, 3H), 3.65-3.79 (m, 2H), 3.45-3.54 (m, 1H), 3.35-3.43
(m, 1H), 1.86-2.02 (m, 2H), 1.70-1.86 (m, 2H), 1.34 (s, 12H); MS
ESI 362.3 [M+H].sup.+, calcd for
[C.sub.19H.sub.28BNO.sub.5+H].sup.+ 362.2.
Synthesis of 4-(4-bromophenoxy)piperidine-1-carbaldehyde
##STR00053##
[0295] The title compound was synthesized according to Method A
utilizing 4-(4-bromophenoxy)piperidine HCl salt and formic acid and
obtained as a yellow solid (885 mg, 91% yield). .sup.1H NMR (400
MHz, CDCl.sub.3) .delta. ppm 8.07 (s, 1H), 7.58 (d, J=8.78 Hz, 2H),
6.71 (d, J=9.03 Hz, 2H), 4.54-4.61 (m, 1H), 3.56-3.68 (m, 3H),
3.29-3.40 (m, 1H), 1.76-1.98 (m, 4H); MS ESI [M+H].sup.+ 284.0,
calcd for [C.sub.12H.sub.14BrNO.sub.2+H].sup.+ 284.03.
Synthesis of
4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)piperidine-1-ca-
rbaldehyde
##STR00054##
[0297] A microwave oven vial was charged with
4-(4-bromophenoxy)piperidine-1-carbaldehyde (480 mg, 1.68 mmols),
bis(pinacolato)diboron (513 mg, 2.02 mmols), KOAc (495 mg, 5.05
mmols) and DMF (8 mL). The mixture was purged with Ar for 2 min,
then PdCl.sub.2(dppf).DCM (69 mg, 0.05 mmol) was added and the vial
was sealed. The resulting mixture was stirred at 85.degree. C. for
2 h with microwave irradiation and then was filtered through
Celite. The filtrate was concentrated under reduced pressure. The
residue was purified by flash chromatography (EtOAc/hexanes 0% to
100%) to give the title compound as a light yellow solid (473 mg,
85%). .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. ppm 8.06 (s, 1H),
7.77 (d, J=8.53 Hz, 2H), 6.88-6.94 (d, J=8.53 Hz, 2H) 4.65-4.72 (m,
1H), 3.55-3.69 (m, 3H), 3.29-3.39 (m, 1H), 1.90 (m, 4H), 1.34 (s,
12H); MS ESI [M-C.sub.4H.sub.9+H].sup.+ 332.3, calcd for
[C.sub.18H.sub.26BNO.sub.4+H].sup.+ 332.20.
Synthesis of 1-(2-fluoroethyl)-4-(4-iodophenoxy)piperidine
##STR00055##
[0299] To the solution of 1-(2-fluoroethyl)piperidin-4-ol (500 mg,
3.4 mmols), 1-fluoro-4-iodobenzene (0.39 mL, 3.4 mmols) in
anhydrous DMF (6 mL) was added 60% NaH (272 mg, 6.8 mmols) in
portions at rt. The resulting reaction mixture was stirred at
85.degree. C. for 3 d under Ar. After cooled down to rt, the
mixture was poured into ice/H.sub.2O (5 mL/mmol) and stirred for 10
min before filtration to give the title compound as a light yellow
solid (746 mg, 63% yield). .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. ppm 7.50-7.59 (m, 2H), 6.65-6.73 (m, 2H), 4.65 (t, J=5.02
Hz, 1H), 4.49-4.56 (m, 1H), 4.26-4.35 (m, 1H), 2.74-2.84 (m, 2H),
2.70 (t, J=5.02 Hz, 1H), 2.43 (t, J=8.28 Hz, 2H), 1.95-2.05 (m,
2H), 1.79-1.90 (m, 2H), 0.88 (d, J=11.04 Hz, 1H); MS ESI
[M+H].sup.+ 350.0, calcd for [C.sub.19H.sub.29BFNO.sub.3+H].sup.+
350.04.
Synthesis of
1-(2-fluoroethyl)-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pheno-
xy)piperidine
##STR00056##
[0301] The title compound was synthesized according to Method E
utilizing 1-(2-fluoroethyl)-4-(4-iodophenoxy)piperidine and
obtained as a yellow solid (33 mg, 30% yield). .sup.1H NMR (400
MHz, CDCl.sub.3) .delta. ppm 7.75 (d, J=8.53 Hz, 2H), 6.90 (d,
J=8.53 Hz, 2H), 4.73 (t, J=4.77 Hz, 1H), 4.61 (t, J=4.77 Hz, 1H),
4.43-4.52 (m, 1H), 2.84-2.91 (m, 3H), 2.77-2.83 (m, 1H), 2.55-2.67
(m, 2H), 2.07-2.18 (m, 2H), 1.86-1.99 (m, 2H), 1.34 (s, 12H); MS
ESI [M+H].sup.+ 350.1, calcd for
[C.sub.19H.sub.29BFNO.sub.3+H].sup.+ 350.23.
Synthesis of
2-(dimethylamino)-1-(4-(4-iodophenoxy)piperidin-1-yl)ethanone
##STR00057##
[0303] The title compound was synthesized according to the Method A
utilizing 4-(4-iodophenoxy)piperidine HCl salt and
2-(dimethylamino)acetic acid and obtained as a yellow solid (739
mg, 95% yield). .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. ppm
7.52-7.60 (m, 2H), 6.66-6.73 (m, 2H), 4.50 (tt, J=6.6, 3.5 Hz, 1H),
3.79 (dd, J=8.8, 4.0 Hz, 2H), 3.57-3.66 (m, 1H), 3.48-3.57 (m, 1H),
3.13 (s, 2H), 2.29 (s, 6H), 1.73-2.00 (m, 4H); MS ESI [M+H].sup.+
389.1, calcd for [C.sub.15H.sub.211N.sub.2O.sub.2+H].sup.+
389.07.
Synthesis of
2-(dimethylamino)-1-(4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)ph-
enoxy)piperidin-1-yl)ethanone
##STR00058##
[0305] The title compound was synthesized according to General
Method F utilizing
2-(dimethylamino)-1-(4-(4-iodophenoxy)piperidin-1-yl)ethanone and
obtained as a pale solid (380 mg, 91% yield). .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. ppm 7.76 (d, J=8.53 Hz, 2H), 6.90 (d, J=8.53
Hz, 2H), 4.62 (br. s., 1H), 3.61-3.82 (m, 3H), 3.47-3.57 (m, 1H),
3.30 (m, 2H), 2.31-2.47 (m, 6H), 1.74-2.02 (m, 4H), 1.34 (s, 9 H);
MS ESI [M+H].sup.+ 389.1, calcd for
[C.sub.21H.sub.33BN.sub.2O.sub.4+H].sup.+ 389.26.
Synthesis of 2-(4-(4-bromophenoxy)piperidin-1-yl)acetic acid
##STR00059##
[0307] The solution of ethyl
2-(4-(4-bromophenoxy)piperidin-1-yl)acetate (680 mg, 2 mmols), 2N
NaOH (8 mL) in MeOH (8 mL) was stirred at rt for 30 min before
solvent was removed under reduced pressure. The residue was
suspended in H.sub.2O and adjusted pH to 1 with 5% HCl. The
resulting solution was concentrated under reduced pressure. The
residue was purified with RP column to give a TFA salt of the title
compound as a white solid (392 mg, 46% yield). .sup.1H NMR (400
MHz, CD.sub.3OD) .delta. ppm 7.41-7.46 (m, 2H), 6.96 (d, J=8.8 Hz,
2H), 4.67-4.73 (m, 1H), 3.93 (s, 2H), 3.35-3.57 (m, 4H), 2.08-2.29
(m, 4H); MS ESI [M+H].sup.+ 314.2, calcd for
[C.sub.13H.sub.16BrNO.sub.3+H].sup.+ 314.04.
Synthesis of
2-(4-(4-iodophenoxy)piperidin-1-yl)-N,N-dimethylacetamide
##STR00060##
[0309] The title compound was synthesized according to Method A
utilizing 2-(4-(4-bromophenoxy)piperidin-1-yl)acetic acid TFA salt
and dimethylamine and obtained as a yellow solid (171 mg, 100%
yield). .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. ppm 7.22-7.29 (m,
2H), 6.66-6.73 (m, 2H), 4.19 (dt, J=7.7, 3.8 Hz, 1H), 3.11 (s, 2H),
3.00 (s, 3H), 2.86 (s, 3H), 2.64-2.74 (m, 2H), 2.28-2.38 (m, 2H),
1.86-1.97 (m, 2H), 1.67-1.78 (m, 2H); MS ESI [M+H].sup.+ 341.2,
calcd for [C.sub.15H.sub.21BrN.sub.2O.sub.2+H].sup.+ 341.09.
Synthesis of
N,N-dimethyl-2-(4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy-
)piperidin-1-yl)acetamide
##STR00061##
[0311] The title compound was synthesized according to Method E
utilizing 2-(4-(4-iodophenoxy)piperidin-1-yl)-N,N-dimethylacetamide
and obtained as a white solid (74 mg, 41% yield). .sup.1H NMR (400
MHz, CDCl.sub.3) .delta. ppm 7.74 (d, J=8.5 Hz, 2H), 6.89 (d, J=8.5
Hz, 2H), 4.36-4.45 (m, 1H), 3.22 (s, 2H), 3.09 (s, 3H), 2.96 (s,
3H), 2.79 (br. s., 2H), 2.48 (br. s., 2H), 1.97-2.08 (m, 2H), 1.85
(m, 2H), 1.33 (s, 12H); MS ESI [M+H].sup.+ 389.2, calcd for
[C.sub.21H.sub.33BN.sub.2O.sub.4+H].sup.+ 389.26.
Synthesis of 4-(4-iodophenoxy)-1-(oxetan-3-yl)piperidine
##STR00062##
[0313] The suspension of 4-(4-iodophenoxy)piperidine HCl salt (528
mg, 1.55 mmols) in EtOAc was washed with satd aqNaHCO.sub.3. The
organic layer was dried over Na.sub.2SO.sub.4 and concentrated
under reduced pressure. The residue was dissolved in DCE (4 mL)
followed by adding of NaBH(OAc).sub.3 (493 mg, 2.33 mmols),
3-oxtane (112 mg, 1.55 mmols), and HOAc (3 drops). The resulting
suspension was stirred at rt for 2 h before the solvent was removed
under reduced pressure. The residue was washed with satd
aqNaHCO.sub.3 and extracted with EtOAc. The combined organic layer
was dried over Na.sub.2SO.sub.4 and concentrated under reduced
pressure to give the title compound as a yellow solid (460 mg, 83%
yield). .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. ppm 7.51-7.59 (m,
2H), 6.65-6.72 (m, 2H), 4.60-4.70 (m, 4H), 4.28-4.38 (m, 1H), 3.51
(quin, J=6.5 Hz, 1H), 2.54 (br. s., 2H), 2.20 (br. s., 2H),
1.93-2.04 (m, 2H), 1.79-1.92 (m, 2H); MS ESI [M+H].sup.+ 360.0,
calcd for [C.sub.14H.sub.18INO.sub.2+H].sup.+ 360.05.
Synthesis of
1-(oxetan-3-yl)-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy-
)piperidine
##STR00063##
[0315] The title compound was synthesized according to Method E
utilizing 4-(4-iodophenoxy)-1-(oxetan-3-yl)piperidine and obtained
as a pale solid (468 mg, 62% yield). .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. ppm 7.70 (d, J=8.5 Hz, 2H), 6.84 (d, J=8.5 Hz,
2H), 4.55-4.65 (m, 4H), 4.37-4.43 (m, 1H), 3.47 (t, J=6.5 Hz, 1H),
2.50 (d, J=7.8 Hz, 2H), 2.19 (br. s., 2H), 1.91-2.01 (m, 2H), 1.84
(td, J=6.7, 3.4 Hz, 2H), 1.28 (s, 12H); MS ESI [M+H].sup.+ 360.1,
calcd for [C.sub.20H.sub.30BNO.sub.4+H].sup.+ 360.23.
Synthesis of diisopropyl
(4-((3R,4S)-3-fluoro-1-methylpiperidin-4-yl)oxy)phenyl)boronate
compound with diisopropyl
(4-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)oxy)phenyl)boronate, a
1:1 mixture
[0316] ##STR00064## [0317] A. (3R,4S)-tert-butyl
3-fluoro-4-(4-iodophenoxy)piperidine-1-carboxylate compound with
(3S,4R)-tert-butyl
3-fluoro-4-(4-iodophenoxy)piperidine-1-carboxylate (1:1 mixture)
was synthesized according to General Method H utilizing
1-fluoro-4-iodobenzene (0.80 g, 3.6 mmol), (3R,4S)-tert-butyl
3-fluoro-4-hydroxypiperidine-1-carboxylate/(3S,4R)-tert-butyl
3-fluoro-4-hydroxypiperidine-1-carboxylate (1:1 mixture) (0.73 g,
3.3 mmol) and NaH (60% in mineral oil, 0.17, 4.3 mmol) in anh DMF
(20 mL) under. Ar. After 2 d of heating at 80.degree. C. the
reaction was quenched with H.sub.2O/MeOH, concentrated under
reduced pressure. The residue was taken into DCM (70 mL) and
stirred with TFA (8 mL) at 0.degree. C. for 3 h. The reaction was
then concentrated under reduced pressure and purified by RP HPLC
(Biotage C18 100 g, 5-9% MeOH/H.sub.2O+0.1% TFA) to afford
cis-3-fluoro-4-(4-iodophenoxy)piperidine 2,2,2-trifluoroacetate as
a tan solid. MS ESI [M+H].sup.+ 321.9, calcd for
[C.sub.11H.sub.13FINO: +H].sup.+ 322.0 [0318] B. The material (0.47
g, 1.1 mmol) in MeCN (70 mL) was treated with HCHO (30% in
H.sub.2O, 0.72 mL, 9.7 mmol) followed by NaBH(OAc).sub.3 (0.69 g,
3.2 mmol) at rt. After overnight stirring, the reaction was
concentrated under reduced pressure and filtered through PoraPak CX
columns (2.times.2 g. Waters) using MeOH to load and rinse and 2 M
NH.sub.3MeOH to elute. The crude material was subsequently purified
by lash chromatography (SiO.sub.2, 0-40% 2 M NH.sub.3/MeOH in DCM)
to afford cis-3-fluoro-4-(4-iodophenoxy)-1-methylpiperidine as a
clear gum (0.23 g, 64%). 1H NMR (400 MHz, CD.sub.3OD) .delta. ppm
7.59 (d, J=8.80 Hz, 2H), 6.82 (d, J=8.80 Hz, 2H), 4.78-4.84 (m,
1H), 4.44-4.60 (m, 1H), 3.09 (br. s., 1H), 2.82 (br. s., 1H),
2.50-2.73 (m, 1H), 2.45 (m, 1H), 2.39 (s, 3H), 2.03-2.17 (m, 1H),
1.88-2.00 (m, 1H); MS ESI 336.0 [M+H].sup.+ calcd for
[C.sub.12H.sub.15FINO: +H].sup.+ 336.0. [0319] C. To a stirred
solution of cis-3-fluoro-4-(4-iodophenoxy)-1-methylpiperidine (0.12
g, 0.33 mmol) in anh THF (5 mL) under Ar was added n-BuLi (1.6 M in
hexanes, 0.45 mL, 0.72 mmol) dropwise at -78.degree. C. The
reaction was stirred for 15 min at the temperature before
B(Oi--Pr).sub.3 (1.2 mL, 5.2 mmol) was added rapidly. After
additional 30 min at -78.degree. C. the reaction was removed from
the cooling bath and stirred for 1 h before it was concentrated
under reduced pressure to afford a crude mixture of
cis-(4-((3-fluoro-1-methylpiperidin-4-yl)oxy)phenyl)boronic acid
and diisopropyl
(4-((cis-3-fluoro-1-methylpiperidin-4-yl)oxy)phenyl)boronate as an
off-white solid (0.34 g) that was used without further
purification. MS ESI [M+H].sup.+ 254.1, calcd for
[C.sub.12H.sub.17BFNO.sub.3: +H].sup.+ 254.1.
Synthesis of
(1R,3r,5S)-8-methyl-3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phe-
noxy)-8-azabicyclo[3.2.1]octane
[0320] ##STR00065## [0321] A.
(1R,3r,5S)-3-(4-iodophenoxy)-8-methyl-8-azabicyclo[3.2.1]octane was
synthesized according to method H utilizing 1-fluoro-4-iodobenzene
(2.99 g, 13.5 mmol),
(1R,3r,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-ol (1.9 g, 13.5
mmol) and NaH (60% in oil, 0.64 g, 16.1 mmol) in DMF (40 mL). After
1 d of heating at 85.degree. C., the reaction was quenched with
MeOH and concentrated under reduced pressure. The residue was
paartioned between satd aq NaHCO.sub.3 and EtOAc. The aq layer was
extracted with EtOAc (2.times.). The organic fractions were
combined, dried (Na.sub.2SO.sub.4) and concentrated under reduced
pressure. The crude material was purified by RP HPLC (Biotage C18
100 g, 5-90% MeOH/H.sub.2O+0.1% TFA) to TFA salt of
(1R,3r,5S)-3-(4-iodophenoxy)-8-methyl-8-azabicyclo[3.2.1]octane as
an off-white solid (2.0 g, 33%). .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. ppm 7.60 (d, J=8.78 Hz, 2H), 6.62 (d, J=8.78 Hz, 2H), 4.65
(t, J=4.89 Hz, 1H), 3.79 (br. s., 2H), 2.71-2.83 (m, 5H), 2.55-2.47
(m, 2H), 2.15-2.32 (m, 4H); MS ESI 344.0 [M+H]*, calcd for
[C.sub.14H.sub.18INO: +H].sup.+ 344.0; [0322] B.
(1R,3r,5S)-8-methyl-3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phe-
noxy)-8-azabicyclo[3.2.1]octane was synthesized according to
General Method E utilizing
(1R,3r,5S)-3-(4-iodophenoxy)-8-methyl-8-azabicyclo[3.2.1]octane
2,2,2-trifluoroacetate (0.50 g, 1.1 mmol). The to afford, after aq
workup (satd aq NaHCO.sub.3/DCM) followed by a flash chromatography
(25 g SiO.sub.2, 0-30% MeOH-DCM), the desired compound as an
off-white solid (14 mg, 13%). .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. ppm 7.79 (d, J=8.53 Hz, 2H), 6.84 (d, J=8.78 Hz, 2H), 4.81
(br. s., 1H), 3.82 (br. s., 2H), 3.38-3.18 (m, 2H), 2.77 (s, 3H),
2.63-2.54 (m, 2H), 2.21-2.36 (m, 4H), 134 (s, 12H); MS ESI 344.2
[M+H].sup.+, calcd for [C.sub.20H.sub.30BNO.sub.3: +H].sup.+
344.2;
Synthesis of
4,4,5,5-tetramethyl-2-(4-((tetrahydro-2H-pyran-4-yl)oxy)phenyl)-1,3,2-dio-
xaborolane
##STR00066##
[0324] The title compound was synthesized according to general
Method E by using a solution of
4-(4-bromophenoxy)tetrahydro-2H-pyran (800 mg, 3.11 Mmmol) in DMF
(12 mL) was added bis(pinacolato)diboron (948 mg, 3.73 mmol), KOAc
(916 mg, 9.33 mmol) and PdCl.sub.2dppf (254 mg, 0.311 mmol) under
Ar. The degassed suspension under Ar was sealed and heated in an
oil bath at 125.degree. C. for 5 h. The reaction mixture was
diluted using EtOAc (60 mL) and H.sub.2O (36 mL). The organic layer
was separated and aq. layer extracted with EtOAc (36 mL). The
combined EtOAc layer was washed with H.sub.2O and brine, dried
(Na.sub.2SO.sub.4) and concentrated under vacuum at 40.degree.
C./100 mbar to give crude brown thick oil. The crude oily product
purified by Biotage (50 g SiO2, 0-30% EtOAc in Hexane) to give
title compound (cream color solid, 728 mg, 77%). .sup.1H NMR (400
MHz, CDCl.sub.3) .delta. 7.76-7.74 (d, J=2.8 Hz, 2H), 6.92 (d,
J=2.8 Hz, 2H), 4.59-4.53 (m, 1H), 4.01-3.96 (m, 2H), 3.62-3.57 (m,
2H), 2.05-2.0 (m, 2H), 1.84-1.77 (m, 2H), 1.34 (s, 12H); MS ESI
305.1 [M+H].sup.+, calcd for [C.sub.17H.sub.25BO.sub.4+H].sup.+
305.1.
Synthesis of 1-(4-bromo-2-methoxyphenyl)-4-methylpiperazine
##STR00067##
[0326] The title compound was synthesized according to the General
Method C, utilizing 5-bromo-2-iodoanisole (683 mg, 2.18 mmol),
1-methylpiperazine (262 mg, 2.62 mmol), CuI (83 mg, 0.44 mmol),
BINOL (125 mg, 0.44 mmol), K.sub.3PO.sub.4 (924 mg, 4.36 mmol), and
DMF (4 mL) and purified using flash chromatography (SiO.sub.2,
Biotage 25 g, 5-25% MeOH in CH.sub.2Cl.sub.2) to give the title
compound (light yellow solid, 213 mg, 34%). .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. ppm 7.01 (d, J=8.3 Hz, 1H), 6.94 (s, 1H), 6.76
(d, J=8.3 Hz, 1H), 3.83 (s, 3H), 3.27 (br. s, 4H), 2.99 (br. s,
4H), 2.59 (s, 3H).
Synthesis of
1-(2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-4-met-
hylpiperazine
##STR00068##
[0328] The title compound was synthesized according to the General
Method E utilizing 1-(4-bromo-2-methoxyphenyl)-4-methylpiperazine
(200 mg, 0.70 mmol), Bis(pinacolato)diboron (213 mg, 0.84 mmol),
PdCl.sub.2dppf (17 mg, 0.021 mmol), KOAc (206 mg, 2.1 mmol), and
DMSO (10 mL). The mixture was charged with Ar and heated at
85.degree. C. in the microwave reactor for 2 h. Purification by
flash chromatography (SiO.sub.2, Biotage 25 g, 5-25% MeOH in
CH.sub.2Cl.sub.2) gave the title compound (brown solid, 63 mg,
27%). MS ESI 333.3 [M+H].sup.+, calcd for
[C.sub.18H.sub.29BN.sub.2O.sub.3+H].sup.+ 333.2.
Synthesis of
1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperidin-4-one
##STR00069##
[0330] The title compound was synthesized according to general
Method E by using a mixture of 1-(4-Bromophenyl)piperidin-4-one
(1.5 g, 5.9 mmol), Bis(pinacolato)diboron (2.62 g, 10.3 mmol), KOAc
(1.73 g, 17.7 mmol) and DMF (15 mL) was purged with Ar for 10 min.
PdCl.sub.2dppf (0.32 g, 0.44 mmol) was added in round bottom flask
and heated at 125.degree. C. for 4 h in oil bath under Ar. The
reaction mixture was diluted using 10% sodium chloride solution
(100 mL) and the product extracted with EtOAc (2.times.100 mL) and
the combined EtOAc layer was washed with brine (2.times.25 mL),
dried (Na.sub.2SO.sub.4), and concentrated under vacuum at
40.degree. C./100 mbar to give crude brown thick oil. The crude
oily mass purified by flash chromatography (50 g SiO2, 0-40% EtOAc
in Hexane) to give the title compound (pale yellow solid, 584 mg,
33%). .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. ppm 7.77 (d, J=8.8
Hz, 2H), 6.97 (d, J=8.8 Hz, 2H), 3.71 (t, J=6.0 Hz, 4H), 2.56 (t,
J=6.0 Hz, 4H), 1.34 (s, 12H); MS ESI 302 [M+H].sup.+, calcd for
[C.sub.17H.sub.24BNO.sub.3+H].sup.+ 302.1
Synthesis of
1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperidin-4-ol
##STR00070##
[0332] Using Method F with excess HBpin (3 equiv) at 100.degree. C.
for 17 h, from 1-(4-bromophenyl)piperidin-4-one (1.4885 g, 5.86
mmol), after aq. work-up with EtOAc, purification by flash
chromatography (SiO2, 50-60% EtOAc in hexane) gave the title
compound (1.59 g, 80% pure, 72%). .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. ppm 7.70 (d, J=8.8 Hz, 2H), 6.91 (d, J=8.8 Hz, 2H), 3.88
(tt, J=8.6, 4.2 Hz, 1H), 3.68 (dt, J=13.1, 4.1 Hz, 2H), 3.00 (ddd,
J=12.7, 10.1, 3.0 Hz, 2H), 1.92-2.04 (m, 2H), 1.60-1.73 (m, 2H),
1.33 (s, 12H).
Synthesis of (1-(4-iodophenyl)piperidin-4-yl)methanol
##STR00071##
[0334] The title compound was synthesized according to the General
Method I utilizing piperidin-4-ylMeOHEtOH and obtained as a white
solid (989 mg, 31% yield). .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. ppm 7.50 (d, J=9.03 Hz, 2H), 6.71 (d, J=9.03 Hz, 2H),
3.65-3.72 (m, 2H), 3.53-3.58 (m, 2H), 2.72 (td, J=12.55, 2.51 Hz,
2H), 1.82-1.89 (m, 2H), 1.62-1.73 (m, 1H), 1.35-1.45 (m, 2H), 1.32
(t, J=5.40 Hz, 1H); MS ESI [M+H].sup.+ 318.0, calcd for
[C.sub.12H.sub.16INO+H].sup.+ 318.04.
Synthesis of
(1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperidin-4-yl)-
methanol
##STR00072##
[0336] The title compound was synthesized according to Method E
utilizing (1-(4-iodophenyl)piperidin-4-yl)methanol and obtained as
a bright brown solid (272 mg, 70% yield). .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. ppm 7.70 (d, J=8.78 Hz, 2H), 6.91 (d, J=8.78
Hz, 2H), 3.85 (d, J=12.55 Hz, 2H), 3.55 (d, J=6.53 Hz, 2H), 2.79
(td, J=12.36, 2.64 Hz, 2H), 1.85 (d, J=13.05 Hz, 2H), 1.64-1.77 (m,
1H), 1.51-1.63 (m, 2H), 1.39 (br. s., 1H), 1.33 (s, 12H); MS ESI
[M+H].sup.+ 318.1, calcd for [C.sub.12H.sub.16INO+H].sup.+
318.22.
Synthesis of 1-(4-bromophenyl)-4-methylpiperidin-4-ol
##STR00073##
[0338] The mixture of 1-(4-bromophenyl)piperidin-4-one (254 mg, 1
mmol) in anhydrous THF (10 mL) was cooled down to -78.degree. C.
MeMgCl (3M in THF, 1.7 mL, 5 mmols) was added dropwise and stirred
at -78.degree. C. for 0.5 h then at 0.degree. C. for 2 h. The
reaction was quenched with satd aqNH.sub.4Cl solution dropwise at
0.degree. C. The mixture was poured into brine and extracted with
EtOAc. The combined organic layer was dried over Na.sub.2SO.sub.4
and concentrated under reduced pressure to provide the title
compound as a yellow solid (262 mg, 97% yield). .sup.1H NMR (400
MHz, CDCl.sub.3) .delta. ppm 7.33 (d, J=8.78 Hz, 2H), 6.83 (d,
J=8.78 Hz, 2H), 3.33 (dt, J=12.49, 4.17 Hz, 2H), 3.11-3.22 (m, 2H),
1.65-1.83 (m, 4H), 1.31 (s, 3H); MS ESI [M+H].sup.+ 270.2, calcd
for [C.sub.12H.sub.16BrNO+H].sup.+ 270.05.
Synthesis of
4-methyl-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperid-
in-4-ol
##STR00074##
[0340] The title compound was synthesized according to Method E
utilizing 1-(4-bromophenyl)-4-methylpiperidin-4-ol and obtained as
a white solid (42 mg, 27% yield). .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. ppm 7.71 (d, J=8.78 Hz, 2H), 6.92 (d, J=8.78 Hz, 2H), 3.49
(dt, J=12.80, 4.39 Hz, 2H), 3.27 (br. s., 2H), 1.63-1.81 (m, 4H),
1.56 (s, 3H), 1.33 (s, 12H); MS ESI [M+H].sup.+ 318.3, calcd for
[C.sub.18H.sub.28BNO.sub.3+H].sup.+ 318.22.
Synthesis of methyl 1-(4-iodophenyl)piperidine-4-carboxylate
##STR00075##
[0342] The title compound was synthesized according to the General
Method I utilizing methyl piperidine-4-carboxylate and obtained as
a yellow solid (471 mg, 14% yield). .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. ppm 7.48-7.54 (m, 2H), 6.70 (d, J=9.03 Hz, 2H),
3.72 (s, 3H), 3.61 (d, J=12.80 Hz, 2H), 2.79 (td, J=12.05, 2.76 Hz,
2H), 2.47 (s, 1H), 2.03 (d, J=13.30 Hz, 2H), 1.82-1.92 (m, 2H); MS
ESI [M+H].sup.+ 346.0, calcd for
[C.sub.13H.sub.16INO.sub.2+H].sup.+ 346.03.
Synthesis of 2-(1-(4-iodophenyl)piperidin-4-yl)propan-2-ol
##STR00076##
[0344] The title compound was synthesized according to the Method
of 1-(4-bromophenyl)-4-methylpiperidin-4-ol utilizing
1-(4-iodophenyl)piperidine-4-carboxylate and obtained as a white
solid (81 mg, 81% yield). .sup.1H NMR (400 MHz, CDCl.sub.3) .delta.
ppm 7.50 (d, J=9.0 Hz, 2H), 6.71 (d, J=9.0 Hz, 2H), 3.74 (d, J=12.3
Hz, 2H), 2.65 (t, J=11.4 Hz, 2H), 1.87 (m, J=9.8 Hz, 2H), 1.40-1.54
(m, 3H), 1.17-1.26 (m, 6H); MS ESI [M+H].sup.+ 346.1, calcd for
[C.sub.14H.sub.20INO+H].sup.+ 346.07.
Synthesis of
2-(1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperidin-4-y-
l)propan-2-ol
##STR00077##
[0346] The title compound was synthesized according to General
Method F utilizing 2-(1-(4-iodophenyl)piperidin-4-yl)propan-2-ol
and obtained as a white solid (74 mg, 91% yield). .sup.1H NMR (400
MHz, CDCl.sub.3) .delta. ppm 7.70 (d, J=8.78 Hz, 2H), 6.92 (d,
J=8.78 Hz, 2H), 3.90 (d, J=12.30 Hz, 2H), 2.72 (t, J=12.42 Hz, 2H),
1.85 (br. s., 2H), 1.47 (br. s., 3H), 1.29-1.37 (m, 12H), 1.18-1.25
(m, 6H); MS ESI [M+H].sup.+ 346.1, calcd for
[C.sub.20H.sub.32BNO.sub.3+H].sup.+ 346.26.
Synthesis of
(2S,6R)-2,6-dimethyl-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)ph-
enyl)morpholine
[0347] ##STR00078## [0348] A.
(2S,6R)-4-(4-iodophenyl)-2,6-dimethylmorpholine was synthesized
according to the General Method I utilizing 1,4-diiodobenzene (2.4
g, 7.3 mmol) and (2R,6S)-2,6-dimethylmorpholine (1.0 g, 8.8 mmol).
After heating for 2 d, the crude reaction mixture was cooled to rt,
diluted with EtOAc (100 mL) and filtered through Celite. The
filtrate was then washed (H.sub.2O, brine), dried
(Na.sub.2SO.sub.4) and concentrated under reduced pressure to
provide as a light yellow solid (2.2 g) which was purified by flash
chromatography (SiO.sub.2, 0-20% MeOH-DCM) affording
(2S,6R)-4-(4-iodophenyl)-2,6-dimethylmorpholine as a light yellow
solid (0.68 g, 30%). MS ESI [M+H].sup.+318.0, calcd for
[C.sub.12H.sub.16INO+H].sup.+ 318.0; [0349] B.
(2S,6R)-2,6-Dimethyl-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)ph-
enyl)morpholine was synthesized according to the General Method F
utilizing (2S,6R)-4-(4-iodophenyl)-2,6-dimethylmorpholine (0.20 g,
0.63 mmol). The crude reaction mixture was concentrated under
reduced pressure, taken in DCM and filtred through a column made of
two layers (Celite (10 g) and silica gel (10 g)) using
hexanes-EtOAc as the eluent (1:1 then 1:3) to afford a pale yellow
solid (0.25 g, 125%) which was used without further purification.
MS ESI 318.2 [M+H].sup.+, calcd for
C.sub.18H.sub.28BNO.sub.3+H].sup.+ 318.2.
Synthesis of tert-butyl 1H-indazol-5-ylcarbamate
##STR00079##
[0351] A DMF (15 mL) solution of aminoindazole (1.0 g, 7.5 mmol)
and DIPEA (2.0 mL, 11 mmol) was treated with Boc.sub.2O (1.7 g, 7.7
mmol) (50% added in one portion as a solid, and 50% as a solution
in anh DMF (1 mL)) at 0.degree. C. The reaction was stirred with
the cooling for 1.5 h and then allowed to warm slowly to rt
overnight. Later it was diluted with H.sub.2O to .about.100 mL. A
tan precipitate was collected by filtration, washed with H.sub.2O
and dried to afford the product as a light tan solid (1.7 g, 94%).
.sup.1H NMR (400 MHz, DMSO-d6) .delta. ppm 12.90 (s., 1H), 9.27 (s,
1H), 7.94 (s, 1H), 7.87 (br.s, 1H), 7.41 (d, J=8.80 Hz, 1H), 7.33
(d, J=9.2 Hz, 1H), 1.47 (s, 9H). MS ESI 233.9 [M+H].sup.+, calcd
for [C.sub.12H.sub.15N.sub.3O.sub.2+H].sup.+ 234.0.
B. tert-butyl 3-iodo-1H-indazol-5-ylcarbamate
##STR00080##
[0353] To a cooled (0.degree. C.) DMF (30 mL) solution t-butyl
1H-indazol-5-ylcarbamate (1.6 g, 6.9 mmol) and K.sub.2CO.sub.3 (3.8
g, 27.6 mmol) was added I.sub.2 (1.8 g, 7.1 mmol) in one portion.
The reaction was stirred with cooling for 3 h and then treated with
10% aq NaHSO.sub.3 (50 mL) and subsequently with H.sub.2O (150 mL).
A filtration and washing (H.sub.2O) of the ppt provided crude
material which after purification by flash chromatography
(SiO.sub.2, 70 g, 0 to 6% MeOH in DCM) and recrystallization from
EtOAc/hexanes yielded tert-butyl 3-iodo-1H-indazol-5-ylcarbamate
(3) as an off-white solid (1.9 g, 78%). .sup.1H NMR (400 MHz,
Acetone-d6) .delta. ppm 12.54 (br. s., 1H), 8.51 (br. s., 1H), 7.87
(br.s., 1H), 7.24-7.66 (m, 2H), 1.51 (s, 9H); MS ESI [M+H].sup.+
359.9 (100)].sup.+, calcd for
[C.sub.12H.sub.14IN.sub.3O.sub.2+H].sup.+ 360.0.
Synthesis of
(R)--N-(3-iodo-1H-indazol-5-yl)-2-methoxy-2-phenylacetamide
[0354] ##STR00081## [0355] A.
(R)--N-(1H-indazol-5-yl)-2-methoxy-2-phenylacetamide was
synthesized according to the General Method A utilizing
1H-indazol-5-amine (0.50 g, 3.76 mmol),
(R)-2-methoxy-2-phenylacetic (0.65 g, 3.9 mmol),
N-ethyl-N-isopropylpropan-2-amine (1.3 mL, 7.5 mmol) and TBTU (1.27
g, 3.9 mmol) in DMF (10 mL). The
(R)--N-(1H-indazol-5-yl)-2-methoxy-2-phenylacetamide was
precipitated by addition of H1120, filtered and dried to provide a
tan solid (0.81 g) which was used without further purification. MS
ESI 282.1 [M+H].sup.+, calcd for [C.sub.16H.sub.15N.sub.3O.sub.2:
+H].sup.+ 281.1; [0356] B.
(R)--N-(3-iodo-1H-indazol-5-yl)-2-methoxy-2-phenylacetamide was
prepared according to the General method B using (0.81 g, 2.8
mmol), 12 (1.4 g, 5.7 mmol) and KOH (0.48 g, 8.5 mmol) in DMF (8
mL) to provide the desired compound as a white solid (0.58 g, 50%).
MS ESI 408.1 [M+H].sup.+, calcd for
[C.sub.16H.sub.14IN.sub.3O.sub.2+H].sup.+ 408.1;
Synthesis of 2-(pyrrolidin-1-yl)-2-(thiophen-3-yl)acetic acid
##STR00082##
[0358] The title compound was synthesized according to general
Method D by using a glyoxylic acid monohydrate (10.79 g, 0.11 mol)
and pyrrolidine (9.69 mL, 0.11 mol) was combined with DCM (375 mL)
and sonicated for 15 minutes. Thiophene-3-boronic acid (15 g, 0.11
mol) was added and the mixture was stirred at room temperature for
24 h. the solid was filtered and washed with little DCM to gave 38
g crude product as crop-1. The mother liquor concentrated under
reduced pressure to give an additional 4 g as crop-2. The combined
crude product purified by Biotgae SNAP 100 g silica column
(gradient 0-50% MeOH in DCM) gave the title compound as a cream
solid (21.7 g, 70%). .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 7.66
(dd, J=2.8 Hz, J=1.2 Hz, 1H), 7.53 (dd, J=5.2 Hz, J=2.8 Hz, 1H),
7.28 (dd, J=5.2 Hz, J=1.2 Hz, 1H), 4.65 (s, 1H), 3.06 (br.s, 2H),
2.04-1.95 (br.s, 4H), 2H merged with solvent peak; MS ESI 212
[M+H].sup.+, calcd for [C.sub.10H.sub.13NO.sub.2S+H].sup.+
212.07.
Synthesis of
N-(3-iodo-1H-indazol-5-yl)-2-(pyrrolidin-1-yl)-2-(thiophen-3-yl)acetamide
##STR00083##
[0360] Using method A, 3-iodo-1H-indazol-5-amine (2.53 g, 9.76
mmol) and 2-(pyrrolidin-1-yl)-2-(thiophen-3-yl)acetic acid (1.69 g,
8.0 mmol) in DMF (57.5 mL) were stirred at rt for 29 h. The
reaction mixture was added dropwise into 400 mL H.sub.2O and the
precipitate was collected by filtration, transferred using a
mixture of acetone and EtOH, and concentrated to dryness.
Purification on Biotage Isolera (silica, 60-90% EtOAc/Hexane) gave
the title compound (1.61 g, 44%) which was used without further
purification. .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. ppm 7.83
(s, 1H), 7.49-7.56 (m, 2H), 7.44-7.48 (m, 1H), 7.39-7.44 (m, 1H),
7.33 (d, J=5.0 Hz, 1H), 4.11 (s, 1H), 2.67 (d, J=6.0 Hz, 2H), 2.51
(d, J=5.8 Hz, 2H), 1.81-1.87 (m, 5H).
Synthesis of
N-(3-iodo-1H-indazol-5-yl)-2-(pyrrolidin-1-yl)-2-(thiophen-2-yl)acetamide
##STR00084##
[0361] A. 2-(pyrrolidin-1-yl)-2-(thiophen-2-yl)acetic acid
[0362] The title compound was synthesized according to general
Method D by using a glyoxylic acid monohydrate (1.08 g, 11.7 mmol)
and pyrrolidine (0.97 mL, 11.7 mol) was combined with DCM (45 mL)
and sonicated for 15 minutes. Thiophene-2-boronic acid (1.5 g, 11.7
m mol) was added and the mixture was stirred at room temperature
for 24 h. the solid was filtered and washed with little DCM to gave
2.2 g crude product. The crude product purified by Biotgae SNAP 50
g silica column (0-30% MeOH in DCM) gave the title compound as an
off white solid (1.97 g, 79%). .sup.1H NMR (400 MHz, CD.sub.3OD)
.delta. 7.54-7.53 (br.s, 1H), 7.35 (s, 1H), 7.07 (s, 1H), 3.42-3.35
(br.s, 2H), 3.13 (br.s, 2H), 2.02 (br.s, 4H), 1H merged with
solvent peak; MS ESI 212 [M+H].sup.+, calcd for
[C.sub.10H.sub.13NO.sub.2S+H].sup.+ 212.07.
B.
N-(1H-indazol-5-yl)-2-(pyrrolidin-1-yl)-2-(thiophen-2-yl)acetamide
[0363] To a cooled (0-5.degree. C.) solution of
2-(pyrrolidin-1-yl)-2-(thiophen-2-yl)acetic acid (200 mg, 0.946
mmol) in DCM (8 mL) was added DMAP (10 mg) followed by TEA (0.53
mL, 3.79 mmol) and (CH.sub.3).sub.3COCl (0.14 mL, 1.14 mmol) added
slowly at the same temperature. After 1 h stirring at 0.degree. C.
5-amino-1H-indazole (145 mg, 1.09 mmol) added to the reaction mass
in one lot and stirred the reaction mass at rt for 24 h. The
reaction mass diluted with DCM (20 mL) washed with H.sub.2O and
dried (Na.sub.2SO.sub.4) and concentrated under reduced pressure to
give the title compound as a brown oil. The crude product purified
by Biotgae SNAP 25 g silica column (0-10% MeOH in DCM) gave the
title compound as a brown solid (210 mg, 68%). .sup.1H NMR (400
MHz, DMSO-d.sub.6) .delta. ppm 12.96 (s, 1H), 10.08 (s, 1H), 8.07
(s, 1H), 7.98 (s, 1H), 7.46-7.41 (m, 3H), 7.12 (s, 1H), 6.95 (s,
1H), 4.33 (s, 1H), 1.69 (br.s, 4H), 4H merged with solvent peak; MS
ESI 327 [M+H].sup.+, calcd for [C.sub.17H.sub.18N.sub.4OS+H].sup.+
327.1.
C.
N-(3-iodo-1H-indazol-5-yl)-2-(piperidin-1-yl)-2-thiophen-3-yl)acetamide
[0364] The title compound was synthesized according to general
Method B by using a solution of
N-(1H-indazol-5-yl)-2-(piperidin-1-yl)-2-(thiophen-2-yl)acetamide
(143 mg, 0.438 mmol) in DMF (2.14 mL) and K.sub.2CO.sub.3 (242 mg,
1.75 mmol) was added I.sub.2 (122 mg, 0.481 mmol) in one portion.
The reaction was stirred at rt for 24 h and then treated with 5% aq
Na.sub.2S.sub.2O.sub.3.5H.sub.2O (20 mL). The product was extracted
using EtOAc (25 mL) and washed with of H.sub.2O (5 mL) followed by
brine (5 mL), dried (Na.sub.2SO.sub.4) and concentrated under
vacuum to give brown oily residue. The crude product was purified
by Biotgae SNAP 25 g silica column (0-80% EtOAc in hexanes) to give
a yellow solid (78 m g, 39%). .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. ppm 11.06-10.88 (br.s, 1H), 9.14 (s, 1H), 7.74 (s, 1H),
7.62-7.60 (m, 1H), 7.42-7.40 (m, 1H), 7.26 (s, 1H), 7.12 (s, 1H),
6.97 (s, 1H), 4.31 (s, 1H), 2.70 (br.s, 2H),), 2.62 (br.s, 2H),
1.86 (br.s, 4H); MS ESI 453.1 [M+H].sup.+, calcd for
[C.sub.17H.sub.171N.sub.4OS+H].sup.+ 453.02
Synthesis of
(S)-2-((S)-2-methylpyrrolidin-1-yl)-2-(thiophen-3-yl)acetamide
##STR00085##
[0366] To a mixture of (S)-2-methylpyrrolidine (1.07 g, 12.6 mmol),
glyoxylic acid hydrate (1.16 g, 12.6 mmol) in DCM (50 mL) was added
thiophen-3-ylboronic acid (1.59 g, 12.6 mmol). The resulting
mixture was stirred for 3 h at rt. Oil formed on the sides of flask
and MeOH (5 mL) was added to make a clear solution. Reaction was
stirred overnight ar rt. After removing all the solvents, the
residue was purified by Biotage column system (gradient: MeOH/DCM 0
to 30%) to give
(S)-2-((S)-2-methylpyrrolidin-1-yl)-2-(thiophen-3-yl)acetic acid as
a beige solid (1.294 g, 46%). .sup.1H NMR (400 MHz, CD.sub.3OD)
.delta. 7.68 (dd, J=2.8, 1.2 Hz, 1H), 7.52 (dd, J=5.0, 3.0 Hz, 1H),
7.29 (dd, J=5.0, 0.8 Hz, 1H), 4.71 (s, 1H), 3.71-3.60 (m, 1H),
3.25-3.16 (m, 1H), 3.06-2.88 (s, br, 1H), 2.37-2.25 (m, 1H),
2.07-1.89 (m, 2H), 1.84-1.74 (m, 1H), 1.50 (pseudo s, 3H).
Synthesis of
3-iodo-N-(1-phenylpropyl)-1H-indazole-5-carboxamide
##STR00086##
[0368] The title compound was synthesized according to Method A
utilizing 1-phenylpropan-1-amine and obtained as a yellow solid
(583 mg, 72% yield). .sup.1H NMR (400 MHz, CDCl.sub.3) .delta.=8.08
(d, J=0.8 Hz, 1H), 7.97-7.91 (m, 1H), 7.57 (d, J=8.8 Hz, 1H),
7.45-7.39 (m, 2H), 7.35 (s, 2H), 7.26 (d, J=7.3 Hz, 1H), 5.05-4.98
(m, 1H), 2.05-1.89 (m, 2H), 1.02 (t, J=7.3 Hz, 3H); MS ESI
[M+H].sup.+ 406.1, calcd for [C.sub.17H.sub.16IN30+H].sup.+
406.04.
Synthesis of 1-cyclohexylpropan-1-amine
##STR00087##
[0370] The mixture of 1-cyclohexylpropan-1-one (1402.2 mg, 10
mmols), NH.sub.4OAc (9249.6 mg, 120 mmols), NaCNBH.sub.3 (2513.6
mg, 40 mmols) in MeOH (80 mL) was reflaxed overnight. The resulting
reaction mixture was cooled down to rt and concentrated under
reduced pressure. The residue was added 1 M NaOH (100 mL) and
stirred for 20 min. The mixture was extracted with Et.sub.2O. The
combined organic layers were dried over Na.sub.2SO.sub.4 and
concentrated under reduced pressure to provide the title compound
as white crystals (380 mg, 27% yield). .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. ppm 2.55-2.41 (dt, J=8.2, 4.1 Hz, 1H),
1.81-1.46 (m, 7H), 1.33-1.08 (m, 4H), 1.08-0.96 (m, 2H), 0.93 (t,
J=8.2 Hz, 3H); MS ESI [M+H].sup.+ 142.1, calcd for
[C.sub.9H.sub.19N+H].sup.+ 142.16.
Synthesis of
N-(1-cyclohexylpropyl)-3-iodo-1H-indazole-5-carboxamide
##STR00088##
[0372] The mixture of 1-cyclohexylpropan-1-amine (380 mg, 2.69
mmols), 3-iodo-1H-indazole-5-carboxylic acid (774.9 mg, 2.69
mmols), DIPEA (1.33 mL, 8.07 mmols) in DMF (8 mL) was cooled down
to 0.degree. C. and added TBTU (863.8 mg, 2.69 mmols). After
stirring at 0.degree. C. for 1 h, H.sub.2O was added followed by
EtOAc. The organic layer was separated and washed with H.sub.2O for
three times and then with brine followed by dried over
Na.sub.2SO.sub.4 and concentrated under reduced pressure to provide
the title compound as a light yellow solid (418 mg, 38% yield).
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. ppm 10.65 (s, 1H), 7.92
(m, 2H), 7.54 (d, J=8.8 Hz, 1H), 5.89 (d, J=4.1 Hz, 1H), 4.02 (m,
1H), 1.86-1.67 (m, 6H), 1.56-1.44 (m, 2H), 1.31-1.06 (m, 4H), 0.99
(t, J=8.2 Hz, 3H); MS ESI [M+H].sup.+ 412.3, calcd for
[C.sub.17H.sub.22IN.sub.3O+H].sup.+ 412.09.
Synthesis of
3-iodo-N-(2-methyl-2-morpholinopropyl)-1H-indazole-5-carboxamide
##STR00089##
[0374] The title compound was synthesized according to Method A
utilizing 2-methyl-2-morpholinopropan-1-amine and obtained as a
white solid (65 mg, 15% yield). .sup.1H NMR (400 MHz, CD.sub.3OD)
.delta. ppm 8.02 (s, 1H), 7.93 (d, J=8.78 Hz, 1H), 7.62 (d, J=8.28
Hz, 1H), 3.72-3.78 (m, 4H), 2.70 (br. s., 4H), 1.15 (s, 6H); MS ESI
[M+H].sup.+ 429.0, calcd for
[C.sub.16H.sub.211N.sub.4O.sub.2+H].sup.+ 429.08.
Synthesis of
3-iodo-N-(2-morpholino-2-(thiophen-3-yl)ethyl)-1H-indazole-5-carboxamide
##STR00090##
[0376] The title compound was synthesized according to Method A
utilizing 2-morpholino-2-(thiophen-3-yl)ethanamine and obtained as
an off-white solid (180 mg, 37% yield). .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. ppm 7.88 (s, 1H), 7.83 (d, J=8.78 Hz, 1H), 7.56
(d, J=8.78 Hz, 1H), 7.43-7.48 (m, 1H), 7.32 (m, J=2.50 Hz, 1H),
7.15 (d, J=5.02 Hz, 1H), 3.96-4.05 (m, 2H), 3.64-3.76 (m, 5H),
2.54-2.64 (m, 2H), 2.51 (br. s., 2H); MS ESI [M+H].sup.+ 483.1,
calcd for [C.sub.18H.sub.19IN.sub.4O.sub.2S+H].sup.+ 483.04.
Synthesis of
(S)--N-(1-cyclohexylethyl)-1H-indazole-5-carboxamide
##STR00091##
[0378] The title compound was synthesized according to the General
Method A utilizing 1H-indazole-5 carboxylic acid (500 mg, 3.1
mmol), (s)-(+)-1-cyclohexylethyl amine (349 mg, 3.1 mmol), TBTU
(992 mg, 3.1 mmol), DIPEA (1.1 mL, 6.2 mmol), and DMF (15 mL) to
give the title compound (off-white solid, 850 mg, 100%). .sup.1H
NMR (400 MHz, CD.sub.3OD) .delta. ppm 8.29 (s, 1H), 8.16 (s, 1H),
7.85 (d, J=8.8 Hz, 1H), 7.59 (d, J=9.0 Hz, 1H), 3.92-4.01 (m, 1H),
1.74-1.92 (m, 4H), 1.64-1.71 (m, 1H), 1.44-1.55 (m, 1H), 1.22 (d,
J=6.8 Hz, 6H), 0.99-1.13 (m, 2H); MS ESI 272.1 [M+H].sup.+, calcd
for [C.sub.16H.sub.21N30+H].sup.+ 272.2.
Synthesis of
(S)--N-(1-cyclohexylethyl)-3-iodo-1H-indazole-5-carboxamide
##STR00092##
[0380] The title compound was synthesized according to the General
Method B utilizing
(S)--N-(1-cyclohexylethyl)-1H-indazole-5-carboxamide (850 mg, 3.2
mmol), I.sub.2 (1.59 g, 6.4 mmol), K.sub.2CO.sub.3 (1.32 g, 9.6
mmol), and DMF (15 mL) to give the title compound (light orange
solid, 846 mg, 67%). .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. ppm
7.99-8.03 (m, 1H), 7.86 (d, J=8.8 Hz, 1H), 7.56 (d, J=8.0 Hz, 1H),
3.91-4.02 (m, 1H), 1.72-1.91 (m, 4H), 1.61-1.72 (m, 1H), 1.44-1.56
(m, 1H), 1.13-1.34 (m, 6H), 0.98-1.11 (m, 2H); MS ESI 398.2
[M+H].sup.+, calcd for [C.sub.16H.sub.20IN.sub.3O+H].sup.+
398.1.
Synthesis of
(S)--N-(cyclopropyl(phenyl)methyl)-3-iodo-1H-indazole-5-carboxamide
##STR00093##
[0382] The title compound was synthesized according to the General
Method A utilizing 3-iodo-1H-indazole-5-carboxylic acid (79 mg,
0.79 mmol), (s)-cycloproylphenylmethylamine HCl (50 mg, 0.27 mmol),
TBTU (87 mg, 0.27 mmol), DIPEA (0.14 mL, 0.81 mmol), and DMF (4 mL)
to give the title compound (orange solid, 110 mg, 98%). .sup.1H NMR
(400 MHz, CD.sub.3OD) .delta. ppm 8.09 (s, 1H), 7.95 (dd, J=8.9,
1.6 Hz, 1H), 7.56 (d, J=8.8 Hz, 1H), 7.43-7.50 (m, 2H), 7.33 (t,
J=7.6 Hz, 2H), 7.24 (t, J=7.3 Hz, 1H), 4.46 (d, J=9.5 Hz, 1H),
1.34-1.46 (m, 1H), 0.66 (d, J=8.0 Hz, 2H), 0.48 (m, 2H); MS ESI
418.1 [M+H].sup.+, calcd for [C.sub.18H.sub.16IN.sub.3O+H].sup.+
418.0.
Synthesis of
(R)--N-(cyclopropyl(phenyl)methyl)-3-iodo-1H-indazole-5-carboxamide
##STR00094##
[0384] The title compound was synthesized according to the General
Method A utilizing 3-iodo-1H-indazole-5-carboxylic acid (160 mg,
0.55 mmol), (R)-cycloproylphenylmethylamine HCl (100 mg, 0.55
mmol), TBTU (177 mg, 0.55 mmol), DIPEA (0.29 mL, 1.65 mmol), and
DMF (8 mL) to give the title compound (orange solid, 232 mg, 100%).
.sup.1H NMR (400 MHz, CD.sub.3OD) .delta. ppm 8.09 (s, 1H), 7.95
(dd, J=8.8, 1.51 Hz, 1H), 7.55 (d, J=8.8 Hz, 1H), 7.44-7.50 (m,
2H), 7.32 (t, J=7.5 Hz, 2H), 7.22 (t, J=7.3 Hz, 1H), 4.46 (d, J=9.5
Hz, 1H), 1.39 (br. s, 1H), 0.61-0.68 (m, 2H), 0.39-0.52 (m, 2H); MS
ESI 418.1 [M+H].sup.+, calcd for
[C.sub.18H.sub.16IN.sub.3O+H].sup.+ 418.0.
Synthesis of
(R)--N-(1-cyclohexylethyl)-1H-indazole-5-carboxamide
##STR00095##
[0386] The title compound was synthesized according to the General
Method A utilizing 1H-indazole-5 carboxylic acid (500 mg, 3.1
mmol), (R)-(-)-1-cyclohexylethylamine (392 mg, 3.1 mmol), TBTU (992
mg, 3.1 mmol), DIPEA (1.1 mL, 6.2 mmol), and DMF (15 mL) to give
the title compound (off-white solid, 800 mg, 96%). MS ESI 272.2
[M+H].sup.+, calcd for [C.sub.16H.sub.21N30+H].sup.+ 272.2.
Synthesis of
(R)--N-(1-cyclohexylethyl)-3-iodo-1H-indazole-5-carboxamide
##STR00096##
[0388] The title compound was synthesized according to the General
Method B utilizing
(R)--N-(1-cyclohexylethyl)-1H-indazole-5-carboxamide (800 mg, 3.0
mmol), I.sub.2 (1.5 g, 5.9 mmol), K.sub.2CO.sub.3 (1.22 g, 8.9
mmol), and DMF (15 mL) to give the title compound (pale yellow
solid, 825 mg, 70%). .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. ppm
8.02 (s, 1H), 7.91 (dd, J=8.8, 1.5 Hz, 1H), 7.56 (d, J=8.8 Hz, 1H),
3.91-4.02 (m, 1H), 1.73-1.91 (m, 4H), 1.61-1.72 (m, 1H), 1.45-1.56
(m, 1H), 1.13-1.34 (m, 6H), 0.98-1.12 (m, 2H); MS ESI 398.2
[M+H].sup.+, calcd for [C.sub.16H.sub.20IN.sub.3O+H].sup.+
398.1
Synthesis of
(R)-3-iodo-N-(1-(thiophen-2-yl)ethyl)-1H-indazole-5-carboxamide
##STR00097##
[0390] The title compound was synthesized according to the General
Method A utilizing 3-iodo-1H-indazole-5-carboxylic acid (86 mg,
0.30 mmol), (R)-1-(2-thienyl)ethylamine (50 mg, 0.30 mmol), TBTU
(96 mg, 0.30 mmol), DIPEA (0.15 mL, 0.90 mmol), and DMF (5 mL).
Purification by flash chromatography (SiO.sub.2, Biotage 25 g,
5-25% MeOH in CH.sub.2Cl.sub.2) gave the title compound (yellow
solid, 70 mg, 59%). .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. ppm
8.06 (s, 1H), 7.94 (dd, J=8.8, 1.5 Hz, 1H), 7.56 (dd, J=8.8, 0.8
Hz, 1H), 7.27 (dd, J=5.1, 1.1 Hz, 1H), 7.05 (dt, J=3.5, 1.0 Hz,
1H), 6.96 (dd, J=5.0, 3.5 Hz, 1H), 5.57 (q, J=6.9 Hz, 1H), 1.69 (d,
J=7.0 Hz, 3H); MS ESI 398.1 [M+H].sup.+, calcd for
[C.sub.14H.sub.12IN.sub.3OS+H].sup.+ 398.0.
Synthesis of
(R)-3-iodo-N-(1-(thiophen-2-yl)propyl)-1H-indazole-5-carboxamide
##STR00098##
[0392] The title compound was synthesized according to the General
Method A utilizing 3-iodo-1H-indazole-5-carboxylic acid (75 mg,
0.26 mmol), (R)-1-(2-thienyl)propylamine (50 mg, 0.26 mmol), TBTU
(83 mg, 0.26 mmol), DIPEA (0.14 mL, 0.78 mmol), and DMF (4 mL) to
give the title compound (yellow oil, 90 mg, 84%). .sup.1H NMR (400
MHz, CD.sub.3OD) .delta. ppm 8.07 (dd, J=1.8, 0.8 Hz, 1H), 7.94
(dd, J=8.9, 1.6 Hz, 1H), 7.57 (dd, J=8.9, 0.6 Hz, 1H), 7.27 (dd,
J=5.1, 1.1 Hz, 1H), 7.06 (dt, J=2.4, 1.1 Hz, 1H), 6.97 (dd, J=5.3,
3.5 Hz, 1H), 5.34 (t, J=7.5 Hz, 1H), 2.01-2.12 (m, 2H), 1.05 (t,
J=7.3 Hz, 3H); MS ESI 412.0 [M+H].sup.+, calcd for
[C.sub.15H.sub.14IN.sub.3OS+H].sup.+ 412.0.
Synthesis of
(S)--N-(3-hydroxy-1-phenylpropyl)-3-iodo-1H-indazole-5-carboxamide
##STR00099##
[0394] The title compound was synthesized according to the General
Method A utilizing 3-iodo-1H-indazole-5-carboxylic acid (288 mg, 1
mmol), (S)-3-phenyl-beta-alaminol (151 mg, 1 mmol), TBTU (321 mg, 1
mmol), DIPEA (0.52 mL, 3 mmol), and DMF (15 mL) Purification by
flash chromatography (SiO.sub.2, Biotage 25 g, 0-25% MeOH in
CH.sub.2Cl.sub.2) gave the title compound (white solid, 203 mg,
48%). .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 13.70 (s,
1H), 8.93 (d, J=8.0 Hz, 1H), 8.07 (s, 1H), 7.94 (d, J=8.3 Hz, 1H),
7.59 (d, J=8.5 Hz, 1H), 7.40 (d, J=7.5 Hz, 2H), 7.33 (t, J=7.5 Hz,
2H), 7.22 (t, J=7.0 Hz, 1H), 5.15-5.23 (m, 1H), 4.56-4.61 (m, 1H),
3.39-3.52 (m, 2H), 2.02-2.14 (m, 1H), 1.86-1.98 (m, 1H), 1.19-1.29
(m, 1H); MS ESI 422.1 [M+H].sup.+, calcd for
[C.sub.17H.sub.16IN.sub.3O.sub.2+H].sup.+ 422.0.
Synthesis of
3-iodo-N-(1-(2-methylbenzyl)cyclopropyl)-1H-indazole-5-carboxamide
##STR00100##
[0396] The title compound was synthesized according to the General
Method A utilizing 3-iodo-1H-indazole-5-carboxylic acid (288 mg, 1
mmol), 1-(2-methylbenzyl)cyclopropanamine HCl (197 mg, 1 mmol),
TBTU (321 mg, 1 mmol), DIPEA (0.52 mL, 3 mmol), and DMF (15 mL)
Purification by flash chromatography (SiO.sub.2, Biotage 25 g,
0-25% MeOH in CH.sub.2Cl.sub.2) gave the title compound (off-white
solid, 193 mg, 45%); MS ESI 432.1 [M+H].sup.+, calcd for
[C.sub.19H.sub.18IN.sub.3O+H].sup.+ 432.1.
Synthesis of
(R)--N-(3-hydroxy-1-phenylpropyl)-3-iodo-1H-indazole-5-carboxamide
##STR00101##
[0398] The title compound was synthesized according to the General
Method A utilizing 3-iodo-1H-indazole-5-carboxylic acid (288 mg, 1
mmol), (R)-3-phenyl-beta-alaminol (151 mg, 1 mmol), TBTU (321 mg, 1
mmol), DIPEA (0.52 mL, 3 mmol), and DMF (15 mL) Purification by
flash chromatography (SiO.sub.2, Biotage 25 g, 0-25% MeOH in
CH.sub.2Cl.sub.2) gave the title compound (white solid, 247 mg,
59%). .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 13.70 (s,
1H), 8.93 (d, J=8.3 Hz, 1H), 8.06 (s, 1H), 7.94 (d, J=9.0 Hz, 1H),
7.59 (d, J=8.5 Hz, 1H), 7.40 (d, J=7.5 Hz, 2H), 7.33 (t, J=7.5 Hz,
2H), 7.22 (t, J=7.5 Hz, 1H), 5.15-5.24 (m, 1H), 4.59 (br. s., 1H),
3.45 (br. s., 2H), 2.02-2.15 (m, 1H), 1.86-1.98 (m, 1H), 1.22-1.29
(m, 1H); MS ESI 422.1 [M+H].sup.+, calcd for
[C.sub.17H.sub.16IN.sub.3O.sub.2+H].sup.+ 422.0.
Synthesis of 2-cyclopentyl-2-(2-methoxyphenyl)acetic acid
##STR00102##
[0400] Methyl 2-(2-methoxyphenyl)acetate (900 mg, 5 mmol) and 60%
NaH (240 mg, 6 mmol) were dissolved in DMF (25 mL) and cooled to
0.degree. C. Cyclopentyl bromide (745 mg, 5 mmol) was added and the
reaction was gradually warmed to RT. The reaction was stirred at RT
for 16 h and then partitioned between EtOAc (100 mL) and
NaHCO.sub.3 (150 mL). The mixture was washed with brine (150 mL),
dried over MgSO.sub.4 and the solvent was removed under reduced
pressure. Saponification was conducted by addition of 2 M NaOH (20
mL) and heating at 60.degree. C. for 16 h. The mixture was then
acidified with 2 M HCl and then extracted with EtOAc. The solution
was dried over MgSO.sub.4 and concentrated to give the title
compound (yellow solid, 760 mg, 65%). .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. ppm 7.39 (dd, J=7.6, 1.6 Hz, 1H), 7.24 (td,
J=7.8, 1.3 Hz, 1H), 6.95 (m, 1H), 6.89 (d, J=8.3 Hz, 1H), 3.94 (d,
J=11.0 Hz, 1H), 3.84 (s, 3H), 2.48-2.60 (m, 1H), 1.93-2.04 (m, 1H),
1.51-1.76 (m, 3H), 1.39-1.51 (m, 2H), 1.32-1.39 (m, 1H), 0.97-1.07
(m, 1H); MS ESI 235.1 [M+H].sup.+, calcd for
[C.sub.14H.sub.18O.sub.3+H].sup.+ 235.1.
Synthesis of
2-cyclopentyl-N-(3-iodo-1H-indazol-5-yl)-2-(2-methoxyphenyl)acetamide
##STR00103##
[0402] The title compound was synthesized according to the General
Method A utilizing 3-iodo-1H-indazol-5-amine (221 mg, 0.85 mmol),
2-cyclopentyl-2-(2-methoxyphenyl)acetic acid (200 mg, 0.85 mmol),
TBTU (273 mg, 0.85 mmol), DIPEA (0.44 mL, 2.55 mmol), and DMF (10
mL) Purification by flash chromatography (SiO.sub.2, Biotage 25 g,
0-25% MeOH in CH.sub.2Cl.sub.2) gave the title compound (orange
solid, 81 mg, 20%). MS ESI 476.2 [M+H].sup.+, calcd for
[C.sub.21H.sub.22IN.sub.3O.sub.2+H].sup.+ 476.1.
Synthesis of
N-(cyclopentyl(phenyl)methyl)-3-iodo-1H-indazole-5-carboxamide
##STR00104##
[0404] The title compound was synthesized according to the General
Method A utilizing 3-iodo-1H-indazole-5-carboxylic acid (288 mg, 1
mmol), cyclopentyl(phenyl)methanamine (204 mg, 1 mmol), TBTU (321
mg, 1 mmol), DIPEA (0.52 mL, 3 mmol), and DMF (7 mL) to gave the
title compound (yellow solid, 445 mg, 97%). .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. ppm 8.03 (s, 1H), 7.90 (dd, J=8.7, 1.6 Hz, 1H),
7.56 (d, J=8.8 Hz, 1H), 7.44 (d, J=7.3 Hz, 2H), 7.33 (t, J=7.5 Hz,
2H), 7.24 (t, J=7.5 Hz, 1H), 4.83 (d, J=11.0 Hz, 1H), 2.48-2.61 (m,
1H), 1.95-2.07 (m, 1H), 1.35-1.79 (m, 6H), 1.14-1.26 (m, 1H).
Synthesis of 2-cyclopentyl-2-(2-fluorophenyl)acetic acid
##STR00105##
[0406] Ethyl (2-fluorophenyl)acetate (900 mg, 5 mmol) and 60% NaH
(240 mg, 6 mmol) were dissolved in DMF (25 mL) and cooled to
0.degree. C. Cyclopentyl bromide (745 mg, 5 mmol) was added and the
reaction was gradually warmed to RT. Reaction was stirred at RT for
16 h and then partitioned between EtOAc (100 mL) and NaHCO.sub.3
(150 mL). The reaction was washed with brine (150 mL), dried over
MgSO.sub.4 and solvent was removed under reduced pressure.
Saponification was conducted by addition of 2 M NaOH (20 mL) and
heating at 60.degree. C. for 16 h. The mixture was then acidified
with 2 M HCl and then extracted with EtOAc. The solution was dried
over MgSO.sub.4 and concentrated to give the title compound (yellow
solid, 800 mg, 72%). .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. ppm
7.46 (t, J=6.6 Hz, 1H), 7.20-7.26 (m, 1H), 7.12 (t, J=7.5 Hz, 1H),
7.05 (t, J=9.2 Hz, 1H), 3.78 (d, J=11.0 Hz, 1H), 2.47-2.60 (m, 1H),
1.93-2.04 (m, 1H), 1.54-1.75 (m, 3H), 1.41-1.54 (m, 2H), 1.29-1.41
(m, 1H), 0.98-1.12 (m, 1H).
Synthesis of
2-cyclopentyl-2-(2-fluorophenyl)-N-(3-iodo-1H-indazol-5-yl)acetamide
##STR00106##
[0408] The title compound was synthesized according to the General
Method A utilizing 3-iodo-1H-indazol-5-amine (518 mg, 2 mmol),
2-cyclopentyl-2-(2-fluorophenyl)acetic acid (444 mg, 2 mmol), TBTU
(642 mg, 2 mmol), DIPEA (1 mL, 6 mmol), and DMF (10 mL)
Purification by flash chromatography (SiO.sub.2, Biotage 25 g,
0-25% MeOH in CH.sub.2Cl.sub.2) gave the title compound (yellow
oil, 217 mg, 23%). Some di-acetylate by product was also collected
as a yellow solid (201 mg, 15%). .sup.1H NMR (400 MHz, CD.sub.3OD)
.delta. ppm 8.08 (d, J=9.0 Hz, 1H), 7.54 (td, J=7.5, 1.6 Hz, 1H),
7.20-7.27 (m, 1H), 7.01-7.14 (m, 3H), 6.66 (d, J=2.3 Hz, 1H), 5.24
(d, J=11.3 Hz, 1H), 2.68-2.82 (m, 1H), 1.87-2.00 (m, 1H), 1.59-1.78
(m, 3H), 1.43-1.59 (m, 2H), 1.20-1.36 (m, 2H).
Synthesis of cyclohexyl(phenyl)methanamine
##STR00107##
[0410] The title compound was synthesized according to the General
Method G, utilizing cyclohexylphenyl ketone (1.5 g, 8.0 mmol),
NH.sub.4OAc (7.4 g, 96 mmol), NaCNBH.sub.3 (2 g, 32 mmol), and MeOH
(30 mL) to give the title compound (clear oil, 1.41 g, 93%).
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. ppm 7.27-7.39 (m, 3H),
7.23 (d, J=7.3 Hz, 2H), 4.24 (br. s., 2H), 3.58 (d, J=8.3 Hz, 1H),
1.83-1.98 (m, 1H), 1.72-1.83 (m, 1H), 1.63 (br. d, J=8.5 Hz, 3H),
1.19-1.38 (m, 2H), 1.11 (d, J=8.5 Hz, 2H), 0.91-1.05 (m, 1H),
0.71-0.87 (m, 1H).
Synthesis of
N-(cyclohexyl(phenyl)methyl)-3-iodo-1H-indazole-5-carboxamide
##STR00108##
[0412] The title compound was synthesized according to the General
Method A utilizing 3-iodo-1H-indazole-5-carboxylic acid (576 mg, 2
mmol), cyclohexyl(phenyl)methanamine (378 mg, 2 mmol), TBTU (642
mg, 2 mmol), DIPEA (1 mL, 6 mmol), and DMF (6 mL) to gave the title
compound (yellow solid, 917 mg, 100%). .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. ppm 8.03 (s, 1H), 7.90 (d, J=8.8 Hz, 1H), 7.55
(d, J=9.0 Hz, 1H), 7.40 (d, J=7.3 Hz, 2H), 7.33 (s, 3H), 4.79 (d,
J=10.0 Hz, 1H), 2.04-2.16 (m, 1H), 1.59-2.01 (m, 4H), 1.12-1.41 (m,
6H), 0.86-1.02 (m, 1H).
Synthesis of phenyl(tetrahydro-2H-pyran-4-yl)methanone
##STR00109##
[0414] SOCl.sub.2 (8 mL) was added to
tetrahydro-2H-pyran-4-carboxylic acid (3.0 g, 23.1 mmol) and the
resulting mixture was heated at 85.degree. C. (oil temp.) for 1 h
and cooled to rt. Removal of volatile materials gave crude acid
chloride as pale yellow liquid. It was diluted with benzene (12 mL)
and added slowly to a suspension of AlCl.sub.3 (5.84 g, 43.8 mmol)
in benzene (12 mL). After addition, the resulting mixture was
heated at 75.degree. C. for 1 h, cooled to rt, poured onto
ice/H.sub.2O, extracted with DCM and purified by flash
chromatography (EtOAc/hex 20%) to give
phenyl(tetrahydro-2H-pyran-4-yl)methanone (light yellow solid,
3.154 g, 72%). .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.64 (d,
J=7.6 Hz, 2H), 7.58 (t, J=7.4 Hz, 1H), 7.49 (t, J=7.6 Hz, 2H), 4.07
(tt, J=11.6 Hz, 2.8 Hz, 2H), 3.58 (dt, J=11.6 Hz, 2.5 Hz, 2H),
3.54-3.48 (m, 1H), 1.96-1.84 (m, 2H), 1.83-1.77 (m, 2H).
Synthesis of phenyl(tetrahydro-2H-pyran-4-yl)methanamine
##STR00110##
[0416] A mixture of phenyl(tetrahydro-2H-pyran-4-yl)methanone (950
m g, 5 mmol), NH.sub.4OAc (4.62 g, 60 mmol) and NaCNBH.sub.3 (1.26
g, 20 mmol) in MeOH (30 mL) was heated O/N at 60.degree. C. It was
diluted with H.sub.2O, extracted with DCM and purifed by flash
chromatography (MeOH/DCM 0-20%) to give
phenyl(tetrahydro-2H-pyran-4-yl)methanamine (white solid, 262 mg,
42%). .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 7.42-7.28 (m, 5H),
3.98 (dd, J=11.2 Hz, 3.6 Hz, 1H), 3.81 (dd, J=11.6 Hz, 2.8 Hz, 1H),
3.68 (d, J=8.8 Hz, 1H), 3.42 (dt, J=12.0 Hz, 2.0 Hz, 1H), 3.26 (dt,
J=11.6 Hz, 2.8 Hz, 1H), 1.96-1.85 (m, 2H), 1.46-1.34 (m, 1H),
1.26-1.10 (m, 2H); MS ESI 175.0 [M+H].sup.+, calcd for
[C.sub.12H.sub.17NO--NH.sub.3+H].sup.+ 175.1.
Synthesis of
3-iodo-N-(phenyl(tetrahydro-2H-pyran-4-yl)methyl)-1H-indazole-5-carboxami-
de
##STR00111##
[0418] To a solution of phenyl(tetrahydro-2H-pyran-4-yl)methanamine
(262 mg, 1.37 mmol), 3-iodo-1H-indazole-5-carboxamide (395 mg, 1.37
mmol) in DMF (5 mL) at 0.degree. C. was added TBTU (440 mg, 1.37
mmol), followed by .sup.iPr.sub.2NEt (0.48 mL, 2.74 mmol). The
resulting mixture was stirred at 0.degree. C. for 30 min, quenched
with H.sub.2O and stirred for 10 min at rt. Suction filtration gave
crude
3-iodo-N-(phenyl(tetrahydro-2H-pyran-4-yl)methyl)-1H-indazole-5-carboxami-
de (off white solid, 589 mg). MS ESI 462.1 [M+H].sup.+, calcd for
[C.sub.20H.sub.21N.sub.3O+H].sup.+ 462.1.
Synthesis of
N-(2-cyclopentyl-2-phenylethyl)-3-iodo-1H-indazole-5-carboxamide
##STR00112##
[0419] The title compound was synthesized according to the General
Method A utilizing 3-iodo-1H-indazole-5-carboxylic acid (500 mg,
1.74 mmol), 2-cyclopentyl-2-phenylethanamine (329 mg, 1.74 mmol),
TBTU (559 mg, 1.74 mmol), DIPEA (0.90 mL, 5.21 mmol), and DMF (6
mL) to gave the title compound (yellow solid, 602 mg, 75%). .sup.1H
NMR (400 MHz, CD.sub.3OD) .delta. ppm 7.65-7.70 (m, 2H), 7.49 (d,
J=9.0 Hz, 1H), 7.17-7.34 (m, 5H), 3.80-3.91 (m, 1H), 3.45-3.56 (m,
1H), 2.80-2.85 (m, 1H), 2.12-2.23 (m, 1H), 2.00-2.12 (m, 1H),
1.38-1.77 (m, 6H), 0.99-1.11 (m, 1H); MS ESI 460.2 [M+H].sup.+,
calcd for [C.sub.21H.sub.221N.sub.3O+H].sup.+ 460.1.
Synthesis of cyclopentyl(pyridin-2-yl)methanamine
##STR00113##
[0421] The title compound was synthesized according to the General
Method G, utilizing cyclopentyl-2-pyridyl ketone (1 g, 5.7 mmol),
NH.sub.4OAc (5.3 g, 69 mmol), NaCNBH.sub.3 (1.4 g, 23 mmol), and
MeOH (20 mL) to give the title compound (clear oil, 931 g, 93%).
.sup.1H NMR (400 MHz, CD.sub.3OD) .delta. ppm 8.50 (d, J=4.0 Hz,
1H), 7.80 (t, J=7.9 Hz, 1H), 7.41 (d, J=8.0 Hz, 1H), 7.31 (t, J=5.0
Hz, 1H), 3.76 (d, J=8.8 Hz, 1H), 2.14-2.27 (m, 1H), 1.88-1.99 (m,
1H), 1.36-1.75 (m, 5H), 1.25-1.35 (m, 1H), 1.12-1.24 (m, 1H).
Synthesis of
N-(cyclopentyl(pyridin-2-yl)methyl)-3-iodo-1H-indazole-5-carboxamide
##STR00114##
[0423] The title compound was synthesized according to the General
Method A utilizing 3-iodo-1H-indazole-5-carboxylic acid (1.52 g,
5.28 mmol), cyclopentyl(pyridin-2-yl)methanamine (930 mg, 5.28
mmol), TBTU (1.69 mg, 5.28 mmol), DIPEA (2.75 mL, 15.8 mmol), and
DMF (10 mL) to gave the title compound (pale yellow solid, 1.76 g,
75%). .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. ppm 8.50-8.57 (m,
1H), 8.07 (s, 1H), 7.93 (d, J=9.3 Hz, 1H), 7.82 (t, J=7.4 Hz, 1H),
7.57 (d, J=8.8 Hz, 1H), 7.51 (d, J=7.5 Hz, 1H), 7.32 (dd, J=6.6,
5.4 Hz, 1H), 5.01 (d, J=9.8 Hz, 1H), 2.48-2.62 (m, 1H), 1.94-2.05
(m, 1H), 1.48-1.78 (m, 5H), 1.23-1.42 (m, 2H); MS ESI 447.1
[M+H].sup.+, calcd for [C.sub.19H.sub.19IN.sub.4O+H].sup.+
447.1.
Synthesis of cyclobutyl(pyridin-2-yl)methanamine
##STR00115##
[0425] The title compound was synthesized according to the General
Method G, utilizing cyclobutyl-2-pyridyl ketone (1 g, 6.2 mmol),
NH.sub.4OAc (5.8 g, 74 mmol), NaCNBH.sub.3 (1.6 g, 25 mmol), and
MeOH (20 mL) to give the title compound (clear oil, 991 mg, 98%).
.sup.1H NMR (400 MHz, CD.sub.3OD) .delta. ppm 8.49 (d, J=4.3 Hz,
1H), 7.78 (td, J=7.6, 1.8 Hz, 1H), 7.39 (d, J=7.8 Hz, 1H),
7.26-7.32 (m, 1H), 3.88 (d, J=9.3 Hz, 1H), 2.55-2.65 (m, 1H),
2.09-2.20 (m, 1H), 1.64-2.01 (m, 6H).
Synthesis of
N-(cyclobutyl(pyridin-2-yl)methyl)-3-iodo-1H-indazole-5-carboxamide
##STR00116##
[0427] The title compound was synthesized according to the General
Method A utilizing 3-iodo-1H-indazole-5-carboxylic acid (1.76 g,
6.1 mmol), cyclobutyl(pyridin-2-yl)methanamine (990 mg, 6.1 mmol),
TBTU (1.96 mg, 6.1 mmol), DIPEA (3.2 mL, 18 mmol), and DMF (10 mL)
to gave the title compound (pale yellow solid, 1.83 g, 69%).
.sup.1H NMR (400 MHz, CD.sub.3OD) .delta. ppm 8.51 (d, J=4.8 Hz,
1H), 8.08 (s, 1H), 7.94 (dd, J=8.7, 0.9 Hz, 1H), 7.80 (td, J=7.6,
1.4 Hz, 2H), 7.57 (d, J=8.8 Hz, 1H), 7.48 (d, J=8.0 Hz, 1H),
7.27-7.32 (m, 1H), 5.19 (d, J=10.3 Hz, 1H), 2.86-2.97 (m, 1H),
2.16-2.26 (m, 1H), 1.77-2.05 (m, 5H); MS ESI 433.1 [M+H].sup.+,
calcd for [C.sub.18H.sub.171N.sub.4O+H].sup.+ 433.0.
Synthesis of (1-methylpiperidin-4-yl)(phenyl)methanone
##STR00117##
[0429] In a microwave vial, 4-benzylpiperidine HCl (650 mg, 2.89
mmol) was dissolved in formic acid (3 mL) and formalin (937 .mu.L,
11.6 mmol) was added. The vial was sealed and placed in microwave
reactor and heated at 150.degree. C. for 5 min. LC-MS was checked
and then concentrated. The residue was partitioned between EtOAC
(20 mL) and 0.5 M NaOH (30 mL), washed with brine and then dried
using MgSO.sub.4 and under reduced pressure to give the title
compound (clear oil, 520 mg, 89%). .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. ppm 7.97-8.06 (m, 2H), 7.65 (t, J=7.5 Hz, 1H),
7.54 (t, J=7.3 Hz, 2H), 3.69-3.81 (m, 1H), 3.61 (d, J=11.5 Hz, 2H),
3.18 (t, J=13.6 Hz, 2H), 2.92 (s, 3H), 2.16 (d, J=14.8 Hz, 2H),
1.92 (q, J=13.6 Hz, 2H).
Synthesis of (1-methylpiperidin-4-yl)(phenyl)methanamine
##STR00118##
[0431] Using Method G, (1-methylpiperidin-4-yl)(phenyl)methanone
(520 mg, 2.56 mmol), MeOH (15 mL), NH.sub.4OAc (2.37 g, 30 mmol),
and NaCNBH.sub.3 (645 mg, 10.2 mmol) gave the title compound (clear
oil, 503 mg, 96%). MS ESI [M+H].sup.+ 205.1, calcd for
[C.sub.13H.sub.20N.sub.2+H].sup.+ 205.2.
Synthesis of
N-(3-iodo-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-5-yl)-2-(pyrrolidin-1-y-
l)-2-(thiophen-3-yl)acetamide
##STR00119##
[0433] The title compound was synthesized according to the Method A
utilizing 3-iodo-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-5-amine
(686 mg, 2 mmol), 2-(pyrrolidin-1-yl)-2-(thiophen-3-yl)acetic acid
(422 mg, 2 mmol), TBTU (642 mg, 2 mmol), DIPEA (1 mL, 6 mmol), and
DMF (10 mL). Purification by flash chromatography (SiO.sub.2,
Biotage 25 g, 0-30% MeOH in CH.sub.2Cl.sub.2) gave the title
compound (yellow solid, 921 mg, 86%). .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. ppm 7.83 (s, 1H), 7.62 (d, J=8.8 Hz, 1H), 7.56
(d, J=8.5 Hz, 1H), 7.50 (br. s, 1H), 7.38-7.45 (m, 1H), 7.30-7.36
(m, 1H), 5.76 (d, J=7.3 Hz, 1H), 4.11 (s, 1H), 3.92-4.00 (m, 1H),
3.72-3.82 (m, 1H), 2.62-2.71 (m, 2H), 2.38-2.55 (m, 3H), 2.06-2.16
(m, 1H), 1.95-2.05 (m, 1H), 1.56-1.90 (m, 7H), 1.24-1.35 (m, 1H);
MS ESI 537.2 [M+H].sup.+, calcd for
[C.sub.22H.sub.251N.sub.4O.sub.2S+H].sup.+ 537.1.
Synthesis of
2-cyclopentyl-N-(3-iodo-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-5-yl)-2-(-
thiophen-3-yl)acetamide
##STR00120##
[0435] The title compound was synthesized according to the General
Method A utilizing
3-iodo-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-5-amine (172 mg, 0.5
mmol), 2-(cyclopentyl)-2-(thiophen-3-yl)acetic acid (105 mg, 0.5
mmol), TBTU (160 mg, 0.5 mmol), DIPEA (0.26 mL, 1.5 mmol), and DMF
(10 mL) Purification by flash chromatography (SiO.sub.2, Biotage 25
g, 0-30% MeOH in CH.sub.2Cl.sub.2) gave the title compound (white
solid, 260 mg, 97%). .sup.1H NMR (400 MHz, CD3OD) .delta. ppm 7.98
(s, 1H), 7.84 (s, 1H), 7.61 (d, J=9.0 Hz, 1H), 7.49-7.54 (m, 1H),
7.34-7.39 (m, 1H), 7.28-7.31 (m, 1H), 7.21 (d, J=5.0 Hz, 1H),
5.73-5.78 (m, 1H), 3.93-4.00 (m, 1H), 3.74-3.82 (m, 1H), 3.54 (d,
J=11.0 Hz, 1H), 2.61-2.70 (m, 1H), 2.39-2.51 (m, 1H), 2.07-2.15 (m,
1H), 1.88-2.05 (m, 2H), 1.77-1.86 (m, 1H), 1.60-1.77 (m, 5H),
1.50-1.59 (m, 2H), 1.30-1.41 (m, 1H), 1.09-1.22 (m, 1H).
Synthesis of
N-(1H-indazol-5-yl)-2-(piperidin-1-yl)-2-(thiophen-3-yl)acetamide
##STR00121##
[0436] A. 2-(Piperidin-1-yl)-2-(thiophen-3-yl)acetic acid
[0437] The title compound was synthesized according to general
Method D by using glyoxylic acid monohydrate (1.8 g, 19 mmol) and
piperidine (1.93 mL, 19 mmol) in CH.sub.2Cl.sub.2 (75 mL) and
sonicating for 15 min. Thiophene-3-boronic acid (2.5 g, 19 mmol)
was added and the mixture was stirred at rt for 24 h. Purification
by Biotage (50 g SiO2, 0-30% MeOH in DCM) gave the title compound
(cream solid, 3.4 g, 77%). .sup.1H NMR (400 MHz, CD.sub.3OD)
.delta. 7.58 (s, 1H), 7.33 (s, 2H), 4.70 (s, 1H), 3.71-3.63 (br.m,
2H), 3.17 (br.s, 2H), 1.94-1.93 (br.m, 2H), 1.83-1.80 (br.m, 2H),
1.55-1.53 (br.s, 2H); MS ESI 226.1 [M+H].sup.+, calcd for
[C.sub.11H.sub.15NO.sub.2S+H].sup.+ 226.1.
B.
N-(1H-indazol-5-yl)-2-(piperidin-1-yl)-2-(thiophen-3-yl)acetamide
[0438] (CH.sub.3).sub.3COCl (1.82 mL, 0.014 mol) was added slowly
to a cooled (0-5.degree. C.) solution of
2-(piperidin-1-yl)-2-(thiophen-3-yl)acetic acid (3.0 g, 13 mmol),
DMAP (81 mg) and TEA (7.5 mL, 53 mmol) in DCM (150 mL). After 1 h
stirring at 0.degree. C. 5-amino-1H-indazole (1.95 g, 14 mmol)
added and the mixture was stirred at rt for 24 h. The reaction
mixture was washed with H.sub.2O, dried (Na.sub.2SO.sub.4) and
concentrated under vacuum. The crude product was heated in 1:1
hexane-isopropyl alcohol (40 mL) at 75.degree. C. for 30 min and
the product filtered at rt to give the first crop of title compound
(off white solid, 2.65 g). The filtrate concentrated under reduced
pressure and purified by flash chromatography (SiO2, 0-15% MeOH in
DCM) to give the second crop (360 mg, combined yield 3.01 g, 66%).
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. ppm 10.1 (br.s., 1H),
8.51 (br. s., 1H), 9.57 (s, 1H), 8.14 (s, 1H), 8.04 (d, J=0.8 Hz,
1H), 7.51-7.45 (m, 2H), 7.32-7.31 (m, 1H), 7.06 (dd, J=5.2 Hz,
J=1.2 Hz, 1H), 4.22 (s, 1H), 2.49-2.40 (br.m, 4H), 1.67-1.61 (br.m,
6H); MS ESI 341.1 [M+H].sup.+, calcd for
[C.sub.18H.sub.20N4OS+H].sup.+ 341.4.
Synthesis of
N-(3-iodo-1H-indazol-5-yl)-2-(piperidin-1-yl)-2-(thiophen-3-yl)acetamide
##STR00122##
[0440] The title compound was synthesized according to general
Method B from
N-(1H-indazol-5-yl)-2-(piperidin-1-yl)-2-(thiophen-3-yl)acetamide
(3.0 g, 8.8 mmol), K.sub.2CO.sub.3 (4.87 g, 8.8 mmol) and 12 (2.45
g, 9.6 mmol) in DMF (24 mL). The reaction was stirred at rt for 24
h and then treated with 5% aq, Na.sub.2S.sub.2O.sub.3.5H.sub.2O
(200 mL). The solid was filtered and washed with H.sub.2O
(4.times.25 mL) to give crude brown solid. The crude product was
purified by flash chromatography (SiO2, 0-80% EtOAc in Hexane) to
give the title compound (pale yellow solid, 1.8 g, 44%). .sup.1H
NMR (400 MHz, CDCl.sub.3) .delta. ppm 10.4 (s, 1H), 9.62 (s, 1H),
7.83 (d, J=1.2 Hz, 1H), 7.62 (dd, J=8.8 Hz, J=3.2 Hz, 1H), 7.44 (d,
J=8.8 Hz, 1H), 7.34-7.32 (m, 1H), 7.07 (d, J=4 Hz, 1H), 4.25 (s,
1H), 2.49 (br.m, 4H), 1.69 (br.m, 4H), 1.48 (br.s., 2H); MS ESI
467.1 [M+H].sup.+, calcd for [C.sub.18H.sub.19IN.sub.4OS+H].sup.+
467.
Synthesis of
N-(cyclopentyl(thiophen-3-yl)methyl)-3-iodo-1H-indazole-5-carboxamide
##STR00123##
[0441] A. cyclopentyl(thiophen-3-yl)methanamine
[0442] The title compound was prepared using Method G from
cyclopentyl-3-thienyl ketone (3.5 g, 19.4 mmol) at 60.degree. C.
for 24 h. Evaporation of MeOH and addition of 2 M NaOH (50 mL),
extraction using EtOAc (2.times.100 mL), and purification by flash
chromatography (SiO2, 0-20% MeOh in DCM) gave the title compound
(colorless oil, 3.25 g, 92.5%). .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. ppm 7.44-7.42 (m, 1H), 7.27 (t, J=2 Hz, 1H), 7.412-7.10 (m,
1H), 3.74 (t, J=8.4 Hz, 1H), 2.09-1.99 (m, 1H), 1.76-1.68 (m, 1H),
1.58-1.29 (m, 6H), 1.16-1.14 (m, 1H).
B.
N-(cyclopentyl(thiophen-3-yl)methyl)-3-iodo-1H-indazole-5-carboxamide
[0443] The title compound was prepared using Method A by from
cyclopentyl(thiophen-3-yl)methanamine (3.25 g, 17.9 mmol),
3-iodo-1H-indazol-5-carboxylic acid (5.16 g, 17.9 mmol), DIPEA
(12.49 mL, 71.6 mmol) and TBTU (5.74 g, 17.9 mmol) in DMF (49 mL)
at 20.degree. C. for 4 h. The mixture was poured into H.sub.2O (1.3
L) and the solid was collected by filtration and washed with
H.sub.2O to provide the title compound (cream color solid, 7.95 g,
98%). .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 13.72 (br.s,
1H), 8.86 (t, J=8.8 Hz, 1H), 7.92-7.9 (m, 1H), 7.58 (t, J=8.8 Hz,
1H), 7.46-7.44 (m, 1H), 7.39-7.38 (m, 1H), 7.22 (d, J=4.8 Hz, 1H),
4.98 (t, J=9.6 Hz, 1H), 1.81-1.78 (m, 1H), 1.61-1.32 (m, 7H),
1.2-1.17 (m, 1H); MS ESI 452 [M+H].sup.+, calcd for
[C.sub.18H.sub.18IN.sub.3OS+H].sup.+ 452.
Synthesis of
N-(1-(2-chlorophenyl)-2-methylpropyl)-3-iodo-1H-indazole-5-carboxamide
##STR00124##
[0444] A. 1-(2-chlorophenyl)-2-methylpropan-1-ol
[0445] A solution of 2-chlorobenzaldehyde (2.75 g) in Et.sub.2O (30
mL) was slowly added to a solution of isopropyl magnesium bromide
(obtained from 0.98 g of magnesium and 4.85 g 2-bromopropane in 70
mL anhydrous Et.sub.2O) at 0.degree. C. The reaction mixture was
stirred for 1 h at 0.degree. C., and then quenched with aq. 25%
NH.sub.4Cl (100 mL). The organic layer was separated and the aq.
layer was extracted with EtOAc (50 mL). The combined organic layer
was washed with H.sub.2O and brine, dried (Na.sub.2SO.sub.4) and
concentrated under vacuum. Purification by flash chromatography
(SiO2, 0-25% EtOAc in Hexane) gave the title compound (clear
colorless oil, 1.5 g, 41%). .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. 7.52 (d, J=7.2 Hz, 1H), 7.37-7.31 (m, 2H), 7.25-7.21 (m,
1H), 5.27 (d, J=4.4 Hz, 1H), 4.68 (dd, J=5.2 Hz, 1H), 1.88-1.80 (m,
1H), 0.86 (dd, J=17.2 Hz, J=6.8 Hz, 6H).
B. 1-(2-chlorophenyl)-2-methyl-propan-1-one
[0446] A solution of 1-(2-chlorophenyl)-2-methylpropan-1-ol (1.5 g
in 15 mL DCM) was added to a suspension of PCC (2.62 g in 30 mL
DCM) at 25.degree. C., monitoring the reaction by TLC. The reaction
was complete in 2 h. Et.sub.2O (120 mL) was added and the reaction
mixture was stirred for 15 min. The supernatent was decanted, dried
(Na.sub.2SO.sub.4) and concentrated under vacuum. Purification by
flash chromatography (SiO2, 0-10% EtOAc in Hexane) gave the title
compound (clear colorless oil, 1.24 g, 82%). .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 7.41-7.27 (m, 4H), 3.37-3.30 (m, 1H), 1.19 (d,
J=6.8 Hz, 6H).
C. 1-(2-chlorophenyl)-2-methylpropan-1-amine
[0447] The title compound was prepared using Method G from
1-(2-chlorophenyl)-2-methyl-propan-1-one (1.5 g, 8.2 mmol) at
65.degree. C. for 24 h. Evaporation of MeOH and addition of 3M NaOH
(100 mL), extraction using EtOAc (2.times.100 mL), and purification
by flash chromatography (SiO2, 0-25% DCM in MeOH) to give the title
compound (colorless oil, 348 mg, 23%). .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 7.38-7.21 (m, 4H), 4.87 (br.s, 2H), 4.16
(d, J=8.0 Hz, 1H), 2.12-2.04 (m, 1H), 1.02 (d, JJ=6.4 Hz, 3H), 0.82
(d, J=6.8 Hz, 3H); MS ESI 184.08. [M+H].sup.+, calcd for
[C.sub.10H.sub.14ClN+H].sup.+ 184.08.
D.
N-(1-(2-chlorophenyl)-2-methylpropyl)-3-iodo-1H-indazole-5-carboxamide
[0448] The title compound was synthesized according to general
Method A by using 1-(2-chlorophenyl)-2-methylpropan-1-amine (0.55
g, 2.99 mmol), DMF (11 mL), 3-iodo-1H-indazole-5-carboxylic acid
(863 mg, 2.99 mmol), DIPEA (2.09 mL, 11.98 mmol) and TBTU (960 mg,
2.99 mmol). The resultant reaction mass stirred at 25.degree. C.
for 12 h and then quenched it in H.sub.2O (440 mL). The solid
collected by filtration and was washed with H.sub.2O to provide the
title compound (cream color solid, 1.29 g, 95%). .sup.1H NMR (400
MHz, DMSO-d.sub.6) .delta. 13.76 (s, 1H), 8.91 (d, J=8.8 Hz, 1H),
7.91 (d, J=9.2 Hz, 1H), 7.74-7.66 (m, 1H), 7.59 (d, J=8.8 Hz, 1H),
7.46-7.22 (m, 4H), 5.27 (t, J=9.2 Hz, 1H), 2.20-2.15 (m, 1H), 1.08
(d, J=6.0 Hz, 3H), 0.79 (d, J=6.8 Hz, 3H); MS ESI 454 [M+H].sup.+,
calcd for [C.sub.18H.sub.17CIlN.sub.3O+H].sup.+ 454.
Synthesis of
N-(cyclobutyl(phenyl)methyl)-3-iodo-1H-indazole-5-carboxamide
##STR00125##
[0449] A. cyclobutyl(phenyl)methanamine
[0450] Using Method G, cyclobutyl(phenyl)methanone (1.06 mL, 13.9
mmol) gave the title compound (1.12 g, 100%) which was used crude.
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. ppm 7.28-7.35 (m, 4H),
7.21-7.27 (m, 1H), 3.80 (d, J=9.3 Hz, 1H), 2.46-2.56 (m, 1H),
2.10-2.21 (m, 1H), 1.67-1.93 (m, 5H).
B.
N-(cyclobutyl(phenyl)methyl)-3-iodo-1H-indazole-5-carboxamide
[0451] Using Method A, 3-iodo-1H-indazole-5-carboxylic acid (285.4
mg, 0.99 mmol) and cyclobutyl(phenyl)methanamine (177.2 mg, 1.10
mmol) gave the title compound (brown solid, 334 mg, 78%) after
purification on the Biotage (RPC18, 10-95% MeOH in 0.1%
TFA-H.sub.2O). .sup.1H NMR (400 MHz, Acetone-d.sub.6) .delta. ppm
12.89 (m, 0H), 8.24 (d, J=7.8 Hz, 1H), 8.09 (s, 1H), 8.04 (dd,
J=8.8, 1.3 Hz, 1H), 7.64 (d, J=8.8 Hz, 1H), 7.47 (d, J=7.5 Hz, 2H),
7.33 (t, J=7.5 Hz, 2H), 7.23 (t, J=7.5 Hz, 1H), 5.21 (dd, J=10.2,
8.9 Hz, 1H), 2.18 (d, J=5.3 Hz, 1H), 1.94-2.03 (m, 1H), 1.80-1.93
(m, 4H). MS ESI 432.1 [M+H].sup.+, calcd for
[C.sub.19H.sub.18IN.sub.3O+H].sup.+ 432.06.
Synthesis of
(R)--N-((3-chlorothiophen-2-yl)(cyclopropyl)methyl)-3-iodo-1H-indazole-5--
carboxamide
##STR00126##
[0453] Using Method A, 3-iodo-1H-indazole-5-carboxylic acid (161.0
mg, 0.56 mmol) and
(R)-(3-chlorothiophen-2-yl)(cyclopropyl)methanamine hydrochloride
(125.2 mg, 0.56 mmol) in DMF (6 mL) were stirred at rt for 29 h.
The reaction mixture was added dropwise into 70 mL H.sub.2O and the
precipitate was collected by filtration, transferred using a
mixture of acetone and EtOH, and concentrated to dryness.
Purification by flash chromatography (SiO2, 0-40% EtOAc/DCM) gave
the title compound (light tan solid, 209.3 mg, 85% pure, 70%) which
was used without further purification. .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. ppm 8.08 (s, 1H), 7.94 (dd, J=8.8, 1.5 Hz, 1H),
7.58 (d, J=9.0 Hz, 1H), 7.39 (d, J=5.5 Hz, 1H), 6.94 (d, J=5.3 Hz,
1H), 4.97 (d, J=9.0 Hz, 1H), 1.51 (td, J=8.4, 3.8 Hz, 1H),
0.62-0.74 (m, 2H), 0.50-0.62 (m, 2H).
Synthesis of
(S)--N-((3-chlorothiophen-2-yl)(cyclopropyl)methyl)-3-iodo-1H-indazole-5--
carboxamide
##STR00127##
[0455] Using Method A following the work-up Method for the
corresponding (R) enantiomer, 3-iodo-1H-indazole-5-carboxylic acid
(161.5 mg, 0.56 mmol) and
(S)-(3-chlorothiophen-2-yl)(cyclopropyl)methanamine hydrochloride
(125.2 mg, 0.56 mmol) gave the title compound (beige solid, 218 mg,
85% pure, 72%) which was used without further purification. .sup.1H
NMR (400 MHz, CD.sub.3OD) .delta. ppm 8.08 (s, 1H), 7.94 (dd,
J=8.8, 1.5 Hz, 1H), 7.58 (d, J=9.0 Hz, 1H), 7.39 (d, J=5.5 Hz, 1H),
6.94 (d, J=5.3 Hz, 1H), 4.97 (d, J=9.0 Hz, 1H), 1.51 (td, J=8.4,
3.8 Hz, 1H), 0.62-0.74 (m, 2H), 0.50-0.62 (m, 2H).
Synthesis of
(R)--N-(1-(2-chlorophenyl)propyl)-3-iodo-1H-indazole-5-carboxamide
##STR00128##
[0457] Using Method A, 3-iodo-1H-indazole-5-carboxylic acid (488.7
mg, 1.7 mmol) and (R)-1-(2-chlorophenyl)propan-1-amine
hydrochloride (349.7 mg, 1.7 mmol) gave the title compound (white
solid, 650.3 mg, 95% pure, 83%) after aq. work-up with EtOAc and
purification by flash chromatography (SiO2, 5-30% EtOAc in DCM).
.sup.1H NMR (400 MHz, CD.sub.3OD) .delta. ppm 8.11 (s, 1H), 7.95
(dd, J=8.9, 1.6 Hz, 1H), 7.59 (d, J=8.5 Hz, 1H), 7.51 (dd, J=7.7,
1.4 Hz, 1H), 7.41 (dd, J=7.8, 1.4 Hz, 1H), 7.31 (td, J=7.5, 1.5 Hz,
1H), 7.21-7.27 (m, 1H), 5.46 (dd, J=8.9, 5.9 Hz, 1H), 1.87-2.01 (m,
2H), 1.09 (t, J=7.3 Hz, 3H). MS ESI 440.2 [M+H].sup.+, calcd for
[C.sub.17H.sub.15CIlN.sub.3O+H].sup.+ 440.0.
Synthesis of
(S)--N-(1-(2-chlorophenyl)propyl)-3-iodo-1H-indazole-5-carboxamide
##STR00129##
[0459] Using Method A, 3-iodo-1H-indazole-5-carboxylic acid (490.2
mg, 1.7 mmol) and (S)-1-(2-chlorophenyl)propan-1-amine
hydrochloride (348.6 mg, 1.69 mmol) gave the title compound (white
solid, 525.5 mg, 70.7%) after aq. work-up with EtOAc and
purification by flash chromatography (SiO2, 5-30% EtOAc in DCM).
.sup.1H NMR (400 MHz, Acetone-d.sub.6) .delta. ppm 12.89 (s, 1H),
8.39 (d, J=8.5 Hz, 1H), 8.16 (s, 1H), 8.07 (dd, J=8.8, 1.5 Hz, 1H),
7.67 (s, 1H), 7.65 (td, J=3.8, 1.6 Hz, 1H), 7.43 (dd, J=7.5, 1.6
Hz, 1H), 7.33 (td, J=7.5, 1.6 Hz, 1H), 7.27 (td, J=7.5, 1.6 Hz,
1H), 5.55 (td, J=8.2, 6.3 Hz, 1H), 1.88-1.96 (m, 2H), 1.08 (t,
J=7.4 Hz, 3H). MS ESI 440.2 [M+H].sup.+, calcd for
[C.sub.17H.sub.15ClIN.sub.3O+H].sup.+ 440.0.
Synthesis of
(R)--N-(1-(2-fluorophenyl)ethyl)-3-iodo-1H-indazole-5-carboxamide
##STR00130##
[0460] A. (R)-1-(2-fluorophenyl)ethanamine hydrochloride
[0461] To (R)-2-methylpropane-2-sulfinamide (121 mg, 1.0 mmol),
Ti(OEt).sub.4 (0.41 mL, 2.0 mmol) in THF (2.0 mL) was added
1-(2-fluorophenyl)ethanone (0.15 mL, 1.2 mmol) and the mixture
heated to 70.degree. C. for 18 h. The reaction was then cooled to
-48.degree. C. and NaBH.sub.4 (151 mg, 4.0 mmol) was added and the
reaction was allowed to warm to rt and stir for 4 h at which time
it was quenched with MeOH, brine was added (5 mL), and the
resulting slurry was filtered through Celite washing with EtOAc.
The resulting filtrate was extracted with EtOAc washing with brine
and the material purified by column chromatography (silica gel,
98:2 CH.sub.2Cl.sub.2/MeOH) which gave 189 mg, 78% of
(R)--N--((R)-1-(2-fluorophenyl)ethyl)-2-methylpropane-2-sulfinamide
which was 58% de by NMR. This material was taken up in MeOH (3.5
mL) and HCl (1.6 mL of a 1.0M solution in Et.sub.2O) was added and
the reaction stirred for 1.5 h. The solvent was then removed and
the product precipitated with Et.sub.2O (10 mL) and filtered to
give 109 mg, 62% (over the 2 steps) of a white solid (58% ee).
B.
(R)--N-(1-(2-fluorophenyl)ethyl)-3-iodo-1H-indazole-5-carboxamide
[0462] General Method A was used except using
(R)-1-(2-fluorophenyl)ethanamine hydrochloride (109 mg, 0.621
mmol), 3-iodo-1H-indazole-5-carboxylic acid (179 mg, 0.621 mmol),
TBTU (209 mg, 0.652 mmol), DIPEA (0.44 mL, 2.5 mmol), and DMF (3.5
mL). Obtained 120 mg of product, 47%. .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. ppm 8.09 (s, 1H), 7.94 (d, J=9.2 Hz, 1H), 7.57
(d, J=9.2 Hz, 1H), 7.45 (t, J=7.2 Hz, 1H), 7.30-7.25 (m, 1H),
7.16-7.07 (m, 2H), 5.51 (q, J=7.2 Hz, 1H), 1.60 (d, J=7.2 Hz, 3H);
MS ESI 410.1 [M+H].sup.+, calcd for
[C.sub.16H.sub.13FIN.sub.3O+H].sup.+ 410.02.
Synthesis of
(R)--N-(1-(2-chlorophenyl)propyl)-3-iodo-1H-indazole-5-carboxamide
##STR00131##
[0464] Prepared in the same way as
(R)--N-(1-(2-fluorophenyl)ethyl)-3-iodo-1H-indazole-5-carboxamide
except substituting 1-(2-chlorophenyl)propan-1-one. The ee was
determined to be 36% using the Method described for
(R)--N-(1-(2-fluorophenyl)ethyl)-3-iodo-1H-indazole-5-carboxamide.
MS ESI 440.0 [M+H].sup.+, calcd for
[C.sub.17H.sub.15ClIN.sub.3O+H].sup.+ 440.00.
Synthesis of
(S)--N-(cyclopropyl(thiophen-2-yl)methyl)-3-iodo-1H-indazole-5-carboxamid-
e
##STR00132##
[0466] Prepared in the same way as
(R)--N-(1-(2-fluorophenyl)ethyl)-3-iodo-1H-indazole-5-carboxamide
except substituting cyclopropyl(thiophen-2-yl)methanone. The ee was
determined to be 50% using the Method described for
(R)--N-(1-(2-fluorophenyl)ethyl)-3-iodo-1H-indazole-5-carboxamide.
MS ESI 424.0 [M+H].sup.+, calcd for
[C.sub.16H.sub.14IN.sub.3OS+H].sup.+ 424.00.
Synthesis of
(S)-3-iodo-N-(2-methoxy-1-phenylethyl)-1H-indazole-5-carboxamide
##STR00133##
[0468] General Method A was used except using
(S)-2-methoxy-1-phenylethanamine (0.30 mL, 2.0 mmol),
3-iodo-1H-indazole-5-carboxylic acid (576 mg, 2.0 mmol), TBTU (640
mg, 2.0 mmol), DIPEA (1.4 mL, 8.0 mmol), and DMF (13 mL). Obtained
575 mg, 68% of the product as a white solid. MS ESI 422.0
[M+H].sup.+, calcd for [C.sub.17H.sub.16IN.sub.3O.sub.2+H].sup.+
422.04.
Synthesis of
(R)-3-iodo-N-(1-(3-methoxyphenyl)propyl)-1H-indazole-5-carboxamide
##STR00134##
[0470] General Method A was used except using
(R)-1-(3-methoxyphenyl)propan-1-amine hydrochloride (202 mg, 1.0
mmol), 3-iodo-1H-indazole-5-carboxylic acid (288 mg, 1.0 mmol),
TBTU (320 mg, 1.0 mmol), DIPEA (0.70 mL, 4.0 mmol), and DMF (6.0
mL). Obtained 336 mg, 77% of the product as a white solid. MS ESI
436.0 [M+H].sup.+, calcd for
[C.sub.18H.sub.18IN.sub.3O.sub.2+H].sup.+ 436.05.
Synthesis of ethyl 2-cyclopentyl-2-(pyridin-2-yl)acetate
##STR00135##
[0472] The solution of ethyl 2-(pyridin-2-yl)acetate (2 g, 12.1
mmols) in anhydrous DMF (20 mL) was cooled down to 0.degree. C.
followed by adding of 60% NaH (581 mg, 14.5 mmols) in portions and
bromocyclopentane (1.98 g, 13.3 mmols) dropwise. The resulting
suspension was stirred at rt for 2 h before H.sub.2O was added. The
mixture was extracted with EtOAc. The organic layer was washed with
H.sub.2O for three times and brine for one time before dried over
Na.sub.2SO.sub.4 and concentrated under reduced pressure to give
the title compound as a yellow oil (370 mg, 52% yield). .sup.1H NMR
(400 MHz, CDCl.sub.3) .delta. ppm 8.55 (d, J=4.8 Hz, 1H), 7.65 (td,
J=7.7, 1.8 Hz, 1H), 7.40 (d, J=8.0 Hz, 1H), 7.17 (ddd, J=7.4, 5.0,
0.9 Hz, 1H), 4.04-4.23 (m, 2H), 3.58 (d, J=11.0 Hz, 1H), 2.58-2.75
(m, 1H), 1.88-2.01 (m, 1H), 1.24-1.54 (m, 5H), 1.22 (t, J=7.2 Hz,
3H), 1.07 (dq, J=12.4, 8.2 Hz, 1H), 0.79-0.92 (m, 1H); MS ESI
[M+H].sup.+ 234.0, calcd for [C.sub.14H.sub.19NO.sub.2+H].sup.+
234.15.
Synthesis of 2-cyclopentyl-2-(pyridin-2-yl)acetic acid
##STR00136##
[0474] The title compound was synthesized according to the Method
of 2-(4-(4-bromophenoxy)piperidin-1-yl)acetic acid utilizing ethyl
2-cyclopentyl-2-(pyridin-2-yl)acetate and obtained as a colourless
gel (216 mg, 43% yield). .sup.1H NMR (400 MHz, CD.sub.3OD) .delta.
ppm 8.75 (d, J=5.3 Hz, 1H), 8.45-8.53 (m, 1H), 8.08 (d, J=7.8 Hz,
1H), 7.86-7.95 (m, 1H), 3.85 (d, J=11.0 Hz, 1H), 2.66 (m, J=10.5,
9.0, 9.0 Hz, 1H), 1.99-2.10 (m, 1H), 1.39-1.82 (m, 6H), 1.04-1.16
(m, 1H); MS ESI [M+H].sup.+ 206.1, calcd for
[C.sub.12H.sub.15NO.sub.2+H].sup.+ 206.12.
Synthesis of
2-cyclopentyl-N-(3-iodo-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-5-yl)-2-(-
pyridin-2-yl)acetamide
##STR00137##
[0476] The title compound was synthesized according to Method A
utilizing 2-cyclopentyl-2-(pyridin-2-yl)acetic acid and
3-iodo-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-5-amine and obtained
as a brown solid (178 mg, 23% yield). .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. ppm 10.06 (br. s., 1H), 8.63 (d, J=4.0 Hz, 1H),
7.64-7.80 (m, 2H), 7.43-7.58 (m, 2H), 7.20-7.38 (m, 3H), 5.64 (d,
J=8.0 Hz, 1H), 3.98 (d, J=10.5 Hz, 1H), 3.70 (t, J=9.3 Hz, 1H),
3.42-3.56 (m, 1H), 2.60-2.75 (m, 1H), 2.51 (d, J=9.5 Hz, 1H),
1.88-2.21 (m, 3H), 1.33-1.82 (m, 9H), 1.00-1.15 (m, 1H); MS ESI
[M+H].sup.+ 531.2, calcd for
[C.sub.24H.sub.271N.sub.4O.sub.2+H].sup.+ 531.13.
Synthesis of
2-cyclopentyl-N-(3-iodo-1H-indazol-5-yl)-2-(pyridin-2-yl)acetamide
##STR00138##
[0478] The solution of
2-cyclopentyl-N-(3-iodo-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-5-yl)-2-(-
pyridin-2-yl)acetamide (178 mg, 0.34 mmol) and TsOH.H.sub.2O (288
mg, 1.51 mmols) in MeOH (3 mL) was stirred at 125.degree. C. for 3
h with microwave irradiation in a sealed vial before concentrated
under reduced pressure. The residue was purified by flash
chromatography (MeOH/DCM 0%-10%) to give the title compound as a
light yellow solid (104 mg, 69% yield). .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. ppm 8.48 (dd, J=4.9, 0.9 Hz, 1H), 7.85 (d,
J=1.3 Hz, 1H), 7.76 (td, J=7.7, 1.8 Hz, 1H), 7.60 (d, J=7.8 Hz,
1H), 7.40-7.51 (m, 2H), 7.27 (ddd, J=7.5, 5.0, 1.0 Hz, 1H), 3.59
(d, J=11.0 Hz, 1H), 2.68-2.84 (m, 1H), 1.94 (dd, J=11.7, 4.6 Hz,
1H), 1.35-1.76 (m, 6H), 0.99-1.12 (m, 1H); MS ESI [M+H].sup.+
447.1, calcd for [C.sub.19H.sub.19IN40+H].sup.+ 447.07.
Synthesis of
2-cyclopropyl-N-(3-iodo-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-5-yl)-2-p-
henylacetamide
##STR00139##
[0480] The title compound was synthesized according to Method A
utilizing 2-cyclopropyl-2-phenylacetic acid and
3-iodo-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-5-amine and obtained
as a pale solid (120 mg, 70% yield). .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. ppm 7.88 (s, 1H), 7.70 (d, J=5.5 Hz, 1H),
7.25-7.44 (m, 6H), 5.59 (dd, J=9.3, 2.0 Hz, 1H), 3.97 (d, J=11.5
Hz, 1H), 3.64-3.74 (m, 1H), 2.88 (d, J=9.8 Hz, 1H), 2.40-2.54 (m,
1H), 2.07-2.17 (m, 1H), 1.95-2.04 (m, 1H), 1.58-1.79 (m, 3H),
1.48-1.58 (m, 1H), 0.74-0.85 (m, 1H), 0.56-0.69 (m, 1H), 0.44-0.54
(m, 1H), 0.24 (dq, J=9.5, 4.9 Hz, 1H); MS ESI [M+H].sup.+ 502.2,
calcd for [C.sub.23H.sub.24IN.sub.3O.sub.2+H].sup.+ 502.10.
Synthesis of
2-cyclopropyl-N-(3-iodo-1H-indazol-5-yl)-2-phenylacetamide
##STR00140##
[0482] The title compound was synthesized according to the Method
of
2-cyclopentyl-N-(3-iodo-1H-indazol-5-yl)-2-(pyridin-2-yl)acetamide
utilizing
2-cyclopropyl-N-(3-iodo-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-
-5-yl)-2-phenylacetamide and obtained as a white solid (87 mg, 87%
yield). .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. ppm 7.80 (s, 1H),
7.38-7.49 (m, 6H), 7.33-7.37 (m, 1H), 2.91 (d, J=9.3 Hz, 1H),
0.82-0.91 (m, 1H), 1.20-1.27 (m, 1H), 0.63-0.71 (m, 1H), 0.50-0.61
(m, 1H), 0.27-0.34 (m, 1H); MS ESI [M+H].sup.+ 418.1, calcd for
[C.sub.18H.sub.16IN.sub.3O+H].sup.+ 418.04.
Synthesis of
(R)-2-cyclopropyl-N-(3-iodo-1H-indazol-5-yl)-2-(pyridin-2-yl)acetamide
##STR00141##
[0484] The title compound was synthesized according to Method A
utilizing (R)-cyclopropyl(pyridin-2-yl)methanamine and obtained as
a light yellow solid (334 mg, 80% yield). .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. ppm 8.51-8.55 (m, 1H), 8.13-8.16 (m, 1H),
7.95-8.00 (m, 1H), 7.81-7.86 (m, 1H), 7.53-7.61 (m, 2H), 7.30-7.36
(m, 1H), 4.49-4.53 (m, 1H), 1.38-1.48 (m, 1H), 0.68-0.75 (m, 1H),
0.51-0.64 (m, 3H); MS ESI [M+H].sup.+ 419.0, calcd for
[C.sub.17H.sub.15INO.sub.4+H].sup.+ 419.04.
Synthesis of
(S)-2-cyclopropyl-N-(3-iodo-1H-indazol-5-yl)-2-(pyridin-2-yl)acetamide
##STR00142##
[0486] The title compound was synthesized according to Method A
utilizing (S)-cyclopropyl(pyridin-2-yl)methanamine and obtained as
a yellow solid (874 mg, 77% yield). .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. ppm 8.51-8.55 (m, 1H), 8.13-8.16 (m, 1H),
7.95-8.00 (m, 1H), 7.81-7.86 (m, 1H), 7.53-7.61 (m, 2H), 7.30-7.36
(m, 1H), 4.49-4.53 (m, 1H), 1.38-1.48 (m, 1H), 0.68-0.75 (m, 1H),
0.51-0.64 (m, 3H); MS ESI [M+H].sup.+ 419.0, calcd for
[C.sub.17H.sub.15INO.sub.4+H].sup.+ 419.04.
Synthesis of
(R)-2-(3-chloropyridin-2-yl)-2-cyclopropyl-N-(3-iodo-1H-indazol-5-yl)acet-
amide
##STR00143##
[0488] The title compound was synthesized according to Method A
utilizing (R)-(3-chloropyridin-2-yl)(cyclopropyl)methanamine and
obtained as a white solid (322 mg, 78% yield). .sup.1H NMR (400
MHz, CDCl.sub.3) .delta. ppm 13.10 (s, 1H), 8.49-8.50 (m, 1H),
8.00-8.02 (d, J=9.6 Hz, 1H), 7.95 (s, 1H), 7.84-7.86 (dd, J=8.8,
0.8 Hz, 1H), 7.67-7.69 (m, 1H), 7.40-7.42 (d, J=8.8 Hz, 1H),
7.16-7.19 (m, 1H), 5.46-5.50 (t, J=8.0 Hz, 1H), 1.37-1.45 (m, 1H),
0.61-0.66 (m, 1H), 0.47-0.58 (m, 3H); MS ESI [M+H].sup.+ 453.2,
calcd for [C.sub.17H.sub.14CIlNO.sub.4+H].sup.+ 453.00.
Synthesis of
(S)-2-(3-chloropyridin-2-yl)-2-cyclopropyl-N-(3-iodo-1H-indazol-5-yl)acet-
amide
##STR00144##
[0490] The title compound was synthesized according to Method A
utilizing (S)-(3-chloropyridin-2-yl)(cyclopropyl)methanamine and
obtained as a yellow solid (863 mg, 83% yield). .sup.1H NMR (400
MHz, CDCl.sub.3) .delta. ppm 13.10 (s, 1H), 8.49-8.50 (m, 1H),
8.00-8.02 (d, J=9.6 Hz, 1H), 7.95 (s, 1H), 7.84-7.86 (dd, J=8.8,
0.8 Hz, 1H), 7.67-7.69 (m, 1H), 7.40-7.42 (d, J=8.8 Hz, 1H),
7.16-7.19 (m, 1H), 5.46-5.50 (t, J=8.0 Hz, 1H), 1.37-1.45 (m, 1H),
0.61-0.66 (m, 1H), 0.47-0.58 (m, 3H); MS ESI [M+H].sup.+453.2,
calcd for [C.sub.17H.sub.14Cl.sub.1NO.sub.4+H].sup.+ 453.00.
Synthesis of
3-(4-((1-methylpiperidin-4-yl)oxy)phenyl)-1H-indazol-5-amine
##STR00145##
[0492] Tert-butyl (3-iodo-1H-indazol-5-yl)carbamate (398 mg, 1.11
mmol),
1-methyl-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)piperi-
dine (530 mg, 1.67 mmol), and LiCl (141 mg, 3.33 mmol) were
dissolved into dioxane (7.0 mL) and 2 M aq Na.sub.2CO.sub.3 (2.8
mL) in a microwave vial. The mixture was purged with Ar for 15 min
at which time Pd(PPh.sub.3).sub.4 (96 mg, 0.083 mmol) was added.
The vial was sealed and heated in the microwave at 120.degree. C.
for 3 h. The reaction was cooled, the solvent removed and the
residue purified by column chromatography (silica gel, 90:10
CH.sub.2Cl.sub.2/MeOH) which gave 230 mg of BOC protected material
which was dissolved into CH.sub.2Cl.sub.2 (5 mL) and TFA (0.5 mL)
was added. The reaction was stirred for 3 h. The solvent was
removed and product precipitated with Et.sub.2O which gave after
drying 235 mg, 38% of a brown solid as the di-TFA salt. .sup.1H NMR
(400 MHz, CD.sub.3OD) .delta. ppm 8.01 (s, 1H), 7.90-7.86 (m, 2H),
7.73 (d, J=8.8 Hz, 1H), 7.42 (d, J=9.0, 1H), 7.23-7.16 (m, 2H),
4.88 (bs, 1H), 3.66-3.39 (m, 2H), 3.39-3.00 (m, 2H), 2.95-2.89 (m,
3H), 2.46-2.29 (m, 2H), 2.17-1.90 (m, 2H); MS ESI 323.1
[M+H].sup.+, calcd for [C.sub.19H.sub.22N40+H].sup.+ 323.19.
Synthesis of 3-(4-morpholinophenyl)-1H-indazol-5-amine
##STR00146##
[0494] The same procedure was followed as for
3-(4-((1-methylpiperidin-4-yl)oxy)phenyl)-1H-indazol-5-amine
bis(2,2,2-trifluoroacetate) using tert-butyl
(3-iodo-1H-indazol-5-yl)carbamate (359 mg, 1.0 mmol) and
4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)morpholine
(434 mg, 1.5 mmol). Obtained 210 mg of an impure brown solid as the
di-TFA salt which was used for subsequent synthetic steps; MS ESI
295.1 [M+H].sup.+, calcd for [C.sub.17H.sub.18N.sub.4O+H].sup.+
295.16.
Preparation of Exemplary Compounds of the Invention
Example A1
N-(3-(3-(morpholinomethyl)phenyl)-1H-indazol-5-yl)-2-(pyrrolidin-1-yl)-2-(-
thiophen-3-yl)acetamide
##STR00147##
[0496] To a mixture of
N-(3-iodo-1H-indazol-5-yl)-2-(pyrrolidin-1-yl)-2-(thiophen-3-yl)acetamide
(56.6 mg, 0.125 mmol) and
4-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)morpholine
(33.3 mg, 0.11 mmol) in PhCH.sub.3/EtOH (1.5 mL/3 mL) was added 1 M
aq Na.sub.2CO.sub.3 (0.3 mL, 0.3 mmol), followed by
Pd(PPh.sub.3).sub.4 (5.8 mg, 0.005 mmol). The resulting mixture was
purged with Ar and microwaved 30 min at 125.degree. C. After
removal of solvents, it was purified by flash chromatography
(EtOAc/hex 0 to 100%, then MeOH/DCM 5-15%) and then triturated with
Et.sub.2O to give the title compound as beige solid (15 mg, 27%).
.sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.37 (s, 1H), 7.91 (s,
1H), 7.83 (d, J=6.8 Hz, 1H), 7.55-7.47 (m, 4H), 7.45-7.39 (m, 2H),
7.35 (dd, J=4.8 Hz, 1H), 4.15 (s, 1H), 3.72 (t, J=4.6 Hz, 4H), 3.65
(s, 2H), 2.75-2.65 (m, 2H), 2.60-2.50 (m, 6H), 1.90-1.85 (m, 4H);
MS ESI 502.2 [M+H].sup.+, calcd for
[C.sub.28H.sub.31N.sub.5O.sub.2S+H].sup.+ 502.2.
Example A2
N-(3-(4-(4-methylpiperazin-1-yl)phenyl)-1H-indazol-5-yl)-2-(pyrrolidin-1-y-
l)-2-(thiophen-3-yl)acetamide
##STR00148##
[0498] The title compound was synthesized according to general
Method C by using a mixture of
N-(3-iodo-1H-indazol-5-yl)-2-(pyrrolidin-1-yl)-2-(thiophen-3-yl)acetamide
(50 mg, 0.11 mmol),
1-methyl-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperaz-
ine (40 mg, 0.13 mmol), Pd(PPh.sub.3).sub.4 (6.35 mg, 0.005 mmol)
and 1 M aq Na.sub.2CO.sub.3 (0.22 mL) in PhMe/EtOH (2.25 mL, 2:1
mixture) in vial under Ar was heated under microwave irradiation at
125.degree. C. for 2 h. The reaction mixture was diluted with EtOAc
(10 mL) and washed with H.sub.2O (5 mL) followed by brine (5 mL),
dried (Na.sub.2SO.sub.4) and concentrated under vacuum to give
brown oily residue. The crude product was purified by flash
chromatography (100 g SiO.sub.2 column, 0-10% 2 M NH.sub.3-MeOH in
DCM; then by RP HPLC C18 60 g column, 10-80% MeOH in 0.1%
TFA-H.sub.2O) to give the title compound as a TFA salt (pale yellow
solid, 21 mg, 26%). .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.35
(s, 1H), 7.85-7.83 (m, 3H), 7.64 (br.s, 1H), 7.54-7.49 (m, 2H),
7.38 (dd, J=4.4 Hz, 1H), 7.19 (d, J=8.4 Hz, 2H), 5.26 (s, 1H),
3.98-3.86 (br.m, 3H), 3.67-3.60 (m, 2H), 3.17-3.11 (br.m, 4H), 3.00
(s, 3H), 2.26-2.14 (br.m, 3H), 2.02-2.01 (br.s, 1H), 2H merged with
solvent peak, MS ESI 501.1[M+H].sup.+, calcd for
[C.sub.28H.sub.32N6OS+H].sup.+ 501.2.
Example A3
N-(3-(4-(morpholinomethyl)phenyl)-1H-indazol-5-yl)-2-(pyrrolidin-1-yl)-2-(-
thiophen-3-yl)acetamide
##STR00149##
[0500] To a mixture of
N-(3-iodo-1H-indazol-5-yl)-2-(pyrrolidin-1-yl)-2-(thiophen-3-yl)acetamide
(181 mg, 0.4 mmol) and
4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)morpholine
(121 mg, 0.4 mmol) in EtOH (10 mL) was added 1 M aq
Na.sub.2CO.sub.3 (0.8 mL, 0.8 mmol), followed by
Pd(PPh.sub.3).sub.4 (23 mg, 0.02 mmol). The resulting mixture was
purged with Ar and microwaved 1 h at 125.degree. C. After removal
of solvents, it was redissolved in DMF/MeOH/TFA (4 mL/1 mL/0.5 mL),
filtered thru microfilter and purified by PREP-HPLC twice to give
the title compound as a di-TFA salt (off white solid, 52 mg, 18%).
.sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.40 (s, 1H), 8.05 (d,
J=8.0 Hz, 2H), 7.89-7.85 (m, 1H), 7.68 (d, J=8.0 Hz, 2H), 7.63 (dd,
J=4.8 Hz, 2.8 Hz, 1H), 7.60-7.52 (m, 2H), 7.38 (dd, J=4.8 Hz, 0.8
Hz, 1H), 5.32 (s, 1H), 4.44 (s, 2H), 4.10-3.05 (m, 12H), 2.30-1.95
(m, 4H); MS ESI 502.1 [M+H].sup.+, calcd for
[C.sub.28H.sub.31N.sub.5O.sub.2S+H].sup.+ 502.2.
Example A4
N-(3-(4-morpholinophenyl)-1H-indazol-5-yl)-2-(pyrrolidin-1-yl)-2-(thiophen-
-3-yl)acetamide
##STR00150##
[0502] Aq. Na.sub.2CO.sub.3 (2 M, 1.0 mL, 2.0 mmol) was added to a
solution of
N-(3-iodo-1H-indazol-5-yl)-2-(pyrrolidin-1-yl)-2-(thiophen-3-yl)acetamide
(300.2 mg, 0.66 mmol), (4-morpholinophenyl)boronic acid (191.2 mg,
0.93 mmol) and PdCl.sub.2(dppf).DCM (52.0 mg, 0.064 mmol) in 1:1
PhMe:EtOH (14 mL), and the mixture was heated in microwave for 3 h
at 120.degree. C. The product was partitioned between EtOAc (250
mL) and H.sub.2O (25 mL), and the aq. layer was extracted with
EtOAc (4.times.100 mL). The combined organic layers were washed
sequentially with H.sub.2O (25 mL) and brine (25 mL), dried
(Na.sub.2SO.sub.4), filtered and evaporated in vacuo. Purification
by flash chromatography (SiO2, 0-10% MeOH in DCM; followed by
RPC18, 10-80% MeOH in 0.1% TFA-H.sub.2O) gave the title compound as
the TFA salt (yellow powder, 265.1 mg, 56%). .sup.1H NMR (400 MHz,
CDOD) .delta. ppm 8.38 (d, J=1.25 Hz, 1H), 7.87 (dd, J=3.01, 1.25
Hz, 1H), 7.82 (d, J=8.78 Hz, 2H), 7.67 (dd, J=5.02, 3.01 Hz, 1H),
7.53 (d.sub.AB, J=9.00 Hz, 1H), 7.48 (d.sub.ABd, J=9.00, 1.70 Hz,
1H), 7.38 (dd, J=5.02, 1.25 Hz, 1H), 7.16 (d, J=8.78 Hz, 2H), 5.20
(s, 1H), 3.87-3.92 (m, 4H), 3.25-3.30 (m, 4H), 3.13-3.24 (m, 1H),
3.10 (br. s., 1H), 2.20-2.29 (m, 1H), 2.10-2.20 (m, 2H), 2.01 (br.
s., 1H). MS ESI 488.3 [M+H].sup.+, calcd for
[C.sub.27H.sub.29N.sub.5O.sub.2S+H].sup.+ 488.21.
Example A5
N-(3-(4-(2-(dimethylamino)ethoxy)phenyl)-1H-indazol-5-yl)-2-(pyrrolidin-1--
yl)-2-(thiophen-3-yl)acetamide
##STR00151##
[0504] To a mixture of
N-(3-iodo-1H-indazol-5-yl)-2-(pyrrolidin-1-yl)-2-(thiophen-3-yl)acetamide
(226 mg, 0.5 mmol) and
N,N-dimethyl-2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)et-
hanamine (146 mg, 0.5 mmol) in EtOH (10 mL) was added 1 M aq
Na.sub.2CO.sub.3 (1 mL, 1 mmol), followed by Pd(PPh.sub.3).sub.4
(23 mg, 0.02 mmol). The resulting mixture was purged with Ar and
microwaved 1 h at 125.degree. C. Additional Pd(PPh.sub.3).sub.4
(11.6 mg, 0.01 mmol) was added and the reaction mixture was purged
with Ar and microwaved 2 h at 125.degree. C. After removal of
solvents, it was purified by flash chromatography (MeOH/DCM 5-15%,
then pure MeOH) and prep-HPLC to give the title compound as a
di-TFA salt (white solid, 114 mg, 32%). .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. 8.34 (s, 1H), 7.88-7.83 (m, 3H), 7.59 (dd,
J=4.8 Hz, 3.2 Hz, 1H), 7.53 (s, 2H), 7.38 (d, J=5.2 Hz, 1H), 7.13
(d, J=8.8 Hz, 2H), 5.35 (s, 1H), 4.38 (t, J=4.6 Hz, 2H), 3.83 (brs,
1H), 3.60 (t, J=4.6 Hz, 2H), 3.35-3.05 (m, 3H), 2.98 (s, 6H),
2.25-1.90 (m, 4H); MS ESI 490.2 [M+H].sup.+, calcd for
[C.sub.27H.sub.31N.sub.5O.sub.2S+H].sup.+ 490.2.
Example A6
N-(3-(4-(2-morpholinoethyl)phenyl)-1H-indazol-5-yl)-2-(pyrrolidin-1-yl)-2--
(thiophen-3-yl)acetamide
##STR00152##
[0506] To a mixture of
N-(3-iodo-1H-indazol-5-yl)-2-(pyrrolidin-1-yl)-2-(thiophen-3-yl)acetamide
(181 mg, 0.4 mmol) and
4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenethyl)morpholine
(127 mg, 0.4 mmol) in EtOH (10 mL) was added 1 M aq
Na.sub.2CO.sub.3 (0.8 mL, 0.8 mmol), followed by
Pd(PPh.sub.3).sub.4 (23 mg, 0.02 mmol). The resulting mixture was
purged with Ar and microwaved 2 h at 125.degree. C. Additional
Pd(PPh.sub.3).sub.4 (11.6 mg, 0.01 mmol) was added and the reaction
mixture was purged with Ar and microwaved 1 h at 125.degree. C.
After removal of solvents, it was purified by flash chromatography
(MeOH/DCM 5-15%, then pure MeOH) and prep-HPLC to give the title
compound as a di-TFA salt (white solid, 85 mg, 29%). .sup.1H NMR
(400 MHz, CD.sub.3OD) .delta. 8.38 (s, 1H), 7.92-7.85 (m, 3H),
7.64-7.59 (m, 1H), 7.54 (s, 2H), 7.44 (d, J=8.0 Hz, 2H), 7.38 (d,
J=4.4 Hz, 1H), 5.32 (s, 1H), 4.12-4.03 (m, 2H), 3.90-3.77 (m, 3H),
3.63-3.55 (m, 2H), 3.47-3.40 (m, 2H), 3.26-3.06 (m, 7H), 2.30-1.90
(m, 4H); MS ESI 516.2 [M+H].sup.+, calcd for
[C.sub.29H.sub.33N.sub.5O.sub.2S+H].sup.+ 516.2.
Example A7
N-(3-(4-((1-methylpiperidin-4-yl)oxy)phenyl)-1H-indazol-5-yl)-2-(pyrrolidi-
n-1-yl)-2-(thiophen-3-yl)acetamide
##STR00153##
[0508] Using Method C2, three vials each containing
N-(3-iodo-1H-indazol-5-yl)-2-(pyrrolidin-1-yl)-2-(thiophen-3-yl)acetamide
(400 mg, 0.882 mmol) and
1-methyl-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)piperi-
dine (368 mg, 1.05 mmol) with 15% catalyst in PhMe:EtOH (8 mL:4 mL)
were heated for 5 h at 125.degree. C. in the microwave. The
combined reactions were extracted with EtOAc, and purified by flash
chromatography (SiO2, 0-80% MeOH in DCM); followed by purification
with prep HPLC and Biotage RPC18, 10-90% MeOH in 0.1% TFA-H.sub.2O,
the title compound was obtained as the TFA salt (off-white solid,
545 mg, 27.6%). .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. ppm 8.36
(s, 1H), 7.82-7.91 (m, 3H), 7.64 (dd, J=5.0, 3.0 Hz, 1H), 7.49-7.57
(m, 2H), 7.38 (dd, J=5.1, 1.1 Hz, 1H), 7.11-7.22 (m, 2H), 5.29 (s,
1H), 4.62-4.73 (m, 0.33 H), 3.87 (br. s., 1H), 3.60-3.69 (m, 0.67
H), 3.49-3.34 (m, 3.33 H), 3.02-3.27 (m, 3H), 2.94, 2.93 (2-s, 3H),
2.43 (d, J=14.3 Hz, 0.67 H), 1.86-2.34 (m, 8H). MS ESI 516.2
[M+H].sup.+, calcd for [C.sub.29H.sub.33N.sub.5O.sub.2S+H].sup.+
516.24.
Example A8
N-(3-(3-methoxy-4-(piperidin-4-yloxy)phenyl)-1H-indazol-5-yl)-2-(pyrrolidi-
n-1-yl)-2-(thiophen-3-yl)acetamide
##STR00154##
[0510] The title compound was synthesized according to the General
Method C, utilizing
N-(3-iodo-1H-indazol-5-yl)-2-(pyrrolidin-1-yl)-2-(thiophen-3-yl)acetamide
(50 mg, 0.11 mmol), 4-(1-boc-piperidin-4-yloxy)-3-methoxyphenyl
boronic acid (46 mg, 0.13 mmol), PdCl.sub.2dppf (4.5 mg, 0.0055
mmol), satd. aq Na.sub.2CO.sub.3 (0.5 mL), and 1.5 mL of PhMe:EtOH
(1:1). The vial was charged with Ar and heated in the microwave
reactor at 125.degree. C. for 2 h. The mixture was purified by
RPHPLC, treated with using DCM/TFA for 1 h, followed by trituration
with Et.sub.2O to give the title compound as a TFA salt (beige
solid, 54 mg, 65%). .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. ppm
8.45 (s, 1H), 7.86 (br. s, 1H), 7.62-7.68 (m, 1H), 7.44-7.59 (m,
4H), 7.37 (d, J=5.0 Hz, 1H), 7.21 (d, J=8.3 Hz, 1H), 5.24 (s, 1H),
4.71 (br. s, 1H), 3.98 (s, 3H), 3.80-3.92 (m, 1H), 3.44-3.56 (m,
3H), 3.02-3.28 (m, 5H), 2.13 (br. s, 7H), 1.90-2.05 (m, 1H); MS ESI
532.2 [M+H].sup.+, calcd for
[C.sub.29H.sub.33N.sub.5O.sub.3S+H].sup.+ 532.2.
Example A9
N-(3-(4-(4-hydroxypiperidin-1-yl)phenyl)-1H-indazol-5-yl)-2-(pyrrolidin-1--
yl)-2-(thiophen-3-yl)acetamide
##STR00155##
[0511] A.
N-(3-(4-(4-oxopiperidin-1-yl)phenyl)-1H-indazol-5-yl)-2-(pyrroli-
din-1-yl)-2-(thiophen-3-yl)acetamide
[0512] The title compound was synthesized according to general
Method C by using a sealed degassed mixture of
N-(3-iodo-1H-indazol-5-yl)-2-(pyrrolidin-1-yl)-2-(thiophen-3-yl)acetamide
(700 mg, 1.54 mmol),
1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperidin-4-one
(466 mg, 1.54 mmol), Pd(PPh.sub.3).sub.4 (139 mg, 0.12 mmol), 1 M
aq Na2CO3 (3.1 mL) in PhMe/EtOH (14 mL, 2:1 mixture) under Ar was
heated under microwave irradiation at 125.degree. C. for 3 h. The
reaction mixture was diluted with EtOAc (42 mL) and washed it with
of H.sub.2O (2.times.15 mL) followed by brine (20 mL), dried
(Na.sub.2SO.sub.4), and concentrated under vacuum. Purification by
flash chromatography (100 g SiO2, 0-10% MeOH in DCM; then 25 g SiO2
column; 0-40% MeOH in DCM) gave the title compound (light brown
solid, 300 mg, 39%). MS ESI 500.2 [M+H].sup.+, calcd for
[C.sub.28H.sub.30N.sub.4O.sub.3S+H].sup.+ 500.6.
B.
N-(3-(4-(4-hydroxypiperidin-1-yl)phenyl)-1H-indazol-5-yl)-2-(pyrrolidin-
-1-yl)-2-(thiophen-3-yl)acetamide
[0513] To a solution of
N-(3-(4-(4-oxopiperidin-1-yl)phenyl)-1H-indazol-5-yl)-2-(pyrrolidin-1-yl)-
-2-(thiophen-3-yl)acetamide (340 mg, 0.68 mmol) in a mixture of DCM
(3.4 mL) and MeOH (6.8 mL) was added NaBH.sub.4 (52 mg, 1.36 mmol)
in two lots at rt. The reaction mixture was stirred at rt for 5 h,
and then concentrated under reduced pressure. The residue treated
with 25% aq NH.sub.4Cl solution (10 mL) and the product was
extracted with EtOAc (100 mL, 25 mL), washed with H.sub.2O followed
by brine, dried (Na.sub.2SO.sub.4), and concentrated under vacuum.
Purification by RP HPLC provided the title compound as a TFA salt
(yellow solid, 230 g, 46%). .sup.1H NMR (400 MHz, CD.sub.3OD)
.delta. ppm 8.42 (m, 1H), 8.13 (dd, J=6.8 Hz, J=2 Hz, 2H), 7.89
(dd, J=2.8 Hz, J=1.2 Hz, 1H), 7.79 (s, 1H), 7.77 (s, 1H), 7.64-7.62
(m, 1H), 7.59-7.53 (m, 2H), 7.39 (dd, J=4.8 Hz, J=1.2 Hz, 1H), 5.36
(s, 1H), 4.12-4.1 (m, 1H), 3.90-3.85 (m, 3H), 3.66-3.61 (m, 2H),
3.30-3.05 (br.m, 2H), 2.29-2.01 (br.m, 8H), 1H merged with solvent
peak; MS ESI 502.1 [M+H].sup.+, calcd for
[C.sub.28H.sub.31N.sub.5O.sub.2S+H].sup.+ 502.2
Example A10
N-(3-(3-methoxy-4-(4-methylpiperazin-1-yl)phenyl)-1H-indazol-5-yl)-2-(pyrr-
olidin-1-yl)-2-(thiophen-3-yl)acetamide
##STR00156##
[0515] The title compound was synthesized according to the General
Method C, utilizing
N-(3-iodo-1H-indazol-5-yl)-2-(pyrrolidin-1-yl)-2-(thiophen-3-yl)acetamide
(50 mg, 0.11 mmol),
1-(2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-4-met-
hylpiperazine (43 mg, 0.13 mmol), PdCl.sub.2dppf (4.5 mg, 0.0055
mmol), satd. aq Na.sub.2CO.sub.3 (0.5 mL), and 1.5 mL of PhMe:EtOH
(1:1). The vial was charged with Ar and heated in the microwave
reactor at 125.degree. C. for 2 h. Purification by RP HPLC,
followed by flash chromatography (SiO.sub.2, Biotage 25 g, 5-25%
MeOH in CH.sub.2Cl.sub.2) to give the title compound (white solid,
11 mg, 19%) .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. ppm 8.40 (s,
1H), 7.44-7.55 (m, 5H), 7.39-7.44 (m, 1H), 7.33 (d, J=5.3 Hz, 1H),
7.09 (d, J=7.8 Hz, 1H), 4.18 (s, 1H), 3.97 (s, 3H), 3.08-3.24 (m,
4H), 2.73 (br. s, 6H), 2.49-2.59 (m, 2H), 2.42 (s, 3H), 1.86 (br.
s, 4H); MS ESI 531.4 [M+H].sup.+, calcd for
[C.sub.29H.sub.34N.sub.6O.sub.2S+H].sup.+ 531.3.
Example A11
N-(3-(4-(4-methylpiperazin-1-yl)phenyl)-1H-indazol-5-yl)-1,2,3,4-tetrahydr-
onaphthalene-1-carboxamide
##STR00157##
[0517] To a mixture of
N-(3-iodo-1H-indazol-5-yl)-1,2,3,4-tetrahydronaphthalene-1-carboxamide
(167 mg, 0.4 mmol) and
1-methyl-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperaz-
ine (121 mg, 0.4 mmol) in EtOH (12 mL) was added 1 M aq Na2CO3 (0.8
mL, 0.8 mmol), followed by Pd(PPh.sub.3).sub.4 (23 mg, 0.02 mmol).
The resulting mixture was purged with Ar and microwaved 3 h at
125.degree. C. After removal of solvents, it was redissolved in DMF
(5 mL), flitered and purified by prep-HPLC to give the title
compound as white solid (135 mg, 59%) in TFA salt. .sup.1H NMR (400
MHz, CD.sub.3OD) .delta. 8.50 (s, 1H), 7.54 (d, J=8.0 Hz, 2H), 7.48
(s, 2H), 7.10 (d, J=7.2 Hz, 1H), 7.07-6.97 (m, 3H), 6.86 (d, J=8.4
Hz, 2H), 3.88 (t, J=6.6 Hz, 1H), 3.61 (d, J=11.2 Hz, 2H), 3.37 (d,
J=10.0 Hz, 2H), 2.94 (quint, J=12.4 Hz, 4H), 2.80-2.63 (m, 5H; s,
3H at 2.75), 2.12-1.95 (m, 3H), 1.71-1.59 (m, 1H); MS ESI 466.3
[M+H].sup.+, calcd for [C.sub.29H.sub.31N.sub.5O+H].sup.+
466.3.
Example A12
N-(cyclopropyl(phenyl)methyl)-3-(4-morpholinophenyl)-1H-indazole-5-carboxa-
mide
##STR00158##
[0519] The title compound was synthesized according to the General
Method C, utilizing
N-(cyclopropyl(phenyl)methyl)-3-iodo-1H-indazole-5-carboxamide (50
mg, 0.12 mmol), 4-morpholinophenylboronic acid pinacol ester (40
mg, 0.14 mmol), PdCl.sub.2dppf (4.9 mg, 0.006 mmol), satd.
Na.sub.2CO.sub.3 (0.5 mL), and 1.5 mL of PhMe:EtOH (1:1). The vial
was charged with Ar and heated in the microwave reactor at
125.degree. C. for 2 h. Purification by RP HPLC, followed by
trituration with Et.sub.2O gave the title compound as a TFA salt
(beige solid, 11 mg, 16%). .sup.1H NMR (400 MHz, CD.sub.3OD)
.delta. ppm 8.60 (s, 1H), 7.87-7.98 (m, 3H), 7.58 (d, J=8.8 Hz,
1H), 7.47 (d, J=7.0 Hz, 2H), 7.31 (t, J=7.2 Hz, 2H), 7.22 (t, J=6.8
Hz, 1H), 7.15 (d, J=7.8 Hz, 2H), 4.48 (d, J=9.5 Hz, 1H), 3.86 (br.
s, 4H), 3.25 (br. s, 4H), 1.34-1.44 (m, 1H), 0.64 (m, 2H), 0.46 (m,
2H); MS ESI 453.3 [M+H].sup.+, calcd for
[C.sub.28H.sub.28N.sub.4O.sub.2+H].sup.+ 453.2.
Example A13
N-(cyclopropyl(phenyl)methyl)-3-(3-methoxy-4-(piperidin-4-yloxy)phenyl)-1H-
-indazole-5-carboxamide
##STR00159##
[0521] The title compound was synthesized according to the General
Method C, utilizing
N-(cyclopropyl(phenyl)methyl)-3-iodo-1H-indazole-5-carboxamide (50
mg, 0.12 mmol), 4-(1-boc-piperidin-4-yloxy)-3-methoxyphenyl boronic
acid (49 mg, 0.14 mmol), PdCl.sub.2dppf (4.9 mg, 0.006 mmol), satd.
Na.sub.2CO.sub.3 (0.5 mL), and 1.5 mL of PhMe:EtOH (1:1). The vial
was charged with Ar and heated in the microwave reactor at
125.degree. C. for 2 h. The mixture was purified by RPHPLC, treated
with DCM/TFA for 1 h, followed by trituration with Et.sub.2O to
give the title compound as a TFA salt (white solid, 25 mg, 34%).
.sup.1H NMR (400 MHz, CD.sub.3OD) .delta. ppm 8.59 (s, 1H), 7.95
(d, J=8.5 Hz, 1H), 7.54-7.66 (m, 3H), 7.48 (d, J=7.3 Hz, 2H), 7.33
(t, J=7.7 Hz, 2H), 7.17-7.27 (m, 2H), 4.69 (br. s, 1H), 4.48 (d,
J=9.5 Hz, 1H), 3.96 (s, 3H), 3.44-3.55 (m, 2H), 3.18-3.27 (m, 2H),
2.11 (m, 4H), 1.34-1.46 (m, 1H), 0.66 (d, J=8.3 Hz, 2H), 0.41-0.54
(m, 2H); MS ESI 497.4 [M+H].sup.+, calcd for
[C.sub.30H.sub.32N.sub.4O.sub.3+H].sup.+ 497.3.
Example A14
N-(3-(benzo[d][1,3]dioxol-5-yl)-1H-indazol-5-yl)-2-(pyrrolidin-1-yl)-2-(th-
iophen-3-yl)acetamide
##STR00160##
[0523] To a mixture of
N-(3-iodo-1H-indazol-5-yl)-2-(pyrrolidin-1-yl)-2-(thiophen-3-yl)acetamide
(90 mg, 0.2 mmol) and
2-(benzo[d][1,3]dioxol-5-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane
(50 mg, 0.2 mmol) in EtOH (4.5 mL) was added 1 M aq
Na.sub.2CO.sub.3 (0.4 mL, 0.4 mmol), followed by
Pd(PPh.sub.3).sub.4 (11.6 mg, 0.01 mmol). The resulting mixture was
purged with Ar and microwaved 2.5 h at 125.degree. C. After removal
of solvents, it was redisslved in DMF (5 mL), filtered and purified
by prep-HPLC twice to give the title compound as light brown solid
(49.3 mg, 44%) in TFA salt. .sup.1H NMR (400 MHz, CD.sub.3OD)
.delta. 8.35 (t, J=1.2 Hz, 1H), 7.87 (dd, J=2.8 Hz, 1.2 Hz, 1H),
7.63 (dd, J=5.0 Hz, 3.0 Hz, 1H), 7.54-7.47 (m, 2H), 7.39-7.36 (m,
2H), 7.34 (d, J=1.6 Hz, 1H), 6.95 (d, J=8.0 Hz, 1H), 6.01 (s, 2H),
5.28 (s, 1H), 3.87 (brs, 1H), 3.35-3.05 (m, 3H), 2.30-1.90 (m, 4H);
MS ESI 447.2 [M+H].sup.+, calcd for
[C.sub.24H.sub.22N.sub.4O.sub.3+H].sup.+ 447.1
Example A15
N-(3-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-1H-indazol-5-yl)-2-(pyrrolidin--
1-yl)-2-(thiophen-3-yl)acetamide
##STR00161##
[0525] To a mixture of
N-(3-iodo-1H-indazol-5-yl)-2-(pyrrolidin-1-yl)-2-(thiophen-3-yl)acetamide
(90 mg, 0.2 mmol) and
2-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-4,4,5,5-tetramethyl-1,3,2-dioxabo-
rolane (54 mg, 0.2 mmol) in EtOH (4.5 mL) was added 1 M aq Na2CO3
(0.4 mL, 0.4 mmol), followed by Pd(PPh.sub.3).sub.4 (11.6 mg, 0.01
mmol). The resulting mixture was purged with Ar and microwaved 2.5
h at 125.degree. C. After removal of solvents, it was redisslved in
DMF (5 mL), filtered and purified by prep-HPLC to give the title
compound as a TFA salt (light brown solid, 58.8 mg, 51%). .sup.1H
NMR (400 MHz, CD.sub.3OD) .delta. 8.35 (t, J=0.8 Hz, 1H), 7.86 (dd,
J=2.8 Hz, 1.2 Hz, 1H), 7.62 (dd, J=5.0 Hz, 3.0 Hz, 1H), 7.50 (s,
2H), 7.39-7.34 (m, 3H), 6.94 (d, J=8.8 Hz, 1H), 5.27 (s, 1H), 4.28
(s, 4H), 3.86 (brs, 1H), 3.35-3.05 (m, 3H), 2.30-1.90 (m, 4H); MS
ESI 461.2 [M+H].sup.+, calcd for
[C.sub.25H.sub.24N.sub.4O.sub.3S+H].sup.+ 461.2
Example A16
N-(3-(1-methylindolin-5-yl)-1H-indazol-5-yl)-2-(pyrrolidin-1-yl)-2-(thioph-
en-3-yl)acetamide
##STR00162##
[0527] To a mixture of
N-(3-iodo-1H-indazol-5-yl)-2-(pyrrolidin-1-yl)-2-(thiophen-3-yl)acetamide
(90 mg, 0.2 mmol) and
1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indoline
(52 mg, 0.2 mmol) in EtOH (4.5 mL) was added 1 M aq Na2CO3 (0.4 mL,
0.4 mmol), followed by Pd(PPh.sub.3).sub.4 (11.6 mg, 0.01 mmol).
The resulting mixture was purged with Ar and microwaved 2.5 h at
125.degree. C. After removal of solvents, it was redissolved in DMF
(5 mL), filtered and purified by prep-HPLC to give the title
compound as a TFA salt (brown solid, 27.2 mg, 24%). .sup.1H NMR
(400 MHz, CD.sub.3OD) .delta. 8.36 (t, J=1.2 Hz, 1H), 7.88 (dd,
J=2.8 Hz, 1.2 Hz, 1H), 7.83-7.79 (m, 2H), 7.64 (dd, J=5.2 Hz, 2.8
Hz, 1H), 7.55 (pesudo s, 2H), 7.38 (dd, J=4.8 Hz, 1.2 Hz, 1H), 7.18
(d, J=8.4 Hz, 1H), 5.28 (s, 1H), 3.88 (brs, 1H), 3.70 (t, J=7.6 Hz,
2H), 3.27-3.04 (m, 8H; s, 3H at 2.86), 2.30-1.90 (m, 4H); MS ESI
458.1 [M+H].sup.+, calcd for [C.sub.26H.sub.27N.sub.5OS+H].sup.+
458.2.
Example A17
N-(3-(4-methyl-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-1H-indazol-5-yl)-2-
-(pyrrolidin-1-yl)-2-(thiophen-3-yl)acetamide
##STR00163##
[0529] To a mixture of
N-(3-iodo-1H-indazol-5-yl)-2-(pyrrolidin-1-yl)-2-(thiophen-3-yl)acetamide
(90 mg, 0.2 mmol) and
4-methyl-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydro-2H-b-
enzo[b][1,4]oxazine (55 mg, 0.2 mmol) in EtOH (4.5 mL) was added 1
M aq Na.sub.2CO.sub.3 (0.4 mL, 0.4 mmol), followed by
Pd(PPh.sub.3).sub.4 (11.6 mg, 0.01 mmol). The resulting mixture was
purged with Ar and microwaved 2.5 h at 125.degree. C. After removal
of solvents, it was redisslved in DMF (5 mL), filtered and purified
by prep-HPLC to give the title compound as a TFA salt (dark yellow
solid, 37.4 mg, 32%) in TFA salt. .sup.1H NMR (400 MHz, CD.sub.3OD)
.delta. 8.36 (s, 1H), 7.86 (d, J=2.0 Hz, 1H), 7.64 (dd, J=4.8 Hz,
2.8 Hz, 1H), 7.50 (s, 2H), 7.39-7.33 (m, 2H), 7.25 (d, J=1.6 Hz,
1H), 6.83 (d, J=8.4 Hz, 1H), 5.24 (s, 1H), 4.31 (t, J=4.2 Hz, 1H),
3.87 (brs, 1H), 3.35-3.05 (m, 5H), 2.95 (s, 3H), 2.27-1.92 (m, 4H);
MS ESI 474.2 [M+H].sup.+, calcd for
[C.sub.26H.sub.27N.sub.5O.sub.2S+H].sup.+ 474.2.
Example A18
N-(3-(4-((1-methylpiperidin-4-yl)oxy)phenyl)-1H-indazol-5-yl)-1,2,3,4-tetr-
ahydronaphthalene-1-carboxamide
##STR00164##
[0531] To a mixture of
N-(3-iodo-1H-indazol-5-yl)-1,2,3,4-tetrahydronaphthalene-1-carboxamide
(167 mg, 0.4 mmol) and
1-methyl-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)piperi-
dine (130 mg, 0.44 mmol) in EtOH (10 mL) was added 1 M aq
Na.sub.2CO.sub.3 (0.8 mL, 0.8 mmol), followed by
Pd(PPh.sub.3).sub.4 (23 mg, 0.02 mmol). The resulting mixture was
purged with Ar and microwaved 2 h at 130.degree. C. After removal
of solvents, it was redisslved in DMF/TFA (5 mL/0.5 mL), filtered
and purified by prep-HPLC to give the title compound as a TFA salt
(white solid, 130 mg, 55%). .sup.1H NMR (400 MHz, CD.sub.3OD)
.delta. 8.49 (s, 1H), 7.85-7.77 (m, 2H), 7.54-7.46 (m, 2H),
7.16-6.97 (m, 6H), 4.65-4.61 (m, 0.7H), 4.50-4.42 (m, 0.3H), 3.91
(t, J=7.0 Hz, 1H), 3.50-3.44 (m, 0.7H), 3.30-3.17 (m, 2.8H;
partially overlapped with CD.sub.3OD solvent residue), 3.07-2.98
(m, 0.7H), 2.86-2.70 (m, 5.3H), 2.27-1.65 (m, 8H); MS ESI 481.3
[M+H].sup.+, calcd for [C.sub.30H.sub.32N.sub.4O.sub.2+H].sup.+
481.3.
Example A19
N-(cyclopropyl(phenyl)methyl)-3-(3-methoxy-4-((1-methylpiperidin-4-yl)oxy)-
phenyl)-1H-indazole-5-carboxamide
##STR00165##
[0533] The title compound was synthesized according to the General
Method C, utilizing
N-(cyclopropyl(phenyl)methyl)-3-iodo-1H-indazole-5-carboxamide (70
mg, 0.17 mmol),
4-(2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)-1-me-
thylpiperidine (70 mg, 0.20 mmol), PdCl.sub.2dppf (6.9 mg, 0.0085
mmol), satd. Na.sub.2CO.sub.3 (0.5 mL), and 1.5 mL of PhMe:EtOH
(1:1). The vial was charged with Ar and heated in the microwave
reactor at 125.degree. C. for 2 h. Purification by RPHPLC, followed
by trituration with Et.sub.2O gave the title compound as a TFA salt
(white solid, 26 mg, 25%). .sup.1H NMR (400 MHz, CD.sub.3OD)
.delta. ppm 8.59 (s, 1H), 7.95 (d, J=8.3 Hz, 1H), 7.52-7.67 (m,
3H), 7.48 (d, J=7.0 Hz, 2H), 7.33 (t, J=7.0 Hz, 2H), 7.13-7.28 (m,
2H), 4.71 (br. s., 1H), 4.51-4.59 (m, 0.3 H), 4.48 (br. t., J=8.2
Hz, 1H), 3.90-4.02 (m, 3H), 3.56-3.67 (m, 0.7H), 3.37-3.52 (m,
1.3H), 3.07-3.19 (m, 0.7H), 2.84-2.97 (m, 3H), 1.87-2.43 (m, 5H),
1.35-1.45 (m, 1H), 0.65 (d, J=7.8 Hz, 2H), 0.37-0.54 (m, 2H); MS
ESI 511.6 [M+H].sup.+, calcd for
[C.sub.31H.sub.34N.sub.4O.sub.3+H].sup.+ 511.3.
Example A20
N-(3-(3,4-dihydro-2H-benzo[b][1,4]dioxepin-7-yl)-1H-indazol-5-yl)-2-(pyrro-
lidin-1-yl)-2-(thiophen-3-yl)acetamide
##STR00166##
[0535] To a mixture of
N-(3-iodo-1H-indazol-5-yl)-2-(pyrrolidin-1-yl)-2-(thiophen-3-yl)acetamide
(90 mg, 0.2 mmol) and
(3,4-dihydro-2H-benzo[b][1,4]dioxepin-7-yl)boronic acid (39 mg, 0.2
mmol) in EtOH (4.5 mL) was added 1 M aq Na.sub.2CO.sub.3 (0.4 mL,
0.4 mmol), followed by Pd(PPh.sub.3).sub.4 (11.6 mg, 0.01 mmol).
The resulting mixture was purged with Ar and microwaved 2.5 h at
125.degree. C. After removal of solvents, it was redisslved in DMF
(5 mL), filtered, purified by prep-HPLC twice and triturated with
Et.sub.2O to give the title compound as a TFA salt (light brown
solid, 33.5 mg, 28%). .sup.1H NMR (400 MHz, CD.sub.3OD) .delta.
8.36 (s, 1H), 7.87 (dd, J=2.8 Hz, J=1.2 Hz, 1H), 7.64 (dd, J=5.0
Hz, 3.0 Hz, 1H), 7.52 (d, J=1.2 Hz, 2H), 7.49 (d, J=2.0 Hz, 1H),
7.46 (dd, J=8.2 Hz, 2.2 Hz, 1H), 7.38 (dd, J=4.8 Hz, 1.2 Hz, 1H),
7.08 (d, J=8.4 Hz, 1H), 5.26 (s, 1H), 4.27-4.18 (m, 4H), 3.87 (brs,
1H), 3.35-3.05 (m, 3H), 2.25-1.93 (m, 6H); MS ESI 475.3
[M+H].sup.+, calcd for [C.sub.26H.sub.26N.sub.4O.sub.3S+H].sup.+
475.2.
Example A21
N-(3-(3-methoxy-4-((1-methylpiperidin-4-yl)oxy)phenyl)-1H-indazol-5-yl)-2--
(pyrrolidin-1-yl)-2-(thiophen-3-yl)acetamide
##STR00167##
[0537] The title compound was synthesized according to the General
Method C, utilizing
N-(3-iodo-1H-indazol-5-yl)-2-(pyrrolidin-1-yl)-2-(thiophen-3-yl)acetamide
(76 mg, 0.17 mmol),
4-(2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)-1-me-
thylpiperidine (70 mg, 0.20 mmol), PdCl.sub.2dppf (6.9 mg, 0.0085
mmol), satd. aq Na.sub.2CO.sub.3 (0.5 mL), and 1.5 mL of PhMe:EtOH
(1:1). The vial was charged with Ar and heated in the microwave
reactor at 125.degree. C. for 2 h. Purification by RPHPLC, followed
by trituration with Et.sub.2O gave the title compound as a bis-TFA
salt (light brown solid, 41 mg, 31%). .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. ppm 8.45 (s, 1H), 7.87 (s, 1H), 7.63 (br. s.,
1H), 7.42-7.59 (m, 4H), 7.37 (d, J=4.8 Hz, 1H), 7.20 (d, J=8.0 Hz,
1H), 5.29 (s, 1H), 4.65-4.76 (m, 1H), 4.50-4.61 (m, 0.3 H), 3.98
(s, 3H), 3.55-3.69 (m, 0.7H), 3.37-3.54 (m, 4H), 3.06-3.27 (m, 3H),
2.93 (s, 3H), 1.89-2.50 (m, 8H); MS ESI 546.1 [M+H].sup.+, calcd
for [C.sub.30H.sub.35N.sub.5O.sub.3S+H].sup.+ 546.3.
Example A22
N-(3-(4-morpholinophenyl)-1H-indazol-5-yl)-1,2,3,4-tetrahydronaphthalene-1-
-carboxamide
##STR00168##
[0539] To a mixture of
N-(3-iodo-1H-indazol-5-yl)-1,2,3,4-tetrahydronaphthalene-1-carboxamide
(167 mg, 0.4 mmol) and (4-morpholinophenyl)boronic acid (91 mg,
0.44 mmol) in EtOH (12 mL) was added 1 M aq Na.sub.2CO.sub.3 (0.8
mL, 0.8 mmol), followed by Pd(PPh.sub.3).sub.4 (23 mg, 0.02 mmol).
The resulting mixture was purged with Ar and microwaved 2 h at
125.degree. C. After removal of solvents, it was purified by flash
chromatography (MeOH/DCM 0-10%) and prep-HPLC to give the title
compound as a TFA salt (light yellow solid, 59.8 mg, 26%). .sup.1H
NMR (400 MHz, CD.sub.3OD) .delta. 8.49 (s, 1H), 8.43 (d, J=8.8 Hz,
2H), 7.49 (s, 2H), 7.16-7.02 (m, 6H), 3.90 (t, J=7.0 Hz, 1H), 3.81
(t, J=4.6 Hz, 4H), 3.19 (brs, 4H), 2.89-2.70 (m, 2H), 2.18-2.02 (m,
3H), 1.77-1.67 (m, 1H); MS ESI 453.3 [M+H].sup.+, calcd for
[C.sub.28H.sub.28N.sub.4O.sub.2+H].sup.+ 453.2.
Example A23
N-(3-(4-(morpholinomethyl)phenyl)-1H-indazol-5-yl)-1,2,3,4-tetrahydronapht-
halene-1-carboxamide
##STR00169##
[0541] To a mixture of
N-(3-iodo-1H-indazol-5-yl)-1,2,3,4-tetrahydronaphthalene-1-carboxamide
(167 mg, 0.4 mmol) and
4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)morpholine
(121 mg, 0.4 mmol) in EtOH (12 mL) was added 1 M aq
Na.sub.2CO.sub.3 (0.8 mL, 0.8 mmol), followed by
Pd(PPh.sub.3).sub.4 (23 mg, 0.02 mmol). The resulting mixture was
purged with Ar and microwaved 2 h at 125.degree. C. After removal
of solvents, it was redissolved in DMF/TFA (6 mL/0.5 mL) and
purified by prep-HPLC to give the title compound as a TFA salt
(white solid, 135 mg, 58%). .sup.1H NMR (400 MHz, CD.sub.3OD)
.delta. 8.50 (s, 1H), 7.98 (d, J=8.0 Hz, 2H), 7.56-7.47 (m, 4H),
7.15 (d, J=7.2 Hz, 1H), 7.12-7.03 (m, 3H), 4.26 (s, 2H), 3.98-3.88
(m, 3H), 3.67 (t, J=12.0 Hz, 2H), 3.28 (d, J=11.6 Hz, 2H), 3.08 (t,
J=10.8 Hz, 2H), 2.86-2.69 (m, 2H), 2.20-2.02 (m, 3H), 1.77-1.67 (m,
1H); MS ESI 467.3 [M+H].sup.+, calcd for
[C.sub.29H.sub.30N.sub.4O.sub.2+H].sup.+ 467.2.
Example A24
N-(cyclopropyl(phenyl)methyl)-3-(4-((1-methylpiperidin-4-yl)oxy)phenyl)-1H-
-indazole-5-carboxamide
##STR00170##
[0543] The title compound was synthesized according to the General
Method C, utilizing
N-(cyclopropyl(phenyl)methyl)-3-iodo-1H-indazole-5-carboxamide (200
mg, 0.48 mmol), (4-((1-methylpiperidin-4-yl)oxy)phenyl)boronic acid
pinacol ester (152 mg, 0.48 mmol), PdCl.sub.2dppf (20 mg, 0.024
mmol), satd. Na.sub.2CO.sub.3 (1.25 mL), and 3.75 mL of PhMe:EtOH
(1:1). The vial was charged with Ar and heated in the microwave
reactor at 125.degree. C. for 2 h. Purification by RP HPLC,
followed by flash chromatography (SiO.sub.2, Biotage 25 g, 0-30%
MeOH in CH.sub.2Cl.sub.2) gave the title compound (white solid, 80
mg, 35%). .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. ppm 8.60 (s,
1H), 7.95 (d, J=9.0 Hz, 1H), 7.90 (d, J=8.8 Hz, 2H), 7.59 (d, J=8.8
Hz, 1H), 7.47 (d, J=7.5 Hz, 2H), 7.31 (t, J=7.5 Hz, 2H), 7.22 (t,
J=7.5 Hz, 1H), 7.08 (d, J=8.8 Hz, 2H), 4.55 (br. s, 1H), 4.47 (d,
J=9.3 Hz, 1H), 2.91-3.03 (m, 2H), 2.63-2.76 (m, 2H), 2.50 (s, 3H),
2.02-2.14 (m, 2H), 1.85-1.98 (m, 2H), 1.34-1.44 (m, 1H), 0.64 (d,
J=8.3 Hz, 2H), 0.45 (dd, J=9.5, 4.52 Hz, 2H); MS ESI 481.4
[M+H].sup.+, calcd for [C.sub.30H.sub.32N.sub.4O.sub.2+H].sup.+
481.3
Example A25
N-(3-(4-((1-methylpiperidin-4-yl)amino)
phenyl)-1H-indazol-5-yl)-2-(pyrrolidin-1-yl)-2-thiophen-3-yl)acetamide
##STR00171##
[0544] A.
1-methyl-N-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pheny-
l)piperidin-4-amine
[0545] NaBH(OAc).sub.3 (290 mg, 1.36 mmol) was added to a solution
of N-methyl-4-piperidone (155 mg, 1.36 mmol) in 1,2-dichloroethane
(10 mL) at rt. Then
4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (200 mg,
0.912 mmol) and 2-3 drop of acetic acid under N.sub.2 were added to
the mixture at rt and stirring was continued for 18 h. Satd
aqNaHCO.sub.3 (10 mL) was added in one lot at the same temperature
and the mixture was stirred for 15 min. DCM (10 mL) was then added
and the layers were separated. The aq. layer was extracted using
DCM (10 mL), and the combined organic layer was washed with brine
and dried (Na.sub.2SO.sub.4). Then solvent was removed under
vacuum. The resultant oily residue purified by Biotage (25 g
SiO.sub.2 column, 0-50% MeOH in DCM) to give the title compound
(cream solid, 84 mg, 29%). .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 7.63 (d, J=8.8 Hz, 2H), 6.58 (d, J=8.8 Hz, 2H), 3.77 (d,
J=7.6 Hz, 1H), 3.35 (br.s, 1H), 2.82-2.79 (br.d, 1H), 2.30 (s, 3H),
2.14 (t, J=1.2 Hz, 2H), 2.07-2.03 (m, 2H), 1.66 (br.s, 1H),
1.54-1.45 (m, 2H), 1.32 (s, 12H); MS ESI 317.1[M+H].sup.+, calcd
for [C.sub.18H.sub.29BN.sub.2O.sub.2+H].sup.+ 317.2.
B. N-(3-(4-((1-methylpiperidin-4-yl)amino)
phenyl)-1H-indazol-5-yl)-2-(pyrrolidin-1-yl)-2-thiophen-3-yl)acetamide
[0546] The title compound was synthesized according to general
Method C by using a sealed degassed mixture of
N-(3-iodo-1H-indazol-5-yl)-2-(pyrrolidin-1-yl)-2-(thiophen-3-yl)acetamide
(50 mg, 0.11 mmol),
1-methyl-N-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperid-
in-4-amine (42 mg, 0.13 mmol), Pd (PPh.sub.3).sub.4 (7 mg, 0.005
mmol), 1 M aq Na.sub.2CO.sub.3 (0.22 mL) in PhMe/EtOH (2.25 mL,
1:0.5 mixture) under Ar was heated under microwave irradiation at
125.degree. C. for 2 h. The reaction mixture was diluted with EtOAc
(10 mL) and washed with H.sub.2O and brine (5 mL each), dried
(Na.sub.2SO.sub.4), and concentrated under vacuum to give brown
oily residue. The crude product was purified by Biotage (100 g
SiO2, 0-10% 2 M NH.sub.3-MeOH in DCM; then RP column C18 60 g,
10-80% MeOH in 0.1% TFA-H.sub.2O) to give the title compound as a
TFA salt (pale yellow solid, 9 mg, 11%). .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. 8.34 (s, 1H), 7.87 (t, J=1.6 Hz, 1H), 7.72 (d,
J=8.4 Hz, 2H), 7.66 (dd, J=3.2 Hz, J=5.2 Hz 1H), 7.53-7.50 (m, 2H),
7.38 (dd, J=4.8 Hz, J=1.2 Hz, 2H), 6.89-6.85 (m, 2H), 5.23 (s, 1H),
4.44 (t, J=4.8 Hz, 1H), 3.88-3.60 (br.m, 4H), 3.26-3.09 (br.m, 4H),
2.92 (s, 3H), 2.38-2.34 (br.m, 2H), 2.24-2.15 (br.m, 4H), 2.01-1.97
(br.m, 1H), 1.79-1.70 (br.m, 1H); MS ESI 515.1 [M+H].sup.+, calcd
for [C.sub.29H.sub.34N6OS+H].sup.+ 515.2.
Example A26
(R)-3-(4-((1-methylpiperidin-4-yl)oxy)phenyl)-N-(1,2,3,4-tetrahydronaphtha-
len-1-yl)-1H-indazole-5-carboxamide
##STR00172##
[0548] To a solution of (R)-1,2,3,4-tetrahydronaphthalen-1-amine
(735 mg, 5 mmol), 1H-indazole-5-carboxylic acid (810 g, 5 mmol) in
DMF (30 mL) was added .sup.iPr.sub.2NEt (2.61 mL, 15 mmol),
followed by TBTU (1.605 g, 5 mmol). The resulting mixture was
stirred for 2 h at 0.degree. C. Attempted iodination failed so was
quenched with Na.sub.2S.sub.2O.sub.3/H.sub.2O to give
(R)--N-(1,2,3,4-tetrahydronaphthalen-1-yl)-1H-indazole-5-carboxamide
(orange solid, 1.64 g, may contain H.sub.2O). .sup.1H NMR (400 MHz,
DMSO-d6) .delta. 0.79 (s, 1H), 8.76 (d, J=8.4 Hz, 1H), 8.39 (s,
1H), 8.18 (s, 1H), 7.92 (dd, J=8.6 Hz, 1.4 Hz, 1H), 7.56 (d, J=8.8
Hz, 1H), 7.23-7.10 (m, 4H), 5.30-5.20 (m, 1H), 2.85-2.70 (m, 2H),
2.05-1.90 (m, 2H), 1.90-1.70 (m, 2H); MS ESI 292.1 [M+H].sup.+,
calcd for [C.sub.18H.sub.17N30+H].sup.+ 292.1.
[0549] A solution of
(R)--N-(1,2,3,4-tetrahydronaphthalen-1-yl)-1H-indazole-5-carboxamide
(29.1 mg, 0.1 mmol), NBS (19.6 mg, 0.11 mmol) in EtOH (5 mL) was
refluxed for 1 h. Additional
(R)--N-(1,2,3,4-tetrahydronaphthalen-1-yl)-1H-indazole-5-carboxamide
(582 mg, 2 mmol), NBS (392 mg, 2.2 mmol) and EtOH (30 mL) were
added and it was refluxed for 4 h. After removal of solvents, it
was purified by flash chromatography (MeOH/DCM 0-10%) to give crude
(R)-3-bromo-N-(1,2,3,4-tetrahydronaphthalen-1-yl)-1H-indazole-5-carboxami-
de (dark beige solid, 0.77 g). .sup.1H NMR (400 MHz, CDCl.sub.3) 6
MS ESI 370.0 [M+H].sup.+, calcd for
[C.sub.18H.sub.16BrN.sub.3O+H].sup.+ 370.0.
[0550] To a mixture of
(R)-3-bromo-N-(1,2,3,4-tetrahydronaphthalen-1-yl)-1H-indazole-5-carboxami-
de (163 mg, 0.44 mmol) and
1-methyl-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)piperi-
dine (127 mg, 0.4 mmol) in EtOH (12 mL) was added 1 M aq
Na.sub.2CO.sub.3 (0.8 mL, 0.8 mmol), followed by
Pd(PPh.sub.3).sub.4 (23 mg, 0.02 mmol). The resulting mixture was
purged with Ar and microwaved 2 h at 130.degree. C. After removal
of solvents, it was redissolved in DMF/TFA (6 mL/0.5 mL) and
purified by prep-HPLC to give the title compound as a TFA salt
(white solid, 85 mg, 36%). .sup.1H NMR (400 MHz, CD.sub.3OD)
.delta. 8.59 (s, 1H), 7.97-7.88 (m, 3H), 7.58 (d, J=8.0 Hz, 1H),
7.27-7.23 (m, 1H), 7.14-7.05 (m, 5H), 5.35 (t, J=6.6 Hz, 1H),
4.80-4.76 (m, 0.7H), 4.65-4.56 (m, 0.3H), 3.64-3.57 (m, 0.7H),
3.43-3.28 (m, 2.6H; partially overlapped with CD.sub.3OD solvent
residue), 3.21-3.13 (m, 0.7H), 2.91 (s, 3H), 2.90-2.72 (m, 2H),
2.42-1.76 (m, 8H); MS ESI 481.4 [M+H].sup.+, calcd for
[C.sub.30H.sub.32N.sub.4O.sub.2+H].sup.+ 481.3.
Example A27
(R)-2-methoxy-N-(3-(4-((1-methylpiperidin-4-yl)oxy)phenyl)-1H-indazol-5-yl-
)-2-phenylacetamide
##STR00173##
[0551] The title compound was synthesized according to the General
Method C utilizing
((R)--N-(3-iodo-1H-indazol-5-yl)-2-methoxy-2-phenylacetamide (0.060
g, 0.15 mmol),
1-methyl-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)piperi-
dine (71 mg, 0.22 mmol), PdCl.sub.2dppfCH.sub.2Cl.sub.2 (7 mg, 0.09
mmol), satd aq Na.sub.2CO.sub.3 (0.5 mL) in PhMe (1.5 mL) and EtOH
(1.5 mL) under microwave heating (130.degree. C., 90 min). The
title compound was isolated as a white powder (42.5 mg, 60%).
.sup.1H NMR (400 MHz, CD.sub.3OD) .delta. ppm 8.36 (d, J=1.00 Hz,
1H), 7.83 (d, J=8.78 Hz, 2H), 7.47-7.59 (m, 4H), 7.31-7.45 (m, 3H),
7.07 (d, J=8.78 Hz, 2H), 4.83 (s, 1H), 4.52 (br. s., 1H), 3.46 (s,
3H), 2.85 (br. s., 2H), 2.55 (br. s., 2H), 2.42 (s, 3H), 1.98-2.12
(m, 2H), 1.93-1.82 (br.s, 2H); MS ESI [M+H].sup.+ 471.3, calcd for
[C.sub.28H.sub.30N.sub.4O.sub.3+H].sup.+ 471.2.
Example A28
N-(3-(4-(piperidin-4-yloxy)phenyl)-1H-indazol-5-yl)-2-(pyrrolidin-1-yl)-2--
(thiophen-3-yl)acetamide
##STR00174##
[0552] A. tert-butyl
4-(4-(5-(2-(pyrrolidin-1-yl)-2-(thiophen-3-yl)acetamido)-1H-indazol-3-yl)-
phenoxy)piperidine-1-carboxylate
[0553] Using Method C2,
N-(3-iodo-1H-indazol-5-yl)-2-(pyrrolidin-1-yl)-2-(thiophen-3-yl)acetamide
(132.8 mg, 0.294 mmol) and tert-butyl
4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)piperidine-1-ca-
rboxylate (142.3 mg, 0.352 mmol) gave the title compound after 3 h
at 120.degree. C. in the microwave (102.7 mg, 58%) after work-up
using a PoraPak Rxn CX followed by purification by flash
chromatography (SiO2, 50-100 EtOAc in DCM). .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. ppm 8.42 (s, 1H), 7.89 (d, J=8.8 Hz, 2H), 7.47
(dd, J=8.8, 2.0 Hz, 1H), 7.44 (d, J=8.8 Hz, 1H), 7.34 (s, 1H),
7.29-7.33 (m, 1H), 7.15 (dd, J=5.0, 1.3 Hz, 1H), 7.04 (d, J=8.8 Hz,
2H), 4.54 (dt, J=7.1, 3.6 Hz, 1H), 4.16 (s, 1H), 3.70-3.79 (m, 2H),
3.33-3.41 (m, 2H), 2.67 (d, J=6.8 Hz, 2H), 2.56 (d, J=6.0 Hz, 2H),
1.96 (br. s., 2H), 1.74-1.89 (m, 6H), 1.49 (s, 9H). MS ESI 602.4
[M+H].sup.+, calcd for [C.sub.33H.sub.39N.sub.5O.sub.4S+H].sup.+
602.38.
B.
N-(3-(4-(piperidin-4-yloxy)phenyl)-1H-indazol-5-yl)-2-(pyrrolidin-1-yl)-
-2-(thiophen-3-yl)acetamide
[0554] Tert-butyl
4-(4-(5-(2-(pyrrolidin-1-yl)-2-(thiophen-3-yl)acetamido)-1H-indazol-3-yl)-
phenoxy)piperidine-1-carboxylate (102 mg, 0.169 mmol) was dissolved
in DCM (4 mL) and TFA (1 mL) was added. The resulting mixture was
stirred at rt for 3 h. The crude reaction mixture was partitioned
between EtOAc (150 mL) and satd aq NaHCO.sub.3 (25 mL). The organic
layer was washed with H.sub.2O (25 mL) and brine (25 mL), dried
(Na.sub.2SO.sub.4), filtered and concentrated to dryness.
Purification by flash chromatography (SiO2, 0-20% 2 M NH.sub.3-MeOH
in DCM) gave the title compound (beige solid, 26.8 mg, 31%).
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. ppm 9.25 (s, 1H), 8.41
(d, J=1.0 Hz, 1H), 7.86 (d, J=8.8 Hz, 2H), 7.44 (dd, J=9.0, 1.8 Hz,
1H), 7.40 (d, J=8.6 Hz, 1H), 7.32-7.35 (m, 1H), 7.29-7.32 (m, 1H),
7.15 (dd, J=4.9, 1.1 Hz, 1H), 7.01 (d, J=8.8 Hz, 2H), 4.45 (tt,
J=7.7, 3.8 Hz, 1H), 4.16 (s, 1H), 3.15-3.23 (m, 2H), 2.82 (ddd,
J=12.4, 8.8, 3.4 Hz, 2H), 2.63-2.71 (m, 2H), 2.51-2.58 (m, 2H),
2.06 (ddt, J=12.7, 6.4, 3.2, 3.2 Hz, 3H), 1.84 (br. s., 4H), 1.75
(dtd, J=12.8, 8.5, 8.5, 3.9 Hz, 2H). MS ESI 502.2 [M+H].sup.+,
calcd for [C.sub.28H.sub.31N.sub.5O.sub.2S+H].sup.+ 502.23.
Example A29.
2-(pyrrolidin-1-yl)-N-(3-(4-((tetrahydro-2H-pyran-4-yl)oxy)phenyl)-1H-ind-
azol-5-yl)-2-(thiophen-3-yl)acetamide
##STR00175##
[0556] The title compound was synthesized according to general
Method C by using a sealed degassed mixture of
N-(3-iodo-1H-indazol-5-yl)-2-(pyrrolidin-1-yl)-2-(thiophen-3-yl)acetamide
(800 mg, 1.76 mmol),
4,4,5,5-tetramethyl-2-(4-((tetrahydro-2H-pyran-4-yl)oxy)phenyl)-1,3,2-dio-
xaborolane (538 mg, 1.76 mmol), Pd(PPh.sub.3).sub.4 (204 mg, 0.176
mmol), 1 M aq Na.sub.2CO.sub.3 (3.54 mL) in PhMe/EtOH (20 mL, 1:0.5
mixture) under Ar was heated under microwave irradiation at
125.degree. C. for 4 h. The reaction mixture was diluted with EtOAc
(120 mL) and washed with H.sub.2O (20 mL) followed by brine (20
mL), dried (Na.sub.2SO.sub.4) and concentrated under vacuum to give
brown oily residue. The crude product was purified by Biotage (100
g SiO2, 0-20% MeOH in DCM; then RP HPLC C18 60 g column, 10-80%
MeOH in 0.1% TFA-H.sub.2O) to give the title compound as a TFA salt
(light brown solid, 355 mg, 32.5%). .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. 8.38 (s, 1H), 7.87-7.80 (m, 3H), 7.64-7.62 (m,
1H), 7.54-7.48 (m, 2H), 7.38 (d, J=5.2 Hz, 1H), 7.09 (d, J=8.4 Hz,
2H), 5.26 (s, 1H), 4.65-4.59 (m, 1H), 3.99-3.86 (br.m, 3H),
3.63-3.57 (br.m, 2H), 3.21-3.08 (br.m, 2H), 2.16-2.03 (br.m, 7H)
1.78-1.72 (br.m, 2H); MS ESI 503.3 [M+H].sup.+, calcd for
[C.sub.28H.sub.30N.sub.4O.sub.3S+H].sup.+ 503.6.
Example A30
N-(3-(4-((1-isopropylpiperidin-4-yl)oxy)phenyl)-1H-indazol-5-yl)-2-(pyrrol-
idin-1-yl)-2-(thiophen-3-yl)acetamide
##STR00176##
[0558] Using Method C2,
N-(3-iodo-1H-indazol-5-yl)-2-(pyrrolidin-1-yl)-2-(thiophen-3-yl)acetamide
(53.1 mg, 0.117 mmol) and
1-isopropyl-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)pip-
eridine (47 mg, 0.14 mmol) heated for 3 h at 120.degree. C. in the
microwave followed by work-up using a PoraPak RXn CX followed by
purification by flash chromatography (RPRPC18, 10-80% MeOH in 0.1%
TFA-H.sub.2O; repeated PoraPak work-up; then SiO2, 0-20% 2 M
NH.sub.3-MeOH in DCM) gave the title compound (beige solid, 14.0
mg, 22%). .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. ppm 9.23 (s,
1H), 8.39 (d, J=1.3 Hz, 1H), 7.87 (d, J=8.8 Hz, 2H), 7.47 (dd,
J=9.0, 1.5 Hz, 1H), 7.39 (d, J=9.0 Hz, 1H), 7.32-7.35 (m, 1H),
7.29-7.32 (m, 1H), 7.15 (dd, J=4.9, 1.1 Hz, 1H), 7.03 (d, J=8.8 Hz,
2H), 4.39 (tt, J=7.3, 3.8 Hz, 1H), 4.15 (s, 1H), 2.77-2.90 (m, 3H),
2.62-2.72 (m, 2H), 2.42-2.59 (m, 4H), 2.03-2.14 (m, 2H), 1.87-1.95
(m, 2H), 1.84 (br. s., 4H), 1.11 (d, J=6.5 Hz, 6H). MS ESI 544.2
[M+H].sup.+, calcd for [C.sub.31H.sub.37N.sub.5O.sub.2S+H].sup.+
544.27.
Example A31
N-(3-(4-((1-methylpiperidin-4-yl)oxy)phenyl)-1H-indazol-5-yl)-2-(piperidin-
-1-yl)-2-(thiophen-3-yl)acetamide
##STR00177##
[0560] The title compound was synthesized according to general
Method C by using a mixture of
N-(3-iodo-1H-indazol-5-yl)-2-(piperidin-1-yl)-2-(thiophen-3-yl)acetamide
(125 mg, 0.268 mmol),
1-methyl-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)piperi-
dine (103 mg, 0.324 mmol), Pd(PPh.sub.3).sub.4 (15.5 mg, 0.0134
mmol) and 1 M aq Na.sub.2CO.sub.3 (0.54 mL) in PhMe/EtOH (3.75 mL,
2:1 mixture) in vial under Ar was heated under microwave
irradiation at 125.degree. C. for 2 h. The reaction mixture was
diluted with EtOAc (10 mL) and washed it with of H.sub.2O (5 mL)
followed by brine (5 mL), dried (Na.sub.2SO.sub.4) and concentrated
under vacuum. Purification by prep-HPLC gave the title compound as
a TFA salt (off white solid, 27 mg, 16%). .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. 8.37 (s, 1H), 7.88-7.84 (m, 3H), 7.67-7.65 (m,
1H), 7.55-7.49 (m, 2H), 7.39 (dd, J=5.2 Hz, J=1.2 Hz, 1H), 7.21 (d,
J=9.2 Hz, 1H), 7.16 (d, J=8.4 Hz, 1H), 5.21 (s, 1H), 3.78-3.75 (m,
1H), 3.67-3.60 (br.m, 1H), 3.46-3.36 (br.m, 3H), 3.22-3.08 (br.m,
3H), 2.95 (s, 3H), 2.46-2.43 (br.m, 2H), 2.18-1.79 (br.m, 7H),
1.6-1.51 (br.m, 1H), 1H merged with solvent peak; MS ESI 530.2
[M+H].sup.+, calcd for [C.sub.30H.sub.35N.sub.5O.sub.2S+H].sup.+
530.2
Example A32
N-(3-(4-morpholinophenyl)-1H-indazol-5-yl)-2-(piperidin-1-yl)-2-(thiophen--
3-yl)acetamide
##STR00178##
[0562] The title compound was synthesized according to general
Method C by using a sealed degassed mixture of
N-(3-iodo-1H-indazol-5-yl)-2-(piperidin-1-yl)-2-(thiophen-3-yl)acetamide
(125 mg, 0.268 mmol), 4-(Morpholino)phenylboronic acid (67 mg,
0.268 mmol), Pd(PPh.sub.3).sub.4 (15.5 mg, 0.013 mmol), 1 M aq
Na.sub.2CO.sub.3 (0.80 mL) in PhMe/EtOH (3.75 mL, 1:0.5 mixture)
under Ar was heated under microwave irradiation at 125.degree. C.
for 2 h. The reaction mixture was diluted with EtOAc (25 mL) and
washed with H.sub.2O followed by brine (10 mL each), dried
(Na.sub.2SO.sub.4) and concentrated under vacuum. Purification by
flash chromatography (SiO2, 0-20% MeOH in DCM, then RP HPLC C18 60
g, 10-80% MeOH in 0.1% TFA-H.sub.2O) gave the title compound as a
TFA salt (yellow solid, 51 mg, 26%). .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. 8.40 (s, 1H), 7.88-7.83 (m, 3H), 7.66-7.64 (m,
1H), 7.54-7.48 (m, 2H), 7.38 (dd, J=5.2 Hz, J=1.2 Hz, 1H), 7.20 (d,
J=8.8 Hz, 2H), 5.20 (s, 1H), 3.89 (t, J=4.8 Hz, 4H), 3.78-3.75
(br.m, 1H), 3.35-3.77 (m, 4H), 3.19-3.07 (br.m, 2H), 2.94-2.88
(br.m, 1H) 2.02-1.82 (br.m, 5H), 1.56-1.54 (br.m, 1H); MS ESI 502.3
[M+H].sup.+, calcd for [C.sub.28H.sub.31N.sub.5O.sub.2S+H].sup.+
502.2.
Example A33
N-(cyclopropyl(thiophen-3-yl)methyl)-3-(4-((1-methylpiperidin-4-yl)oxy)phe-
nyl)-1H-indazole-5-carboxamide
##STR00179##
[0564] The title compound was synthesized according to the General
Method C, utilizing
N-(cyclopropyl(thiophen-3-yl)methyl)-3-iodo-1H-indazole-5-carboxamide
(100 mg, 0.24 mmol), (4-((1-methylpiperidin-4-yl)oxy)phenyl)boronic
acid pinacol ester (75 mg, 0.24 mmol), PdCl.sub.2dppf (10 mg, 0.012
mmol), satd. aq Na.sub.2CO.sub.3 (1 mL), and 3 mL of PhMe:EtOH
(1:1). The vial was charged with Ar and heated in the microwave
reactor at 125.degree. C. for 2 h. Purification by RPHPLC, followed
by trituration with Et.sub.2O gave the title compound as a TFA salt
(beige solid, 70 mg, 49%). .sup.1H NMR (400 MHz, CD.sub.3OD)
.delta. ppm 8.58 (s, 1H), 7.95 (d, J=8.8 Hz, 3H), 7.61 (d, J=8.8
Hz, 1H), 7.33-7.39 (m, 2H), 7.15-7.23 (m, 3H), 4.74-4.86 (m, 2H),
4.57-4.66 (m, 1H), 3.33-3.50 (m, 3H), 2.93 (s, 3H), 2.04-2.33 (m,
4H), 1.39-1.49 (m, 1H), 0.68-0.76 (m, 1H), 0.59-0.67 (m, 1H),
0.43-0.53 (m, 2H); MS ESI 487.4 [M+H].sup.+, calcd for
[C.sub.28H.sub.30N.sub.4O.sub.2S+H].sup.+ 487.2.
Example A34
N-(3-(3-chloro-4-(piperidin-4-yloxy)phenyl)-1H-indazol-5-yl)-2-(pyrrolidin-
-1-yl)-2-(thiophen-3-yl)acetamide
##STR00180##
[0565] A. tert-butyl
4-(2-chloro-4-(5-(2-(pyrrolidin-1-yl)-2-(thiophen-3-yl)acetamido)-1H-inda-
zol-3-yl)phenoxy)piperidine-1-carboxylate
[0566] Using Method C2,
N-(3-iodo-1H-indazol-5-yl)-2-(pyrrolidin-1-yl)-2-(thiophen-3-yl)acetamide
(71.3 mg, 0.158 mmol) and tert-butyl
4-(2-chloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)piperi-
dine-1-carboxylate (92.3 mg, 90% pure, 0.19 mmol) gave the title
compound after 3 h at 120.degree. C. in the microwave (68.4 mg,
68%) after aq. work-up using EtOAc followed by purification by
flash chromatography (SiO2, 50-100% EtOAc in DCM). .sup.1H NMR (400
MHz, CDCl.sub.3) .delta. ppm 9.26 (s, 1H), 8.39 (s, 1H), 7.98 (d,
J=2.0 Hz, 1H), 7.78 (dd, J=8.5, 2.0 Hz, 1H), 7.48 (dd, J=9.0, 1.8
Hz, 1H), 7.43 (d, J=9.0 Hz, 1H), 7.33-7.35 (m, 1H), 7.31 (dd,
J=5.0, 3.0 Hz, 1H), 7.16 (dd, J=4.8, 1.3 Hz, 1H), 7.06 (d, J=8.8
Hz, 1H), 4.60 (tt, J=6.2, 3.1 Hz, 1H), 4.17 (s, 1H), 3.65-3.73 (m,
2H), 3.43-3.53 (m, 2H), 2.68 (d, J=7.0 Hz, 2H), 2.56 (d, J=6.0 Hz,
2H), 1.88-1.99 (m, 4H), 1.85 (br. s., 4H), 1.49 (s, 9H).
B.
N-(3-(3-chloro-4-(piperidin-4-yloxy)phenyl)-1H-indazol-5-yl)-2-(pyrroli-
din-1-yl)-2-(thiophen-3-yl)acetamide
[0567] Tert-butyl
4-(2-chloro-4-(5-(2-(pyrrolidin-1-yl)-2-(thiophen-3-yl)acetamido)-1H-inda-
zol-3-yl)phenoxy)piperidine-1-carboxylate (102 mg, 0.169 mmol) was
dissolved in DCM (3 mL) and TFA (0.75 mL) was added. The resulting
mixture was stirred at rt for 1 h, then the mixture was
concentrated to dryness, and 2 M NH.sub.3-MeOH ( ) was added and
the mixture was concentrated to dryness. Purification by flash
chromatography (SiO2, 0-20% 2 M NH.sub.3-MeOH in DCM) followed by
PoraPak Rxn Cx work-up gave the title compound (beige solid, 48.3
mg, 85%). .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. ppm 8.37 (d,
J=1.3 Hz, 1H), 7.98 (d, J=2.0 Hz, 1H), 7.77 (dd, J=8.5, 2.0 Hz,
1H), 7.47 (dd, J=9.0, 1.6 Hz, 1H), 7.41 (d, J=9.0 Hz, 1H),
7.33-7.36 (m, 1H), 7.29-7.33 (m, 1H), 7.16 (dd, J=5.0, 1.3 Hz, 1H),
7.05 (d, J=8.5 Hz, 1H), 4.45-4.53 (m, 1H), 4.16 (s, 1H), 3.16-3.27
(m, 2H), 2.78 (ddd, J=12.4, 8.6, 3.4 Hz, 2H), 2.63-2.72 (m, 2H),
2.51-2.59 (m, 2H), 2.04 (ddt, J=12.8, 6.5, 3.0, 3.0 Hz, 3H),
1.75-1.89 (m, 6H). MS ESI 536.1 [M+H].sup.+, calcd for
[C.sub.28H.sub.30ClN.sub.5O.sub.2S+H].sup.+ 536.19.
Example A35
N-(cyclopropyl(thiophen-3-yl)methyl)-3-(4-morpholinophenyl)-1H-indazole-5--
carboxamide
##STR00181##
[0569] The title compound was synthesized according to the General
Method C, utilizing
N-(cyclopropyl(thiophen-3-yl)methyl)-3-iodo-1H-indazole-5-carboxamide
(100 mg, 0.24 mmol), 4-morpholinophenylboronic acid pinacol ester
(81 mg, 0.28 mmol), PdCl.sub.2dppf (10 mg, 0.012 mmol), satd.
Na.sub.2CO.sub.3 (0.5 mL), and 1.5 mL of PhMe:EtOH (1:1). The vial
was charged with Ar and heated in the microwave reactor at
125.degree. C. for 2 h. Purification by RPHPLC, followed by
trituration with Et.sub.2O gave the title compound as a TFA salt
(white solid, 40 mg, 29%). .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. ppm 13.25 (s, 1H), 9.02 (d, J=8.8 Hz, 1H), 8.57 (s, 1H),
7.87-7.96 (m, 3H), 7.58 (d, J=8.8 Hz, 1H), 7.46-7.51 (m, 1H),
7.40-7.44 (m, 1H), 7.20 (d, J=5.8 Hz, 1H), 7.12 (d, J=9.0 Hz, 2H),
4.58 (t, J=9.3 Hz, 1H), 3.74-3.80 (m, 4H), 3.17-3.23 (m, 4H),
1.33-1.44 (m, 1H), 0.58-0.67 (m, 1H), 0.48-0.57 (m, 1H), 0.35-0.47
(m, 2H); MS ESI 459.3 [M+H].sup.+, calcd for
[C.sub.26H.sub.26N.sub.4O.sub.2S+H].sup.+ 459.2.
Example A36
2-cyclopentyl-N-(3-(4-((1-methylpiperidin-4-yl)oxy)phenyl)-1H-indazol-5-yl-
)-2-(thiophen-3-yl)acetamide
##STR00182##
[0570] A. ethyl 2-cyclopentyl-2-(thiophen-3-yl)acetate
[0571] NaH (0.26 g, 6.5 mmol) was added portion wise to a solution
of ethyl 3-thiophene acetate (0.88 mL, 5.8 mmol) in DMF (20 mL) at
rt under Ar. After stirring for 5 min, cyclopentyl bromide (0.70
mL, 6.9 mmol) was added and stirring was continued for 18 h at
25.degree. C. 20% NH.sub.4Cl (50 mL) was added and the product was
extracted using EtOAc (2.times.50 mL), and the combined EtOAc layer
was washed with H.sub.2O and brine and dried (Na.sub.2SO.sub.4) and
concentrated under vacuum. Purification by flash chromatography
(SiO2, 0-25% EtOAc in Hexane) gave the title compound (colorless
oil, 1.04 g, 74%). .sup.1H NMR (400 MHz, CDCl.sub.3) .delta.
7.26-7.25 (m, 1H), 7.16-7.7.15 (m, 1H), 7.12 (dd, J=4.8 Hz, J=1.2
Hz, 1H), 4.18-4.06 (m, 2H), 3.45 (d, J=10.8 Hz, 1H), 2.51-2.49 (m,
1H), 1.86-1.83 (m, 1H), 1.46-1.49 (m, 6H), 1.24 (t, J=7.2 Hz, 3H),
1.12-1.05 (m, 1H).
B. 2-cyclopentyl-2-(thiophen-3-yl)acetic acid
[0572] NaOH (2 M, 5.45 mL, 10.9 mmol) was added to a solution of
ethyl 2-cyclopentyl-2-(thiophen-3-yl)acetate (1.04 g, 4.3 mmol) in
MeOH (10.4 mL) at rt. The reaction mixture was refluxed for 2.5 h,
and then concentrated under reduced pressure. The residue was
acidified to .sub.pH 2 using conc. HCl and the product was
extracted using DCM (25 mL, 10 mL). The combined organic layer was
washed with H.sub.2O and brine, dried (Na.sub.2SO.sub.4) and
concentrated under vacuum to give the title compound (off white
solid, 0.89 g, 97%). .sup.1H NMR (400 MHz, CDCl.sub.3) .delta.
7.29-7.27 (m, 1H), 7.18-7.7.17 (m, 1H), 7.12-7.1 (m, 1H), 3.47 (d,
J=10.8 Hz, 1H), 2.55-2.45 (m, 1H), 1.95-1.89 (m, 1H), 1.71-1.48 (m,
5H), 1.35-1.26 (m, 1H), 1.12-1.05 (m, 1H).
C.
2-cyclopentyl-N-(3-(4-((1-methylpiperidin-4-yl)oxy)phenyl)-1H-indazol-5-
-yl)-2-(thiophen-3-yl)acetamide
[0573] The title compound was synthesized according to general
Method A using 2-cyclopentyl-2-(thiophen-3-yl)acetic acid 19.1 mg,
0.09 mmol), DMF (1.5 mL),
3-(4-((1-methylpiperidin-4-yl)oxy)phenyl)-1H-indazol-5-amine
trifluoroacetate (50 mg, 0.09 mmol), DIPEA (80 uL, 0.45 mmol) and
TBTU (29.1 mg, 0.09 mmol). After 24 h at rt, direct purification by
flash chromatography (SiO2, 0-25% MeOH in DCM; then RP HPLC C18 60
g, 10-80% MeOH in 0.1% TFA-H.sub.2O) gave the title compound as a
TFA salt (off white solid, 31 mg, 54%). .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. 10.08 (s, 1H), 8.43-8.42 (m, 1H), 7.88-7.8 (m,
2H), 7.52 (d, J=9.2 Hz, 1H), 7.40-7.35 (m, 2H), 7.31-7.3 (m, 1H),
7.22 (dd, J=5.2 Hz, J=1.2 Hz, 1H), 7.18-7.15 (m, 2H), 4.85 (s, 1H),
3.65-3.54 (m, 2H), 3.44-3.34 (br.m, 3H), 2.94 (d, J=4.4 Hz, 3H),
2.70-2.64 (m, 1H), 2.45-2.28 (m, 2H), 2.15-1.91 (br.m, 3H),
1.75-1.53 (br.m, 5H), 1.40-1.35 (m, 1H), 1.18-1.31 (m, 1H); MS ESI
515.1 [M+H].sup.+, calcd for
[C.sub.30H.sub.34N.sub.4O.sub.2S+H].sup.+515.2
Example A37
2-methoxy-N-(3-(4-((1-methylpiperidin-4-yl)oxy)phenyl)-1H-indazol-5-yl)-2--
(thiophen-3-yl)acetamide
##STR00183##
[0575] The title compound was synthesized according to general
Method A by using 2-methoxy-2-(thiophen-2-yl)acetic acid (15.6 mg,
0.09 mmol), DMF (1.5 mL),
3-(4-((1-methylpiperidin-4-yl)oxy)phenyl)-1H-indazol-5-amine
trifluoroacetate (50 mg, 0.09 mmol), DIPEA (80 uL, 0.45 mmol) and
TBTU (29.1 mg, 0.09 mmol). After 24 h at rt, direct purification by
flash chromatography (SiO2, 0-25% MeOH in DCM; then RP HPLC C18 60
g, 10-80% MeOH in 0.1% TFA-H.sub.2O) gave the title compound as a
TFA salt (off white solid, 27 mg, 50%). .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. 8.41 (s, 1H), 7.89-7.85 (br.t, 2H), 7.55-7.52
(m, 3H), 7.45 (dd, J=4.8 Hz, J=2.8 Hz, 1H), 7.23 (d, J=1.2 Hz, 1H),
7.19-7.112 (m, 2H), 4.95 (s, 1H), 3.65-3.6 (br.m, 1H), 3.38-3.58
(br.m, 1H), 3.48 (s, 3H), 3.62-3.41 (br.m, 3H), 2.94 (s, 3H),
2.45-28 (br.m, 2H), 2.14-1.88 (br.m, 2H); MS ESI 477.2 [M+H].sup.+,
calcd for [C.sub.26H.sub.28N.sub.4O.sub.3S+H].sup.+ 477.2.
Example A38
(S)--N-(1-cyclohexylethyl)-3-(4-((1-methylpiperidin-4-yl)oxy)phenyl)-1H-in-
dazole-5-carboxamide
##STR00184##
[0577] The title compound was synthesized according to the General
Method C, utilizing
(S)--N-(1-cyclohexylethyl)-3-iodo-1H-indazole-5-carboxamide (100
mg, 0.25 mmol), (4-((1-methylpiperidin-4-yl)oxy)phenyl)boronic acid
pinacol ester (96 mg, 0.30 mmol), PdCl.sub.2dppf (10 mg, 0.012
mmol), satd. aq Na.sub.2CO.sub.3 (1 mL), and 4 mL of PhMe:EtOH
(1:1). The vial was charged with Ar and heated in the microwave
reactor at 125.degree. C. for 2 h. Purification by RPHPLC, followed
by trituration with Et.sub.2O gave the title compound as a TFA salt
(white solid, 35 mg, 24%). .sup.1H NMR (400 MHz, CD.sub.3OD)
.delta. ppm 8.52 (s, 1H), 7.87-7.99 (m, 3H), 7.60 (d, J=8.5 Hz,
1H), 7.14-7.25 (m, 2H), 4.64-4.74 (m, 0.3H), 3.93-4.05 (m, 1H),
3.60-3.69 (m, 0.7H), 3.34-3.49 (m, 2.7H), 3.13-3.27 (m, 1.3H), 2.95
(s, 3H), 2.42-2.50 (m, 0.7H), 2.27-2.38 (m, 1.3H), 2.05-2.18 (m,
1.3H), 1.73-1.97 (m, 4.7H), 1.62-1.73 (m, 1H), 1.44-1.57 (m, 1H),
1.14-1.35 (m, 6H), 1.01-1.14 (m, 2H); MS ESI 461.4 [M+H].sup.+,
calcd for [C.sub.28H.sub.36N.sub.4O.sub.2+H].sup.+ 461.3.
Example A39
2-methyl-N-(3-(4-((1-methylpiperidin-4-yl)oxy)phenyl)-1H-indazol-5-yl)-1,2-
,3,4-tetrahydroisoquinoline-1-carboxamide
##STR00185##
[0579] To a mixture of
2-methyl-1,2,3,4-tetrahydroisoquinoline-1-carboxylic acid
hydrochloride (25 mg, 0.1 mmol) and
3-(4-((1-methylpiperidin-4-yl)oxy)phenyl)-1H-indazol-5-amine
di-trifluoroacetic acid (55 mg, 0.1 mmol) in DMF (5 mL) at
0.degree. C. was added TBTU (32 mg, 0.1 mmol), followed by
.sup.iPr.sub.2NEt (0.09 mL, 0.5 mmol). The resulting mixture was
stirred for 30 min at 0.degree. C. Additional
3-(4-((1-methylpiperidin-4-yl)oxy)phenyl)-1H-indazol-5-amine
di-trifluoroacetic acid (5.5 mg, 0.01 mmol) and TBTU (3.2 mg, 0.01
mmol) were added and it was stirred for 30 min at 0.degree. C.
After removal of Pr.sub.2NEt, it was purified by prep-HPLC twice to
give the title compound as a di-TFA salt (white solid, 51.3 mg,
71%). .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.46 (t, J=0.8 Hz,
1H), 7.90-7.84 (m, 2H), 7.64 (dd, J=9.0 Hz, 1.8 Hz, 1H), 7.60 (d,
J=9.2 Hz, 1H), 7.49 (d, J=7.2 Hz, 1H), 7.41-7.32 (m, 3H), 7.19-7.10
(m, 2H), 5.34 (s, 1H), 5.34-5.31 (m, 0.7H), 4.68-4.60 (m, 0.3H),
4.03 (brs, 0.8H), 3.65-3.58 (m, 1.7H), 3.45-3.33 (m, 3.4H;
partially overlapped with CD.sub.3OD solvent residue), 3.23-3.12
(m, 4.7H; s, 3H at 3.14), 2.92-2.91 (two s at 2.92 and 2.91, total
3H), 2.44-2.37 (m, 0.7H), 2.30-2.23 (m, 1.3H), 2.18-2.08 (m, 1.3H),
1.98-1.86 (m, 0.7H); MS ESI 496.2 [M+H].sup.+, calcd for
[C.sub.30H.sub.33N.sub.5O.sub.2+H].sup.+ 496.3.
Example A40
(S)--N-(1-cyclohexylethyl)-3-(4-morpholinophenyl)-1H-indazole-5-carboxamid-
e
##STR00186##
[0581] The title compound was synthesized according to the General
Method C, utilizing
(S)--N-(1-cyclohexylethyl)-3-iodo-1H-indazole-5-carboxamide (80 mg,
0.20 mmol), 4-morpholinophenylboronic acid pinacol ester (58 mg,
0.20 mmol), PdCl.sub.2dppf (8 mg, 0.01 mmol), satd. aq
Na.sub.2CO.sub.3 (0.5 mL), and 1.5 mL of PhMe:EtOH (1:1). The vial
was charged with Ar and heated in the microwave reactor at
125.degree. C. for 2 h. Purification by RPHPLC, followed by
trituration with Et.sub.2O gave the title compound (white solid, 18
mg, 21%). .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. ppm 8.55 (s,
1H), 7.90 (d, J=8.8 Hz, 3H), 7.58 (d, J=8.8 Hz, 1H), 7.13 (d, J=8.5
Hz, 2H), 3.92-4.03 (m, 1H), 3.82-3.89 (m, 4H), 3.24 (br. s, 4H),
1.70-1.90 (m, 4H), 1.61-1.69 (m, 1H), 1.44-1.55 (m, 1H), 1.22 (d,
J=6.8 Hz, 6H), 0.97-1.12 (m, 2H); MS ESI 433.4 [M+H].sup.+, calcd
for [C.sub.26H.sub.32N.sub.4O.sub.2+H].sup.+ 433.3.
Example A41
(S)--N-(3-(4-((1-methylpiperidin-4-yl)oxy)phenyl)-1H-indazol-5-yl)-2-((S)--
2-methylpyrrolidin-1-yl)-2-(thiophen-3-yl)acetamide
##STR00187##
[0583] To a mixture of
(S)-2-((S)-2-methylpyrrolidin-1-yl)-2-(thiophen-3-yl)acetic acid
(22.5 mg, 0.1 mmol) and
3-(4-((1-methylpiperidin-4-yl)oxy)phenyl)-1H-indazol-5-amine
di-trifluoroacetic acid (55 mg, 0.1 mmol) in DMF (5 mL) at
0.degree. C. was added TBTU (32.1 mg, 0.1 mmol), followed by
.sup.iPr.sub.2NEt (0.09 mL, 0.5 mmol). The resulting mixture was
stirred for 10 min at 0.degree. C. After removal of iPr.sub.2NEt,
it was purified by prep-HPLC to give the title compound as di-TFA
salt (white solid, 31.1 mg, 71%). .sup.1H NMR (400 MHz, CD.sub.3OD)
.delta. 8.35 (s, 1H), 7.91-7.93 (m, 3H), 7.64 (dd, J=5.0 Hz, 3.0
Hz, 1H), 7.54 (s, 2H), 7.41 (d, J=4.8 Hz, 1H), 7.21-7.13 (m, 2H),
5.33 (s, 1H), 4.89-4.85 (m, 0.7H), 4.72-4.64 (m, 0.3H), 3.84 (q,
J=7.2 Hz, 1H), 3.68-3.62 (m, 0.7H), 3.48-3.12 (m, 5.3H; partially
overlapped with CD.sub.3OD solvent residue), 2.95-2.94 (two s at
2.95 and 2.94, total 3H), 2.48-2.26 (m, 3H), 2.20-1.82 (m, 5H),
1.53 (d, J=6.4 Hz, 3H); MS ESI 530.2 [M+H].sup.+, calcd for
[C.sub.30H.sub.35N.sub.5O.sub.2S+H].sup.+ 530.3.
Example A42
(S)--N-(cyclopropyl(phenyl)methyl)-3-(4-((1-methylpiperidin-4-yl)oxy)pheny-
l)-1H-indazole-5-carboxamide
##STR00188##
[0585] The title compound was synthesized according to the General
Method C, utilizing
(S)--N-(cyclopropyl(phenyl)methyl)-3-iodo-1H-indazole-5-carboxamide
(110 mg, 0.26 mmol), (4-((1-methylpiperidin-4-yl)oxy)phenyl)boronic
acid pinacol ester (84 mg, 0.26 mmol), PdCl.sub.2dppf (11 mg, 0.013
mmol), satd. aq Na.sub.2CO.sub.3 (1 mL), and 4 mL of PhMe:EtOH
(1:1). The vial was charged with Ar and heated in the microwave
reactor at 125.degree. C. for 5 h. Purification by RPHPLC, followed
by flash chromatography (SiO.sub.2, Biotage 25 g, 5-25% MeOH in
CH.sub.2Cl.sub.2) and trituration with Et.sub.2O gave the title
compound (white solid, 8.5 mg, 7%). .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. ppm 8.60 (s, 1H), 7.91 (m, 3H), 7.59 (d, J=9.5
Hz, 1H), 7.48 (d, J=7.3 Hz, 2H), 7.32 (t, J=7.5 Hz, 2H), 7.23 (t,
J=7.3 Hz, 1H), 7.10 (d, J=8.8 Hz, 2H), 4.53 (br. s, 1H), 4.47 (d,
J=9.5 Hz, 1H), 2.77-2.88 (m, 2H), 2.45-2.59 (m, 2H), 2.39 (s, 3H),
2.01-2.13 (m, 2H), 1.82-1.94 (m, 2H), 1.34-1.45 (m, 1H), 0.60-0.72
(m, 2H), 0.39-0.53 (m, 2H); MS ESI 481.4 [M+H].sup.+, calcd for
[C.sub.30H.sub.32N.sub.4O.sub.2+H].sup.+ 481.3.
Example A43
N-(3-(4-(3-(dimethylamino)propoxy)phenyl)-1H-indazol-5-yl)-2-(pyrrolidin-1-
-yl)-2-(thiophen-3-yl)acetamide
##STR00189##
[0587] The title compound was synthesized according to general
Method C by using a mixture of
N-(3-iodo-1H-indazol-5-yl)-2-(pyrrolidin-1-yl)-2-(thiophen-3-yl)acetamide
(75 mg, 0.165 mmol),
N,N-dimethyl-3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)pr-
opan-1-amine (60.7 mg, 0.198 mmol), PdCl.sub.2dppf (11.6 mg, 0.016
mmol) and 1 M aq Na.sub.2CO.sub.3 (0.33 mL) in PhMe/EtOH (2.25 mL,
2:1 mixture) under Ar with heating under microwave irradiation at
130.degree. C. for 2 h. The reaction mixture was diluted with EtOAc
(22.5 mL) and washed with H.sub.2O (10 mL) and brine (10 mL), dried
(Na.sub.2SO.sub.4) and concentrated under vacuum and. Purification
by flash chromatography (SiO2, 0-10% 2 M NH.sub.3-MeOH in DCM; then
RP HPLC C18 60 g, 10-80% MeOH in 0.1% TFA-H.sub.2O) to give the
title compound as a TFA salt (light pink solid, 20 mg, 17%).
.sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.35 (s, 1H), 7.88-7.83
(m, 3H), 7.66-7.64 (m, 1H), 7.55-7.49 (m, 2H), 7.38 (dd, J=5.2 Hz,
J=1.2 Hz, 1H), 7.13 (d, J=6.8 Hz, 2H), 5.24 (s, 1H), 4.21 (t, J=5.6
Hz, 2H), 3.88-3.86 (br.m, 1H), 3.41 (t, J=7.6 Hz, 2H), 3.26-3.09
(br.m, 2H), 2.98 (s, 6H), 2.31-1.92 (br.m, 6H), 1H merged with
solvent peak; MS ESI 504.2[M+H].sup.+, calcd for
[C.sub.28H.sub.33N.sub.5O.sub.2S+H].sup.+ 504.2.
Example A44
2-(pyrrolidin-1-yl)-N-(3-(4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-indazol--
5-yl)-2-(thiophen-3-yl)acetamideamide
##STR00190##
[0589] Using Method C2,
N-(3-iodo-1H-indazol-5-yl)-2-(pyrrolidin-1-yl)-2-(thiophen-3-yl)acetamide
(59.8 mg, 0.132 mmol) and
(4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)boronic acid (42.6 mg, 0.181
mmol) gave the title compound after 3 h at 120.degree. C. in the
microwave as the TFA salt (beige solid, 59.1 mg, 60%) after
purification by flash chromatography (SiO2, 0-20% 2 M NH.sub.3-MeOH
in DCM; followed by RPRP HPLC, 10-80% MeOH in 0.1% TFA-H.sub.2O).
.sup.1H NMR (400 MHz, CD.sub.3OD) .delta. ppm 8.36 (t, J=1.5 Hz,
1H), 7.86-7.91 (m, 3H), 7.65 (dd, J=5.0, 3.0 Hz, 1H), 7.50-7.57 (m,
2H), 7.38 (dd, J=5.1, 1.4 Hz, 1H), 7.17-7.22 (m, 2H), 5.28 (s, 1H),
4.41-4.46 (m, 2H), 3.88 (br. s., 1H), 3.78 (dt, J=10.2, 5.1 Hz,
2H), 3.67-3.75 (m, 2H), 3.22-3.30 (m, 3H), 3.19 (br. s., 1H), 3.10
(br. s., 1H), 2.05-2.28 (m, 7H), 1.92-2.04 (m, 1H). MS ESI 516.2
[M+H].sup.+, calcd for [C.sub.29H.sub.33N.sub.5O.sub.2S+H].sup.+
516.24.
Example A45
N-(3-(4-(3-morpholinopropoxy)phenyl)-1H-indazol-5-yl)-2-(pyrrolidin-1-yl)--
2-(thiophen-3-yl)acetamide
##STR00191##
[0591] Using Method C2,
N-(3-iodo-1H-indazol-5-yl)-2-(pyrrolidin-1-yl)-2-(thiophen-3-yl)acetamide
(59.9 mg, 0.132 mmol) and
(4-(3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)propyl)morp-
holine (60.9 mg, 0.175 mmol) gave the title compound after 3 h at
120.degree. C. in the microwave as the TFA salt (off-white powder,
30.6 mg, 30%) after purification by flash chromatography (SiO2,
5-15% MeOH in DCM; followed by RPRP HPLC, 10-80% MeOH in 0.1%
TFA-H.sub.2O). .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. ppm
8.35-8.38 (m, 1H), 7.88 (dd, J=2.9, 1.4 Hz, 1H), 7.85 (d, J=8.8 Hz,
2H), 7.63-7.67 (m, 1H), 7.49-7.56 (m, 2H), 7.38 (dd, J=5.3, 1.3 Hz,
1H), 7.12 (d, J=8.8 Hz, 2H), 5.27 (s, 1H), 4.21 (t, J=5.6 Hz, 2H),
4.11 (d, J=12.3 Hz, 2H), 3.88 (br. s., 1H), 3.81 (t, J=12.3 Hz,
2H), 3.60 (d, J=12.3 Hz, 2H), 3.40-3.48 (m, 2H), 3.16-3.27 (m, 3H),
3.10 (br. s., 1H), 2.27-2.36 (m, 2H), 2.23 (d, J=11.5 Hz, 1H),
2.09-2.19 (m, 2H), 2.01 (br. s., 1H). MS ESI 546.3 [M+H].sup.+,
calcd for [C.sub.30H.sub.35N.sub.5O.sub.3S+H].sup.+ 546.25.
Example A46
1-(2,6-diethylphenyl)-3-(3-(4-((1-methylpiperidin-4-yloxy)phenyl)-1H-indaz-
ol-5-yl)urea
##STR00192##
[0593] A solution of
3-(4-((1-methylpiperidin-4-yl)oxy)phenyl)-1H-indazol-5-amine
bis(2,2,2-trifluoroacetate) (40 mg, 0.073 mmol), DIPEA (64 uL,
0.368 mmol), and DMF (1.0 mL) was cooled to 0.degree. C. and then
1,3-diethyl-2-isocyanatobenzene (25 uL, 0.145 mmol) was added
dropwise. The reaction was stirred for 2 h while warming to rt. A
mixture of mono- and di-urea products were obtained which was
treated directly with NaOMe (80 uL of a 25% wt solution in MeOH)
and the mixture stirred for 15 min and then transferred to a
separatory funnel with EtOAc (15 mL). The mixture was then washed
with (satd. aq NaHCO.sub.3 (2.times.10 mL), H.sub.2O (1.times.10
mL), brine (1.times.10 mL)). The organic layer was dried over
MgSO4, filtered, and the solvent removed. The resulting residue was
purified by prep-HPLC which gave 19 mg, 43% of the desired product
isolated as its TFA salt (a white powder). .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. ppm 8.26 (s, 1H), 7.87-7.83 (m, 2H), 7.49 (d,
J=8.8 Hz, 1H), 7.30 (d, J=8.8 Hz, 1H), 7.22-7.09 (m, 5H), 4.83 (bs,
1H), 3.62-3.31 (m, 2H), 3.30-3.14 (m, 2H), 2.92-2.91 (m, 3H),
2.72-2.67 (m, 4H), 2.42-2.25 (m, 2H), 2.11-1.86 (m, 2H), 1.22 (t,
J=7.6 Hz, 6H); MS ESI 498.5 [M+H].sup.+, calcd for
[C.sub.30H.sub.35N.sub.5O.sub.2+H].sup.+ 498.29.
Example A47
(S)-2-((S)-2-methylpyrrolidin-1-yl)-N-(3-(4-morpholinophenyl)-1H-indazol-5-
-yl)-2-(thiophen-3-yl)acetamide
##STR00193##
[0595] To a mixture of tert-butyl (3-iodo-1H-indazol-5-yl)carbamate
(1.077 g, 3 mmol) and (4-morpholinophenyl)boronic acid (652 mg,
3.15 mmol) in EtOH (12 mL) was added 2 M Na.sub.2CO.sub.3 (3 mL, 6
mmol), followed by Pd(PPh.sub.3).sub.4 (104 mg, 0.09 mmol). The
resulting mixture was purged with Ar and microwaved 3 h at
125.degree. C. Repeated this reaction twice on the same scale. All
three reactions were combined, diluted with H.sub.2O, extracted
with EtOAc and purified by flash chromatographye (MeOH/DCM 0-25%)
to give 4.20 g of brown solid. It was redissolved in DCM (20 mL)
and treated with TFA (10 mL). After stirring for 3 h at rt, it was
concentrated and purified by biotage RP column (5-90% MeOH in 0.1%
TFA-H.sub.2O) to give 3-(4-morpholinophenyl)-1H-indazol-5-amine as
a di-TFA salt (light puple solid, 866 mg, 55%). .sup.1H NMR (400
MHz, CD3OD) .delta. 8.05 (s, 1H), 7.84 (d, J=7.2 Hz, 2H), 7.72 (d,
J=8.0 Hz, 1H), 7.44 (d, J=8.4 Hz, 1H), 7.17 (d, J=7.2 Hz, 2H),
4.00-3.80 (m, 4H), 3.40-3.20 (m, 4H); MS ESI 295.0 [M+H].sup.+,
calcd for [C.sub.17H.sub.18N40+H].sup.+ 295.1.
[0596] To a mixture of
(S)-2-((S)-2-methylpyrrolidin-1-yl)-2-(thiophen-3-yl)acetic acid
(22.5 mg, 0.1 mmol) and 3-(4-morpholinophenyl)-1H-indazol-5-amine
di-trifluoroacetic acid (52.2 mg, 0.1 mmol) in DMF (5 mL) at
0.degree. C. was added TBTU (32.1 mg, 0.1 mmol), followed by
.sup.iPr.sub.2NEt (0.07 mL). After stirring for 5 min at 0.degree.
C., additional iPr.sub.2NEt (0.02 mL) was added and the resulting
mixture was stirred for 30 min at 0.degree. C. After removal of
.sup.iPr.sub.2NEt, it was purified by prep-HPLC to give the title
compound as a di-TFA salt (white solid, 14.1 mg, 19%). .sup.1H NMR
(400 MHz, CD.sub.3OD) .delta. 8.37 (t, J=1.6 Hz, 1H), 7.89 (d,
J=1.6 Hz, 1H), 7.86 (d, J=8.8 Hz, 2H), 7.65 (dd, J=5.0 Hz, 3.0 Hz,
1H), 7.57-7.49 (m, 2H), 7.41 (d, J=4.8 Hz, 1H), 7.23 (d, J=8.4 Hz,
2H), 5.23 (s, 1H), 3.92 (t, J=4.8 Hz, 4H), 3.84 (q, J=6.7 Hz, 1H),
3.36-3.25 (m, 5H; partially buried under CD.sub.3OD solvent
residue), 3.20-3.12 (m, 1H), 2.46-2.36 (m, 1H), 2.06 (quint, J=7.1
Hz, 2H), 1.90-1.83 (m, 1H), 1.54 (d, J=6.4 Hz, 3H); MS ESI 502.3
[M+H].sup.+, calcd for [C.sub.26H.sub.28N.sub.6O.sub.2S+H].sup.+
502.2.
Example A48
(R)--N-(1-cyclohexylethyl)-3-(4-morpholinophenyl)-1H-indazole-5-carboxamid-
e
##STR00194##
[0598] The title compound was synthesized according to the General
Method C, utilizing
(R)--N-(1-cyclohexylethyl)-3-iodo-1H-indazole-5-carboxamide (100
mg, 0.25 mmol), 4-morpholinophenylboronic acid pinacol ester (55
mg, 0.25 mmol), PdCl.sub.2dppf (10 mg, 0.013 mmol), satd. aq
Na.sub.2CO.sub.3 (1.5 mL), and 3.5 mL of PhMe:EtOH (1:1). The vial
was charged with Ar and heated in the microwave reactor at
125.degree. C. for 2 h. Purification by RP HPLC, followed by flash
chromatography (SiO.sub.2, Biotage 25 g, 5-25% MeOH in
CH.sub.2Cl.sub.2), and passed through a PoraPak column to give the
title compound (beige solid, 32 mg, 30%). .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. ppm 8.55 (s, 1H), 7.85-7.92 (m, 3H), 7.57 (d,
J=8.8 Hz, 1H), 7.09 (d, J=8.8 Hz, 2H), 3.93-4.02 (m, 1H), 3.81-3.87
(m, 4H), 3.17-3.23 (m, 4H), 1.76 (br. s, 4H), 1.61-1.69 (m, 1H),
1.44-1.55 (m, 1H), 1.22 (d, J=6.8 Hz, 6H), 1.06 (d, J=2.5 Hz, 2H);
MS ESI 433.4 [M+H].sup.+, calcd for
[C.sub.26H.sub.32N.sub.4O.sub.2+H].sup.+ 433.3.
Example A49
(S)--N-(cyclopropyl(phenyl)methyl)-3-(4-morpholinophenyl)-1H-indazole-5-ca-
rboxamide
##STR00195##
[0600] The title compound was synthesized according to the General
Method C, utilizing
(S)--N-(cyclopropyl(phenyl)methyl)-3-iodo-1H-indazole-5-carboxamide
(50 mg, 0.12 mmol), 4-morpholinophenylboronic acid pinacol ester
(35 mg, 0.12 mmol), PdCl.sub.2dppf (10 mg, 0.012 mmol), satd. aq
Na.sub.2CO.sub.3 (1.5 mL), and 3.5 mL of PhMe:EtOH (1:1). The vial
was charged with Ar and heated in the microwave reactor at
125.degree. C. for 2 h. Purification by RP HPLC, followed by flash
chromatography (SiO.sub.2, Biotage 25 g, 5-25% MeOH in
CH.sub.2Cl.sub.2) to give the title compound (beige solid, 13 mg,
24%). .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. ppm 8.61 (s, 1H),
7.91-7.98 (m, 3H), 7.60 (d, J=8.8 Hz, 1H), 7.48 (d, J=7.3 Hz, 2H),
7.33 (t, J=7.5 Hz, 2H), 7.20-7.28 (m, 3H), 4.48 (d, J=9.5 Hz, 1H),
3.86-3.93 (m, 4H), 3.31-3.35 (m, 4H), 1.35-1.46 (m, 1H), 0.66 (d,
J=8.0 Hz, 2H), 0.41-0.53 (m, 2H); MS ESI 453.3 [M+H].sup.+, calcd
for [C.sub.28H.sub.28N.sub.4O.sub.2+H].sup.+ 453.2.
Example A50
N-(3-(4-((2S,6R)-2,6-dimethylmorpholino)phenyl)-1H-indazol-5-yl)-2-(pyrrol-
idin-1-yl)-2-(thiophen-3-yl)acetamide
##STR00196##
[0601] The title compound was synthesized according to the General
Method C2 utilizing
N-(3-iodo-1H-indazol-5-yl)-2-(pyrrolidin-1-yl)-2-(thiophen-3-yl)acetamide
(0.070 g, 0.15 mmol),
(2S,6R)-2,6-dimethyl-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)ph-
enyl)morpholine (0.064 g, 0.62 mmol) to provide the title compound
as a white powder (7.2 mg, 9%). .sup.1H NMR (400 MHz,
acetone-d.sub.6) .delta. ppm 12.02-12.30 (br, 1H), 9.59 (s, 1H),
8.58 (s, 1H), 7.89 (d, J=8.78 Hz, 2H), 7.67 (d, J=8.78 Hz, 1H),
7.50-7.59 (m, 2H), 7.45 (dd, J=5.02, 3.01 Hz, 1H), 7.34 (dd,
J=4.89, 1.13 Hz, 1H), 7.10 (d, J=9.03 Hz, 2H), 4.12 (s, 1H),
3.73-3.83 (m, 2H), 3.69 (d, J=12.30 Hz, 2H), 2.70-2.62 (m, 2H),
2.45-2.56 (m, 2H), 2.32-2.42 (m, 2H), 1.81 (dt, J=6.27, 3.14 Hz,
4H), 1.23 (d, J=6.27 Hz, 6H); MS ESI 516.2 [M+H].sup.+, calcd for
[C.sub.29H.sub.33N.sub.5O.sub.2S+H].sup.+ 516.2.
Example A51
(R)--N-(cyclopropyl(phenyl)methyl)-3-(4-morpholinophenyl)-1H-indazole-5-ca-
rboxamide
##STR00197##
[0603] The title compound was synthesized according to the General
Method C, utilizing
(R)--N-(cyclopropyl(phenyl)methyl)-3-iodo-1H-indazole-5-carboxamide
(60 mg, 0.14 mmol), 4-morpholinophenylboronic acid pinacol ester
(42 mg, 0.14 mmol), PdCl.sub.2dppf (11 mg, 0.014 mmol), satd. aq
Na.sub.2CO.sub.3 (1.5 mL), and 3.5 mL of PhMe:EtOH (1:1). The vial
was charged with Ar and heated in the microwave reactor at
125.degree. C. for 2 h. Purification by RPHPLC, followed by passing
through PoraPak column gave the title compound (beige solid, 18 mg,
28%). .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. ppm 8.61 (s, 1H),
7.86-7.97 (m, 3H), 7.59 (d, J=8.8 Hz, 1H), 7.48 (d, J=7.3 Hz, 2H),
7.33 (t, J=7.5 Hz, 2H), 7.23 (t, J=7.3 Hz, 1H), 7.13 (d, J=9.0 Hz,
2H), 4.44-4.51 (m, 1H), 3.86 (s, 4H), 3.25 (s, 4H), 1.36-1.45 (m,
1H), 0.62-0.69 (m, 2H), 0.42-0.52 (m, 2H); MS ESI 453.4
[M+H].sup.+, calcd for [C.sub.28H.sub.28N.sub.4O.sub.2+H].sup.+
453.2.
Example A52
Intentionally Omitted
Example A53
(R)-3-(4-morpholinophenyl)-N-(1-(thiophen-2-yl)ethyl)-1H-indazole-5-carbox-
amide
##STR00198##
[0605] The title compound was synthesized according to the General
Method A, utilizing 3-(4-morpholinophenyl)-1H-indazole-5-carboxylic
acid (98 mg, 0.30 mmol), (1R)-1-(2-thienyl)ethylamine HCl (50 mg,
0.30 mmol), TBTU (96 mg, 0.30 mmol), DIPEA (0.16 mL, 0.90 mmol),
and DMF (5 mL). Purification by RP HPLC, followed by passing
through PoraPak column gave the title compound (white solid, 31 mg,
24%). .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. ppm 8.59 (s, 1H),
7.86-7.96 (m, 3H), 7.59 (d, J=8.5 Hz, 1H), 7.25-7.30 (m, 1H), 7.13
(d, J=8.8 Hz, 2H), 7.04-7.08 (m, 1H), 6.95-6.99 (m, 1H), 5.56-5.64
(m, 1H), 3.86 (s, 4H), 3.21-3.26 (m, 4H), 1.70 (d, J=7.0 Hz, 3H);
MS ESI 433.4 [M+H].sup.+, calcd for
[C.sub.24H.sub.24N.sub.4O.sub.2S+H].sup.+ 433.2.
Example A54
Intentionally Omitted
Example A55
(R)-3-(4-((1-methylpiperidin-4-yl)oxy)phenyl)-N-(1-(thiophen-2-yl)ethyl)-1-
H-indazole-5-carboxamide
##STR00199##
[0607] The title compound was synthesized according to the General
Method C, utilizing
(R)-3-iodo-N-(1-(thiophen-2-yl)ethyl)-1H-indazole-5-carboxamide (70
mg, 0.18 mmol), (4-((1-methylpiperidin-4-yl)oxy)phenyl)boronic acid
pinacol ester (56 mg, 0.18 mmol), PdCl.sub.2dppf (15 mg, 0.018
mmol), satd. aq Na.sub.2CO.sub.3 (1.5 mL), and 3.5 mL of PhMe:EtOH
(1:1). The vial was charged with Ar and heated in the microwave
reactor at 125.degree. C. for 2 h. Purification by RP HPLC,
followed by trituration with Et.sub.2O gave the title compound as a
TFA salt (white solid, 44 mg, 43%). .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. ppm 8.57 (s, 1H), 7.89-7.99 (m, 3H), 7.60 (d,
J=8.8 Hz, 1H), 7.27 (d, J=4.8 Hz, 1H), 7.11-7.22 (m, 2H), 7.05 (br.
s, 1H), 6.96 (t, J=4.3 Hz, 1H), 5.59 (s, 1H), 4.58-4.72 (m, 0.3H),
3.60-3.69 (m, 0.7H), 3.33-3.47 (m, 3H), 3.14-3.24 (m, 1H), 2.93 (s,
3H), 2.39-2.48 (m, 0.7H), 2.23-2.35 (m, 1.3H), 2.12 (br. s, 1.3H),
1.83-1.98 (m, 0.7H), 1.70 (d, J=6.8 Hz, 3H); MS ESI 461.3
[M+H].sup.+, calcd for [C.sub.26H.sub.28N.sub.4O.sub.2S+H].sup.+
461.2.
Example A56
1-(2-fluorophenyl)-3-(3-(4-((1-methylpiperidin-4-yl)oxy)phenyl)-1H-indazol-
-5-yl)urea
##STR00200##
[0609] Using Method J with
3-(4-((1-methylpiperidin-4-yl)oxy)phenyl)-1H-indazol-5-amine
bis(2,2,2-trifluoroacetate) (96 mg, 0.174 mmol),
1-fluoro-2-isocyanatobenzene (39 uL, 0.348 mmol), DIPEA (150 uL,
0.87 mmol), and DMF (2.0 mL) gave the title compound as a TFA salt
(17 mg, 21%, a tan solid). .sup.1H NMR (400 MHz, CD.sub.3OD)
.delta. ppm 8.30 (s, 1H), 8.08 (t, J=7.6 Hz, 1H), 7.91-7.88 (m,
2H), 7.51 (d, J=9.0 Hz, 1H), 7.28 (d, J=8.6 Hz, 1H), 7.20-7.02 (m,
5H), 4.83 (bs, 1H), 3.64-3.41 (m, 2H), 3.30-2.93 (m, 2H), 2.93 (bs,
3H), 2.46-2.28 (m, 2H), 2.13-1.89 (m, 2H); MS ESI 460.3
[M+H].sup.+, calcd for [C.sub.26H.sub.26FN.sub.5O.sub.2+H].sup.+
460.21.
Example A57
N-(3-(3-chloro-4-((1-methylpiperidin-4-yl)oxy)phenyl)-1H-indazol-5-yl)-2-(-
pyrrolidin-1-yl)-2-(thiophen-3-yl)acetamide
##STR00201##
[0611] Using Method C2,
N-(3-iodo-1H-indazol-5-yl)-2-(pyrrolidin-1-yl)-2-(thiophen-3-yl)acetamide
(52.7 mg, 0.116 mmol) and
4-(2-chloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)-1-met-
hylpiperidine (61.8 mg, 80% pure, 0.14 mmol) were heated for 3 h at
125.degree. C. in the microwave. Aq. work-up using EtOAc followed
by purification by flash chromatography (RP HPLC, 10-80% MeOH in
0.1% TFA-H.sub.2O; then SiO2, 10-20% MeOH in DCM), gave the title
compound (white solid, 15.4 mg, 24%). .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. ppm 8.34 (m, J=1.0 Hz, 1H), 7.92 (d, J=2.3 Hz,
1H), 7.79 (dd, J=8.5, 2.3 Hz, 1H), 7.49-7.56 (m, 3H), 7.42 (dd,
J=5.0, 3.0 Hz, 1H), 7.34 (dd, J=5.0, 1.3 Hz, 1H), 7.22 (d, J=8.5
Hz, 1H), 4.60 (br. s., 1H), 4.14 (s, 1H), 2.75-2.84 (m, 2H),
2.64-2.73 (m, 2H), 2.47-2.57 (m, 4H), 2.37 (s, 3H), 2.00-2.10 (m,
2H), 1.89-1.99 (m, 2H), 1.85 (t, J=5.8 Hz, 4H). MS ESI 550.1
[M+H].sup.+, calcd for [C.sub.29H.sub.32ClN.sub.5O.sub.2S+H].sup.+
550.20.
Example A58
(R)-3-(4-morpholinophenyl)-N-(1-(thiophen-2-yl)propyl)-1H-indazole-5-carbo-
xamide
##STR00202##
[0613] The title compound was synthesized according to the General
Method A, utilizing 3-(4-morpholinophenyl)-1H-indazole-5-carboxylic
acid (84 mg, 0.26 mmol), (1R)-1-(2-thienyl)propylamine HCl (50 mg,
0.26 mmol), TBTU (83 mg, 0.26 mmol), DIPEA (0.14 mL, 0.78 mmol),
and DMF (5 mL). Purification by RP HPLC, followed by passing
through PoraPak column gave the title compound (white solid, 34 mg,
29%). .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. ppm 8.59 (s, 1H),
7.82-7.95 (m, 3H), 7.57 (d, J=8.8 Hz, 1H), 7.26 (dd, J=5.0, 1.0 Hz,
1H), 7.03-7.11 (m, 3H), 6.95 (dd, J=4.9, 3.6 Hz, 1H), 5.31-5.39 (m,
1H), 3.80-3.87 (m, 4H), 3.16-3.23 (m, 4H), 2.06 (d, J=7.3 Hz, 2H),
1.04 (t, J=7.3 Hz, 3H); MS ESI 447.3 [M+H].sup.+, calcd for
[C.sub.25H.sub.26N.sub.4O.sub.2S+H].sup.+ 447.2.
Example A59
N-(3-(3-methyl-4-morpholinophenyl)-1H-indazol-5-yl)-2-(pyrrolidin-1-yl)-2--
(thiophen-3-yl)acetamide
##STR00203##
[0615] To a mixture of
N-(3-iodo-1H-indazol-5-yl)-2-(pyrrolidin-1-yl)-2-(thiophen-3-yl)acetamide
(136 mg, 0.3 mmol) and (3-methyl-4-morpholinophenyl)boronic acid
(73 mg, 0.33 mmol) in EtOH (4 mL) was added 1 M aq Na.sub.2CO.sub.3
(0.6 mL, 0.6 mmol), followed by Pd(PPh.sub.3).sub.4 (17 mg, 0.015
mmol). The resulting mixture was purged with Ar and microwaved 2 h
at 120.degree. C. After removal of solvents, it was redissolved in
DMF/TFA (6 mL/0.5 mL), purified by prep-HPLC, followed by PoraPak
and acification with TFA to give the title compound as a di-TFA
salt (white solid, 162.4 mg, 74%). .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. 8.38 (s, 1H), 7.87 (d, J=1.6 Hz, 1H), 7.81-7.76
(m, 2H), 7.61-7.52 (m, 3H), 7.42 (d, J=8.0 Hz, 1H), 7.38 (dd, J=5.2
Hz, 0.8 Hz, 1H), 5.35 (s, 1H), 4.02-3.96 (m, 4H), 3.90-3.80 (m,
1H), 3.35-3.25 (m, 5H), 3.20-3.04 (m, 2H), 2.48 (s, 3H), 2.25-1.93
(m, 4H); MS ESI 502.2 [M+H].sup.+, calcd for
[C.sub.28H.sub.31N.sub.5O.sub.2S+H].sup.+502.2.
Example A60
N-(3-(3-fluoro-4-morpholinophenyl)-1H-indazol-5-yl)-2-(pyrrolidin-1-yl)-2--
(thiophen-3-yl)acetamide
##STR00204##
[0617] To a mixture of
N-(3-iodo-1H-indazol-5-yl)-2-(pyrrolidin-1-yl)-2-(thiophen-3-yl)acetamide
(136 mg, 0.3 mmol) and (3-fluoro-4-morpholinophenyl)boronic acid
(74 mg, 0.33 mmol) in EtOH (4 mL) was added 1 M aq Na.sub.2CO.sub.3
(0.6 mL, 0.6 mmol), followed by Pd(PPh.sub.3).sub.4 (17 mg, 0.015
mmol). The resulting mixture was purged with Ar and microwaved 2 h
at 120.degree. C. After removal of solvents, it was redissolved in
DMF/TFA (6 mL/0.5 mL), purified by prep-HPLC to give the title
compound as a di-TFA salt (pale yellow solid, 84.3 mg, 38%).
.sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.40 (s, 1H), 7.87 (dd,
J=2.8 Hz, 1.2 Hz, 1H), 7.65-7.61 (m, 2H), 7.57 (dd, J=13.8 Hz, 1.8
Hz, 1H), 7.52 (s, 2H), 7.38 (dd, J=5.2 Hz, 1.2 Hz, 1H), 7.07 (t,
J=8.6 Hz, 1H), 5.31 (s, 1H), 3.92-3.78 (m, 5H), 3.35-3.25 (m, 1H),
3.22-3.03 (m, 6H), 2.25-1.92 (m, 4H); MS ESI 506.3 [M+H].sup.+,
calcd for [C.sub.27H.sub.28FN.sub.5O.sub.2S+H].sup.+ 506.2.
Example A61
N-(cyclopropyl(phenyl)methyl)-3-(3-morpholinophenyl)-1H-indazole-5-carboxa-
mide
##STR00205##
[0619] The title compound was synthesized according to the General
Method C, utilizing
N-(cyclopropyl(phenyl)methyl)-3-iodo-1H-indazole-5-carboxamide (100
mg, 0.24 mmol), 3-(4-morpholino)phenylboronic acid pinacol ester
(69 mg, 0.24 mmol), Pd(PPh.sub.3).sub.4 (28 mg, 0.024 mmol), satd.
aq Na.sub.2CO.sub.3 (1.25 mL), and 3.75 mL of PhMe:EtOH (1:1). The
vial was charged with Ar and heated in the microwave reactor at
125.degree. C. for 2 h. Purification by RPHPLC, followed by
trituration with Et.sub.2O gave the title compound as beige solid
(39 mg, 36%). .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. ppm 8.58
(s, 1H), 7.94 (dd, J=8.7, 1.4 Hz, 1H), 7.62 (d, J=8.8 Hz, 1H),
7.40-7.55 (m, 5H), 7.34 (t, J=7.6 Hz, 2H), 7.24 (t, J=7.3 Hz, 1H),
7.05-7.10 (m, 1H), 4.48 (t, J=8.5 Hz, 1H), 3.84-3.89 (m, 4H),
3.22-3.27 (m, 4H), 1.33-1.44 (m, 1H), 0.62-0.69 (m, 2H), 0.41-0.54
(m, 2H); MS ESI 453.4 [M+H].sup.+, calcd for
[C.sub.28H.sub.28N.sub.4O.sub.2+H].sup.+ 453.2.
Example A62
1-(2-chlorophenyl)-3-(3-(4-((1-methylpiperidin-4-yl)oxy)phenyl)-1H-indazol-
-5-yl)urea
##STR00206##
[0621] Using Method J,
3-(4-((1-methylpiperidin-4-yl)oxy)phenyl)-1H-indazol-5-amine
bis(2,2,2-trifluoroacetate) (111 mg, 0.202 mmol),
1-chloro-2-isocyanatobenzene (49 uL, 0.404 mmol) and DIPEA (180 uL,
1.01 mmol) in DMF (2.0 mL) gave the title compound as a TFA salt.
(34 mg, 35%, an off-white solid). .sup.1H NMR (400 MHz, CD.sub.3OD)
.delta. ppm 8.33 (s, 1H), 8.11 (d, J=7.3 Hz, 1H), 7.92-7.88 (m,
2H), 7.52 (d, J=8.8 Hz, 1H), 7.41 (d, J=8.4 Hz, 1H), 7.31-7.26 (m,
2H), 7.21-7.13 (m, 2H), 7.04 (t, J=7.9, 1H), 4.83 (bs, 1H),
3.66-3.39 (m, 2H), 3.30-3.18 (m, 2H), 2.95 (bs, 3H), 2.48-2.30 (m,
2H), 2.14-1.89 (m, 2H); MS ESI 476.4 [M+H].sup.+, calcd for
[C.sub.26H.sub.26ClN.sub.5O.sub.2+H].sup.+ 476.19.
Example A63
(R)-3-(4-((1-methylpiperidin-4-yl)oxy)phenyl)-N-(1-(thiophen-2-yl)propyl)--
1H-indazole-5-carboxamide
##STR00207##
[0623] The title compound was synthesized according to the General
Method C, utilizing
(R)-3-iodo-N-(1-(thiophen-2-yl)propyl)-1H-indazole-5-carboxamide
(90 mg, 0.22 mmol), (4-((1-methylpiperidin-4-yl)oxy)phenyl)boronic
acid pinacol ester (69 mg, 0.22 mmol), PdCl.sub.2dppf (25 mg, 0.022
mmol), satd. Na.sub.2CO.sub.3 (1.25 mL), and 3.75 mL of PhMe:EtOH
(1:1). The vial was charged with Ar and heated in the microwave
reactor at 125.degree. C. for 2 h. Purification by RPHPLC, followed
by flash chromatography (SiO.sub.2, Biotage 25 g, 0-40% MeOH in
CH.sub.2Cl.sub.2) gave the title compound (white solid, 18 mg,
17%). .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. ppm 8.58 (s, 1H),
7.93 (dd, J=8.8, 1.5 Hz, 1H), 7.88 (d, J=8.8 Hz, 2H), 7.58 (d,
J=8.8 Hz, 1H), 7.25 (dd, J=5.0, 1.0 Hz, 1H), 7.05 (s, 3H), 6.94
(dd, J=5.0, 3.5 Hz, 1H), 5.34 (t, J=7.5 Hz, 1H), 4.45 (br. s, 1H),
2.71 (br. s, 2H), 2.36 (br. s, 2H), 2.29 (s, 3H), 1.95-2.12 (m,
4H), 1.82 (br. d, J=7.5 Hz, 2H), 1.03 (t, J=7.3 Hz, 3H); MS ESI
475.3 [M+H].sup.+, calcd for
[C.sub.27H.sub.30N.sub.4O.sub.2S+H].sup.+ 475.2.
Example A64
N-(cyclopropyl(phenyl)methyl)-3-(3-methyl-4-morpholinophenyl)-1H-indazole--
5-carboxamide
##STR00208##
[0625] To a mixture of
N-(cyclopropyl(phenyl)methyl)-3-iodo-1H-indazole-5-carboxamide
(83.4 mg, 0.2 mmol) and (3-methyl-4-morpholinophenyl)boronic acid
(44.2 mg, 0.2 mmol) in EtOH (4 mL) was added 1 M aq
Na.sub.2CO.sub.3 (0.4 mL, 0.4 mmol), followed by
Pd(PPh.sub.3).sub.4 (11.6 mg, 0.01 mmol). The resulting mixture was
purged with Ar and microwaved 2 h at 125.degree. C. After removal
of solvents, it was purified by flash chromatography (MeOH/DCM
0-15%), PoraPak and prep-HPLC to give the title compound as a TFA
salt (light yellow solid, 36.3 mg, 31%). .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. 8.06 (pseudo s, 1H), 7.96 (dd, J=8.8 Hz, 1.6
Hz, 1H), 7.85-7.80 (m, 2H), 7.60 (dd, J=8.8 Hz, 0.8 Hz, 1H), 7.49
(pseudo d, J=7.2 Hz, 2H), 7.36-7.30 (m, 2H), 7.28-7.21 (m, 2H),
4.48 (d, J=9.6 Hz, 1H), 3.90 (t, J=4.4 Hz, 4H), 3.06 (t, J=4.4 Hz,
4H), 2.44 (s, 3H), 1.46-1.36 (m, 1H), 1.20-1.13 (m, 2H), 1.03-0.93
(m, 2H); MS ESI 467.4 [M+H].sup.+, calcd for
[C.sub.29H.sub.30N.sub.4O.sub.2+H].sup.+ 467.2.
Example A65
N-(cyclopropyl(phenyl)methyl)-3-(3-fluoro-4-morpholinophenyl)-1H-indazole--
5-carboxamide
##STR00209##
[0627] To a mixture of
N-(cyclopropyl(phenyl)methyl)-3-iodo-1H-indazole-5-carboxamide
(83.4 mg, 0.2 mmol) and (3-fluoro-4-morpholinophenyl)boronic acid
(45 mg, 0.2 mmol) in EtOH (4 mL) was added 1 M aq Na.sub.2CO.sub.3
(0.4 mL, 0.4 mmol), followed by Pd(PPh.sub.3).sub.4 (11.6 mg, 0.01
mmol). The resulting mixture was purged with Ar and microwaved 2 h
at 125.degree. C. After removal of solvents, it was purified by
flash chromatography (MeOH/DCM 0-15%), PoraPak and prep-HPLC to
give the title compound as a TFA salt (yellowish white solid, 32.4
mg, 28%). .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.62 (pseudo s,
1H), 7.96 (dd, J=8.8 Hz, 1.6 Hz, 1H), 7.88 (psedo d, J=8.4 Hz, 1H),
7.73 (dd, J=14.0 Hz, 2.0 Hz, 1H), 7.61 (d, J=8.8 Hz, 1H), 7.49 (d,
J=7.6 Hz, 2H), 7.34 (t, J=7.6 Hz, 2H), 7.24 (t, J=7.4 Hz, 1H),
7.20-7.13 (m, 1H), 4.49 (d, J=9.2 Hz, 1H), 3.87 (t, J=4.6 Hz, 4H),
3.17-3.11 (m, 4H), 1.46-1.38 (m, 1H), 1.21-1.13 (m, 2H), 1.05-0.93
(m, 2H); MS ESI 471.4 [M+H].sup.+, calcd for
[C.sub.28H.sub.27FN.sub.4O.sub.2+H].sup.+ 471.2.
Example A66
1-(2-chlorophenyl)-3-(3-(4-morpholinophenyl)-1H-indazol-5-yl)urea
##STR00210##
[0629] Using Method J, 3-(4-morpholinophenyl)-1H-indazol-5-amine
bis(2,2,2-trifluoroacetate) (69 mg, 0.234 mmol),
1-chloro-2-isocyanatobenzene (58 uL, 0.468 mmol) and DIPEA (160 uL,
0.936 mmol) in DMF (2.0 mL) gave the title compound as a TFA salt
(7.6 mg, 7.2%, a white solid). .sup.1H NMR (400 MHz, DMSO-d6)
.delta. ppm 12.96 (s, 1H), 9.46-9.48 (m, 1H), 8.28 (s, 2H), 8.20
(dd, J=8.28, 1.51 Hz, 1H), 7.79 (d, J=8.78 Hz, 2H), 7.49 (dd,
J=17.44, 8.41 Hz, 1H), 7.28-7.33 (m, 2H), 7.10 (d, J=8.78 Hz, 2H),
7.00-7.05 (m, 1H), 3.75-3.79 (m, 4H), 3.17-3.21 (m, 4H); MS ESI
448.4 [M+H].sup.+, calcd for
[C.sub.24H.sub.22ClN.sub.5O.sub.2+H].sup.+ 448.15.
Example A67
N-(3-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-indazol-5-yl)-2-(pyrrol-
idin-1-yl)-2-(thiophen-3-yl)acetamide
##STR00211##
[0631] The title compound was synthesized according to general
Method C by using a sealed degassed mixture of
N-(3-iodo-1H-indazol-5-yl)-2-(pyrrolidin-1-yl)-2-(thiophen-3-yl)acetamide
(75 mg, 0.165 mmol),
1-methyl-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)piperaz-
ine (53 mg, 0.165 mmol), PdCl.sub.2dppf (14 mg, 0.0165 mmol), 1 M
aq Na.sub.2CO.sub.3 (0.17 mL) in PhMe/EtOH (3 mL, 1:0.5 mixture)
under Ar with heateding under microwave irradiation at 125.degree.
C. for 2.5 h. The reaction mixture was diluted with EtOAc (15 mL)
and washed with H.sub.2O (2.times.5 mL) and brine (5 mL), dried
(Na.sub.2SO.sub.4) and concentrated under vacuum. Purification by
flash chromatography (SiO2, 0-80% MeOH in DCM) followed by RPHPLC
gave the title compound as a TFA salt (light brown solid, 22 mg,
9%). .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.41 (s, 1H), 8.01
(d, J=8.0 Hz, 2H), 7.88-7.87 (m, 1H), 7.66-7.62 (m, 3H), 7.58-7.51
(m, 2H), 7.38-7.37 (m, 1H), 5.26 (s, 1H), 4.20 (s, 2H), 3.88-3.87
(br.s, 1H), 3.51 (br.s, 4H), 3.13-3.10 (br.m, 3H), 2.96 (s, 3H),
2.25-1.96 (br.m, 5H), 3H merged with solvent peak, MS ESI 515.2
[M+H].sup.+, calcd for [C.sub.29H.sub.34N6OS+H].sup.+ 515.2.
Example A68
N-(3-(4-(cyclohexylamino)phenyl)-1H-indazol-5-yl)-2-(pyrrolidin-1-yl)-2-(t-
hiophen-3-yl)acetamide
##STR00212##
[0633] To a mixture of
4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (657 mg, 3
mmol) and cyclohexanone (0.31 mL, 3 mmol) in DCE (30 mL) was added
NaBH(OAc).sub.3 (1.272 g, 6 mmol). The resulting mixture was cooled
to 0.degree. C. before HOAc (0.5 mL) was added. After stirring O/N
at rt, it was quenched with satd aqNaHCO.sub.3 (5 mL) and H.sub.2O
(30 mL), extracted with DCM and purified by flash chromatography
(EtOAc/hex 0-45%) to give
N-cyclohexyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)anili-
ne (off white solid, 705 mg, 78%). .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 7.62 (d, J=7.6 Hz, 2H), 6.56 (d, J=7.2 Hz, 2H),
3.35-3.25 (m, 1H), 2.12-2.02 (m, 2H), 1.72-1.62 (m, 2H), 4.45-1.10
(m, 18H); MS ESI 302.1 [M+H].sup.+, calcd for
[C.sub.18H.sub.28BNO.sub.2+H].sup.+ 302.1.
[0634] To a mixture of
N-(3-iodo-1H-indazol-5-yl)-2-(pyrrolidin-1-yl)-2-(thiophen-3-yl)acetamide
(136 mg, 0.3 mmol) and
N-cyclohexyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline
in EtOH (4 mL) was added 1 M aq Na2CO3 (0.6 mL, 0.6 mmol), followed
by Pd(PPh.sub.3).sub.4 (17.4 mg, 0.015 mmol). The resulting mixture
was purged with Ar and microwaved 2 h at 120.degree. C. Additional
Pd(PPh.sub.3).sub.4 (17.4 mg, 0.015 mmol) was added and the
resulting mixture was purged with Ar and microwaved 2 h at
125.degree. C. After removal of solvents, it was redissolved in
DMF/TFA (6 mL/0.5 mL), purified by prep-HPLC and PoraPak to give
the title compound (white solid, 52.3 mg, 35%). .sup.1H NMR (400
MHz, CD.sub.3OD) .delta. 8.33 (s, 1H), 7.65 (pseudo d, J=8.8 Hz,
2H), 7.51-7.43 (m, 3H), 7.38 (dd, J=9.0 Hz, 3.0 Hz, 1H), 7.30 (dd,
J=5.2 Hz, 1.2 Hz, 1H), 6.72 (pseudo d, J=8.8 Hz, 2H), 4.08 (s, 1H),
3.29-3.21 (m, 1H), 2.68-2.58 (m, 2H), 2.50-2.42 (m, 2H), 2.07-1.98
(m, 2H), 1.85-1.72 (m, 6H), 1.68-1.62 (m, 1H), 1.45-1.32 (m, 2H),
1.30-1.12 (m, 3H); MS ESI 500.2 [M+H].sup.+, calcd for
[C.sub.29H.sub.33N.sub.5OS+H].sup.+ 500.2.
Example A69
N-(1-cyclohexylpropyl)-3-(4-((1-methylpiperidin-4-yl)oxy)phenyl)-1H-indazo-
le-5-carboxamide
##STR00213##
[0636] The title compound was synthesized according to Method C3
utilizing N-(1-cyclohexylpropyl)-3-iodo-1H-indazole-5-carboxamide
and
1-methyl-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)piperi-
dine and obtained as a yellow solid (20 mg, 18% yield). .sup.1H NMR
(400 MHz, CD.sub.3OD) .delta. ppm 8.57 (s, 1H), 7.92 (m, 3H), 7.60
(d, J=8.8 Hz, 1H), 7.08 (d, J=8.8 Hz, 2H), 4.47 (m, 1H), 3.87 (m,
1H), 2.72 (br, 2H), 2.37 (br, 2H), 2.30 (s, 3H), 2.05 (br, 2H),
1.83 (m, 3H), 1.74 (m, 3H), 1.65 (m, 1H), 1.51 (m, 2H), 1.22 (m,
4H), 1.08 (m, 2H), 0.95 (t, J=7.2 Hz, 3H); MS ESI [M+H].sup.+
475.4, calcd for [C.sub.29H.sub.38N.sub.4O.sub.2+H].sup.+
475.31.
Example A70
N-(3-(4-(cyclopentylamino)phenyl)-1H-indazol-5-yl)-2-(pyrrolidin-1-yl)-2-(-
thiophen-3-yl)acetamide
##STR00214##
[0638] To a mixture of
4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (876 mg, 4
mmol) and cyclopentanone (0.36 mL, 4 mmol) in DCE (30 mL) was added
NaBH(OAc).sub.3 (1.484 g, 7 mmol), followed by HOAc (0.5 mL). The
resulting mixture was stirred O/N at rt, quenched with satd
aqNaHCO.sub.3 (10 mL) and H.sub.2O (30 mL), extracted with DCM and
purified by flash chromatography (EtOAc/hex 0-45%) to give
N-cyclopentyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline
(off white solid, 393 mg, 34%). .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 7.63 (d, J=8.0 Hz, 2H), 6.58 (d, J=8.0 Hzz, 2H), 3.82
(quint, J=6.2 Hz, 1H), 2.08-1.98 (m, 1H), 1.78-1.56 (m, 4H),
1.52-1.43 (m, 2H), 1.33 (s, 12H); MS ESI 288.1 [M+H].sup.+, calcd
for [C.sub.17H.sub.26BNO.sub.2+H].sup.+ 288.2.
[0639] To a mixture of
N-(3-iodo-1H-indazol-5-yl)-2-(pyrrolidin-1-yl)-2-(thiophen-3-yl)acetamide
(136 mg, 0.3 mmol) and
N-cyclopentyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline
(96 mg, 0.33 mmol) in EtOH (4 mL) was added 1 M aq Na.sub.2CO.sub.3
(0.6 mL, 0.6 mmol), followed by Pd(PPh.sub.3).sub.4 (35 mg, 0.03
mmol). The resulting mixture was purged with Ar and microwaved 3 h
at 125.degree. C. After removal of solvents, it was purified by
flash chromatography, PoraPak and prep-HPLC to give the title
compound as a di-TFA salt (yellow solid, 51.9 mg, 24%). .sup.1H NMR
(400 MHz, CD.sub.3OD) .delta. 8.43 (pseudo s, 1H), 8.08 (pseudo d,
J=8.8 Hz, 2H), 7.87 (dd, J=3.0 Hz, 1.4 Hz, 1H), 7.64 (dd, J=5.0 Hz,
3.0 Hz, 1H), 7.60-7.52 (m, 4H), 7.39 (dd, J=5.2 Hz, 1.2 Hz, 1H),
5.33 (s, 1H), 4.02 (quint, J=6.7 Hz, 1H), 3.86 (brs, 1H), 3.35-3.05
(m, 3H), 2.30-1.95 (m, 6H), 1.93-1.67 (m, 6H); MS ESI 486.2
[M+H].sup.+, calcd for [C.sub.28H.sub.31N.sub.5OS+H].sup.+
486.2.
Example A71
2-(pyrrolidin-1-yl)-N-(3-(4-((tetrahydro-2H-pyran-4-yl)amino)phenyl)-1H-in-
dazol-5-yl)-2-(thiophen-3-yl)acetamide
##STR00215##
[0641] To a mixture of
4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (1.095 mg, 5
mmol), dihydro-2H-pyran-4(3H)-one (550 mg, 5 mmol) and
NaBH(OAc).sub.3 (1.696 g, 8 mmol) in DCE (30 mL) was added HOAc
(0.5 mL). The resulting mixture was stirred O/N at rt, quenched
with satd aq NaHCO.sub.3 (10 mL) and H.sub.2O (30 mL), extracted
with DCM and purified by flash chromatography (EtOAc/hex 0-45%) to
give
N-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)tetrahydro-2H-py-
ran-4-amine (beige solid, 0.65 g, 43%). .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 7.64 (d, J=8.0 Hz, 2H), 6.60 (d, J=8.0 Hz, 2H),
4.01 (dt, J=12.0 Hz, 3.2 Hz, 2H), 3.60-3.45 (m, 3H), 2.08-2.00 (m,
2H), 1.60-1.44 (m, 2H), 1.33 (s, 12H); MS ESI 304.1 [M+H].sup.+,
calcd for [C.sub.17H.sub.26BNO.sub.3+H].sup.+ 304.2.
[0642] To a mixture of
N-(3-iodo-1H-indazol-5-yl)-2-(pyrrolidin-1-yl)-2-(thiophen-3-yl)acetamide
(136 mg, 0.3 mmol) and
N-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)tetrahydro-2H-py-
ran-4-amine (100 mg, 0.33 mmol) in EtOH (4 mL) was added 1 M aq
Na2CO3 (0.6 mL, 0.6 mmol), followed by Pd(PPh.sub.3).sub.4 (34.7
mg, 0.03 mmol). The resulting mixture was purged with Ar and
microwaved 3 h at 125.degree. C. After removal of solvents, it was
purified by flash chromatography (MeOH/DCM 0-20%), PoraPak and
prep-HPLC to give the title compound as a di-TFA salt (yellow
solid, 21.9 mg, 10%). .sup.1H NMR (400 MHz, CD.sub.3OD) .delta.
8.42 (t, J=0.8 Hz, 1H), 8.03 (d, J=8.8 Hz, 2H), 7.88 (dd, J=3.2 Hz,
1.2 Hz, 1H), 7.65 (dd, J=5.2 Hz, 3.2 Hz, 1H), 7.57 (dd, J=8.8 Hz,
0.4 Hz, 1H), 7.54 (dd, J=8.4 Hz, 1.6 Hz, 1H), 7.43 (d, J=8.8 Hz,
2H), 7.38 (dd, J=8.8 Hz, 1.4 Hz, 1H), 5.23 (s, 1H), 4.08-4.00 (m,
2H), 3.93-3.72 (m, 2H), 3.48 (dt, J=11.8 Hz, 1.8 Hz, 2H), 3.35-3.05
(m, 3H), 2.28-2.09 (m, 3H), 2.06-1.95 (m, 3H), 1.80-1.69 (m, 2H);
MS ESI 502.2 [M+H].sup.+, calcd for
[C.sub.28H.sub.31N.sub.5O.sub.2S+H].sup.+ 502.2.
Example A72
1-ethyl-3-(3-(4-morpholinophenyl)-1H-indazol-5-yl)-1-phenylurea
##STR00216##
[0643] A.
3-(4-morpholinophenyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-5-
-amine
[0644] The same procedure was followed as for
3-(4-((1-methylpiperidin-4-yl)oxy)phenyl)-1H-indazol-5-amine
bis(2,2,2-trifluoroacetate) instead using
3-iodo-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-5-amine (30 mg,
0.087 mmol) and
4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)morpho-
line (38 mg, 0.131 mmol). Obtained 36 mg of an impure product which
was used for subsequent synthetic steps.
B.
1-ethyl-3-(3-(4-morpholinophenyl)-1H-indazol-5-yl)-1-phenylurea
[0645] To a solution of triphosgene (8 mg, 0.027 mmol) in
CH.sub.2Cl.sub.2 (0.4 mL) cooled to 0.degree. C. was added dropwise
over 15 min a solution of
3-(4-morpholinophenyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-5-amine
(30 mg, 0.074 mmol) in DIPEA (28 uL, 0.16 mmol) and
CH.sub.2Cl.sub.2 (0.6 mL). After stirring for an additional 15 min
a solution of N-ethylaniline (10 uL, 0.074 mmol), DIPEA (13 uL,
0.074 mmol) and CH.sub.2Cl.sub.2 (0.5 mL) was added. After 3 h the
reaction was quenched with MeOH (0.5 mL) and the solvent was
removed. The residue was taken up in EtOH (0.4 mL) and HCl (0.1 mL
of a 1 M solution in Et.sub.2O) was added and the mixture heated to
50.degree. C. for 2 h. The solvent was removed and the residue
purified by prep-HPLC which gave 5.0 mg of the product isolated as
its TFA salt (29%, a tan solid). .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. ppm 8.03 (s, 1H), 7.84 (d, J=8.0 Hz, 2H), 7.51-7.17 (m,
6H), 7.02 (d, J=7.6 Hz, 2H), 6.14 (s, 1H), 3.92-3.82 (m, 6H), 3.24
(bs, 4H), 1.18 (bs, 3H); MS ESI 442.3 [M+H].sup.+, calcd for
[C.sub.26H.sub.27N.sub.5O.sub.2+H].sup.+ 442.22.
Example A73
N-(3-(4-((1-methylpiperidin-4-yl)oxy)phenyl)-1H-indazol-5-yl)-3,4-dihydroq-
uinoline-1(2H)-carboxamide
##STR00217##
[0646] A.
3-(4-((1-methylpiperidin-4-yl)oxy)phenyl)-1-(tetrahydro-2H-pyran-
-2-yl)-1H-indazol-5-amine
[0647] The same procedure was followed as for
3-(4-((1-methylpiperidin-4-yl)oxy)phenyl)-1H-indazol-5-amine
bis(2,2,2-trifluoroacetate) instead using
3-iodo-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-5-amine (300 mg,
0.874 mmol) and
1-methyl-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phen-
oxy)piperidine (416 mg, 1.31 mmol). Obtained 130 mg of an impure
product which was used for subsequent synthetic steps; MS ESI 407.1
[M+H].sup.+, calcd for [C.sub.24H.sub.30N.sub.4O.sub.2+H].sup.+
407.24.
B.
N-(3-(4-((1-methylpiperidin-4-yl)oxy)phenyl)-1H-indazol-5-yl)-3,4-dihyd-
roquinoline-1(2H)-carboxamide
[0648] To a solution of triphosgene (14 mg, 0.046 mmol) in
CH.sub.2Cl.sub.2 (0.6 mL) cooled to 0.degree. C. was added dropwise
over 15 min a solution of
3-(4-((1-methylpiperidin-4-yl)oxy)phenyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-
-indazol-5-amine (50 mg, 0.123 mmol) in DIPEA (47 uL, 0.271 mmol)
and CH.sub.2Cl.sub.2 (0.9 mL). After stirring for an additional 15
min a solution of 1,2,3,4-tetrahydroquinoline (15 uL, 0.123 mmol),
DIPEA (21 uL, 0.123 mmol) and CH.sub.2Cl.sub.2 (0.8 mL) was added.
After 3 h the reaction was quenched with MeOH (0.5 mL) and the
solvent was removed. The residue was taken up in EtOH (0.4 mL) and
HCl (0.1 mL of a 1 M solution in Et.sub.2O) was added and the
mixture heated to 50.degree. C. for 2 h. The solvent was removed
and the residue purified by prep-HPLC which gave the product as its
TFA salt (2.0 mg, 3.3%, a white film). .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. ppm 8.14 (s, 1H), 7.90-7.86 (m, 2H), 7.49 (d,
J=9.0 Hz, 1H), 7.43-7.36 (m, 2H), 7.21-7.11 (m, 4H), 7.05 (t, J=8.5
Hz, 1H), 4.83 (bs, 1H), 3.82-3.79 (m, 2H), 3.65-3.35 (m, 2H),
3.30-3.18 (m, 2H), 2.93 (bs, 3H), 2.82 (t, J=6.4 Hz, 2H), 2.45-2.28
(m, 2H), 2.14-1.88 (m, 4H); MS ESI 482.3 [M+H].sup.+, calcd for
[C.sub.29H.sub.31N.sub.5O.sub.2+H].sup.+ 482.26.
Example A74
N-(2-methyl-2-morpholinopropyl)-3-(4-((1-methylpiperidin-4-yl)oxy)phenyl)--
1H-indazole-5-carboxamide
##STR00218##
[0650] A TFA salt of the title compound was synthesized according
to Method C3 utilizing
3-iodo-N-(2-methyl-2-morpholinopropyl)-1H-indazole-5-carboxamide
and
1-methyl-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)piperi-
dine obtained as a white solid (38 mg, 35% yield). .sup.1H NMR (400
MHz, CD.sub.3OD) .delta. ppm 8.66 (s, 1H), 7.98 (m, 3H), 7.65 (d,
J=8.8 Hz, 1H), 7.20 (m, 2H), 4.96, 4.86 (s, m, 1H), 4.13 (m, 2H),
3.86 (m, 2H), 3.70 (m, 4H), 3.60 (m, 1H), 3.33 (m, 4H), 2.93 (s,
3H), 2.42, 2.28 (m, 2H), 2.17, 1.95 (m, 2H), 1.48 (s, 6H); MS ESI
[M+H].sup.+ 492.2, calcd for
[C.sub.28H.sub.37N.sub.5O.sub.3+H].sup.+ 492.30.
Example A75
3-(4-((1-methylpiperidin-4-yl)oxy)phenyl)-N-(2-morpholino-2-(thiophen-3-yl-
)ethyl)-1H-indazole-5-carboxamide
##STR00219##
[0652] The title compound was synthesized according to Method C3
utilizing
3-iodo-N-(2-morpholino-2-(thiophen-3-yl)ethyl)-1H-indazole-5-carboxamide
and
1-methyl-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)pi-
peridine and obtained as a white solid (19 mg, 15% yield). .sup.1H
NMR (400 MHz, CD.sub.3OD) .delta. ppm 8.35 (s, 1H), 7.87 (d, J=8.78
Hz, 2H), 7.80 (dd, J=8.78, 1.51 Hz, 1H), 7.57 (d, J=8.78 Hz, 1H),
7.43 (dd, J=4.89, 2.89 Hz, 1H), 7.27-7.32 (m, 1H), 7.06-7.15 (m,
3H), 4.52 (br. s., 1H), 3.93-4.04 (m, 2H), 3.63-3.74 (m, 5H), 2.78
(br. s., 2H), 2.39-2.62 (m, 6H), 2.35 (s, 3H), 2.07 (br. s., 2H),
1.89 (br. s., 2H); MS ESI [M+H].sup.+ 546.3, calcd for
[C.sub.30H.sub.35N.sub.5O.sub.3S+H].sup.+ 546.25.
Example A76
1-(2,6-dichlorophenyl)-3-(3-(4-((1-methylpiperidin-4-yl)oxy)phenyl)-1H-ind-
azol-5-yl)urea
##STR00220##
[0654] Using Method J,
3-(4-((1-methylpiperidin-4-yl)oxy)phenyl)-1H-indazol-5-amine
bis(2,2,2-trifluoroacetate) (50 mg, 0.11 mmol),
1,3-dichloro-2-isocyanatobenzene (43 mg, 0.23 mmol) and DIPEA (100
uL, 0.58 mmol) in DMF (1.2 mL) gave the title compound as a TFA
salt (10 mg, 14%, a brown powder). .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. ppm 8.25 (s, 1H), 7.89-7.86 (m, 2H), 7.52-7.41
(m, 3H), 7.34-7.25 (m, 2H), 7.17-7.10 (m, 2H), 4.84 (bs, 1H),
3.63-3.36 (m, 2H), 3.30-3.15 (m, 2H), 2.92 (bs, 3H), 2.43-2.26 (m,
2H), 2.11-1.87 (m, 2H); MS ESI 510.3 [M+H].sup.+, calcd for
[C.sub.26H.sub.25Cl.sub.2N.sub.5O.sub.2+H].sup.+ 510.15.
Example A77
1-(2-chloro-4,6-dimethylphenyl)-3-(3-(4-((1-methylpiperidin-4-yl)oxy)pheny-
l)-1H-indazol-5-yl)urea
##STR00221##
[0656] Using Method J,
3-(4-((1-methylpiperidin-4-yl)oxy)phenyl)-1H-indazol-5-amine
bis(2,2,2-trifluoroacetate) (50 mg, 0.11 mmol),
1-chloro-2-isocyanato-3,5-dimethylbenzene (42 mg, 0.23 mmol) and
DIPEA (100 uL, 0.58 mmol) in DMF (1.2 mL) gave the title compound
as a TFA salt (16 mg, 23%, a brown powder). .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. ppm 8.24 (s, 1H), 7.88-7.84 (m, 2H), 7.49 (d,
J=8.9 Hz, 1H), 7.31 (d, J=8.9 Hz, 1H), 7.17-7.09 (m, 3H), 7.05 (s,
1H), 4.83 (bs, 1H), 3.63-3.33 (m, 2H), 3.30-3.15 (m, 2H), 2.92 (bs,
3H), 2.45-2.23 (m, 2H), 2.37 (s, 3H), 2.36 (s, 3H), 2.12-1.87 (m,
2H); MS ESI 504.3 [M+H].sup.+, calcd for
[C.sub.28H.sub.30ClN.sub.5O.sub.2+H].sup.+ 504.22.
Example A78
N-(3-(4-(methyl(tetrahydro-2H-pyran-4-yl)amino)phenyl)-1H-indazol-5-yl)-2--
(pyrrolidin-1-yl)-2-(thiophen-3-yl)acetamide
##STR00222##
[0658] To a solution of 37% formalin (0.21 mL, 3 mmol) in DCE/MeOH
(20 mL/4 mL) was added
N-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)tetrahydro-2H-py-
ran-4-amine (303 mg, 1 mmol) and NaBH(OAc).sub.3 (424 mg, 2 mmol).
Additional 37% formalin (37% in H.sub.2O, 0.21 mL, 3 mmol) and
NaBH(OAc).sub.3 (424 mg, 2 mmol) were added and the reaction
mixture was stirred for 2 h at rt, and then quenched with satd aq
NaHCO3 (10 mL) and H.sub.2O (30 mL), extracted with DCM and
purified by flash chromatography (0-45% MeOH/DCM) to give
N-methyl-N-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)tetrahy-
dro-2H-pyran-4-amine (pink solid, 224 mg). .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. MS ESI 318.1 [M+H].sup.+, calcd for
[C.sub.18H.sub.28BNO.sub.3+H].sup.+ 318.2.
[0659] To a mixture of
N-(3-iodo-1H-indazol-5-yl)-2-(pyrrolidin-1-yl)-2-(thiophen-3-yl)acetamide
(136 mg, 0.3 mmol) and
N-methyl-N-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)tetrahy-
dro-2H-pyran-4-amine (100 mg, 0.315 mmol) in EtOH (4 mL) was added
1 M aq Na.sub.2CO.sub.3 (0.6 mL, 0.6 mmol), followed by
Pd(PPh.sub.3).sub.4 (69 mg, 0.06 mmol). The resulting mixture was
purged with Ar and microwaved 3 h at 125.degree. C. After removal
of solvents, it was purified by flash chromatography (0-20%
MeOH/DCM), prep-HPLC and PoraPak to give the title compound (white
solid, 44.8 mg, 29%). .sup.1H NMR (400 MHz, CD.sub.3OD) .delta.
8.38 (s, 1H), 7.72 (d, J=8.8 Hz, 2H), 7.51-7.43 (m, 3H), 7.34 (dd,
J=5.0 Hz, 3.0 Hz, 1H), 7.29 (dd, J=5.2 Hz, 0.8 Hz, 1H), 6.87 (d,
J=8.8 Hz, 2H), 4.07 (s, 1H), 3.95 (dd, J=11.4 Hz, 4.2 Hz, 2H), 3.84
(tt, J=11.6 Hz, 3.8 Hz, 1H), 3.44 (t, J=11.0 Hz, 2H), 2.72 (s, 3H),
2.64-2.56 (m, 2H), 2.47-2.39 (m, 2H), 1.82-1.70 (m, 6H), 1.60-1.53
(m, 2H); MS ESI 516.3 [M+H].sup.+, calcd for
[C.sub.29H.sub.33N.sub.5O.sub.2S+H].sup.+ 516.2.
Example A79
(R)-2-((S)-2-methylpyrrolidin-1-yl)-N-(3-(4-morpholinophenyl)-1H-indazol-5-
-yl)-2-(thiophen-2-yl)acetamide
##STR00223##
[0660] A.
(R)-2-((S)-2-methylpyrrolidin-1-yl)-2-(thiophen-2-yl)acetic
acid
[0661] Using Method D, (S)-2-methylpyrrolidine (0.135 mL, 1.57
mmol) and thiophen-2-ylboronic acid (201.1 mg, 1.57 mmol) gave the
title compound (off-white solid, 330.1 mg, 93%) which was used
without purification. NMR (400 MHz, CD.sub.3OD) .delta. ppm 7.57
(d, J=4.5 Hz, 1H), 7.36 (dd, J=3.5, 1.0 Hz, 1H), 7.10 (dd, J=5.3,
3.5 Hz, 1H), 3.63-3.73 (m, 1H), 3.19-3.28 (m, 1H), 2.24-2.39 (m,
1H), 1.92-2.08 (m, 2H), 1.74-1.85 (m, 1H), 1.50 (d, J=6.53 Hz,
3H).
B.
(R)-2-((S)-2-methylpyrrolidin-1-yl)-N-(3-(4-morpholinophenyl)-1H-indazo-
l-5-yl)-2-(thiophen-2-yl)acetamide
[0662]
(1-Cyano-2-ethoxy-2-oxoethylidenaminooxy)dimethylamino-morpholino-c-
arbenium hexafluorophosphate (35.2 mg, 0.082 mmol) was added to an
ice-cooled mixture of
(R)-2-((S)-2-methylpyrrolidin-1-yl)-2-(thiophen-2-yl)acetic acid
(16.5 mg, 0.073 mmol), 3-(4-morpholinophenyl)-1H-indazol-5-amine
bis(2,2,2-trifluoroacetate) (39.9 mg, 0.076 mmol) and DIPEA (0.05
mL, 0.28 mmol) in DMF (1.0 mL) under Ar. The resulting mixture was
stirred in ice bath for 1 h, then allowed to warm to rt and stirred
for a further 22 h. The product was partitioned between EtOAc (200
mL) and satd aqNaHCO.sub.3 (25 mL), and the aq. layer was extracted
with EtOAc (2.times.25 mL). The combined organic layer was washed
with H.sub.2O (25 mL) and brine (25 mL), dried (Na.sub.2SO.sub.4),
filtered, and concentrated to dryness. Purification by flash
chromatography (SiO2, 0-10% MeOH in DCM; followed by RPRP HPLC,
10-80% MeOH in 0.1% TFA-H.sub.2O) followed by purification by
another prep HPLC gave the title compound as the TFA salt (yellow
solid film, 14.0 mg, 26%). .sup.1H NMR (400 MHz, CD.sub.3OD)
.delta. ppm 8.38 (t, J=1.3 Hz, 1H), 7.85 (d, J=8.3 Hz, 2H), 7.71
(d, J=5.3 Hz, 1H), 7.49-7.59 (m, 3H), 7.20 (m, J=5.0, 3.5 Hz, 3H),
5.50 (s, 1H), 3.90 (t, J=4.8 Hz, 4H), 3.79-3.87 (m, 1H),
.about.3.30 (4H, obscured by solvent), 2.40 (dd, J=13.3, 7.8 Hz,
1H), 2.06 (t, J=7.0 Hz, 2H), 1.86 (dq, J=13.2, 6.5 Hz, 1H), 1.52
(d, J=6.3 Hz, 3H); MS ESI 502.3 [M+H].sup.+, calcd for
[C.sub.28H.sub.31N.sub.5O.sub.2S+H].sup.+ 502.23.
Example A80
N-(3-(3-amino-4-((1-methylpiperidin-4-yl)oxy)phenyl)-1H-indazol-5-yl)-2-(p-
yrrolidin-1-yl)-2-(thiophen-3-yl)acetamide
##STR00224##
[0663] A.
1-methyl-4-(2-nitro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2--
yl)phenoxy)piperidine
[0664] DIAD (0.25 mL, 1.26 mmol) was added drop-wise to a solution
of PPh.sub.3 (315 mg, 1.20 mmol),
2-nitro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenol
(199.8 mg, 0.785 mmol) and 1-methylpiperidin-4-ol (138.3 mg, 1.20
mmol) in DCM (8 mL) under Ar and the reaction was stirred at rt for
3.5 d. Purification by flash chromatography without work-up or
evaporation (SiO2, 5-35% MeOH in DCM) gave the title compound (36.0
mg, 80% pure, 13%). .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. ppm
8.25 (d, J=1.5 Hz, 1H), 7.93 (dd, J=8.3, 1.5 Hz, 1H), 7.63-7.71 (m,
1H), 7.52-7.58 (m, 1H), 7.43-7.50 (m, 1H), 7.06 (d, J=8.5 Hz, 1H),
4.82 (br. s., 1H), 2.87-3.05 (m, 4H), 2.61 (s, 3H), 2.28-2.40 (m,
3H), 2.09 (d, J=13.8 Hz, 2H), 1.32-1.36 (m, 15H). MS ESI 363.1
[M+H].sup.+, calcd for [C.sub.18H.sub.27BN.sub.2O.sub.5+H].sup.+
363.21.
B.
N-(3-(4-((1-methylpiperidin-4-yl)oxy)-3-nitrophenyl)-1H-indazol-5-yl)-2-
-(pyrrolidin-1-yl)-2-(thiophen-3-yl)acetamide
[0665] Using Method C2,
N-(3-iodo-1H-indazol-5-yl)-2-(pyrrolidin-1-yl)-2-(thiophen-3-yl)acetamide
(39.9 mg, 0.088 mmol) and
1-methyl-4-(2-nitro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenox-
y)piperidine (35 mg, 80% pure, 0.077 mmol) gave the title compound
after 3 h at 125.degree. C. in the microwave (34.8 mg, 57%) after
purification by flash chromatography (SiO2, 15-30% MeOH in DCM;
followed by RPRP HPLC, 10-80% MeOH in 0.1% TFA-H.sub.2O). .sup.1H
NMR (400 MHz, CD.sub.3OD) .delta. ppm 8.39-8.46 (m, 1.8H),
8.32-8.37 (m, 0.2H), 8.16-8.25 (m, 1H), 7.86-7.91 (m, 1H),
7.62-7.68 (m, 1H), 7.50-7.61 (m, 4H), 7.34-7.43 (m, 1H), 5.28-5.32
(m, 1H), 5.12-5.18 (m, 1H), 3.80-3.95 (m, 1.2H), 3.64-3.73 (m,
0.8H), 3.46-3.55 (m, 2H), 3.33-3.42 (m, 2H), 3.16-3.28 (m, 1H),
3.03-3.15 (m, 1H), 2.96 (s, 3H), 2.43-2.53 (m, 0.8H), 2.31-2.41 (m,
1.6H), 2.10-2.29 (m, 5H), 1.93-2.08 (m, 1H). MS ESI 561.2
[M+H].sup.+, calcd for [C.sub.29H.sub.32N.sub.6O.sub.4S+H].sup.+
561.23.
C.
N-(3-(3-amino-4-((1-methylpiperidin-4-yl)oxy)phenyl)-1H-indazol-5-yl)-2-
-(pyrrolidin-1-yl)-2-(thiophen-3-yl)acetamide
[0666] A mixture of Pd/C (10%, 18.1 mg, 0.017 mmol) and
N-(3-(4-((1-methylpiperidin-4-yl)oxy)-3-nitrophenyl)-1H-indazol-5-yl)-2-(-
pyrrolidin-1-yl)-2-(thiophen-3-yl)acetamide (34.8 mg, 0.062 mmol)
in MeOH (5 mL) was stirred at rt with H.sub.2 balloon for 2.5 h,
and then filtered through Celite, rinsing with MeOH (25 mL). After
concentration to dryness, purification by RP HPLC (, 10-80% MeOH in
0.1% TFA-H.sub.2O) followed by PoraPak Rxn Cx work-up gave the
title compound (yellow solid, 6.5 mg, 20%). .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. ppm 8.34 (s, 1H), 7.47-7.52 (m, 3H), 7.42 (dd,
J=4.9, 2.9 Hz, 1H), 7.32-7.35 (m, 2H), 7.22 (dd, J=8.3, 2.0 Hz,
1H), 6.98 (d, J=8.5 Hz, 1H), 4.47 (br. s., 1H), 4.11 (s, 1H), 2.77
(br. s., 2H), 2.67 (d, J=6.0 Hz, 3H), 2.46-2.55 (m, 3H), 2.40 (br.
s., 2H), 2.33 (s, 3H), 2.06 (br. s., 2H), 1.89 (d, J=9.5 Hz, 2H),
1.84 (br. s., 4H). MS ESI 531.1 [M+H].sup.+, calcd for
[C.sub.29H.sub.34N.sub.6O.sub.2S+H].sup.+ 531.25.
Example A81
1-(4-methoxy-2-methylphenyl)-3-(3-(4-((1-methylpiperidin-4-yl)oxy)phenyl)--
1H-indazol-5-yl)urea
##STR00225##
[0668] Using Method J,
3-(4-((1-methylpiperidin-4-yl)oxy)phenyl)-1H-indazol-5-amine
bis(2,2,2-trifluoroacetate) (50 mg, 0.11 mmol),
1-isocyanato-4-methoxy-2-methylbenzene (33 uL, 0.23 mmol) and DIPEA
(100 uL, 0.58 mmol) in DMF (1.2 mL) gave the title compound as a
TFA salt (25 mg, 36%, a beige powder). .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. ppm 8.26 (s, 1H), 7.89-7.86 (m, 2H), 7.49 (d,
J=8.8 Hz, 1H), 7.36 (d, J=8.8 Hz, 1H), 7.28 (d, J=8.9 Hz, 1H),
7.19-7.12 (m, 2H), 6.81 (d, J=2.6 Hz, 1H), 6.75 (dd, J.sub.1=8.4
Hz, J.sub.2=2.5 Hz, 1H), 4.83 (bs, 1H), 3.77 (s, 3H), 3.64-3.32 (m,
2H), 3.30-3.15 (m, 2H), 2.93 (bs, 3H), 2.47-2.29 (m, 2H), 2.29 (s,
3H), 2.14-1.91 (m, 2H); MS ESI 486.3 [M+H].sup.+, calcd for
[C.sub.28H.sub.31N.sub.5O.sub.3+H].sup.+ 486.25.
Example A82
N-(3-(4-morpholinophenyl)-1H-indazol-5-yl)-2-(pyrrolidin-1-yl)-2-(thiophen-
-2-yl)acetamide
##STR00226##
[0670] To a mixture of 2-(pyrrolidin-1-yl)-2-(thiophen-2-yl)acetic
acid (85 mg, 0.4 mmol), 3-(4-morpholinophenyl)-1H-indazol-5-amine
di-trifluoroacetic acid (229 mg, 0.44 mmol) and TBTU (128 mg, 0.4
mmol) in DMF (6 mL) at 0.degree. C. was added .sup.iPr.sub.2NEt
(0.28 mL, 1.6 mmol). The resulting mixture was stirred for 1 h at
0.degree. C. and purified by prep-HPLC to give the title compound
as a di-TFA salt (yellow solid, 263 mg, 92%). .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. 8.39 (s, 1H), 7.88 (d, J=8.4 Hz, 2H), 7.52 (d,
J=4.8 Hz, 1H), 7.54 (s, 2H), 7.51 (dd, J=3.2 Hz, 0.8 Hz, 1H),
7.33-7.26 (m, 2H), 7.12 (dd, J=5.2 Hz, 3.6 Hz, 1H), 5.78 (s, 1H),
3.89 (t, J=4.6 Hz, 4H), 3.40-3.10 (m, 8H), 2.20-1.90 (m, 4H); MS
ESI 488.3 [M+H].sup.+, calcd for
[C.sub.27H.sub.32N.sub.5O.sub.2S+H].sup.+ 488.2.
Example A83
N-(3-(4-(4-hydroxypiperidin-1-yl)phenyl)-1H-indazol-5-yl)-2-(piperidin-1-y-
l)-2-(thiophen-3-yl)acetamide
##STR00227##
[0672] The title compound was synthesized according to general
Method C by using a sealed degassed mixture of
N-(3-iodo-1H-indazol-5-yl)-2-(piperidin-1-yl)-2-(thiophen-3-yl)acetamide
(75 mg, 0.16 mmol),
1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperidin-4-ol
(90 mg, 0.17 mmol), Pd(PPh.sub.3).sub.4 (14 mg, 0.012 mmol), 1 M aq
Na.sub.2CO.sub.3 (0.32 mL) in PhMe/EtOH (3 mL, 1:0.5 mixture) under
Ar with heating under microwave irradiation at 130.degree. C. for 3
h. The reaction mixture was diluted with EtOAc (20 mL) and washed
with H.sub.2O (2.times.10 mL) and brine (10 mL), dried
(Na.sub.2SO.sub.4) and concentrated under vacuum. Purification by
flash chromatography (SiO2, 0-15% MeOH in DCM) followed by RPHPLC
and passing through a PoraPak column with 1 M NH.sub.3-MeOH to
elute gave the title compound (off white solid, 36 mg, 43%).
.sup.1H NMR (400 MHz, CD.sub.3OD) .delta. ppm 8.35 (m, 1H), 7.79
(d, J=8.8 Hz, 2H), 7.49 (s, 2H), 7.45-7.41 (m, 1H), 7.42-7.40 (m,
1H), 7.26 (dd, J=4.8 Hz, J=1.2 Hz, 1H), 7.10 (d, J=9.2 Hz, 2H),
4.14 (s, 1H), 3.79-3.74 (m, 1H), 3.68-3.63 (m, 2H), 2.97-2.91
(br.m, 2H), 2.45 (br.s, 4H), 2.04-1.96 (br.m, 2H), 1.70-1.61 (br.m,
6H), 1.49-1.47 (br.m, 2H); MS ESI 516.2 [M+H].sup.+, calcd for
[C.sub.29H.sub.33N.sub.5O.sub.2S+H].sup.+ 516.2.
Example A84
N-(cyclopropyl(phenyl)methyl)-3-(4-(4-hydroxypiperidin-1-yl)phenyl)-1H-ind-
azole-5-carboxamide
##STR00228##
[0674] Using Method C2,
N-(cyclopropyl(phenyl)methyl)-3-iodo-1H-indazole-5-carboxamide
(51.3 mg, 0.12 mmol) and
1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperidin-4-ol
(77.8 mg, 65% pure, 0.16 mmol) gave the title compound after 5 h at
125.degree. C. in the microwave as the TFA salt (yellow solid film,
22.2 mg, 31%). .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. ppm 8.63
(s, 1H), 8.21 (d, J=8.8 Hz, 2H), 7.99 (dd, J=8.8, 1.5 Hz, 1H), 7.74
(d, J=8.5 Hz, 2H), 7.66 (d, J=8.8 Hz, 1H), 7.50 (d, J=7.3 Hz, 2H),
7.34 (t, J=7.5 Hz, 2H), 7.25 (t, J=7.3 Hz, 1H), 4.50 (d, J=9.5 Hz,
1H), 4.10 (tt, J=7.1, 3.6 Hz, 1H), 3.89 (ddd, J=11.9, 8.3, 3.4 Hz,
2H), 3.55-3.66 (m, 2H), 2.18-2.31 (m, 2H), 2.02 (dtd, J=14.3, 7.2,
7.2, 3.6 Hz, 2H), 1.38-1.48 (m, 1H), 0.62-0.75 (m, 2H), 0.42-0.56
(m, 2H). MS ESI 467.4 [M+H].sup.+, calcd for
[C.sub.29H.sub.30N.sub.4O.sub.2+H].sup.+ 467.25.
Example A85
N-((1-methylpiperidin-4-yl)(phenyl)methyl)-3-(4-morpholinophenyl)-1H-indaz-
ole-5-carboxamide
##STR00229##
[0676] The title compound was synthesized according to the General
Method A, utilizing 3-(4-morpholinophenyl)-1H-indazole-5-carboxylic
acid (100 mg, 0.31 mmol),
(1-methylpiperidin-4-yl)(phenyl)methanamine (63 mg, 0.31 mmol),
TBTU (100 mg, 0.31 mmol), DIPEA (0.16 mL, 0.93 mmol), and DMF (5
mL). Purification by flash chromatography (SiO.sub.2, Biotage 25 g,
5-75% MeOH in CH.sub.2Cl.sub.2) followed by RPHPLC, and trituration
with Et.sub.2O gave the title compound as a bis-TFA salt (light
yellow solid, 18 mg, 8%). .sup.1H NMR (400 MHz, CD.sub.3OD) .delta.
ppm 8.55 (s, 1H), 7.87 (s, 3H), 7.59 (d, J=8.53 Hz, 1H), 7.46 (d,
J=6.78 Hz, 2H), 7.39 (t, J=7.53 Hz, 2H), 7.30 (t, J=7.50 Hz, 1H),
7.14 (d, J=8.78 Hz, 2H), 4.92-4.96 (m, 1H), 3.83-3.91 (m, 4H),
3.55-3.62 (m, 1H), 3.41-3.49 (m, 1H), 3.21-3.27 (m, 4H), 2.86-3.03
(m, 2H), 2.85 (s, 3H), 2.17-2.35 (m, 2H), 1.40-1.72 (m, 3H); MS ESI
511.2 [M+H].sup.+, calcd for
[C.sub.31H.sub.35N.sub.5O.sub.2+H].sup.+ 510.3.
Example A86
1-(2,6-diethylphenyl)-3-(3-(4-morpholinophenyl)-1H-indazol-5-yl)urea
##STR00230##
[0678] Using Method J, 3-(4-morpholinophenyl)-1H-indazol-5-amine
bis(2,2,2-trifluoroacetate) (78 mg, 0.150 mmol),
1,3-diethyl-2-isocyanatobenzene (52 uL, 0.30 mmol) and DIPEA (130
uL, 0.75 mmol) in DMF (1.5 mL) gave the title compound as a TFA
salt (25 mg, 36%, a yellow solid). .sup.1H NMR (400 MHz, d6-DMSO)
.delta. ppm 8.77 (s, 1H), 8.26 (s, 1H), 7.77 (d, J=8.8 Hz, 2H),
7.62 (s, 1H), 7.45 (d, J=8.5 Hz, 1H), 7.31 (d, J=8.2 Hz, 1H),
7.18-7.06 (m, 5H), 3.75 (bs, 4H), 3.16 (bs, 4H), 2.60 (q, J=8.0 Hz,
4H), 1.14 (t, J=7.2 Hz, 6H); MS ESI 470.3 [M+H].sup.+, calcd for
[C.sub.28H.sub.31N.sub.5O.sub.2+H].sup.+ 470.26.
Example A87
N-(3-(4-(4-hydroxypiperidin-1-yl)phenyl)-1H-indazol-5-yl)-2-methoxy-2-(thi-
ophen-3-yl)acetamide
##STR00231##
[0679] A. tert-butyl
(3-(4-(4-hydroxypiperidin-1-yl)phenyl)-1H-indazol-5-yl)carbamate
[0680] The title compound was synthesized according to general
Method C from tert-butyl (3-iodo-1H-indazol-5-yl)carbamate (445 mg,
1.23 mmol) and
1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperidin-4-ol
(376 mg, 1.23 mmol) with Pd(PPh.sub.3).sub.4 (100 mg, 0.086 mmol)
and 1 M aq Na2CO3 (3.0 mL) in PhMe/EtOH (8.9 mL, 2:1 mixture) under
Ar with heating under microwave irradiation at 130.degree. C. for 5
h. The reaction mixture was diluted with EtOAc (25 mL) and washed
(H.sub.2O (15 mL), brine (20 mL)), dried (Na.sub.2SO.sub.4) and
concentrated under vacuum. Purification by flash chromatography
(SiO.sub.2, 0-20% MeOH in DCM) gave the title compound (185 mg).
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.17 (s, 1H), 7.79 (d,
J=8.4 Hz, 2H), 7.45 (d, J=8.8 Hz, 1H), 7.36 (d, J=9.2 Hz, 1H), 7.08
(d, J=8.8 Hz, 2H), 3.77-3.72 (m, 1H), 3.63-3.62 (br.m, 2H),
2.93-2.86 (m, 2H), 1.98-1.94 (br.m, 2H), 1.68-1.59 (br.m, 2H), 1.53
(s, 9H); MS ESI 409.3 [M+H].sup.+, calcd for
[C.sub.23H.sub.28N.sub.4O.sub.3+H].sup.+ 409.2.
B. 1-(4-(5-amino-1H-indazol-3-yl)phenyl)piperidin-4-ol
[0681] CF.sub.3COOH (3 mL) was added to a solution of tert-butyl
(3-(4-(4-hydroxypiperidin-1-yl)phenyl)-1H-indazol-5-yl)carbamate
(185 mg) in DCM (2 mL) at rt and the mixture was stirred for 24 h.
Concentration under vacuum gave the title compound as a 2.times.TFA
salt (brown solid, 167 mg, 25%, 2 steps). .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. 8.07 (d, J=1.2 Hz, 1H), 7.98 (d, J=8.8 Hz, 2H),
7.76 (d, J=8.8 Hz, 1H), 7.45-7.43 (m, 3H), 5.36-5.30 (m, 1H),
3.74-3.70 (m, 2H), 3.52-3.46 (m, 3H), 2.34-2.29 (m, 2H), 2.15-2.07
(m, 2H); MS ESI 309.1 [M+H].sup.+, calcd for
[C.sub.18H.sub.20N40+H].sup.+ 309.1.
C.
N-(3-(4-(4-hydroxypiperidin-1-yl)phenyl)-1H-indazol-5-yl)-2-methoxy-2-(-
thiophen-3-yl)acetamide
[0682] The title compound was synthesized according to general
Method A by using 2-methoxy-2-(thiophen-2-yl)acetic acid (30 mg,
0.172 mmol), DMF (3 mL),
1-(4-(5-amino-1H-indazol-3-yl)phenyl)piperidin-4-ol
trifluoroactetate (94 mg, 0.175 mmol), DIPEA (152 uL, 0.80 mmol)
and TBTU (56 mg, 0.174 mmol). After stirring for 24 h at rt and
concentrated under reduced pressure, direct purification using
Biotage (SiO2, 0-25% MeOH in DCM; then RP HPLC C18 60 g, 10-80%
MeOH in 0.1% TFA-H.sub.2O) gave the title compound as a TFA salt
(cream color solid, 38 mg, 54%). .sup.1H NMR (400 MHz, CD.sub.3OD)
.delta. ppm 8.48 (d, J=0.4 Hz, 1H), 8.16 (d, J=8.8 Hz, 2H), 7.77
(d, J=8.8 Hz, 2H), 7.59-7.53 (m, 3H), 7.45 (dd, J=5.2 Hz, J=3.2 Hz,
1H), 7.23 (dd, J=4.8 Hz, J=0.8 Hz, 1H), 4.96 (s, 1H), 4.15-4.09 (m,
1H), 3.91-3.85 (m, 2H), 3.68-3.62 (m, 2H), 3.48 (s, 3H), 2.29-2.23
(br.m, 2H), 2.08-2.201 (br.m, 2H); MS ESI 463.1 [M+H].sup.+, calcd
for [C.sub.25H.sub.26N.sub.4O.sub.3S+H].sup.+ 463.1
Example A88
N-(3-(4-(4-hydroxypiperidin-1-yl)phenyl)-1H-indazol-5-yl)-2-(pyrrolidin-1--
yl)-2-(thiophen-2-yl)acetamide
##STR00232##
[0684] To a mixture of 2-(pyrrolidin-1-yl)-2-(thiophen-2-yl)acetic
acid (25.5 mg, 0.12 mmol),
1-(4-(5-amino-1H-indazol-3-yl)phenyl)piperidin-4-ol
di-trifluoroacetic acid (64 mg, 0.12 mmol) and TBTU (39 mg, 0.12
mmol) in DMF (6 mL) at 0.degree. C. was added .sup.iPr.sub.2NEt
(0.084 mL, 0.48 mmol). The resulting mixture was sonicated to make
a clear solution and stirred for 10 min at 0.degree. C. It was
quenched with H.sub.2O (30 mL) and satd aqNaHCO.sub.3 (10 mL),
extracted with EtOAc and purified by prep-HPLC and PoraPak to give
the title compound (white solid, 18.5 mg, 31%). .sup.1H NMR (400
MHz, CD.sub.3OD) .delta. 8.33 (t, J=0.8 Hz, 1H), 7.77 (pseudo d,
J=8.8 Hz, 2H), 7.53-7.47 (m, 2H), 7.39 (dd, J=5.0 Hz, 0.6 Hz, 1H),
7.21 (dd, J=3.6 Hz, 1.2 Hz, 1H), 7.09 (pseudo d, J=8.8 Hz, 2H),
6.99 (dd, J=5.2 Hz, 3.6 Hz, 1H), 4.31 (s, 1H), 3.77 (sept, J=4.4
Hz, 1H), 3.66 (tt, J=12.8 Hz, 4.0 Hz, 2H), 2.97-2.90 (m, 2H),
2.73-2.65 (m, 2H), 2.60-2.53 (m, 2H), 2.02-1.95 (m, 2H), 1.89-1.80
(m, 4H), 1.70-1.61 (m, 2H); MS ESI 502.2 [M+H].sup.+, calcd for
[C.sub.28H.sub.31N.sub.5O.sub.2S+H].sup.+ 502.2.
Example A89
N-(3-(4-(4-hydroxy-4-methylpiperidin-1-yl)phenyl)-1H-indazol-5-yl)-2-(pyrr-
olidin-1-yl)-2-(thiophen-3-yl)acetamide
##STR00233##
[0686] The title compound was synthesized according to Method C3
utilizing
N-(3-iodo-1H-indazol-5-yl)-2-(pyrrolidin-1-yl)-2-(thiophen-3-yl)acetamide
and
4-methyl-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pip-
eridin-4-ol and obtained as a white solid (15 mg, 22% yield).
.sup.1H NMR (400 MHz, CD.sub.3OD) .delta. ppm 8.33 (s, 1H), 7.77
(d, J=8.8 Hz, 2H), 7.49 (m, 3H), 7.40 (m, 1H), 7.33 (dd, J=4.2 Hz,
1 Hz, 1H), 7.08 (d, J=8.8 Hz, 2H), 4.10 (s, 1H), 3.38 (m, 2H), 3.23
(m, 2H), 2.65 (br, 2H), 2.48 (br, 2H), 1.82 (m, 4H), 1.72 (m, 4H),
1.26 (s, 3H); MS ESI [M+H].sup.+ 516.2, calcd for
[C.sub.29H.sub.33N.sub.5O.sub.2S+H].sup.+ 516.25.
Example A90
N-(3-(4-methyl-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepin-7-yl)-1H-indazol-5--
yl)-2-(pyrrolidin-1-yl)-2-(thiophen-3-yl)acetamide
##STR00234##
[0687] A.
7-bromo-4-methyl-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepine
[0688] Tert-butyl
7-bromo-2,3-dihydrobenzo[f][1,4]oxazepine-4(5H)-carboxylate (388
mg, 1.18 mmol) was dissolved into CH.sub.2Cl.sub.2 (6.0 mL) and TFA
(0.6 mL) and the resulting solution strirred for 3 h and then the
solvent was removed. The resulting residue was then dissolved into
THF (3.0 mL) and formalin (48 uL, 0.644 mmol), and NaBH(OAc).sub.3
were added. The reaction was stirred for 2 h at which time the
mixture was transferred to a separatory funnel with EtOAc (20 mL)
and then washed with satd aq NaHCO.sub.3 ((2.times.20 mL), and
brine (1.times.20 mL). The organic layer was dried over MgSO.sub.4
filtered and the solvent removed to give 82 mg, 58% of the product
as a colourless oil. MS ESI 243.9 [M+H].sup.+, calcd for
[C.sub.10H.sub.12BrNO+H].sup.+ 244.02.
B.
4-methyl-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3,4,5-tetrah-
ydrobenzo[f][1,4]oxazepine
[0689] To a solution of
7-bromo-4-methyl-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepine (82 mg,
0.340 mmol), TEA (140 uL, 1.02 mmol), dioxane (1.0 mL), and
4,4,5,5-tetramethyl-1,3,2-dioxaborolane (74 uL, 0.510 mmol) under
Ar was added S-Phos (6.0 mg, 0.014 mmol) and
Cl.sub.2Pd(CH.sub.3CN).sub.2 (1.0 mg, 0.034 mmol) and the reaction
heated to 110.degree. C. for 2 h. The mixture was transferred to a
separatory funnel with EtOAc (15 mL) and washed with NaHCO.sub.3
(satd) (10 mL), H.sub.2O (10 mL), and brine (10 mL). The organic
layer was dried over MgSO.sub.4, and the solvent removed to give 82
mg, 84% of the product as brown oil. MS ESI 290.1 [M+H].sup.+,
calcd for [C.sub.16H.sub.24BNO.sub.3+H].sup.+ 290.19.
C.
N-(3-(4-methyl-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepin-7-yl)-1H-indazol-
-5-yl)-2-(pyrrolidin-1-yl)-2-(thiophen-3-yl)acetamide
[0690] A solution of
4-methyl-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3,4,5-tetrahyd-
robenzo[f][1,4]oxazepine (75 mg, 0.259 mmol),
N-(3-iodo-1H-indazol-5-yl)-2-(pyrrolidin-1-yl)-2-(thiophen-3-yl)acetamide
(98 mg, 0.216 mmol), LiCl (27 mg, 0.648 mmol), Na.sub.2CO.sub.3
(0.54 mL of a 2 M solution), and dioxane (1.5 mL) was purged with
Ar for 15 min at which time Pd(PPh.sub.3).sub.4 (13 mg, 0.011 mmol)
was added and the reaction heated to 125.degree. C. in a microwave
reactor for 3 h. The solvent was then removed and the product
purified by prep-HPLC which yielded 20 mg of the product as its
bis-TFA salt (19%, a white powder). .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. ppm 8.31 (s, 1H), 7.77-7.75 (m, 2H), 7.55-7.49
(m, 3H), 7.43-7.41 (m, 1H), 7.33 (d, J=5.1 Hz, 1H), 7.12 (d, J=7.9
Hz, 1H), 4.14-4.10 (m, 3H), 3.87 (s, 2H), 3.03-3.01 (m, 2H),
2.69-2.66 (m, 2H), 2.51-2.49 (m, 2H), 2.47 (s, 3H), 1.86-1.83 (m,
4H); MS ESI 488.1 [M+H].sup.+, calcd for
[C.sub.27H.sub.29N.sub.5O.sub.2S+H].sup.+ 488.21.
Example A91
N-(3-(4-((1-methylpiperidin-4-yl)oxy)phenyl)-1H-indazol-5-yl)-2-(pyrrolidi-
n-1-yl)-2-(thiophen-2-yl)acetamide
##STR00235##
[0692] To a mixture of crude
N-(3-iodo-1H-indazol-5-yl)-2-(pyrrolidin-1-yl)-2-(thiophen-2-yl)acetamide
(150 mg, assuming 0.3 mmol) and
1-methyl-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)piperi-
dine (95 mg, 0.3 mmol) in EtOH (4 mL) was added 1 M aq Na2CO3 (0.6
mL, 0.6 mmol), followed by Pd(PPh.sub.3).sub.4 (17 mg, 0.015 mmol).
The resulting mixture was purged with Ar and microwaved 3 h at
125.degree. C. After removal of solvents, it was purified by flash
chromatography (EtOAc/hex 0-100%, then MeOH/DCM 0-20%, then 0.02 M
NH.sub.3 in MeOH) and prep-HPLC to give the title compound as a
di-TFA salt (light brown solid, 25.1 mg, 11%). .sup.1H NMR (400
MHz, CD.sub.3OD) .delta. 8.37 (pseudo s, 1H), 7.90-7.83 (m, 2H),
7.69 (d, J=8.8 Hz, 1H), 7.58-7.51 (m, 3H), 7.22-7.14 (m, 3H), 5.50
(s, 1H), 4.90-4.87 (m, 0.7H), 4.73-4.65 (m, 0.3H), 4.00-3.10 (m,
8H), 2.95-2.94 (two s at 2.95 and 2.94, 3H), 2.47-1.88 (m, 8H); MS
ESI 516.2 [M+H].sup.+, calcd for
[C.sub.29H.sub.33N.sub.5O.sub.2S+H].sup.+ 516.2.
Example A92
N-(3-(4-(1-Methylpiperidin-4-yloxy)phenyl)-1H-indazol-5-yl)-2-o-tolylaceta-
mide
##STR00236##
[0694] The title compound was synthesized according to Method C,
utilizing N-(3-iodo-1H-indazol-5-yl)-2-o-tolylacetamide (100 mg,
0.26 mmol),
1-methyl-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)piperi-
dine (89 mg, 0.28 mmol), Pd(PPh.sub.3).sub.4 (30 mg, 0.026 mmol), 2
M Na.sub.2CO.sub.3 (0.26 mL), PhMe (4 mL), and EtOH (2 mL). H2O (30
mL) was added and the product was extracted into EtOAc (4.times.30
mL). The combined organic layers were dried over MgSO.sub.4,
filtered and evaporated in vacuo. Purification by flash
chromatography (Biotage, 25 g HP-SIL, 100% EtOAc, then 2-30% MeOH
in DCM) followed by RPHPLC gave the title compound as a white solid
(163 mg, 11%). The title compound was isolated as a TFA salt.
.sup.1H NMR (400 MHz, CD.sub.3OD) .delta. ppm 8.44 (d, J=1.2 Hz,
1H), 7.87-7.83 (m, 2H), 7.52 (d, J=8.9 Hz, 1H), 7.43 (dd, J=8.9,
1.8 Hz, 1H), 7.29-7.26 (m, 1H), 7.21-7.09 (m, 5H), 4.81 (m, 0.76H),
4.60 (m, 0.38H), 3.78 (s, 2H), 3.60 (d, J=12 Hz, 0.71H), 3.40-3.32
(m, 2.43H), 3.16 (td, J=12.9, 2.3 Hz, 0.74H), 2.91, 2.90 (2 s, 3H),
2.41-2.38 (m, 3.6H), 2.26 (d, J=16 Hz, 1.4H), 2.13-2.04 (m, 1.4H),
1.93-1.87 (m, 0.72H); MS ESI 455.3 [M+H].sup.+, calcd for
[C.sub.28H.sub.30N.sub.4O.sub.2+H].sup.+ 455.24.
Example A93
N-(3-(1,4-dimethyl-2,3,4,5-tetrahydro-1H-benzo[e][1,4]diazepin-7-yl)-1H-in-
dazol-5-yl)-2-(pyrrolidin-1-yl)-2-(thiophen-3-yl)acetamide
##STR00237##
[0696] The title compound was prepared using Method C3 from
N-(3-iodo-1H-indazol-5-yl)-2-(pyrrolidin-1-yl)-2-(thiophen-3-yl)acetamide
and tert-butyl
7-bromo-2,3-dihydro-1H-benzo[e][1,4]diazepine-4(5H)-carboxylate.
The product was isolated as its bis-TFA salt (22%, a pale-yellow
solid). .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. ppm 8.37 (s, 1H),
7.95 (d, J=8.3 Hz, 1H), 7.90 (s, 1H), 7.87 (s, 1H), 7.66-7.64 (m,
1H), 7.54 (s, 2H), 7.36 (d, J=4.0 Hz, 1H), 7.26 (d, J=8.4 Hz, 1H),
4.58-4.42 (m, 2H), 3.98-3.35 (m, 5H), 3.29-3.09 (m, 4H), 3.06 (s,
3H), 3.03 (s, 3H), 2.25-1.95 (m, 4H); MS ESI 501.2 [M+H].sup.+,
calcd for [C.sub.28H.sub.32N6OS+H].sup.+ 501.24.
Example A94
N-(3-(4-(4-Methyl-2-oxopiperazin-1-yl)phenyl)-1H-indazol-5-yl)-2-(pyrrolid-
in-1-yl)-2-(thiophen-3-yl)acetamide
##STR00238##
[0697] A. 1-(4-Iodophenyl)-4-methylpiperazin-2-one
[0698] CuI (0.081 g, 0.42 mmol) was added to an Ar-purged solution
of 1,4-diiodobenzene (1.7 g, 5.1 mmol), 4-methylpiperazin-2-one
(0.50 g, 4.3 mmol),
trans-N.sup.1,N.sup.4-dimethylcyclohexane-1,4-diamine (0.14 mL,
0.85 mmol), and K.sub.3PO.sub.4 (1.8 g, 8.5 mmol) in dioxane (10
mL). The resulting mixture was heated at 110.degree. C. for 8 h in
a Biotage microwave reactor. H.sub.2O (30 mL) was added and the
product was extracted into EtOAc (4.times.30 mL). The combined
organic layers were dried over MgSO.sub.4, filtered and evaporated
in vacuo. Purification by flash chromatography (Biotage, 25 g
HP-SIL, EtOAc then 2-10% MeOH in DCM) gave the title compound as a
yellow solid (0.74 g, 55%). .sup.1H NMR (400 MHz, CD.sub.3OD)
.delta. ppm 7.76 (d, J=8.6 Hz, 2H), 7.11 (d, J=8.7 Hz, 2H), 3.70
(t, J=5.4 Hz, 2H), 3.24 (s, 2H), 3.28 (t, J=5.6 Hz, 2H), 2.40 (s,
3H); MS ESI 316.9 [M+H].sup.+, calcd for
[C.sub.11H.sub.13IN.sub.2O+H].sup.+ 317.01.
B.
4-Methyl-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piper-
azin-2-one
[0699] The title compound was synthesized according to Method F,
utilizing 1-(4-iodophenyl)-4-methylpiperazin-2-one (74 mg, 2.3
mmol), 4,4,5,5-tetramethyl-1,3,2-dioxaborolane (0.44 mL, 3.0 mmol),
Cl.sub.2Pd(CH.sub.3CN).sub.2 (3.0 mg, 0.012 mmol), SPhos (20 mg,
0.047 mmol), NEt.sub.3 (1.0 mL, 7.0 mmol) and dioxane (1.0 mL).
H.sub.2O (30 mL) was added and the product was extracted into EtOAc
(4.times.30 mL). The combined organic layers were dried over
MgSO.sub.4, filtered and evaporated in vacuo. Purification by flash
chromatography (Biotage, 25 g HP-SIL, EtOAc then 2-20% MeOH in DCM)
gave the title compound as a white solid (0.14 g, 20%). .sup.1H NMR
(400 MHz, CD.sub.3OD) .delta. ppm 7.81 (d, J=8.4 Hz, 2H), 7.33 (d,
J=8.4 Hz, 2H), 3.74 (t, J=5.2 Hz, 2H), 3.27 (s, 2H), 2.85 (t, J=5.5
Hz, 2H), 2.42 (s, 3H), 1.35 (s, 12H); MS ESI 317.1 [M+H].sup.+,
calcd for [C.sub.17H.sub.25BN.sub.2O.sub.3+H].sup.+ 317.20.
C.
N-(3-(4-(4-Methyl-2-oxopiperazin-1-yl)phenyl)-1H-indazol-5-yl)-2-(pyrro-
lidin-1-yl)-2-(thiophen-3-yl)acetamide
[0700] The title compound was synthesized according to Method C,
utilizing
N-(3-iodo-1H-indazol-5-yl)-2-(pyrrolidin-1-yl)-2-(thiophen-3-yl)acetamide
(182 mg, 0.40 mmol),
4-methyl-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperaz-
in-2-one (140 mg, 0.44 mmol), Pd(PPh.sub.3).sub.4 (51 mg, 0.044
mmol), 2 M Na.sub.2CO.sub.3 (0.44 mL), PhMe (4 mL), and EtOH (2
mL). H.sub.2O (30 mL) was added and the product was extracted into
EtOAc (4.times.30 mL). The combined organic layers were dried over
MgSO.sub.4, filtered and evaporated in vacuo. Purification by flash
chromatography (Biotage, 50 g HP-SIL, 100% EtOAc, then 2-20% MeOH
in DCM) followed by RPHPLC gave the title compound as a white solid
(111 mg, 33%). The title compound was isolated as a di-TFA salt.
.sup.1H NMR (400 MHz, CD.sub.3OD) .delta. ppm 8.24 (d, J=1.0 Hz,
1H), 8.03 (d, J=8.6 Hz, 2H), 7.87 (dd, J=2.9, 1.2 Hz, 1H), 7.66
(dd, J=5.1, 3.0 Hz, 1H), 7.59-7.50 (m, 4H), 7.38 (dd, J=5.0, 1.2
Hz, 1H), 5.24 (s, 1H), 4.18 (s, 2H), 4.10 (t, J=5.4 Hz, 2H),
3.87-3.83 (br m, 1H), 3.82 (t, J=5.9 Hz, 2H), 3.20-3.02 (br m, 2H),
3.13 (s, 3H), 2.26-1.97 (br m, 4H); MS ESI 515.1 [M+H].sup.+, calcd
for [C.sub.28H.sub.30N.sub.6O.sub.2S+H].sup.+ 515.22.
Example A95
N-(3-(4-(4-(hydroxymethyl)piperidin-1-yl)phenyl)-1H-indazol-5-yl)-2-(pyrro-
lidin-1-yl)-2-(thiophen-3-yl)acetamide
##STR00239##
[0702] The title compound was synthesized according to Method C3
utilizing
N-(3-iodo-1H-indazol-5-yl)-2-(pyrrolidin-1-yl)-2-(thiophen-3-yl)acetamide
and
(1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperidin-4-
-yl)methanol and obtained as a white solid (15 mg, 12% yield).
.sup.1H NMR (400 MHz, CD.sub.3OD) .delta. ppm 8.34 (s, 1H), 7.76
(d, J=8.8 Hz, 2H), 7.49 (m, 3H), 7.39 (m, 1H), 7.33 (m, 1H), 7.06
(d, J=8.8 Hz, 2H), 4.10 (s, 1H), 3.77 (m, 2H), 3.44 (d, J=6.4 Hz,
2H), 2.68 (m, 4H), 2.48 (br, 2H), 1.83 (m, 6H), 1.62 (m, 1H), 1.37
(m, 2H); MS ESI [M+H].sup.+ 516.2, calcd for
[C.sub.29H.sub.33N.sub.5O.sub.2S+H].sup.+ 516.24.
Example A96
N-(3-(3-(4-Methylpiperazine-1-carbonyl)phenyl)-1H-indazol-5-yl)-2-(pyrroli-
din-1-yl)-2-(thiophen-3-yl)acetamide
##STR00240##
[0704] The title compound was synthesized according to Method C,
utilizing
N-(3-iodo-1H-indazol-5-yl)-2-(pyrrolidin-1-yl)-2-(thiophen-3-yl)acetamide
(200 mg, 0.44 mmol),
(4-methylpiperazin-1-yl)(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)p-
henyl)methanone (160 mg, 0.49 mmol), Pd(PPh.sub.3).sub.4 (51 mg,
0.044 mmol), 2 M Na.sub.2CO.sub.3 (0.50 mL), PhMe (4 mL), and EtOH
(2 mL). H.sub.2O (30 mL) was added and the product was extracted
into EtOAc (4.times.30 mL). The combined organic layers were dried
over MgSO.sub.4, filtered and evaporated in vacuo. Purification by
flash chromatography (Biotage, 50 g HP-SIL, 100% EtOAc, then 2-25%
MeOH in DCM) followed by RP HPLC gave the title compound as a light
brown solid as isolated as a di-TFA salt (111 mg, 33%). .sup.1H NMR
(400 MHz, CD.sub.3OD) .delta. ppm 8.41 (s, 1H), 8.08 (d, J=7.9 Hz,
1H), 8.03 (s, 1H), 7.80 (dd, J=2.9, 1.2 Hz, 1H), 7.69-7.64 (m, 2H),
7.57-7.54 (m, 3H), 7.38 (dd, J=5.1, 1.2 Hz, 1H), 5.29 (s, 1H),
3.89-3.36 (br m, 5H), 3.31-3.13 (br m, 4H), 2.96 (s, 3H), 2.25-1.98
(br m, 4H); MS ESI 529.1 [M+H].sup.+, calcd for
[C.sub.29H.sub.32N.sub.6O.sub.2S+H].sup.+ 529.23.
Example A97
(R)-2-((R)-2-methylpyrrolidin-1-yl)-N-(3-(4-morpholinophenyl)-1H-indazol-5-
-yl)-2-(thiophen-3-yl)acetamide
##STR00241##
[0706] To a mixture of
(R)-2-((R)-2-methylpyrrolidin-1-yl)-2-(thiophen-3-yl)acetic acid
(22.5 mg, 0.1 mmol), 3-(4-morpholinophenyl)-1H-indazol-5-amine
di-trifluoroacetic acid (57.2 mg, 0.1 mmol) and COMU (47.1 mg, 0.11
mmol) in DMF (6 mL) at -20.degree. C. was added .sup.iPr.sub.2NEt
(0.07 mL, 0.4 mmol). The resulting mixture was stirred for 1 h at
-20.degree. C. After removal of .sup.iPr.sub.2NEt, it was purified
by prep-HPLC, PoraPak and flash chromatographyflash chromatography
(EtOAc/hex 0-100%, then MeOH/DCM 10-20%) to give the title compound
(pale yellow solid, 18.1 mg, 36%). .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. 8.38 (s, 1H), 7.80 (d, J=8.8 Hz, 2H), 7.51 (s,
2H), 7.43 (dd, J=2.8 Hz, 1.2 Hz, 1H), 7.40 (dd, J=4.8 Hz, 2.8 Hz,
1H), 7.23 (dd, J=5.2 Hz, 1.2 Hz, 1H), 7.06 (d, J=8.8 Hz, 2H), 4.56
(s, 1H), 3.83 (t, J=4.8 Hz, 4H), 3.18 (t, J=4.8 Hz, 4H), 2.95-2.86
(m, 1H), 2.83-2.73 (m, 1H), 2.39 (dd, J=13.8 Hz, 8.2 Hz, 1H),
2.30-1.91 (m, 1H), 1.87-1.74 (m, 1H), 1.70-1.59 (m, 1H), 1.55-1.45
(m, 1H), 1.17 (d, J=6.4 Hz, 3H); MS ESI 502.3 [M+H].sup.+, calcd
for [C.sub.26H.sub.28N.sub.6O.sub.2S+H].sup.+ 502.2.
Example A98
N-(cyclopropyl(phenyl)methyl)-3-(4-((1-(2-methoxyethyl)piperidin-4-yl)oxy)-
phenyl)-1H-indazole-5-carboxamide
##STR00242##
[0708] The title compound was prepared using Method C3 from
N-(cyclopropyl(phenyl)methyl)-3-iodo-1H-indazole-5-carboxamide (70
mg, 0.168 mmol) and
1-(2-methoxyethyl)-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phen-
oxy)piperidine (79 mg, 0.218 mmol) which gave 42 mg of product
isolated as its TFA salt (47%, a pale-yellow powder). .sup.1H NMR
(400 MHz, CD.sub.3OD) .delta. ppm 8.58 (s, 1H), 7.97-7.93 (m, 3H),
7.61 (d, J=8.8 Hz, 1H), 7.48 (d, J=7.3 Hz, 2H), 7.35-7.31 (m, 2H),
7.26-7.15 (m, 3H), 4.87 (bs, 1H), 4.48 (d, J=9.6 Hz, 1H), 3.76-3.70
(m, 2H), 3.54-3.22 (m, 9H), 2.45-2.28 (m, 2H), 2.19-1.94 (m, 2H),
1.45-1.33 (m, 1H), 0.68-0.63 (m, 2H), 0.50-0.47 (m, 2H); MS ESI
525.4 [M+H].sup.+, calcd for
[C.sub.32H.sub.36N.sub.4O.sub.3+H].sup.+ 525.29.
Example A99
N-(3-(3-((1-methylpiperidin-4-yl)oxy)phenyl)-1H-indazol-5-yl)-2-(pyrrolidi-
n-1-yl)-2-(thiophen-3-yl)acetamide
##STR00243##
[0709] A. 4-(3-bromophenoxy)-1-methylpiperidine
[0710] To a solution of 4-(3-bromophenoxy)piperidine (500 mg, 1.7
mmol) in formic acid (13.11 mL) was added formalin (0.51 mL). The
solution was heated to 150.degree. C. for 15 min under microwave
irradiation. The solvent was removed in vacuo. The residue was made
alkaline using 50% KOH (10 mL) and the product was extracted using
DCM (2.times.25 mL). The organic layer was washed with brine, dried
(Na.sub.2SO.sub.4) and concentrated to give the title compound as a
colorless thick oil (360 mg, 78%). .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 15-7.06 (m, 3H), 6.85-6.82 (m, 1H), 4.29 (br.m,
1H), 2.68 (br.s, 2H), 2.31 (br.s, 5H), 2.02-197 (br.m, 2H),
1.88-1.80 (br.m, 2H); MS ESI 272 [M+H].sup.+, calcd for
[C.sub.12H.sub.16BrNO+H].sup.+ 270
B.
1-methyl-4-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)pipe-
ridine
[0711] The title compound was synthesized according to general
Method E by using a solution of
4-(3-bromophenoxy)-1-methylpiperidine (350 mg, 1.29 mmol) in DMF
(5.25 mL) was added Bis(pinacolato)diboron (576 mg, 2.26 mmol),
KOAc (381 mg, 3.88 mmol) and PdCl.sub.2dppf (80 mg, 0.097 mmol)
under Ar. The degassed suspension was sealed and heated in an oil
bath at 125.degree. C. for 3 h. The product was partitioned between
EtOAc (50 mL) and H.sub.2O (25 mL). The aq. layer was extracted
with EtOAc (50 mL) and the combined EtOAc layer was washed with
H.sub.2O and brine, dried (Na.sub.2SO.sub.4) and concentrated under
vacuum. Purification by flash chromatography (SiO2, 0-50% DCM in
MeOH) gave title compound (brown thick oil, 148 mg, 36%). .sup.1H
NMR (400 MHz, CDCl.sub.3) .delta. 7.41 (d, J=7.2 Hz, 1H), 7.35 (d,
J=2.0 Hz, 1H), 7.31-7.28 (m, 1H), 7.02 (dd, J=8.0 Hz, J=2.0 Hz,
1H), 4.47 (s, 1H), 2.78-2.76 (br.m, 2H), 2.53-2.48 (br.s, 2H), 2.41
(s, 3H), 2.12 (br.s, 2H), 1.98-1.92 (br.s, 2H), 1.35 (s, 12H); MS
ESI 318.2 [M+H].sup.+, calcd for
[C.sub.18H.sub.18BNO.sub.3+H].sup.+ 318.2.
C.
N-(3-(3-((1-methylpiperidin-4-yl)oxy)phenyl)-1H-indazol-5-yl)-2-(pyrrol-
idin-1-yl)-2-(thiophen-3-yl)acetamide
[0712] The title compound was synthesized according to general
Method C from
N-(3-iodo-1H-indazol-5-yl)-2-(pyrrolidin-1-yl)-2-(thiophen-3-yl)acet-
amide (200 mg, 0.44 mmol),
1-methyl-4-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)piperi-
dine (141 mg, 0.44 mmol) with PdCl.sub.2dppf (72 mg, 0.088 mmol)
adn 1 M aq Na2CO3 (0.89 mL) in PhMe/EtOH (9 mL, 2:1 mixture) under
Ar with heating under microwave irradiation at 125.degree. C. for 5
h. The reaction mixture was diluted with EtOAc (40 mL) and washed
with H.sub.2O and brine, dried (Na.sub.2SO.sub.4) and concentrated
under vacuum. Purification by flash chromatography (SiO2, 0-20% 2
M-NH.sub.3-MeOH in DCM), then by RPHPLC gave the title compound as
a TFA salt (light brown solid, 31 mg, 9%). .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. 8.41 (d, J=8.0 Hz, 1H), 7.88-7.87 (m, 1H), 7.66
(dd, J=5.2 Hz, J=3.2 Hz, 1H), 7.57-7.44 (m, 5H), 7.39 (dd, J=4.8
Hz, J=1.2 Hz, 1H), 7.13-7.05 (m, 1H), 5.27 (s, 1H), 4.7-4.69 (m,
0.39H), 3.88-3.84 (br.s, 1H), 3.67 (br.d, 1H), 3.43-3.37 (br.m,
3H), 3.24-3.11 (br.m, 3H), 2.95 (s, 3H), 2.48-1.89 (br.m, 9H),
0.61H merged with solvent peak, MS ESI 516.1[M+H].sup.+, calcd for
[C.sub.29H.sub.33N.sub.5O.sub.2S+H].sup.+ 516.2.
Example A100
N-(cyclobutyl(phenyl)methyl)-3-(4-(4-hydroxypiperidin-1-yl)phenyl)-1H-inda-
zole-5-carboxamide
##STR00244##
[0714] Using Method C2,
N-(cyclobutyl(phenyl)methyl)-3-iodo-1H-indazole-5-carboxamide (69.8
mg, 0.162 mmol) and
1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperidin-4-ol
(73.1 mg, 80% pure, 0.19 mmol) gave the title compound as the TFA
salt (pale pink solid, 42.2 mg, 49%) after heating in a sealed vial
at 125.degree. C. for 14 h and purification by flash chromatography
(SiO2, 10-50% acetone in DCM; followed by RPRP HPLC, 10-90% MeOH in
0.1% TFA-H.sub.2O). .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. ppm
8.83 (d, J=7.8 Hz, 0.2H partially exchanged), 8.56 (s, 1H), 8.18
(d, J=8.5 Hz, 2H), 7.93 (d, J=8.8 Hz, 1H), 7.73 (d, J=8.5 Hz, 2H),
7.63 (d, J=9.0 Hz, 1H), 7.41 (d, J=7.5 Hz, 2H), 7.32 (t, J=7.5 Hz,
2H), 7.20-7.26 (m, 1H), 5.10 (d, J=10.5 Hz, 1H), 4.05-4.14 (m, 1H),
3.83-3.93 (m, 2H), 3.54-3.67 (m, 2H)
[0715] MS ESI 481.4 [M+H], calcd for
[C.sub.30H.sub.32N.sub.4O.sub.2+H].sup.+ 481.26.
Example A101
N-(cyclopropyl(thiophen-3-yl)methyl)-3-(4-(4-hydroxypiperidin-1-yl)phenyl)-
-1H-indazole-5-carboxamide
##STR00245##
[0717] Using Method C2,
N-(cyclopropyl(thiophen-3-yl)methyl)-3-iodo-1H-indazole-5-carboxamide
(50.0 mg, 0.118 mmol) and
1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperidin-4-ol
(53.7 mg, 80% pure, 0.14 mmol) gave the title compound as the TFA
salt (pale pink solid, 26.8 mg, 39%) after heating in microwave at
125.degree. C. for 3 h and purification by flash chromatography
(SiO2, 25-50% acetone in DCM; followed by RPRP HPLC, 10-90% MeOH in
0.1% TFA-H.sub.2O). .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. ppm
8.63 (s, 1H), 8.24 (d, J=8.8 Hz, 2H), 7.99 (dd, J=8.9, 1.4 Hz, 1H),
7.78 (d, J=8.8 Hz, 2H), 7.67 (d, J=8.8 Hz, 1H), 7.36-7.40 (m, 2H),
7.21 (t, J=3.3 Hz, 1H), 4.64 (d, J=9.3 Hz, 1H), 4.11 (tt, J=7.0,
3.3 Hz, 1H), 3.91 (ddd, J=12.0, 8.4, 3.4 Hz, 2H), 3.65 (ddd,
J=11.9, 7.7, 3.5 Hz, 2H), 2.21-2.31 (m, 2H), 2.04 (dtd, J=14.2,
7.2, 7.2, 3.5 Hz, 2H), 1.41-1.51 (m, 1H), 0.74 (td, J=8.3, 3.8 Hz,
1H), 0.65 (td, J=8.3, 4.8 Hz, 1H), 0.45-0.56 (m, 2H). MS ESI 473.3
[M+H].sup.+, calcd for [C.sub.27H.sub.28N.sub.4O.sub.2S+H].sup.+
473.20.
Example A102
N-(3-(4-((1-(2-fluoroethyl)piperidin-4-yl)oxy)phenyl)-1H-indazol-5-yl)-2-(-
pyrrolidin-1-yl)-2-(thiophen-3-yl)acetamide
##STR00246##
[0719] The title compound was synthesized according to Method C3
utilizing
N-(3-iodo-1H-indazol-5-yl)-2-(pyrrolidin-1-yl)-2-(thiophen-3-yl)acetamide
and
1-(2-fluoroethyl)-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)p-
henoxy)piperidine and obtained as a white solid (20 mg, 10% yield).
.sup.1H NMR (400 MHz, CD.sub.3OD) .delta. ppm 8.33 (s, 1H), 7.82
(d, J=8.8 Hz, 2H), 7.51 (m, 3H), 7.42 (m, 1H), 7.33 (dd, J=4.8 Hz,
0.8 Hz, 1H), 7.08 (d, J=8.8 Hz, 2H), 4.67 (t, J=4.8 Hz, 1H), 4.55
(t, J=4.8 Hz, 1H), 4.51 (m, 1H), 4.13 (s, 1H), 2.86 (m, 2H), 2.80
(t, J=4.8 Hz, 1H), 2.73 (t, J=4.8 Hz, 1H), 2.70 (m, 2H), 2.52 (m,
2H), 1.82 (m, 6H); MS ESI [M+H].sup.+ 548.2, calcd for
[C.sub.30H.sub.34FN.sub.5O.sub.2S+H].sup.+ 548.25.
Example A103
2-cyclopropyl-N-(3-(4-(4-hydroxypiperidin-1-yl)phenyl)-1H-indazol-5-yl)-2--
phenylacetamide
##STR00247##
[0721] The title compound was synthesized according to general
Method A by using 2-cyclopropyl-2-phenylacetic acid (16 mg, 0.09
mmol), DMF (2 mL),
1-(4-(5-amino-1H-indazol-3-yl)phenyl)piperidin-4-ol
trifluoroacetate (48.7 mg, 0.0.9 mmol), DIPEA (80 uL, 0.55 mmol)
and TBTU (29 mg, 0.09 mmol). After stirring for 24 h at rt,
concentration under reduced pressure and direct purification using
Biotage (SiO2, 0-25% MeOH in DCM; then RP HPLC C18 60 g, 10-80%
MeOH in 0.1% TFA-H.sub.2O) gave the title compound as a TFA salt
(beige color solid, 21 mg, 40%). .sup.1H NMR (400 MHz, CD.sub.3OD))
.delta. ppm 8.50 (m, 1H), 8.16 (d, J=8.0 Hz, 2H), 7.77 (d, J=8.0
Hz, 2H), 7.57 (d, J=9.2 Hz, 1H), 7.51 (d, J=7.6 Hz, 2H), 7.42 (d,
J=9.2 Hz, 1H), 7.37-7.33 (m, 2H), 7.28-7.25 (m, 1H), 4.11 (s, 1H),
3.98-3.87 (m, 2H), 3.65 (br.s, 2H), 2.94 (d, J=9.6 Hz, 1H),
2.25-2.23 (br.m, 2H), 2.05 (br.s, 2H), 1.6 (br.s, 1H), 0.70-0.62
(br.m, 2H), 0.48-0.28 (br.m, 2H); MS ESI 467.4. [M+H].sup.+, calcd
for [C.sub.29H.sub.30N.sub.4O.sub.2+H].sup.+ 467.2
Example A104
N-(cyclopropyl(phenyl)methyl)-3-(4-((1-(2-hydroxyethyl)piperidin-4-yl)oxy)-
phenyl)-1H-indazole-5-carboxamide
##STR00248##
[0723] The title compound was prepared using Method C3 from
N-(cyclopropyl(phenyl)methyl)-3-iodo-1H-indazole-5-carboxamide (60
mg, 0.144 mmol) and
2-(4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)piperidin-1--
yl)ethanol (70 mg, 0.202 mmol) which gave 23 mg of product isolated
as its TFA salt (31%, a white solid). .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. ppm 8.58 (s, 1H), 7.97-7.93 (m, 3H), 7.61 (d,
J=8.8 Hz, 1H), 7.48 (d, J=7.3 Hz, 2H), 7.36-7.32 (m, 2H), 7.26-7.16
(m, 3H), 4.87 (bs, 1H), 4.48 (d, J=9.5 Hz, 1H), 3.92-3.30 (m, 8H),
2.45-2.29 (m, 2H), 2.22-1.98 (m, 2H), 1.43-1.33 (m, 1H), 0.71-0.64
(m, 2H), 0.50-0.48 (m, 2H); MS ESI 511.5 [M+H].sup.+, calcd for
[C.sub.31H.sub.34N.sub.4O.sub.3+H].sup.+ 511.27.
Example A105
rel-N-(3-(4-(((1r,4r)-4-hydroxycyclohexyl)amino)phenyl)-1H-indazol-5-yl)-2-
-(pyrrolidin-1-yl)-2-(thiophen-3-yl)acetamide
##STR00249##
[0725] To a mixture of 1,4-diiodobenzene (3.299 g, 10 mmol),
trans-4-aminocyclohexanol (1.15 g, 10 mmol), CuI (391 mg, 2 mmol),
BINOL (572 mg, 2 mmol) and K3PO4 (4.24 g, 20 mmol) was added DMF
(30 mL). The resulting mixture was purged with Ar and stirred at rt
for 2 d. It was diluted with EtOAc (60 mL) and MeOH (30 mL),
sonicated, filtered through Celite (rinsed with EtOAc/MeOH),
concentrated and purified by flash chromatography (EtOAc/hex
0-100%) to give rel-(1r,4r)-4-((4-iodophenyl)amino)cyclohexanol as
blackish white solid (2.367 g, 75%). .sup.1H NMR (400 MHz, DMSO-d6)
.delta..quadrature.7.28 (d, J=8.8 Hz, 2H), 6.39 (d, J=8.8 Hz, 2H),
5.59 (d, J=8.0 Hz, 1H), 4.54 (br, s, 1H), 3.45-3.35 (m, 1H),
3.14-3.04 (m, 1H), 1.93-1.77 (m, 4H), 1.30-1.18 (m, 2H), 1.17-1.06
(m, 2H); MS ESI 318.0 [M+H].sup.+, calcd for
[C.sub.12H.sub.16INO+H].sup.+ 318.0.
[0726] To a mixture of
rel-(1r,4r)-4-((4-iodophenyl)amino)cyclohexanol (951 mg, 3 mmol),
Pd(CH.sub.3CN).sub.2Cl.sub.2 (15.6 mg, 0.06 mmol) and
dicyclohexyl(2',6'-dimethoxy-[1,1'-biphenyl]-2-yl)phosphine (98.5
mg, 0.24 mmol) in 1,4-dioxane (4.5 mL) was added Et.sub.3N (1.3 mL,
9 mmol), followed by pinacolborane (1.74 mL, 12 mmol) slowly. After
addition, the resulting mixture was purged with Ar and microwaved 2
h at 110.degree. C. It was combined with a 0.4 mmol scale reaction.
After removal of solvents, it was purified by flash chromatography
(EtOAc/hex 0-100%) to give
rel-(1r,4r)-4-((4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pheny-
l)amino)cyclohexanol (white solid, 1.028 g, 95%). .sup.1H NMR (400
MHz, CD.sub.3OD) .delta. 7.52 (d, J=8.4 Hz, 2H), 6.55 (d, J=8.4 Hz,
2H), 3.61-3.52 (m, 1H), 3.28-3.19 (m, 1H), 2.09-1.92 (m, 4H),
1.46-1.33 (m, 2H), 1.29 (s, 12H), 1.25-1.15 (m, 2H); MS ESI 318.1
[M+H].sup.+, calcd for [C.sub.18H.sub.28BNO.sub.3+H].sup.+
318.2.
[0727] To a mixture of
N-(3-iodo-1H-indazol-5-yl)-2-(pyrrolidin-1-yl)-2-(thiophen-3-yl)acetamide
(181 mg, 0.4 mmol) and
rel-(1r,4r)-4-((4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)ami-
no)cyclohexanol (127 mg, 0.4 mmol) in EtOH (10 mL) was added 1 M aq
Na.sub.2CO.sub.3 (0.8 mL, 0.8 mmol), followed by
Pd(PPh.sub.3).sub.4 (23 mg, 0.02 mmol). The resulting mixture was
purged with Ar and microwaved 3 h at 125.degree. C. Additional
Pd(PPh.sub.3).sub.4 (23 mg, 0.02 mmol) was added and the reaction
mixture was purged with Ar and microwaved 3 h at 125.degree. C.
After removal of solvents, it was purified by flash chromatography
(MeOH/DCM 0-25%), biotage RP column (MeOH/H.sub.2O (1% TFA) 0-50%)
and flash chromatography (EtOAc/hex 10-100%, then MeOH/DCM 0-20%)
to give the title compound (light brown solid, 21.2 mg, 10%).
.sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.31 (s, 1H), 7.66 (d,
J=8.4 Hz, 2H), 7.53-7.45 (m, 3H), 7.42 (dd, J=5.2 Hz, 2.8 Hz, 1H),
7.33 (dd, J=5.2 Hz, 1.2 Hz, 1H), 6.74 (d, J=8.4 Hz, 2H), 4.16 (s,
1H), 3.65-3.56 (m, 1H), 3.32-3.25 (m, 1H), 2.74-2.67 (m, 2H),
2.57-2.48 (m, 2H), 2.15-2.08 (m, 2H), 2.03-1.95 (m, 2H), 1.90-1.80
(m, 4H), 1.49-1.38 (m, 2H), 1.32-1.22 (m, 2H); MS ESI 516.3
[M+H].sup.+, calcd for [C.sub.29H.sub.33N.sub.5O.sub.2S+H].sup.+
516.2.
Example A106
rel-N-(cyclopropyl(phenyl)methyl)-3-(4-(((1r,4r)-4-hydroxycyclohexyl)amino-
)phenyl)-1H-indazole-5-carboxamide
##STR00250##
[0729] To a mixture of
N-(cyclopropyl(phenyl)methyl)-3-iodo-1H-indazole-5-carboxamide (167
mg, 0.4 mmol) and
rel-(r,4r)-4-((4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)amin-
o)cyclohexanol (127 mg, 0.4 mmol) in EtOH (10 mL) was added 1 M aq
Na2CO3 (0.8 mL, 0.8 mmol), followed by Pd(PPh.sub.3).sub.4 (46 mg,
0.04 mmol). The resulting mixture was purged with Ar and microwaved
5 h at 125.degree. C. After removal of solvents, it was purified by
flash chromatography (MeOH/DCM 0-20%), biotage RP column
(MeOH/H.sub.2O (1% TFA) 0-100%), PoraPak, flash chromatography
(EtOAc/hex 10-100%) and PoraPak to give the title compound (light
yellow solid, 55.4 mg, 29%). .sup.1H NMR (400 MHz, CD.sub.3OD)
.delta. 8.63 (s, 1H), 7.93 (dd, J=8.8 Hz, 1.6 Hz, 1H), 7.73 (d,
J=8.4 Hz, 2H), 7.54 (d, J=9.2 Hz, 1H), 7.45 (d, J=7.2 Hz, 2H), 7.29
(t, J=7.6 Hz, 2H), 7.20 (t, J=7.6 Hz, 1H), 6.72 (d, J=8.8 Hz, 2H),
4.46 (d, J=8.8 Hz, 1H), 3.61-3.53 (m, 1H), 3.27-3.19 (m, 1H),
2.11-2.03 (m, 2H), 2.00-1.92 (m, 2H), 1.45-1.32 (m, 3H), 1.28-1.17
(m, 2H), 0.65-0.56 (m, 2H), 0.50-0.37 (m, 2H); MS ESI 481.5
[M+H].sup.+, calcd for [C.sub.30H.sub.32N.sub.4O.sub.2+H].sup.+
481.3.
Example A107
(R)-2-methoxy-N-(3-(4-((1-(2-methoxyethyl)piperidin-4-yl)oxy)phenyl)-1H-in-
dazol-5-yl)-2-phenylacetamide
##STR00251##
[0731] The title compound was prepared using Method C3 from
(R)--N-(3-iodo-1H-indazol-5-yl)-2-methoxy-2-phenylacetamide (60 mg,
0.147 mmol) and
1-(2-methoxyethyl)-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-
-2-yl)phenoxy)piperidine (64 mg, 0.176 mmol) which gave 29 mg of
product isolated as its TFA salt (38%, an off-white solid). .sup.1H
NMR (400 MHz, CD.sub.3OD) .delta. ppm 8.40 (s, 1H), 7.87-7.83 (m,
2H), 7.54-7.48 (m, 4H), 7.42-7.33 (m, 3H), 7.18-7.11 (m, 2H), 4.87
(bs, 1H), 4.83 (s, 1H), 3.76-3.21 (m, 8H), 3.50 (s, 3H), 3.46 (s,
3H), 2.43-2.27 (m, 2H), 2.19-1.94 (m, 2H); MS ESI 515.4
[M+H].sup.+, calcd for [C.sub.30H.sub.34N.sub.4O.sub.4+H].sup.+
515.27.
Example A108
3-(4-(1-Methylpiperidin-4-yloxy)phenyl)-N-(2-morpholinobenzyl)-1H-indazole-
-5-carboxamide
##STR00252##
[0732] A.
3-Iodo-N-(2-morpholinobenzyl)-1H-indazole-5-carboxamide
[0733] The title compound was synthesized according to Method A,
utilizing 3-iodo-1H-indazole-5-carboxylic acid (150 mg, 0.52 mmol),
(2-morpholinophenyl)methanamine (120 mg, 0.0.57 mmol), TBTU (184
mg, 0.57 mmol), DIPEA (0.36 mL, 2.1 mmol), and DMF (4 mL). H2O (20
mL) was added and the product was extracted into EtOAc (4.times.20
mL). The combined organic layers were dried over MgSO.sub.4,
filtered and evaporated in vacuo. The residue was then dissolved in
MeOH (20 mL) and poured into a preconditioned 20 mL PoraPak Rxn Cx
cartridge. The MeOH (30 mL) rinse was discarded and the product was
eluted with 2 M NH3 in MeOH (30 mL). The solvent was removed in
vacuo, and the product was used without further purification (99%,
240 mg). .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. ppm 8.08 (s,
1H), 7.98-7.96 (m, 1H), 7.57 (d, J=8.9 Hz, 1H), 7.37-7.32 (m, 1H),
7.26 (t, J=7.5 Hz, 1H), 7.18 (d, J=7.8 Hz, 1H), 7.10 (t, J=7.2 Hz,
1H), 4.76 (s, 2H), 3.84 (br m, 4H), 2.92-2.86 (br m, 4H); MS ESI
463.1 [M+H].sup.+, calcd for
[C.sub.19H.sub.191N.sub.4O.sub.2+H].sup.+ 463.06.
B.
3-(4-(1-Methylpiperidin-4-yloxy)phenyl)-N-(2-morpholinobenzyl)-1H-indaz-
ole-5-carboxamide
[0734] The title compound was synthesized according to Method C,
utilizing 3-iodo-N-(2-morpholinobenzyl)-1H-indazole-5-carboxamide
(113 mg, 0.24 mmol),
1-methyl-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy-
)piperidine (85 mg, 0.27 mmol), Pd(PPh.sub.3).sub.4 (28 mg, 0.024
mmol), 2 M Na.sub.2CO.sub.3 (0.30 mL), PhMe (4 mL), and EtOH (2
mL). H.sub.2O (30 mL) was added and the product was extracted into
EtOAc (4.times.30 mL). The combined organic layers were dried over
MgSO.sub.4, filtered and evaporated in vacuo. Purification by flash
chromatography (Biotage, 25 g HP-SIL, 2-30% MeOH in DCM) followed
by RP HPLC (Biotage, 60 g C18-H, 0.1% TFA-H.sub.2O in MeOH, 10-90%)
gave the title compound as a white solid (45 mg, 29%). The title
compound was isolated as a TFA salt. .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. ppm 8.65 (s, 1H), 8.01 (dd, J=8.8 Hz, 1.4 Hz,
1H), 7.95 (t, J=8.6 Hz, 2H), 7.72 (d, J=7.9 Hz, 1H), 7.55-7.50 (m,
4H), 7.23 (d, J=8.8 Hz, 1.3H), 7.18 (d, J=8.8 Hz, 0.7H), 4.89-4.85
(br m, 1H), 4.77-4.67 (m, 2.4H), 4.24 (br m, 4H), 3.65-3.58 (br m,
4H), 3.47-3.36 (m, 3H), 3.23 (td, J=12.9, 2.8 Hz, 0.85H), 2.94,
2.93 (2 s, 3H), 2.47-2.43 (m, 0.7H), 2.33-2.30 (m, 1.4H), 2.20-2.12
(m, 1.4H), 2.00-1.89 (m, 0.74H); MS ESI 526.3 [M+H].sup.+, calcd
for [C.sub.31H.sub.35N.sub.5O.sub.3+H].sup.+ 526.27.
Example A109
3-(4-(1-Methylpiperidin-4-yloxy)phenyl)-N-(2-(morpholinomethyl)benzyl)-1H--
indazole-5-carboxamide
##STR00253##
[0735] A.
3-Iodo-N-(2-(morpholinomethyl)benzyl)-1H-indazole-5-carboxamide
[0736] The title compound was synthesized according to Method A,
utilizing 3-iodo-1H-indazole-5-carboxylic acid (150 mg, 0.52 mmol),
(2-(morpholinomethyl)phenyl)methanamine (118 mg, 0.0.57 mmol), TBTU
(184 mg, 0.57 mmol), DIPEA (0.36 mL, 2.1 mmol), and DMF (4 mL). H2O
(20 mL) was added and the product was extracted into EtOAc
(4.times.20 mL). The combined organic layers were dried over
MgSO.sub.4, filtered and evaporated in vacuo. The residue was then
dissolved in MeOH (20 mL) and poured into a preconditioned 20 mL
PoraPak Rxn Cx cartridge. The MeOHEtOH (30 mL) rinse was discarded
and the product was eluted with 2 M NH.sub.3 in MeOHEtOH (30 mL).
The solvent was removed in vacuo, and the product was used without
further purification (220 mg, 89%). .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. ppm 8.01 (s, 1H), 7.92 (dd, J=8.8, 1.6 Hz, 1H),
7.61 (d, J=8.8 Hz, 1H), 7.45 (d, J=7.5 Hz, 1H), 7.34-7.25 (m, 4H),
4.77 (s, 2H), 3.64 (s, 2H), 3.56 (t, J=4.7 Hz, 4H), 2.47 (br m,
4H); MS ESI 477.2 [M+H].sup.+, calcd for
[C.sub.20H.sub.21IN.sub.4O.sub.2+H].sup.+ 477.07.
B.
3-(4-(1-Methylpiperidin-4-yloxy)phenyl)-N-(2-(morpholinomethyl)benzyl)--
1H-indazole-5-carboxamide
[0737] The title compound was synthesized according to Method C,
utilizing
3-iodo-N-(2-(morpholinomethyl)benzyl)-1H-indazole-5-carboxamide
(110 mg, 0.23 mmol),
1-methyl-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)piperi-
dine (81 mg, 0.25 mmol), Pd(PPh.sub.3).sub.4 (27 mg, 0.023 mmol), 2
M Na.sub.2CO.sub.3 (0.30 mL), PhMe (4 mL), and EtOH (2 mL). H2O (30
mL) was added and the product was extracted into EtOAc (4.times.30
mL). The combined organic layers were dried over MgSO.sub.4,
filtered and evaporated in vacuo. Purification by flash
chromatography (Biotage, 25 g HP-SIL, EtOAc then 2-30% MeOH in DCM)
followed by RP HPLC (Biotage, 60 g Rp-C18-H, 0.1% TFA-H.sub.2O in
MeOH, 10-90%) gave the title compound as a white solid (53 mg,
30%). The title compound was isolated as a di-TFA salt. .sup.1H NMR
(400 MHz, CD.sub.3OD) .delta. ppm 8.65 (s, 1H), 8.00-7.94 (m, 3H),
7.66-7.63 (m, 2H), 7.54 (td, J=7.4, 1.1 Hz, 1H), 7.46 (d, J=6.8 Hz,
1H), 7.40 (t, J=7.4 Hz, 1H), 7.25-7.18 (m, 2H), 4.81-4.69 (m,
0.5H), 4.64, 4.63 (2 s, 2H), 4.13-4.11 (m, 2H), 4.00 (t, J=11.9 Hz,
2H), 3.67-3.65 (m, 0.68H), 3.53-3.40 (m, 5H), 3.24 (td, J=12.7, 2.4
Hz, 1H), 2.96, 2.95 (2 s, 3H), 2.47-2.44 (m, 0.65H), 2.34-2.30 (m,
1.3H), 2.21-2.14 (m, 1.4H), 2.00-1.90 (m, 0.71H); MS ESI 540.3
[M+H].sup.+, calcd for [C.sub.32H.sub.37N.sub.5O.sub.3+H].sup.+
540.29.
Example A 110
N-(cyclopentyl(thiophen-3-yl)methyl)-3-(4-((1-methylpiperidin-4-yl)oxy)phe-
nyl)-1H-indazol-5-carboxamide
##STR00254##
[0739] The title compound was synthesized according to general
Method C from
N-(cyclopentyl(thiophen-3-yl)methyl)-3-iodo-1H-indazole-5-carboxamid-
e (150 mg, 0.332 mmol) and
1-methyl-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)piperi-
dine (106 mg, 0.334 mmol) with PdCl.sub.2dppf (35 mg, 0.042 mmol)
and 1 M aq Na2CO3 (0.64 mL) in PhMe/EtOH (3.75 mL, 2:1 mixture)
under Ar with heating under microwave irradiation at 125.degree. C.
for 4 h. The reaction mixture was diluted with EtOAc (25 mL) and
washed with H.sub.2O (10 mL) and brine (10 mL), dried
(Na.sub.2SO.sub.4) and concentrated under vacuum. Purification by
flash chromatography (SiO2, 0-20% 2 M NH.sub.3-MeOH in DCM; then RP
HPLC C18 60 g, 10-80% MeOH in 0.1% TFA-H.sub.2O) gave the title
compound as a TFA salt (off white solid, 60 mg, 28%). .sup.1H NMR
(400 MHz, CD.sub.3OD), .delta. 8.52 (s, 1H), 7.94-7.88 (m, 3H), 7.6
(d, J=8.8 Hz, 1H), 7.36-7.32 (m, 2H), 7.20-7.13 (m, 3H), 5.08 (d,
J=6.0 Hz, 1H), 4.85 (s, 1H), 3.66 (t, J=13.6 Hz, 1H), 3.44-3.32 (m,
5H), 3.23 (br.m, 1H), 2.59-2.53 (br.m, 1H), 2.45-2.27 (m, 2H),
2.16-1.87 (m, 3H), 1.74-1.44 (br.m, 6H), 1.28-1.25 (m, 1H); MS ESI
515.4[M+H].sup.+, calcd for
[C.sub.30H.sub.34N.sub.4O.sub.2S+H].sup.+ 515.2.
Example A111
N-(3-(4-(4-(2-hydroxypropan-2-yl)piperidin-1-yl)phenyl)-1H-indazol-5-yl)-2-
-(pyrrolidin-1-yl)-2-(thiophen-3-yl)acetamide
##STR00255##
[0741] The title compound was synthesized according to Method C3
utilizing
N-(3-iodo-1H-indazol-5-yl)-2-(pyrrolidin-1-yl)-2-(thiophen-3-yl)acetamide
and
2-(1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperidin-
-4-yl)propan-2-ol and obtained as a white solid (21 mg, 23% yield).
.sup.1H NMR (400 MHz, CD.sub.3OD) .delta. ppm 8.43 (s, 1H), 8.15
(d, J=8.8 Hz, 2H), 7.88 (m, 1H), 7.83 (d, J=8.8 Hz, 2H), 7.65 (m,
1H), 7.58 (m, 2H), 7.38 (d, J=5.2 Hz, 1H), 5.31 (s, 1H), 3.83 (m,
3H), 3.70 (m, 2H), 3.33 (m, 2H), 3.15 (m, 2H), 2.16 (m, 5H), 1.92
(m, 3H), 1.27 (s, 6H); MS ESI [M+H].sup.+ 544.2, calcd for
[C.sub.31H.sub.37N.sub.5O.sub.2S+H].sup.+ 544.27.
Example A112
N-(cyclopropyl(phenyl)methyl)-3-(4-(4-(2-hydroxypropan-2-yl)piperidin-1-yl-
)phenyl)-1H-indazole-5-carboxamide
##STR00256##
[0743] The title compound was synthesized according to Method C3
utilizing
N-(cyclopropyl(phenyl)methyl)-3-iodo-1H-indazole-5-carboxamide and
2-(1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperidin-4-y-
l)propan-2-ol and obtained (white solid, 21 mg, 22% yield). .sup.1H
NMR (400 MHz, CD.sub.3OD) .delta. ppm 8.63 (s, 1H), 7.95 (dd,
J=8.78, 1.51 Hz, 1H), 7.85 (d, J=8.78 Hz, 2H), 7.58 (d, J=8.78 Hz,
1H), 7.48 (d, J=7.28 Hz, 2H), 7.32 (t, J=7.53 Hz, 2H), 7.23 (m,
J=7.28 Hz, 1H), 7.09 (d, J=8.78 Hz, 2H), 5.49 (s, 1H), 4.48 (d,
J=9.54 Hz, 1H), 3.84 (d, J=12.30 Hz, 2H), 2.66 (t, J=11.04 Hz, 2H),
1.87 (d, J=9.29 Hz, 2H), 1.46 (d, J=3.51 Hz, 3H), 1.18 (s, 6H),
0.65 (d, J=8.28 Hz, 2H), 0.46 (d, J=15.31 Hz, 2H); MS ESI
[M+H].sup.+ 509.5, calcd for
[C.sub.32H.sub.36N.sub.4O.sub.2+H].sup.+ 509.29.
Example A 113
N-(3-(3-(dimethylamino)-4-((1-methylpiperidin-4-yl)oxy)phenyl)-1H-indazol--
5-yl)-2-(pyrrolidin-1-yl)-2-(thiophen-3-yl)acetamide
##STR00257##
[0744] A. 4-(4-bromo-2-nitrophenoxy)-1-methylpiperidine
[0745] NaH (0.54 g, 13 mmol) was added portion wise to a solution
of N-methyl-4-piperidinol (1.13 g, 11 mmol) in DMF (14 mL) at rt
under Ar, followed by a solution of 4-bromo-1-fluoro-2-nitrobenzene
(2.0 g, 9 mmol) in DMF (6 mL). The reaction mixture was heated at
75.degree. C. for 16 h. The product was partitioned between 20%
NaCl and EtOAc (2.times.300 mL), and the combined EtOAc layer was
washed with H.sub.2O and brine, dried (Na.sub.2SO.sub.4) and
concentrated under vacuum to give the title compound (yellowish
orange oil, 2.78 g, 97%). .sup.1H NMR (400 MHz, CD.sub.3Cl.sub.3)
7.94 (d, J=2.4 Hz, 1H), 7.60 (dd, J=8.8 Hz, J=2.4 Hz, 1H), 6.98 (d,
J=9.2 Hz, 1H), 4.52 (s, 1H), 2.60 (br.s, 2H), 2.40 (br.s, 2H), 2.31
(s, 3H), 2.03-1.89 (m, 4H); MS ESI 316.9 [M+H].sup.+, calcd for
[C.sub.12H.sub.15BrN.sub.2O.sub.3+H].sup.+ 315
B. 5-bromo-2-((1-methylpiperidin-4-yl)oxy)aniline
[0746] 1 M HCl (10 mL) was added slowly over 15 min to a suspension
4-(4-bromo-2-nitrophenoxy)-1-methylpiperidine (2.75 g, 8.7 mmol)
and iron powder (9.75 g, 174 mmol) in PhMe (30 mL) and EtOH (10 mL)
at 60.degree. C. The reaction mixture was gradually heated to
100.degree. C. and stirred for 4 h. The solid sludge was filtered
through SiO2 pad at 90.degree. C. and washed with hot EtOAc. The
organic layer was washed with 1 M aq Na.sub.2CO.sub.3 (50 mL) and
brine and dried (Na.sub.2SO.sub.4) and concentrated under vacuum.
Purification by flash chromatography (SiO2, 0-75% MeOH in DCM) gave
the title compound (brown solid, 1.0 g, 40%). .sup.1H NMR (400 MHz,
CDCl.sub.3)) .delta. ppm 6.85 (d, J=2.0 Hz, 1H), 6.79 (dd, J=8.8
Hz, J=2.4 Hz, 1H), 6.66 (d, J=8.8 Hz, 1H), 4.28 (s, 1H),), 3.86 (s,
2H), 2.69-2.66 (br.s, 2H), 2.31 (s, 5H), 2.06-2.02 (br.m, 2H),
1.91-1.83 (br.m, 2H); MS ESI 287 [M+H].sup.+, calcd for
[C.sub.12H.sub.17BrN.sub.2O+H].sup.+ 285.
C. 5-bromo-N,N-dimethyl-2-((1-methylpiperidin-4-yl)oxy)aniline
[0747] NaBH(OAc).sub.3 (3.3 g, 15.5 mmol) was added to an ice
cooled solution of 5-bromo-2-((1-methylpiperidine-4-yl)oxy) aniline
(0.74 g, 2.6 mmol) and 37% aq. solution of formaldehyde (2.11 g, 26
mmol) in MeCN (22.2 mL). The reaction mixture was stirred overnight
at RT and then concentrated under vacuum. The product was
partitioned between 2 M Na.sub.2CO.sub.3 and EtOAc. The aq. layer
was extracted with EtOAc and the combined EtOAc layer was washed
with H.sub.2O and brine, dried (Na.sub.2SO.sub.4) and concentrated
under vacuum. Purification by flash chromatography (SiO2, 0-25% DCM
in MeOH) gave the title compound (thick brown oil, 0.65 g, 80%).
.sup.1H NMR (400 MHz, CDCl.sub.3)) .delta. ppm 6.99-6.97 (t, J=2.4
Hz, 2H), 6.73 (d, J=9.2 Hz, 1H), 4.30 (br.t, 1H), 2.80 (s, 6H),
2.76-2.73 (br.s, 2H), 2.31 (s, 3H), 2.29-2.65 (br.m, 2H), 2.05-2.0
(br.m, 2H), 1.92-1.84 (m, 2H); MS ESI 313 [M+H].sup.+, calcd for
[C.sub.14H.sub.21BrN.sub.2O+H].sup.+ 313.1
D.
N,N-dimethyl-2-((1-methylpiperidin-4-yl)oxy)-5-(4,4,5,5-tetramethyl-1,3-
,2-dioxaborolan-2-yl)aniline
[0748] Using Method E with
5-bromo-N,N-dimethyl-2-((1-methylpiperidin-4-yl)oxy)aniline (200
mg, 0.638 mmol) in DMF (3 mL) at 125.degree. C. for 4 h, aq.
work-up and purification by flash chromatography (SiO2, 0-30% 2 M
NH.sub.3-MeOH in DCM) gave the title compound (brown color solid,
74 mg, 32%). .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. ppm
7.41-7.36 (m, 2H), 6.86 (d, J=8 Hz, 1H), 4.44 (br.d, 1H), 2.82 (s,
6H), 2.75-2.73 (br.s, 2H), 2.32 (br.d, 5H), 2.09-2.05 (br.m, 2H),
1.97-1.89 (br.m, 2H), 1.33 (s, 12H); MS ESI 361.2 [M+H].sup.+,
calcd for [C.sub.20H.sub.33BN.sub.2O.sub.3+H].sup.+ 361.2
E.
N-(3-(3-(dimethylamino)-4-((1-methylpiperidin-4-yl)oxy)phenyl)-1H-indaz-
ol-5-yl)-2-(pyrrolidin-1-yl)-2-(thiophen-3-yl)acetamide
[0749] According to general Method C2,
N-(3-iodo-1H-indazol-5-yl)-2-(pyrrolidin-1-yl)-2-(thiophen-3-yl)acetamide
(90 mg, 0.195 mmol) and
N,N-dimethyl-2-((1-methylpiperidin-4-yl)oxy)-5-(4,4,5,5-tetramethyl-1,3,2-
-dioxaborolan-2-yl)aniline (72 mg, 0.98 mmol) were heated under
microwave irradiation at 125.degree. C. for 4 h in PhMe/EtOH (2.7
mL, 2:1 mixture). Purification by flash chromatography (SiO2, 0-50%
2 M NH.sub.3-MeOH in DCM; then RP HPLC C18RP HPLC C18 60 g, 10-80%
MeOH in 0.1% TFA-H.sub.2O) gave the title compound as a TFA salt
(off white solid, 30 mg, 19%). .sup.1H NMR (400 MHz, CD.sub.3OD).
.sup.1H NMR (400 MHz, CD.sub.3OD). .delta. 8.44 (d, J=12.4 Hz, 1H),
8.26 (s, 1H), 80.8-80.5 (m, 1H), 7.88 (t, J=2.0 Hz, 1H), 7.66 (dd,
J=5.2 Hz, J=3.2 Hz, 1H), 7.58-7.54 (m, 3H), 7.39 (d, J=8.0 Hz, 1H),
5.30 (s, 1H), 5.11 (s, 0.6H), 3.87 (br.s, 1H), 3.75-3.71 (br.m,
1H), 3.60-3.57 (br.m, 2H), 3.43 (d, J=16.8 Hz, 6H), 3.28-3.1 (br.m,
3H), 2.97 (s, 3H), 2.56-2.53 (br.m, 1H), 2.46-2.42 (br.m, 1H),
2.31-1.99 (br.m, 6H), 1H merged with solvent peak; MS ESI 559.2
[M+H].sup.+, calcd for [C.sub.31H.sub.38N.sub.6O.sub.2S+H].sup.+
559.3.
Example A114
1-(2,6-diethylphenyl)-3-(3-(4-methyl-2,3,4,5-tetrahydrobenzo[f][1,4]oxazep-
in-7-yl)-1H-indazol-5-yl)urea
##STR00258##
[0751] Using Method J,
3-(4-methyl-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepin-7-yl)-1H-indazol-5-am-
ine bis(2,2,2-trifluoroacetate) (74 mg, 0.152 mmol),
1,3-diethyl-2-isocyanatobenzene (52 uL, 0.300 mmol) and DIPEA (130
uL, 0.750 mmol) in DMF (1.5 mL) gave the title compound as a TFA
salt (29 mg, 41%, a brown solid). .sup.1H NMR (400 MHz, CD.sub.3OD)
.delta. ppm 8.39 (s, 1H), 7.99-7.96 (m, 2H), 7.52 (d, J=8.8 Hz,
1H), 7.28-7.10 (m, 5H), 4.62 (s, 2H), 4.54-4.51 (bs, 1H), 4.18-4.10
(bs, 1H), 3.73 (bs, 2H), 3.08-3.03 (m, 3H), 2.71 (q, J=7.2 Hz, 4H),
1.24 (t, J=7.6 Hz, 6H); MS ESI 470.4 [M+H].sup.+, calcd for
[C.sub.28H.sub.31N.sub.5O.sub.2+H].sup.+ 470.26.
Example A115
tert-butyl
4-(4-(5-(2-(pyrrolidin-1-yl)-2-(thiophen-3-yl)acetamido)-1H-ind-
azol-3-yl)phenoxy)piperidine-1-carboxylate
##STR00259##
[0753] The title compound was synthesized according to Method C3
utilizing
N-(3-iodo-1H-indazol-5-yl)-2-(pyrrolidin-1-yl)-2-(thiophen-3-yl)acetamide
and tert-butyl
4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)piperidine-1-ca-
rboxylate and obtained as a pale white solid (14 mg, 21% yield).
.sup.1H NMR (400 MHz, CD.sub.3OD) .delta. ppm 8.33 (s, 1H), 7.81
(d, J=8.8 Hz, 2H), 7.50 (m, 3H), 7.42 (dd, J=4.8 Hz, 2.8 Hz, 1H),
7.33 (m, 1H), 7.07 (d, J=8.8 Hz, 2H), 4.63 (m, 1H), 4.14 (s, 1H),
3.73 (m, 2H), 3.33 (m, 2H), 2.69 (m, 2H), 2.51 (m, 2H), 1.90 (m,
2H), 1.70 (m, 4H), 1.48 (s, 9H); MS ESI [M+H].sup.+602.4, calcd for
[C.sub.33H.sub.39N.sub.5O.sub.4S+H].sup.+ 602.28.
Example A116
N-(3-(4-(4-methoxypiperidin-1-yl)phenyl)-1H-indazol-5-yl)-2-(pyrrolidin-1--
yl)-2-(thiophen-3-yl)acetamide
##STR00260##
[0755] To a solution of
1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperidin-4-ol
(152 mg, 0.5 mmol) in DMF (5 mL) at rt was added 60% NaH (40 mg, 1
mmol). The resulting mixture was stirred at rt for 10 min before
MeI (0.031 mL, 0.5 mmol) was added. After addition, the resulting
mixture was stirred O/N at rt. This reaction was repeated on 1 mmol
sacle (rt, 2 h). Both reactions were combined, queched with satd
aqNH.sub.4Cl (5 mL) and H.sub.2O (100 mL), extracted with EtOAc and
purified by flash chromatography (EtOAc/hex 0-30%) to give
4-methoxy-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperi-
dine (white solid, 95 mg, 20%). MS ESI 318.1 [M+H].sup.+, calcd for
[C.sub.18H.sub.28BNO.sub.3+H].sup.+ 318.2.
[0756] To a mixture of
N-(3-iodo-1H-indazol-5-yl)-2-(pyrrolidin-1-yl)-2-(thiophen-3-yl)acetamide
(136 mg, 0.3 mmol) and
4-methoxy-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperi-
dine (95 mg, 0.3 mmol) in EtOH (4 mL) was added 1 M aq Na2CO3 (0.6
mL, 0.6 mmol), followed by Pd(PPh.sub.3).sub.4 (17.4 mg, 0.015
mmol). The resulting mixture was purged with Ar and microwaved 4 h
at 125.degree. C. After removal of solvents, it was purified by
flash chromatography (EtOAc/hex 0-100%, then MeOH/DCM 15%), biotage
RP column (MeOH/H.sub.2O (1% TFA) 0-100%) to give the title
compound as a di-TFA salt
[0757] (light yellow solid, 57.6 mg, 26%). .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. 8.42 (s, 1H), 8.11 (d, J=8.4 Hz, 2H), 7.88 (dd,
J=2.8 Hz, 1.2 Hz, 1H), 7.74 (br d, J=8.0 Hz, 2H), 7.64 (dd, J=5.0
Hz, 3.0 Hz, 1H), 7.60-7.53 (m, 2H), 7.39 (dd, J=4.8 Hz, 1.2 Hz,
1H), 5.33 (s, 1H), 3.90-3.77 (m, 3H), 3.71-3.64 (m, 1H), 3.62-3.53
(m, 2H), 3.44 (s, 3H), 3.35-3.05 (m, 3H), 2.31-1.93 (m, 8H); MS ESI
516.2 [M+H].sup.+, calcd for
[C.sub.27H.sub.32N.sub.5O.sub.2S+H].sup.+ 516.2.
Example A117
N-(cyclopropyl(thiophen-3-methyl-3-yl)methyl)-3-(4-((1-(2-hydroxyethyl)pip-
eridin-4-yl)oxy)phenyl)-1H-indazole-5-carboxamide
##STR00261##
[0759] The title compound was prepared using Method C3 from
N-(cyclopropyl(thiophen-3-yl)methyl)-3-iodo-1H-indazole-5-carboxamide
(40 mg, 0.095 mmol) and
2-(4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)piperidin-1--
yl)ethanol (43 mg, 0.124 mmol) which gave 14 mg of product isolated
as its TFA salt (23%, a white solid). .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. ppm 9.04 (bs, 1H), 8.58 (s, 1H), 7.96-7.94 (m,
3H), 7.61 (d, J=8.8 Hz, 1H), 7.37 (bs, 2H), 7.22-7.15 (m, 3H), 4.87
(bs, 1H), 4.65-4.61 (m, 1H), 3.91-3.28 (m, 12H), 2.45-2.29 (m, 2H),
2.21-1.95 (m, 2H), 1.44-1.40 (m, 1H), 0.73-0.63 (m, 2H), 0.50-0.48
(m, 2H); MS ESI 517.3 [M+H].sup.+, calcd for
[C.sub.29H.sub.32N.sub.4O.sub.3S+H].sup.+ 517.23.
Example A 118.
N-(3-4-((1-formylpiperidin-4-yl)oxy)phenyl)-1H-indazol-5-yl)-2-(pyrrolidi-
n-1-yl)-2-(thiophen-3-yl)acetamide
##STR00262##
[0761] The title compound was synthesized according to Method C3
utilizing
N-(3-iodo-1H-indazol-5-yl)-2-(pyrrolidin-1-yl)-2-(thiophen-3-yl)acetamide
and
4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)piperidine--
1-carbaldehyde and obtained as a yellow solid (39 mg, 35% yield).
.sup.1H NMR (400 MHz, CD.sub.3OD) .delta. ppm 8.35 (s, 1H), 8.04
(s, 1H), 7.82 (d, J=8.8 Hz, 2H), 7.50 (m, 3H), 7.40 (m, 1H), 7.33
(m, 1H), 7.08 (d, J=8.8 Hz, 2H), 4.72 (m, 1H), 4.16 (s, 1H), 3.75
(m, 2H), 3.67 (m, 2H), 3.52 (m, 2H), 3.41 (m, 2H), 2.67 (m, 2H),
2.51 (m, 2H), 1.98 (m, 2H), 1.80 (m, 6H); MS ESI [M+H].sup.+ 530.4,
calcd for [C.sub.29H.sub.31N.sub.5O.sub.3S+H].sup.+ 530.22.
Example A119
N-(cyclopropyl(o-tolyl)methyl)-3-(4-morpholinophenyl)-1H-indazole-5-carbox-
amide
##STR00263##
[0763] To a 20 mL microwave vial charged with Mg powder (240 mg, 10
mmol), THF (10 mL) was added bromocyclopropane (1.21 g, 10 mmol).
The resulting mixture was stirred for 30 min at rt before
2-methylbenzonitrile (468 mg, 4 mmol) was added. It was microwaved
10 min at 100.degree. C., cooled to rt and added dropwise to a cold
solution of NaBH.sub.4 (380 mg, 10 mmol) in MeOH (25 mL) at
0.degree. C. The resulting mixture was stirred for 15 min at rt,
concentrated and purified by flash chromatography (MeOH/DCM 0-20%)
to give cyclopropyl(o-tolyl)methanamine (yellow oil which
solidified upon standing, 0.70 g, 87%). .sup.1H NMR (400 MHz,
CD3OD) .delta. 8.49 (d, J=7.6 Hz, 1H), 7.27-7.22 (m, 1H), 7.20-7.17
(m, 2H), 3.75 (d, J=8.4 Hz, 1H), 2.35 (s, 3H), 1.37-1.27 (m, 1H),
0.71-0.63 (m, 1H), 0.53-0.46 (m, 1H), 0.38-0.31 (m, 1H), 0.29-0.33
(m, 1H); MS ESI 145.0 [M+H], calcd for
[C.sub.11H.sub.15N--NH.sub.3+H].sup.+ 145.1.
[0764] To a solution of 3-iodo-1H-indazole-5-carboxylic acid (1.44
g, 5 mmol) and (4-morpholinophenyl)boronic acid (1.09 g, 5.25 mmol)
in DMF (10 mL) was added a solution of K.sub.3PO.sub.4 (3.18 g, 15
mmol) in H.sub.2O (4 mL), followed by Pd(PPh.sub.3).sub.4 (116 mg,
0.1 mmol). The resulting mixture was purged with Ar and microwaved
5 h at 120.degree. C. Repeated this reaction on the same sacle and
the two reactions were combined. After separation of DMF layer, the
aq. layer was extracted with EtOAc. The combined organic layers
were concentrated to dryess, suspended in MeOH (60 mL), treated
with 4 mL of TFA, sonicated and filtered to give
3-(4-morpholinophenyl)-1H-indazole-5-carboxylic acid (yellow solid,
1.162 g, 36%). .sup.1H NMR (400 MHz, DMSO-d6) .delta. 13.4 (s, 1H),
12.8 (br, s, 1H), 8.61 (s, 1H), 7.94 (dd, J=8.8 Hz, 1H), 7.83 (d,
J=8.8 Hz, 2H), 7.61 (d, J=8.8 Hz, 1H), 7.13 (d, J=8.8 Hz, 2H), 3.77
(t, J=4.8 Hz, 4H), 3.20 (t, J=4.8 Hz, 4H); MS ESI 324.1
[M+H].sup.+, calcd for [C.sub.18H.sub.17N.sub.3O.sub.3+H].sup.+
324.1.
[0765] To a solution of cyclopropyl(o-tolyl)methanamine (80.5 mg,
0.5 mmol), 3-(4-morpholinophenyl)-1H-indazole-5-carboxylic acid
(194 mg, 0.6 mmol) and TBTU (160.5 mg, 0.5 mmol) in DMF (6 mL) was
added .sup.iPr.sub.2NEt (0.174 mL, 1 mmol). The resulting mixture
was stirred for 30 min at rt. After removal of .sup.iPr.sub.2NEt,
it was purified by prep-HPLC, PoraPak and flash chromatography
(MeOH/DCM 10-20%) to give the title compound (white solid, 88.7 mg,
38%). .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.99 (d, J=8.0 Hz,
0.5H, NH), 8.58 (s, 1H), 7.91 (d, J=8.8 Hz, 1H), 7.78 (d, J=8.4 Hz,
2H), 7.56 (d, J=7.6 Hz, 1H; partially overlapped with the peak at
7.53), 7.53 (d, J=8.8 Hz, 1H; partially overlapped with the peak at
7.56), 7.14-7.04 (m, 3H), 6.92 (d, J=8.8 Hz, 2H), 4.90-4.86 (m, 1H;
partially buried under H.sub.2O peak), 3.74 (t, J=4.6 Hz, 4H), 3.05
(t, J=4.8 Hz, 4H), 2.37 (s, 3H), 1.45-1.35 (m, 1H), 0.63-0.42 (m,
3H), 0.33-0.27 (m, 1H); MS ESI 467.5 [M+H].sup.+, calcd for
[C.sub.29H.sub.30N.sub.4O.sub.2+H].sup.+ 467.2.
Example A120
N-(3-(4-(3-Hydroxyazetidin-1-yl)phenyl)-1H-indazol-5-yl)-2-(pyrrolidin-1-y-
l)-2-(thiophen-3-yl)acetamide
##STR00264##
[0766] A. Azetidin-3-ol
[0767] A solution of tert-butyl 3-hydroxyazetidine-1-carboxylate
(1.0 g, 5.84 mmol) and TFA (5 mL) in DCM (10 mL) was stirred at rt
for 1 h. The solvent was removed in vacuo. The residue was then
dissolved in MeOH (20 mL) and poured into a preconditioned 20 mL
PoraPak Rxn Cx cartridge. The MeOHEtOH (30 mL) rinse was discarded
and the product was eluted with 2 M NH.sub.3 in MeOHEtOH (30 mL).
The solvent was removed in vacuo, and the product was used without
further purification. .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. ppm
4.56 (quint, J=6.8 Hz, 1H), 3.64 (t, J=7.0 Hz, 2H), 3.50 (t, J=7.0
Hz, 2H); MS ESI 74.2 [M+H].sup.+, calcd for
[C.sub.cH.sub.7NO+H].sup.+ 74.05.
B. 1-(4-Iodophenyl)azetidin-3-ol
[0768] The title compound was synthesized according to Method I,
utilizing 1,4-diiodobenzene (470 mg, 1.4 mmol), azetidin-3-ol (125
mg, 1.7 mmol), CuI (54 mg, 0.29 mmol), BINOL (82 mg, 0.29 mmol),
and K.sub.3PO.sub.4 (610 mg, 2.9 mmol) in DMF (5 mL). The mixture
was diluted with EtOAc, filtered through a cake of Celite and the
filtrate was concentrated to give the crude product. Purification
by flash chromatography (Biotage, 25 g HP-SIL, 20-100% EtOAc in
Hexanes) gave the title compound as a white solid (262 mg, 67%).
.sup.1H NMR (400 MHz, CD.sub.3OD) .delta. ppm 7.43 (d, J=8.8 Hz,
2H), 6.27 (d, J=8.8 Hz, 2H), 4.65 (quint, J=4.9 Hz, 1H), 4.10 (t,
J=7.4 Hz, 2H), 3.57 (dd, J=8.4, 4.9 Hz, 2H); MS ESI 275.9
[M+H].sup.+, calcd for [C.sub.9H.sub.10INO+H].sup.+ 275.98.
C.
1-(4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)azetidin-3-ol
[0769] The title compound was synthesized according to Method E,
utilizing 1-(4-Iodophenyl)azetidin-3-ol (290 mg, 0.96 mmol),
bis(pinacolato)diboron (366 mg, 1.4 mmol), PdCl.sub.2(dppf) (39 mg,
0.048 mmol), KOAc (280 mg, 2.9 mmol) and DMSO (4.0 mL). The
reaction was quenched with satd aqNaHCO.sub.3 solution, extracted
with EtOAc, dried over MgSO.sub.4, filtered, and concentrated to
dryness. Purification by flash chromatography (Biotage, 50 g
HP-SIL, 10-50% EtOAc in Hexanes) gave the title compound as a
yellow oil (260 mg, 100%). .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. ppm 7.65 (d, J=8.4 Hz, 2H), 6.40 (d, J=8.4 Hz, 2H), 4.98
(quint, J=4.8 Hz, 1H), 4.18 (dd, J=15, 8.0 Hz, 2H), 3.76 (dd,
J=8.4, 4.6 Hz, 2H), 1.31 (s, 12H); MS ESI 276.0 [M+H].sup.+, calcd
for [C.sub.15H.sub.22BNO.sub.3+H].sup.+ 276.17.
D.
N-(3-(4-(3-Hydroxyazetidin-1-yl)phenyl)-1H-indazol-5-yl)-2-(pyrrolidin--
1-yl)-2-(thiophen-3-yl)acetamide
[0770] The title compound was synthesized according to Method C,
utilizing
N-(3-iodo-1H-indazol-5-yl)-2-(pyrrolidin-1-yl)-2-(thiophen-3-yl)acetamide
(360 mg, 0.79 mmol),
1-(4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)azetidin-3-ol
(240 mg, 0.87 mmol), Pd(PPh.sub.3).sub.4 (92 mg, 0.079 mmol), 2 M
Na.sub.2CO.sub.3 (0.80 mL), PhMe (4 mL), and EtOH (2 mL). H2O (30
mL) was added and the product was extracted into EtOAc (4.times.30
mL). The combined organic layers were dried over MgSO.sub.4,
filtered and evaporated in vacuo. Purification by flash
chromatography (Biotage, 50 g HP-SIL, 20-100% EtOAc in hexanes,
then 2-15% MeOH in DCM) followed by RPHPLC gave the title compound
as a bright yellow solid (90 mg, 16%). The title compound was
isolated as a di-TFA salt. .sup.1H NMR (400 MHz, CD.sub.3OD)
.delta. ppm 8.37 (s, 1H), 7.87 (dd, J=2.9, 1.3 Hz, 2H), 7.80 (d,
J=8.6 Hz, 2H), 7.63 (dd, J=5.1, 3.0 Hz, 1H), 7.52 (d, J=1.1 Hz,
2H), 7.38 (dd, J=5.1, 1.2 Hz, 1H), 6.84 (br d, J=7.4 Hz, 2H), 5.27
(s, 1H), 4.74 (quint, J=5.1 Hz, 1H), 4.39-4.34 (br m, 2H),
3.90-3.78 (br m, 3H), 3.30-3.02 (br m, 3H), 3.13 (s, 3H), 2.16-1.90
(br m, 4H); MS ESI 474.1 [M+H].sup.+, calcd for
[C.sub.26H.sub.27N.sub.5O.sub.2S+H].sup.+ 474.19.
Example A121
N-(cyclobutyl(thiophen
methyl-3-yl)(4-((methylpiperidin-4-yl)oxy)phenyl)-1H-indazole-5-carboxami-
de
##STR00265##
[0772] A mixture of cyclobutyl(thiophen-3-yl)methanone (1.04 g,
6.27 mmol), NH.sub.4OAc (5.85 g, 75.24 mmol) and NaCNBH.sub.3 (1.58
g, 25.08 mmol) in MeOH (30 mL) was heated at 65.degree. C. for 3 h,
then left O/N at 65.degree. C. After removal of solvent, it was
purifed by flash chromatography (MeOH/DCM 0-30%) to give
cyclobutyl(thiophen-3-yl)methanamine (colorless oil, 1.194 g).
.sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 7.55-7.50 (m, 2H), 7.17
(dd, J=4.8 Hz, 1.2 Hz, 1H), 4.37 (d, J=10.0 Hz, 1H), 2.93-2.82 (m,
1H), 2.29-2.19 (m, 1H), 2.05-1.75 (m, 5H); MS ESI 151.0
[M+H].sup.+, calcd for [C.sub.9H.sub.13NS--NH.sub.3+H].sup.+
151.1.
[0773] To a solution of cyclobutyl(thiophen-3-yl)methanamine (1.194
g, 6.27 mmol), 3-iodo-1H-indazole-5-carboxamide (1.81 g, 6.27 mmol)
in DMF (20 mL) at 0.degree. C. was added TBTU (2.01 g, 6.27 mmol),
followed by .sup.iPr.sub.2NEt (2.18 mL, 12.54 mmol). The resulting
mixture was stirred at 0.degree. C. for 1 h, quenched with H.sub.2O
(70 mL) and stirred for 1.5 h at rt. Suction filtration gave crude
N-(cyclobutyl(thiophen-3-yl)methyl)-3-iodo-1H-indazole-5-carboxamide
(light beige solid, 2.512 g). .sup.1H NMR (400 MHz, DMSO-d6)
.delta. 13.69 (s, 1H), 8.75 (d, J=8.8 Hz, 1H), 8.04 (s, 1H), 7.94
(dd, J=4.6 Hz, 1.4 Hz, 1H), 7.58 (d, J=8.8 Hz, 1H), 7.45 (dd, J=4.8
Hz, 2.8 Hz, 1H), 7.35 (d, J=3.2 Hz, 1H), 7.14 (dd, J=4.8 Hz, 0.8
Hz, 1H), 5.19 (t, J=9.4 Hz, 1H), 2.10-2.00 (m, 1H), 2.00-1.88 (m,
1H), 1.86-1.70 (m, 5H); MS ESI 438.0 [M+H].sup.+, calcd for
[C.sub.17H.sub.16IN.sub.3OS+H].sup.+ 438.0.
[0774] To a mixture of crude
N-(cyclobutyl(thiophen-3-yl)methyl)-3-iodo-1H-indazole-5-carboxamide
(262 mg, 0.6 mmol) and
1-methyl-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)piperi-
dine (159 mg, 0.5 mmol) in EtOH (15 mL) was added 1 M aq
Na.sub.2CO.sub.3 (1 mL, 1 mmol), followed by Pd(PPh.sub.3).sub.4
(29 mg, 0.025 mmol). The resulting mixture was purged with Ar and
microwaved 4 h at 125.degree. C. After removal of solvents, it was
purified by flash chromatography (MeOH/DCM 0-100%, then 0.05 NH3 in
MeOH/DCM 20%), PoraPak and prep-HPLC to give the title compound as
a TFA salt (light yellow solid, 65.8 mg, 21%). .sup.1H NMR (400
MHz, CD.sub.3OD) .delta. 8.55 (s, 1H), 7.94-7.88 (m, 3H), 7.59 (d,
J=8.8 Hz, 1H), 7.33 (dd, J=5.0 Hz, 3.0 Hz, 1H), 7.26 (pseudo d,
J=3.2 Hz, 1H), 7.17-7.10 (m, 3H), 5.26 (d, J=6.4 Hz, 1H), 4.83-4.78
(m, 0.7H), 4.68-4.58 (m, 0.3H), 3.66-3.58 (m, 0.7H), 3.45-3.33 (m,
2.6H), 3.23-3.15 (m, 0.7H), 2.98-2.87 (m, 4H; s, 3H at 2.93),
2.45-1.80 (m, 10H); MS ESI 501.5 [M+H].sup.+, calcd for
[C.sub.29H.sub.32N.sub.4O.sub.2S+H].sup.+ 501.2.
Example A122
N-(cyclopropyl(phenyl)methyl)-3-(4-((1-(2-fluoroethyl)piperidin-4-yl)oxy)p-
henyl)-1H-indazole-5-carboxamide
##STR00266##
[0776] The title compound was synthesized according to Method C3
utilizing
N-(cyclopropyl(phenyl)methyl)-3-iodo-1H-indazole-5-carboxamide and
1-(2-fluoroethyl)-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pheno-
xy)piperidine and obtained (white solid, 8 mg, 11% yield). .sup.1H
NMR (400 MHz, CD.sub.3OD) .delta. ppm 8.61 (s, 1H), 7.96 (dd, J=8.8
Hz, 1.6 Hz, 1H), 7.91 (d, J=8.8 Hz, 2H), 7.60 (d, J=8.8 Hz, 1H),
7.49 (d, J=7.2 Hz, 2H), 7.34 (m, 2H), 7.24 (m, 1H), 7.12 (d, J=8.8
Hz, 2H), 4.66 (t, J=4.8 Hz, 1H), 4.54 (t, J=4.8 Hz, 1H), 4.48 (d,
J=9.6 Hz, 1H), 2.87 (m, 2H), 2.80 (t, J=4.8 Hz, 1H), 2.73 (t, J=4.8
Hz, 1H), 2.51 (t, J=8.8 Hz, 1H), 2.08 (m, 2H), 1.87 (m, 2H), 1.41
(m, 2H), 0.66 (m, 2H), 0.47 (m, 2H); MS ESI [M+H].sup.+ 513.4,
calcd for [C.sub.31H.sub.33FN.sub.4O.sub.2+H].sup.+ 513.27.
Example A123
N-(cyclobutyl(thiophen-3-yl)methyl)-3-(4-morpholinophenyl)-1H-indazole-5-c-
arboxamide
##STR00267##
[0778] To a mixture of crude
N-(cyclobutyl(thiophen-3-yl)methyl)-3-iodo-1H-indazole-5-carboxamide
(262 mg, 0.6 mmol) and (4-morpholinophenyl)boronic acid (104 mg,
0.5 mmol) in EtOH (15 mL) was added 1 M aq Na.sub.2CO.sub.3 (1 mL,
1 mmol), followed by Pd(PPh.sub.3).sub.4 (29 mg, 0.025 mmol). The
resulting mixture was purged with Ar and microwaved 4 h at
125.degree. C. It was diluted with H.sub.2O, extracted with DCM and
purified by flash chromatography (MeOH/DCM 0-20%), PoraPak,
prep-HPLC, flash chromatography (EtOAc/hex 0-95%) and trituration
with MeOH to give the title compound (white solid, 57.1 mg, 24%).
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 11.14 (s, 1H, NH), 8.49
(s, 1H), 7.87 (d, J=8.0 Hz, 2H), 7.74 (d, J=8.4 Hz, 1H), 7.36 (d,
J=8.8 Hz, 1H), 7.17 (s, 1H), 7.09 (d, J=4.4 Hz, 1H), 7.01 (d, J=8.4
Hz, 2H), 6.40 (d, J=8.8 Hz, 1H), 5.40 (t, J=8.6 Hz, 1H), 3.89
(pseudo s, 4H), 3.22 (pseudo s, 4H), 2.91-2.80 (m, 1H), 2.20-1.75
(m, 8H); MS ESI 473.4 [M+H].sup.+, calcd for
[C.sub.27H.sub.28N.sub.4O.sub.2S+H].sup.+ 473.2.
Example A124
1-(2,6-diethylphenyl)-3-(3-(4-(4-methylmorpholin-2-yl)phenyl)-1H-indazol-5-
-yl)urea
##STR00268##
[0779] A. 2-(4-bromophenyl)-4-tosylmorpholine
[0780] To an ice-cooled solution of
2-amino-1-(4-bromophenyl)ethanol (500 mg, 2.31 mmol) in NEt.sub.3
(0.48 mL, 3.47 mmol) and CH.sub.2Cl.sub.2 (10 mL) was added tosyl
chloride (440 mg, 2.31 mmol) and the reaction stirred for 18 h. The
mixture was diluted with CH.sub.2Cl.sub.2 (100 mL), washed with
brine (2.times.50 mL) and the organic layer dried over MgSO.sub.4.
The organic layer was filtered and the solvent removed to give the
intermediate
N-(2-(4-bromophenyl)-2-hydroxyethyl)-4-methylbenzenesulfonamide
which was dissolved into CH.sub.2Cl.sub.2 (15 mL). The solution was
cooled to 0.degree. C., NaH (245 mg of 60% wt suspension) was
added, the mixture stirred for 5 min and then
(2-bromoethyl)diphenylsulfonium trifluoromethanesulfonate (931 mg,
2.10 mmol) was added and the reaction was allowed to warm to rt
overnight. The reaction was then quenched with H.sub.2O (2 mL) and
extracted with CH.sub.2Cl.sub.2 (50 mL) and the organic layer
washed with brine (1.times.25 mL). The solvent was removed and the
residue titurated with 9:1 hexanes/Et.sub.2O which gave after
drying 613 mg, 88% of the product as a white solid. MS ESI 396.7
[M+H].sup.+, calcd for [C.sub.17H.sub.18BrNO.sub.3S+H].sup.+
396.03.
B. 2-(4-bromophenyl)-4-methylmorpholine
[0781] 2-(4-Bromophenyl)-4-tosylmorpholine (509 mg, 1.28 mmol),
phenol (242 mg, 2.57 mmol) were dissolved into HBr (33% wt solution
in AcOH) and the mixture heated to 55.degree. C. for 3 h. The
reaction was cooled and the product precipitated with Et2O and
filtered washing with Et2O to give the de-protected material which
was then dissolved into THF (7.5 mL) and then formalin (0.24 mL,
3.26 mmol) followed by NaBH(OAc).sub.3 (752 mg, 3.55 mmol) were
added and the mixture stirred for 18 h. The reaction was poured
into a separatory funnel containing NaHCO.sub.3 (50 mL) and then
extracted with EtOAc (2.times.50 mL). The organic layers were
separated and washed with brine (1.times.50 mL), dried over
MgSO.sub.4 and the solvent removed to give the 243 mg, 64% of the
product as a brown oil. MS ESI 257.9 [M+H].sup.+, calcd for
[C.sub.11H.sub.14BrNO+H].sup.+ 258.03.
C. 3-(4-(4-methylmorpholin-2-yl)phenyl)-1H-indazol-5-amine
bis(2,2,2-trifluoroacetate)
[0782] The boronic ester was prepared from
2-(4-bromophenyl)-4-methylmorpholine using general Method F which
was used directly for the Suzuki coupling. The same procedure was
then followed as for
3-(4-((1-methylpiperidin-4-yl)oxy)phenyl)-1H-indazol-5-amine
bis(2,2,2-trifluoroacetate) using tert-butyl
(3-iodo-1H-indazol-5-yl)carbamate (112 mg, 0.312 mmol) and
4-methyl-2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)morphol-
ine (123 mg, 0.406 mmol). Obtained 45 mg of an impure brown solid
which was used for subsequent synthetic steps; MS ESI 309.1
[M+H].sup.+, calcd for [C.sub.18H.sub.20N40+H].sup.+ 309.17.
D.
1-(2,6-diethylphenyl)-3-(3-(4-(4-methylmorpholin-2-yl)phenyl)-1H-indazo-
l-5-yl)urea
[0783] Using Method J,
3-(4-(4-methylmorpholin-2-yl)phenyl)-1H-indazol-5-amine
bis(2,2,2-trifluoroacetate) (45 mg, 0.085 mmol),
1,3-diethyl-2-isocyanatobenzene (29 uL, 0.168 mmol) and DIPEA (73
uL, 0.42 mmol) in DMF (0.5 mL) gave the title compound as a TFA
salt (23 mg, 56%, a white solid). .sup.1H NMR (400 MHz, CD.sub.3OD)
.delta. ppm 8.29 (s, 1H), 7.97 (d, J=8.3 Hz, 2H), 7.56-7.51 (m,
3H), 7.31 (d, J=8.8 Hz, 1H), 7.21-7.16 (m, 3H), 4.78-4.75 (m, 1H),
4.34-4.30 (m, 1H), 4.00-3.94 (m, 1H), 3.70-3.67 (m, 1H), 3.56-3.52
(m, 1H), 3.31-3.28 (m, 1H), 3.17-3.13 (m, 1H), 2.97 (s, 3H), 2.70
(q, J=7.6 Hz, 4H), 1.23 (t, J=7.6 Hz, 6H); MS ESI 484.5
[M+H].sup.+, calcd for [C.sub.29H.sub.33N.sub.5O.sub.2+H].sup.+
484.27.
Example A125
(S)--N-(3-hydroxy-1-phenylpropyl)-3-(4-((1-methylpiperidin-4-yl)oxy)phenyl-
)-1H-indazole-5-carboxamide
##STR00269##
[0785] The title compound was synthesized according to the General
Method C, utilizing
(S)--N-(3-hydroxy-1-phenylpropyl)-3-iodo-1H-indazole-5-carboxamide
(50 mg, 0.11 mmol), (4-((1-methylpiperidin-4-yl)oxy)phenyl)boronic
acid pinacol ester (41 mg, 0.13 mmol), Pd(PPh.sub.3).sub.4 (6.4 mg,
0.0055 mmol), satd. Na.sub.2CO.sub.3 (1.5 mL), and 3.5 mL of
PhMe:EtOH (1:1). The vial was charged with Ar and heated in the
microwave reactor at 125.degree. C. for 2 h. Purification by
RPHPLC, followed by trituration with Et.sub.2O gave the title
compound as a TFA salt (white solid, 20 mg, 30%). .sup.1H NMR (400
MHz, CD.sub.3OD) .delta. ppm 8.56 (s, 1H), 7.87-7.97 (m, 3H), 7.61
(d, J=8.5 Hz, 1H), 7.44 (d, J=7.8 Hz, 2H), 7.34 (t, J=7.5 Hz, 1H),
7.12-7.27 (m, 3H), 5.29-5.38 (m, 1H), 4.62-4.73 (m, 0.3H),
3.58-3.73 (m, 2.7H), 3.34-3.49 (m, 3H), 3.15-3.27 (m, 1H), 2.94 (s,
3H), 2.39-2.50 (m, 0.7H), 2.25-2.35 (m, 1.3H), 2.05-2.22 (m, 3.3H),
1.83-1.98 (m, 0.7H); MS ESI 485.4 [M+H].sup.+, calcd for
[C.sub.29H.sub.32N.sub.4O.sub.3+H].sup.+ 485.3.
Example A126
N-(cyclopropyl(phenyl)methyl)-3-(4-((1-formylpiperidin-4-yl)oxy)phenyl)-1H-
-indazole-5-carboxamide
##STR00270##
[0787] The title compound was synthesized according to Method C3
utilizing
N-(cyclopropyl(phenyl)methyl)-3-iodo-1H-indazole-5-carboxamide and
4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)piperidine-1-ca-
rbaldehyde and obtained as a yellow solid (14 mg, 27% yield).
.sup.1H NMR (400 MHz, CD.sub.3OD) .delta. ppm 8.61 (s, 1H), 8.03
(s, 1H), 7.89-7.98 (m, 3H), 7.59 (d, J=8.78 Hz, 1H), 7.48 (d,
J=7.28 Hz, 2H), 7.32 (t, J=7.53 Hz, 2H), 7.23 (m, J=7.53 Hz, 1H),
7.12 (d, J=8.78 Hz, 2H), 4.69-4.77 (m, 1H), 4.45-4.51 (m, 1H),
3.62-3.79 (m, 2H), 3.49-3.58 (m, 1H), 3.37-3.46 (m, 1H), 1.91-2.08
(m, 2H), 1.72-1.91 (m, 2H), 1.34-1.46 (m, 1H), 0.65 (d, J=8.28 Hz,
2H), 0.41-0.53 (m, 2H); MS ESI [M+H].sup.+ 495.3, calcd for
[C.sub.30H.sub.30N.sub.4O.sub.3+H].sup.+ 495.24.
Example A127
Intentionally Omitted
Example A128
(R)--N-(1-(2-chlorophenyl)propyl)-3-(4-((1-(2-methoxyethyl)piperidin-4-yl)-
oxy)phenyl)-1H-indazole-5-carboxamide
##STR00271##
[0789] Using Method C3,
(R)--N-(1-(2-chlorophenyl)propyl)-3-iodo-1H-indazole-5-carboxamide
(66 mg, 0.150 mmol) and
1-(2-methoxyethyl)-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phen-
oxy)piperidine (69 mg, 0.190 mmol) gave the title compound as a TFA
salt (10 mg, 12%, a pale-yellow solid). .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. ppm 8.88 (bs, 1H), 8.57 (s, 1H), 7.96-7.93 (m,
3H), 7.62 (d, J=8.0 Hz, 1H), 7.49 (d, J=6.0 Hz, 1H), 7.42-7.16 (m,
4H), 5.47-5.45 (m, 1H), 4.87 (bs, 1H), 3.76-3.70 (m, 3H), 3.54-3.30
(m, 9H), 2.44-2.29 (m, 2H), 2.18-1.90 (m, 4H), 1.05 (t, J=7.5 Hz,
3H); MS ESI 547.7 [M+H].sup.+, calcd for
[C.sub.31H.sub.35ClN.sub.4O.sub.3+H].sup.+ 547.25.
Example A129
(R)--N-(1-(2-fluorophenyl)ethyl)-3-(4-((1-(2-methoxyethyl)piperidin-4-yl)o-
xy)phenyl)-1H-indazole-5-carboxamide
##STR00272##
[0791] Using Method C3,
(R)--N-(1-(2-fluorophenyl)ethyl)-3-iodo-1H-indazole-5-carboxamide
(61 mg, 0.150 mmol) and
1-(2-methoxyethyl)-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phen-
oxy)piperidine (69 mg, 0.190 mmol) gave the title compound as a TFA
salt (24 mg, 31% a white solid). .sup.1H NMR (400 MHz, CD.sub.3OD)
.delta. ppm 8.57 (s, 1H), 7.97-7.93 (m, 3H), 7.61 (d, J=8.8 Hz,
1H), 7.47-7.43 (m, 1H), 7.29-7.06 (m, 5H), 5.55-5.50 (m, 1H), 4.87
(bs, 1H), 3.77-3.70 (m, 3H), 3.54-3.22 (m, 8H), 2.45-2.28 (m, 2H),
2.17-1.97 (m, 2H), 1.60 (d, J=7.2 Hz, 3H); MS ESI 517.4
[M+H].sup.+, calcd for [C.sub.30H.sub.33FN.sub.4O.sub.3+H].sup.+
517.26.
Example A130
N-(cyclopropyl(phenyl)methyl)-3-(4-((1-(2-(dimethylamino)acetyl)piperidin--
4-yl)oxy)phenyl)-1H-indazole-5-carboxamide
##STR00273##
[0793] The title compound was synthesized according to Method C3
utilizing
N-cyclopropyl(phenyl)methyl)-3-iodo-1H-indazole-5-carboxamide and
2-(dimethylamino)-1-(4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)ph-
enoxy)piperidin-1-yl)ethanone and obtained as a pale yellow solid
(66 mg, 56% yield). .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. ppm
8.60 (s, 1H), 7.95 (m, J=8.53 Hz, 3H), 7.61 (d, J=8.78 Hz, 1H),
7.50 (d, J=7.03 Hz, 2H), 7.35 (t, J=7.65 Hz, 2H), 7.25 (m, J=7.28
Hz, 1H), 7.16 (d, J=8.78 Hz, 2H), 4.73-4.80 (m, 1H), 4.49 (d,
J=9.54 Hz, 1H), 3.74-3.92 (m, 2H), 3.67 (s, 3H), 3.47-3.55 (m, 1H),
2.58 (s, 6H), 1.96-2.14 (m, 2H), 1.76-1.93 (m, 2H), 1.37-1.47 (m,
1H), 0.64-0.70 (m, 2H), 0.44-0.53 (m, 2H); MS ESI [M+H].sup.+
552.5, calcd for [C.sub.33H.sub.37N.sub.5O.sub.3+H].sup.+
552.30.
Example A131
(R)--N-(1-(2-chlorophenyl)propyl)-3-(4-((1-methylpiperidin-4-yl)oxy)phenyl-
)-1H-indazole-5-carboxamide
##STR00274##
[0795] The title compound was prepared using Method C3 from
(R)--N-(1-(2-chlorophenyl)propyl)-3-iodo-1H-indazole-5-carboxamide
(58 mg, 0.132 mmol) and
1-methyl-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)piperi-
dine (55 mg, 0.172 mmol) which gave 39 mg of product isolated as
its TFA salt (59%, an orange solid). .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. ppm 8.57 (s, 1H), 7.95-7.91 (m, 3H), 7.61 (d,
J=8.8 Hz, 1H), 7.55 (d, J=7.0 Hz, 1H), 7.39 (d, J=8.0 Hz, 1H),
7.30-7.14 (m, 4H), 5.47-5.43 (m, 1H), 4.87 (bs, 1H), 3.65-3.17 (m,
4H), 2.93-2.92 (m, 3H), 2.44-2.27 (m, 2H), 2.15-1.86 (m, 4H), 1.07
(t, J=7.2 Hz, 3H); MS ESI 503.5 [M+H].sup.+, calcd for
[C.sub.29H.sub.31ClN.sub.4O.sub.2+H].sup.+ 503.22.
Example A132
N-(cyclopropyl(o-tolyl)methyl)-3-(4-((1-methylpiperidin-4-yl)oxy)phenyl)-1-
H-indazole-5-carboxamide
##STR00275##
[0797] To a solution of cyclopropyl(o-tolyl)methanamine (2.82 g,
17.5 mmol), 3-iodo-1H-indazole-5-carboxamide (5.04 g, 17.5 mmol) in
DMF (20 mL) at 0.degree. C. was added TBTU (5.62 g, 17.5 mmol),
followed by .sup.iPr.sub.2NEt (6.08 mL, 35 mmol). The resulting
mixture was stirred at 0.degree. C. for 30 min, quenched with
H.sub.2O till total volume about 250 mL and stirred for 30 min at
rt. Suction filtration gave crude
N-(cyclopropyl(o-tolyl)methyl)-3-iodo-1H-indazole-5-carboxamide
(beige solid, 7.53 g). MS ESI 432.1 [M+H].sup.+, calcd for
[C.sub.19H.sub.18IN.sub.3O+H].sup.+ 432.0.
[0798] To a mixture of crude
N-(cyclopropyl(o-tolyl)methyl)-3-iodo-1H-indazole-5-carboxamide
(190 mg, 0.44 mmol) and
1-methyl-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)piperi-
dine (127 mg, 0.4 mmol) in EtOH (12 mL) was added 1 M aq Na2CO3
(0.8 mL, 0.8 mmol), followed by Pd(dppf)Cl.sub.2-CH.sub.2Cl.sub.2
(33 mg, 0.04 mmol). The resulting mixture was purged with Ar and
microwaved 4 h at 125.degree. C. It was diluted with H.sub.2O,
extracted with DCM and purified by flash chromatography (MeOH/DCM
0-100%, then 0.05 NH.sub.3 in MeOH), biotage RP column
(MeOH/H.sub.2O (1% TFA) 5-80%) and prep-HPLC to give the title
compound as a TFA salt (white solid, 24.0 mg, 10%). .sup.1H NMR
(400 MHz, CD.sub.3OD) .delta. 8.54 (s, 1H), 7.98-7.90 (m, 3H), 7.61
(d, J=7.6 Hz, 1H; partially overlapped with the peak at 7.59), 7.59
(d, J=8.8 Hz, 1H; partially overlapped with the peak at 7.61),
7.22-7.12 (m, 5H), 4.90 (1H, buried under H.sub.2O peak?),
4.88-4.85 (m, 0.7H; partially buried under H.sub.2O peak),
4.71-4.62 (m, 0.3H), 3.67-3.62 (m, 0.7H), 3.47-3.34 (m, 2.6H),
3.25-3.17 (m, 0.7H), 2.95-2.94 (two s at 2.95 and 2.94, 3H),
2.47-2.38 (m, 3.7H; s, 3H at 2.42), 2.33-2.26 (m, 1.3H), 2.17-2.07
(m, 1.3H), 1.98-1.86 (0.7H), 1.52-1.42 (m, 1H), 0.71-0.64 (m, 1H),
0.63-0.56 (m, 1H), 0.55-0.46 (m, 1H), 0.40-0.33 (m, 1H); MS ESI
495.4 [M+H].sup.+, calcd for
[C.sub.31H.sub.34N.sub.4O.sub.2+H].sup.+ 495.4.
Example A133
N-(3-(4-((1-methylpiperidin-4-yl)oxy)phenyl)-1H-indazol-5-yl)-2-(pyrrolidi-
n-1-yl)-2-(o-tolyl)acetamide
##STR00276##
[0800] To a solution of 2-(pyrrolidin-1-yl)-2-(o-tolyl)acetic acid
(3.00 g, assuming 10 mmol), 3-iodo-1H-indazol-5-amine hydrochloride
salt (2.94 g, 10 mmol) in DMF (40 mL) at 0.degree. C. was added
TBTU (3.21 g, 10 mmol), followed by .sup.iPr.sub.2NEt (5.22 mL, 30
mmol). The resulting mixture was stirred at 0.degree. C. for 2 h,
quenched with H.sub.2O (300 mL) and stirred for 30 min at rt.
Suction filtration gave crude
N-(3-iodo-1H-indazol-5-yl)-2-(pyrrolidin-1-yl)-2-(o-tolyl)acetamide
(brown solid, 3.19 g). LC-MS indicated a mixture of desired product
N-(3-iodo-1H-indazol-5-yl)-2-(pyrrolidin-1-yl)-2-(o-tolyl)acetamide
and di-acylated byproduct. MS ESI 461.1 [M+H].sup.+, calcd for
[C.sub.20H.sub.21IN.sub.4O+H].sup.+ 461.1.
[0801] To a mixture of crude
N-(3-iodo-1H-indazol-5-yl)-2-(pyrrolidin-1-yl)-2-(o-tolyl)acetamide
(213 mg, assuming 0.4 mmol) and
1-methyl-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)piperi-
dine (127 mg, 0.4 mmol) in EtOH (12 mL) was added 1 M aq Na2CO3
(1.0 mL, 1.0 mmol), followed by Pd(dppf)Cl.sub.2-CH.sub.2Cl.sub.2
(33 mg, 0.04 mmol). The resulting mixture was purged with Ar and
microwaved 4 h at 125.degree. C. It was diluted with H.sub.2O,
extracted with DCM and purified by flash chromatography (MeOH/DCM
0-100%, then 0.05 NH.sub.3 in MeOH), biotage RP column
(MeOH/H.sub.2O (1% TFA) 5-60%) and prep-HPLC to give the title
compound as a TFA salt (light brown solid, 56.1 mg, 19%). .sup.1H
NMR (400 MHz, CD.sub.3OD) .delta. 8.23 (s, 1H), 7.88-7.83 (m, 2H),
7.76 (d, J=7.6 Hz, 1H), 7.54 (pseudo t, J=9.0 Hz, 2H), 7.43-7.34
(m, 3H), 7.20-7.13 (m, 2H), 5.45 (s, 1H), 4.90-4.85 (m, 0.7H),
4.72-4.64 (m, 0.3H), 3.92 (br s, 0.7H), 3.58-3.52 (m, 0.7H),
3.50-2.98 (m, 6.4H), 2.95-2.94 (two s at 2.95 and 2.94, 3H), 2.67
(s, 3H), 2.47-1.88 (m, 8H); MS ESI 524.2 [M+H].sup.+, calcd for
[C.sub.32H.sub.37N.sub.5O.sub.2+H].sup.+ 524.3.
Example A134
(R)--N-(1-(2-fluorophenyl)ethyl)-3-(4-((1-methylpiperidin-4-yl)oxy)phenyl)-
-1H-indazole-5-carboxamide
##STR00277##
[0803] The title compound was prepared using Method C3 from
(R)--N-(1-(2-fluorophenyl)ethyl)-3-iodo-1H-indazole-5-carboxamide
(47 mg, 0.115 mmol) and
1-methyl-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)piperi-
dine (48 mg, 0.150 mmol) which gave 23 mg of product isolated as
its TFA salt (43%, a white solid). .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. ppm 8.57 (s, 1H), 7.97-7.93 (m, 3H), 7.61 (d,
J=8.8 Hz, 1H), 7.47-7.43 (m, 1H), 7.28-7.07 (m, 5H), 5.55-5.50 (m,
1H), 4.87 (bs, 1H), 3.66-3.20 (m, 4H), 2.95-2.94 (m, 3H), 2.48-2.30
(m, 2H), 2.15-1.89 (m, 2H), 1.60 (d, J=6.8 Hz, 3H); MS ESI 473.4
[M+H].sup.+, calcd for [C.sub.28H.sub.29FN.sub.4O.sub.2+H].sup.+
473.24.
Example A135
(R)--N-(3-(4-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)oxy)phenyl)-1H-inda-
zol-5-yl)-2-methoxy-2-phenylacetamide
##STR00278##
[0804] The title compound was synthesized according to the General
Method C2 utilizing
((R)--N-(3-iodo-1H-indazol-5-yl)-2-methoxy-2-phenylacetamide (0.14
g, 0.34 mmol), a crude mixture of
(4-((3-fluoro-1-methylpiperidin-4-yl)oxy)phenyl)boronic acid and
diisopropyl
(4-((cis-3-fluoro-1-methylpiperidin-4-yl)oxy)phenyl)boronate
diisopropyl (0.16 g, .about.0.48 mmol) to provide the title
compound as a white powder (22 mg, 13%). .sup.1H NMR (400 MHz,
acetrone-d6) .delta. ppm 11.82-12.49 (br.s., 1H), 9.43 (br. s.,
1H), 8.63 (d, J=1.51 Hz, 1H), 7.94 (d, J=9.03 Hz, 2H), 7.74 (dd,
J=8.91, 1.88 Hz, 1H), 7.51-7.59 (m, 3H), 7.30-7.44 (m, 3H), 7.16
(d, J=9.03 Hz, 2H), 4.91-4.98 (m, 0.5H), 4.85 (s, 1H), 4.80-4.83
(m, 0.5H), 4.69 (br. s., 1H), 3.47 (s, 3H), 2.94 (br. s., 1H),
2.46-2.74 (m, 2H), 2.40-2.31 (m., 1H), 2.29 (s, 3H), 1.99-2.18 (m,
1H), 1.84-1.99 (m, 1H); MS ESI 489.3 [M+H].sup.+, calcd for
[C.sub.28H.sub.29FN.sub.4O.sub.3+H].sup.+ 489.2.
Example A136
N-(cyclopropyl(2-fluorophenyl)methyl)-3-(4-((1-methylpiperidin-4-yl)oxy)ph-
enyl)-1H-indazole-5-carboxamide
##STR00279##
[0806] To a 20 mL microwave vial charged with Mg powder (480 mg, 20
mmol), THF (15 mL) was added bromocyclopropane (2.42 g, 20 mmol).
The resulting mixture was stirred for 30 min at rt before
2-fluorobenzonitrile (1.21 g, 10 mmol) was added. It was microwaved
20 min at 100.degree. C., cooled to rt and added dropwise to a cold
solution of NaBH.sub.4 (760 mg, 20 mmol) in MeOH (60 mL) at
0.degree. C. The resulting mixture was stirred for 30 min at rt,
quchend with H.sub.2O, extracted with DCM and purified by flash
chromatography (MeOH/DCM 0-20%) to give
cyclopropyl(2-fluorophenyl)methanamine (yellow oil, 843 mg, 51%).
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.52 (dt, J=7.4 Hz, 1H),
7.31-7.24 (m, 1H), 7.18 (t, J=7.6 Hz, 1H), 7.10-7.04 (m, 1H), 3.45
(d, J=9.2 Hz, 1H), 1.25-1.16 (m, 1H), 0.67-0.60 (m, 1H), 0.49-0.37
(m, 2H), 0.29-0.22 (m, 1H); MS ESI 149.0 [M+H].sup.+, calcd for
[C.sub.10H.sub.12FN--NH.sub.3+H].sup.+149.1.
[0807] To a solution of cyclopropyl(2-fluorophenyl)methanamine (828
mg, 5.02 mmol), 3-iodo-1H-indazole-5-carboxamide (1.45 g, 5.02
mmol) in DMF (20 mL) at 0.degree. C. was added TBTU (1.62 g, 5.02
mmol), followed by .sup.iPr.sub.2NEt (1.75 mL, 10.05 mmol). The
resulting mixture was stirred at 0.degree. C. for 30 min, quenched
with H.sub.2O till total volume about 130 mL and stirred for 15 min
at rt. Suction filtration gave crude
N-(cyclopropyl(2-fluorophenyl)methyl)-3-iodo-1H-indazole-5-carboxam-
ide (pale yellow solid, 2.068 g). ESI 436.1 [M+H].sup.+, calcd for
[C.sub.18H.sub.15FIN.sub.3O+H].sup.+ 436.0.
[0808] To a mixture of crude
N-(cyclopropyl(2-fluorophenyl)methyl)-3-iodo-1H-indazole-5-carboxamide
(218 mg, 0.5 mmol) and
1-methyl-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)piperi-
dine (127 mg, 0.4 mmol) in EtOH (12 mL) was added 1 M aq Na2CO3
(0.8 mL, 0.8 mmol), followed by Pd(PPh.sub.3).sub.4 (46 mg, 0.04
mmol). The resulting mixture was purged with Ar and microwaved 4 h
at 125.degree. C. After removal of solvents, it was purified by
prep-HPLC to give the title compound as a TFA salt (off white
solid, 69.4 mg, 28%). .sup.1H NMR (400 MHz, CD.sub.3OD) .delta.
8.56 (s, 1H), 7.96-7.88 (m, 3H), 7.61-7.53 (m, 2H), 7.28-7.22 (m,
1H), 7.16-7.04 (m, 4H), 4.81-4.78 (m, 0.7H; partially overlapped
with the peak at 4.76), 4.76 (d, J=9.6 Hz, 1H; partially overlapped
with the peak at 4.81-4.78), 4.66-4.58 (m, 0.3H), 3.65-3.58 (m,
0.7H), 3.43-3.28 (m, 2.6H), 3.22-3.13 (m, 0.7H), 2.91 (s, 3H),
2.41-2.35 (m, 0.7H), 2.27-2.20 (m, 1.3H), 2.15-2.05 (m, 1.3H),
1.96-1.85 (m, 0.7H), 1.48-1.38 (m, 1H), 1.22-1.13 (m, 1H),
1.10-1.03 (m, 1H), 1.02-0.90 (m, 2H); MS ESI 499.4 [M+H].sup.+,
calcd for [C.sub.30H.sub.31FN.sub.4O.sub.2+H].sup.+ 499.2.
Example A137
(R)--N-(3-hydroxy-1-phenylpropyl)-3-(4-((1-methylpiperidin-4-yl)oxy)phenyl-
)-1H-indazole-5-carboxamide
##STR00280##
[0810] The title compound was synthesized according to the General
Method C, utilizing
(R)--N-(3-hydroxy-1-phenylpropyl)-3-iodo-1H-indazole-5-carboxamide
(50 mg, 0.11 mmol), (4-((1-methylpiperidin-4-yl)oxy)phenyl)boronic
acid pinacol ester (41 mg, 0.13 mmol), Pd(PPh.sub.3).sub.4 (6.4 mg,
0.0055 mmol), satd. Na.sub.2CO.sub.3 (1.5 mL), and 3.5 mL of
PhMe:EtOH (1:1). The vial was charged with Ar and heated in the
microwave reactor at 125.degree. C. for 2 h. Purification by
RPHPLC, followed by trituration with Et.sub.2O gave the title
compound as a TFA salt (white solid, 23 mg, 35%). .sup.1H NMR (400
MHz, CD.sub.3OD) .delta. ppm 8.56 (s, 1H), 7.89-7.97 (m, 3H), 7.61
(d, J=9.0 Hz, 1H), 7.44 (d, J=7.0 Hz, 2H), 7.34 (t, J=7.6 Hz, 2H),
7.13-7.27 (m, 3H), 5.29-5.38 (m, 1H), 4.63-4.73 (m, 0.3H),
3.59-3.75 (m, 2.7H), 3.33-3.52 (m, 3H), 3.15-3.27 (m, 1H),
2.91-2.97 (m, 3H), 2.40-2.49 (m, 0.7H), 2.26-2.36 (m, 1.3H),
2.05-2.21 (m, 3.3H), 1.85-1.98 (m, 0.7H); MS ESI 485.4 [M+H].sup.+,
calcd for [C.sub.29H.sub.32N.sub.4O.sub.3+H].sup.+ 485.3.
Example A138
2-cyclopropyl-N-(3-(4-((1-methylpiperidin-4-yl)oxy)phenyl)-1H-indazol-5-yl-
)-2-phenylacetamide
##STR00281##
[0812] To a solution of 2-cyclopropyl-2-phenylacetic acid (20 mg,
0.113 mmol) in DMF (2 mL) was added
3-(4-((1-methylpiperidin-4-yl)oxy)phenyl)-1H-indazol-5-amine
trifluoroacetate (62.5 mg, 0.113 mmol), DIPEA (102 uL, 0.565 mmol)
and TBTU (36 mg, 0.113 mmol). The reaction mass was stirred for 24
h at rt and concentrated under reduced pressure. Purification by
flash chromatography (SiO2, 0-40% 2 M NH.sub.3-MeOH in DCM; then RP
HPLC C18RP 60 g, 10-80% MeOH in 0.1% TFA-H.sub.2O) followed by
passing through a PoraPak column with 2 M NH.sub.3-MeOH to elute
gave the title compound (white solid, 29 mg, 51%). .sup.1H NMR (400
MHz, CD.sub.3OD) .delta. 8.45 (d, J=1.2 Hz, 1H), 7.88-7.84 (m, 2H),
7.52-7.48 (m, 3H), 7.43-7.42 (m, 1H), 7.41-7.40 (m, 2H), 7.36-7.32
(m, 1H), 7.17-7.10 (m, 2H), 4.83 (s, 1H), 3.64 (m, 1H), 3.42-3.37
(m, 3H), 3.21-3.19 (br.m, 1H), 2.93-2.90 (m, 3H), 2.43-2.26 (m,
2H), 2.14-2.10 (m, 2H), 1.60-1.57 (br.m, 1H), 0.71-0.61 (m, 2H),
0.48-0.44 (m, 1H), 0.27-0.23 (m, 1H); MS ESI 481.4. [M+H].sup.+,
calcd for [C.sub.30H.sub.32N.sub.4O.sub.2+H].sup.+ 481.6.
Example A139
N-(cyclopropyl(phenyl)methyl)-3-(4-(4-methylmorpholin-2-yl)phenyl)-1H-inda-
zole-5-carboxamide
##STR00282##
[0814] The title compound was prepared using Method C3 from
N-(cyclopropyl(phenyl)methyl)-3-iodo-1H-indazole-5-carboxamide (65
mg, 0.155 mmol) and
4-methyl-2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)morphol-
ine (61 mg, 0.201 mmol) which gave 36 mg of product isolated as its
TFA salt (50%, a white solid). .sup.1H NMR (400 MHz, CD.sub.3OD)
.delta. ppm 8.61 (s, 1H), 8.06 (d, J=8.3 Hz, 2H), 7.97 (d, J=8.8
Hz, 1H), 7.64-7.59 (m, 3H), 7.48 (d, J=7.5 Hz, 2H), 7.36-7.22 (m,
3H), 4.89 (bs, 1H), 4.49 (d, J=9.6 Hz, 1H), 4.34-4.31 (m, 1H),
4.03-3.98 (m, 1H), 3.72-3.69 (m, 1H), 3.57-3.54 (m, 1H), 3.31-3.13
(m, 2H), 2.98 (s, 3H), 1.44-1.34 (m, 1H), 0.71-0.64 (m, 2H),
0.52-0.48 (m, 2H); MS ESI 467.4 [M+H].sup.+, calcd for
[C.sub.29H.sub.30N.sub.4O.sub.2+H].sup.+ 467.24.
Example A140
N-(cyclopropyl(phenyl)methyl)-3-(4-(2-morpholinoethoxy)phenyl)-1H-indazole-
-5-carboxamide
##STR00283##
[0815] A TFA salt of the title compound was synthesized according
to Method C3 utilizing
N-(cyclopropyl(phenyl)methyl)-3-iodo-1H-indazole-5-carboxamide and
4-(2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)ethyl)morpho-
line without running through PoraPak and obtained as a white solid
(56 mg, 77% yield). .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. ppm
8.59 (s, 1H), 7.96 (d, J=8.78 Hz, 3H), 7.61 (d, J=8.78 Hz, 1H),
7.49 (d, J=7.28 Hz, 2H), 7.33 (t, J=7.53 Hz, 2H), 7.21-7.28 (m,
1H), 7.17 (d, J=8.78 Hz, 2H), 4.40-4.53 (m, 3H), 3.96-4.15 (m, 2H),
3.86 (br. s., 2H), 3.51-3.71 (m, 4H), 3.32 (br. s, 2H), 1.34-1.47
(m, 1H), 0.66 (d, J=8.03 Hz, 2H), 0.42-0.53 (m, 2H); MS ESI
[M+H].sup.+ 497.4, calcd for
[C.sub.30H.sub.32N.sub.4O.sub.3+H].sup.+ 497.26.
Example A141
N-(Cyclopropyl(o-tolyl)methyl)-3-(4-(3-hydroxyazetidin-1-yl)phenyl)-1H-ind-
azole-5-carboxamide
##STR00284##
[0817] The title compound was synthesized according to Method C,
utilizing
N-(cyclopropyl(o-tolyl)methyl)-3-iodo-1H-indazole-5-carboxamide
(142 mg, 0.33 mmol),
1-(4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)azetidin-3-ol
(100 mg, 0.36 mmol), Pd(PPh.sub.3).sub.4 (38 mg, 0.033 mmol), 2 M
Na.sub.2CO.sub.3 (0.40 mL), PhMe (4 mL), and EtOH (2 mL). H2O (30
mL) was added and the product was extracted into EtOAc (4.times.30
mL). The combined organic layers were dried over MgSO.sub.4,
filtered and evaporated in vacuo. Purification by flash
chromatography (Biotage, 50 g HP-SIL, 20-100% EtOAc in hexanes)
followed by RP flash chromatography (Biotage, 60 g RP HPLC C18-,
0.1% TFA-H.sub.2O in MeOH, 10-90%) gave the title compound as a
yellow solid (44 mg, 23%). The title compound was isolated as a TFA
salt. .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. ppm 8.54 (s, 1H),
7.90 (dd, J=8.8, 1.5 Hz, 1H), 7.86 (d, J=8.5 Hz, 2H), 7.61 (d,
J=7.6 Hz, 1H), 7.56 (d, J=8.8 Hz, 1H), 7.21-7.13 (m, 3H), 6.78 (d,
J=8.5 Hz, 2H), 4.89-4.84 (m, 1H), 4.72 (quint, J=5.4 Hz, 1H), 4.30
(t, J=7.9 Hz, 2H), 7.79 (dd, J=8.7, 5.0 Hz, 2H), 2.41 (s, 3H),
1.48-1.41 (br m, 1H), 0.69-0.63 (br m, 1H), 0.61-0.54 (br m, 1H),
0.52-0.46 (br m, 1H), 0.38-0.32 (br m, 1H); MS ESI 453.2
[M+H].sup.+, calcd for [C.sub.28H.sub.28N.sub.4O.sub.2+H].sup.+
453.22.
Example A142
N-(2-(hydroxymethyl)benzyl)-3-(4-((1-methylpiperidin-4-yl)oxy)phenyl)-1H-i-
ndazole-5-carboxamide
##STR00285##
[0819] The title compound was synthesized according to the General
Method A utilizing
3-(4-((1-methylpiperidin-4-yl)oxy)phenyl)-1H-indazole-5-carboxylic
acid (34 mg, 0.1 mmol), (2-aminomethyl-phenyl)-MeOHEtOH (14 mg, 0.1
mmol), TBTU (32 mg, 0.1 mmol), DIPEA (52 .mu.L, 0.3 mmol), and DMF
(4 mL) Purification by RPHPLC, followed by trituration with
Et.sub.2O gave the title compound as a TFA salt (white solid, 50
mg, 86%). .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. ppm 8.58 (s,
1H), 7.89-7.97 (m, 3H), 7.60 (d, J=8.8 Hz, 1H), 7.37-7.44 (m, 2H),
7.24-7.31 (m, 2H), 7.17 (d, J=8.8 Hz, 2H), 4.78 (s, 2H), 4.72 (s,
2H), 3.44 (br. s, 2H), 3.32 (br. s, 2H), 2.92 (s, 3H), 2.06-2.32
(m, 4H); MS ESI 471.3 [M+H].sup.+, calcd for
[C.sub.28H.sub.30N.sub.4O.sub.3+H].sup.+ 471.2.
Example A143
N-(2-methyl-1-(o-tolyl)propyl)-3-(4-((1-methylpiperidin-4-yl)oxy)phenyl)-1-
H-indazole-5-carboxamide
##STR00286##
[0821] To a 20 mL microwave vial charged with Mg powder (240 mg, 20
mmol), THF (15 mL) was added 2-bromopropane (2.46 g, 20 mmol). The
resulting mixture was stirred for 30 min at rt before
2-methylbenzonitrile (1.21 g, 10 mmol) was added. It was microwaved
15 min at 100.degree. C., cooled to rt and added dropwise to a cold
solution of NaBH.sub.4 (760 mg, 20 mmol) in MeOH (45 mL) at
0.degree. C. The resulting mixture was stirred for 30 min at rt,
quchend with H.sub.2O, extracted with DCM and purified by flash
chromatography (MeOH/DCM 0-20%) to give crude
2-methyl-1-(o-tolyl)propan-1-amine (yellow oil, 167 mg). .sup.1H
NMR (400 MHz, CDCl.sub.3) .delta. 7.37 (d, J=7.6 Hz, 1H), 7.23-7.18
(m, 1H), 7.12 (d, J=4.0 Hz, 2H), 3.88 (d, J=7.6 Hz, 1H), 2.34 (s,
3H), 1.95-1.85 (m, 1H), 1.02 (d, J=6.4 Hz, 3H), 0.81 (d, J=6.8 Hz,
3H); MS ESI 147.0 [M+H].sup.+, calcd for
[C.sub.11H.sub.17N+H].sup.+ 147.1.
[0822] To a solution of 3-iodo-1H-indazole-5-carboxylic acid (576
g, 2 mmol) and
1-methyl-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phen-
oxy)piperidine (634 mg, 2) in DMF (9 mL) was added a solution of
K.sub.3PO.sub.4 (1.272 g, 6 mmol) in H.sub.2O (3 mL), followed by
Pd(dppf)Cl.sub.2-CH.sub.2Cl.sub.2 (82 mg, 0.1 mmol). The resulting
mixture was purged with Ar and microwaved 5 h at 120.degree. C. The
DMF layer was separated, concentrated and purified by flash
chromatography (MeOH/DCM 0-100% then 0.05 M NH.sub.3 in MeOH) to
give
3-(4-((1-methylpiperidin-4-yl)oxy)phenyl)-1H-indazole-5-carboxylic
acid (brown solid, 140 mg, 20%). .sup.1H NMR (400 MHz, DMSO-d6)
.delta. 13.4 (s, 1H), 8.60 (s, 1H), 7.96 (dd, J=8.8 Hz, 1.2 Hz,
1H), 7.87 (d, J=8.8 Hz, 2H), 7.60 (d, J=8.8 Hz, 1H), 7.13 (d, J=8.8
Hz, 2H), 4.48-4.40 (m, 1H), 2.70-2.55 (m, 2H), 2.25-2.10 (m, 5H; s,
3H at 2.20), 2.05-1.90 (m, 2H), 1.74-1.60 (m, 2H); MS ESI 352.2
[M+H].sup.+, calcd for [C.sub.20H.sub.21N.sub.3O.sub.3+H].sup.+
352.2.
[0823] To a flask charged with crude
2-methyl-1-(o-tolyl)propan-1-amine (32 mg, 0.2 mmol) and TBTU (32
mg, 0.1 mmol) was added a solution of
3-(4-((1-methylpiperidin-4-yl)oxy)phenyl)-1H-indazole-5-carboxylic
acid (33 mg, 0.1 mmol) in DMF (2.5 mL) followed by
.sup.iPr.sub.2NEt (0.05 mL, 0.3 mmol). The resulting mixture was
stirred for 30 min at rt and purified by prep-HPLC and PoraPak to
give the title compound (pale yellow solid, 24.2 mg, 49%). .sup.1H
NMR (400 MHz, CD.sub.3OD) .delta. 8.52 (s, 1H), 7.90-7.93 (m, 3H),
7.56 (d, J=8.8 Hz, 1H), 7.44 (d, J=7.6 Hz, 1H), 7.18-7.07 (m, 3H),
7.05 (d, J=8.8 Hz, 2H), 5.10 (d, J=10.4 Hz, 1H), 4.50-4.42 (m, 1H),
2.77-2.68 (m, 2H), 2.53 (s, 3H), 2.44-2.33 (m, 2H), 2.32 (s, 3H),
2.28-2.18 (m, 1H), 2.07-1.99 (m, 2H), 1.87-1.78 (m, 2H), 1.18 (d,
J=6.4 Hz, 3H), 0.80 (d, J=6.8 Hz, 3H); MS ESI 497.4 [M+H].sup.+,
calcd for [C.sub.31H.sub.36N.sub.4O.sub.2+H].sup.+ 497.3.
Example A144
N-(1-(2-chlorophenyl)-2-methylpropyl)-3-(4-((1-methylpiperidin-4-yl)oxy)ph-
enyl)-1H-indazole-5-carboxamide
##STR00287##
[0824] Method 1
A. 1-(2-chlorophenyl)-2-methylpropan-1-amine
[0825] To a 20 mL microwave vial charged with Mg powder (240 mg, 20
mmol), THF (15 mL) was added 2-bromopropane (2.46 g, 20 mmol). The
resulting mixture was stirred for 30 min at rt before
2-chlorobenzonitrile (1.10 g, 8 mmol) was added. It was microwaved
15 min at 100.degree. C., cooled to rt and added dropwise to a cold
solution of NaBH.sub.4 (760 mg, 20 mmol) in MeOH (45 mL) at
0.degree. C. The resulting mixture was stirred for 20 min at rt,
quchend with H.sub.2O, extracted with DCM and purified by flash
chromatography (MeOH/DCM 0-20%) to give crude
1-(2-chlorophenyl)-2-methylpropan-1-amine (brown oil, 543 mg).
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.48 (dd, J=7.6 Hz, 1.6
Hz, 1H), 7.38 (dd, J=8.0 Hz, 1.2 Hz, 1H), 7.33 (dt, J=7.6 Hz, 1.2
Hz, 1H), 7.23 (dt, J=7.6 Hz, 1.4 Hz, 1H), 4.13 (d, J=7.2 Hz, 1H),
2.03-1.95 (m, 1H), 1.02 (d, J=6.4 Hz, 3H), 0.83 (d, J=6.8 Hz, 3H);
MS ESI 166.9 [M+H].sup.+, calcd for
[C.sub.10H.sub.14ClN--NH.sub.3+H].sup.+ 167.1.
B.
N-(1-(2-chlorophenyl)-2-methylpropyl)-3-(4-((1-methylpiperidin-4-yl)oxy-
)phenyl)-1H-indazole-5-carboxamide
[0826] To a flask charged with crude
1-(2-chlorophenyl)-2-methylpropan-1-amine (36 mg, 0.2 mmol) and
TBTU (32 mg, 0.1 mmol) was added a solution of
3-(4-((1-methylpiperidin-4-yl)oxy)phenyl)-1H-indazole-5-carboxylic
acid (33 mg, 0.1 mmol) in DMF (2.5 mL) followed by
.sup.iPr.sub.2NEt (0.05 mL, 0.3 mmol). The resulting mixture was
stirred for 30 min at rt and purified by prep-HPLC to give the
title compound as a TFA salt (light brown solid, 36.8 mg, 58%).
.sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.85 (d, J=8.0 Hz, 0.2H,
NH), 8.52 (s, 1H), 7.93-7.87 (m, 3H), 7.59 (d, J=8.8 Hz, 1H), 7.55
(dd, J=7.8 Hz, 1.4 Hz, 1H), 7.39 (dd, J=8.0 Hz, 1.2 Hz, 1H), 7.30
(dd, J=7.6 Hz, 1.2 Hz, 1H), 7.22 (dt, J=7.6 Hz, 1.6 Hz, 1H),
7.19-7.12 (m, 2H), 5.38 (d, J=9.6 Hz, 1H), 4.87-4.82 (m, 0.7H),
4.70-4.62 (m, 0.3H), 3.67-3.62 (m, 0.7H), 3.46-3.33 (m, 2.6H),
3.25-3.17 (m, 0.7H), 2.94-2.93 (two s at 2.94 and 2.93, 3H),
2.47-2.38 (m, 0.7H), 2.33-2.24 (m, 2.3H), 2.18-2.07 (m, 1.3H),
1.98-1.87 (m, 0.7H), 1.17 (d, J=6.8 Hz, 3H), 0.87 (d, J=6.8 Hz,
3H); MS ESI 517.5 [M+H].sup.+, calcd for
[C.sub.30H.sub.33ClN.sub.4O.sub.2+H].sup.+ 517.2.
Method 2
[0827] The title compound was synthesized according to general
Method C2 using
N-(1-(2-chlorophenyl)-2-methylpropyl)-3-iodo-1H-indazol-5-carboxami-
de (400 mg, 0.88 mmol) and
1-methyl-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)piperi-
dine (280 mg, 0.88 mmol) with PdCl.sub.2dppf (68 mg, 0.083 mmol)
and 1 M aq Na2CO3 (1.76 mL, 1.76 mmol) in PhMe/EtOH (13 mL, 1:1
mixture) with heating under microwave irradiation at 125.degree. C.
for 3.5 h. The product was extracted with EtOAc (50 mL), washed
with H.sub.2O (15 mL) and brine (15 mL), dried (Na.sub.2SO.sub.4)
and concentrated under vacuum. Purification by flash chromatography
(SiO2, 0-50% 1 M NH.sub.3-MeOH in DCM; then RP HPLC C18 120 g,
10-80% MeOH 0.1% TFA-H.sub.2O) gave the title compound as a TFA
salt (light brown solid, 231 mg, 41.6%). .sup.1H NMR and MS ESI
were identical to that obtained in Method 1.
Example A144
Intentionally Omitted
Example A145
(R)-2-methoxy-N-(3-(4-((1-methylpiperidin-4-yl)methoxy)phenyl)-1H-indazol--
5-yl)-2-phenylacetamide
[0828] ##STR00288## [0829] A.
4-((4-iodophenoxy)methyl)-1-methylpiperidine was synthesized
according to General Method H utilizing 1-fluoro-4-iodobenzene
(0.70 g, 3.1 mmol), ((1-methylpiperidin-4-yl)methanol (0.41 g, 3.1
mmol) and NaH (60% in oil, 0.15 g, 3.7 mmol (3.7) in DMF (10 mL) as
a light orange solid (0.82 g, 79%). .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. ppm 7.53 (d, J=7.50 Hz, 2H), 6.65 (d, J=7.50
Hz, 2H), 3.75 (d, J=6.27 Hz, 2H), 2.88 (d, J=11.54 Hz, 2H), 2.28
(s, 3H), 1.95 (td, J=11.80, 2.26 Hz, 2H), 1.69-1.86 (m, 3H),
1.33-1.47 (m, 2H); MS ESI [M+H].sup.+ 332.0, calcd for
[C.sub.13H.sub.18INO+H].sup.+ 332.0. [0830] B. A stirred solution
of 4-((4-iodophenoxy)methyl)-1-methylpiperidine (0.40 g, 1.2 mmol)
in anh THF (10 mL) under Ar was treated with n-BuLi (1.6 M in
hexanes, 1.5 mL, 2.4 mmol) dropwise at 78.degree. C. After 20 min
of stirring at the temperature, B(Oi--Pr).sub.3 (2.8 mL, 12.0 mmol)
was added rapidly. After additional 1 h at the temperature, the
reaction was removed from the cooling bath and stirred for 1 h at
rt before it was concentrated under reduced pressure to afford a
crude mixture of the title compound and
(4-((1-methylpiperidin-4-yl)methoxy)phenyl)boronic acid as a light
orange solid (1.0 g) that was used without further purification. MS
ESI 250.0 [M+H].sup.+, calcd for [C.sub.13H.sub.20BNO.sub.3:
+H].sup.+ 250.1. [0831] C.
(R)-2-methoxy-N-(3-(4-((1-methylpiperidin-4-yl)methoxy)phenyl)--
1H-indazol-5-yl)-2-phenylacetamide was synthesized according to the
General Method C2 utilizing
((R)--N-(3-iodo-1H-indazol-5-yl)-2-methoxy-2-phenylacetamide (0.14
g, 0.34 mmol), a crude mixture of diisopropyl
(4-((1-methylpiperidin-4-yl)methoxy)phenyl)boronate (0.33 g,
.about.0.4 mmol) to provide the title compound as a TFA salt: a
white powder (30 mg, 25%). .sup.1H NMR (400 MHz, CD.sub.3OD)
.delta. ppm 8.39 (s, 1H), 7.84 (d, J=8.78 Hz, 2H), 7.49-7.58 (m,
4H), 7.30-7.45 (m, 3H), 7.07 (d, J=8.78 Hz, 2H), 4.84 (s, 1H), 3.98
(d, J=5.27 Hz, 2H), 3.63-3.53 (m, 2H), 3.47 (s, 3H), 3.11-3.01 (br.
m., 2H), 2.89 (s, 3H), 2.20-2.09 (m, 3H), 1.76-1.61 (br. m., 2H);
MS ESI 485.3 [M+H].sup.+, calcd for
[C.sub.29H.sub.32N.sub.4O.sub.3+H].sup.+ 485.2.
Example A146
N-(3-(4-(1-Methylpiperidin-4-yloxy)phenyl)-1H-indazol-5-yl)isochroman-1-ca-
rboxamide
##STR00289##
[0832] A. Isochroman-1-carboxylic acid
[0833] A mixture of 2-phenylEtOH (4 mL, 33 mmol) and glyoxylic acid
hydrate (3.4 g, 37 mmol) in TFA (15 mL) was heated in a microwave
reactor at 120.degree. C. for 16 h. The solvent was removed in
vacuo. The residue was then dissolved in H.sub.2O and aq NH.sub.4OH
was added until the pH of the solution was over 7. The aq layer was
washed with EtOAc (3.times.40 mL). 2 M HCl was added to the aq
layer until the pH of the solution was less than 3. The product was
extracted into EtOAc (4.times.40 mL). The combined organic layers
were dried over MgSO.sub.4, filtered and evaporated in vacuo.
Trituration with hexanes provided the title compound as a yellow
solid (4.4 g, 74%). .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. ppm
7.56-7.54 (m, 2H), 7.27-7.22 (m, 2H), 7.17-7.15 (m, 1H), 5.39 (s,
1H), 4.34-4.28 (m, 1H), 4.05-3.99 (m, 1H), 2.98-2.84 (m, 2H); MS
ESI 178.9 [M+H].sup.+, calcd for [C.sub.10H.sub.10O.sub.3+H].sup.+
179.06.
B.
N-(3-Iodo-1-(isochroman-1-carbonyl)-1H-indazol-5-yl)isochroman-1-carbox-
amide
[0834] The title compound was synthesized according to Method A,
utilizing 3-iodo-1H-indazol-5-amine (400 mg, 1.5 mmol),
isochroman-1-carboxylic acid (300 mg, 1.7 mmol), TBTU (545 mg, 1.7
mmol), DIPEA (1.1 mL, 6.2 mmol), and DMF (8 mL). H2O (20 mL) was
added and the precipitate was collected, rinsing with H2O (10
mL.times.3). Purification by flash chromatography (Biotage, 25 g
HP-SIL, 10-50% EtOAc in hexanes) gave the title compound as a light
yellow solid (270 mg, 30%). .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. ppm 8.71 (s, 1H), 8.33 (d, J=8.9 Hz, 1H), 8.09 (dd, J=4.4,
1.9 Hz, 1H), 7.85-7.82 (m, 1H), 7.62-7.58 (m, 1H), 7.29-7.08 (m,
5H), 6.78 (s, 1H), 5.38 (s, 1H), 4.54-4.49 (m, 1H), 4.37-4.33 (m,
1H), 4.11-4.05 (m, 1H), 4.01-3.95 (m, 1H), 3.19-3.13 (m, 1H),
3.01-2.95 (m, 2H), 2.83-2.78 (m, 1H); MS ESI 580.1 [M+H].sup.+,
calcd for [C.sub.27H.sub.22IN.sub.3O.sub.4+H].sup.+ 580.07.
C.
N-(3-(4-(1-methylpiperidin-4-yloxy)phenyl)-1H-indazol-5-yl)isochroman-1-
-carboxamide
[0835] The title compound was synthesized according to Method C,
utilizing
N-(3-iodo-1-(isochroman-1-carbonyl)-1H-indazol-5-yl)isochroman-1-carboxam-
ide (120 mg, 0.21 mmol),
1-methyl-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)piperi-
dine (72 mg, 0.23 mmol), Pd(PPh.sub.3).sub.4 (24 mg, 0.021 mmol), 2
M Na.sub.2CO.sub.3 (0.4 mL), PhMe (4 mL), and EtOH (2 mL). H2O (30
mL) was added and the product was extracted into EtOAc (4.times.30
mL). The combined organic layers were dried over MgSO.sub.4,
filtered and evaporated in vacuo. Purification by flash
chromatography (Biotage, 25 g HP-SIL, 100% EtOAc, then 2-10% MeOH
in DCM) followed by RPHPLC gave the title compound as a TFA salt.
The salt was then dissolved in MeOH (20 mL) and poured into a
preconditioned 20 mL PoraPak Rxn Cx cartridge. The MeOHEtOH (30 mL)
rinse was discarded and the product was eluted with 2 M NH.sub.3 in
MeOHEtOH (30 mL). The solvent was removed in vacuo to afford the
title compound as a white solid (32 mg, 32%). .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. ppm 8.34 (s, 1H), 7.81 (d, J=8.6 Hz, 2H),
7.55-7.48 (m, 3H), 7.23-7.15 (m, 3H), 7.03 (d, J=8.6 Hz, 2H), 5.33
(s, 1H), 4.50-4.40 (m, 1H), 4.33-4.28 (m, 1H), 3.94-3.88 (m, 1H),
3.17-3.09 (m, 1H), 2.78-2.70 (m, 3H), 2.40-2.29 (m, 1H), 2.10-1.90
(m, 2H), 1.85-1.75 (m, 2H); MS ESI 483.4 [M+H].sup.+, calcd for
[C.sub.29H.sub.30N.sub.4O.sub.3+H].sup.+ 483.23.
Example A147
N-(cyclopropyl(thiophen-2-yl)methyl-3-(4-((methyl)-3-(4-((1-methylpiperidi-
n-4-yl)oxy)phen)-1H-indazole-5-carboxamide
##STR00290##
[0837] A mixture of cyclopropyl(thiophen-2-yl)methanone (3.04 g, 10
mmol), NH.sub.4OAc (18.48 g, 240 mmol) and NaCNBH.sub.3 (5.04 g, 80
mmol) in MeOH (60 mL) was heated at 65.degree. C. O/N. After
removal of solvent, it was purifed by flash chromatography
(MeOH/DCM 0-20%) to give cyclopropyl(thiophen-2-yl)methanamine
(colorless oil, 876 mg, 42%). .sup.1H NMR (400 MHz,
CD.sub.3Cl.sub.3) .delta. 7.33 (dd, J=5.2 Hz, 1H), 7.20 (d, J=7.6
Hz, 1H), 7.04 (dd, J=5.2 Hz, 3.8 Hz, 1H), 3.78 (d, J=10.0 Hz, 1H),
1.50-1.38 (m, 1H), 0.90-0.75 (m, 2H), 0.67-0.60 (m, 1H), 0.52-0.43
(m, 1H); MS ESI 137.0 [M+H].sup.+, calcd for
[C.sub.8H.sub.11NS--NH.sub.3+H].sup.+ 137.0.
[0838] To a flask charged with crude
cyclopropyl(thiophen-2-yl)methanamine (30 mg, 0.2 mmol) and TBTU
(32 mg, 0.1 mmol) was added a solution of
3-(4-((1-methylpiperidin-4-yl)oxy)phenyl)-1H-indazole-5-carboxylic
acid (33 mg, 0.1 mmol) in DMF (2.5 mL) followed by
.sup.iPr.sub.2NEt (0.05 mL, 0.3 mmol). The resulting mixture was
stirred for 30 min at rt and purified by prep-HPLC, PoraPak, flash
chromatography (MeOH/CM 0-100%, then 0.05 M NH.sub.3 in MeOH) and
prep-HPLC to give the title compound as a TFA salt (white solid,
7.9 mg, 13%). .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.61 (s,
1H), 8.00-7.94 (m, 3H), 7.63 (d, J=8.8 Hz, 1H), 7.29 (d, J=5.2 Hz,
1H), 7.23-7.13 (m, 3H), 6.98 (t, J=4.2 Hz, 1H), 4.85-4.65 (m, 2H;
1H, J=5.6 Hz at 4.77), 3.68-3.18 (m, 4H), 2.95-2.94 (two s at 2.95
and 2.94, 3H), 2.49-2.28 (m, 2H), 2.18-1.87 (m, 2H), 1.57-1.47 (m,
1H), 0.82-0.75 (m, 1H), 0.71-0.62 (m, 1H), 0.60-0.50 (m, 2H); MS
ESI 487.4 [M+H].sup.+, calcd for
[C.sub.28H.sub.30N.sub.4O.sub.2S+H].sup.+ 487.2.
Example A148
2-cyclopentyl-N-(3-(4-((1-methylpiperidin-4-yl)oxy)phenyl)-1H-indazol-5-yl-
)-2-phenylacetamide
##STR00291##
[0840] To a mixture of 2-cyclopentyl-2-phenylacetic acid (1.02 g, 5
mmol), 3-iodo-1H-indazol-5-amine (1.30 g, 5 mmol) in DMF (10 mL) at
0.degree. C. was added TBTU (1.61 g, 5 mmol), followed by
.sup.iPr.sub.2NEt (1.74 mL, 10 mmol). The resulting mixture was
stirred at rt for 2 h, quenched with H.sub.2O, extracted with EtOAc
and purified by flash chromatography (EtOAc.hex 0-100%) to give
N-(cyclopentyl(phenyl)methyl)-3-iodo-1H-indazole-5-carboxamide
(light brown solid, 422 mg, 19%). .sup.1H NMR (400 MHz, DMSO-d6)
.delta. 13.40 (s, 1H), 7.92 (s, 1H), 7.47-7.41 (m, 4H), 7.32 (t,
J=7.4 Hz, 2H), 7.24 (d, J=8.0 Hz, 1H), 2.70-2.50 (m, 1H), 1.90-0.95
(m, 8H).
[0841] To a mixture of
N-(cyclopentyl(phenyl)methyl)-3-iodo-1H-indazole-5-carboxamide (214
mg, 0.5 mmol) and
1-methyl-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)piperi-
dine (127 mg, 0.4 mmol) in EtOH (12 mL) was added 1 M aq Na2CO3
(0.8 mL, 0.8 mmol), followed by Pd(PPh.sub.3).sub.4 (46 mg, 0.04
mmol). The resulting mixture was purged with Ar and microwaved 4 h
at 125.degree. C. After removal of solvents, it was purified by
prep-HPLC and PoraPak to give the title compound (light brown
solid, 60.2 mg, 30%). .sup.1H NMR (400 MHz, CD.sub.3OD) .delta.
8.38 (s, 1H), 7.76 (d, J=8.8 Hz, 2H), 7.48-7.45 (m, 4H), 7.27 (t,
J=7.4 Hz, 2H), 7.20 (d, J=7.2 Hz, 1H), 6.95 (d, J=8.8 Hz, 2H),
4.38-4.31 (m, 1H), 3.39 (d, J=7.2 Hz, 1H), 2.78-2.60 (m, 3H),
2.36-2.23 (m, 5H; s, 3H at 2.26), 2.00-1.90 (m, 3H), 1.81-1.32 (m,
8H), 1.10-1.00 (m, 1H); MS ESI 509.5 [M+H].sup.+, calcd for
[C.sub.32H.sub.36N.sub.4O.sub.2+H].sup.+ 509.3.
Example A149
Intentionally Omitted
Example A150
N-((2-chlorophenyl)(cyclopropyl)methyl)-3-(4-((1-methylpiperidin-4-yl)oxy)-
phenyl)-1H-indazole-5-carboxamide
##STR00292##
[0843] To a 20 mL microwave vial charged with Mg powder (480 mg, 20
mmol), THF (15 mL) was added bromocyclopropane (2.42 g, 20 mmol).
The resulting mixture was stirred for 30 min at rt before
2-chlorobenzonitrile (1.10 g, 8 mmol) was added. It was microwaved
15 min at 100.degree. C., cooled to rt and added dropwise to a cold
solution of NaBH.sub.4 (760 mg, 20 mmol) in MeOH (45 mL) at
0.degree. C. The resulting mixture was stirred for 20 min at rt,
quchend with H.sub.2O, extracted with DCM and purified by flash
chromatography (MeOH/DCM 0-20%) to give
cyclopropyl(2-chlorophenyl)methanamine (light orange oil, 1.12 g,
77%). .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 7.62 (dd, J=8.0 Hz,
1.6 Hz, 1H), 7.37 (dd, J=8.0 Hz, 1.2 Hz, 1H), 7.33 (dt, J=7.6 Hz,
1.2 Hz, 1H), 7.23 (dd, J=7.6 Hz, 1.6 Hz, 1H), 3.74 (d, J=8.8 Hz,
1H), 1.28-1.19 (m, 1H), 0.67-0.60 (m, 1H), 0.48-0.35 (m, 2H),
0.32-0.26 (m, 1H); MS ESI 164.9 [M+H].sup.+, calcd for
[C.sub.10H.sub.12ClN--NH.sub.3+H].sup.+ 165.0.
[0844] To a solution of cyclopropyl(2-chlorophenyl)methanamine
(1.12 g, 6.17 mmol), 3-iodo-1H-indazole-5-carboxamide (1.68 g, 5.85
mmol) in DMF (30 mL) was added TBTU (1.88 g, 5.85 mmol), followed
by .sup.iPr.sub.2NEt (2.03 mL, 11.7 mmol). The resulting mixture
was stirred at rt for 30 min, quenched with H.sub.2O and stirred
for 30 min at rt. Suction filtration gave crude
N-((2-chlorophenyl)(cyclopropyl)methyl)-3-iodo-1H-indazole-5-carboxamide
(pale yellow solid, 2.582 g). MS ESI 452.2 [M+H].sup.+, calcd for
[C.sub.18H.sub.15ClN.sub.3O+H].sup.+ 452.0.
[0845] To a mixture of crude
N-((2-chlorophenyl)(cyclopropyl)methyl)-3-iodo-1H-indazole-5-carboxamide
(226 mg, 0.5 mmol) and
1-methyl-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)piperi-
dine (127 mg, 0.4 mmol) in EtOH (10 mL) was added 1 M aq Na2CO3 (1
mL, 1 mmol), followed by Pd(PPh.sub.3).sub.4 (46 mg, 0.04 mmol).
The resulting mixture was purged with Ar and microwaved 4 h at
125.degree. C. After removal of solvents, it was purified by
prep-HPLC and PoraPak to give the title compound (white solid, 59.0
mg, 29%). .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.58 (s, 1H),
7.92 (dd, J=9.0 Hz, 1.4 Hz, 1H), 7.84 (d, J=8.4 Hz, 2H), 7.63 (dd,
J=7.8 Hz, 1.4 Hz, 1H), 7.55 (d, J=8.8 Hz, 1H), 7.32 (dd, J=8.0 Hz,
0.8 Hz, 1H), 7.23 (t, J=7.6 Hz, 1H), 7.16 (dt, J=7.6 Hz, 1.6 Hz,
1H), 6.99 (d, J=8.8 Hz, 2H), 4.99 (d, J=8.8 Hz, 1H), 4.40-4.30 (m,
1H), 2.71-2.62 (m, 2H), 2.37-2.25 (m, 5H; s, 3H at 2.27), 2.02-1.93
(m, 2H), 1.83-1.73 (m, 2H), 1.45-1.35 (m, 1H), 0.67-0.60 (m, 1H),
0.55-0.45 (m, 3H); MS ESI 515.4 [M+H].sup.+, calcd for
[C.sub.30H.sub.31ClN.sub.4O.sub.2+H].sup.+ 515.2.
Example A151
N-(cyclopropyl(2-methoxyphenyl)methyl)-3-(4-((1-methylpiperidin-4-yl)oxy)p-
henyl)-1H-indazole-5-carboxamide
##STR00293##
[0847] To a 20 mL microwave vial charged with Mg powder (480 mg, 20
mmol), THF (15 mL) was added bromocyclopropane (2.42 g, 20 mmol).
The resulting mixture was stirred for 30 min at rt before
2-methoxybenzonitrile (1.064 g, 8 mmol) was added. It was
microwaved 15 min at 100.degree. C., cooled to rt and added
dropwise to a cold solution of NaBH.sub.4 (760 mg, 20 mmol) in MeOH
(45 mL) at 0.degree. C. The resulting mixture was stirred for 20
min at rt, quchend with H.sub.2O, extracted with DCM and purified
by flash chromatography (MeOH/DCM 0-20%) to give
cyclopropyl(2-methoxyphenyl)methanamine (light orange oil which
partially solidied upon standing, 933 mg, 77%). .sup.1H NMR (400
MHz, CD.sub.3OD) .delta. 7.36 (dd, J=7.4 Hz, 1.4 Hz, 1H), 7.25 (dt,
J=7.4 Hz, 1.6 Hz, 1H), 6.98 (d, J=8.4 Hz, 1H), 6.94 (dt, J=7.4 Hz,
1.0 Hz, 1H), 3.86 (s, 3H), 3.76 (d, J=9.2 Hz, 1H), 1.34-1.24 (m,
1H), 0.66-0.59 (m, 1H), 0.49-0.41 (m, 1H), 0.40-0.33 (m, 1H),
0.23-0.16 (m, 1H); MS ESI 161.0 [M+H].sup.+, calcd for
[C.sub.11H.sub.15NO--NH.sub.3+H].sup.+ 161.1.
[0848] To a solution of cyclopropyl(2-methoxyphenyl)methanamine
(933 mg, 5.27 mmol), 3-iodo-1H-indazole-5-carboxamide (1.44 g, 5
mmol) in DMF (25 mL) was added TBTU (1.61 g, 5 mmol), followed by
.sup.iPr.sub.2NEt (2.03 mL, 11.7 mmol). The resulting mixture was
stirred at rt for 30 min, quenched with H.sub.2O and stirred for 30
min at rt. Suction filtration gave crude
N-(cyclopropyl(2-methoxyphenyl)methyl)-3-iodo-1H-indazole-5-carboxamide
(off white solid, 2.068 g). MS ESI 448.1 [M+H].sup.+, calcd for
[C.sub.19H.sub.81N.sub.3O.sub.2+H].sup.+ 448.0.
[0849] To a mixture of crude
N-(cyclopropyl(2-methoxyphenyl)methyl)-3-iodo-1H-indazole-5-carboxamide
(224 mg, 0.5 mmol) and
1-methyl-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)piperi-
dine (127 mg, 0.4 mmol) in EtOH (10 mL) was added 1 M aq Na2CO3 (1
mL, 1 mmol), followed by Pd(PPh.sub.3).sub.4 (46 mg, 0.04 mmol).
The resulting mixture was purged with Ar and microwaved 4 h at
125.degree. C. After removal of solvents, it was purified by
prep-HPLC and PoraPak to give the title compound (white solid, 53.7
mg, 26%). .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.55 (s, 1H),
7.90 (dd, J=8.8 Hz, 1.6 Hz, 1H), 7.86 (d, J=8.8 Hz, 2H), 7.56 (d,
J=8.8 Hz, 1H), 7.40 (dd, J=7.6 Hz, 1.6 Hz, 1H), 7.19 (dt, J=7.8 Hz,
1.6 Hz, 1H), 7.02 (d, J=8.8 Hz, 2H), 6.94 (d, J=8.8 Hz, 1H), 6.89
(t, J=7.4 Hz, 1H), 4.83 (d, J=9.2 Hz, 1H), 4.43-4.35 (m, 1H), 3.84
(s, 3H), 2.73-2.64 (m, 2H), 2.37-2.25 (m, 5H; s, 3H at 2.27),
2.03-1.94 (m, 2H), 1.85-1.74 (m, 2H), 1.49-1.39 (m, 1H), 0.62-0.52
(m, 1H), 0.50-0.38 (m, 3H); MS ESI 511.4 [M+H].sup.+, calcd for
[C.sub.31H.sub.34N.sub.4O.sub.3+H].sup.+ 511.3.
Example A152
Intentionally Omitted
Example A153
3-(4-((1-(2-methoxyethyl)piperidin-4-yl)oxy)phenyl)-N-(1-phenylpropyl)-1H--
indazole-5-carboxamide
##STR00294##
[0851] The title compound was synthesized according to Method C3
utilizing 3-iodo-N-(1-phenylpropyl)-1H-indazole-5-carboxamide and
1-(2-methoxyethyl)-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phen-
oxy)piperidine and obtained as a yellow solid (30 mg, 32% yield).
.sup.1H NMR (400 MHz, CD.sub.3OD) .delta. ppm 8.58 (s, 1H), 7.94
(dd, J=8.78, 1.51 Hz, 1H), 7.90 (d, J=8.53 Hz, 2H), 7.59 (d, J=8.78
Hz, 1H), 7.41 (d, J=7.53 Hz, 2H), 7.32 (t, J=7.53 Hz, 2H),
7.19-7.25 (m, 1H), 7.10 (d, J=8.78 Hz, 2H), 5.03 (t, J=7.53 Hz,
1H), 4.58 (br. s., 1H), 3.62 (t, J=5.40 Hz, 2H), 3.38 (s, 3H), 3.08
(t, J=8.16 Hz, 2H), 2.92 (t, J=5.02 Hz, 2H), 2.82 (br. s., 2H),
2.05-2.16 (m, 2H), 1.85-2.04 (m, 4H), 1.00 (t, J=7.28 Hz, 3H); MS
ESI [M+H].sup.+ 513.5, calcd for
[C.sub.31H.sub.36N.sub.4O.sub.3+H].sup.+ 513.29.
Example A154
(S)--N-(cyclopropyl(thiophen-3-yl)methyl-3-(4-((1-(2-meth-3-(4-((1-(2-oxye-
thyl)piperidin-4-yl)oxy)phenyl)-1H-indazole-5-carboxamide
##STR00295##
[0853] The title compound was prepared using Method C3 from
(S)--N-(cyclopropyl(thiophen-3-yl)methyl)-3-iodo-1H-indazole-5-carboxamid-
e (60 mg, 0.142 mmol) and
1-(2-methoxyethyl)-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phen-
oxy)piperidine (67 mg, 0.185 mmol) which gave 48 mg of product
isolated as its TFA salt (64%, a pale-yellow solid). .sup.1H NMR
(400 MHz, CD.sub.3OD) .delta. ppm 8.58 (s, 1H), 7.98-7.94 (m, 3H),
7.61 (d, J=8.7 Hz, 1H), 7.38-7.36 (m, 2H), 7.22-7.16 (m, 3H), 4.87
(bs, 1H), 4.61 (d, J=9.6 Hz, 1H), 3.76-3.22 (m, 11H), 2.46-2.29 (m,
2H), 2.20-1.97 (m, 2H), 1.48-1.43 (m, 1H), 0.76-0.64 (m, 2H),
0.55-0.47 (m, 2H); MS ESI 531.4 [M+H].sup.+, calcd for
[C.sub.30H.sub.34N.sub.4O.sub.3S+H].sup.+ 531.24.
Example A155
N-(cyclopentyl(thiophen-3-yl)methyl)-3-(4-((1-(2-methoxyethyl)piperidin-4--
yl)oxy)phenyl)-1H-indazole-5-carboxamide
##STR00296##
[0855] The title compound was prepared using Method C3 from
N-(cyclopentyl(thiophen-3-yl)methyl)-3-iodo-1H-indazole-5-carboxamide
(75 mg, 0.166 mmol) and
1-(2-methoxyethyl)-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phen-
oxy)piperidine (78 mg, 0.216 mmol) which gave 34 mg of product
isolated as its TFA salt (37%, a pale-yellow solid). .sup.1H NMR
(400 MHz, CD.sub.3OD) .delta. ppm 8.51 (s, 1H), 7.95-7.88 (m, 3H),
7.60 (d, J=8.8 Hz, 1H), 7.37-7.32 (m, 2H), 7.22-7.15 (m, 3H), 5.05
(d, J=10.4 Hz, 1H), 4.87 (bs, 1H), 3.77-3.19 (m, 11H), 2.59-1.92
(m, 6H), 1.69-1.23 (m, 7H); MS ESI 559.4 [M+H].sup.+, calcd for
[C.sub.32H.sub.38N.sub.4O.sub.3S+H].sup.+ 559.27.
Example A156
2-cyclopentyl-2-(2-methoxyphenyl)-N-(3-(4-((1-methylpiperidin-4-yl)oxy)phe-
nyl)-1H-indazol-5-yl)acetamide
##STR00297##
[0857] The title compound was synthesized according to the General
Method C, utilizing
2-cyclopentyl-N-(3-iodo-1H-indazol-5-yl)-2-(2-methoxyphenyl)acetamide
(50 mg, 0.10 mmol), (4-((1-methylpiperidin-4-yl)oxy)phenyl)boronic
acid pinacol ester (33 mg, 0.1 mmol), Pd(PPh.sub.3).sub.4 (6 mg,
0.005 mmol), satd. Na.sub.2CO.sub.3 (1.25 mL), and 3.75 mL of
PhMe:EtOH (1:1). The vial was charged with Ar and heated in the
microwave reactor at 125.degree. C. for 2 h. Purification by
RPHPLC, followed by trituration with Et.sub.2O gave the title
compound as a TFA salt (a beige solid, 16 mg, 25%). .sup.1H NMR
(400 MHz, CD.sub.3OD) .delta. ppm 8.40 (s, 1H), 7.81-7.89 (m, 2H),
7.55 (dd, J=7.8, 1.5 Hz, 1H), 7.49 (d, J=9.3, 1 H), 7.38 (dd,
J=8.9, 1.9 Hz, 1H), 7.08-7.25 (m, 3H), 6.91-7.00 (m, 2H), 4.57-4.69
(m, 0.3H), 4.01 (d, J=11.0 Hz, 1H), 3.89 (s, 3H), 3.57-3.65 (m,
0.7H), 3.32-3.47 (m, 3H), 3.13-3.25 (m, 0.7H), 2.89-2.96 (m, 3H),
2.66-2.79 (m, 1H), 2.37-2.48 (m, 0.7H), 2.23-2.34 (m, 1.3H),
2.03-2.16 (m, 1.3H), 1.82-2.00 (m, 1.3H), 1.70-1.81 (m, 1H),
1.40-1.70 (m, 5.7H), 1.03-1.16 (m, 1H); MS ESI 539.4 [M+H].sup.+,
calcd for [C.sub.33H.sub.38N.sub.4O.sub.3+H].sup.+ 539.3.
Example A157
N-(cyclopropyl(phenyl)methyl-3-(4-((1)oxetan-3-yl)piperidin-4-yl)oxy)pheny-
l)-1H-indazole-5-carboxamide
##STR00298##
[0859] The title compound was synthesized according to Method C3
utilizing
N-(cyclopropyl(phenyl)methyl)-3-iodo-1H-indazole-5-carboxamide and
1-(oxetan-3-yl)-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy-
)piperidine and obtained as a yellow solid (38 mg, 38% yield).
.sup.1H NMR (400 MHz, CD.sub.3OD) .delta. ppm 8.62 (s, 1H), 7.96
(dd, J=8.78, 1.51 Hz, 1H), 7.89 (d, J=8.78 Hz, 2H), 7.59 (d, J=8.78
Hz, 1H), 7.47 (d, J=7.28 Hz, 2H), 7.27-7.33 (t, J=7.6 Hz, 2H),
7.18-7.24 (m, 1H), 7.03 (d, J=8.78 Hz, 2H), 4.69 (t, J=6.27 Hz,
2H), 4.58 (t, J=6.27 Hz, 2H), 4.47 (d, J=9.54 Hz, 1H), 4.39-4.45
(m, 1H), 3.47 (quin, J=6.46 Hz, 1H), 2.55 (br. s., 2H), 2.20 (d,
J=7.78 Hz, 2H), 1.96-2.06 (m, 2H), 1.74-1.86 (m, 2H), 1.33-1.44 (m,
1H), 0.58-0.68 (m, 2H), 0.39-0.51 (m, 2H); MS ESI [M+H].sup.+
523.3, calcd for [C.sub.32H.sub.34N.sub.4O.sub.3+H].sup.+
523.27.
Example A158
N-(cyclopropyl(phenyl)methyl)-3-(4-((1-(2-(dimethylamino)-2-oxoethyl)piper-
idin-4-yl)oxy)phenyl)-1H-indazole-5-carboxamide
##STR00299##
[0861] The title compound was synthesized according to Method C3
utilizing
N-(cyclopropyl(phenyl)methyl)-3-iodo-1H-indazole-5-carboxamide and
N,N-dimethyl-2-(4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy-
)piperidin-1-yl)acetamide and obtained as a white solid (28 mg, 27%
yield). .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. ppm 8.61 (s, 1H),
7.96 (dd, J=8.78, 1.51 Hz, 1H), 7.91 (d, J=8.78 Hz, 2H), 7.60 (d,
J=8.78 Hz, 1H), 7.48 (d, J=7.28 Hz, 2H), 7.32 (t, J=7.53 Hz, 2H),
7.19-7.26 (m, 1H), 7.09 (d, J=8.78 Hz, 2H), 4.43-4.59 (m, 2H), 3.55
(br. s., 2H), 3.07 (s, 3H), 3.01 (m, J=7.03 Hz, 2H), 2.96 (s, 3H),
2.73 (br. s., 2H), 2.06-2.16 (m, 2H), 1.95 (br. s., 2H), 1.40 (m,
J=8.66, 4.14 Hz, 1H), 0.65 (d, J=8.28 Hz, 2H), 0.47 (dd, J=9.41,
4.64 Hz, 2H); MS ESI [M+H].sup.+ 552.4, calcd for
[C.sub.33H.sub.37N.sub.5O.sub.3+H].sup.+ 552.30.
Example A159
N-(cyclopentyl(phenyl)methyl)-3-(4-((1-methylpiperidin-4-yl)oxy)phenyl)-1H-
-indazole-5-carboxamide
##STR00300##
[0863] The title compound was synthesized according to the General
Method C, utilizing
N-(cyclopentyl(phenyl)methyl)-3-iodo-1H-indazole-5-carboxamide (100
mg, 0.21 mmol), (4-((1-methylpiperidin-4-yl)oxy)phenyl)boronic acid
pinacol ester (67 mg, 0.21 mmol), Pd(PPh.sub.3).sub.4 (12 mg, 0.010
mmol), satd. Na.sub.2CO.sub.3 (1.25 mL), and 3.75 mL of PhMe:EtOH
(1:1). The vial was charged with Ar and heated in the microwave
reactor at 125.degree. C. for 2 h. Purification by RPHPLC, followed
by trituration with Et.sub.2O gave the title compound as a TFA salt
(light yellow solid, 44 mg, 34%). .sup.1H NMR (400 MHz, CD.sub.3OD)
.delta. ppm 8.51 (s, 1H), 7.86-7.95 (m, 3H), 7.58 (d, J=8.8 Hz,
1H), 7.44 (d, J=7.3 Hz, 2H), 7.32 (t, J=7.5 Hz, 2H), 7.11-7.25 (m,
3H), 4.83 (d, J=10.8 Hz, 1H), 4.60-4.72 (m, 0.3H), 3.59-3.67 (m,
0.7H), 3.33-3.47 (m, 2.7H), 3.14-3.25 (m, 0.7H), 2.91-2.96 (m, 3H),
2.47-2.59 (m, 1H), 2.38-2.47 (m, 0.7H), 2.24-2.33 (m, 1.3H),
2.04-2.18 (m, 1.3H), 1.84-2.04 (m, 1.7H), 1.58-1.78 (m, 3.3H),
1.36-1.58 (m, 3.3H), 1.13-1.26 (m, 1H); MS ESI 509.4 [M+H].sup.+,
calcd for [C.sub.32H.sub.36N.sub.4O.sub.2+H].sup.+ 509.3.
Example A160
N-(cyclopropyl(pyridin-2-yl)methyl)-3-(4-((1-formylpiperidin-4-yl)oxy)phen-
yl)-1H-indazole-5-carboxamide
##STR00301##
[0865] The title compound was synthesized according to Method C3
utilizing
N-(cyclopropyl(pyridin-2-yl)methyl)-3-iodo-1H-indazole-5-carboxamide
and
4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)piperidine-1-ca-
rbaldehyde and obtained as a white solid (36 mg, 29% yield).
.sup.1H NMR (400 MHz, CD.sub.3OD) .delta. ppm 8.77 (dd, J=5.77,
0.75 Hz, 1H), 8.70 (s, 1H), 8.56 (t, J=7.15 Hz, 1H), 8.20 (d,
J=8.03 Hz, 1H), 7.90-8.01 (m, 4H), 7.63 (d, J=8.78 Hz, 1H), 7.15
(d, J=8.78 Hz, 2H), 4.72-4.80 (m, 1H), 4.49 (d, J=10.04 Hz, 1H),
3.64-3.82 (m, 2H), 3.39-3.58 (m, 2H), 1.92-2.10 (m, 2H), 1.71-1.90
(m, 2H), 1.45-1.58 (m, 1H), 0.84-0.95 (m, 1H), 0.58-0.81 (m, 3H);
MS ESI [M+H].sup.+ 496.3, calcd for
[C.sub.29H.sub.29N.sub.5O.sub.3+H].sup.+ 496.23.
Example A161
N-(cyclopentyl(phenyl)methyl)-3-(4-((1-(2-methoxyethyl)piperidin-4-yl)oxy)-
phenyl)-1H-indazole-5-carboxamide
##STR00302##
[0867] The title compound was synthesized according to the General
Method C, utilizing
N-(cyclopentyl(phenyl)methyl)-3-iodo-1H-indazole-5-carboxamide (100
mg, 0.21 mmol),
(4-((1-(2-methoxyethyl)-piperidin-4-yl)oxy)phenyl)boronic acid
pinacol ester (76 mg, 0.21 mmol), Pd(PPh.sub.3).sub.4 (12 mg, 0.010
mmol), satd. Na.sub.2CO.sub.3 (1.25 mL), and 3.75 mL of PhMe:EtOH
(1:1). The vial was charged with Ar and heated in the microwave
reactor at 125.degree. C. for 2 h. Purification by RPHPLC, followed
by trituration with Et.sub.2O gave the title compound as a TFA salt
(white solid, 42 mg, 30%). .sup.1H NMR (400 MHz, CD.sub.3OD)
.delta. ppm 8.51 (s, 1H), 7.86-7.94 (m, 3H), 7.58 (d, J=8.5 Hz,
1H), 7.43 (d, J=7.3 Hz, 2H), 7.31 (t, J=7.5 Hz, 2H), 7.10-7.25 (m,
3H), 4.83 (d, J=8.3 Hz, 1H), 4.60-4.71 (m, 0.3H), 3.66-3.77 (m,
2.7H), 3.45-3.56 (m, 1.3H), 3.43 (s, 3H), 3.31-3.43 (m, 3.3H),
3.14-3.27 (m, 1H), 2.46-2.59 (m, 1H), 2.34-2.45 (m, 0.7H),
2.10-2.32 (m, 3H), 1.90-2.05 (m, 1.7H), 1.35-1.77 (m, 6H),
1.12-1.25 (m, 1H); MS ESI 554.2 [M+H].sup.+, calcd for
[C.sub.34H.sub.40N.sub.4O.sub.3+H].sup.+ 553.3.
Example A162
2-cyclopentyl-2-(2-fluorophenyl)-N-(3-(4-((1-methylpiperidin-4-yl)oxy)phen-
yl)-1H-indazol-5-yl)acetamide
##STR00303##
[0869] The title compound was synthesized according to the General
Method C, utilizing
2-cyclopentyl-N-(1-(2-cyclopentyl-2-(2-fluorophenyl)acetyl)-3-(4-((1-meth-
ylpiperidin-4-yl)oxy)phenyl)-1H-indazol-5-yl)-2-(2-fluorophenyl)acetamide
(100 mg, 0.15 mmol), (4-((1-methylpiperidin-4-yl)oxy)phenyl)boronic
acid pinacol ester (48 mg, 0.15 mmol), Pd(PPh.sub.3).sub.4 (9 mg,
0.0075 mmol), satd. Na.sub.2CO.sub.3 (1.25 mL), and 3.75 mL of
PhMe:EtOH (1:1). The vial was charged with Ar and heated in the
microwave reactor at 125.degree. C. for 2 h. Purification by
RPHPLC, followed by trituration with Et.sub.2O gave the title
compound as a TFA salt (white solid, 38 mg, 40%). .sup.1H NMR (400
MHz, CD3OD) .delta. ppm 8.40 (dd, J=4.8, 1.2 Hz, 1H), 7.82-7.89 (m,
2H), 7.66-7.73 (m, 1H), 7.50 (d, J=9.0 Hz, 1H), 7.37-7.43 (m, 1H),
7.23-7.30 (m, 1H), 7.05-7.20 (m, 4H), 4.59-4.71 (m, 0.3H), 3.88 (m,
J=11.3, 1 H), 3.58-3.67 (m, 0.7H), 3.33-3.47 (m, 3H), 3.13-3.26 (m,
0.7H), 2.89-2.96 (m, 3H), 2.64-2.77 (m, 1H), 2.37-2.48 (m, 0.7H),
2.23-2.35 (m, 1.3H), 2.03-2.16 (m, 1.3H), 1.84-2.00 (m, 1.7H),
1.40-1.81 (m, 6.3H), 1.05-1.18 (m, 1H); MS ESI 527.4 [M+H].sup.+,
calcd for [C.sub.32H.sub.35FN.sub.4O.sub.2+H].sup.+ 527.3.
Example A163
(S)--N-(cyclopropyl(thiophen-2-yl)methyl)-3-(4-((1-(2-methoxyethyl)piperid-
in-4-yl)oxy)phenyl)-1H-indazole-5-carboxamide
##STR00304##
[0871] The title compound was prepared using Method C3 from
(S)--N-(cyclopropyl(thiophen-2-yl)methyl)-3-iodo-1H-indazole-5-carboxamid-
e (110 mg, 0.260 mmol) and
1-(2-methoxyethyl)-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phen-
oxy)piperidine (122 mg, 0.338 mmol) which gave 77 mg of product
isolated as its TFA salt (56%, an off-white solid). .sup.1H NMR
(400 MHz, CD.sub.3OD) .delta. ppm 8.60 (s, 1H), 7.97-7.94 (m, 3H),
7.61 (d, J=8.9 Hz, 1H), 7.27 (d, J=5.3 Hz, 1H), 7.20-7.12 (m, 3H),
6.98-6.96 (m, 1H), 4.87 (bs, 1H), 4.75 (d, J=9.6 Hz, 1H), 3.76-3.19
(m, 11H), 2.42-1.95 (m, 4H), 1.54-1.48 (m, 1H), 0.80-0.67 (m, 2H),
0.55-0.49 (m, 2H); MS ESI 531.5 [M+H].sup.+, calcd for
[C.sub.30H.sub.34N.sub.4O.sub.3S+H].sup.+ 531.24.
Example A164
(S)--N-(2-methoxy-1-phenylethyl)-3-(4-((1-(2-methoxyethyl)piperidin-4-yl)o-
xy)phenyl)-1H-indazole-5-carboxamide
##STR00305##
[0873] The title compound was prepared using Method C3 from
(S)-3-iodo-N-(2-methoxy-1-phenylethyl)-1H-indazole-5-carboxamide
(110 mg, 0.260 mmol) and
1-(2-methoxyethyl)-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phen-
oxy)piperidine (122 mg, 0.338 mmol) which gave 97 mg of product
isolated as its TFA salt (71%, off white solid). .sup.1H NMR (400
MHz, CD.sub.3OD) .delta. ppm 8.58 (s, 1H), 7.96-7.93 (m, 3H), 7.61
(d, J=8.8 Hz, 1H), 7.43 (d, J=7.6 Hz, 2H), 7.28-7.15 (m, 5H),
5.42-5.38 (m, 1H), 4.87 (bs, 1H), 3.84-3.68 (m, 5H), 3.53-3.19 (m,
11H), 2.43-2.27 (m, 2H), 2.19-1.96 (m, 2H); MS ESI 529.5
[M+H].sup.+, calcd for [C.sub.31H.sub.36N.sub.4O.sub.4+H].sup.+
529.28.
Example A165
Intentionally Omitted
Example A166
(R)--N-((3-chlorothiophen-2-yl)(cyclopropyl)methyl)-3-(4-((1-methylpiperid-
in-4-yl)oxy)phenyl)-1H-indazole-5-carboxamide
##STR00306##
[0875] Using Method C2,
(R)--N-((3-chlorothiophen-2-yl)(cyclopropyl)methyl)-3-iodo-1H-indazole-5--
carboxamide (76.6 mg, 85% pure, 0.142 mmol) and
1-methyl-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)piperi-
dine (46.1 mg, 0.145 mmol) for 2 h at 125.degree. C. in the
microwave, the mixture was passed through a PoraPak Rxn Cx with
acetone/MeOH and the product was eluted with 2 M NH.sub.3-MeOH.
Purification by flash chromatography (SiO2, 5-25% MeOH in DCM, then
25% 2 M NH.sub.3-MeOH in DCM; followed by RPRP HPLC, 10-90% MeOH in
0.1% TFA-H.sub.2O) gave the title compound as the TFA salt (beige
solid, 28.9 mg, 32%). .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. ppm
9.15 (d, J=7.5 Hz, 0.2H partially exchanged), 8.57 (s, 1H),
7.88-7.98 (m, 3H), 7.61 (d, J=9.0 Hz, 1H), 7.38 (d, J=5.3 Hz, 1H),
7.11-7.23 (m, 2H), 6.94 (s, 1H), 4.97 (d, J=8.8 Hz, 1H), 4.61-4.72
(m, 0.35H), 3.65 (d, J=12.5 Hz, 0.65H), 3.34-3.48 (m, 3H),
3.16-3.26 (m, 65H), 2.95, 2.94 (2-s, 3H), 2.44 (d, J=14.6 Hz,
0.7H), 2.26-2.35 (m, 1.3H), 2.06-2.19 (m, 1.3H), 1.86-1.99 (m,
0.7H), 1.45-1.56 (m, 1H), 0.61-0.73 (m, 2H), 0.50-0.61 (m, 2H). MS
ESI 521.4 [M+H].sup.+, calcd for
[C.sub.28H.sub.29ClN.sub.4O.sub.2S+H].sup.+ 521.18.
Example A167
(S)--N-((3-chlorothiophen-2-yl)(cyclopropyl)methyl)-3-(4-((1-methylpiperid-
in-4-yl)oxy)phenyl)-1H-indazole-5-carboxamide
##STR00307##
[0877] Using Method C2,
(S)--N-((3-chlorothiophen-2-yl)(cyclopropyl)methyl)-3-iodo-1H-indazole-5--
carboxamide (102.1 mg, 85% pure, 0.19 mmol) and
1-methyl-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)piperi-
dine (60.4 mg, 0.19 mmol) for 2 h at 130.degree. C. in the
microwave, the mixture was passed through a PoraPak Rxn Cx with
acetone/MeOH and the product was eluted with 2 M NH.sub.3-MeOH.
Purification by flash chromatography (SiO2, 15% MeOH in DCM, then
15-35% 2 M NH.sub.3-MeOH in DCM; followed by RPRP HPLC, 10-90% MeOH
in 0.1% TFA-H.sub.2O) gave the title compound as the TFA salt
(beige solid, 31.8 mg, 26%). .sup.1H NMR (400 MHz, CD.sub.3OD)
.delta. ppm 9.15 (d, J=7.5 Hz, 0.2H partially exchanged), 8.57 (s,
1H), 7.88-7.98 (m, 3H), 7.61 (d, J=9.0 Hz, 1H), 7.38 (d, J=5.3 Hz,
1H), 7.11-7.23 (m, 2H), 6.94 (s, 1H), 4.97 (d, J=8.8 Hz, 1H),
4.61-4.72 (m, 0.35H), 3.65 (d, J=12.5 Hz, 0.65H), 3.34-3.48 (m,
3H), 3.16-3.26 (m, 65H), 2.95, 2.94 (2-s, 3H), 2.44 (d, J=14.6 Hz,
0.7H), 2.26-2.35 (m, 1.3H), 2.06-2.19 (m, 1.3H), 1.86-1.99 (m,
0.7H), 1.45-1.56 (m, 1H), 0.61-0.73 (m, 2H), 0.50-0.61 (m, 2H). MS
ESI 521.4 [M+H].sup.+, calcd for
[C.sub.28H.sub.29ClN.sub.4O.sub.2S+H].sup.+ 521.18.
Example A168
Intentionally Omitted
Example A169
(R)--N-(3-(4-((1-formylpiperidin-4-yl)oxy)phenyl)-1H-indazol-5-yl)-2-metho-
xy-2-phenylacetamide
##STR00308##
[0878] The title compound was synthesized according to Method C3
utilizing
(R)--N-(3-iodo-1H-indazol-5-yl)-2-methoxy-2-phenylacetamide and
4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)piperidine-1-ca-
rbaldehyde and obtained as an off-white solid (59 mg, 50% yield).
.sup.1H NMR (400 MHz, CD.sub.3OD) .delta. ppm 8.39 (d, J=1.00 Hz,
1H), 7.95 (s, 1H), 7.78 (d, J=8.78 Hz, 2H), 7.44-7.56 (m, 4H),
7.25-7.38 (m, 3H), 6.96 (d, J=8.78 Hz, 2H), 4.80 (s, 1H), 4.54 (dt,
J=6.53, 3.51 Hz, 1H), 3.59-3.69 (m, 1H), 3.47-3.57 (m, 1H),
3.37-3.45 (m, 4H), 3.20-3.30 (m, 1H), 1.75-1.92 (m, 2H), 1.57-1.74
(m, 2H); MS ESI [M+H].sup.+ 485.4, calcd for
[C.sub.28H.sub.28N.sub.4O.sub.4+H].sup.+ 485.22.
Example A170
N-(cyclohexyl(phenyl)methyl)-3-(4-((1-methylpiperidin-4-yl)oxy)phenyl)-1H--
indazole-5-carboxamide
##STR00309##
[0880] The title compound was synthesized according to the General
Method C, utilizing
N-(cyclohexyl(phenyl)methyl)-3-iodo-1H-indazole-5-carboxamide (100
mg, 0.22 mmol), (4-((1-methylpiperidin-4-yl)oxy)phenyl)boronic acid
pinacol ester (70 mg, 0.22 mmol), Pd(PPh.sub.3).sub.4 (13 mg, 0.01
mmol), satd. aq Na.sub.2CO.sub.3 (1.25 mL), and 3.75 mL of
PhMe:EtOH (1:1). The vial was charged with Ar and heated in the
microwave reactor at 125.degree. C. for 2 h. Purification by
RPRPHPLC gave the title compound as a TFA salt (white solid, 46 mg,
33%). .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. ppm 8.51 (s, 1H),
7.85-7.96 (m, 3H), 7.58 (d, J=8.8 Hz, 1H), 7.40 (d, J=7.3 Hz, 2H),
7.32 (t, J=7.6 Hz, 2H), 7.10-7.26 (m, 3H), 4.81 (d, J=10.0 Hz, 1H),
4.60-4.70 (m, 0.3H), 3.59-3.68 (m, 0.7H), 3.33-3.47 (m, 3H),
3.13-3.25 (m, 0.7H), 2.89-2.96 (m, 3H), 2.37-2.45 (m, 0.7H),
2.23-2.33 (m, 1.3H), 2.03-2.17 (m, 2.4H), 1.84-1.97 (m, 1.7H),
1.74-1.84 (m, 1H), 1.60-1.71 (m, 2H), 1.08-1.39 (m, 6.3H),
0.86-0.99 (m, 1H); MS ESI 523.5 [M+H].sup.+, calcd for
[C.sub.33H.sub.38N.sub.4O.sub.2+H].sup.+ 523.3.
Example A171
N-(cyclopropyl(pyridin-2-yl)methyl)-3-(4-((1-(oxetan-3-yl)piperidin-4-yl)o-
xy)phenyl)-1H-indazole-5-carboxamide
##STR00310##
[0881] The title compound was synthesized according to Method C3
utilizing
N-(cyclopropyl(pyridin-2-yl)methyl)-3-iodo-1H-indazole-5-carboxamide
and
1-(oxetan-3-yl)-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy-
)piperidine and obtained as a white solid (23 mg, 23% yield).
.sup.1H NMR (400 MHz, CD.sub.3OD) .delta. ppm 8.65 (s, 1H), 8.52
(d, J=4.02 Hz, 1H), 7.96 (dd, J=8.91, 1.38 Hz, 1H), 7.92 (d, J=8.53
Hz, 2H), 7.81 (td, J=7.65, 1.76 Hz, 1H), 7.60 (d, J=9.29 Hz, 1H),
7.53 (d, J=8.03 Hz, 1H), 7.27-7.34 (m, 1H), 7.09 (d, J=8.78 Hz,
2H), 4.65-4.74 (m, 2H), 4.61 (t, J=6.27 Hz, 2H), 4.51 (d, J=9.54
Hz, 2H), 3.52 (quin, J=6.40 Hz, 1H), 2.61 (br. s., 2H), 2.25 (br.
s., 2H), 2.01-2.11 (m, 2H), 1.78-1.90 (m, 2H), 1.35-1.46 (m, 1H),
0.69 (br. s., 1H), 0.48-0.63 (m, 3H); MS ESI [M+H].sup.+ 524.2,
calcd for [C.sub.31H.sub.33N.sub.5O.sub.3+H].sup.+ 524.27.
Example A172
2-(azetidin-1-yl)-N-(3-(4-morpholinophenyl)-1H-indazol-5-yl)-2-(thiophen-3-
-yl)acetamide
##STR00311##
[0883] A mixture of thiophen-3-ylboronic acid (5.61 g, 43.9 mmol)
and glyoxylic acid monohydrate (4.04 g, 43.9 mmol) in DCM (200 mL)
was stirred for 5 min at rt before azetidine (2.50 g, 43.9 mmol)
was added. The resulting mixture was stirred O/N at rt. White
precipitates formed were collected by suction filtration, rinsed
with DCM and dried to give
2-(azetidin-1-yl)-2-(thiophen-3-yl)acetic acid as a H.sub.3BO.sub.3
salt (light beige solid, 10.968 g). .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. 7.64 (s, 1H), 7.52 (t, 1H), 7.19 (d, J=4.8 Hz,
1H), 4.45-3.50 (m, 4H), 2.60-2.30 (m, 2H); MS ESI 197.9
[M+H].sup.+, calcd for [C.sub.9H.sub.11NO.sub.2S+H].sup.+
198.0.
[0884] To a mixture of 2-(azetidin-1-yl)-2-(thiophen-3-yl)acetic
acid H.sub.3BO.sub.3 salt (52 mg, 0.2 mmol),
3-(4-morpholinophenyl)-1H-indazol-5-amine di-trifluoroacetic acid
(259 mg, 90% pure, 0.2 mmol) in DMF (5 mL) at 0.degree. C. was
added TBTU (65 mg, 0.2 mmol), followed by .sup.iPr.sub.2NEt (0.14
mL, 0.8 mmol). The resulting mixture was stirred for 30 min at
0.degree. C. It was purified by prep-HPLC and PoraPak to give the
title compound (pale yellow solid, 8.0 mg, 8%). .sup.1H NMR (400
MHz, CD.sub.3OD) .delta. 8.32 (s, 1H), 7.80 (d, J=8.8 Hz, 2H),
7.52-7.49 (m, 3H), 7.41 (dd, J=8.6 Hz, 3.0 Hz, 1H), 7.25 (d, J=4.8
Hz, 1H), 7.09 (d, J=8.8 Hz, 2H), 4.21 (s, 1H), 3.86 (t, J=4.8 Hz,
4H), 3.40 (q, J=6.8 Hz, 2H), 3.27-3.18 (m, 6H), 2.15 (quint, 7.0
Hz, 2H); MS ESI 474.2 [M+H].sup.+, calcd for
[C.sub.26H.sub.27N.sub.5O.sub.2S+H].sup.+ 474.2.
Example A173
(S)--N-(2-methoxy-1-phenylethyl)-3-(4-((1-methylpiperidin-4-yl)oxy)phenyl)-
-1H-indazole-5-carboxamide
##STR00312##
[0886] The title compound was prepared using Method C3 from
(S)-3-iodo-N-(2-methoxy-1-phenylethyl)-1H-indazole-5-carboxamide
(68 mg, 0.166 mmol) and
1-methyl-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)piperi-
dine (70 mg, 0.216 mmol) which gave product as a white solid (34
mg, 43% yield) isolated as its TFA salt. .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. ppm 8.58 (s, 1H), 7.97-7.93 (m, 3H), 7.62 (d,
J=8.8 Hz, 1H), 7.44 (d, J=7.6 Hz, 2H), 7.28-7.15 (m, 5H), 5.42-5.39
(m, 1H), 4.87 (bs, 1H), 3.84-3.68 (m, 3H), 3.42-3.30 (m, 6H),
2.95-2.93 (m, 3H), 2.47-2.30 (m, 2H), 2.15-2.10 (m, 2H); MS ESI
485.4 [M+H].sup.+, calcd for
[C.sub.29H.sub.32N.sub.4O.sub.3+H].sup.+ 485.26.
Example A174
(R)--N-(1-(3-methoxyphenyl)propyl)-3-(4-((1-methylpiperidin-4-yl)oxy)pheny-
l)-1H-indazole-5-carboxamide
##STR00313##
[0888] The title compound was prepared using Method C3 from
(R)-3-iodo-N-(1-(3-methoxyphenyl)propyl)-1H-indazole-5-carboxamide
(70 mg, 0.161 mmol) and
1-methyl-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)piperi-
dine (66 mg, 0.209 mmol) which gave of product (26 mg) isolated as
its TFA salt (gave 26 mg, 33%, a white solid). .sup.1H NMR (400
MHz, CD.sub.3OD) .delta. ppm 8.55 (s, 1H), 7.95-7.91 (m, 3H), 7.60
(d, J=8.8 Hz, 1H), 7.26-7.13 (m, 3H), 6.99-6.87 (m, 2H), 6.79 (m,
1H), 5.01-4.97 (m, 1H), 4.87 (bs, 1H), 3.97 (s, 3H), 3.65-3.17 (m,
4H), 2.94-2.93 (m, 3H), 2.45-2.27 (m, 2H), 2.15-1.89 (m, 2H), 1.00
(t, J=7.2 Hz, 3H); MS ESI 500.2 [M+H].sup.+, calcd for
[C.sub.30H.sub.34N.sub.4O.sub.3+H].sup.+ 499.27.
Example A175
N-(3-(4-((1-(2-methoxyethyl)piperidin-4-yl)oxy)phenyl)-1H-indazol-5-yl)-2--
(pyrrolidin-1-yl)-2-(thiophen-3-yl)acetamide
##STR00314##
[0890] The title compound was prepared using Method C3 from
N-(3-iodo-1H-indazol-5-yl)-2-(pyrrolidin-1-yl)-2-(thiophen-3-yl)acetamide
(42 mg, 0.093 mmol) and
1-(2-methoxyethyl)-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phen-
oxy)piperidine (44 mg, 0.121 mmol) which gave 10 mg of product
isolated as its di-TFA salt (10 mg, 19%, a white solid). .sup.1H
NMR (400 MHz, CD.sub.3OD) .delta. ppm 8.35 (s, 1H), 7.87-7.83 (m,
3H), 7.66-7.64 (m, 1H), 7.55-7.48 (m, 2H), 7.37 (d, J=5.1 Hz, 1H),
7.21-7.14 (m, 2H), 5.21 (bs, 1H), 4.87 (bs, 1H), 3.89-3.71 (m, 4H),
3.55-3.05 (m, 11H), 2.44-2.28 (m, 2H), 2.18-1.95 (m, 2H); MS ESI
560.2 [M+H].sup.+, calcd for
[C.sub.31H.sub.37N.sub.5O.sub.3S+H].sup.+ 560.27.
Example A176
2-cyclopentyl-N-(3-(4-((1-formylpiperidin-4-yl)oxy)phenyl)-1H-indazol-5-yl-
)-2-(pyridin-2-yl)acetamide
##STR00315##
[0892] The mixture of
2-cyclopentyl-N-(3-iodo-1H-indazol-5-yl)-2-(pyridin-2-yl)acetamide
(50 mg, 0.112 mmol),
4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)piperidine-1-ca-
rbaldehyde (41 mg, 0.123 mmol), Pd(PPh.sub.3).sub.4 (13 mg, 0.011
mmol), LiCl (14 mg, 0.336 mmol), 2 M aq Na.sub.2CO.sub.3 solution
(0.28 mL, 0.56 mmol) in dioxane (1 mL) was stirred at 125.degree.
C. for 3 h with microwave irradiation under Ar. The resulting
reaction mixture was filtered through Celite and the filtrate was
concentrated under reduced pressure. The residue was purified by
prep HPLC followed by running through PoraPak to give the title
compound as a peach solid (39 mg, 67% yield). .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. ppm 8.48 (d, J=5.02 Hz, 1H), 8.41 (s, 1H), 8.00
(s, 1H), 7.79 (d, J=8.53 Hz, 2H), 7.75 (td, J=7.78, 1.76 Hz, 1H),
7.62 (d, J=8.03 Hz, 1H), 7.43-7.51 (m, 2H), 7.23-7.29 (m, 1H), 7.01
(d, J=8.78 Hz, 2H), 4.62 (tt, J=6.87, 3.42 Hz, 1H), 3.69 (td,
J=8.53, 4.02 Hz, 1H), 3.56-3.65 (m, 2H), 3.40-3.49 (m, 1H),
3.28-3.38 (m, 1H), 2.79 (m, J=10.79 Hz, 1H), 1.82-2.01 (m, 3H),
1.36-1.79 (m, 8H), 1.08 (dd, J=12.30, 8.03 Hz, 1H); MS ESI
[M+H].sup.+ 524.4, calcd for
[C.sub.31H.sub.33N.sub.5O.sub.3+H].sup.+ 524.27.
Example A177
3-(4-((1-methylpiperidin-4-yl)oxy)phenyl)-N-(phenyl(tetrahydro-2H-pyran-4--
yl)methyl)-1H-indazole-5-carboxamide
##STR00316##
[0894] The title compound was synthesized according to the General
Method C, utilizing
3-iodo-N-(phenyl(tetrahydro-2H-pyran-4-yl)methyl)-1H-indazole-5-carboxami-
de (100 mg, 0.22 mmol),
(4-((1-methylpiperidin-4-yl)oxy)phenyl)boronic acid pinacol ester
(70 mg, 0.22 mmol), Pd(PPh.sub.3).sub.4 (13 mg, 0.01 mmol), satd.
aq Na.sub.2CO.sub.3 (1.25 mL), and 3.75 mL of PhMe:EtOH (1:1). The
vial was charged with Ar and heated in the microwave reactor at
125.degree. C. for 2 h. Purification by RPRPHPLC, followed by
trituration with Et.sub.2O gave the title compound as a TFA salt
(white solid, 25 mg, 18%). .sup.1H NMR (400 MHz, CD.sub.3OD)
.delta. ppm 8.52 (s, 1H), 7.90 (dd, J=8.9, 2.9 Hz, 3H), 7.58 (d,
J=8.8 Hz, 1H), 7.42 (d, J=6.8 Hz, 2H), 7.33 (t, J=7.5 Hz, 2H), 7.25
(d, J=7.3 Hz, 1H), 7.09-7.18 (m, 2H), 4.85 (d, J=10.5 Hz, 1H),
4.59-4.69 (m, 0.3H), 3.94-4.02 (m, 1H), 3.81-3.89 (m, 1H),
3.57-3.67 (m, 0.7H), 3.34-3.46 (m, 3.7H), 3.28 (d, J=2.0 Hz, 0.7H),
2.89-2.95 (m, 3H), 2.34-2.45 (m, 0.7H), 2.24 (br. s., 1.5H),
2.04-2.21 (m, 2.7H), 1.84-2.00 (m, 1.7H), 1.38-1.53 (m, 1H),
1.12-1.31 (m, 3H); MS ESI 525.4 [M+H].sup.+, calcd for
[C.sub.32H.sub.36N.sub.4O.sub.3+H].sup.+ 525.3.
Example A178
N-(cyclopropyl(phenyl)methyl)-3-(4-(((1R,3r,5S)-8-methyl-8-azabicyclo[3.2.-
1]octan-3-yl)oxy)phenyl)-1H-indazole-5-carboxamide
##STR00317##
[0896] The title compounds was synthesized according to the General
Method C2 utilizing
2-cyclopropyl-N-(3-iodo-1H-indazol-5-yl)-2-phenylacetamide (90 mg,
0.22 mmol) and
(1R,3r,5S)-8-methyl-3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phe-
noxy)-8-azabicyclo[3.2.1]octane (0.14 g, .about.0.31 mmol) to
afford the title compound as a white powder (7.5 mg, 7%). .sup.1H
NMR (400 MHz, CD.sub.3OD) .delta. ppm 8.61 (s, 1H), 7.89-8.00 (m,
3H), 7.61 (d, J=8.78 Hz, 1H), 7.49 (d, J=7.28 Hz, 2H), 7.33 (t,
J=7.53 Hz, 2H), 7.24 (t, J=7.30 Hz, 1H), 7.04 (d, J=8.78 Hz, 2H),
4.69 (t, J=4.77 Hz, 1H), 4.48 (d, J=9.29 Hz, 1H), 3.44 (br. s.,
2H), 2.50 (s, 3H), 2.02-2.37 (m, 8H), 1.48-1.37 (m, 1H), 0.70-0.62
(m, 2H), 0.52-0.42 (m, 2H); MS ESI 507.3 [M+H].sup.+, calcd for
[C.sub.32H.sub.34N.sub.4O.sub.2+H].sup.+ 507.3.
Example A179
2-cyclopentyl-N-(3-(4-((1-methylpiperidin-4-yl)oxy)phenyl)-1H-indazol-5-yl-
)-2-(pyridin-2-yl)acetamide
##STR00318##
[0898] The title compound was synthesized according to Method C3
utilizing
2-cyclopentyl-N-(3-iodo-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-5-yl)-2-(-
pyridin-2-yl)acetamide and
1-methyl-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)piperi-
dine and obtained as a white solid (18 mg, 32% yield). .sup.1H NMR
(400 MHz, CD.sub.3OD) .delta. ppm 8.47-8.53 (m, 1H), 8.37 (d,
J=1.00 Hz, 1H), 7.75-7.85 (m, 3H), 7.64 (d, J=8.03 Hz, 1H),
7.43-7.52 (m, 2H), 7.31 (ddd, J=7.28, 5.02, 1.00 Hz, 1H), 7.05 (d,
J=8.78 Hz, 2H), 4.46 (br. s., 1H), 3.61 (d, J=11.04 Hz, 1H),
2.64-2.87 (m, 3H), 2.39 (br. s., 2H), 2.27-2.33 (m, 3H), 1.90-2.09
(m, 3H), 1.40-1.89 (m, 8H), 1.11 (m, J=12.55, 8.03 Hz, 1H); MS ESI
[M+H].sup.+ 510.2, calcd for
[C.sub.31H.sub.35N.sub.5O.sub.2+H].sup.+ 510.29.
Example A180
N-(cyclopropyl(pyridin-2-yl)methyl)-3-(4-(4-(2-hydroxypropan-2-yl)piperidi-
n-1-yl)phenyl)-1H-indazole-5-carboxamide
##STR00319##
[0900] The title compound was synthesized according to Method C3
utilizing
N-(cyclopropyl(pyridin-2-yl)methyl)-3-iodo-1H-indazole-5-carboxamide
and
2-(1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperidin-4-y-
l)propan-2-ol and obtained as a white solid (16 mg, 16% yield).
.sup.1H NMR (400 MHz, CD.sub.3OD) .delta. ppm 8.67 (s, 1H), 8.51
(d, J=4.77 Hz, 1H), 7.95 (dd, J=8.78, 1.51 Hz, 1H), 7.86 (d, J=8.78
Hz, 2H), 7.79 (td, J=7.78, 1.76 Hz, 1H), 7.58 (d, J=8.78 Hz, 1H),
7.52 (d, J=7.78 Hz, 1H), 7.29 (ddd, J=6.90, 5.65, 1.00 Hz, 1H),
7.09 (d, J=9.03 Hz, 2H), 4.50 (d, J=9.29 Hz, 1H), 3.84 (d, J=12.05
Hz, 2H), 2.65 (t, J=11.29 Hz, 2H), 1.86 (d, J=9.79 Hz, 2H),
1.34-1.54 (m, 4H), 1.17 (s, 6H), 0.67 (m, J=8.00 Hz, 1H), 0.47-0.61
(m, 3H); MS ESI [M+H].sup.+ 510.2, calcd for
[C.sub.31H.sub.35N.sub.5O.sub.2+H].sup.+ 510.29.
Example A181
2-ethoxy-N-(3-(4-((1-methylpiperidin-4-yl)oxy)phenyl)-1H-indazol-5-yl)-2-p-
henylacetamide
[0901] ##STR00320## [0902] A.
2-Ethoxy-N-(3-iodo-1H-indazol-5-yl)-2-phenylacetamide was
synthesized according to Method A utilizing
3-iodo-1H-indazol-5-amine (200 mg, 0.77 mmol) and
2-ethoxy-2-phenylacetic acid (155 mg, 0.86 mmol), TBTU (250 mg,
0.78 mmol) and DIPEA (0.36 mL, 2.3 mmol) in DMF (5 mL). The crude
material was precipitated by adding H2O, collected by filtration,
dried and taken into MeOH (5 mL). Heating with MeONa (1.3 mL,
25%.sub.wt in MeOH, 6.0 mmol) at 50.degree. C. for 45 min, cooling
to rt, concentration to dryness followed by flash chromatography
(SiO.sub.2, 2-25% MeOH in DCM) provided
2-ethoxy-N-(3-iodo-1H-indazol-5-yl)-2-phenylacetamide as an
off-white solid (121 mg, 37%). MS ESI 422.1 [M+H].sup.+, calcd for
[C.sub.17H.sub.16IN.sub.3O+H].sup.+ 422.0. [0903] B.
2-Ethoxy-N-(3-(4-((1-methylpiperidin-4-yl)oxy)phenyl)-1H-indazol-5-yl)-2--
phenylacetamide synthesized according to the General Method C2
utilizing 2-ethoxy-N-(3-iodo-1H-indazol-5-yl)-2-phenylacetamide (63
mg, 0.15 mmol),
1-methyl-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)piperi-
dine (62 mg, 0.19 mmol), PdCl.sub.2dppfCH.sub.2Cl.sub.2 (7 mg,
0.009 mmol), satd aq Na.sub.2CO.sub.3 (0.5 mL) in PhMe (1.5 mL) and
EtOH (1.5 mL) under microwave heating (130.degree. C., 2 h). The
title compound was isolated after flash chromatography (SiO.sub.2,
0-60% MeOH-DCM) followed by four separate purifications using: (a)
RP HPLC (Biotage C18 column, MeOH--H2O+0.1% TFA), (b) PoraPak, (c)
prepTLC (SiO.sub.2, 10% 7M NH3/MeOH in DCM) and (d) trituration
with hexanes; as a white powder (9.6 mg, 13%). .sup.1H NMR (400
MHz, CD3OD) .quadrature. ppm 8.35 (d, J=1.00 Hz, 1H), 7.84 (d,
J=8.78 Hz, 2H), 7.48-7.59 (m, 4H), 7.30-7.44 (m, 3H), 7.09 (d,
J=8.78 Hz, 2H), 4.94 (s, 1H), 4.55 (br. s., 1H), 3.56-3.75 (m, 2H),
2.88 (br. s., 2H), 2.57 (br. s., 2H), 2.43 (s, 3H), 2.07 (br.s.,
2H), 1.92 (br. s., 2H), 1.33 (t, J=7.03 Hz, 3H); MS ESI [M+H].sup.+
485.3, calcd for [C.sub.29H.sub.32N.sub.4O.sub.3+H].sup.+
485.2.
Example A182
N-(cyclopropyl(2-fluorophenyl)methyl)-3-(4-((1-formylpiperidin-4-yl)oxy)ph-
enyl)-1H-indazole-5-carboxamide
##STR00321##
[0905] The title compound was synthesized according to Method C3
utilizing
N-(cyclopropyl(2-fluorophenyl)methyl)-3-iodo-1H-indazole-5-carboxamide
and
4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)piperidine--
1-carbaldehyde and obtained as a white solid (10 mg, 14% yield).
.sup.1H NMR (400 MHz, CD.sub.3OD) .delta. ppm 8.59 (s, 1H), 8.04
(s, 1H), 7.88-7.96 (m, 3H), 7.52-7.62 (m, 2H), 7.26 (m, J=7.78 Hz,
1H), 7.02-7.19 (m, 4H), 4.69-4.79 (m, 2H), 3.76 (s, 2H), 3.47-3.56
(m, 1H), 3.38-3.46 (m, 1H), 1.91-2.08 (m, 2H), 1.78 (br. s., 2H),
1.38-1.49 (m, 1H), 0.67 (d, J=4.02 Hz, 1H), 0.38-0.62 (m, 3H); MS
ESI [M+H].sup.+ 513.4, calcd for
[C.sub.30H.sub.29FN.sub.4O.sub.3+H].sup.+ 513.23.
Example A183
2-(cyclopentyloxy)-N-(3-(4-((1-methylpiperidin-4-yl)oxy)phenyl)-1H-indazol-
-5-yl)-2-phenylacetamide
[0906] ##STR00322## [0907] A. To a DCM (20 mL) solution of
tert-butyl (3-iodo-1H-indazol-5-yl)carbamate (200 mg, 0.56 mmol)
was added TFA (2 mL) dropwise at rt. The reaction was stirred to 70
min before more TFA (1 mL). The stirring was continued overnight.
The reaction mixture was concentrated to dryness under reduced
pressure to provide 3-iodo-1H-indazol-5-amine
2,2,2-trifluoroacetate. The light brown residue was taken into anh.
DMF (8 mL) and subjected to the conditions described by method A
utilizing utilizing tert-butyl (3-iodo-1H-indazol-5-yl)carbamate
(200 mg, 0.56 mmol) and sodium 2-(cyclopentyloxy)-2-phenylacetate
(0.28 mg, 1.2 mmol), TBTU (0.51 g, 2.8 mmol) and DIPEA (0.5 mL, 3.2
mmol) in DMF (5 mL). The crude material was precipitated by adding
H2O, collected by filtration, dried (0.29 g, brown solid) and taken
into MeOH (20 mL). The reaction was heated with MeONa (1.0 mL,
25%.sub.wt in MeOH, 4.6 mmol) at 50.degree. C. for 1 h and left
standing at rt overnight. Concentration to dryness under reduced
pressure, followed by flash chromatography (SiO.sub.2, 0-20% MeOH
in DCM) followed by RP HPLC (Biotage C18, 10-90% MeOH--H2O+0.1%
TFA) provided
2-(cyclopentyloxy)-N-(3-iodo-1H-indazol-5-yl)-2-phenylacetamide (71
mg, 28%) as a light tan solid. MS ESI 462.2 [M+H].sup.+, calcd for
[C.sub.20H.sub.20IN.sub.3O.sub.2+H].sup.+ 462.1. [0908] B.
2-(Cyclopentyloxy)-N-(3-(4-((1-methylpiperidin-4-yl)oxy)phenyl)-1H-indazo-
l-5-yl)-2-phenylacetamide was synthesized according to the General
Method C2 utilizing
2-(cyclopentyloxy)-N-(3-iodo-1H-indazol-5-yl)-2-phenylacetamide (71
mg, 0.15 mmol),
1-methyl-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)piperi-
dine (68 mg, 0.21 mmol), PdCl.sub.2dppfCH.sub.2Cl.sub.2 (6.3 mg,
0.0077 mmol), satd aq Na.sub.2CO.sub.3 (0.5 mL) in PhMe (1.5 mL)
and EtOH (1.5 mL) under microwave heating (130.degree. C., 2 h). A
TFA salt of the title compound was isolated after flash
chromatography (SiO.sub.2, 0-60% MeOH-DCM) followed by RP HPLC
(Biotage C18 column, MeOH--H.sub.2O+0.1% TFA) as a white powder
(36.8 mg, 38%). .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. ppm 8.35
(s, 1H), 7.82 (d, J=8.78 Hz, 2H), 7.48-7.58 (m, 4H), 7.37 (d,
J=7.28 Hz, 3H), 7.05 (d, J=8.78 Hz, 2H), 4.98 (s, 1H), 4.38-4.54
(m, 1H), 4.11 (br. s., 1H), 2.73 (br. s., 2H), 2.39 (br. s., 2H),
2.31 (s, 3H), 2.03 (br. s., 2H), 1.70-1.96 (m, 8H), 1.58 (dd,
J=7.53, 4.77 Hz, 2H); MS ESI [M+H].sup.+ 524.4, calcd for
[C.sub.32H.sub.36N.sub.4O.sub.3+H].sup.+ 524.3.
Example A184
N-(3-(4-((1-(oxetan-3-yl)piperidin-4-yl)oxy)phenyl)-1H-indazol-5-yl)-2-(py-
rrolidin-1-yl)-2-(thiophen-3-yl)acetamide
##STR00323##
[0910] The title compound was synthesized according to Method C3
utilizing
N-(3-iodo-1H-indazol-5-yl)-2-(pyrrolidin-1-yl)-2-(thiophen-3-yl)acetamide
and
1-(oxetan-3-yl)-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phe-
noxy)piperidine and obtained as a pale solid (20 mg, 20% yield).
.sup.1H NMR (400 MHz, CD.sub.3OD) .delta. ppm 8.36 (s, 1H), 7.81
(d, J=8.78 Hz, 2H), 7.46-7.52 (m, 3H), 7.35-7.42 (m, 1H), 7.29-7.35
(m, 1H), 7.02 (d, J=8.78 Hz, 2H), 4.66 (m, J=13.30 Hz, 2H), 4.57
(t, J=6.27 Hz, 2H), 4.37-4.47 (m, 1H), 4.10 (s, 1H), 3.41-3.50 (m,
1H), 2.59-2.69 (m, 2H), 2.44-2.59 (m, 4H), 2.12-2.23 (m, 2H),
1.95-2.05 (m, 2H), 1.82 (br. s., 6H); MS ESI [M+H].sup.+ 558.2,
calcd for [C.sub.31H.sub.35N.sub.5O.sub.3S+H].sup.+ 558.25.
Example A185
2-cyclopropyl-N-(3-(4-((1-(oxetan-3-yl)piperidin-4-yl)oxy)phenyl)-1H-indaz-
ol-5-yl)-2-phenylacetamide
##STR00324##
[0912] The title compound was synthesized according to Method C3
utilizing
2-cyclopropyl-N-(3-iodo-1H-indazol-5-yl)-2-phenylacetamide and
1-(oxetan-3-yl)-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy-
)piperidine and obtained as a pale solid (21 mg, 42% yield).
.sup.1H NMR (400 MHz, CD.sub.3OD) .delta. ppm 8.42 (s, 1H), 7.80
(d, J=8.78 Hz, 2H), 7.48 (dd, J=7.28, 3.01 Hz, 4H), 7.28-7.35 (m,
2H), 7.24 (m, J=7.28 Hz, 1H), 7.01 (d, J=8.78 Hz, 2H), 4.62-4.69
(m, 2H), 4.57 (t, J=6.27 Hz, 2H), 4.37-4.46 (m, 1H), 3.46 (quin,
J=6.46 Hz, 1H), 2.91 (d, J=10.04 Hz, 1H), 2.50-2.59 (m, 2H),
2.12-2.23 (m, 2H), 1.94-2.05 (m, 2H), 1.73-1.85 (m, 2H), 1.53-1.63
(m, 1H), 0.55-0.73 (m, 2H), 0.39-0.50 (m, 1H), 0.18-0.28 (m, 1H);
MS ESI [M+H].sup.+ 523.4, calcd for
[C.sub.32H.sub.34N.sub.4O.sub.3+H].sup.+ 523.27.
Example A186
N-(cyclopropyl(thiophen-3-methyl-3-yl)methyl)-3-(4-((1-formylpiperidin-4-y-
l)oxy)phen)-1H-indazole-5-carboxamide
##STR00325##
[0914] The title compound was synthesized according to Method C3
utilizing
N-(cyclopropyl(thiophen-3-yl)methyl)-3-iodo-1H-indazole-5-carboxamide
and
4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)piperidine-1-ca-
rbaldehyde and obtained as a pale solid (18 mg, 31% yield). .sup.1H
NMR (400 MHz, CD.sub.3OD) .delta. ppm 8.61 (s, 1H), 8.02 (s, 1H),
7.96 (dd, J=8.78, 1.51 Hz, 1H), 7.90 (d, J=8.53 Hz, 2H), 7.59 (d,
J=8.78 Hz, 1H), 7.31-7.36 (m, 2H), 7.15-7.21 (m, 1H), 7.08 (d,
J=8.78 Hz, 2H), 4.69 (dt, J=6.84, 3.48 Hz, 1H), 4.62 (d, J=9.54 Hz,
1H), 3.60-3.77 (m, 2H), 3.44-3.53 (m, 1H), 3.36-3.43 (m, 1H),
1.89-1.99 (m, 2H), 1.67-1.84 (m, 2H), 1.42 (dd, J=9.16, 4.64 Hz,
1H), 0.70 (dd, J=8.78, 4.52 Hz, 1H), 0.61 (dd, J=8.03, 4.27 Hz,
1H), 0.47 (td, J=8.41, 4.77 Hz, 2H); MS ESI [M+H].sup.+ 501.3,
calcd for [C.sub.28H.sub.28N.sub.4O.sub.3S+H].sup.+ 501.20.
Example A187
2-isopropoxy-N-(3-(4-((1-methylpiperidin-4-yl)oxy)phenyl)-1H-indazol-5-yl)-
-2-phenylacetamide
##STR00326##
[0916] N-(3-iodo-1H-indazol-5-yl)-2-isopropoxy-2-phenylacetamide
was synthesized according to Method A utilizing
3-iodo-1H-indazol-5-amine 2,2,2-trifluoroacetate (300 mg, 0.80
mmol), and 2-isopropoxy-2-phenylacetic acid (312 mg, 1.6 mmol),
TBTU (516 mg, 1.6 mmol) and DIPEA (0.50 mL, 3.2 mmol) in DMF (5
mL). The crude material was partitioned between H.sub.2O and EtOAc.
The organic layer was washed (satd aq NaHCO.sub.3, H.sub.2O), dried
(Na.sub.2SO.sub.4) and concentrated under reduced pressure. The
resultant pale orange oil (0.55 g) was taken into MeOH (20 mL) and
heated with MeONa (2.0 mL, 25%.sub.wt in MeOH, 9.2 mmol) at
50.degree. C. for 2 h. Later the reaction mixture was cooled to rt,
concentrated under reduced pressure and puried by flash
chromatography (SiO.sub.2, 0-10% MeOH in DCM) provided
N-(3-iodo-1H-indazol-5-yl)-2-isopropoxy-2-phenylacetamide as a
light tan foam (141 mg, 40%). .sup.1H NMR (400 MHz,
METHANOL-d.sub.4) .delta. ppm 7.83 (s, 1H), 7.54-7.61 (m, 3H), 7.50
(d, J=7.50 Hz, 1H), 7.26-7.44 (m, 3H), 5.06 (s, 1H), 3.71-3.86 (m,
1H), 1.33 (d, J=6.02 Hz, 3H), 1.26 (d, J=6.02 Hz, 3H); MS ESI 436.1
[M+H].sup.+, calcd for [C.sub.18H.sub.181N.sub.3O.sub.2+H].sup.+
436.0.
[0917]
2-isopropoxy-N-(3-(4-((1-methylpiperidin-4-yl)oxy)phenyl)-1H-indazo-
l-5-yl)-2-phenylacetamide was synthesized according to the General
Method C2 utilizing
N-(3-iodo-1H-indazol-5-yl)-2-isopropoxy-2-phenylacetamide (100 mg,
0.23 mmol),
1-methyl-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)piperi-
dine (94.7 mg, 0.30 mmol), PdCl.sub.2dppfCH.sub.2Cl.sub.2 (9.4 mg,
0.011 mmol), satd aq Na.sub.2CO.sub.3 (0.5 mL) in PhMe (1.5 mL) and
EtOH (1.5 mL) under microwave heating (130.degree. C., 2 h). A TFA
salt of
2-isopropoxy-N-(3-(4-((1-methylpiperidin-4-yl)oxy)phenyl)-1H-indazol-5-yl-
)-2-phenylacetamide was isolated after flash chromatography (SiO2,
5-90% MeOH-DCM) followed by RP HPLC (Biotage C18 column,
MeOH--H.sub.2O+0.1% TFA) as a white powder (39.3 mg, 28%). .sup.1H
NMR (400 MHz, CD.sub.3OD) .delta. ppm 8.34 (s, 1H), 7.82 (d, J=8.78
Hz, 2H), 7.46-7.60 (m, 4H), 7.27-7.42 (m, 3H), 7.07 (d, J=8.78 Hz,
2H), 5.05 (s, 1H), 4.48 (br. s., 1H), 3.79 (spt, J=6.30 Hz, 1H),
2.74 (br. s., 2H), 2.40 (br. s., 2H), 2.32 (s, 3H), 2.04 (br. s.,
2H), 1.85 (br. s., 2H), 1.32 (d, J=6.02 Hz, 3H), 1.25 (d, J=6.27
Hz, 3H); MS ESI [M+H].sup.+ 499.4, calcd for
[C.sub.30H.sub.34N.sub.4O.sub.3+H].sup.+ 499.3.
Example A188
3-(3-chloro-4-((1-methylpiperidin-4-yl)oxy)phenyl)-N-(cyclopropyl(phenyl)m-
ethyl)-1H-indazole-5-carboxamide
##STR00327##
[0919] The title compound was synthesized according to the General
Method C, utilizing
N-(cyclopropyl(phenyl)methyl)-3-iodo-1H-indazole-5-carboxamide (100
mg, 0.24 mmol),
4-(2-chloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)-1-met-
hylpiperidine (84 mg, 0.24 mmol), Pd(PPh.sub.3).sub.4 (14 mg, 0.012
mmol), satd. aq Na.sub.2CO.sub.3 (1.25 mL), and 3.75 mL of
PhMe:EtOH (1:1). The vial was charged with Ar and heated in the
microwave reactor at 125.degree. C. for 2 h. Purification by
RPRPHPLC, followed by trituration with Et.sub.2O gave the title
compound as a TFA salt (white solid, 58 mg, 38%). .sup.1H NMR (400
MHz, CD.sub.3OD) .delta. ppm 8.57 (s, 1H), 8.04-8.09 (m, 1H),
7.91-7.99 (m, 2H), 7.63 (d, J=8.5 Hz, 1H), 7.49 (d, J=7.5 Hz, 2H),
7.30-7.39 (m, 3H), 7.25 (t, J=7.5 Hz, 1H), 4.68-4.78 (m, 0.3H),
4.46-4.53 (m, 1H), 3.62-3.70 (m, 0.7H), 3.35-3.53 (m, 3H),
3.14-3.26 (m, 1H), 2.91-2.98 (m, 3H), 2.42-2.51 (m, 0.7H),
2.29-2.38 (m, 1.3H), 2.08-2.20 (m, 1.3H), 1.92-2.06 (m, 0.7H),
1.36-1.46 (m, 1H), 0.63-0.71 (m, 2H), 0.43-0.54 (m, 2H); MS ESI
515.5 [M+H].sup.+, calcd for
[C.sub.30H.sub.31ClN.sub.4O.sub.2+H].sup.+ 515.2.
Example A189
N-(3-(4-((1-(oxetan-3-yl)azetidin-3-yl)oxy)phenyl)-1H-indazol-5-yl)-2-(pyr-
rolidin-1-yl)-2-(thiophen-3-yl)acetamide
##STR00328##
[0921] To a solution of tert-butyl 3-hydroxyazetidine-1-carboxylate
(8.65 g, 50 mmol) in DMF (100 mL) at rt was added NaH (60% in
mineral oil, 2.20 g, 55 mmol). After stirring for 5 min at rt,
1-fluoro-4-iodobenzene (11.10 g, 50 mmol) was added and the
resulting mixture was heated at 85.degree. C. (oil temp.) for 5 h,
then O/N at 80.degree. C. (oil temp.). After cooling to rt, it was
quenched with H.sub.2O (350 mL) and stirred for 15 min at rt. The
resulting precipitates were collected by suction filtration, washed
with H.sub.2O and dried to give tert-butyl
3-(4-iodophenoxy)azetidine-1-carboxylate (yellow solid, 12.792 g,
68%). .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.56 (d, J=9.2 Hz,
2H), 6.53 (d, J=8.8 Hz, 2H), 4.87-4.80 (m, 1H), 4.29 (dd, J=7.4 Hz,
2.6 Hz, 2H), 4.99 (dd, J=9.8 Hz, 4.2 Hz, 2H), 4.46 (s, (H); MS ESI
319.9 [M+H].sup.+, calcd for
[C.sub.14H.sub.18INO.sub.3--C.sub.4H9+H].sup.+320.0.
[0922] To a solution of tert-butyl
3-(4-iodophenoxy)azetidine-1-carboxylate (2.66 g, 7.10 mmol) in DCM
(30 mL) was added TFA (10 mL). The resulting mixture was stirred
O/N at rt. After removal of solvents, it was basified with satd aq
NaHCO.sub.3 (50 mL), extracted with DCM and evaporated to give
3-(4-iodophenoxy)azetidine (off white solid, 1.87 g, 96%). .sup.1H
NMR (400 MHz, DMSO-d6) .delta. 7.61 (d, J=8.8 Hz, 2H), 6.90 (d,
J=8.8 Hz, 2H), 5.00 (quint, J=5.6 Hz, 1H), 4.18-4.40 (m, 2H),
3.80-3.74 (m, 2H); MS ESI 275.8 [M+H].sup.+, calcd for
[C.sub.9H.sub.10INO+H].sup.+ 276.0.
[0923] To a suspension of 3-(4-iodophenoxy)azetidine (2.20 g, 8
mmol) in DCE (100 mL) was added oxetan-3-one (860 mg, 12 mmol),
followed by NaBH(OAc).sub.3 (3.40 g, 16 mmol) and HOAc (0.2 mL).
The resulting mixture was stirred O/N at rt. Additional
oxetan-3-one (126 mg, 3 mmol) and NaBH(OAc).sub.3 (850 mg g, 4
mmol) and the resulting mixture was stirred for 3 h at rt. It was
quenched with satd aq NaHCO.sub.3 (30 mL) and H.sub.2O (30 mL),
extracted with DCM and evaporated to give crude
3-(4-iodophenoxy)-1-(oxetan-3-yl)azetidine (light yellow solid,
2.34 g). .sup.1H NMR (400 MHz, DMSO-d6) .delta. 7.58 (d, J=8.8 Hz,
2H), 6.68 (d, J=8.8 Hz, 2H), 4.81 (quint, J=5.6 Hz, 1H), 4.55 (t,
J=6.6 Hz, 2H), 4.33 (t, J=5.8 Hz, 2H), 3.78-3.68 (m, 3H), 3.13-3.07
(m, 2H); MS ESI 331.9 [M+H].sup.+, calcd for
[C.sub.12H.sub.14IN.sub.2O+H].sup.+ 332.0.
[0924] To a mixture of crude
3-(4-iodophenoxy)-1-(oxetan-3-yl)azetidine (1.17 g, 3.53 mmol),
Bis(pinacolato)diboron (988 mg, 3.89 mmol), KOAc (1.04 g, 10.6
mmol) was added DMF (10 mL), followed by
Pd(dppf)Cl.sub.2-CH.sub.2Cl.sub.2 (86 mg, 3 mol %). The resulting
mixture was purged with Ar and microwaved 2 h at 85.degree. C. This
reaction was repeated on the same scale, combined, diluted with
H.sub.2O, extracted with EtOAc and purifed by flash chromatography
(MeOH/DCM 0-15%) twice to give crude
1-(oxetan-3-yl)-3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy-
)azetidine (brown oil, 1.996 g). .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 8.02 (s, 1H), 7.74 (d, J=8.4 Hz, 2H), 6.77 (d, J=8.4 Hz,
2H), 4.93-4.86 (quint, 1H), 4.73 (t, J=6.8 Hz, 2H), 4.57 (pesudo t,
J=6.0 Hz, 2H), 3.92-3.85 (m, 3H), 3.33-3.28 (m, 2H), 1.33 (s, 12H);
MS ESI 332.1 [M+H].sup.+, calcd for
[C.sub.18H.sub.26BNO.sub.4+H].sup.+ 332.2.
[0925] To a mixture of
N-(3-iodo-1H-indazol-5-yl)-2-(pyrrolidin-1-yl)-2-(thiophen-3-yl)acetamide
(181 mg, 0.4 mmol) and
1-(oxetan-3-yl)-3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy-
)azetidine (125 mg, 0.38 mmol) in EtOH (10 mL) was added 1 M aq
Na2CO3 (0.8 mL, 0.8 mmol), followed by Pd(PPh.sub.3).sub.4 (23 mg,
0.02 mmol). The resulting mixture was purged with Ar and microwaved
3 h at 125.degree. C. After removal of solvents, it was purified by
prep-HPLC, PoraPak and flash chromatography (MeOH/DCM 0-20%) to
give the title compound (white solid, 54.5 mg, 26%). .sup.1H NMR
(400 MHz, CD.sub.3OD) .delta. 8.34 (s, 1H), 7.80 (d, J=8.8 Hz, 2H),
7.51-7.47 (m, 3H), 7.38 (dd, J=8.8 Hz, 2.8 Hz, 1H), 7.31 (dd, J=9.0
Hz, 1.0 Hz, 1H), 6.88 (d, J=8.8 Hz, 2H), 4.85 (quint, J=5.6 Hz,
1H), 4.72 (t, J=6.8 Hz, 2H), 4.48 (dd, J=6.8 Hz, 5.2 Hz, 2H), 4.13
(s, 1H), 3.85-3.77 (m, 3H), 3.29 (dd, J=9.2 Hz, 5.2 Hz, 2H),
2.70-2.62 (m, 2H), 2.53-2.45 (m, 2H), 1.85-1.76 (m, 4H); MS ESI
530.2 [M+H].sup.+, calcd for
[C.sub.29H.sub.31N.sub.5O.sub.3S+H].sup.+ 530.2.
Example A190
N-(cyclopropyl(phenyl)methyl)-3-(4-((1-(oxetan-3-yl)azetidin-3-yl)oxy)phen-
yl)-1H-indazole-5-carboxamide
##STR00329##
[0927] To a mixture of
N-(cyclopropyl(phenyl)methyl)-3-iodo-1H-indazole-5-carboxamide (168
mg, 0.4 mmol) and
1-(oxetan-3-yl)-3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy-
)azetidine (125 mg, 0.38 mmol) in EtOH (10 mL) was added 1 M aq
Na2CO3 (0.8 mL, 0.8 mmol), followed by Pd(PPh.sub.3).sub.4 (23 mg,
0.02 mmol). The resulting mixture was purged with Ar and microwaved
3 h at 125.degree. C. After removal of solvents, it was purified by
prep-HPLC, PoraPak and flash chromatography (MeOH/DCM 0-20%) to
give the title compound (white solid, 43.6 mg, 22%). .sup.1H NMR
(400 MHz, CD.sub.3OD) .delta. 8.61 (s, 1H), 7.96 (d, J=8.8 Hz, 1H),
7.90 (d, J=8.8 Hz, 2H), 7.59 (d, J=8.8 Hz, 1H), 7.47 (d, J=7.6 Hz,
2H), 7.31 (t, J=7.4 Hz, 2H), 7.22 (t, J=7.2 Hz, 1H), 6.93 (d, J=8.8
Hz, 2H), 4.90-4.86 (m, 1H, partially buried by H.sub.2O peak), 4.74
(t, J=6.8 Hz, 2H), 4.45-4.45 (m, 3H), 3.89-3.80 (m, 3H), 3.35-3.28
(m, 2H; overlapped with CD.sub.3OD solvent residue), 1.44-1.34 (m,
1H), 0.68-0.59 (m, 2H), 0.51-0.39 (m, 2H); MS ESI 495.4
[M+H].sup.+, calcd for [C.sub.30H.sub.30N.sub.4O.sub.3+H].sup.+
495.2.
Example A191
2-(azetidin-1-yl)-N-(3-(4-((1-methylpiperidin-4-yl)oxy)phenyl)-1H-indazol--
5-yl)-2-(thiophen-3-yl)acetamide
##STR00330##
[0929] A suspension of 2-(azetidin-1-yl)-2-(thiophen-3-yl)acetic
acid H.sub.3BO.sub.3 salt (2.59 g, 10 mmol) and
3-iodo-1H-indazol-5-amine (2.59 g, 10 mmol) in DMF (50 mL) was
sonicated and stirred for 15 min at rt unitl a homogeneous
suspension was obtained. TBTU (3.21 g, 10 mmol) was added at
0.degree. C., followed by iPr.sub.2NEt (5.22 mL, 30 mmol). The
resulting mixture was stirred for 1 h at 0.degree. C., quenched
with H2O (200 mL), stirred for 10 min at rt, suction filtered and
dried to give crude
2-(azetidin-1-yl)-N-(3-iodo-1H-indazol-5-yl)-2-(thiophen-3-yl)acetamide
(brown solid, 2.973 g). LC-MS indicated a mixture of desired
product
2-(azetidin-1-yl)-N-(3-iodo-1H-indazol-5-yl)-2-(thiophen-3-yl)acetamide
and di-acylated byproduct. .sup.1H NMR (400 MHz, CDCl.sub.3) 6 MS
ESI 439.0 [M+H].sup.+, calcd for
[C.sub.16H.sub.15IN.sub.4OS+H].sup.+ 439.0.
[0930] To a mixture of crude
2-(azetidin-1-yl)-N-(3-iodo-1H-indazol-5-yl)-2-(thiophen-3-yl)acetamide
(290 mg, assuming 0.5 mmol) and
1-methyl-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)piperi-
dine (158 mg, 0.5 mmol) in EtOH (12 mL) was added 1 M aq Na2CO3
(1.5 mL, 1.5 mmol), followed by Pd(PPh.sub.3).sub.4 (58 mg, 0.05
mmol). The resulting mixture was purged with Ar and microwaved 4 h
at 125.degree. C. After removal of solvents, it was purified by
prep-HPLC, PoraPak, flash chromatography (MeOH/DCM 0-100%), biotage
RP column (MeOH/H.sub.2O (1% TFA) 5-80%) and PoraPak to give the
title compound (white solid, 35 mg, 14%). .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. 8.33 (s, 1H), 7.81 (d, J=8.8 Hz, 2H), 7.52-7.47
(m, 3H), 7.39 (dd, J=9.0 Hz, 3.0 Hz, 1H), 7.24 (dd, J=5.0 Hz, 1.0
Hz, 1H), 7.03 (d, J=8.8 Hz, 2H), 4.47-4.40 (m, 1H), 4.18 (s, 1H),
3.37 (q, J=7.1 Hz, 2H), 3.20 (q, J=7.1 Hz, 2H), 2.76-2.66 (m, 2H),
2.42-2.32 (m, 2H), 2.29 (s, 3H), 2.12 (quint, J=7.2 Hz, 2H),
2.06-1.97 (m, 2H), 1.86-1.76 (m, 2H); MS ESI 502.2 [M+H].sup.+,
calcd for [C.sub.28H.sub.31N.sub.5O.sub.2S+H].sup.+ 502.2.
Example A192
(R)--N-(1-(2-chlorophenyl)propyl)-3-(4-((1-(oxetan-3-yl)piperidin-4-yl)oxy-
)phenyl)-1H-indazole-5-carboxamide
##STR00331##
[0932] Using Method C2,
(R)--N-(1-(2-chlorophenyl)propyl)-3-iodo-1H-indazole-5-carboxamide
(45.1 mg, 95% pure, 0.097 mmol) and
1-(oxetan-3-yl)-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy-
)piperidine (39.4 mg, 80% pure, 0.088 mmol) gave the title compound
(off-white solid, 18.8 mg, 39%) after 14 h at 125.degree. C. in
reaction block with purification by flash chromatography (SiO2,
50-100% EtOAc in DCM, then 0-15% MeOH in EtOAc; followed by RPRP
HPLC, 10-75% MeOH in 0.1% TFA-H.sub.2O) and PoraPak RXn Cx work-up.
.sup.1H NMR (400 MHz, CD.sub.3OD) .delta. ppm 8.60 (s, 1H),
7.87-7.96 (m, 3H), 7.47-7.52 (m, 1H), 7.39 (d, J=7.8 Hz, 1H),
7.25-7.31 (m, 1H), 7.18-7.24 (m, 1H), 7.09 (d, J=8.8 Hz, 2H), 5.46
(dd, J=9.0, 5.8 Hz, 1H), 4.67-4.73 (m, 2H), 4.62 (t, J=6.3 Hz, 2H),
4.51 (br. s., 1H), 3.53 (quin, J=6.5 Hz, 1H), 2.55-2.67 (m, 2H),
2.19-2.31 (m, 2H), 2.01-2.11 (m, 2H), 1.79-2.00 (m, 4H), 1.07 (t,
J=7.4 Hz, 3H). MS ESI 545.4 [M+H].sup.+, calcd for
[C.sub.31H.sub.33ClN.sub.4O.sub.3+H].sup.+ 545.23.
Example A193
(S)--N-(1-(2-chlorophenyl)propyl)-3-(4-((1-(oxetan-3-yl)piperidin-4-yl)oxy-
)phenyl)-1H-indazole-5-carboxamide
##STR00332##
[0934] Using Method C2,
(S)--N-(1-(2-chlorophenyl)propyl)-3-iodo-1H-indazole-5-carboxamide
(45.3 mg, 0.103 mmol) and
1-(oxetan-3-yl)-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy-
)piperidine (39.4 mg, 80% pure, 0.088 mmol) gave the title compound
(off-white solid, 19.8 mg, 42%) after 14 h at 125.degree. C. in
reaction block with purification by flash chromatography
(SiO.sub.2, 100% EtOAc, then 0-100% DCM, then 0-10% MeOH in DCM;
followed by RPRP HPLC, 10-90% MeOH in 0.1% TFA-H.sub.2O) and
PoraPak RXn Cx work-up. .sup.1H NMR (400 MHz, CD.sub.3OD) .delta.
ppm 8.60 (s, 1H), 7.87-7.96 (m, 3H), 7.47-7.52 (m, 1H), 7.39 (d,
J=7.8 Hz, 1H), 7.25-7.31 (m, 1H), 7.18-7.24 (m, 1H), 7.09 (d, J=8.8
Hz, 2H), 5.46 (dd, J=9.0, 5.8 Hz, 1H), 4.67-4.73 (m, 2H), 4.62 (t,
J=6.3 Hz, 2H), 4.51 (br. s., 1H), 3.53 (quin, J=6.5 Hz, 1H),
2.55-2.67 (m, 2H), 2.19-2.31 (m, 2H), 2.01-2.11 (m, 2H), 1.79-2.00
(m, 4H), 1.07 (t, J=7.4 Hz, 3H). MS ESI 545.4 [M+H].sup.+, calcd
for [C.sub.31H.sub.33ClN.sub.4O.sub.3+H].sup.+ 545.23.
Example A194
N-(cyclopropyl(phenyl)methyl)-3-(3-methoxy-4-((1-(oxetan-3-yl)piperidin-4--
yl)oxy)phenyl)-1H-indazole-5-carboxamide
##STR00333##
[0936] The title compound was synthesized according to the General
Method C, utilizing
N-(cyclopropyl(phenyl)methyl)-3-iodo-1H-indazole-5-carboxamide (50
mg, 0.12 mmol),
4-(2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)-1-(o-
xetan-3-yl)piperidine (46 mg, 0.12 mmol), Pd(PPh.sub.3).sub.4 (7
mg, 0.006 mmol), satd. aq Na.sub.2CO.sub.3 (1.25 mL), and 3.75 mL
of PhMe:EtOH (1:1). The vial was charged with Ar and heated in the
microwave reactor at 125.degree. C. for 2 h. Purification by
RPRPHPLC, followed by trituration with Et.sub.2O gave the title
compound as a TFA salt (white solid, 30 mg, 38%). .sup.1H NMR (400
MHz, CD.sub.3OD) .delta. ppm 8.58 (s, 1H), 7.96 (d, J=8.8 Hz, 1H),
7.54-7.66 (m, 3H), 7.49 (d, J=7.8 Hz, 2H), 7.34 (t, J=7.4 Hz, 2H),
7.25 (t, J=7.8 Hz, 2H), 4.89-4.95 (m, 2H), 4.79-4.86 (m, 2H),
4.44-4.53 (m, 2H), 3.97 (s, 3H), 3.44-3.52 (m, 1H), 3.35-3.44 (m,
2H), 2.21-2.45 (m, 2H), 1.96-2.20 (m, 2H), 1.34-1.46 (m, 1H),
0.62-0.70 (m, 2H), 0.41-0.54 (m, 2H); MS ESI 553.5 [M+H].sup.+,
calcd for [C.sub.33H.sub.36N.sub.4O.sub.4+H].sup.+ 553.3.
Example A195
N-(cyclopropyl(pyridin-2-yl)methyl-3-(3-methoxy-4-((1-(oxetan-3-yl)piperid-
in-4-yl)oxy)phenyl)-1H-indazole-5-carboxamide
##STR00334##
[0938] The title compound was synthesized according to the General
Method C, utilizing
N-(cyclopropyl(pyridin-2-yl)methyl)-3-iodo-1H-indazole-5-carboxamide
(50 mg, 0.12 mmol),
4-(2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)-1-(o-
xetan-3-yl)piperidine (46 mg, 0.12 mmol), Pd(PPh.sub.3).sub.4 (7
mg, 0.006 mmol), satd. aq Na.sub.2CO.sub.3 (1.25 mL), and 3.75 mL
of PhMe:EtOH (1:1). The vial was charged with Ar and heated in the
microwave reactor at 125.degree. C. for 2 h. Purification by
RPRPHPLC, followed by flash chromatography (SiO.sub.2, Biotage 25
g, 0-30% MeOH in CH.sub.2Cl.sub.2) and trituration with Et.sub.2O
gave the title compound (white solid, 23 mg, 35%). .sup.1H NMR (400
MHz, CD.sub.3OD) .delta. ppm 8.65 (s, 1H), 8.49 (d, J=4.0 Hz, 1H),
7.95 (d, J=9.0 Hz, 1H), 7.78 (t, J=7.6 Hz, 1H), 7.46-7.63 (m, 4H),
7.28 (t, J=6.0 Hz, 1H), 7.06 (d, J=8.0 Hz, 1H), 4.66 (t, J=6.3 Hz,
2H), 4.58 (t, J=6.0 Hz, 2H), 4.50 (d, J=9.3 Hz, 1H), 4.33-4.42 (m,
1H), 3.91 (s, 3H), 3.48 (m, 1H), 2.60 (br. s, 2H), 2.16 (br. s,
2H), 1.97 (br. s, 2H), 1.84 (br. s, 2H), 1.32-1.44 (m, 1H),
0.60-0.70 (m, 1H), 0.45-0.59 (m, 3H); MS ESI 554.2 [M+H].sup.+,
calcd for [C.sub.32H.sub.35N.sub.5O.sub.4+H].sup.+ 554.3.
Example A196
(R)--N-(cyclopropyl(pyridin-2-yl)methyl)-3-(4-((1-(oxetan-3-yl)piperidin-4-
-yl)oxy)phenyl)-1H-indazole-5-carboxamide
##STR00335##
[0940] The title compound was synthesized according to Method C3
utilizing
(R)-2-cyclopropyl-N-(3-iodo-1H-indazol-5-yl)-2-(pyridin-2-yl)acetamide
and
1-(oxetan-3-yl)-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phe-
noxy)piperidine and obtained as a white solid (42 mg, 42% yield).
.sup.1H NMR (400 MHz, CD.sub.3OD) .delta. ppm 8.67 (s, 1H), 8.49
(d, J=4.77 Hz, 1H), 7.96 (dd, J=8.78, 1.25 Hz, 1H), 7.89 (d, J=8.78
Hz, 2H), 7.75 (td, J=7.72, 1.63 Hz, 1H), 7.58 (d, J=8.78 Hz, 1H),
7.49 (d, J=8.03 Hz, 1H), 7.22-7.29 (m, 1H), 7.00 (d, J=8.78 Hz,
2H), 4.59-4.67 (m, 2H), 4.55 (t, J=6.15 Hz, 2H), 4.50 (d, J=9.54
Hz, 1H), 4.34-4.43 (m, 1H), 3.42 (quin, J=6.46 Hz, 1H), 2.51 (br.
s., 2H), 2.12 (d, J=7.53 Hz, 2H), 1.96 (br. s., 2H), 1.76 (d,
J=8.28 Hz, 2H), 1.30-1.43 (m, 1H), 0.58-0.69 (m, 1H), 0.44-0.58 (m,
3H); MS ESI [M+H].sup.+ 524.2, calcd for
[C.sub.31H.sub.33N.sub.5O.sub.3+H].sup.+ 524.27.
Example A197
(S)--N-(cyclopropyl(pyridin-2-yl)methyl)-3-(4-((1-(oxetan-3-yl)piperidin-4-
-yl)oxy)phenyl)-1H-indazole-5-carboxamide
##STR00336##
[0941] The title compound was synthesized according to Method C3
utilizing
(S)-2-cyclopropyl-N-(3-iodo-1H-indazol-5-yl)-2-(pyridin-2-yl)acetamide
and
1-(oxetan-3-yl)-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phe-
noxy)piperidine and obtained as a white solid (44 mg, 44% yield).
.sup.1H NMR (400 MHz, CD.sub.3OD) .delta. ppm 8.67 (s, 1H) 8.49 (d,
J=4.77 Hz, 1H), 7.96 (dd, J=8.78, 1.25 Hz, 1H), 7.89 (d, J=8.78 Hz,
2H), 7.75 (td, J=7.72, 1.63 Hz, 1H), 7.58 (d, J=8.78 Hz, 1H), 7.49
(d, J=8.03 Hz, 1H), 7.22-7.29 (m, 1H), 7.00 (d, J=8.78 Hz, 2H),
4.59-4.67 (m, 2H), 4.55 (t, J=6.15 Hz, 2H), 4.50 (d, J=9.54 Hz,
1H), 4.34-4.43 (m, 1H), 3.42 (quin, J=6.46 Hz, 1H), 2.51 (br. s.,
2H), 2.12 (d, J=7.53 Hz, 2H), 1.96 (br. s., 2H), 1.76 (d, J=8.28
Hz, 2H), 1.30-1.43 (m, 1H), 0.58-0.69 (m, 1H), 0.44-0.58 (m, 3H);
MS ESI [M+H].sup.+ 524.2, calcd for
[C.sub.31H.sub.33N.sub.5O.sub.3+H].sup.+ 524.27.
Example A198
3-(3-chloro-4-((1-methylpiperidin-4-yl)oxy)phenyl)-N-(cyclopropyl(pyridin--
2-yl)methyl)-1H-indazole-5-carboxamide
##STR00337##
[0943] The title compound was synthesized according to the General
Method C, utilizing
N-(cyclopropyl(pyridin-2-yl)methyl)-3-iodo-1H-indazole-5-carboxamide
(100 mg, 0.24 mmol),
4-(2-chloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)-1-met-
hylpiperidine (84 mg, 0.24 mmol), Pd(PPh.sub.3).sub.4 (14 mg, 0.012
mmol), satd. aq Na.sub.2CO.sub.3 (1.25 mL), and 3.75 mL of
PhMe:EtOH (1:1). The vial was charged with Ar and heated in the
microwave reactor at 125.degree. C. for 2 h. Purification by
RPRPHPLC, followed by flash chromatography (SiO.sub.2, Biotage 25
g, 0-30% MeOH in CH.sub.2Cl.sub.2) gave the title compound (white
solid, 35 mg, 28%). .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. ppm
8.61 (s, 1H), 8.51 (d, J=4.8 Hz, 1H), 8.00 (d, J=2.3 Hz, 1H), 7.95
(dd, J=8.8, 1.2 Hz, 1H), 7.88 (dd, J=8.5, 2.3 Hz, 1H), 7.80 (td,
J=7.7, 1.6 Hz, 1H), 7.59 (d, J=8.8 Hz, 1H), 7.53 (d, J=8.0 Hz, 1H),
7.30 (dd, J=6.9, 5.4 Hz, 1H), 7.23 (d, J=8.8 Hz, 1H), 4.61 (br. s.,
1H), 4.50 (d, J=9.5 Hz, 1H), 2.80-2.92 (m, 2H), 2.54 (br. s, 2H),
2.37 (s, 3H), 2.00-2.09 (m, 2H), 1.88-1.99 (m, 2H), 1.35-1.45 (m,
1H), 0.65-0.72 (m, 1H), 0.49-0.62 (m, 3H); MS ESI 516.2
[M+H].sup.+, calcd for [C.sub.29H.sub.30ClN.sub.5O.sub.2+H].sup.+
516.2.
Example A199
N-((2-chlorophenyl)(cyclopentyl)methyl)-3-(4-((1-methylpiperidin-4-yl)oxy)-
phenyl)-1H-indazole-5-carboxamide
##STR00338##
[0945] A mixture of (2-chlorophenyl)(cyclopentyl)methanone (2.085
g, 10 mmol), NH.sub.4OAc (9.24 g, 120 mmol) and NaCNBH.sub.3 (2.52
g, 40 mmol) in MeOH (60 mL) was heated at 65.degree. C. for 1 h,
then left O/N at 60.degree. C. After removal of solvent, it was
purifed by flash chromatography (MeOH/DCM 0-20%) to give
(2-chlorophenyl)(cyclopentyl)methanamine (colorless oil, 876 mg,
42%). .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 7.58 (dd, J=7.6 Hz,
1.6 Hz, 1H), 7.54 (dd, J=7.8 Hz, 1.4 Hz, 1H), 7.48 (dt, J=7.6 Hz,
1.6 Hz, 1H), 7.43 (dt, J=7.8 Hz, 1.8 Hz, 1H), 2.58-2.46 (m, 1H),
2.10-2.01 (m, 1H), 1.90-1.78 (m, 1H), 1.77-1.64 (m, 2H), 1.63-1.40
(m, 3H), 1.25-1.14 (m, 1H); MS ESI 193.0 [M+H].sup.+, calcd for
[C.sub.12H.sub.16ClN--NH.sub.3+H].sup.+ 193.1.
[0946] To a solution of (2-chlorophenyl)(cyclopentyl)methanamine
(876 mg, 4.18 mmol), 3-iodo-1H-indazole-5-carboxamide (1.20 g, 4.18
mmol) in DMF (10 mL) at 0.degree. C. was added TBTU (1.34 g, 4.18
mmol), followed by .sup.iPr.sub.2NEt (1.45 mL, 8.36 mmol). The
resulting mixture was stirred at 0.degree. C. for 30 min, quenched
with H.sub.2O and stirred for 10 min at rt. Suction filtration gave
crude
N-((2-chlorophenyl)(cyclopentyl)methyl)-3-iodo-1H-indazole-5-carboxamide
(light beige solid, 1.796 g). 1H NMR (400 MHz, CDCl.sub.3) 6 MS ESI
480.2 [M+H].sup.+, calcd for [C.sub.20H.sub.19ClN.sub.3O+H].sup.+
480.0.
[0947] To a mixture of crude
N-((2-chlorophenyl)(cyclopentyl)methyl)-3-iodo-1H-indazole-5-carboxamide
(241 mg, 0.5 mmol) and
1-methyl-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)piperi-
dine (158 mg, 0.5 mmol) in EtOH (12 mL) was added 1 M aq Na2CO3 (1
mL, 1 mmol), followed by Pd(PPh.sub.3).sub.4 (29 mg, 0.025 mmol).
The resulting mixture was purged with Ar and microwaved 3 h at
125.degree. C. After removal of solvents, it was purified by flash
chromatography (MeOH/DCM 0-20%), prep-HPLC and PoraPak to give the
title compound (white solid, 14.4 mg, 5%). .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. 8.53 (s, 1H), 7.88 (d, J=8.4 Hz, 3H), 7.60-7.55
(m, 2H), 7.38 (dd, J=7.8 Hz, 2.8 Hz, 1H), 7.29 (dt, J=7.6 Hz, 0.8
Hz, 1H), 7.20 (dt, J=7.8 Hz, 1.5 Hz, 1H), 7.08 (d, J=8.8 Hz, 2H),
5.44 (d, J=10.8 Hz, 1H), 4.53-4.46 (m, 1H), 2.80-2.70 (m, 2H),
2.65-2.52 (m, 1H), 2.47-2.36 (m, 2H), 2.33 (s, 3H), 2.10-1.94 (m,
3H), 1.90-1.50 (m, 7H), 1.45-1.38 (m, 2H); MS ESI 543.5
[M+H].sup.+, calcd for [C.sub.32H.sub.35ClN.sub.4O.sub.2+H].sup.+
543.2.
Example A200
2-(azetidin-1-yl)-N-(3-(4-(4-hydroxypiperidin-1-yl)phenyl)-1H-indazol-5-yl-
)-2-(thiophen-3-yl)acetamide
##STR00339##
[0949] To a mixture of 2-(azetidin-1-yl)-2-(thiophen-3-yl)acetic
acid H.sub.3BO.sub.3 salt (34 mg, 0.13 mmol),
1-(4-(5-amino-1H-indazol-3-yl)phenyl)piperidin-4-ol
di-trifluoroacetic acid (70 mg, 0.13 mmol) in DMF (5 mL) at
0.degree. C. was added TBTU (42 mg, 0.13 mmol), followed by
.sup.iPr.sub.2NEt (0.16 mL, 0.91 mmol). The resulting mixture was
stirred for 1 h at 0.degree. C. It was purified by prep-HPLC and
PoraPakPoraPak to give the title compound (white solid, 30.2 mg,
31%). .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.32 (s, 1H), 7.76
(d, J=8.8 Hz, 2H), 7.52-7.46 (m, 3H), 7.39 (dd, J=5.0 Hz, 3.0 Hz,
1H), 7.24 (d, J=4.8 Hz, 1H), 7.07 (d, J=8.4 Hz, 2H), 4.18 (s, 1H),
3.80-3.72 (m, 1H), 3.68-3.60 (m, 2H), 3.37 (q, J=6.9 Hz, 2H), 3.20
(q, J=6.9 Hz, 2H), 2.96-2.87 (m, 2H), 2.12 (quint, J=7.1 Hz, 2H),
2.00-1.92 (m, 2H), 1.70-1.59 (m, 2H); MS ESI 488.2 [M+H].sup.+,
calcd for [C.sub.27H.sub.29N.sub.5O.sub.2S+H].sup.+ 488.2.
Example A201
2-(azetidin-1-yl)-N-(3-(4-(4-(2-hydroxypropan-2-yl)piperidin-1-yl)phenyl)--
1H-indazol-5-yl)-2-(thiophen-3-yl)acetamide
##STR00340##
[0951] A di-TFA salt of the title compound was synthesized
according to Method C3 utilizing
2-(azetidin-1-yl)-N-(3-iodo-1H-indazol-5-yl)-2-(thiophen-3-yl)acetamide
and
2-(1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperidin-
-4-yl)propan-2-ol obtained as an off-white solid (22 mg, 24%
yield). .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. ppm 8.41 (d,
J=1.25 Hz, 1H), 8.15 (d, J=8.78 Hz, 2H), 7.86-7.90 (m, 1H), 7.84
(d, J=8.78 Hz, 2H), 7.64 (dd, J=5.14, 2.89 Hz, 1H), 7.56-7.61 (m,
1H), 7.49-7.55 (m, 1H), 7.30 (dd, J=5.02, 1.25 Hz, 1H), 5.51 (s,
1H), 4.27 (br. s., 3H), 3.63-3.87 (m, 5H), 2.53-2.71 (m, 1H),
2.36-2.53 (m, 1H), 2.21 (d, J=13.80 Hz, 2H), 1.87-2.03 (m, 2H),
1.84 (d, J=12.05 Hz, 1H), 1.23-1.31 (m, 6H); MS ESI [M+H].sup.+
530.2, calcd for [C.sub.31H.sub.33N.sub.5O.sub.3+H].sup.+
530.26.
Example A202
(R)-3-(3-chloro-4-((1-methylpiperidin-4-yl)oxy)phenyl)-N-(3-hydroxy-1-phen-
ylpropyl)-1H-indazole-5-carboxamide
##STR00341##
[0953] The title compound was synthesized according to the General
Method C, utilizing
(R)--N-(3-hydroxy-1-phenylpropyl)-3-iodo-1H-indazole-5-carboxamide
(60 mg, 0.14 mmol),
4-(2-chloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)-1-met-
hylpiperidine (50 mg, 0.14 mmol), Pd(PPh.sub.3).sub.4 (8 mg, 0.007
mmol), satd. aq Na.sub.2CO.sub.3 (1.25 mL), and 3.75 mL of
PhMe:EtOH (1:1). The vial was charged with Ar and heated in the
microwave reactor at 125.degree. C. for 2 h. Purification by
RPHPLC, followed by flash chromatography (SiO.sub.2, Biotage 25 g,
0-30% MeOH in CH.sub.2Cl.sub.2) gave the title compound (white
solid, 22 mg, 30%). .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. ppm
8.54 (s, 1H), 7.99 (d, J=2.0 Hz, 1H), 7.82-7.94 (m, 2H), 7.59 (d,
J=8.8 Hz, 1H), 7.44 (d, J=7.8 Hz, 2H), 7.34 (t, J=7. Hz, 2H),
7.20-7.27 (m, 2H), 5.34 (dd, J=8.0, 6.8 Hz, 1H), 4.59 (br. s, 1H),
3.59-3.72 (m, 2H), 2.73 (br. s, 2H), 2.45 (br. s, 2H), 2.32 (s,
3H), 2.09-2.21 (m, 2H), 2.03 (d, J=3.5 Hz, 2H), 1.86-1.97 (m, 2H);
MS ESI 519.5 [M+H].sup.+, calcd for
[C.sub.29H.sub.31ClN.sub.4O.sub.3+H].sup.+ 519.2.
Example A203
(R)--N-(cyclopropyl(pyridin-2-yl)methyl)-3-(4-((1-formylpiperidin-4-yl)oxy-
)phenyl)-1H-indazole-5-carboxamide
##STR00342##
[0955] A TFA salt of the title compound was synthesized according
to Method C3 utilizing
(R)-2-cyclopropyl-N-(3-iodo-1H-indazol-5-yl)-2-(pyridin-2-yl)acetamide
and
4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)piperidine--
1-carbaldehyde obtained as a white solid (33 mg, 38% yield).
.sup.1H NMR (400 MHz, CD.sub.3OD) .delta. ppm 8.77 (dd, J=5.77,
0.75 Hz, 1H), 8.70 (s, 1H), 8.56 (t, J=7.15 Hz, 1H), 8.20 (d,
J=8.03 Hz, 1H), 7.90-8.01 (m, 4H), 7.63 (d, J=8.78 Hz, 1H), 7.15
(d, J=8.78 Hz, 2H), 4.72-4.80 (m, 1H), 4.49 (d, J=10.04 Hz, 1H),
3.64-3.82 (m, 2H), 3.39-3.58 (m, 2H), 1.92-2.10 (m, 2H), 1.71-1.90
(m, 2H), 1.45-1.58 (m, 1H), 0.84-0.95 (m, 1H), 0.58-0.81 (m, 3H);
MS ESI [M+H].sup.+496.3, calcd for
[C.sub.29H.sub.29N.sub.5O.sub.3+H].sup.+ 496.23.
Example A204
(S)--N-(cyclopropyl(pyridin-2-yl)methyl)-3-(4-((1-formylpiperidin-4-yl)oxy-
)phenyl)-1H-indazole-5-carboxamide
##STR00343##
[0957] A TFA salt of the title compound was synthesized according
to Method C3 utilizing
(S)-2-cyclopropyl-N-(3-iodo-1H-indazol-5-yl)-2-(pyridin-2-yl)acetamide
and
4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)piperidine--
1-carbaldehyde and obtained as a white solid (32 mg, 38% yield).
.sup.1H NMR (400 MHz, CD.sub.3OD) .delta. ppm 8.77 (dd, J=5.77,
0.75 Hz, 1H), 8.70 (s, 1H), 8.56 (t, J=7.15 Hz, 1H), 8.20 (d,
J=8.03 Hz, 1H), 7.90-8.01 (m, 4H), 7.63 (d, J=8.78 Hz, 1H), 7.15
(d, J=8.78 Hz, 2H), 4.72-4.80 (m, 1H), 4.49 (d, J=10.04 Hz, 1H),
3.64-3.82 (m, 2H), 3.39-3.58 (m, 2H), 1.92-2.10 (m, 2H), 1.71-1.90
(m, 2H), 1.45-1.58 (m, 1H), 0.84-0.95 (m, 1H), 0.58-0.81 (m, 3H);
MS ESI [M+H].sup.+ 496.3, calcd for
[C.sub.29H.sub.29N.sub.5O.sub.3+H].sup.+ 496.23.
Example A205
N-(cyclopropyl(phenyl)methyl)-3-(4-((1-formylpiperidin-4-yl)oxy)-3-methoxy-
phenyl)-1H-indazole-5-carboxamide
##STR00344##
[0959] The title compound was synthesized according to the General
Method C, utilizing
N-(cyclopropyl(phenyl)methyl)-3-iodo-1H-indazole-5-carboxamide (100
mg, 0.24 mmol),
4-(2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)piper-
idine-1-carbaldehyde (86 mg, 0.24 mmol), Pd(PPh.sub.3).sub.4 (14
mg, 0.012 mmol), satd. aq Na.sub.2CO.sub.3 (1.25 mL), and 3.75 mL
of PhMe:EtOH (1:1). The vial was charged with Ar and heated in the
microwave reactor at 125.degree. C. for 2 h. Purification by
RPHPLC, followed by flash chromatography (SiO.sub.2, Biotage 25 g,
0-30% MeOH in CH.sub.2Cl.sub.2, twice) gave the title compound
(white solid, 25 mg, 20%). .sup.1H NMR (400 MHz, CD.sub.3OD)
.delta. ppm 8.61 (s, 1H), 8.01 (s, 1H), 7.94 (d, J=8.8 Hz, 1H),
7.50-7.61 (m, 3H), 7.46 (d, J=7.3 Hz, 2H), 7.31 (t, J=7.5 Hz, 2H),
7.22 (t, J=7.3 Hz, 1H), 7.10 (d, J=8.0 Hz, 1H), 4.61 (br. s, 1H),
4.47 (d, J=9.3 Hz, 1H), 3.91 (s, 3H), 3.63-3.78 (m, 2H), 3.44-3.53
(m, 1H), 3.33-3.41 (m, 1H), 1.69-1.99 (m, 4H), 1.32-1.43 (m, 1H),
0.56-0.72 (m, 2H), 0.39-0.53 (m, 2H); MS ESI 525.3 [M+H].sup.+,
calcd for [C.sub.31H.sub.32N.sub.4O.sub.4+H].sup.+ 525.2.
Example A206
N-(cyclopropyl(pyridin-2-yl)methyl)-3-(4-((1-formylpiperidin-4-yl)oxy)-3-m-
ethoxyphenyl)-1H-indazole-5-carboxamide
##STR00345##
[0961] The title compound was synthesized according to the General
Method C, utilizing
N-(cyclopropyl(pyridin-2-yl)methyl)-3-iodo-1H-indazole-5-carboxamide
(100 mg, 0.24 mmol),
4-(2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)piper-
idine-1-carbaldehyde (86 mg, 0.24 mmol), Pd(PPh.sub.3).sub.4 (14
mg, 0.012 mmol), satd. aq Na.sub.2CO.sub.3 (1.25 mL), and 3.75 mL
of PhMe:EtOH (1:1). The vial was charged with Ar and heated in the
microwave reactor at 125.degree. C. for 2 h. Purification by RPHPLC
and trituration with Et.sub.2O gave the title compound (white
solid, 43 mg, 34%). .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. ppm
8.73 (d, J=5.5 Hz, 1H), 8.68 (s, 1H), 8.41-8.49 (m, 1H), 8.10 (d,
J=8.0 Hz, 1H), 8.04 (s, 1H), 7.98 (dd, J=8.9, 1.4 Hz, 1H), 7.85 (t,
J=6.8 Hz, 1H), 7.63 (d, J=9.0 Hz, 1H), 7.54-7.60 (m, 2H), 7.17 (d,
J=8.3 Hz, 1H), 4.63-4.70 (m, 1H), 4.49 (d, J=10.0 Hz, 1H),
3.68-3.80 (m, 2H), 3.48-3.57 (m, 1H), 3.41 (d, J=4.8 Hz, 1H),
1.73-2.03 (m, 4H), 1.43-1.54 (m, 1H), 0.81-0.90 (m, 1H), 0.58-0.77
(m, 3H); MS ESI 526.4 [M+H].sup.+, calcd for
[C.sub.30H.sub.31N.sub.5O.sub.4+H].sup.+ 526.2.
Example A207
N-(2-cyclopentyl-2-phenylethyl)-3-(4-((1-methylpiperidin-4-yl)oxy)phenyl)--
1H-indazole-5-carboxamide
##STR00346##
[0963] The title compound was synthesized according to the General
Method C, utilizing
N-(2-cyclopentyl-2-phenylethyl)-3-iodo-1H-indazole-5-carboxamide
(50 mg, 0.11 mmol), (4-((1-methylpiperidin-4-yl)oxy)phenyl)boronic
acid pinacol ester (35 mg, 0.11 mmol), Pd(PPh.sub.3).sub.4 (6 mg,
0.0055 mmol), satd. aq Na.sub.2CO.sub.3 (0.5 mL), and 1.5 mL of
PhMe:EtOH (1:1). The vial was charged with Ar and heated in the
microwave reactor at 125.degree. C. for 2 h. Purification by RPHPLC
gave the title compound as a TFA salt (white solid, 24 mg, 34%).
.sup.1H NMR (400 MHz, CD.sub.3OD) .delta. ppm 8.19 (s, 1H), 7.85
(t, J=8.3 Hz, 2H), 7.64 (d, J=8.8 Hz, 1H), 7.51 (d, J=8.8 Hz, 1H),
7.21-7.31 (m, 4H), 7.11-7.21 (m, 3H), 4.63-4.73 (m, 0.3H),
3.85-3.93 (m, 1H), 3.62-3.69 (m, 0.7H), 3.34-3.56 (m, 4H),
3.15-3.27 (m, 1H), 2.91-2.97 (m, 3H), 2.75-2.86 (m, 1H), 2.40-2.48
(m, 0.7H), 2.23-2.37 (m, 1.3H), 2.010-2.20 (m, 3.3H), 1.87-2.00 (m,
0.7H), 1.35-1.77 (m, 6H), 0.96-1.10 (m, 1H); MS ESI 523.4
[M+H].sup.+, calcd for [C.sub.33H.sub.38N.sub.4O.sub.2+H].sup.+
523.3.
Example A208
N-(cyclopentyl(pyridin-2-yl)methyl)-3-(4-((1-methylpiperidin-4-yl)oxy)phen-
yl)-1H-indazole-5-carboxamide
##STR00347##
[0965] The title compound was synthesized according to the General
Method C, utilizing
N-(cyclopentyl(pyridin-2-yl)methyl)-3-iodo-1H-indazole-5-carboxamide
(100 mg, 0.22 mmol), (4-((1-methylpiperidin-4-yl)oxy)phenyl)boronic
acid pinacol ester (70 mg, 0.22 mmol), Pd(PPh.sub.3).sub.4 (13 mg,
0.011 mmol), satd. aq Na.sub.2CO.sub.3 (1.25 mL), and 3.75 mL of
PhMe:EtOH (1:1). The vial was charged with Ar and heated in the
microwave reactor at 125.degree. C. for 2 h. Purification by RPHPLC
followed by flash chromatography (SiO.sub.2, Biotage 25 g, 0-30%
MeOH in CH.sub.2Cl.sub.2) gave the title compound (white solid, 43
mg, 38%). .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. ppm 8.57 (s,
1H), 8.51 (d, J=4.3 Hz, 1H), 7.86-7.94 (m, 3H), 7.79 (t, J=7.6 Hz,
1H), 7.59 (d, J=8.8 Hz, 1H), 7.49 (d, J=7.8 Hz, 1H), 7.29 (dd,
J=7.0, 5.0 Hz, 1H), 7.10 (d, J=8.5 Hz, 2H), 5.01 (d, J=10.3 Hz,
1H), 4.52 (br. s, 1H), 2.82 (br. s, 2H), 2.46-2.58 (m, 3H), 2.39
(s, 3H), 1.81-2.12 (m, 5H), 1.45-1.76 (m, 5H), 1.20-1.41 (m, 2H);
MS ESI 510.2 [M+H].sup.+, calcd for
[C.sub.31H.sub.35N.sub.5O.sub.2+H].sup.+ 510.3.
Example A209
N-(cyclopropyl(pyridin-2-yl)methyl)-3-(4-((1-(oxetan-3-yl)azetidin-3-yl)ox-
y)phenyl)-1H-indazole-5-carboxamide
##STR00348##
[0967] To a 20 mL microwave vial charged with Mg powder (240 mg, 10
mmol), THF (10 mL) was added bromocyclopropane (1.21 g, 10 mmol).
The resulting mixture was stirred for 30 min at rt before a
solution of picolinonitrile (520 mg, 5 mmol) in THF (3 mL) was
added. It was microwaved 10 min at 100.degree. C., cooled to rt and
added dropwise to a cold solution of NaBH.sub.4 (380 mg, 10 mmol)
in MeOH (30 mL) at 0.degree. C. The resulting mixture was stirred
for 15 min at rt, quchend with H.sub.2O, extracted with DCM and
purified by flash chromatography (MeOH/DCM 0-30%) to give
cyclopropyl(pyridin-2-yl)methanamine (light brown oil, 590 mg).
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.52 (d, J=4.0 Hz, 1H),
7.82 (dt, J=7.6 Hz, 1.6 Hz, 1H), 7.50 (d, J=8.0 Hz, 1H), 7.34-7.39
(m, 1H), 3.25 (d, J=8.8 Hz, 1H), 1.18-1.10 (m, 1H), 0.70-0.62 (m,
1H), 0.54-0.42 (m, 2H), 0.40-0.34 (m, 1H); MS ESI 132.0
[M+H].sup.+, calcd for [C.sub.9H.sub.12N.sub.2--NH.sub.3+H].sup.+
132.1.
[0968] To a solution of cyclopropyl(pyridin-2-yl)methanamine (575
mg, 3.94 mmol), 3-iodo-1H-indazole-5-carboxamide (1.14 g, 3.94
mmol) in DMF (15 mL) at 0.degree. C. was added TBTU (1.27 g, 3.94
mmol), followed by .sup.iPr.sub.2NEt (1.37 mL, 7.88 mmol). The
resulting mixture was stirred at rt for 30 min, quenched with
H.sub.2O till total volume about 100 mL and stirred for 10 min at
rt. Suction filtration gave crude
N-(cyclopropyl(pyridin-2-yl)methyl)-3-iodo-1H-indazole-5-carboxamide
(off white solid, 1.290 g). MS ESI 419.0 [M+H].sup.+, calcd for
[C.sub.17H.sub.15IN.sub.4O+H].sup.+ 419.0.
[0969] To a mixture of crude
N-(cyclopropyl(pyridin-2-yl)methyl)-3-iodo-1H-indazole-5-carboxamide
(209 mg, 0.5 mmol) and
1-(oxetan-3-yl)-3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy-
)azetidine (166 mg, 0.5 mmol) in EtOH (12 mL) was added 1 M aq
Na2CO3 (1 mL, 1 mmol), followed by Pd(PPh.sub.3).sub.4 (29 mg,
0.025 mmol). The resulting mixture was purged with Ar and
microwaved 4 h at 125.degree. C. After removal of solvents, it was
purified by flash chromatography (MeOH/DCM 0-20%), prep-HPLC and
PoraPak to give the title compound (white solid, 40.0 mg, 16%).
.sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.64 (s, 1H), 8.51 (d,
J=4.4 Hz, 1H), 7.96 (dd, J=9.0 Hz, 1.4 Hz, 1H), 7.92 (d, J=8.8 Hz,
2H), 7.80 (dt, J=7.8 Hz, 1.6 Hz, 1H), 7.60 (d, J=8.8 Hz, 1H), 7.52
(d, J=8.0 Hz, 1H), 7.32-7.27 (m, 1H), 6.96 (d, J=8.8 Hz, 2H),
4.96-4.90 (m, 1H, partially buried under H.sub.2O peak), 4.75 (t,
J=6.6 Hz, 2H), 4.53-4.47 (m, 3H), 3.90-3.83 (m, 3H), 3.38-3.33 (m,
2H, partially overlapped with CD.sub.3OD solvent residue),
1.45-1.35 (m, 1H), 0.72-0.65 (m, 1H), 0.62-0.50 (m, 3H); MS ESI
496.2 [M+H].sup.+, calcd for
[C.sub.29H.sub.29N.sub.5O.sub.3+H].sup.+ 496.2.
Example A210
N-(cyclobutyl(pyridin-2-yl)methyl-3-(4-((1-methylpiperidin-4-yl)oxy)phen)--
1H-indazole-5-carboxamide
##STR00349##
[0971] The title compound was synthesized according to the General
Method C, utilizing
N-(cyclobutyl(pyridin-2-yl)methyl)-3-iodo-1H-indazole-5-carboxamide
(200 mg, 0.46 mmol), (4-((1-methylpiperidin-4-yl)oxy)phenyl)boronic
acid pinacol ester (147 mg, 0.46 mmol), Pd(PPh.sub.3).sub.4 (27 mg,
0.023 mmol), satd. aq Na.sub.2CO.sub.3 (1.25 mL), and 3.75 mL of
PhMe:EtOH (1:1). The vial was charged with Ar and heated in the
microwave reactor at 125.degree. C. for 3 h. Purification by RPHPLC
followed by flash chromatography (SiO.sub.2, Biotage 25 g, 0-30%
MeOH in CH.sub.2Cl.sub.2) gave the title compound (white solid, 70
mg, 31%). .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. ppm 8.58 (s,
1H), 8.51 (d, J=4.3 Hz, 1H), 7.93 (d, J=8.5 Hz, 3H), 7.80 (td,
J=7.8, 1.5 Hz, 1H), 7.60 (d, J=8.8 Hz, 1H), 7.48 (d, J=8.0 Hz, 1H),
7.27-7.33 (m, 1H), 7.14 (d, J=8.5 Hz, 2H), 5.19 (d, J=10.3 Hz, 1H),
4.60 (br. s, 1H), 2.86-2.98 (m, 3H), 2.65 (br. s, 2H), 2.48 (s,
3H), 2.16-2.25 (m, 1H), 2.05-2.16 (m, 2H), 1.86-2.04 (m, 6H),
1.76-1.86 (m, 1H); MS ESI 496.2 [M+H].sup.+, calcd for
[C.sub.30H.sub.33N.sub.5O.sub.2+H].sup.+ 496.3.
Example A211
(R)--N-((3-chloropyridin-2-yl)(cyclopropyl)methyl)-3-(4-((1-formylpiperidi-
n-4-yl)oxy)phenyl)-1H-indazole-5-carboxamide
##STR00350##
[0973] A TFA salt of the title compound was synthesized according
to Method C3 utilizing
(R)-2-(3-chloropyridin-2-yl)-2-cyclopropyl-N-(3-iodo-1H-indazol-5-yl)acet-
amide and
4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)piperi-
dine-1-carbaldehyde obtained as a light yellow solid (42 mg, 48%
yield). .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. ppm 8.64 (s, 1H),
8.53 (d, J=3.51 Hz, 1H), 8.04 (s, 1H), 7.93 (t, J=9.16 Hz, 4H),
7.59 (d, J=9.03 Hz, 1H), 7.36 (dd, J=8.16, 4.89 Hz, 1H), 7.10 (d,
J=8.78 Hz, 2H), 5.13 (d, J=9.03 Hz, 1H), 4.71 (br. s., 1H),
3.62-3.80 (m, 2H), 3.46-3.58 (m, 1H), 3.36-3.46 (m, 1H), 1.97 (d,
J=13.30 Hz, 2H), 1.69-1.86 (m, 2H), 1.51 (d, J=6.27 Hz, 1H),
0.46-0.74 (m, 4H); MS ESI [M+H].sup.+ 530.4, calcd for
[C.sub.29H.sub.28ClN.sub.5O.sub.3+H].sup.+ 530.20.
Example A212
(S)--N-((3-chloropyridin-2-yl)(cyclopropyl)methyl)-3-(4-((1-formylpiperidi-
n-4-yl)oxy)phenyl)-1H-indazole-5-carboxamide
##STR00351##
[0975] The title compound was synthesized according to Method C3
utilizing
(S)-2-(3-chloropyridin-2-yl)-2-cyclopropyl-N-(3-iodo-1H-indazol-5-yl)acet-
amide and
4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)piperi-
dine-1-carbaldehyde and obtained as a light yellow solid (36 mg,
49% yield). .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. ppm 8.63 (s,
1H), 8.46 (d, J=4.52 Hz, 1H), 8.00 (s, 1H), 7.93 (dd, J=8.78, 1.25
Hz, 1H), 7.87 (d, J=8.28 Hz, 2H), 7.79 (d, J=8.28 Hz, 1H), 7.56 (d,
J=8.78 Hz, 1H), 7.20-7.28 (m, 1H), 6.97-7.06 (m, 2H), 5.19 (d,
J=9.03 Hz, 1H), 4.62 (m, J=3.30 Hz, 1H), 3.65-3.75 (m, 1H),
3.55-3.65 (m, 1H), 3.41-3.51 (m, 1H), 3.28-3.39 (m, 1H), 1.92 (br.
s., 2H), 1.71 (br. s., 2H), 1.40-1.53 (m, 1H), 0.54-0.66 (m, 2H),
0.50 (d, J=6.02 Hz, 2H); MS ESI [M+H].sup.+ 530.4, calcd for
[C.sub.29H.sub.28ClN.sub.5O.sub.3+H].sup.+ 530.20.
Example A213
N--((S)-cyclopropyl(pyridin-2-yl)methyl)-3-(4-(((1R,3r,5S)-8-methyl-8-azab-
icyclo[3.2.1]octan-3-yl)oxy)phenyl)-1H-indazole-5-carboxamide
##STR00352##
[0976] The title compounds was synthesized according to the General
Method C2 utilizing
(S)--N-(cyclopropyl(pyridin-2-yl)methyl)-3-iodo-1H-indazole-5-carboxamide
(60 mg, 0.14 mmol) and
(1R,3r,5S)-8-methyl-3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phe-
noxy)-8-azabicyclo[3.2.1]octane (33 mg, 0.099 mmol) to afford
N--((S)-cyclopropyl(pyridin-2-yl)methyl)-3-(4-(((1R,3r,5S)-8-methyl-8-aza-
bicyclo[3.2.1]octan-3-yl)oxy)phenyl)-1H-indazole-5-carboxamide as a
white powder (14.3 mg, 28%). .sup.1H NMR (400 MHz, CD.sub.3OD)
.delta. ppm 8.66 (s, 1H), 8.53 (d, J=4.02 Hz, 1H), 7.89-8.01 (m,
3H), 7.79-7.87 (m, 1H), 7.61 (d, J=8.78 Hz, 1H), 7.54 (s, 1H), 7.32
(dd, J=6.90, 5.40 Hz, 1H), 7.04 (d, J=8.53 Hz, 2H), 4.61-4.72 (m,
1H), 4.50 (d, J=9.54 Hz, 1H), 3.21 (br. s., 2H), 2.34 (s, 3H),
1.98-2.26 (m, 8H), 1.34-1.48 (m, 1H), 0.67-0.77 (m, 1H), 0.46-0.65
(m, 3H); MS ESI 508.2 [M+H].sup.+, calcd for
[C.sub.31H.sub.33N.sub.5O.sub.2+H].sup.+ 508.2.
Example A214
(S)--N-(cyclopropyl(pyridin-2-yl)methyl)-3-(4-((1-methylpiperidin-4-yl)oxy-
)phenyl)-1H-indazole-5-carboxamide
##STR00353##
[0978] The title compound was synthesized according to the General
Method C, utilizing
(S)--N-(cyclopropyl(pyridin-2-yl)methyl)-3-iodo-1H-indazole-5-carboxamide
(50 mg, 0.12 mmol), (4-((1-methylpiperidin-4-yl)oxy)phenyl)boronic
acid pinacol ester (38 mg, 0.12 mmol), Pd(PPh.sub.3).sub.4 (7 mg,
0.006 mmol), satd. aq Na.sub.2CO.sub.3 (1.25 mL), and 3.75 mL of
PhMe:EtOH (1:1). The vial was charged with Ar and heated in the
microwave reactor at 125.degree. C. for 3 h. Purification by RPHPLC
followed by flash chromatography (SiO.sub.2, Biotage 25 g, 0-30%
MeOH in CH.sub.2Cl.sub.2) gave the title compound (white solid, 21
mg, 36%). .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. ppm 8.64 (s,
1H), 8.52 (d, J=4.8 Hz, 1H), 7.94 (s, 3H), 7.82 (td, J=7.6, 1.8 Hz,
1H), 7.60 (d, J=8.8 Hz, 1H), 7.54 (d, J=7.8 Hz, 1H), 7.29-7.35 (m,
1H), 7.12 (d, J=8.8 Hz, 2H), 4.53 (br. s, 1H), 4.50 (d, J=9.5 Hz,
1H), 2.76 (br. s, 2H), 2.43 (br. s, 2H), 2.33 (s, 3H), 2.02-2.11
(m, 2H), 1.81-1.91 (m, 2H), 1.35-1.46 (m, 1H), 0.65-0.74 (m, 1H),
0.49-0.62 (m, 3H); MS ESI 482.2 [M+H].sup.+, calcd for
[C.sub.29H.sub.31N.sub.5O.sub.2+H].sup.+ 482.3.
Example A215
(R)--N-((3-chloropyridin-2-yl)(cyclopropyl)methyl)-3-(4-((1-(oxetan-3-yl)p-
iperidin-4-yl)oxy)phenyl)-1H-indazole-5-carboxamide
##STR00354##
[0980] The title compound was synthesized according to Method C3
utilizing
(R)-2-(3-chloropyridin-2-yl)-2-cyclopropyl-N-(3-iodo-1H-indazol-5-yl)acet-
amide and
1-(oxetan-3-yl)-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-y-
l)phenoxy)piperidine and obtained as a white solid (30 mg, 48%
yield). .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. ppm 8.65 (s, 1H),
8.47 (dd, J=4.64, 1.38 Hz, 1H), 7.94 (dd, J=8.78, 1.51 Hz, 1 H),
7.88 (d, J=8.53 Hz, 2H), 7.81 (dd, J=8.16, 1.38 Hz, 1H), 7.57 (d,
J=8.78 Hz, 1H), 7.25 (dd, J=8.16, 4.64 Hz, 1H), 7.01 (d, J=8.78 Hz,
2H), 5.19 (d, J=9.03 Hz, 1H), 4.60-4.68 (m, 2H), 4.56 (t, J=6.27
Hz, 2H), 4.35-4.45 (m, 1H), 3.44 (quin, J=6.46 Hz, 1H), 2.53 (br.
s., 2H), 2.15 (br. s., 2H), 1.97 (br. s., 2H), 1.78 (d, J=8.53 Hz,
2H), 1.40-1.53 (m, 1H), 0.55-0.66 (m, 2H), 0.43-0.55 (m, 2H); MS
ESI [M+H].sup.+ 558.4, calcd for
[C.sub.31H.sub.32ClN.sub.5O.sub.3+H].sup.+ 558.23.
Example A216
(S)--N-((3-chloropyridin-2-yl)(cyclopropyl)methyl)-3-(4-((1-(oxetan-3-yl)p-
iperidin-4-yl)oxy)phenyl)-1H-indazole-5-carboxamide
##STR00355##
[0982] The title compound was synthesized according to Method C3
utilizing
(S)-2-(3-chloropyridin-2-yl)-2-cyclopropyl-N-(3-iodo-1H-indazol-5-yl)acet-
amide and
1-(oxetan-3-yl)-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-y-
l)phenoxy)piperidine and obtained as a white solid (26 mg, 42%
yield). .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. ppm 8.65 (s, 1H),
8.47 (dd, J=4.64, 1.38 Hz, 1H), 7.94 (dd, J=8.78, 1.51 Hz, 1H),
7.88 (d, J=8.53 Hz, 2H), 7.81 (dd, J=8.16, 1.38 Hz, 1H), 7.57 (d,
J=8.78 Hz, 1H), 7.25 (dd, J=8.16, 4.64 Hz, 1H), 7.01 (d, J=8.78 Hz,
2H), 5.19 (d, J=9.03 Hz, 1H), 4.60-4.68 (m, 2H), 4.56 (t, J=6.27
Hz, 2H), 4.35-4.45 (m, 1H), 3.44 (quin, J=6.46 Hz, 1H), 2.53 (br.
s., 2H), 2.15 (br. s., 2H), 1.97 (br. s., 2H), 1.78 (d, J=8.53 Hz,
2H), 1.40-1.53 (m, 1H), 0.55-0.66 (m, 2H), 0.43-0.55 (m, 2H); MS
ESI [M+H].sup.+ 558.4, calcd for
[C.sub.31H.sub.32ClN.sub.5O.sub.3+H].sup.+ 558.23.
Example B
TTK Inhibition Assay
[0983] Active TTK was purchased from Invitrogen as an amino
terminal GST fusion of full length human TTK. Amino terminal 6
histidine, sumo tagged human TTK (residues 1-275) was expressed in
E. coli, and purified to >95% homogeneity by Ni.sup.2+ agarose,
gel filtration, and ion exchange chromatography.
[0984] TTK activity was measured using an indirect ELISA detection
system. GST-TTK (0.68 nM) was incubated in the presence of 16 .mu.M
ATP (Sigma cat#A7699), 50 mM Hepes pH 7.2, 1 mM EGTA, 10 mM
MgCl.sub.2, and 0.1% Pluronic in a 96 well microtitre plate
pre-coated with amino terminal 6 histidine, sumo tagged TTK (amino
acid residues 1-275). The reaction was allowed to proceed for 30
minutes, followed by 5 washes of the plate with Wash Buffer
(phosphate buffered saline supplemented with 0.2% Tween 20), and
incubation for 30 minutes with a 1:3000 dilution of primary
antibody (Cell Signaling cat#9381). The plate was washed 5 times
with Wash Buffer, incubated for 30 minutes in the presence of
secondary antibody coupled to horse radish peroxidase (BioRad
cat#1721019, 1:3000 concentration), washed an additional 5 times
with Wash Buffer, and incubated in the presence of TMB substrate
(Sigma cat#T0440). The colourimetric reaction was allowed to
continue for 5 minutes, followed by addition of stop solution (0.5
N sulphuric acid), and quantified by detection at 450 nm with
either a monochromatic or filter based plate reader (Molecular
Devices M5 or Beckman DTX880, respectively).
[0985] Compound inhibition was determined at either a fixed
concentration (10 .mu.M) or at a variable inhibitor concentration
(typically 0.5 .mu.M to 0.001 .mu.M in a 10 point dose response
titration). Compounds were pre-incubated in the presence of enzyme
for 5 minutes prior to addition of ATP and the activity remaining
quantified using the above described activity assay. The %
Inhibition of a compound was determined using the following
formula; % Inhibition=100.times.(1-(experimental value-background
value)/(high activity control-background value)). The IC.sub.50
value was determined using a non-linear 4 point logistic curve fit
(XLfit4, IDBS) with the formula; (A+(B/(1+((x/C) D)))), where
A=background value, B=range, C=inflection point, D=curve fit
parameter.
Example C
PLK4 Inhibition Assay
[0986] Active PLK4 was purified from an E. coli expression system
as an amino terminal GST fusion of residues 1-391 of human PLK4.
The protein was purified from clarified cell extracts after
induction at 15.degree. C. overnight using glutathione sepharose,
gel permeation chromatography, and ion exchange (Resource Q). The
resulting protein was dephosphorylated with lambda phosphatase (NEB
cat#P0753), and resolved from the phosphatase using gluthione
sepharose. The dephosphorylated GST-PLK4 was stored in aliquots at
-80.degree. C. until use.
[0987] PLK4 activity was measured using an indirect ELISA detection
system. GST-PLK4 (4 nM) was incubated in the presence of 15 .mu.M
ATP (Sigma cat#A7699), 50 mM HEPES-Na.sup.2+ pH 7.5, 10 mM
MgCl.sub.2, 0.01% Brij 35 (Sigma cat#03-3170), in a 96 well
microtitre plate pre-coated with MBP (Millipore cat#30-011). The
reaction was allowed to proceed for 30 minutes, followed by 5
washes of the plate with Wash Buffer (phosphate buffered saline
supplemented with 0.2% Tween 20), and incubation for 30 minutes
with a 1:3000 dilution of primary antibody (Cell Signaling
cat#9381). The plate was washed 5 times with Wash Buffer, incubated
for 30 minutes in the presence of secondary antibody coupled to
horse radish peroxidase (BioRad cat#1721019, 1:3000 concentration),
washed an additional 5 times with Wash Buffer, and incubated in the
presence of TMB substrate (Sigma cat#T0440). The colourimetric
reaction was allowed to continue for 5 minutes, followed by
addition of stop solution (0.5 N sulphuric acid), and quantified by
detection at 450 nm with either a monochromatic or filter based
plate reader (Molecular Devices M5 or Beckman DTX880,
respectively).
[0988] Compound inhibition was determined at either a fixed
concentration (10 .mu.M) or at a variable inhibitor concentration
(typically 0.5 .mu.M to 0.001 .mu.M in a 10 point dose response
titration). Compounds were pre-incubated in the presence of enzyme
for 15 minutes prior to addition of ATP and the activity remaining
quantified using the above described activity assay. The %
Inhibition of a compound was determined using the following
formula; % Inhibition=100.times.(1-(experimental value-background
value)/(high activity control-background value)). The IC.sub.50
value was determined using a non-linear 4 point logistic curve fit
(XLfit4, IDBS) with the formula; (A+(B/(1+((x/C) D)))), where
A=background value, B=range, C=inflection point, D=curve fit
parameter.
Example D
Aurora B Inhibition Assay
[0989] Aurora B inhibition was determined using the Z-Lyte assay
kit from Invitrogen. The assay was performed using the recommended
manufacturer's instructions with 128 .mu.M ATP and 28 nM Aurora B
(Invitrogen cat #PV3970). The % inhibition values were determined
according to the manufacturer's directions and IC.sub.50 values
were obtained using a non-linear 4 point logistic curve fit
(XLfit4, IDBS)
[0990] In Table 1, IC.sub.50 values for PLK4, TTK and Aurora B
Kinases are indicated as "A," "B," and "C," for those less than or
equal to 5 .mu.M; those greater than 5 .mu.M and less than or equal
to 50 .mu.M; and those greater than 50 .mu.M, respectively. As
shown in Table 1, numerous compounds described herein are effective
TTK inhibitors. In addition, a number of compounds described herein
also inhibit other kinases, including for instance, PLK4 and Aurora
B kinases.
TABLE-US-00001 TABLE 1 Inhibition Data of PLK4, TTK, Aurora A and
Aurora B Kinases IC50 Ranges Example # TTK PLK4 Aurora B Example A1
A A B Example A2 A A A Example A3 A A A Example A4 A A A Example A5
A A B Example A6 A A A Example A7 A A A Example A8 A A A Example A9
A A A Example A10 A A A Example A11 A A A Example A12 A A A Example
A13 A A A Example A14 A A Example A15 A A Example A16 A A A Example
A17 A A A Example A18 A A A Example A19 A A A Example A20 A A A
Example A21 A A A Example A22 A A B Example A23 A A Example A24 A A
A Example A25 A A A Example A26 A A Example A27 A A A Example A28 A
A A Example A29 A A A Example A30 A A A Example A31 A A A Example
A32 A A A Example A33 A A A Example A34 A A A Example A35 A A A
Example A36 A A A Example A37 A A A Example A38 A A A Example A39 A
A A Example A40 A A Example A41 A A A Example A42 A A A Example A43
A A A Example A44 A A A Example A45 A A A Example A46 A A A Example
A47 A A A Example A48 A A Example A49 A A A Example A50 A A A
Example A51 A A A Example A53 A A Example A55 A A A Example A56 A A
Example A57 A A A Example A58 A A A Example A59 A A Example A60 A A
Example A61 A A Example A62 A A Example A63 A A A Example A64 A A
Example A65 A A Example A66 A A Example A67 A A Example A68 A A
Example A69 A A A Example A70 A A Example A71 A A A Example A72 A A
Example A73 A A Example A74 A A Example A75 A A Example A76 A A A
Example A77 A A A Example A78 A A A Example A79 A A A Example A80 A
A A Example A81 A A A Example A82 A A A Example A83 A A A Example
A84 A A A Example A85 A A A Example A86 A A A Example A87 A A
Example A88 A A A Example A89 A A A Example A90 A A A Example A91 A
A A Example A92 A A A Example A93 A A A Example A94 A A Example A95
A A A Example A96 A A B Example A97 A A A Example A98 A A A Example
A99 A A A Example A100 A A A Example A101 A A A Example A102 A A A
Example A103 A A A Example A104 A A A Example A105 A A A Example
A106 A A A Example A107 A A A Example A108 A A A Example A109 A A A
Example A110 A A A Example A111 A A A Example A112 A A A Example
A113 A A A Example A114 A A Example A115 A A Example A116 A A A
Example A117 A A A Example A118 A A A Example A119 A A A Example
A120 A A A Example A121 A A A Example A122 A A Example A123 A A A
Example A124 A A A Example A125 A A A Example A126 A A A Example
A128 A A A Example A129 A A Example A130 A A A Example A131 A A A
Example A132 A A A Example A133 A A A Example A134 A A A Example
A135 A A Example A136 A A A Example A137 A A A Example A138 A A A
Example A139 A A A Example A140 A A Example A141 A A Example A142 A
A Example A143 A A A Example A144 A A A Example A145 A A Example
A146 A A Example A147 A A A Example A148 A A A Example A150 A A A
Example A151 A A A Example A153 A A A Example A154 A A A Example
A155 A A A Example A156 A A Example A157 A A A Example A158 A A A
Example A159 A A A Example A160 A A A Example A161 A A A Example
A162 A A Example A163 A A A Example A164 A A Example A166 A A A
Example A167 A A A Example A169 A A Example A170 A A Example A171 A
A A Example A172 A A A Example A173 A A Example A174 A A A Example
A175 A A A Example A176 A A A Example A177 A A A Example A178 A A A
Example A179 A A A Example A180 A A A Example A181 A A Example A182
A A A Example A183 A A A Example A184 A A A Example A185 A A A
Example A186 A A A Example A187 A A A Example A188 A A A Example
A189 A A A Example A190 A A A Example A191 A A A Example A192 A A A
Example A193 A A A Example A194 A A A Example A195 A A A Example
A196 A A A Example A197 A A A Example A198 A A A Example A199 A A A
Example A200 A A A Example A201 A A A Example A202 A A A Example
A203 A A A Example A204 A A A Example A205 A A A Example A206 A A A
Example A207 A A A Example A208 A A A Example A209 A A A Example
A210 A A A Example A211 A A A Example A212 A A A Example A213 A A A
Example A214 A A A Example A215 A A Example A216 A A
Example E
Cancer Cell Line Data on Exemplary Compounds of the Invention
[0991] Breast cancer cells (MDA-MB-231, MDA-MB-468), colon cancer
cells (HCT116, HT29) and ovarian cancer cells (PA-1, OVCAR-3) were
seeded (1000 to 4000 in 80 .mu.l per well depending on the cell
growth rate) into 96 well plates 24 hours before compound overlay.
Compounds were prepared as 10 mM stock solutions in 100% DMSO which
were diluted with DMEM (Dulbecco's Modified Eagle's Medium) cell
growth Medium (Invitrogen, Burlington, ON, Canada) containing 10%
FBS (Fetal Bovine Serum) to concentrations ranging from 50 nM to
250 .mu.M. Aliquots (20 .mu.l) from each concentration were
overlaid to 80 .mu.l of the pre-seeded cells in the 96 well plates
to make final concentrations of 10 nM to 50 .mu.M. The cells were
cultured for 5 days before the Sulforhodamine B assay (SRB) was
performed to determine the compound's cell growth inhibition
activity.
[0992] Sulforhodamine B (purchased from Sigma, Oakville, ON,
Canada) is a water-soluble dye that binds to the basic amino acids
of the cellular proteins. Thus, colorimetric measurement of the
bound dye provides an estimate of the total protein mass that is
related to the cell number. the cells are fixed in situ by gently
aspirating off the culture media and adding 50 .mu.l ice cold 10%
Trichloroacetic Acid (TCA) per well and incubate at 4.degree. C.
for 30-60 min, The plates are washed with water five times and
allowed to air dry for 5 min. Addition of 50 .mu.l 0.4% (w/v) SRB
solution in 1% (v/v) acetic acid to each well and incubatation for
30 min at RT completes the staining reaction. Following staining,
plates are washed four times with 1% acetic acid to remove unbound
dye and then allowed to air dry for 5 min. The stain is solubilized
with 100 .mu.l of 10 mM Tris pH 10.5 per well. Absorbance is read
at 570 nm.
[0993] The percentage (%) of relative growth inhibition was
calculated by comparing to DMSO treated only cells (100%).
GI.sub.50's were determined for compounds with cytotoxic activity.
The GI.sub.50 was calculated using GraphPad PRISM software
(GraphPad Software, Inc., San Diego, Calif., USA). GI.sub.50
(growth inhibition) is the compound concentration that causes 50%
inhibition of cell growth. In Table 2 below, GI.sub.50 value ranges
for several compound examples against breast cancer cell lines
(MDA-MB-231, MDA-MB-468), colon cancer cell lines (HCT116, HT29)
and ovarian cancer cell lines (PA-1, OVCAR-3) are given. The
example compounds demonstrated varying growth inhibition/cell
killing activity against cells of breast cancer, colon cancer and
ovarian cancer. The GI.sub.50 ranges are indicated as "A," "B,"
"C," and "D," for values less than or equal to 5 .mu.M; those
greater than 5 .mu.M and less than or equal to 20 .mu.M; those
greater than 20 .mu.M and less than or equal to 50 .mu.M; and those
greater than 50 .mu.M, respectively.
TABLE-US-00002 TABLE 2 Cell Growth Inhibition Data Cell Line
GI.sub.50 Range MDA- MDA- Ex. # MB-231 MB-468 HCT116 HT29 PA-1
OVCAR-3 Example A1 A A A Example A2 A A A Example A3 A A A Example
A4 A A A A B Example A5 A A A Example A6 A A A Example A7 A A A A A
B Example A8 A A A Example A9 A A A Example A10 A A A Example A11 A
A A Example A12 A A Example A13 A A A Example A14 A A A Example A15
A A A Example A16 A A A Example A17 A A A Example A18 A A A A A A
Example A19 A A A Example A20 A A A Example A21 A A A Example A22 A
A A Example A23 B A A Example A24 A A A A A A Example A25 A A A A A
Example A26 A A A A A Example A27 B A A A B Example A28 A A A A B
Example A29 B A A A B Example A30 A A A A A Example A31 A A A A A
Example A32 C A A A B Example A33 A A A A A Example A34 A A A A A
Example A35 A A A A A Example A36 A A A A A Example A37 A A A
Example A38 A A A A A Example A39 A A A Example A40 A A A A A
Example A41 A A A A Example A42 A A A A A Example A43 A A A A A
Example A44 A A A A A Example A45 A A A A B Example A46 A A A A A
Example A47 A A A Example A48 A A A A B Example A49 A A A Example
A50 A A A Example A51 A A A Example A53 A A A A B Example A55 A A A
A A Example A56 A A A A B Example A57 A A A A A Example A58 A A A A
A Example A59 A A A A B Example A60 A A A A B Example A61 B B A A B
Example A62 A A A A A Example A63 A A A A A Example A64 B B A A C
Example A65 A A A A B Example A66 B B A A B Example A67 A A A A B
Example A68 A A A A A Example A69 A A A A A Example A70 A A A A
Example A71 A A A Example A72 Example A73 A A A A B Example A74 B A
A A C Example A75 B A A A B Example A76 A A A B Example A77 A A A A
A Example A78 A A A Example A79 A A A Example A80 A A A Example A81
B A A A A Example A82 A A A A Example A83 A A A A Example A84 A A A
A Example A85 A A A A A Example A86 A A A A A Example A87 A A A A
Example A88 A A A A Example A89 A A A A Example A90 A A A A A
Example A91 A A A A A A Example A92 A A A A A A Example A93 A A A A
A B Example A94 Example A95 A A A A Example A96 B B B B B B Example
A97 A A A A Example A98 A A A A A A Example A99 A A A A A A Example
A100 A A A A A Example A101 A A A A Example A102 A A A A B Example
A103 A A A A A Example A104 A A A A A A Example A105 A A A A
Example A106 A A A A Example A107 B A A A A Example A108 A A A A A
A Example A109 A A A A A A Example A110 A A A A A A Example A111 A
A A A Example A112 A A A A A A Example A113 A A A A A A Example
A114 A A A A A B Example A115 A A A A A A Example A116 A A A A A
Example A117 A A A A Example A118 A A A A Example A119 A A A A
Example A120 A A A A Example A121 A A A A A Example A122 A A A A
Example A123 A A A Example A124 A A A A A C Example A125 A A A A A
A Example A126 A A A A A A Example A128 A A A A A A Example A129 A
A A A A B Example A130 A A A A A A Example A131 A A A A A A Example
A132 A A A A A A Example A133 A A A A A A Example A134 A A A A A B
Example A135 A A A A A A Example A136 A A A A A A Example A137 A A
A A A A Example A138 A A A A A A Example A139 A A A A A A Example
A140 A A A A A A Example A141 A A A A A A Example A142 A A A A A B
Example A143 A A A A A A Example A144 A A A A A A Example A145 A A
A A A A Example A146 A A A A A A Example A147 A A A A A A Example
A148 A A A A A A Example A150 A A A A A A Example A151 A A A A A A
Example A153 A A A A A A Example A154 A A A A A A Example A155 A A
A A A A Example A156 A A A A A A Example A157 A A A A A A Example
A158 A A A A A A Example A159 A A A A A A Example A160 A A A A
Example A161 A A A A A A Example A162 A A A A A A Example A163 A A
A A A A Example A164 A A A A A A Example A166 A A A A A A Example
A167 A A A A Example A169 A A A A B Example A170 A A A A A A
Example A171 A A A A A Example A172 A A A A Example A173 A A A A A
B Example A174 A A A A A A Example A175 A A A A A A Example A176 A
A A A A A Example A177 A A A A A A Example A178 A A A A A A Example
A179 A A A A A A Example A180 A A A Example A181 A A A A A Example
A182 A A A Example A183 A A A A A Example A184 A A A A Example A185
A A A Example A186 A A A Example A187 A A A A A Example A188 A A A
A A Example A189 B A A A C Example A190 A A A Example A191 A A A A
A Example A192 A A A A Example A193 A A A A A Example A194 A A A A
A Example A195 A A A Example A196 A A A Example A197 A A A Example
A198 A A A A A Example A199 A A A A A Example A200 A A A Example
A201 A A A Example A202 A A A A A Example A203 A A A Example A204 A
A A Example A205 A A A Example A206 Example A207 Example A208
Example A209 Example A210 Example A211 Example A212 Example A213
Example A214 Example A215 Example A216
Example F
[0994] Colon and Ovarian Cancer Tumor-Initiating Cell Data of
Exemplary Compounds
[0995] Materials and Methods: Non-tissue or tissure cultured
treated T-75 flask and 96-well plates were purchased from VWR.
Vitamin B-27 supplement, MEM NEAA (minimum essential medium non
essential amino acids), sodium pyruvate, L-glutamine, N2
supplement, penicillin-streptomycin and fungizone/amphotericin B
were obtained from Invitrogen. Lipid mixture, heparin and EGF were
purchased from Sigma; bFGF from BD Biosciences. Colon tumor
initiating cells (TICs) were routinely maintained using non-tissue
cultured treated T-75 flasks in DMEM:F12 medium containing 0.2XB-27
supplement, 4 ug/ml heparin, 1XMEM NEAA, 1.times. sodium pyruvate,
1 mM glutamine, 10 pg/ul bFGF, 20 pg/ul EGF, 1.times.N2 supplement,
lipid mixture, penicillin-streptomycin and fungizone/amphotericin
B. Ovarian TICs were routinely maintained using tissue cultured
treated T-75 flasks in DMEM:F12 medium containing 1XB-27
supplement, 4 ug/ml heparin, 20 pg/ul bFGF, 20 pg/ul EGF and
penicillin-streptomycin.
[0996] Assay Protocol:
[0997] Compounds described herein were dissolved in DMSO and
further diluted in cell culture medium for GI50 determination.
Colon TICs were trypsinized and seeded into non-tissue cultured
treated 96-well plates with 4,000 cells/well. After 24 h, compound
was added into the cell culture at different concentrations, and
the final concentration of DMSO was adjusted to 0.1%. Cells were
then cultured at 37.degree. C. for 9 days. Ovarian TICs were
trypsinized and seeded into tissue cultured treated 96-well plates
with 1,000 cells/well. After 24 h, compound was added into the cell
culture at different concentrations, and the final concentration of
DMSO was adjusted to 0.1%. Cells were then cultured at 37.degree.
C. for 6 days. Cell viability was assessed by Alamar Blue assay: 10
ul of Alamar Blue was added into each well. After 4 hours
incubation at 37.degree. C., fluorescence was recorded at
excitation 544 and emission 590. GI.sub.50 (Growth inhibition) was
calculated using GraphPad Prism 4.0 software. Cell growth
inhibition data for compounds described herein is tabulated below
(Table 3). The GI.sub.50 ranges are indicated as "A," "B," "C," and
"D," for values less than or equal to 5 .mu.M; those greater than 5
.mu.M and less than or equal to 20 .mu.M; those greater than 20
.mu.M and less than or equal to 50 .mu.M; and those greater than 50
mM, respectively.
TABLE-US-00003 TABLE 3 Colon Tumor-Initiating Cell Growth
Inhibition Data Example # 12 colon 2393A ovarian Example A4 A A
Example A7 A A Example A9 A A Example A12 A A Example A24 A A
Example A25 A A Example A27 A A Example A29 A A Example A33 A A
Example A35 A A Example A41 A A Example A46 A A Example A89 A A
Example A91 A A Example A98 A A Example A110 A A Example A118 A A
Example A128 A A Example A130 A A Example A131 A A Example A132 A A
Example A133 A A Example A134 A A Example A136 A A Example A137 A A
Example A138 A A Example A144 A A Example A147 A A Example A150 A A
Example A151 A A Example A154 A A Example A157 A A Example A160 A A
Example A163 A A Example A166 A A Example A167 A A Example A169 A A
Example A170 A A Example A171 A A Example A172 A A Example A173 A A
Example A174 A A Example A175 A A Example A176 A A Example A177 A A
Example A178 A A Example A179 A A Example A180 A A Example A181 A A
Example A182 A A Example A183 A A Example A184 A A Example A185 A A
Example A186 A A Example A187 A A Example A188 A A Example A189 A A
Example A190 A A Example A191 A A Example A193 A A
[0998] While this invention has been particularly shown and
described with references to example embodiments thereof, it will
be understood by those skilled in the art that various changes in
form and details may be made therein without departing from the
scope of the invention encompassed by the appended claims.
* * * * *